<SEC-DOCUMENT>0000886163-21-000050.txt : 20210224
<SEC-HEADER>0000886163-21-000050.hdr.sgml : 20210224
<ACCEPTANCE-DATETIME>20210224170322
ACCESSION NUMBER:		0000886163-21-000050
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210224
DATE AS OF CHANGE:		20210224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		21674605

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgnd-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69,d:b69a1c25a15148f9b95ad6e3392de608--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:lgnd="http://www.ligand.com/20201231" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8xLTEtMS0xLTA_0df145ea-10e6-467e-99ff-4606e685d86d">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8yLTEtMS0xLTA_22e670b3-ef9b-4cd3-a4ef-29cbbc5fc3b0">2020</ix:nonNumeric><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8zLTEtMS0xLTA_92dd95dc-7604-43cb-84ff-e7bbdc6e0e7e">FY</ix:nonNumeric><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGV4dHJlZ2lvbjo1Y2ZmMWZhZWNlNTI0NGZjYjhkNDY0NTFjYTMxMmE1MV82Mg_ebc10c45-c38d-43d2-84c0-b65b4e3db6ca">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGV4dHJlZ2lvbjo1Y2ZmMWZhZWNlNTI0NGZjYjhkNDY0NTFjYTMxMmE1MV82Mw_226deebc-ab67-415a-a5c0-9e1d85f50832">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMC0xLTEtNDk2Ng_219e2ce5-02b5-469b-a2fa-1b0d64350836">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124">P42M</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84NS9mcmFnOmVkNDExMTM1MWM1ODQ0ZjFhODg4ZWQxYzFhNWQ3YjBjL3RhYmxlOjIwMDczN2FjMGUxNjQ1YzFhZmM2MjAyOGRmMDJmYTdiL3RhYmxlcmFuZ2U6MjAwNzM3YWMwZTE2NDVjMWFmYzYyMDI4ZGYwMmZhN2JfMS0xLTEtMS0w_ba2dc4e9-e2d3-4273-acee-b9eff8c4f3a4">12.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84NS9mcmFnOmVkNDExMTM1MWM1ODQ0ZjFhODg4ZWQxYzFhNWQ3YjBjL3RhYmxlOjIwMDczN2FjMGUxNjQ1YzFhZmM2MjAyOGRmMDJmYTdiL3RhYmxlcmFuZ2U6MjAwNzM3YWMwZTE2NDVjMWFmYzYyMDI4ZGYwMmZhN2JfMi0xLTEtMS0w_85f0dfd9-4ebb-4163-b113-e3fff61160cf">2.08</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDYvZnJhZzo0Y2JjOWNkMjFhOTU0MzI0YmVjZDI0YTM0NTJlNzZiNS90YWJsZTo5YTQzYjIwZTM2ZTE0YTM3YmQzNDAzZWY2Zjc3NDIwOC90YWJsZXJhbmdlOjlhNDNiMjBlMzZlMTRhMzdiZDM0MDNlZjZmNzc0MjA4XzItMS0xLTEtMA_f0b1bc8a-dc2c-4d0f-b3d8-dcbe48217245">0.0133251</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibf28578e57ba441195176b5789f4dde3_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDYvZnJhZzo0Y2JjOWNkMjFhOTU0MzI0YmVjZDI0YTM0NTJlNzZiNS90YWJsZTo5YTQzYjIwZTM2ZTE0YTM3YmQzNDAzZWY2Zjc3NDIwOC90YWJsZXJhbmdlOjlhNDNiMjBlMzZlMTRhMzdiZDM0MDNlZjZmNzc0MjA4XzItMi0xLTEtMA_1a5134d8-ca4d-414c-ac20-639b93627181">0.0040244</ix:nonFraction><ix:nonNumeric contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4MQ_17ee1139-a959-4580-b6e3-e99ff17f0d7f">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id5ad18ea90a54b5b8bba0e1555ad9875_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idd5c9735b7574d1eb48ed78ec5db3eb5_I20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7153cd81712409ba213861c38901324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d16dd704b74221b973893e02cd3023_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0387ebb91c44aaa14fe5f411316aab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0863c3664c064309a61c97efd34cc22b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74270c6229d54e75bedc1e83d6c7f2d7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824ae14f7d55450f96a50e45e1e00275_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe8f99853d84177abbd1d204189cdc9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076d26d185984399b35b035b9c392324_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd387f8ff7744137980599559a1c5f77_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i346897ea83804fdd8c657865b763ef87_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59bfab0480542cda230d78e7ef5e82e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911fa320b1ef4643bd62d2f1d873e78c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id001411ddc1a48f3be1dce3344a83372_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7054e445350945b5a3ac6b9a4827ce2a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14c67e9b9e04b7093d188b4497bf574_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ee9751e8804e03bbd45e0f38940a0c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a7c5c2af724c429803e6c84d4842b6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37bbc9e048046e88b85c63fa39515f5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67458ea516e439bbc83b615b79b3518_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf82073fee7b42059c5ceb699522c8e2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea39822ada3c494db6a1bf3fd99d48b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i111967c6372740459aedf8ec7bb0ce69_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f450afb88d04c82a9ea8a0fe0f120af_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651d151d6b5945ae854d15dfa48f1c67_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f3bec8971d4633aec80a74abc60a98_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f9c1547a2345d6875efa9ab06fc528_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ce61c0bc144472b7631a9d4df3f9f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5781b4d9f661461796c8363bed666193_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4968cadd8f471d9ce10c3dac04adeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic556fe238be54d7ea1cbe97cfc3b66cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3886328178847949eca5c819b9d1a5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9438636ad1d45ac9d842c540b69c517_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2a6466d039469193ef347cfe3c1115_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb83d5853ca34bfe8b02f1ad840f88e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d45dbab0ab74a33aec9e7b5fc42b546_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3c73811c3a6b413583f19b4f18914422_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec746f5f2a1420e8b4a73e3b14f2911_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f2cab9b1344c4ca4467e441c736d9d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05df3adf0d3445b08cd69ac5d9c78c78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f7c735f7f3a43aab5151e4131cffac0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64ebeef7e4d4fce822fce49568cde02_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd5f6f2356147aaa9c76736d1bbfb27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002a7e38519e40f2946a2312278fcbbf_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66f417c4e0546919bf13f281a215faa_I20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lgnd:right</xbrli:measure></xbrli:unit><xbrli:context id="i5e2203c889594b6d90a943e1d333ba3a_I20100131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b0dfc7fe6b439496e5480f51985a93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefcf79e0add14931bd42a44ad86cb894_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf467e784d54b05975c3202c53c6bd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a9f3d7057749e18b761924cf8ff3cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b989251dff94234ab86b62cbfd1d634_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0edea451a947568476fa7759c97496_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id68885846d2347bdbc1bf3e58a6664b7_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id45ea6b88b7b4ce99056d77dfb9e072a_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba869b10f43242e5b6c4fdd407e85a06_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39c93e649e774e64b8ccfd071af32e96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfcf4342f7f486e81aa9acfe6e847f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cdf88f6a2da48ab9f7072c95808b688_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b43e6ec0024459cad6c7d3d2e8f6e3d_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8918e216e1f459c9ab0ac50491f1cf4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf035009648e4002a74fb15717a19c83_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc3b17ca38f450f93f33b56115ecdac_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbf54fee39c450eaef1dc95742c7f6a_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f6f413f8494ec9b556f99a873dab70_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2353e9253d4a1aa25a32912238e563_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7158892fbf44ed81d8c9568292e404_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569ef336eca149ea8ce1ab7ef2a48105_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib905672f26f34c6ca6ac51ce2c25db59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb8f7f86660458caf621f649275af47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida12bcf9ff53440e84c2633931d5fcca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a6bd9499ad4be8b30f8a074e5a4747_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib762c00218db440eabd64c06b5cbeb17_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b26e3a5c35487591dbea42ea400987_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12906a0a0841439f945d94aff020ae08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e03c8cbe544fe2b60dd5184c74c3fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d572ef2b8494f9fa8c4e977a195c4f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea7a020b78c4b429f74dae393a5908a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74da4f182fe445218f31adabb243815c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7cb20656a8d498d86e9974aeb28d3ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31dbb0c91f244d82be41bfabf480335e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237f75928ac747deb799e5591927eeb2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58de6fecf534ed0a1da850b2cff8a8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44536cfe5ccd4fd58d70bd6fa6a9bbe7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c1d00145a84fc9849e6e8261b1e931_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a84b0ab35142d58562b6af8b4ed5a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a2317a4d4b4c3e918e6cc04ab22e08_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic073f00141a744d8b9364ba86efafc46_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e4954555f1f4c42a396f5d8999d8fa5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c2c62904f340b6aa85bf2c884b4476_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8da33f34df41008bfe20ee259d58b6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f17131fa164971b710daf95103fef2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd93f549e0fa415b9e51a92f0daf7bb7_D20070101-20071231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia580ec3f4bff42659168b12a15f67809_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4bc8d4c0ee94b9dba90c475ab5a47fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4236aad26ee440e0b4e5773018b84e4d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b6ced4e4e74197bd6f08f6e744dd49_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-02</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea99838f3eb4029ace6787bc75b67d4_I20201201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f09740f6734811b4be02fd7bc044ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ab621af16c4274a42e8324d4de973e_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bbacdd5fd54f5989b4a62974637a61_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie261b70fecc64fc3acc322f37f4fbb70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389fb553398f4fb5809d534052c56744_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3839777e750f48b3970c5b559eed73b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3736760d3c7340649ea390cca0ce15fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="acquisition"><xbrli:measure>lgnd:acquisition</xbrli:measure></xbrli:unit><xbrli:context id="ic665f012e5c54711abae64ce09f53a48_D20180101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0213fb27da746f78658b704b667e575_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="pure"><xbrli:measure>lgnd:pure</xbrli:measure></xbrli:unit><xbrli:context id="id7ccafcd4382434aab44acf88304dbff_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937655058f00466eb023f3a052a305a9_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3722684bf7fe44dd891c916f6dafc459_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0825ac3f9e433dbbbf222c70233130_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc05913ba57443492a26d3b59204160_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90111327cda4413486d72b7e169d1885_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203357e791ee4e05a98b8573e4a989e4_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ae29ffee0842cc89e6ee8c5f22ccd8_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0bc7404b304067a3243b8534e113e2_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica518070bfb04532a62ae6496bac0810_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6809a505f14eb48603ff22d2339675_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e4a9163e7b41fe9f7db2ee091c394e_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c5bd0218924d9ba52a0cf66da8376b_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e224ad1e1fc4df0a08700f496a00009_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058f44a298dc4b5cba311ad359517ca8_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386227a58a154f12b0c88d447866796f_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3e28c670344068a7dccc625bd2d1a3_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib636b729155f4a749fd149d8b766cfd7_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightForInternalResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia074696e58a149c1995c46517312190b_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief985e0d5a6e476ca3e8f1deefd76040_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc30f6eb26f47a0a96ce21282bdd8d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be13e965a8f4da5b69ebbcc4a009825_D20200909-20200909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-09</xbrli:startDate><xbrli:endDate>2020-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f1407f97f14a568173adad6da04c53_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145875c08ac643eb987fa42283dc0c10_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:EarnoutRightsForPartnerResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e76f65e64ab4ec5a35fb2b202c36fda_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e1fdefc6b2b422989b6e605a3d10f27_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48f53a633bb468199177a6ba86fca12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15ddfad84344f9092e1706ff640ffc9_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ed9c03cb994049a1d3a5de61dbd7e8_D20200908-20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7604f5c2dda42bcadd9b8697034b298_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23c947370d64bf7b1e94889103679fd_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeed7ae64c0d4c0a83986dde7c9fa1d7_I20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6329bfacc0e46999912decad0f41945_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96dc5cd222804e959a28968aa702662d_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f10778634c436b8efd5b90ec1f5c3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff99e585e3164b03a575580fc0b45900_I20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c19ea46b38444f6b60a4af0f07a64a5_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9013bb387c441fb61e592bae9e466f_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c35816fc7c45c68db42cb9ad26c032_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b31bfa216b54d2e87051f21519216ee_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6c60fab2814867a46699ae1d38afb9_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c70e7e03138499ea135008f92ae636a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b304285ad04468834c9942bcb940c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e787593a0f4a95ae7e6faf6902fb14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0b482524274e4f862807e22f04339d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b897c6c62a4eb0b9c455c2a5e3c9c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d7240c3b2641f7b93fefce9ba43997_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c05d3e8a024a8480cfb6b10bc43054_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066e6e259ad14a0083f5921dcfe54962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0128c7696ac747c0b7cb29daf26b7d23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib655d0debbde4feb93a3f225e8d31237_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8884ec54ac6436b9f6405038ca8d51e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i985674008c3e482dae7633f65d66191f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c24d33a6514e0e90a361e94093f011_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325849b89a604daf9659e7cd5fca620c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8dc920224d41959a40fbf2fb518de0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c7cd32e8b844f784308ca4fe584644_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137c86d7cd6446daa9d2bb7abb2b4ec3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66b0db35db44f8c8369e77da14013ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9b6c6ceb9d7450496a7b9d016f7dbbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c8f26d622543f39f164698f8b83b7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ab0ec6924f4304a39b0bf8f5001c7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a70d84e512248ac9fba2353f9f99a60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1c28bffdd04f8392e2e09f40101997_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia485d5109cc4438e997246e17ebfc4ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8606ca98858540a5963136c5f3cd6569_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98368e7d660497ca20cee33026379c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fc9d0e319d49ed89ca0eebf9f35bff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5029c0e076064d15bcaaa31e3d8187fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f8caf1622a41fa91f4942f87f67bde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac63a2559a74326abe6d930f6accfb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b487fdb37824d4f9ef1a0400ee9dccf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1dd4fca49c48fb9be8bec85e267e45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033d9d285210428ca8efab5d8a1ee24d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539792c492b3485dbdd59cf131d570cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abb3f5f216147b0bc15b06e777edd38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09c77184f6647d4bfadfba8681652ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d368fdfb8cc44779ec8d9c4b178bb55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74f3ffda69b453e9607122edad77fdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100d3ad1f1d043d7ba7a409ef38f47a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92c7c3420a147f186540d32f570459b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bed8cb3b0ed4b978d1785374324f715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0af1caad2ec4bb3b5063b4f40c26520_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3faaf97bade2466badfff2a3a6a9a037_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9480b683b415427882bd5e8708c90123_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044b313dd18245adafea8294b91bf524_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97080b1df6004dca997119afd07fb422_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf5ad2f46ec4ee98ca750ce92cee1c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb7ec904b154a24ac4500272466e24c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3b19e4b35e406ebcd52022bb02eda0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce9786861db4e7cab91a951db9a86ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21553bca1b1431b87f6ef73264c6a08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6055eb2a56ee4de58267511ac1b63e34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d83a1f143a24e3f875bf1146a570289_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078cb5087cab4be7ba5189ff529510ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a273d6b52d4ba48768b5519b0c3665_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3bca9d1ae7450e90354484c1d5f005_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia57d66428a1f493aa864bbf8e827485c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5cf083ca134bf79668ec12b74a240c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfb0ea4403e4557afd920f82e95aaab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5202115d56d44835a5e19d2567442658_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13aae0d9ac5c46eda486f9147f718cc7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35aa47334744f07856c9d53b543fcc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77b8c8ad9a5c4b95bcdd1ef1f93fd6cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945a71f3ec5741968deafb92ba14c4d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic218f09432544a61968a84902b4b6b12_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebb572aba124b47ac39a33fd2538183_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5a9499dd5044ea8aea5a77be53c4ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb7330e33f14407916171e7e0d390c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020a06568fff458680224e0c17f7e1e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd39e73b51b426faf5d3000ec040cab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5f225519564e599eb1b5523a3a9fd0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42909e8f9c30495abe5bb1c928de6828_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546f06ef7f934d938a78d35cc7bd6f13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee3c61a29b7d488e9481564d3568bfc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c7e8aa3d64f4299bb8749e88d06bc86_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37b745566de4dda9b10c642d417c89d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9cc73ea0d9c420c800a11a503944b1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb52bcb659e47438837272f49d907bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e9c330c7d843a6b978f225237f75fe_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>lgnd:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="idf639990efe546a2ae48d957d3513d96_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>lgnd:day</xbrli:measure></xbrli:unit><xbrli:context id="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034232aba8564ecda5fc7d8eb72396d9_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28107efd47144a3abd7964318b557020_D20181231-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f492ad4dfa64cb6b2319778404cfec8_D20181001-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62894ef4375a4892a57a4a49a14e7ac1_D20190815-20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-15</xbrli:startDate><xbrli:endDate>2019-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if187349176e84ceda4964da4edd883be_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eec6b1c21f0498da88860217bd3e1b7_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220b0c6c496e42fc8ea7dccfde48d81d_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35fa90cf89940babbfb526c040370f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18f5551b94641ff880e77978a598895_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a15352b902e4da3bb0205dc843b9a3f_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661dd10b9d474519ba9a2208b86c8de9_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc84240a812d4182830716e5492a75f0_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief51a740808646c0be978c4781f49b06_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323e527963b14f6ab5f0f11b66cf75a8_D20180522-20180619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65069fa42dbc40d2941743d3f4afb5f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i352234f55c94428c9659aebe6d102ea0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c815b5da3a452d8a7e3e5be67a017e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69a1d348c964f9585625ef80a9b7fa8_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50cd7daf68e54877a8d9e082be5523ad_I20210128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350edb2222fc4ac0a3c6507827c9b80d_D20210128-20210128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-28</xbrli:startDate><xbrli:endDate>2021-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2786e1861d4292b0275af1d7b92525_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf28578e57ba441195176b5789f4dde3_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a4018efce8403baff24ddd52876e90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114a6a856e5944a982c509306ce6ccda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3644aaff90b0425b94d88bd354d543ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide70d0b7f442498693f401787562d65e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882b43ad553b45d298444f65918a460d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b17149c809471b94d0d5841711e32b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee918a3da8aa4671b06dc59a2cafc994_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63fcda9c6a804dc59452ea6868c24acd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eea505c815c4979a95d55f6145b57ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d6097c094df4052a9ce95b736093c1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9459b2ffac154d2e998968c36fce5d3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a8ac2029b245f392545bc4eda8d56e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d69bc05694444f0adbc0858ee3a6715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14454ce086d24095ba714d9760e0fb96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f4b58b88f645d89c208af91b28f2cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>lgnd:position</xbrli:measure></xbrli:unit><xbrli:context id="i44a1b1bd10fa49dead7f5c9e02e131de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc43418c7cf4e05b0c7f76c2cc94620_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646d4825dcfe46109944de937f3380eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88bf4f32a33946e492417f9d2dc73c52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453759ea8cff4f2ab3008749a56e3265_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3ae4a6112a4341988947a8a9dd966c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9dc7611933a43fe92197068c75cff82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d307d89e01d4dc1a92c17f8c98db873_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc4e97847f9451da65751e2c293f78c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e81490ee5e44b6f8903898601190850_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14712e5300454f86a3bed5deb1f6d271_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4833f2fd94e489fb8b7467d472e39b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8faf4085074f419d9384b54bc96efbf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1128ec95e7954d9c91d5362eeae281d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6602a2330fa646ef83a50932115be131_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c6ced26abf49119a93a11e832e5a52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2153eb1062134c4caa172f7dd8ec0db3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5666f75fbad04ecc8c0e8a27df194c97_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6283a65f02747708d90a686259eb715_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13b7e192f2c8428f85754de4b57ade3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380589f68b0345c98cb55270231bdd72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3791d21ca45848d09706bba5675782e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f29ffa2d604282aa3977c1329d5123_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6420ef91bf1d4a1bba260796e56a4947_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5fa7210a5ce4cf1a32446731c009ebf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264ffb3aecca43f8bd0831902d08bf27_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24cc2ace08aa413b9bb245ce5edda280_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4db53852ed4656a0f1f7d4738cf64b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b713c7049f465f8770df03d4238b33_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie528dc87bee94f8caf3f8a1e273dd57e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82f7ae16d724ecc956f678166ebf230_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2792a74cce448d9d3e648d7b956be5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42695687f81e405c9d3cdbe7d31e2a8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a106a25b78411482849d23ad9a09e8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc06096f96b64e82ac914c97075da05d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd0e4043c1aa44d99e0496901785ab2b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c0367d73764a1aa9aef7ba6ff77792_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953919e814ac433bba490fdfd486bf52_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40ca45f254145e681e785bbb6305a78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d99a0a13be944d08abee4b0e2287edd_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ccd602f6fa46788dc3ed55853a87b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbaf2eb117fe4ea38353a1add365f4de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2feaed30df5b4d19a7bfe180fab28929_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea3774c1e854faabbb9b9bd56df18b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821fcc2beda34395937a25762f2616bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66de6c8533c64de1b961a16a8db0723a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa8849f70694c158893145638a42fb0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic614e71f57294a5ba7f5c4c3d606053f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7268d74272cc4722ab1c1b9e43253848_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaefa4ff41be4dc6899f87dced50851d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79e2805487e43c19b53a5d41d9eda6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0842e1697e470bbb3fd3777f23811c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28daf0e5db1049f18fd204ea459bc201_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff77d9443603499199481d702061cfc3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69928414acf4456c871c5c27e2b76219_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if56ecb42bfb845cdbf6b43bfa81634cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd51de929754bda9511cd8c27350601_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1115896595ee46f58722433b8bebfcc6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b624942505415386809d9280250f36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c71624a82f425e97a2dd558100c435_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26da0a13ba874bfeb0373d75e17b5d4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0398cc7bf5994c79a7c821c2a8c34c80_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304f82f2dad244e382a657b3d676fb43_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931b931a1abf45438f4f158f651d36c0_I20190123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e34e1285b384e0d8ee4bc840f707708_I20190911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ab16e1f7dff4858bc4003f7815ab55f_D20190911-20190911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-11</xbrli:startDate><xbrli:endDate>2019-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lgnd:patent</xbrli:measure></xbrli:unit><xbrli:context id="i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:LupinPatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="civil_complaint"><xbrli:measure>lgnd:civil_complaint</xbrli:measure></xbrli:unit><xbrli:context id="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338fe8a7f9a14546aadd061a86a8794a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9dac967dc794fbabfc9e438958fbe78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7f6ee2f38047f4bf987be2ec85087b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cb5a20013b480c8b516e20e1aace66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df4a7ca341f4c80b8357649cb1d8155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7d29ba6dd34ca2ac02b4e24d20ead9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0176de2e50c3447c864e3818f9715431_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00351799e1f0421bb7f825c963509503_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55d7c252e32432b8ac5deb25dbbe252_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib69a1c25a15148f9b95ad6e3392de608_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzE2_5a5bbb9e-bff3-4770-9414-585cc268bb0e">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6ZmUxMjRhYWU2NDNiNDMyMmEzMDA3YWY5ZTJmMWQ0YjUvdGFibGVyYW5nZTpmZTEyNGFhZTY0M2I0MzIyYTMwMDdhZjllMmYxZDRiNV8wLTAtMS0xLTA_ec834805-a5aa-407b-aa2e-0068e4eee58c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yMTk5MDIzMjU5Mjky_99427b2b-5b61-467f-9de6-8cd2da7e17de">December 31, 2020</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:2.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6NTUyNTg1NGVhNTFjNDIxMzhlYjczMWUzNzAzMDczYWQvdGFibGVyYW5nZTo1NTI1ODU0ZWE1MWM0MjEzOGViNzMxZTM3MDMwNzNhZF8wLTAtMS0xLTA_18a554a6-f859-4801-ae19-eee306885d71">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEw_b36f2c84-2cd3-475d-b227-720efc5645d7">001-33093</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><img src="lgnd-20201231_g1.jpg" alt="lgnd-20201231_g1.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEx_aa6986c9-38a0-4a21-873b-60ddad41aa5a">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8wLTAtMS0xLTA_f6d0281d-0d31-4ff2-9038-a1469b1e1d4a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8wLTItMS0xLTA_5916388d-4bec-4ea9-98ec-976591d8d202">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8zLTAtMS0xLTA_8f1f08f0-c811-42d5-9c3c-bfac7587273f">3911 Sorrento Valley Boulevard, Suite 110</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl80LTAtMS0xLTA_83f7a559-6bb0-4ee5-bbbd-2b9c7b88d639">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl81LTAtMS0xLTA_61fef456-386a-4c91-be92-cb60bf987e5f">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl81LTItMS0xLTA_f324b9af-053d-4d2d-bfb4-208953247104">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEy_26f5bfd4-eda1-4b80-9e0d-94c081b55386">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEz_da08a50d-7b91-409d-9167-9f3ff17eac38">550-7500</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:36.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTAtMS0xLTA_a1ff2250-054d-4751-8700-021e7a19b2c8">Common Stock, par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTEtMS0xLTA_4b8678c3-3e35-4510-acd3-0cdd51c2e76e">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTItMS0xLTA_d9046087-418b-4370-b8c5-aa0e4e41156d">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA5_5befc269-3a1a-4815-94cc-c8bc777a5cd0">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA1_95593080-d159-432c-b0bf-db5ff1d4973b">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ndicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzE0_531345ea-7c2d-4827-addd-f7510f793ac9">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA2_18481c53-628f-4348-9be9-c342940c8a44">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTAtMS0xLTA_3e6110d0-1003-46f0-b02b-7a7482062423">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;Filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;Filer&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTgtMS0xLTA_c646c22b-40a1-4629-aede-5b48218ff9a1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTEwLTEtMS0w_c6407533-0de7-48e0-9a18-f8f0cef6b3ad">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yMTk5MDIzMjU5NjY0_fc9745ee-2bfd-43ae-a647-d6b232a935ce">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA3_b7a17849-2cbd-47a8-aeb7-a34166f35a11">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant&#8217;s voting and non-voting stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="id5ad18ea90a54b5b8bba0e1555ad9875_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yNTY2_59f549c6-f46c-4a9f-bf2b-28cd50565ff6">1.2</ix:nonFraction> billion based on the last sales price of the Registrant&#8217;s Common Stock on the Nasdaq Global Market of the Nasdaq Stock Market LLC on June&#160;30, 2020. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;18, 2021, the Registrant had <ix:nonFraction unitRef="shares" contextRef="idd5c9735b7574d1eb48ed78ec5db3eb5_I20210218" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zMTc5_f100cf77-6284-4fd7-ab30-9a9605e5e2c3">16,612,422</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the Registrant&#8217;s 2021 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2020 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_7"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_16">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_19">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_22">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_25">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_28">40</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_34">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_37">Selected Consolidated Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_37">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_40">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_52">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_52">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_55">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_55">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_133">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_133">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_136">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_136">97</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_145">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_145">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_148">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_148">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_151">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_151">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_154">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_154">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_157">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_157">100</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_163">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_163">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_166">Form 10-K - Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_163">101</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_169">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_169">106</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:24pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GLOSSARY OF TERMS AND ABBREVIATIONS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviation</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$245.0 million aggregate principal amount of convertible senior unsecured notes due 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$750.0 million aggregate principal amount of convertible senior unsecured notes due 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AAALAC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accreditation of Laboratory Animal Care International</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ab Initio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ab Initio Biotherapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Abvivo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Abvivo, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ACOVA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ACOVA, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ADHF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute decompensated heart failure</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Aldeyra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Aldeyra Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amended Interest Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ANDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">API</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active pharmaceutical ingredient</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aptevo Therapeutics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arcus </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arcus Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASCO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">American Society of Clinical Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASCT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Autologous Stem Cell Transplantation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aurobindo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aurobindo Pharma Ltd</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo Med, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter International, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene Switzerland GmbH</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx Corp.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bexson Biomedical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bexson Biomedical, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biologics license application</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CStone Pharmaceuticals (Suzhou) Co., Ltd. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardioxyl</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardioxyl Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CI-AKI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contrast-induced acute kidney injury</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Code of Conduct</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Code of Conduct and Ethics Policy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherus Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition of Matter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Note</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Convertible Promissory Note</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COPD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix Cardiovascular, Inc. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix Asset Sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset sale from CorMatrix to Aziyo</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COSO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Committee of Sponsoring Organizations of the Treadway Commission</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CRO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Research Organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystal Bioscience, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cumulus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cumulus Oncology, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CVR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent value right</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo Company, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dianomi Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DMF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Master File</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental, Social and Governance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eli Lilly</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extracellular matrix</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental Protection Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan, as amended and restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FSGS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Focal segmental glomerulosclerosis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Generally accepted accounting principles in the United States</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GBM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Glioblastoma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genagon</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genagon Therapeutics AB</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GCSF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulocyte-colony stimulating factor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GigaGen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GigaGen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GPCR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">G-protein coupled receptor</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GRA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Glucagon receptor antagonist </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HanAll</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HanAll Biopharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Harbour BioMed Shanghai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HBV</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hepatitis B Virus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HCC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hepatocellular Carcinoma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma Pharmaceuticals PLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HNO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nitroxyl</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hovione</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hovione FarmCiencia, S.A.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Icagen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-Process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRAK4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interleukin-1 Receptor Associated Kinase-4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iMBP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iMetabolic Biopharma Corporation </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunovant Sciences GmbH</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kira Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kira Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KSQ Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KSQ Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liver targeting prodrug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lundbeck A/S</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mineral Coated Microparticle</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., Inc.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merrimack</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merrimack Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metavant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Metavant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Millennium</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Millennium Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MLA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master License Agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MRSA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methicillin-resistant Staphylococcus aureu</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NASH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-alcoholic steatohepatitis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOLs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Open Monoclonal Technology, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orange Book</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Publication identifying drug products approved by the FDA based on safety and effectiveness</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Original Interest Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Par Pharmaceutical, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PFS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Progression-free Survival</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacopeia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacopeia, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue Repair</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">PhoreMost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">PhoreMost Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-Partum Depression</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roivant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roivant Sciences GMBH</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selective Androgen Receptor Modulator</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor Pharmaceuticals, Inc., or RODES, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis, SA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix Pharmaceuticals, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SII</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serum Institute of India</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda Pharmaceuticals Company Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Talem </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Talem Therapeutics LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taurus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taurus Biosciences LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Act</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Tax Cuts and Jobs Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Actavis, LLC </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TG Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TG Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR-Beta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thyroid hormone receptor beta</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Valanbio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Valanbio Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VDP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis Design Platform</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VentiRx Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis plc</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona Pharma plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking Therapeutics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vireo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vireo Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi Biologics Ireland Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WuXi Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Platform License Agreement, dated March 23, 2015, by and between Ligand and WuXi, as amended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong Medicine Research</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X-ALD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X-linked adrenoleukodystrophy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">xCella Biosciences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">xCella Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila Healthcare, Ltd</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_13"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position, royalties and milestones under license agreements, Captisol material sales, product development, and product regulatory filings and approvals, and the timing thereof, as well as other statements that are not historical. You should be aware that the occurrence of any of the events discussed under the caption &#8220;Risk Factors&#8221; could negatively affect our results of operations and financial condition and the trading price of our stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Ligand Pharmaceuticals Incorporated,&#8221; &#8220;Ligand,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Partner Information</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding partnered products and programs comes from information publicly released by our partners and licensees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trademarks</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our trademarks, trade names and service marks referenced herein include Ligand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LTP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LTP Technology&#8482;, OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OmniMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OmniRat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OmniFlic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OmniClic&#8482;, OmniChicken</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, xCella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, xCella Biosciences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, xPloration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Icagen&#8482;, Pfenex Expression Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and XRPro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which are protected under applicable intellectual property laws and are our property. All other trademarks, trade names and service marks including Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Livogiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Zulresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Minnebro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Baxdela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Carnexiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Conbriza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and Duavee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, &#8482; or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to such trademarks, trade names and service marks. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We employ research technologies such as antibody discovery technologies, ion channel discovery technology, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas fluorescens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein expression technology, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. We currently have partnerships and license agreements with over 130 pharmaceutical and biotechnology companies. Over 300 programs are in various stages of commercialization, development or research and are fully funded by our collaboration partners and licensees. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and postpartum depression, among others. Our collaboration partners and licensees have programs currently in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. We have over 1,400 issued patents worldwide.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies. Fully-funded programs, which we refer to as "shots on goal," are those for which our partners pay all of the development and commercialization costs. For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept and then seek partners to continue development and potential commercialization.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. We believe that focusing on discovery and early-stage drug development while benefiting from our partners&#8217; development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of three primary elements: royalties from commercialized products, sale of Captisol material, and contract revenue from license, milestone and other service payments. In addition to discovering and developing our own proprietary drugs, we selectively pursue acquisitions to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see impact of COVID-19 pandemic described in Item 8. Consolidated Financial Statements -Note 1, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. For additional information on the various risks posed by COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">2020 and Recent Major Business Highlights</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Transactions and Strategic Investments</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our business model, we pursued novel investments to augment our technology platforms and assets.  </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we closed the acquisition of the core assets, partnered programs and ion channel technology from Icagen for $15.1 million in cash. Icagen will also be entitled to receive up to an additional contingent earn-out payment of $25 million based on certain revenue achievements. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we acquired two privately held companies that strengthen and complement our OmniAb platform's technology stack. We acquired xCella Biosciences, Inc. for $7.1 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5.1 million in cash plus non-transferable CVRs. In addition, we invested $2.5 million in a new company, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minotaur Therapeutics, which is led by Taurus Biosciences&#8217; founder, in exchange for royalties on products from future programs.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we acquired Pfenex Inc. including its proprietary protein expression technology and existing collaboration contracts with Jazz Pharmaceuticals, Merck, Serum Institute of India and Alvogen, each of which has the potential to pay royalties. In October 2020, our partner Merck announced additional positive data from two Phase 3 studies with V114, which uses the protein expression technology, evaluating the safety, tolerability and immunogenicity of the investigational 15-valent pneumococcal conjugate vaccine. In November 2020, Merck announced they had submitted applications to the U.S. FDA and European Medicines Agency (EMA) for licensure of V114 for use in adults 18 years of age and older. Merck announced on January 12, 2021 that FDA accepted the BLA for V114 for priority review with a Prescription Drug User Fee Act (PDUFA) date of July 18, 2021. In December 2020, Jazz Pharmaceuticals initiated the submission of a BLA to the FDA seeking market approval for JZP-458, which is a recombinant Erwinia asparaginase produced using the protein expression platform that has resulted in a robust process showing manufacturing consistency and efficiency. The BLA was initiated and will be reviewed under the Real-Time Oncology Review (RTOR) pilot program, an initiative of the FDA's Oncology Center of Excellence designed to expedite the delivery of safe and effective cancer treatments to patients.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we sold the Vernalis research operations and internal programs to HitGen Inc. for $26.7&#160;million in cash. Under the terms of the agreement, we retained economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate and Governance Highlights</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to policies and practices focused on environmental sustainability, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on such ESG policies and practices, we believe we can affect a meaningful and positive change in our community and maintain our open, collaborative corporate culture. We will continue our proactive shareholder and employee engagement in 2021.  See www.ligand.com for information about our ESG policies and practices.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">OmniAb Technology Platform Updates</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to invest in and expand the OmniAb Technology platform. We entered into four new OmniAb platform license agreements in 2020 with Pandion Therapeutics, Adept Therapeutics, The Wistar Institute and RubrYc Therapeutics.  In addition to the four platform license deals completed in 2020, we estimate that we and our partners initiated over 50 new programs in 2020.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our scientists and our partners presented data highlighting the utility of the OmniAb platform at multiple conferences throughout the year, and we published multiple papers in peer-reviewed journals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development-stage OmniAb partners continue to report progress clinically; notable advancements include:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen presented safety and response data of the OmniAb-derived teclistamab (anti-BCMA x CD3 T cell redirecting bispecific antibody) Phase 1 dose escalation trial for relapsed/refractory multiple myeloma at the 2020 American Society for Hematology (ASH) conference. Teclistamab showed a manageable safety profile with an overall response rate (ORR) of 73 percent (16/22) at the recommended subcutaneous (SC) Phase 2 dose. In addition, updated results for the intravenous formulation demonstrate the durability of responses. Janssen announced that it has chosen the recommended Phase 2 dose for the SC formulation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gloria Biosciences submitted an application for marketing approval in China for OmniAb-derived zimberelimab for the treatment of classical Hodgkin lymphoma, marking multiple OmniAb drug applications filed seeking approval.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arcus Biosciences and Taiho Pharmaceutical announced Taiho&#8217;s exercise of its option for an exclusive license to zimberelimab (also known as AB122) for Japan and other Asian countries, excluding China.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CStone announced an agreement to out-license ex-Greater China rights for sugemalimab (CStone licensed worldwide rights from our licensee WuXi) and CS1003 (anti-PD-1) to EQRx. Under the terms of the agreement, CStone will receive an upfront payment of $150 million and is eligible to receive up to $1.15 billion in milestone payments as well as separate tiered royalties. EQRx will obtain exclusive rights to lead development and commercialization worldwide, excluding certain territories in Asia. In October 2020, CStone entered into a major partnership with Pfizer for the commercialization of sugemalimab in greater China. As part of the partnership, Pfizer invested $200 million in CStone shares, and CStone is eligible to receive up to $280 million in milestone payments and additional royalties.  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CStone announced that China&#8217;s National Medical Products Administration accepted CStone&#8217;s New Drug Application for sugemalimab combined with chemotherapy for the first-line treatment of advanced squamous and non-squamous </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-small cell lung cancer (NSCLC). CStone previously announced updated results from two clinical studies of sugemalimab at the 2020 Chinese Society of Clinical Oncology Annual Meeting and announced that sugemalimab met the primary endpoint as first-line treatment in stage IV squamous and non-squamous NSCLC. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CStone and Blueprint Medicines initiated a Phase 1b/2 clinical trial of fisogatinib in combination with OmniAb-derived CS1001 for patients with hepatocellular carcinoma. CStone announced the first patient was dosed in a proof-of-concept study of OmniAb-derived CS1001 in combination with Bayer's regorafenib in patients with advanced solid tumors.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aptevo announced two complete remissions in the ongoing APVO436 Phase 1/1b clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Preliminary data indicating that OmniAb-derived APVO436 was well tolerated with a manageable safety profile were presented at the 2020 ASH conference.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Immunovant announced positive results from its Phase 2a proof-of-concept study of OmniAb-derived IMVT-1401 (also known as batoclimab, HL161, or HBM9161) in thyroid eye disease. IMVT-1401 is a novel investigational anti-FcRn antibody delivered by subcutaneous injection. The results showed a 65% mean reduction in total IgG observed from baseline to end of treatment, with a pharmacodynamic response nearly identical to modeled predictions for the dosing regimen tested in the trial. In February 2021, Immunovant announced a voluntary pause in its ongoing clinical trials of IMVT-1401 due to elevated total cholesterol and LDL levels in Phase 2b trial of thyroid eye disease.  Immunovant announced that it plans to continue development of IMVT-1401 following discussions with regulators and protocol modifications. In addition, Immunovant announced positive topline results from a multicenter, placebo-controlled Phase 2a trial (ASCEND MG) of IMVT-1401, in patients with myasthenia gravis (MG). </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">Harbour announced first patient dosing of Phase 1b/2a study of Batoclimab for treating neuromyelitis optica spectrum disorder. On January 27, 2021 Harbour announced that China Center for Drug Evaluation granted Breakthrough Therapy designation to Batoclimab for the treatment of adult patients with MG. This designation indicates that the development and review of Batoclimab in adults with MG will be expedited.  </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol Technology Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Captisol business unit achieved its highest sales ever in 2020 and we anticipate substantial continued demand for Captisol. We are investing to significantly expand annual manufacturing capacity for Captisol. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead utilizes Captisol to solubilize the active ingredient for Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(remdesivir), the first FDA approved anti-viral treatment for severe COVID-19. The drug has now been authorized or approved for use in numerous countries around the world. Gilead announced the formation of a consortium of generic pharmaceutical companies to manufacture remdesivir for the developing world. We have supplied, established initial agreements or are in supply discussions with those companies, and are prepared to meet the Captisol needs of all companies manufacturing remdesivir as well as the needs from our other Captisol partners.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made the decision to conduct a Phase 2 trial for Captisol-enabled Iohexol  that we believe could serve as the basis for potential registration of the product candidate. CE-Iohexol is an iodine-based contrast agent for hospital-based imaging procedures. The market for iodinated contrast agents is substantial, with approximately 20 million imaging procedures per year in the U.S., representing an estimated $1.5 billion in sales. The objective of the CE-Iohexol clinical trial will be to demonstrate a reduction in the incidence of contrast-induced acute kidney injury and an equivalent image quality compared to GE&#8217;s Omnipaque</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vernalis Design Platform (VDP) Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December  2020, we sold our Vernalis research operations and internal programs to HitGen Inc. for $26.7 million in cash. Under the terms of the agreement, we retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. We continued to expand our portfolio of VDP-derived partnerships during 2020, prior to the sale. Notable VDP developments include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We entered into an exclusive worldwide license agreement with Neuritek Therapeutics to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform. Neuritek plans to develop V158866 for post-traumatic stress disorder and other CNS diseases. Under the terms of the agreement, we received an upfront license fee and are eligible to receive over $240 million in milestones and tiered royalties on net sales of six to eight percent. Neuritek has secured approximately $27 million in a capital commitment from GEM Global Yield LLC SCS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2021, Verona Pharma announced ensifentrine delivered by a pressurized metered-dose inhaler (pMDI) met all of the primary and secondary lung function endpoints in the 7 day, Phase 2 clinical trial in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The magnitude of improvement in lung function was dose-ordered and highly statistically significant at peak and over the 12-hour dosing interval compared with placebo, and supports twice-daily dosing of ensifentrine via pMDI for the treatment of COPD. Verona is evaluating nebulized ensifentrine in the pivotal Phase 3 ENHANCE-1 and 2 clinical trials for COPD maintenance treatment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Icagen Technology Platform Updates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance partnership programs following our 2020 acquisition of the core assets from Icagen Inc. The following developments occurred in 2020:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May of 2020 we expanded our license with Roche by adding a second program to our agreement initiated in December 2018. This new program incorporates Icagen&#8217;s ion channel technology and is directed at a specific ion channel target relevant to neurodegenerative disease. Roche made a cash upfront payment and provides research funding to Icagen for this second program. In addition, Icagen is eligible to receive development and commercialization milestones up to $274 million for each program and royalty payments should a drug be commercialized from any of the collaboration&#8217;s programs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2020, we signed a collaboration agreement with GlaxoSmithKline to identify and develop inhibitors of specific genetically-validated molecular targets relevant to neurological diseases. Under the terms of this agreement we received an upfront payment of $7 million and could receive development, regulatory and commercialization milestones up to $155 million. We will also receive tiered royalties on net sales should any drug from the collaboration be commercialized.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to advance other programs including our collaboration with the Cystic Fibrosis Foundation targeting nonsense suppression as well as multiple internal programs which potentially offer future partnering opportunities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Business Updates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, our partner, Travere, announced that sparsentan achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) in the DUPLEX study after 36 weeks of treatment. Sparsentan demonstrated a statistically significant response on FPRE compared to the active control, irbesartan (p=0.0094). Preliminary results from the interim analysis suggest that sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. Based on the data from the interim analysis, Travere intends to pursue submissions for accelerated approval of sparsentan for FSGS in the second half of 2021. In January the FDA granted sparsentan Orphan Drug Designation for the treatment of IgA nephropathy, and on February 18, 2021, Travere announced the European Commission (EC) had granted orphan designation to sparsentan for the treatment of IgA nephropathy. Topline efficacy data from the ongoing pivotal Phase 3 PROTECT Study in IgA nephropathy, and the 36-week interim proteinuria endpoint analysis, are anticipated in the third quarter of 2021.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of technology platforms that enable elements of drug discovery or development form the basis of our portfolio of fully-funded shots on goal. Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 1,400 patents issued worldwide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OmniAb antibody discovery platform provides our biopharmaceutical industry partners access to the most advanced antibody repertoires and state-of-the-art screening technologies to enable efficient discovery of next-generation novel therapeutics and to deliver the highest quality therapeutic antibody candidates for a wide range of human diseases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the heart of the OmniAb Technology Stack is the Biological Intelligence&#8482; (BI) of our proprietary and validated transgenic animals, including OmniRat, OmniChicken and OmniMouse, each capable of generating high quality fully human antibodies that have been optimized naturally through in vivo affinity maturation. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. Our transgenic animals comprise the most diverse host systems available in the industry and they are optimally leveraged within the OmniAb Technology Stack through AI-enhanced antigen design and immunization methods, paired with high-throughput and microfluidic-based single B cell </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. The OmniAb stack of technologies and differentiating AI and BI features have been combined to offer a highly efficient, scalable and customizable solution for the growing antibody discovery needs of the global biopharmaceutical industry.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the technologies in the OmniAb technology stack through the acquisition of OMT in January 2016, Crystal in October 2017, Ab Initio in July 2019, xCella Biosciences in September 2020 and Taurus Biosciences in September 2020. As of December 31, 2020, we had entered into OmniAb platform license agreements with more than 40 collaboration partners, including 7 partners who have rights through our partnership with WuXi. Our OmniAb partners were working on approximately 170 active programs, of which 15 were in various stages of clinical trials as of December 31, 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol Technology</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas&#8217; Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Gilead&#8217;s Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Amgen&#8217;s Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Baxter International&#8217;s Nexterone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Acrotech Biopharma L.L.C.&#8217;s and CASI Pharmaceuticals&#8217; Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Melinta Therapeutics&#8217; Baxdela&#8482; and Sage Therapeutics&#8217; Zulresso&#8482;. There are many Captisol-enabled products currently in various stages of development. We maintain a broad global patent portfolio for Captisol with more than 400 issued patents worldwide relating to the technology (including over 40 in the U.S.) and with the latest expiration date in 2033. Other patent applications covering methods of making Captisol, if issued, extend to 2040.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to solid Captisol powder, we offer our partners access to cGMP manufactured aqueous Captisol concentrate. This product offering was established in 2017 to reduce cycle time and increase Captisol production capacity for large volume drug products. We maintain both Type IV and Type V DMFs with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. We also have active DMFs in Japan, China and Canada. As of December 31, 2020, Captisol-enabled drugs were being marketed in more than 70 countries, and over 50 partners had Captisol-enabled drugs in development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protein Expression Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Protein Expression Technology Platform is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well-suited for complex, large-scale protein production where traditional systems are not suitable. Multiple global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for numerous commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increasing structural complexities, the Protein Expression Technology Platform is well positioned to meet these growing needs as the most comprehensive broadly available protein production platform in the industry.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Protein Expression Technology through our acquisition of Pfenex in October 2020. Former stockholders of Pfenex received a CVR which would result in payment if FDA determines that teriparatide injection (also referred to as PF708 or Bonsity) is therapeutically equivalent (as will be indicated by assignment of a therapeutic equivalence code that begins with an &#8220;A&#8221; in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations) with respect to the listed product, FORTEO&#174; (teriparatide injection). We estimate that up to an additional $77.8 million in the aggregate will be payable to holders of the CVRs in the event that the CVR payment milestone is timely achieved. As of December 31, 2020, we have agreements with 15 partners for active research collaboration using this technology on more than 25 active programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Technology Platform</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Icagen Technology Platform is a novel drug discovery platform which uses primarily ion channels and transporters which are key components in a wide variety of biological processes that involve rapid changes in cells and we believe have broad therapeutic applicability including cancer, metabolic disease, pain, neurological diseases, infectious diseases and others. The Icagen Technology Platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and computational chemistry applications. Partners in the pharmaceutical industry have leveraged our platform to develop therapeutic candidates to address unmet medical needs. We typically work closely with our partners through therapeutic candidate selection and, our partners are typically responsible for clinical development and commercialization. Our Icagen Technology Platform collaboration agreements typically include developmental milestone payments and royalties based on the net sales of any commercialized therapies. Royalties range from low to high single digits. The royalty terms typically expire upon the last to expire patents on a product-by-product basis.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the Icagen Technology Platform through our acquisition of the core assets of Icagen in April 2020 for $15.1 million in cash. Icagen is entitled to receive up to an additional $25.0 million based on certain revenue achievements. As of December 31, 2020, we have agreements with seven partners for active research collaboration using this technology on a total of 10 active programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HepDirect/LTP Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HepDirect platform is a first generation liver-targeting prodrug technology designed to deliver certain phosphorus-containing drugs to the liver by using a proprietary chemical modification that renders an API biologically inactive until cleaved by a liver-specific enzyme. The HepDirect&#8482; technology may improve the efficacy and/or safety of certain drugs and can be applied to marketed or new drug products to treat liver diseases or diseases caused by hemostasis imbalance of circulating molecules controlled by the liver.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LTP platform is a broad second generation liver-targeting prodrug technology that has an activation mechanism similar to HepDirect but with broader applications and many improved features. The proprietary chemical modifications can be used with many chemical classes of drugs in addition to phosphorus-containing compounds and have multiple chemistry strategies, designed to improve flexibility and success rates.  In addition, the second generation technology eliminates the undesirable by-products released during activation of the first generation prodrugs. As of December 31, 2020, we had active HepDirect/LTP programs with three partners, using this technology across five programs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SUREtechnology Platform (owned by Selexis)</span></div><div style="margin-bottom:6pt;text-indent:26.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired economic rights to various SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform programs from Selexis. The SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs. As of December 31, 2020, we are entitled to certain economic rights to SUREtechnology Platform license agreements with 12 partners developing or having commercialized 20 programs.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Partners and Licensees</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have partnerships and license agreements with over 130 pharmaceutical and biotechnology companies. In addition to the table below, we also have more than 10 undisclosed partners and licensees.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Big Pharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biotech</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biotech, continued</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbott</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABT</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABBA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEIP</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABBV</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABL Bio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298380</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abvivo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adept</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian Labs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boehringer Ingelheim</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALDX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metavant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daiichi Sankyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DSKY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merrimack</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LLY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anebulo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603707</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4523</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APVO</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuritek</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOVN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RCUS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novogen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NVGN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAZZ</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3407</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ascella </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncternal</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck KGaA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRK.DE</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BendaRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OnKure</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NVS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bexson Biomedical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPT</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4528</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cantex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlook</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTLK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4768</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRVS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFE</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR Double-Crane</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600062</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAND</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RHHBY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2616.HK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biologics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4502</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Electra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protagonist</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTGX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEVA</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revision </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty Pharma</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXEL</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RubrYc</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech (Aurobindo)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUROPHARMA</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FRPX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldevron</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seagen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGEN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aytu Bioscience</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AYTU</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genmab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GEN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEEL</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZYO</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genagon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Servier</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beloteca</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genekey Biotech</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Inst. of India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech (Roche)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RHHBY</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Softkemo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genovac</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CTI Biopharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CTIC</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GigaGen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talem</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ferring</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILD</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2437</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordian</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TG Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TGTX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUN</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HanAll</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9420</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tizona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2142</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TVTX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Generium</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tremeau</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SQ Innovation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ichnos</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UBX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vireo Health</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VREOF</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iMetabolic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valanbio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMVT</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Generics</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional Analgesix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vega</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J-Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VenBio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apotex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioCad</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kangchen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRNA</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gedeon Richter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GEDSF</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VKTX</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hikma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIK</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KSQ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virtuoso</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTRS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRNS</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WuXi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603259</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CADILAHC</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhilkang Hongyi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Clinical Stage Partnered Portfolio</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a large portfolio of current and future potential revenue-generating programs, including over 300 fully-funded by our partners. In addition to the table below, we also have more than 100 undisclosed preclinical programs.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Adalvo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Hikma/Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voriconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen/Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aytu</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tuzistra</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECM portfolio</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device/Cardiology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biocad</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teberif</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis/Daiichi-Sankyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnebro</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lundbeck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carnexiv</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frovatriptan</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noxafil-IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Posaconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viviant/Conbriza</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vfend-IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sesquient</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivitra</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryxta/ZyBev</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exemptia</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vortuxi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3/Pivotal or Regulatory Submission Stage</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biocad</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCD-066</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Disorders</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugemalimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimberelimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Generium</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GNR-008</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JZP-458</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganaxalone IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V114</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mekinist (CE-Trametinib)</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlook Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONS-5010</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sutimlimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood Disorders</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Fosphenytoin</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRM197</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilazodone</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pevonedistat</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparsentan</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Respiratory Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimberelimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cantex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CX-01</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CTI Biopharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tosedostat</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elevation Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seribantumab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FYCOMPA</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genmab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gen1046</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harbour</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batoclimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunovant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batoclimab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teclistimab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J-Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPH-203</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M6620</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRM197</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECF843</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPT-302</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biologics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPC-1C</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplindore</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VentiRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motolimod</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK5211</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK2809</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK0214</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK0612</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG-330</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apotex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meloxicam</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Migraine</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aptevo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APVO436</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROR</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gedeon Richter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bevacizumab</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genmab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gen1046</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ-67371244</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JNJ-70218902</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter Bioscience</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viright</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M6233</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIK-665</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCL-201</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTR-01</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protagonist Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTG300</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hematology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revision Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rev0100</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Servier</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S55746/S64315</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symphogen/Servier</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYM022/SYM023/SYM024/SYM025</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-020</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-925</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe and Rare</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-243</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanopatch</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VentiRx Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTX-1463</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Commercial Programs</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple programs under license with other companies that have products that are already being commercialized. The following programs represent components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue. For information about the royalties owed to us for these programs, see &#8220;Royalties&#8221; later in this business section.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Kyprolis (Amgen)</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Amgen for use with Kyprolis (carfilzomib), and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand&#8217;s Captisol technology and is approved in the United States for the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:24.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.085%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" rowspan="5" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Kyprolis is also approved in multiple countries outside the U.S. and Amgen continues to invest significantly in Kyprolis to further expand its label and geography. Amgen&#8217;s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol. Our patents and applications relating to the Captisol component of Kyprolis are not expected to expire until 2033. </span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kyprolis (Amgen)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $250 million</span></td><td colspan="3" style="border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 to $500 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-right:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veklury&#174; (Gilead)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Gilead for sales of Veklury&#174; (remdesivir).  Gilead received marketing approval in the US in October 2020.  Veklury is the first and only antiviral treatment of Covid-19 that is FDA approved. The product has regulatory approvals for the treatment of moderate or severe COVID-19 in over 50 countries and is included in more than 30 ongoing clinical trials.  We are supplying Captisol to Gilead under a recently signed 10-year supply agreement.  We are also supplying Captisol to Gilead&#8217;s voluntary licensing generic partners who are manufacturing remdesivir for 127 low- and middle-income countries.  We receive our commercial compensation for this program through the sale of Captisol.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Teriparatide Injection Product (PF708) (Alvogen/Adalvo)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Teriparatide Injection product with the acquisition of Pfenex Inc. in October 2020. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Teriparatide Injection was developed using our Protein Expression Technology and was approved by the FDA in 2019 in accordance with the 505(b)(2) regulatory pathway, with FORTEO as the reference product. Our partner, Alvogen launched the product in June 2020 in the United States.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., PF708 received marketing authorization throughout the European Union in August 2020 under the tradename Livogiva&#174;, was approved in Saudi Arabia in December 2020 under the name Bonteo, and  is in various stages of regulatory and marketing application processes around the globe and, upon approval, may be marketed as Teriparatide Injection or under various tradenames, such as Bonsity&#174; or Livogiva&#174;. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Alvogen has exclusively licensed the rights to commercialize and manufacture the teriparatide injection product in the United States, while their Adalvo business has the rights to commercialize in the European Union (EU), certain countries in the Middle East and North Africa (MENA), and the rest of world (ROW) territories (the latter defined as all countries outside of the EU, US and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). Kangchen has exclusively licensed to commercialize PF708, upon receipt of applicable marketing authorizations, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and granted a non-exclusive right to conduct development activities in such countries with respect to PF708. Kangchen is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in these countries.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our agreements with Alvogen/Adlavo, we are eligible to receive additional payments of up to $9.0 million based on the achievement of certain development, regulatory, and sales-related milestones.  In addition, we may be eligible to receive tiered royalties on net sales between 25% and 40% prior to an &#8220;A&#8221; therapeutic equivalence designation, which increases to a flat 50% if an &#8220;A&#8221; rating is achieved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our EU, MENA and ROW agreements with Alvogen&#8217;s Adalvo subsidiary, we may be eligible to receive additional upfront and milestone payments of $1.5 million and may also be eligible to receive up to 60% of Alvogen&#8217;s gross profit derived from product sales and regional license fees, if approved, depending on geography, cost of goods sold and sublicense fees.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our agreement with Kangchen, we may be eligible to receive additional payments of up to $22.5 million upon the achievement of certain development, regulatory, and sales-related milestones. We may be eligible to receive double-digit royalties on any net sales of PF708 in Kangchen&#8217;s territory. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evomela (Acrotech and CASI)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Acrotech Biopharma for sales of Evomela in the U.S. and to CASI Pharmaceuticals for sales of Evomela in China. Evomela received market approval by the China National Medical Products Administration (NMPA). It is the only approved and commercially available melphalan product in China. Evomela is a Captisol-enabled melphalan IV formulation which is approved by the FDA for use in two indications:</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A high-dose conditioning treatment prior to ASCT in patients with multiple myeloma. </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China and CASI Pharmaceuticals has rights to market in China. We are eligible to receive over $50 million in potential milestone payments under this agreement and royalties on global net sales of the Captisol-enabled melphalan product. Acrotech and CASI&#8217;s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event within ten years of the commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. The agreement may be terminated by either party for an uncured material breach or unilaterally by Acrotech and CASI by prior written notice.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nexterone (Baxter)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement. Under the terms of the license agreement we will continue to earn milestone payments, royalties, and revenue from Captisol material sales. We are entitled to earn royalties on sales of Nexterone through early 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zulresso (SAGE)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with SAGE, related to SAGE's Zulresso, a Captisol-enabled formulation of brexanolone for the treatment of PPD. Under the terms of the agreement, we receive royalties and revenue from Captisol material sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noxafil-IV (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with Merck related to Merck&#8217;s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use. NOXAFIL-IV is marketed in the United States, EU and Canada. We receive our commercial compensation for this program through the sale of Captisol, and we do not receive a royalty on this program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is marketing bazedoxifene, a selective estrogen receptor modulator, under the brand names Viviant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Pfizer is responsible for the marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women. Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories. Net royalties on annual net sales of Viviant/Conbriza and Duavee/Duavive are each payable to us through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aziyo Portfolio (Aziyo)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a share of revenue from the currently marketed Aziyo portfolio of commercial pericardial repair and CanGaroo&#174;&#160;Envelope ECM products. In addition, we have the potential to receive a share of revenue and potential milestones from the currently marketed CanGaroo&#174;&#160;ECM Envelope for cardiac implantable electronic devices.&#160;Aziyo&#8217;s products are medical devices that are designed to permit the development and regrowth of human tissue.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exemptia, Vivitra, Zybev and Bryxta (Zydus Cadila)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases. Zydus Cadila uses the Selexis technology platform for Exemptia. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Bryxta and Zybev (bevacizumab biosimilar) is marketed in India for various indications. Zydus Cadila uses the Selexis technology platform for Bryxta and Zybev. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minnebro (Exelixis)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minnebro is marketed in Japan for the treatment of hypertension. Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo for the development of esaxerenone, a mineralocorticoid receptor antagonist. Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Selected Development Stage Programs</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms, we consider particularly noteworthy. We are eligible to receive milestone payments and royalties on these programs. This list does not include all of our partnered programs. For information about the royalties owed to Ligand for these programs, see &#8220;Royalties&#8221; later in this business section. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sparsentan (Travere) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Travere, is developing sparsentan for orphan indications of severe kidney diseases, and is running an on-going global pivotal Phase 3 clinical trial (DUPLEX) for sparsentan for the treatment of FSGS. Additionally, Travere is running </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a global pivotal Phase 3 clinical trial (PROTECT) evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare, immune complex mediated chronic glomerular disease. Certain patient groups with severely compromised renal function, including those with FSGS and IgA nephropathy, exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate. Sparsentan, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February of 2021, Travere announced that sparsentan achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) in the DUPLEX Phase 3 study after 36 weeks of treatment. Sparsentan demonstrated a statistically significant response on FPRE compared to the active control, irbesartan (p=0.0094). Preliminary results from the interim analysis suggest that sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. Based on the data from the interim analysis, Travere intends to pursue submissions for accelerated approval of sparsentan for FSGS in the second half of 2021.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Travere has stated that topline efficacy data from the ongoing pivotal Phase 3 PROTECT Study in IgA nephropathy, and the 36-week interim proteinuria endpoint analysis, are anticipated in the third quarter of 2021.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreement with Travere, we may be entitled to receive potential milestones of over $70 million and net royalties on future worldwide sales by Travere. The royalty term is expected to be 10 years following the first commercial sale. Travere is responsible for all development costs related to the program.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%">TR-Beta - VK2809 and VK0214 (Viking) </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:36pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our partner, Viking, is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and NASH. VK2809 is currently in a Phase 2b clinical trial (the VOYAGE study) in patients with biopsy-confirmed NASH. Viking has previously announced positive results from a Phase 2a trial of VK2809 in hypercholesterolemia and fatty liver disease. VK0214 is currently in Phase 1 clinical development, and had been granted orphan drug study by the FDA for the treatment of X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales. Our TR Beta programs partnered with Viking are subject to CVR sharing and a portion of the cash received will be paid out to CVR holders.</span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;text-align:center"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TR-Beta - VK2809 and VK0214</span><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Viking)</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $500 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%</span></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-bottom:2pt solid #000;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5%</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Batoclimab (Immunovant, HanAll and Harbour)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, HanAll has granted Immunovant an exclusive license for the development, manufacture and marketing of Batoclimab for the treatment of pathogenic IgG-mediated autoimmune diseases in the U.S., Canada, Mexico, the EU, the United Kingdom, Switzerland, Latin America, the Middle East and North Africa. Immunovant is currently conducting a Phase 2 clinical trial in myasthenia gravis and other inflammatory diseases. Additionally, HanAll and Harbour BioMed, are collaborating to develop Batoclimab for similar treatment in China and Korea and are currently conducting a Phase 2 trial in China. HanAll retains the rights to Batoclimab in Korea and Harbour will control the marketing in China. As part of our agreement with HanAll, we are entitled to development and regulatory milestones and royalties on potential future sales from HanAll and sublicense revenues from Immunovant and Harbour based on amounts received by HanAll.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">V114 (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) is in late stage clinical development with 17 Phase 3 clinical trials. In October 2020, Merck released additional positive data from two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114 and submitted applications in November 2020 to the FDA and EMA for licensure of V114. On January 12, 2021, Merck announced the FDA accepted the BLA for V114 for priority review with a PDUFA of July 18, 2021. V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. Pneumococcal disease in adults is on the rise in many countries, and V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to CRM197carrier protein, including serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults and are not contained in the currently licensed vaccine for adults.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our CRM197 commercial license agreements, we are eligible to earn an additional $11.5 million in development and regulatory milestones and may also be eligible to receive low single digit royalties derived from net sales, depending on territory. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pneumosil&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Serum Institute of India, SII)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SII began commercialization of its 10-valent pneumococcal conjugate vaccine, Pneumosil&#174; in the second quarter of 2020. Pneumosil is designed primarily to help fight against pneumococcal pneumonia among children, with an advantage of targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries. Pneumosil achieved WHO Prequalification in December 2019, allowing the product to be procured by United Nations agencies and Gavi, the Vaccine Alliance, and subsequently achieved Indian Marketing Authorization in July 2020, and announced commercial launch of the product in India in December 2020. Additionally, SII is currently testing a meningococcal conjugate vaccine in a Phase 3 study in India.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JZP-458 and JZP-341 (Jazz Pharmaceuticals)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing hematologic oncology products with our partner Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, PF745 (JZP-341), a long-acting Erwinia asparaginase, and PF690, a pegaspargase. Both PF743 and PF745 are being developed for the treatment of acute lymphoblastic leukemia and other hematological malignancies. Jazz has worldwide rights to develop and commercialize PF743 and PF745 and an exclusive option to license PF690 subject to certain option triggers.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Jazz agreement, we are eligible to earn remaining milestones of $162.5 million. We may also be eligible to receive tiered royalties on worldwide sales of any product resulting from the collaboration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CRM197 </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRM197 is a non-toxic mutant of diphtheria toxin. It is a well characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic. CRM197 is used in prophylactic and therapeutic vaccine candidates. We have developed CRM197 production strains using our Protein Expression Technology platform and supply preclinical grade and cGMP CRM197 to several vaccine development focused pharmaceutical customers. Our partners Merck &amp; Co., Inc. (Merck) and Serum Institute of India Private Limited (SII) have exclusively licensed unique production strains for use in their conjugate vaccine products and candidates for pneumococcal and meningitis bacterial infections. Pneumococcus bacterium </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Streptococcus pneumoniae)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a leading cause of severe pneumonia and major cause of morbidity and mortality worldwide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pevonedistat - TAK-924 (Millennium/Takeda) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Millennium/Takeda, is currently conducting Phase 3 trials for the development of pevonedistat for the treatment of hematological malignancies and solid tumors. Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor. Under the terms of the clinical-stage agreement, we may be entitled to over $25 million in regulatory and development milestones from Millennium/Takeda, revenue from Captisol material sales, and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensifentrine &#8211; RPL554 (Verona)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Verona, is currently conducting a comprehensive Phase 3 clinical trial to evaluate the efficacy and safety of nebulized ensifentrine in patients with moderate to severe COPD. Under the terms of our agreement with Verona, we are entitled to development and regulatory milestones, including a &#163;5.0 million payment upon the first approval of any regulatory authority, and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teclistamab (Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Janssen, is developing Teclistamab, a BCMAxCD3 bispecific antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting two Phase 2 trials, as a single agent and in combination with daratumumab in multiple myeloma. We are entitled to earn development and regulatory milestones based on the development of Teclistamab.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JNJ-67371244 (Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen is also developing JNJ-67371244, an anti-CD33xCD3 antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase I trial for cancer therapy. We are entitled to earn development and regulatory milestones based on the development of JNJ-67371244.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JNJ-70218902 (Janssen)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen is also developing JNJ-70218902, a T-cell redirecting agent antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase I trial for cancer therapy for patients with metastatic castration resistant prostate cancer. We are entitled to earn development and regulatory milestones based on the development of JNJ-70218902.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">M6223 (Merck KGaA)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Merck KGaA, is currently conducting a Phase 1 trial of M6223, an anti-TIGIT antibody discovered with the OmniAb platform, in patients with metastatic or locally advanced solid unresectable tumors in combination with bintrafusp alfa. Under the terms of the agreement, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SARM - VK5211 (Viking) </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Viking is also developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture. SARMs retain the beneficial properties of androgens without undesired side-effects of steroids or other less selective androgens. In the fourth quarter of 2017, Viking announced positive results from its Phase 2 trial in patients who suffered hip fracture. Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones as well as tiered royalties on potential future sales.</span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SARM - VK5211 (Viking)</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $500 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 to $750 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25%</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:2pt solid #000;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$750 million</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25%</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ganaxalone IV (Marinus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Marinus, is conducting Phase 3 clinical trials with Captisol-enabled ganaxolone IV in patients with PPD and refractory status epilepticus. Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone, a GABAA receptor modulator, for use in humans. We are entitled to development and regulatory milestones, revenue from Captisol material sales, and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APVO436 (Aptevo)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Aptevo, is currently conducting a Phase 1 trial of APVO436 for the treatment of acute myeloid leukemia and high-grade myelodysplastic syndrome.  There is a high unmet medical need for targeted immunotherapies such as APVO436, that can potentially treat patients with relapsed or refractory disease, or patients who cannot tolerate traditional chemotherapy. Under the terms of the agreement with Aptevo, we are entitled to development and regulatory milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gen1046 (GenMab)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, GenMab, is currently conducting a Phase 1/2 trial of Gen1046 for use in patients with malignant solid tumors. Under the terms of the agreement with GenMab, we are entitled to clinical and regulatory milestones and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SYM022 and SYM023 (Symphogen/Servier)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Symphogen (acquired by Servier), is currently conducting Phase 1 trials of SYM022 and SYM023 to determine if it is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy for which no standard therapy is available.  Under the terms of the agreement with Symphogen, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Partnership</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the WuXi Agreement, we have granted WuXi a non-exclusive license to use our OmniRat, OmniMouse and OmniFlic platforms solely to research, develop and make antibodies, and we have agreed to use commercially reasonable efforts to deliver to WuXi animals from such platforms to support WuXi&#8217;s licensing rights under the WuXi Agreement. Further, WuXi has the right to out-license antibodies it discovers (whether for itself or at the direction of out-licensees) under the WuXi Agreement to out-licensees worldwide. We are entitled to royalties in the low single digits on net sales of products. Unless earlier terminated, the term of the WuXi Agreement shall continue indefinitely. Either party may terminate the WuXi Agreement upon specified notice of the other party's uncured material breach of the WuXi Agreement. In addition, we have the right to terminate the WuXi Agreement if WuXi or one of its out-licensees challenges the validity of one of our patents covering the platform and WuXi has the right to terminate the WuXi Agreement for convenience following a specified period after notice of termination.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other earlier stage programs, the following programs have been licensed pursuant to the WuXi Agreement: </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zimberelimab AB122/GLS010/WBP3055 (Arcus and Gloria)</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, WuXi, has outlicensed the rights to certain programs using the OmniAb technology to Arcus and Gloria.  Arcus is conducting multiple Phase 1 trials and a Phase 2 trial to evaluate the safety and tolerability of Zimberelimab in subjects with advanced solid tumors. Additionally, Gloria, has submitted an NDA in China for  the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sugemalimab CS1001 (CStone)</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WuXi has also outlicensed the rights to certain programs using the OmniAb technology to CStone. CStone is currently conducting a Phase 3 trial to evaluate the efficacy and safety of CS1001 to treat patients with natural killer cell/T-cell lymphoma and classical Hodgkin&#8217;s lymphoma. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ciforadenant &#8211; CPI-444 (Corvus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Corvus, is conducting a Phase 1b/2 clinical trial in patients with renal cell carcinoma and metastatic castration resistant prostate cancer to evaluate Ciforadenant, an antagonist of adenosine A2A, in combination with the immunotherapy drug atezolizumab. Positive preliminary data was presented in February at ASCO 2020 Genitourinary Cancers Symposium (ASCO-GU) and additional data was presented at ASCO 2020 in May/June. Ciforadenant is also being evaluated in a Phase 1b/2 trial in combination with atezolizumab in patients with non-small cell lung cancer who have failed no more than two prior regimens. Under the terms of our agreement with Corvus, we are entitled to development and regulatory milestones and tiered royalties on potential future sales. The aggregate potential milestone payments from Corvus are approximately $220 million for all indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FYCOMPA IV (Eisai)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Eisai, recently completed an open-label, single group assignment, multicenter, Phase 2 study in Japan to evaluate the safety and tolerability of intravenous perampanel, formulated with Captisol, as substitute for oral tablets as an adjunctive therapy in patients with partial onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures. The primary endpoint was the number of patients with adverse events and serious adverse events. We are entitled to revenue from Captisol material sales and tiered royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SB206 (Novan) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired certain economic rights to SB206 from Novan in May 2019. SB206 is a topical nitric-oxide antiviral gel for the treatment of viral skin infections, including molluscum contagiosum (MC). MC is an infection which causes skin lesions that affect approximately 6 million people in the United States annually, with the greatest incidence in children aged one to 14 years.  During the first quarter of 2020, Novan announced that it did not achieve statistically significant results for its primary end point from its Phase 3 pivotal trials of SB206 in MC. Novan continues to explore financial as well as strategic options in order to progress SB206.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">PTX - 022 (Palvella) </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="5" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We acquired the economic rights to PTX-022 from Palvella in December 2018. PTX-022 is a novel, topical formulation comprising high-strength rapamycin in development to treat pachyonychia congenita (PC).  PC is a serious, chronically debilitating lifelong monogenic rare skin disease with no approved treatment.  Palvella announced top line results of the Phase 2/3 VALOR study in late 2020. The Phase 3 portion of the study missed the primary endpoint, but significant improvement in the primary endpoint was achieved in the open-label, Phase 2 portion. Palvella plans to share the results with the FDA in the first quarter of 2021.</span></div></td><td colspan="6" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX - 022 (Palvella)</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; $50 million</span></td><td colspan="3" style="border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 to $100 million</span></td><td colspan="3" style="background-color:#cceeff;border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50%</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;$100 million</span></td><td colspan="3" style="border-right:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.80%</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lasofoxifene (Sermonix) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lasofoxifene is a selective estrogen receptor modulator for osteoporosis treatment and other diseases, discovered through the research collaboration between Pfizer and us. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Sermonix has a license for the development of oral lasofoxifene for the United States and additional territories. Under the terms of the agreement, we are entitled to receive over $45 million in potential regulatory and commercial milestone payments as well as royalties on potential future net sales.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sermonix announced in October 2020 the enrollment and dosing of the first patient into the Phase 2 ELAINE 2 clinical trial of lasofoxifene in combination with Eli Lilly&#8217;s FDA-approved CDK 4 and 6 inhibitor, abemaciclib for the treatment of pre- and postmenopausal women with locally advanced metastatic estrogen receptor-positive (ER+)/HER2- breast cancer and an ESR1 mutation. The Phase 2 ELAINE 1 trial, which began enrollment in September 2019, is assessing the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pradefovir (Xi'an Xintong)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chinese licensee, Xi'an Xintong Medicine Research (following its acquisition of Chiva Pharmaceuticals), is developing pradefovir, an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. Pradefovir was developed using Ligand&#8217;s HepDirect technology. In September 2019, Xi'an Xintong Medicine Research reported positive results from a Phase 2 trial of pradefovir, showing good efficacy, safety and tolerability. At the dose of 75 mg, the reduction of DNA viral load, the percentage of no viral load detected, and HBeAg negative conversion rate were better than tenofovir disoproxil fumarate (TDF) after 24 weeks of treatment. Overall incidence of side effects was less than TDF and there was no renal or skeletal toxicity. Xi'an Xintong Medicine Research is planning for a Phase 3 trial. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MB07133 (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chinese licensee Xi'an Xintong Medicine Research is also developing MB07133, a liver specific, HepDirect prodrug of cytarabine monophosphate, for the potential treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma.  MB07133 is currently in Phase 1 in China. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:93%">Summary of Selected Collaborations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK Collaboration</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a license and collaboration agreement with GSK to leverage our unique expertise in small molecule therapeutics targeting transmembrane proteins. The goal of this collaboration is to identify and develop inhibitors of a specific, genetically validated molecular target relevant to neurological diseases. Under the terms of the agreement, we received an upfront payment of $7.0 million and could receive additional development, regulatory and commercialization milestones of up to $154.5 million. We are also entitled to receive tiered royalties should any drug from the collaboration be commercialized. We will be responsible for the majority of preclinical activities up to lead optimization with both Ligand and GSK collaborating to identify candidates of IND-enabling studies. GSK has the exclusive option to license any identified inhibitors and will be responsible for further development and commercialization of any drug candidates identified through the collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, prior to the acquisition by Ligand, Icagen entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders and in May 2020 amended the license and collaboration agreement to include a second target.  These programs incorporate our technology platform for ion channel drug discovery and are directed at specific ion channel targets expressed in neurons. Under the terms of the agreement, Roche paid us on a per target basis an upfront payment for program exclusivity and research funding. In addition, we are eligible to potentially receive development and commercial milestone payments of up to $274 million per program and royalty payments if a drug is commercialized. We will be responsible for most preclinical activities up to lead optimization with both us and Roche applying resources to identify candidates for entry into late stage preclinical and IND enabling studies. Thereafter, Roche will be responsible for the further development and commercialization of the programs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cystic Fibrosis Foundation Collaboration</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, prior to the acquisition by Ligand, Icagen announced an award of up to $11 million from the Cystic Fibrosis Foundation for a project focused on the discovery of therapeutics to treat patients with cystic fibrosis (CF) caused by nonsense mutations. Nonsense mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (&#8220;CFTR&#8221;) gene result in the premature termination of protein synthesis and the formation of truncated, non-functional CFTR. Patients with these mutations in both copies of their CFTR genes currently have no therapies that treat the underlying cause of their disease. The aim of this program is to provide these patients with a transformative therapeutic that will markedly improve their quality of life and lifespan. The award is to support an integrated, multi-year drug discovery initiative.  At the North American Cystic Fibrosis Conference in October 2020, we reported the identification and characterization of a class of small molecule agents that enhance CFTR-PTC mutant readthrough and enable functional CFTR currents in combination with aminoglycosides.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple programs under license with other companies that have products that are already being commercialized. In addition to the table below, we have generally described a typical Captisol and OmniAb royalty arrangement as low- to mid-single digit royalties. The following table represents substantially all of the disclosed information about our royalty arrangements:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Table</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:28.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ligand Licenses With Tiered Royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Meloxicam</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-single digit to low-teen royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DGAT-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0% - 7.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FBPase Inhibitor (VK0612)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5% - 9.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 3.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mineral Coated Microparticle</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dianomi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0% - 3.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Genagon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genagon</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 6.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-GigaGen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GigaGen</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-iMetabolic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iMetabolic</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Kira</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kira</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral EPO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5% - 8.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0% - 9.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARM (VK5211)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% - 9.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan </span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TR Beta (VK2809 and VK0214)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 7.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viviant/Conbriza</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 9.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 10.0%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:28.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ligand Licenses With Fixed Royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-1BB</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhilkang Hongyi</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AB122</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcus</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Fosphenytoin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugemalimab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V114</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmniAb-KSQ Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KSQ Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PCSK-9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genekey</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparsentan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gloria</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Payments (Milestones)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our programs under license with our partners will generate contract payments to us if our partners reach certain development, regulatory and commercial milestones. The following table represents the potential maximum value of our contract payment pipeline on milestones by development stage, technology and partner (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Technology*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Partner*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $800,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $25,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,500,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $600,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$543,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PET</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regulatory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $2,100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$355,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $350,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$296,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $150,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $75,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuritek</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$246,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP/Hep Direct</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,600,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$170,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCE/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,800,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$139,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,600,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$70,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$1,281,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$4,600,000</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">*All tables exclude our annual access fees and collaboration revenue for development work.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Internal Development Programs </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of internal development or unpartnered programs focused on a wide-range of potential indications or disease. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Captisol-enabled (CE)-Iohexol program was established in January 2018 to develop a next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Contrast-induced acute kidney injury (CI-AKI) is the acute impairment of renal function following intravascular administration of an iodinated contrast agent, and occurs most frequently following coronary angiography, percutaneous coronary intervention and contrast-enhanced computed tomography, especially among patients at risk of renal injury such as those with advanced age, diabetes or heart failure. Currently no products are approved to prevent or treat CI-AKI in this setting, and therefore we believe a significant opportunity exists for a safer formulation of contrast agents. The goal is for CE-Iohexol to improve upon the limitations of existing contrast agents and enable a future partner to gain meaningful market share. In July 2019, we announced positive top-line results from a Phase 1 clinical trial CE-Iohexol conducted in Canada. The trial achieved the primary endpoint by demonstrating pharmacokinetic bioequivalence of CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE&#8482;) after IV administration in healthy adults. CE-Iohexol injection was well tolerated, and adverse events were in line with the known safety profile of OMNIPAQUE. We submitted an IND with the FDA in November and received a &#8220;Study May Proceed&#8221; letter in December 2020 along with feedback from the FDA on the clinical plan. We plan to initiate a Phase 2 study in the U.S. in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luminespib/Hsp90 Inhibitor is a Phase 2-ready Hsp90 inhibitor, previously investigated in clinical trials for cancer. Third-party academic drug analyses suggest a potential role for heat shock protein 90 (Hsp90) inhibitors in treating COVID-19 infection. Based on these studies, we are evaluating potential collaborations or partnerships relating to intravenous luminespib (AUY-922) as a potential treatment for patients with COVID-19. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development efforts are led by our teams in Emeryville, California, San Diego, California, and Durham, North Carolina,. The following table represents internal programs eligible for further development or partnership:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:17pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:44.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development Stage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Targeted Indication or Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Iohexol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luminespib/Hsp90 Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Sertraline, Oral Concentrate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depression</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF530 Interferon Beta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomodulatory</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF582 Ranibizumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ocular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCR1 Antagonist</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Busulfan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Cetirizine Injection</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Silymarin for Topical formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun damage</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLT3 Kinase Inhibitors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GCSF Receptor Agonist</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood disorders</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-B7-H3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-TIM3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-TIGIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-CD38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-BDNF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF529 Pegfilgrastim</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF810 Recombinant Peptide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endocrine System</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with a third party manufacturer, Hovione, for Captisol production.  Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing and distribution operations for Captisol are performed primarily at Hovione's Portugal and Ireland facilities. We believe we maintain adequate inventory of Captisol to meet our current and future partner needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers.&#160;If the supply interruption continues beyond a designated period, we may terminate the agreement.&#160;In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current term of the agreement with Hovione is through December 2024. The agreement will automatically renew for successive two year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. We have ongoing minimum purchase commitments under the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. Our OmniAb antibody technology faces competition from suppliers of other transgenic animal systems that are also available for antibody drug discovery such as AbCellera Biologics.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety (EHS)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards. We establish and monitor programs to reduce pollution, prevent injuries, and maintain compliance with applicable regulations. By focusing on such practices, we believe we can affect a meaningful, positive change in our community and maintain a healthy and safe environment. Our animal health facility in Emeryville, California,  has accreditation from Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. We expect to continue our effort and to refine our EHS policies and practices in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries.&#160;We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical&#160;products. These activities are subject to additional regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed products and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Kyprolis</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. Amgen has filed suit against several generic drug companies over their applications to make generic versions of Kyprolis. Several generics have settled with Amgen on confidential terms. However, it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; generic product will be on a date that is held as confidential in 2027 or sooner, depending on certain occurrences. One generic company, Cipla Limited/Cipla USA, Inc. chose not to settle the litigation with Amgen, and proceeded to trial. The District Court upheld the validity of patent claims from three of the patents and Cipla has appealed</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The type of patent protection (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">., composition of matter or use) for each patent listed in the Orange Book and the expiration dates for each patent listed in the Orange Book are provided in the following table.  In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:15.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kyprolis</span></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corresponding Foreign</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Type of Protection</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Patent No.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Expiration Date</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patent Number</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration Date&#8225;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:15.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.698%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,232,818</span></td><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781,688</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,999</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270,026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,101,026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743,720</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,417,042</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/20/2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781,688</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,999</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270,026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,101,026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743,720</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,491,704</span></td><td colspan="3" rowspan="7" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781,688</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,999</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270,026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,101,026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743,720</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,737,112</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2027</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819,353</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,260,835</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,261,236</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,990,155</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,108,509</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/9/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,129,346</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616,569</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,207,125</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781,688</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616,569</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743,720</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM / Use</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,207,126</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616,569</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,207,127</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616,569</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM / Use</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,207,297</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,745,064</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394,423</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616,569</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,493,582</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,517,725</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,511,109</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2029</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,796,134</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,675,629</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081,964</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,714,664</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2029</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and pending patent applications covering Captisol and methods of making Captisol are owned by us. The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see, e.g.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). Other patent applications covering methods of making Captisol, if issued, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potentially have terms to 2040. We have asserted U.S. Patents 8,410,077, 9,200,088, and 9,493,582 against Teva in connection with their attempt to obtain FDA approval to manufacture and sell a generic version of EVOMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also own several patents and pending patent applications covering drug products containing Captisol as a component. The type of patent protection (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., composition of matter or use) and the expiration dates for several issued patents covering Captisol are provided in the following table. In addition, certain related patents and applications in the commercially important jurisdictions of Europe and Japan are listed in the following table.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Captisol</span></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corresponding Foreign</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Type of Protection</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Patent No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Expiration Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patent Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration Date&#8225;</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,114,438</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,708,225</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,141,906</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,538,739</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,117,940</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,708,225</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,141,906</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,538,739</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,668,160</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,708,225</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,141,906</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,538,739</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/22/2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,629,331</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,049,003</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/19/2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,583,668</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846,901</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,829,182</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,952,197</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use/MoM</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,617,352</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/8/2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,583,668</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,952,197</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/MoM</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,202,468</span></td><td colspan="3" rowspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,583,668</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,952,197</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.620%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,703,826</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,583,668</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,945,228</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,335,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,581,078</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,432</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/26/2026</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM / Use</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,635,773</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,410,077</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,200,088</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,750,822</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,117,951</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,780,177</span></td><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/13/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,039,721</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,276,828</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,444,548</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/28/2029</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MoM</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,751,957</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2033</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,814,849</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/14/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,508,944</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/14/2033</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MoM</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,633,462</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/14/2033</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,814,849</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/14/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,508,944</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/14/2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,493,582</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,517,725</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,323,103</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,517,725</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/MoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,040,872</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,557,144</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MoM</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,800,861</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/27/2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,557,144</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/21/2033</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb Technology Stack  </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our OmniAb therapeutic antibody platforms, including OmniRat, OmniMouse and OmniChicken, produce naturally optimized, fully human antibodies in animals. We have received patent protection on OmniAb animals and methods  in over 40 jurisdictions, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the table below). The patents and applications owned by us are expected to expire between 2028 and 2039 and partners are able to use the OmniAb patented technology to generate novel antibodies, which may be entitled to additional patent protection.</span></div><div style="margin-bottom:6pt;text-indent:22pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OmniAb in OmniMouse and OmniRat</span></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corresponding Foreign</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Type of Protection</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Patent No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Expiration Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patent Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration Date&#8225;</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,703,485</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/10/2031</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,152,880</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,336,329</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,603,323</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,823,690</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220,827</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,388,233</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,152,880</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,336,329</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602,323</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,823,690</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220,827</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,072,069</span></td><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,152,880</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,336,329</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602,323</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,823,690</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220,827</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use/MoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,907,157</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2028</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,475,859</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/15/2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931,030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/13/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,705,650</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/13/2033</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,385,132</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/8/2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931,030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/13/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,705,650</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/13/2033</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OmniAb in OmniChicken</span></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corresponding Foreign</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Type of Protection</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Patent No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Expiration Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patent Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration Date&#8225;</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,030,095</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/23/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,271,657</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/2/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,737,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/2/2029</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MoM</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,415,173</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/2/2029</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,271,657</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/2/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,737,707</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/2/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,592,644</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/30/2030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,404,125</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/29/2030</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,549,538</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,010,058</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,172,334</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,687,519</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,362,770</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,756,802</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/11/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/MoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,865,462</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/8/2032</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,689,433</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/23/2032</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Com/MoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,644,178</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/7/2031</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,380,769</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/23/2032</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,713,712</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/23/2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,809,642</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/23/2032</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,394,372</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/16/2032</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,982,062</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/16/2032</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoM/Use</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,555,508</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/16/2032</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vernalis</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our sale of Vernalis (R&amp;D) Limited to HitGen in December 2020, Ligand retained a portfolio of fully-funded shots on goal, which now include RPL554, a Phase 2, novel treatment for COPD, which is partnered with Verona; Ciforadenant, a Phase 1 adenosine A2A receptor antagonist for treatment of solid tumors, partnered with Corvus; Tosedostat, an aminopeptidase inhibitor for treatment of blood cancers, partnered with Cell Therapeutics, Inc. (CTI), S65487, a Bcl-2 inhibitor, and S64315, an Mcl-1 inhibitor for treatment of cancers, both of which are partnered with Servier in collaboration with Novartis, and VER250840 (an oral, selective Chk1 inhibitor for treatment of cancer). These programs and their IP are now owned by Ligand UK Development Limited, which has a worldwide patent portfolio of over 200 granted patents in over 60 countries.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protein Expression Technology Platform</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the Protein Expression Technology Platform through acquisition of Pfenex Inc. in October 2020. This acquisition brought a robust product patent portfolio in the areas of biosimilars, microbial toxin, and vaccine antigen production, as well as a growing number of patents that cover our platform technology (including promoters, secretion leader sequences, methods for high throughput screening, protein expression, strain engineering, marker systems, etc.) useful to the core business. Together there are over 200 issued patents worldwide, and nearly 50 pending applications.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Technology Platform</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we acquired the core assets of Icagen, Inc., an early-stage drug discovery company focused on ion channel and transporter targets. Icagen has a portfolio of over 75 issued patents worldwide and ten pending applications relating to micro X-ray fluorescence-based detection of binding events and transport across barriers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> xCella Biosciences</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we acquired xCella Biosciences, Inc.. xCella&#8217;s platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity which expand our existing single- B cell assay capabilities in the OmniAb technology stack. We acquired one issued patent directed to xCella&#8217;s assay platform, and nearly 20 pending applications, along with access to several technologies owned by Stanford University.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taurus Bioscience </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we acquired Taurus Biosciences which added technologies for discovery and humanization of antibodies from immunized cows or cow-derived libraries in our OmniAb platform technology stack. These antibodies feature some of the longest CDRH3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. We acquired over 15 issued patents along with access to technology owned by The Scripps Research Institute.</span></div><div style="margin-bottom:10pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital Management</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of December 31, 2020, we have 155 employees, of whom 118 are involved directly in scientific research and development activities. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on skilled, experienced, and innovative employees to conduct the operations of our company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">equity awards through our 2002 Stock Incentive Plan;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized health insurance;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">401(k) Plan with matching contributions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tuition assistance program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid time off.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</span></div><div style="margin-bottom:10pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.ligand.com. We make available on our website, without charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission, or SEC. You may obtain copies of these documents by visiting the SEC&#8217;s website at www.sec.gov. These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing. </span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_16"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business, including the businesses of our subsidiaries. You should also consider the other information described in this report. Additional risks not presently known to us or that we currently deem immaterial also may impair our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Reliance on Third Parties:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:81%">Our business is subject to risks arising from epidemic diseases, such as the recent COVID-19 pandemic, which has impacted and could continue to impact our business.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees and partners, patients, communities and business operations, as well as the U.S. and global economy and financial markets. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have restricted in-person access to our executive offices, our administrative employees are mostly working remotely, and we have limited the number of staff in our research and development laboratories and other facilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our partners have reported that their operations have been impacted including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who have contracted the virus or to prevent the spread of the virus. This may lead to clinical trial protocol deviations or to discontinuation of treatment for patients who are currently enrolled in the clinical trials being conducted by us or our partners. In addition, certain of our partners have reported negative impacts on product sales which will impact our royalty revenues. As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business, drug manufacturing and supply chain, nonclinical activities and clinical trials and our partners&#8217; business may be impacted in similar ways, including due to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">delays or difficulties in enrolling patients in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">delays or difficulties in clinical site initiation, including difficulties in recruiting or supporting clinical site investigators and clinical site staff;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">interruption of, or delays in receiving, supplies of Captisol or other product or product candidates from contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may result in cancellations of Captisol orders or refunds if we fail to deliver Captisol timely;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">delays in clinical sites receiving the supplies and materials needed to conduct clinical trials and interruption in global shipping that may affect the transport of clinical trial materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">interruptions in nonclinical studies due to restricted or limited operations at laboratory facility or those of outsourced service providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">limitations on employee resources that would otherwise be focused on the conduct of nonclinical studies or clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">delays in receiving approval from local regulatory authorities to initiate planned clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">interruption or delays to discovery and development pipelines; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if COVID-19 infects our genetically modified animals which form the basis of our OmniAb platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. Further, the spread of COVID-19 has had and may continue to severely impact the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the COVID-19 may impact our business, including our drug manufacturing and supply chain, nonclinical activities, clinical trials and financial condition, including due to impacts on our partners&#8217; businesses, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue based on Kyprolis and Evomela, as well as royalties from our other partnered products, may be lower than expected.</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our royalty revenue is based on sales of Kyprolis by Amgen and sales of Evomela by Acrotech Biopharma. Royalties, including payments from Amgen and Acrotech Biopharma, are expected to be a substantial portion of our ongoing revenues for the foreseeable future. Any setback that may occur with respect to any of our partners' products, and in particular Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including Amgen's or Acrotech Biopharma's failure to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition. For example, we entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. The entry of generic competition for Evomela may materially and adversely affect the revenue we derive from Evomela sales. Also, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences&#8221; and litigation against one other party is awaiting a post-trial judgement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue from sales of Captisol material to our license partners may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of Captisol material to our collaborative partners, including Amgen and Gilead, represent a significant portion of our current revenues. Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock. Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol. In addition, revenue from Captisol sales related to remdesivir may not continue or materially increase due to a number of factors, including: if remdesivir is later shown to not be effective or safe for the treatment of COVID-19; the FDA revises or revokes its approval of remdesivir; if alternative therapies or vaccines are approved; or the risk of COVID-19 infection significantly diminishes, in which case the commercial opportunity could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol from Hovione, our third party manufacturer, primarily at Hovione&#8217;s facilities in Portugal and Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Hovione were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships. In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers, although there is no assurance that we could do so timely or at an acceptable costs, if at all. In addition to manufacturing at Hovione&#8217;s facilities in Ireland and Portugal, we have now added final step processing capacity for Captisol in both the United States and England.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain inventory of Captisol, which has a five year shelf life, at three geographically dispersed storage locations in the United States and Europe. If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions. In addition, we will rely on Hovione to expand manufacturing capacity of Captisol and any failure by Hovione to timely implement such increased capacity could adversely affect our ability to supply Captisol to our partners. While we believe we maintain adequate inventory of Captisol to meet our current partner needs, and our planned expansion of Captisol capacity will be sufficient to meet future partner needs, our estimates and projections for Captisol demand may not be correct and any supply interruptions could materially adversely impact our operating results. In addition, our plan to invest additional capital for the expansion of Captisol manufacturing capacity may not yield a return on investment if future Captisol sales fall below our expectations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on our arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will. If our partners discontinue sales of products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, or choose to utilize a competing product, or if we are unable to establish new licensing and marketing relationships, our financial results and growth prospects would be materially affected. Furthermore, we maintain significant accounts receivable balances with certain customers purchasing Captisol materials, which may result in the concentration of credit risk. We generally do not require any collateral from our customers to secure payment of these accounts receivable. If any of our major customers were to default in the payment of their obligations to us, our business, operating results and cash flows could be adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under most of our Captisol outlicenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high purity patents and foreign equivalents, are not expected to expire until 2029 and our morphology patents and foreign equivalents, are not expected to expire until 2026 in United States, but the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States. If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements could reduce our milestone and license fee revenue, and potential reduce future royalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for developing and commercializing many of our product candidates includes entering into collaboration agreements, outlicenses, and development funding and royalty purchase agreements with corporate partners and others. These agreements give our collaboration partners significant discretion when deciding whether or not to pursue any development program. Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaboration arrangements to develop and commercialize our unpartnered assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborators may develop products, either alone or with others that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our or our partners' programs. If product candidates are approved for marketing under our collaboration programs, revenues we receive will depend on the manufacturing, marketing and sales efforts of our collaboration partners, who generally retain commercialization rights under the collaboration agreements. Generally, our current collaboration partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaboration partners breach (for example, by not making required payments when due, or at all) or terminate their agreements with us or otherwise fail to conduct their collaboration activities successfully, including due to insolvency events, ongoing product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates. Any such dispute or litigation could delay, interrupt or terminate the collaboration research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, and the success of our partnered programs could be adversely affected.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaboration partners terminate their collaborations with us or do not commit sufficient resources to the development, manufacture, marketing or distribution of our partnered programs, we could be required to devote additional resources to our partnered programs, seek new collaboration partners or abandon such partnered programs, all of which could reduce our revenues and otherwise have an adverse effect on our business. For example, several of our collaboration partners using our OmniAb antibody platform have terminated their contracts or substantially reduced their investment in the antibodies discovered based on the platform. Although we expect growth in the net number of partners with one more active programs based on antibodies discovered using our OmniAb platform, there can be no assurance that our partners will continue their programs or that we will be able to find new collaboration partners interested in discovering antibodies based on our OmniAb platform.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective.  We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action.  Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could adversely affect our business. The product development and clinical trials process is complex and uncertain.  For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials.  In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities.  A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials.  The FDA may also require additional clinical trials after regulatory approvals are received.  Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, the ability to obtain adequate supplies of the products to be tested and patient enrollment.  Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied.  Delays in patient enrollment for our or our partners&#8217; trials may result in increased costs and longer development times.  In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations.  As a result, these partners may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct these programs more slowly or in a different manner than expected.  Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA or foreign regulatory approval in a timely manner or the FDA or foreign regulatory authority still may not grant approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate discovery, early-stage development, and product reformulation programs may require substantial additional capital to complete successfully.  Our partners&#8217; development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs.  While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing.  These financings could depress our stock price.  If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our OmniAb antibody platform faces specific risks, including the fact that no product using antibodies from the platform has been approved by the FDA or similar regulatory agency.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our collaboration partners using our OmniAb antibody platform have received approval from the FDA or similar regulatory agency to market a product discovered based on our platform. In addition, only a few of our collaboration partners&#8217; product candidates based on the platform have been tested in late stage clinical trials. If one of our OmniAb collaboration partners&#8217; product candidates fails during preclinical studies or clinical trials, our other OmniAb collaboration partners may decide to abandon product candidates using antibodies generated from the OmniAb platform, whether or not such failure is attributable to the platform. All of our OmniAb collaboration partners may terminate their programs at any time without penalty. In addition, our OmniRat and OmniFlic platforms, which we consider the most promising, are covered by six patents within the U.S. and three patents in the European Union and are subject to the same risks as our patent portfolio discussed elsewhere in this report and our 2019 Annual Report, including the risk that our patents may infringe on third party patent rights or that our patents may be invalidated. As of a result of these factors, the future revenue generated from this platform may be materially lower than what we currently anticipate. Further, we face significant competition from other companies selling human antibody-generating rodents, especially mice which compete with our OmniMouse platform, including the VelocImmune mouse, the AlivaMab mouse, the Trianni mouse and the Kymouse. Many of our competitors have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market competing antibody platforms. Our competitors may render our OmniAb antibody platform obsolete, or limit the commercial value of any product candidates developed using our platform, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages that we believe our platform offers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others.  If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology.  We may not be able to obtain any such licenses on acceptable terms, or at all.  Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products.&#160; Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.&#160; Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.&#160; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We permit our partners to list our patents that cover their branded products in the Orange Book. If a third party files an NDA or ANDA for a generic drug product that relies in whole or in part on studies contained in our partner&#8217;s NDA for their branded product, the third party will have the option to certify to the FDA that, in the opinion of that third party, the patents listed in the Orange Book for our partner&#8217;s branded product are invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug product. A third party certification that a new product will not infringe Orange Book-listed patents, or that such patents are invalid, is called a paragraph IV patent certification. If the third party submits a paragraph IV patent certification to the FDA, a notice of the paragraph IV patent certification must be sent to the NDA owner and the owner of the patents that are subject to the paragraph IV patent certification notice once the third-party&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDA or ANDA is accepted for filing by the FDA. A lawsuit may then be initiated to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of the receipt of notice of a paragraph IV patent certification automatically prevents the FDA from approving the generic NDA or ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the NDA or ANDA applicant, or such shorter or longer period as the court may order. If a patent infringement lawsuit is not initiated within the required 45-day period, the third-party&#8217;s NDA or ANDA will not be subject to the 30-month stay.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several third-parties have challenged, and additional third parties may challenge, the patents covering our partner&#8217;s branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. We may from time to time become party to litigation or other proceedings as a result of Paragraph IV certifications. For example, as a result of the settlement of one such matter, Teva will be permitted to market a generic version of Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential. Also, as noted above, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences&#8221; and litigation against one other party is awaiting a post-trial judgement. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot assure you that all of the potentially relevant prior art information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention-relating to our and our partners&#8217; patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we or our partners may be subject to a third party pre-issuance submission of prior art to the United States Patent and Trademark Office. Even if patents do successfully issue and even if such patents cover our or our partner&#8217;s products or potential products, third parties may initiate litigation or opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our or our partners&#8217; products and compete directly with us and our partners, without payment to us or our partners, or limit the duration of the patent protection of our and our partners&#8217; technology and products. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our partner&#8217;s products. Any adverse outcome of such litigation or other proceedings could result in one or more or our patents being held invalid or unenforceable, which could adversely affect our ability to successfully execute our business strategy and negatively impact our financial condition and results of operations. However, given the unpredictability inherent in litigation, we cannot predict or guarantee the outcome of these matters or any other litigation. Regardless of how these matters are ultimately resolved, these matters may be costly, time-consuming and distracting to our management, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection.  For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol was upheld on appeal.  In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements.  We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position.  We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us.  These agreements may be breached, and we may not have adequate remedies for any breach.  In addition, our competitors may independently discover our trade secrets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights.  If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights.  In addition, if any of our competitors have filed patent applications in the United States which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The validity, scope and enforceability of any patents that cover our partners&#8217; biologic product candidate can be challenged by third parties.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For biologics, the Biologics Price Competition and Innovation Act of 2009, BPCIA, provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological products. Due to the large size and complexity of biological products, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in an Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, sponsors may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our partners&#8217; ability to prevent third parties from competing with their products or product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the products we license to our collaboration partners and the royalties we receive will depend in large part on the extent to which coverage and reimbursement is available from government and health administration authorities, private health maintenance organizations and health insurers, and other healthcare payors. Significant uncertainty exists as to the reimbursement status of healthcare products. Healthcare payors, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products. Even if a product is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover the costs associated with the research, development, marketing and sale of the product. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any product, market acceptance and any sales could be reduced.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is implemented to reign in rising healthcare expenditures. By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted, which included a number of provisions affecting the pharmaceutical industry, including, among other things, annual, non-deductible fees on any entity that manufactures or imports some types of branded prescription drugs and increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether other legislative changes will be adopted, if any, or how such changes would affect our operations or financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners may be subject to federal and state healthcare laws, including fraud and abuse, false claims, physician payment transparency and health information privacy and security laws. Our operations and those of our collaboration partners are subject to various federal and state fraud and abuse laws, including, without limitation, anti-kickback, false claims and physician payment transparency statutes. These laws may impact, among other things, financial arrangements with physicians, sales, marketing and education programs and the manner in which any of those activities are implemented. In addition, we may be subject to federal and state patient privacy regulations. If our operations or those of our collaboration partners are found to be in violation of any of those laws or any other applicable governmental regulations, we or our collaboration partners may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment, exclusion from government healthcare programs or the curtailment or restructuring of operations, any of which could adversely affect our ability to operate our business and our financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners.  For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed which would result in delayed milestone revenues and materially harm our operations of business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in our industry, our partners and we face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates, partnered products or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and product recall or withdrawal from the market and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $10.0&#160;million annual limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer.  If we are sued for any injury caused by our product candidates, partnered products or any future products, our liability could exceed our total assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to handling of hazardous materials and other regulations governing environmental safety.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. Although we have secured clearance from the EPA historically, and currently are operating in material compliance with applicable EPA rules and regulations, our business could be adversely affected if we discover that we or an acquired business is not in material compliance with these rules and regulations. In the future, we may pursue the use of other surfactant substances that will require clearance from the EPA, and we may fail to obtain such clearance. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, which could adversely affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Related to Our Strategic Transactions:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties from strategic acquisitions could adversely affect our stock price, operating results and results of operations.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired IPR&amp;D charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently acquired Pfenex, as well as Taurus and xCella. We may not be able to integrate these acquired businesses successfully, achieve the expected growth prospects and synergies, expected royalties and other economics or operate such businesses profitably.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such acquisitions may disrupt our current plans and operations, we may not be able to retain key personnel or preserve existing business relationships following such acquisitions, and may incur unexpected costs, charges or expenses resulting from completion of the acquisitions. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recently announced the disposition of Vernalis (R&amp;D) Limited. We may not realize expected future benefits from the Vernalis transaction, including from retained licenses and collaboration economics and as a result of indemnification claims under the Vernalis Purchase Agreement and our retention of certain liabilities associated with the Vernalis business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to realize the expected benefits from these acquisitions and Vernalis disposition, our business, results of operations and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Risks:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the royalties from the sales of Kyprolis, Evomela and other products sold by our partners; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the success of our collaboration partners&#8217; preclinical and clinical programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing of Captisol purchases for use in clinical trials and commercial products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our internal development programs, which may change from time to time;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenditures that we may incur to acquire or develop additional product candidates and platform technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the FASB either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued an accounting standard for revenue recognition-Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606-that supersedes most current revenue recognition guidance. The guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services.  The guidance became effective in fiscal 2018. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Ligand estimates and books royalties in the same quarter that our partners report the sale of the underlying product. We rely on our partners&#8217; earning releases and other information from our partners to determine the sales of our partners&#8217; products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $162.4 million and $129.3 million, respectively.  Our federal NOLs expire through </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2037 and our state NOLs begin to expire in 2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if not utilized. Under the Tax Act, any federal NOLs arising in taxable years ending after December 31, 2017 will carry forward indefinitely. As of December&#160;31, 2020, we had federal and California research and development tax credit carryforwards of approximately $9.2 million and $23.1 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2040, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code) if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Furthermore, under the Tax Act, although the treatment of tax losses generated in tax years beginning before December 31, 2017 has generally not changed, tax losses generated in tax years beginning after December 31, 2017 may only offset 80% of our taxable income. This change may require us to pay federal income taxes in future years despite having potentially generated a loss for federal income tax purposes in prior years. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications.  Despite the implementation of security measures, our internal computer systems and those of our partners are vulnerable to damage from cyber-attacks, computer viruses, security breaches, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, could lead to the loss of trade secrets or other intellectual property, could lead to the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business and financial condition could be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits or we could lose key data which could cause us to curtail or cease operations.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of our outstanding convertible notes may result in losses, result in the dilution of existing stockholders, create downward pressure on the price of our common stock, and restrict our ability to take advantage of future opportunities.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million principal amount of the 2023 Notes. The sale of the 2023 Notes may affect our earnings per share figures, as accounting procedures require that we include in our calculation of earnings per share the number of shares of our common stock into which the 2023 Notes are convertible. The convertible notes may be converted into cash and shares of our common stock, if any (subject to our right or obligation to pay cash in lieu of all or a portion of such shares).  If shares of our common stock are issued to the holders of the convertible notes upon conversion, there will be dilution to our shareholders equity and the market price of our shares may decrease due to the additional selling pressure in the market. Any downward pressure on the price of our common stock caused by the sale or potential sale of shares issuable upon conversion of the convertible notes could also encourage short sales by third parties, creating additional selling pressure on our stock.  Upon the occurrence of certain circumstances, holders of the convertible notes may require us to purchase all or a portion of their notes for cash, which may require the use of a substantial amount of cash. If such cash is not available, we may be required to sell other assets or enter into alternate financing arrangements at terms that may or may not be desirable. The existence of the convertible notes and the obligations that we incurred by issuing them may restrict our ability to take advantage of certain future opportunities, such as engaging in future debt or equity financing activities. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $495.3 million aggregate principal amount of 2023 Notes. The notes are convertible into cash, and if applicable, shares of our common stock under certain circumstances, including trading price conditions related to our common stock. Upon conversion, we are required to record a gain or loss for the difference between the fair value of the notes to be extinguished and their corresponding net carrying value. The fair value of the notes to be extinguished depends on our current incremental borrowing rate. If our incremental borrowing rate at the time of conversion is lower than the implied interest rate of the notes, we will record a loss in our consolidated statement of income during the period in which the notes are converted. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to market and credit risks that could diminish their value and these risks could be greater during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our business, financial condition, results of operations, liquidity and cash flows.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are subject to risks of credit defaults and changes in market values. Periods of macroeconomic weakness or recession, heightened volatility or disruption in the financial and credit markets could increase these risks, potentially resulting in other than temporary impairment of assets in our investment portfolio. Any event reducing the estimated fair value of these securities, other than on a temporary basis, could have a material and adverse effect on our business, results of operations, financial condition, liquidity and cash flows. If our investment manager, fails to react appropriately to difficult market, economic and geopolitical conditions, our investment portfolio could incur material losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a risk management framework in place to identify, assess and prioritize risks, including the market and credit risks to which our investments are subject. As part of that framework, we test our investment portfolio based on various market scenarios. Under certain stressed market scenarios, unrealized losses on our investment portfolio could lead to material reductions in its carrying value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in fair value below the amortized cost of a security requires management to assess whether an impairment has occurred. The decision on whether to record an impairment is determined in part by our assessment of the financial condition and prospects of a particular issuer, projections of future cash flows and recoverability of the particular security as well as management&#8217;s assertion of whether it is more likely than not that we will sell the particular security before recovery.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our charter documents and concentration of ownership may hinder or prevent change of control transactions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership.  In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders.  Our directors and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership.  If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine.  To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile and could experience a sudden decline in value.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has recently experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher share-based compensation expense.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future.  Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; comments or opinions by securities analysts or major stockholders or changed securities analysts' reports or recommendations; future sales or shorting of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, public health emergencies, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future to contribute to, increased volatility and diminished expectations for the economy and the markets. For example, the outbreak of a novel strain of coronavirus has affected the People&#8217;s Republic of China and elsewhere and has affected worldwide equity markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_19"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unresolved Staff Comments</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_22"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Properties</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal facilities leased as of December&#160;31, 2020, including the location and size of each facility, and their designated use. We also lease facilities in other locations. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed. </span></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate <br/>Square Feet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate headquarters office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emeryville, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durham, NC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,200</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2022</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_25"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (10), Commitments and Contingencies&#8212;Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_28"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mine Safety Disclosures</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_34"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221; As of February&#160;18, 2021, there were approximately 424 holders of record of the common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding repurchases by us of our common stock during the three months ended December&#160;31, 2020 under the stock repurchase program approved by our board of directors in September 2019, under which we may acquire up to $500 million of our common stock in open market and negotiated purchases for a period of up to three years. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;Purchased&#160;as</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Announced Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum&#160;Dollar&#160;Value&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchased Under the Program                              </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,554&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,554&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the 2021 Annual Meeting Proxy Statement as defined in Item 10 below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalizations. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Index, and of the Nasdaq Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-top:9pt;text-indent:24pt"><img src="lgnd-20201231_g2.jpg" alt="lgnd-20201231_g2.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:646px"/></div><div style="margin-top:9pt;text-align:right;text-indent:24pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center;text-indent:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Value of $100 Invested Over Time</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:37.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite-Total Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ib69a1c25a15148f9b95ad6e3392de608_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selected Consolidated Financial Data</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following selected historical consolidated financial and other data are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and the related notes thereto appearing elsewhere herein and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Our selected statement of operations data set forth below for each of the years ended December&#160;31, 2020, 2019, 2018, 2017 and 2016 and the balance sheet data as of December&#160;31, 2020, 2019, 2018, 2017 and 2016 are derived from our consolidated financial statements.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparability of the information is affected by a variety of factors, including acquisitions and divestitures of businesses, issuance and repayment of debt, share-based compensation expense, and repurchases of common stock under our stock repurchase programs. In addition, the consolidated statements of operations data for each of the years ended December 31, 2017 and 2016 and the selected consolidated balance sheet data as of December 31, 2017 and 2016 set forth in the tables below do not reflect the adoption of Topic 606 and continue to be reported under the standards in effect for those periods. Additionally, the selected consolidated balance sheet data as of December 31, 2018, 2017 and 2016 set forth in the tables below do not reflect the adoption of Topic 842 regarding leases and continue to be reported under Topic 840 for those periods. The selected consolidated financial data in this section are not intended to replace our consolidated financial statements and related notes. Our historical results are not necessarily indicative of our future results.</span></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:42.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,367)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares-basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares-diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:44.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, short-term investments, restricted cash and investments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,099&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (deficit)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,915&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,021&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notes payable, net (including current portion)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_40"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_43"></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) will help readers understand our results of operations, financial condition, and cash flows. It is provided in addition to the accompanying consolidated financial statements and notes. Comparisons under this heading refer to twelve months ended December&#160;31, 2020 and 2019, respectively, unless otherwise indicated. </span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Detailed discussion of our revenue and expenses for twelve months ended December&#160;31, 2020 and 2019. A comparison of our results of operations for twelve months ended December&#160;31, 2019 and 2018 can be found under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on February 27, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity and Capital Resources.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discussion of key aspects of our consolidated statements of cash flows, changes in our financial position, and our financial commitments.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Off-Balance Sheet Arrangements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual Obligations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tabular disclosure of known contractual obligations as of December 31, 2020.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Critical Accounting Policies and Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion of significant changes we believe are important to understand the assumptions and judgments underlying our consolidated financial statements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Recent Accounting Pronouncements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:59.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Captisol Sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,419&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,282&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,137&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is a function of our partners' product sales and the applicable royalty rate. Kyprolis royalty rate is under a tiered royalty rate structure with the highest being 3.0%. Evomela has a fixed royalty rate of 20%. On March 6, 2019, we sold all of our rights, title and interest in and to the Promacta license to RPI. Subsequent to March 6, 2019, we no longer recognize revenue related to sales of Promacta. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (2), Sale of Vernalis R&amp;D and Promacta License.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue decreased in 2020 as compared to 2019 driven primarily by the above mentioned sale of the Promacta license in March 2019, which contributed $14.2 million revenue in 2019. In addition, royalties for 2020 were impacted by the ongoing COVID-19 pandemic. Captisol sales increased year over year in 2020 primarily reflecting higher sales of Captisol for use in the manufacturing of Veklury. Contract revenue increased slightly year over year in 2020. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents royalty revenue by program:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Royalty Revenue </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Royalty Revenue </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expenses</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,578&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses for 2020 increased $51.7 million or 41% compared with 2019. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Captisol increased year over year in 2020 primarily due to higher sales of Captisol during 2020. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles increased year over year in 2020 primarily due to the acquisitions of Icagen in April 2020 and Pfenex in October 2020. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any one time, we are working on multiple programs. As such, we generally do not track our R&amp;D expenses on a specific program basis. Our R&amp;D expenses increased year over year in 2020 due to the costs associated with our acquisitions of Icagen in April 2020 and Pfenex in October 2020, which primarily consisted of salaries and lab costs and intangible amortizations associated with Icagen ($10.4 million) and Pfenex ($13.5 million). The increases were partially offset by a $17.0 million year over year decreases in amortization of other economic rights, primarily consisting of economic rights acquired from Palvella in December 2018 and Novan in February 2019. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased year over year in 2020 primarily due to $20.7 million acquisition and integration related expenses associated with the Pfenex acquisition. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional discussion of the uncertainties surrounding our research and development initiatives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:60.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,933)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,982)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,714)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,171)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense,) net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,383)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,437)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,946)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuation in the gain (loss) from short-term investments is primarily driven by the changes in the fair value of our ownership in Viking common stock and warrants (an unrealized loss of $19.0 million in 2020 as compared to an unrealized gain of $2.9 million in 2019). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term investments. The year over year decrease in 2020 resulted from the decrease in our short-term investment balances due to the usage of funds in share repurchases, the 2023 Notes repurchase and the acquisitions of Icagen, xCella, Taurus and Pfenex during 2020 as well as lower interest rates during 2020.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. The year over year decrease in 2020 was primarily due to lower average debt outstanding balance as compared to the prior year. The 2019 Notes were paid off upon the maturity date in August 2019. During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, decreased year over year in 2020 primarily due to a $5.1 million reduction in the value of our Selexis commercial license right in 2019. See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial License and Other Economic Rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit (expense)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:58.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(807,177)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,337)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(632,287)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Tax Rate</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for 2020 and 2019 was 72% and 21%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In 2020, the variance from the U.S. federal statutory rate of 21% was primarily attributable to the mix of earnings in jurisdictions with lower statutory rates than the U.S. federal statutory tax rate, primarily the United Kingdom.  The items below also had an impact on the difference between our statutory U.S. rate.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.4 million (22.9%) increase from Section 162(m) limitation</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.7 million (15.7%) decrease from the foreign-derived intangible income deduction</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.5 million  (13.8%) increase from state income taxes</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.9 million (8.3%) increase due to non-deductible transaction costs primarily related to the acquisition of Pfenex</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.7 million (6.6%) decrease from research and development tax credits</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.3 million (3.4%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.2 million (0.1%) decrease due to the release of a valuation allowance primarily relating to research and development tax credits.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.9 million (0.1%) decrease from research and development tax credits </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.8 million (0.1%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_46"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had approximately $411.2 million in cash, cash equivalents, and short-term investments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash and cash equivalents and short-term investments decreased by $658.7 million from last year, due to factors described in the "Cash Flow Summary" below. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, which decreased during 2020 primarily from the acquisitions of Icagen, xCella, Taurus and Pfenex, has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. Our short-term investments include U.S. government debt securities, investment-grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 5.8 million shares of common stock in Viking.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued the 2019 Notes with aggregate principal amount of $245.0 million. During 2018, $217.7 million in principal of the 2019 Notes were converted into cash. In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued the 2023 Notes with an aggregate principal amount of $750.0 million. A portion of the proceeds from such issuance totaling $49.7 million were used to repurchase 260,000 shares of our common stock. During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. After the repurchases, $495.3 million in principal amount of the 2023 Notes remain outstanding. We may continue to use cash on hand to repurchase additional 2023 Notes through open-market transactions, including through Rule 10b5-1 trading plan to facilitate open-market repurchases, or otherwise, from time to time. The timing and amount of repurchase transactions will be determined by management based on the evaluation of market conditions, trading price of the 2023 Notes, legal requirements and other factors. The 2023 Notes were not convertible as of December&#160;31, 2020. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, our Board of Directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years. On January 23, 2019, our Board of Directors increased the share repurchase authorization by $150.0 million. The available amount under the $350.0 million repurchase plan was fully utilized during the third quarter of 2019.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2020. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchase of Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $49.1 million in fair value of contingent consideration liabilities associated with the acquisitions to be settled in future periods.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:58.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we generated cash from operations, from the sale of Vernalis R&amp;D business and from issuance of common stock under employee stock plans. During the year we used cash for investing activities, including the acquisition of Pfenex, Icagen, xCella and Taurus. We also used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes and stock repurchases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we generated $827 million from the sale of the Promacta license (including $14.2 million recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019), used cash for net purchases of short-term investments, used $453.0 million to repurchase our common stock, used $103.8 million to pay federal and state estimated income taxes, paid off the remaining balance of the 2019 Notes in the amount of $27.3 million, paid $12.0 million for the purchase of Novan economic rights and paid $11.8 million for the Ab Initio acquisition (net of cash acquired).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we generated cash from operations, from issuance of the 2023 Notes and associated warrants, and from issuance of common stock under employee stock plans. During the same period we used cash for investing activities, including the acquisition of commercial rights, net purchases of short-term investments, payments made to acquire Vernalis, payments to CVR holders and capital expenditures. We also used cash for financing activities, including principal payments related to conversions of the 2019 Notes, payments to purchase the bond hedge associated with the 2023 Notes, payments for taxes related to net share settlement of equity awards and to repurchase shares of our common stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not participate in any transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the fiscal year ended December&#160;31, 2020, we were not involved in any &#8220;off-balance sheet arrangements&#8221; within the meaning of the rules of the SEC.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our office facilities under operating lease arrangements with varying terms through March 2024. The agreements provide for increases in annual rents based on changes in the Consumer Price Index or fixed percentage increases of 3.0%. We had no off-balance sheet arrangements at December 31, 2020, 2019 and 2018.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum payments due under our contractual obligations are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:33.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than&#160;1&#160;year</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3&#160;years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5&#160;years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">        (1)  Amounts represent our commitments under our supply agreement with Hovione for Captisol purchases.</span></div><div style="padding-left:9pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">        (2)  Amounts represent contractual amounts due under our 2023 Notes, including interest based on the fixed rate of 0.75% per year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">        (3)  We lease two office facilities, which we have fully vacated under operating lease arrangements. The lease agreements expire on  February 2023 and April 2024. We sublet the facilities through the end of our lease. As of December&#160;31, 2020, we expect to receive aggregate future minimum lease payments totaling $1.0 million (non-discounted) over the duration of the sublease agreement, which are not included in the table above. </span></div><div style="padding-left:9pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">        (4)  Amounts represent our commitments under our finance lease agreements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_49"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, we adopted ASC 606, which amends the guidance for recognition of revenue from contracts with customers using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. We apply the following five-step model in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material,  are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets &#8212; Impairment Assessments</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly perform reviews to determine if the carrying values of our long-lived assets are impaired. A review of identifiable intangible assets and other long-lived assets is performed when an event occurs indicating the potential for impairment. If indicators of impairment exist, we first assess the impairment evaluation and then assess the recoverability of the affected long-lived assets and compare their fair values to the respective carrying amounts if needed. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of identifiable intangible assets and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we acquired Crystal for total cash consideration of&#160;$27.2 million, plus contingent consideration of up to an additional&#160;$10.5 million&#160;($5.8 million has been paid as of December 31, 2020) over a&#160;five year period following the acquisition date based on certain research milestones and a portion of the payments that we receive from a specified part of the historical Crystal business. The&#160;contingent consideration&#160;is measured at fair value using an income approach valuation technique, specifically with&#160;probability&#160;weighted&#160;and discounted cash flows. The fair value of the liability is assessed at each reporting date and the change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. The fair value of the&#160;contingent&#160;consideration liability&#160;as of&#160;December&#160;31, 2020&#160;was $0.8 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as proceeds are received by us from the sale or partnering of any of the Metabasis drug development programs. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Changes in the fair values are reported in the statement of operations as income (decreases) or expense (increases). The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates for total cash consideration of $15.1 million, and a contingent earn-out payment of up to $25.0 million based on certain revenue milestones with an estimated fair value upon acquisition of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of Icagen. The fair value of the liability is assessed at each reporting date and the change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. The fair value of the&#160;contingent&#160;consideration liability&#160;as of December 31, 2020 was $6.4 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  The preliminary purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a contingent CVR payment of up to $77.8 million of cash payments based on certain specified milestones with an estimated initial fair value of $37.0 million, net of $1.5 million recorded as post-acquisition expenses based on double trigger accelerate feature. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of Pfenex. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. The fair value of the&#160;CVR liability&#160;as of December 31, 2020 was $37.6 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (5), Fair Value Measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                                                                                                                                                                                          </span></div><div style="margin-bottom:6pt;margin-top:14pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_52"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Portfolio Risk</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our investment portfolio included investments in available-for-sale securities of $363.6 million, including the investment in Viking common stock and warrants of $39.1 million. These securities are subject to market risk and may decline in value based on market conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Price Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 Notes include conversion and settlement provisions that are based on the price of our common stock at conversion or maturity of the notes, as applicable. As of December&#160;31, 2020, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our licensing and business operations, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues and profit translated into U.S. dollars. Our license partners sell our products worldwide in currencies other than the U.S. dollar. Because of this, our revenues from royalty payments are subject to risk from changes in exchange rates. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Captisol from Hovione, located in Lisbon, Portugal. Payments to Hovione are denominated and paid in U.S. dollars; however, the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. The effect of an immediate 10% change in foreign exchange rates would not have a material impact on our financial condition, results of operations or cash flows. We do not currently hedge our exposures to foreign currency fluctuations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in interest rates related primarily to our investment portfolio. Our investment policy and strategy are focused on the preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy. We typically invest in highly rated securities, with the primary objective of minimizing the risk of principal loss. Our investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates across all maturities would not materially impact the fair market value of the portfolio in either period. </span></div><div style="text-indent:27pt"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_55"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements and Supplementary Data</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_58"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_61">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_67">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_70">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_70">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_73">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_76">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_79">62</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ib69a1c25a15148f9b95ad6e3392de608_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Ligand Pharmaceuticals Incorporated (the Company) as of December 31, 2020 and 2019, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes, (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;24, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of ASU No. 2016-13</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting of measurement for credit losses on financial instruments effective January 1, 2020, due to the adoption of Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and the related amendments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the account or disclosure to which they relate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><br/>Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition of Pfenex Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As disclosed in Note 4 to the consolidated financial statements, during 2020, the Company completed the acquisition of Pfenex Inc. for total aggregate consideration of $465.1 million. The transaction was accounted for as a business combination. In connection with the acquisition, the Company recognized identified intangible assets which totaled $385 million and principally consisted of contractual relationships and developed technology, and recognized the Contingent Value Right (CVR) liability for acquisition consideration that is payable based on a predefined regulatory milestone if achieved by December 31, 2021 for which there is a maximum earnout of $77.8 million. The Company determines the fair value of the CVR both as part of the initial purchase price allocation, and on an ongoing basis each reporting period until the CVR is settled. As of December 31, 2020, the liability related to the CVR is $37.6 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the Company&#8217;s accounting for its acquisition of Pfenex Inc. was complex due to the significant judgement required by management to determine the fair value of identified intangible assets, and to determine the fair value of the CVR arrangement. The Company used an income approach to measure the value of the contractual relationship and technology-related intangible assets and a discounted cash flow model to value the CVR. Determination of the fair value of the acquired intangible assets was sensitive to the underlying assumptions including the estimated revenue growth rates and timing and the probability of technical and regulatory success. The fair value of CVR was sensitive to the significant underlying assumptions including the probability and timing of achieving the predefined regulatory milestone. These significant assumptions are forward looking and could be affected by future economic and market conditions.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company&#8217;s accounting for acquisitions. For example, we tested  controls over management&#8217;s review of the valuation of intangible assets acquired and CVR, including the valuation models used and the underlying assumptions used to develop such estimates, and management&#8217;s review of the completeness and accuracy of the data used to develop the estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the estimated fair value of the intangible assets and CVR, our audit procedures included, among others, evaluating the Company's use of valuation methodologies, evaluating the prospective financial information and testing the completeness and accuracy of underlying data. We compared the significant assumptions to current industry, market and economic trends and historical results of the acquired business. We also involved internal valuation specialists to assist in our evaluation of the valuation methodology and certain significant assumptions used by the Company. Our internal valuation specialists&#8217; procedures included, among others, developing a range of independent estimates for the discount rates and comparing those to the discount rates selected by management.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment assessment of finite-lived intangibles </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December 31, 2020, the Company&#8217;s finite-lived intangible assets totaled $595.3 million. As discussed in Note 1 to the consolidated financial statements, the Company reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the finite-lived intangibles are not expected to be recovered through future undiscounted cash flows. The Company did not identify indicators of impairment for its finite-lived intangibles at December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s assessment of impairment is challenging due to the high degree of subjective auditor judgment necessary in evaluating management&#8217;s identification of indicators of potential impairment and the related assessment of the severity of such indicators in determining whether a triggering event has occurred that requires the Company to evaluate the recoverability of the asset. A high degree of auditor judgment was required to evaluate the significant inputs used in the assessment for potential triggering events which included market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results. These possible triggering events could have a significant effect on the Company&#8217;s impairment assessment and the determination of whether further quantitative analysis of finite-lived intangible impairment was required.</span></div><div><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding of management&#8217;s process to identify indicators of impairment, including the qualitative analysis and related inputs and assumptions used in performing the analyses. We evaluated the design and tested the operating effectiveness of the controls that address the identification of indicators of impairment. For example, we tested controls over management&#8217;s assessment of indicators of impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the Company&#8217;s evaluation of indicators of impairment for finite-lived intangibles, our audit procedures included, among others, assessing the methodologies and testing the completeness and accuracy of the Company&#8217;s analysis of events or changes in circumstances. As part of our evaluation, we considered market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results, in assessing whether an indicator of impairments exists. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2021</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_64"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNC0xLTEtMS0w_a5b7900b-879c-4c5a-9242-a9e6109a5b5e">47,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNC0zLTEtMS0w_323e7169-7b65-4ccd-bf1d-eaaf63bead7b">71,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNS0xLTEtMS0w_54f39b84-38fa-4360-a885-8b91d6f20350">363,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNS0zLTEtMS0w_52c3a7c9-19e5-4494-b3f6-284f9157e0e9">998,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNy0xLTEtMS0w_253a5a2b-834c-4f69-b35d-b9919f57787a">56,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNy0zLTEtMS0w_0b7da190-8ac0-4e42-bc7d-672089d94f6e">30,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfOC0xLTEtMS0w_9cc0d9e5-e416-4c9f-a400-ac4875698a33">26,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfOC0zLTEtMS0w_bc3125bd-d3f5-4dc7-b833-5ffe3eb73d86">7,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTAtMS0xLTEtMA_8678e118-a389-4ae4-b8d1-459a94249713">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTAtMy0xLTEtMA_71f5db6a-9b4f-49a3-89a6-b60002e89e9f">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTEtMS0xLTEtMA_f1a1acde-3ac2-44fc-92b0-6ddafae120ef">3,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTEtMy0xLTEtMA_8e3103c7-7a74-4c61-9810-5d2d4285838b">4,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTItMS0xLTEtMA_c7d75c41-3dae-4ee2-937e-6f4f7c531668">500,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTItMy0xLTEtMA_8785fe35-c1cf-4241-a5db-b27be64bc89f">1,123,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTMtMS0xLTEtMA_2b48eca7-946c-4c96-b86d-c9b069c12fb4">24,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTMtMy0xLTEtMA_49f2a677-96cb-4d0b-80c1-e24be855bf0b">25,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTQtMS0xLTEtMA_77945f5d-10b3-4fa8-a9f6-ef8caf8e2ef6">595,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTQtMy0xLTEtMA_3fd9402c-1d59-463a-81fd-68972b5b19b1">210,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTUtMS0xLTEtMA_30577564-7a4a-46c3-b137-a764e3b77cf4">189,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTUtMy0xLTEtMA_66ce6909-ce48-45c2-a69c-2fa783412d10">95,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial license and other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTYtMS0xLTEtMA_67ad3a26-db1a-498c-b11d-076e45d6d15f">10,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTYtMy0xLTEtMA_2477d86a-7c9e-4db1-abd4-c45602f315f6">20,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMS0xLTEtMA_e73a0bb2-a93a-4111-9cba-3f52cbf9fead">14,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMy0xLTEtMA_959f3eeb-5473-4d4f-8e4c-4e1784f71f44">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTgtMS0xLTEtMA_f65c1c06-fefa-4168-bfa0-0a1c9e010c3f">6,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTgtMy0xLTEtMA_0f763f7e-2751-47d8-93fe-d68d137cd838">10,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMS0xLTEtMTIzNA_876a3328-339b-41c9-a8ca-96e2332e3ffd">15,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMy0xLTEtMTIzMA_e5e1c71b-dcfc-4265-9377-201c68e7bb54">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTktMS0xLTEtMA_7140f24f-3683-4e44-96f1-9e9a45405d7e">4,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTktMy0xLTEtMA_7f08c311-b339-4d31-a855-94bba4133aa2">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjAtMS0xLTEtMA_4454680a-04e8-432d-8783-0f3e79ff0260">1,362,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjAtMy0xLTEtMA_210ba5b5-fe24-48f8-bcf6-d27bb22676c5">1,494,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjMtMS0xLTEtMA_2ed6f30d-decc-431f-994c-95989ed98ef5">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjMtMy0xLTEtMA_8a048e3b-0778-4ae7-8f30-f4f5a9d9084b">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjQtMS0xLTEtMA_ffaf20dc-a708-4ee8-ab76-673543476126">18,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjQtMy0xLTEtMA_d75f1565-b371-4cce-bea6-86a3d29b39de">8,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjUtMS0xLTEtMA_8f162e00-7a77-478d-b610-94196b6891bb">39,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjUtMy0xLTEtMA_ada6e43c-637e-4d17-b80b-bc7d461741b3">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue   </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtMA_de0a41d0-7c75-4d6a-9d65-6c7e77f38852">29,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMy0xLTEtMA_03f0cec8-882b-4ef0-82a1-14657e422678">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtNDM1NQ_3a17e475-b5bf-45de-8aeb-7268df1d06f7">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMy0xLTEtNDM0OQ_0e24c62b-5563-4d3d-af5e-6e6bdc06870c">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtMzI5NA_edec4244-a7de-4570-a682-743a2396f1c3">6,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjctMy0xLTEtNDg5Ng_4fb683ad-25c9-47f8-b86e-13daad49d24c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjktMS0xLTEtMA_e62099a2-d43d-42e1-a2ed-1cfe9294a449">100,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjktMy0xLTEtMA_69010c11-da35-4e31-b142-4c14c4cdd1bd">17,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 convertible senior notes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzAtMS0xLTEtMA_fc3d8708-836f-4ca3-9736-bc28c45452e7">442,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzAtMy0xLTEtMA_06c9d8fa-d884-4c79-ba7d-261bf2a5ef3e">638,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzEtMS0xLTEtMA_77fd1a78-05a9-4f5d-bc24-eb7299803a4d">9,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzEtMy0xLTEtMA_75c783a8-0e9d-42b1-9c30-185dcb213417">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzItMS0xLTEtMA_6116e46e-5a0e-44c8-9ba3-f91bc384b834">64,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzItMy0xLTEtMA_c946db09-0fc8-414e-a1af-dcb462ead16a">32,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzMtMS0xLTEtMA_87c28f49-8b8d-460d-a078-9d280dbcbc7c">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzMtMy0xLTEtMA_e69094e5-9694-4fa1-9ff2-a8b316ef5fa2">9,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzQtMS0xLTEtMA_d8ee7b35-aaf4-4a48-bcb8-fd068426abef">30,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzQtMy0xLTEtMA_ce56956f-e06d-4f35-9db8-606e3dee9a65">22,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzUtMS0xLTEtMA_b6b89fdf-26ff-46fd-86e7-60e4e593492f">652,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzUtMy0xLTEtMA_764adb3f-fe6e-4f1f-b3a0-d3694200a132">727,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzYtMS0xLTEtMA_ba13fd88-22f8-44df-bbf9-631d971f8b0c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzYtMy0xLTEtMA_b903fc98-bfe1-4fce-a57e-f214fbd2b502"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzI3_45e05943-d2b8-41c7-99b7-c95bdadbaaf0"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzI3_af68105d-2a97-4cda-84ec-c37a332dcb1f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzQx_52a1c28c-01c1-4579-8548-06dab034d55d"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzQx_78745170-d7f3-41af-8f35-99b676800e58">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_0bc1edee-73ad-4011-a057-6184a85db955"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_50baeb07-085a-467a-99a9-fcc8a77bb237"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_7e780e74-5388-4416-bb72-3900bd0e320e"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_cf7f6708-817d-4d57-abde-21a5678793b2">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2020 and 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMS0xLTEtMA_693586b0-0866-45a0-9287-6fea696c4da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMy0xLTEtMA_9702a264-39c1-4970-968a-30f5493c6327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzE5_a3541e4a-a4f9-4ed8-bb41-de22cffb81db"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzE5_ad5e6bf0-d945-47a1-9188-21dbe31c3279">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzMz_b38fbe69-5fc8-4d7c-9387-f760bd9d5a83"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzMz_d96c1535-ef78-4cbe-8246-85f5567ed8d8">60,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzU1_29695590-96e8-4eb4-9589-554b0d788612"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzU1_47b86367-62f3-4a1b-a605-0e3d939260f3">16,080</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzYy_303f6f63-2334-4dbd-b832-9f330f368858"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzYy_eec3b3aa-a97f-4ed6-aa2c-09e0bf6b5097">16,823</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMS0xLTEtMA_60b80b9e-cf57-46e8-a8e8-f1740a0b7513">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMy0xLTEtMA_b379640a-6b60-4880-871d-712ff48c23ed">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDAtMS0xLTEtMA_58c9d275-9645-43c7-97d1-136746fac533">318,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDAtMy0xLTEtMA_35b2e42c-2f41-48e0-b416-04c954545fd2">367,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDEtMS0xLTEtMA_0d6fd849-e917-4b29-bd47-66938fd0f503">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDEtMy0xLTEtMA_04ee680a-90e5-456f-9c44-35c12404689c">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDItMS0xLTEtMA_1f7467eb-b408-4dc9-8743-43af0688f6ec">391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDItMy0xLTEtMA_6556d959-355f-46cc-97d4-cb424d3a5734">400,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDMtMS0xLTEtMA_e56fe4ef-8839-4bfa-ab90-4ccbd065f8ce">709,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDMtMy0xLTEtMA_6bd943bc-2ed0-4e7a-9f37-e9165590dc6a">767,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDQtMS0xLTEtMA_2ac79a54-304b-4190-ad29-c4fff5e60731">1,362,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDQtMy0xLTEtMA_6abde775-a94d-4c90-9db1-90a7b941f88a">1,494,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_67"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:62.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy0xLTEtMS0w_acd3d0ca-a082-4031-82d6-f22da3c1bf84">33,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy0zLTEtMS0w_28aa5e55-c543-454c-b7ac-9309c49d5a4e">46,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d16dd704b74221b973893e02cd3023_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy01LTEtMS0w_20bb3c1c-57d4-4c0d-88ff-cbd01ffc64d0">128,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC0xLTEtMS0w_191a0c76-db11-4604-8fb4-67b4d733fdf4">109,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC0zLTEtMS0w_442c0143-b95b-4caa-804c-5dfdfbc9b19e">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC01LTEtMS0w_62836712-213e-44b0-a580-582b9e2b48bf">29,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS0xLTEtMS0w_eb3a823f-a2ab-4f4d-8774-3816543258db">42,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS0zLTEtMS0w_46142b8c-d6cb-465c-87cb-ff6a8c7297eb">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS01LTEtMS0w_732d4f60-8ed3-4c49-91dc-e63ecd66908f">93,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi0xLTEtMS0w_a12b7f97-b860-4b8d-9056-eb00963698dc">186,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi0zLTEtMS0w_d378bbc2-a5b5-431a-a6ba-cc60531f75cb">120,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi01LTEtMS0w_6cccb8d4-7e21-4f5e-bcf7-0d84d47ae176">251,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC0xLTEtMS0w_1cce1fc7-cff8-486b-b977-6bbd14e9fe5b">30,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC0zLTEtMS0w_cc2610c0-569a-4bcd-9cdf-fc8e4e801c1f">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC01LTEtMS0w_3e14a252-7a6f-45ac-abb1-85678fcbe7c7">6,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS0xLTEtMS0w_8653a583-b7e9-412e-a115-f49cb100cc2c">23,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS0zLTEtMS0w_07c27447-6a1b-4b3f-87b1-1cc50a834da3">16,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS01LTEtMS0w_1bf8532b-32be-40ff-b6b9-6d15ff122abe">15,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtMS0xLTEtMA_ef617d9a-a3f9-419d-93fb-958f0f55a51c">59,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtMy0xLTEtMA_e7203b91-7238-4333-8152-6fc7b0e6379a">55,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtNS0xLTEtMA_3e10086a-3b82-43a9-8a3f-0aa237e666c2">27,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtMS0xLTEtMA_bdd1df6b-f021-44bf-85f3-89d465f9ff58">64,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtMy0xLTEtMA_d80809ae-5747-4caf-b5e9-3caa1ae4fb71">41,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtNS0xLTEtMA_4fc2677b-a405-41bf-8683-edd7a563c10f">37,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItMS0xLTEtMA_68eb4c52-3988-4b01-83a4-1581439f66b4">177,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItMy0xLTEtMA_c3cd7152-f655-41d4-9e27-be56ba3683dd">126,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItNS0xLTEtMA_263db1dd-fc29-44bb-bb2d-8d8163792eb1">87,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0387ebb91c44aaa14fe5f411316aab_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMS0xLTEtNDUzMg_6368b139-71d5-4282-87e7-12cec84dbb20">17,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0863c3664c064309a61c97efd34cc22b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMy0xLTEtNDkzMQ_8bd357d1-aa75-4ad2-ab68-8d88c7d5d544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74270c6229d54e75bedc1e83d6c7f2d7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtNS0xLTEtNDkzMQ_89a4dc3e-a317-439f-b93e-8d9d102877eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824ae14f7d55450f96a50e45e1e00275_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMS0xLTEtMA_5e4eee4f-60cb-4fe1-bd64-13995c94dfed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe8f99853d84177abbd1d204189cdc9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMy0xLTEtMA_7161b66e-be90-423e-af57-f529a8e80a23">812,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076d26d185984399b35b035b9c392324_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtNS0xLTEtMA_6c9bfc90-96d5-4e2b-b748-4d8d7e6ebb6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtMS0xLTEtMA_da823f0d-0c69-42db-ac9f-4b26be9efece">25,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtMy0xLTEtMA_5e970d4b-94a4-43d2-b3ad-cf9103535a4c">807,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtNS0xLTEtMA_9f07dff7-13be-42d1-b9ea-71798e7d6e2d">163,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtMS0xLTEtMA_81a79d5c-65d9-4b68-a9fd-cfb12550a58f">16,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtMy0xLTEtMA_bc10c456-1c35-44aa-9ab6-0173b9a21a0e">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtNS0xLTEtMA_93f35829-26e5-4491-9bc4-28e222fd8be8">50,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctMS0xLTEtMA_624ab436-83c4-4f3e-b4a7-9ec530cc5269">8,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctMy0xLTEtMA_51e52824-aac4-4a1d-a4ef-d4de074ebc22">28,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctNS0xLTEtMA_4b580584-d4d2-4667-899e-65aca9ac70e8">13,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtMS0xLTEtMA_9df12dcb-08b0-494a-b5f5-4a50da180658">27,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtMy0xLTEtMA_d2dc4d23-59ce-4b81-8895-d0a58af85f12">35,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtNS0xLTEtMA_88684f4b-5bdb-47e1-8788-fbddafd16645">48,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktMS0xLTEtMA_92516fcc-6915-43fe-a32b-e10d20a177f4">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktMy0xLTEtMA_f92b23d1-fceb-4fb2-af40-65cea331dd74">4,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktNS0xLTEtMA_bc9d10d3-1d87-43b5-b5d2-3c43da1626d3">6,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtMS0xLTEtMA_f9222e1e-e4d8-4908-8914-daa8bbaf82b5">36,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtMy0xLTEtMA_0e31bc69-0dca-48a9-aaff-c618d282c01e">10,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtNS0xLTEtMA_3256209f-d6ca-4067-a2d3-5afdf3cc89a0">9,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtMS0xLTEtMA_22ee5d60-1170-4888-a565-55ff8e4fb12b">10,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtMy0xLTEtMA_28765865-d706-428a-ac99-e99a3a8d478d">796,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtNS0xLTEtMA_c764bbcc-467b-4a44-b0dc-943972dad1c6">173,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItMS0xLTEtMA_482ae3b8-42fb-4bbb-96fa-4c6abc65cf2f">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItMy0xLTEtMA_eddc59dd-2fe0-4388-a157-c6812dc357a0">167,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItNS0xLTEtMA_023bca65-9607-4558-8646-59b6fc9f7447">30,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtMS0xLTEtMA_1708385d-2b4a-4d43-939f-499e3984c21a">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtMy0xLTEtMA_4db02522-c416-4996-b05b-3c99820fb80f">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtNS0xLTEtMA_98c6cac4-8887-48e5-abde-5c2f2be6f562">143,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtMS0xLTEtMA_cdd08476-14ea-4be3-bcc2-76b8f552c622">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtMy0xLTEtMA_f5cfbe4c-eed9-4d63-be5c-2e5be6c343c6">33.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtNS0xLTEtMA_fbb83081-d250-4885-8aed-4e766b353205">6.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtMS0xLTEtMA_89820d2b-1012-4df9-a58e-9ec15451ff6b">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtMy0xLTEtMA_46f82a12-1b2c-49dc-8a5c-ef236a6dfb26">18,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtNS0xLTEtMA_b6e23b0c-c33d-4fae-ae8d-d77a1a1a63aa">21,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtMS0xLTEtMA_329e916a-c67f-4385-b2b7-ae60815a9309">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtMy0xLTEtMA_48f2faa0-6d85-42e3-853c-867f4b5ec8da">31.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtNS0xLTEtMA_13c37400-6635-4a54-ab3b-f4cef95194bd">5.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in diluted per share calculation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktMS0xLTEtMA_b89fb953-3309-4ae9-9169-d119ff1315d4">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktMy0xLTEtMA_9b3f8e16-7b6d-47f0-aabd-21d7ba9fa381">19,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktNS0xLTEtMA_1ab4a104-59ba-4fd6-8b81-01b4be1f2424">24,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_70"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi0xLTEtMS0w_26c2e6a0-384e-4917-b6e8-4496da8988a4">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi0zLTEtMS0w_3202b1f0-dfc7-40f8-8b4f-1d87e8870d24">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi01LTEtMS0w_94483b0f-21f8-4509-8bd8-c17b1664cf26">143,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy0xLTEtMS0w_f0599c63-4647-4b84-b6c1-fe4e2499fd02">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy0zLTEtMS0w_cb567001-e55a-410c-905b-bfffebc3cdcc">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy01LTEtMS0w_0fdde55b-d06d-437c-954f-53d91c4e2f46">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC0xLTEtMS0w_f91f56ce-9f4c-47f7-b307-c782abc14a51">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC0zLTEtMS0w_f1b82f29-3de5-4972-b785-43900e753f11">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC01LTEtMS0w_4db53640-f1e1-4490-a857-97d3a24d6600">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi0xLTEtMS0w_b144fe3c-7848-46ec-94e9-191ed6e4b7a9">3,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi0zLTEtMS0w_71696353-a4a7-4107-aa8f-40802639d2f9">630,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi01LTEtMS0w_bc95c8aa-0a72-41d0-aea6-1470889dd465">142,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ib69a1c25a15148f9b95ad6e3392de608_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.945%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">capital</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">income (loss)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">deficit</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">equity</span></div></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd387f8ff7744137980599559a1c5f77_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMS0xLTEtMA_6223f524-42b8-4508-bef8-d15a17b8dff3">21,148,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd387f8ff7744137980599559a1c5f77_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMy0xLTEtMA_606d8e52-7d9e-4348-87af-e3cba3f05f10">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346897ea83804fdd8c657865b763ef87_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtNS0xLTEtMA_c0576344-6742-4c09-8ed2-69b98e8ec768">798,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59bfab0480542cda230d78e7ef5e82e_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtNy0xLTEtMA_3318f02a-e44c-42df-9c8a-8107dbc91eeb">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911fa320b1ef4643bd62d2f1d873e78c_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtOS0xLTEtMA_f96adb9c-f200-415b-bc1b-720fdf2b2479">400,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMTItMS0xLTA_1339a01c-e725-41c7-a92b-91a62ef82cfe">399,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtMS0xLTEtMA_9a4cab1a-fe9d-4fe6-b26f-de982b0c932d">399,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtNS0xLTEtMA_d5688300-aa86-435c-b0e3-6d749b66b9b4">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtMTItMS0xLTA_c31d1aba-0899-4181-a69a-62ee7d63034c">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification of equity component of currently redeemable convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTItNS0xLTEtMA_2d8bb92e-2d52-46b7-8073-684f5564cb58">18,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTItMTItMS0xLTA_6309f941-beeb-44fd-b365-2404b1f917d8">18,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTMtNS0xLTEtMA_71437800-f55c-41f1-a9a1-d867683eae8a">20,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTMtMTItMS0xLTA_dd78ccd6-c28a-4755-9ee4-80e7001cd3bf">20,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtMS0xLTEtMA_12828d8c-0431-4675-a10a-67308f50302c">782,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtNS0xLTEtMA_6adc63bf-94de-4647-884b-fdd2b86957fb">127,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtMTItMS0xLTA_a45294d4-070c-45e9-b234-9c9cd6039ec5">127,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTUtNy0xLTEtMA_b2debb6e-b06b-4b03-86e8-484eb118456b">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTUtMTItMS0xLTA_66595342-3fea-42aa-8a55-7eca57724038">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cumulative-effect adjustment from adoption of ASU 2016-01</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7054e445350945b5a3ac6b9a4827ce2a_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtNy0xLTEtMA_0514e11f-8339-482d-8bc7-a26c700e2240">2,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14c67e9b9e04b7093d188b4497bf574_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtOS0xLTEtMA_f04e2b9f-1350-4f71-9a54-b630d2089458">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ee9751e8804e03bbd45e0f38940a0c_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtMTItMS0xLTA_afb142e5-a42d-4834-aded-1958166a5da0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cumulative-effect adjustment from adoption of ASU 2014-09, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7c5c2af724c429803e6c84d4842b6_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTctOS0xLTEtMA_5f506a38-fb6a-48d1-b08f-35f9aba566cd">25,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37bbc9e048046e88b85c63fa39515f5_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTctMTItMS0xLTA_e8e06eaf-65e6-43ce-a733-cde46b821203">25,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivative associated with 2019 Notes and Bond Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTgtNS0xLTEtMA_3df77f91-02c8-4839-82e0-712b09b9ac9f">1,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTgtMTItMS0xLTA_ade79b0f-5079-4c51-a7c3-d6ba0126224b">1,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Loss on settlement of 2019 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTktNS0xLTEtMA_1290c20b-471d-4336-9617-f2970cfb38a4">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTktMTItMS0xLTA_63d98d4d-9598-4943-acf7-f7cd6b037e4f">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Warrant repurchase in connection with 2019 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjAtNS0xLTEtMA_1bd36fd8-78f5-4fa4-b55e-684449ecc155">30,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjAtMTItMS0xLTA_d6640a08-04f6-4258-8326-72cab7c3d632">30,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Loss on repurchase of warrants in connection with 2019 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjEtNS0xLTEtMA_b6fdd6ca-99b5-474b-9c77-7cf0ab9b08de">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjEtMTItMS0xLTA_92ac6282-b24a-497d-8e04-64b99257b830">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax effect on 2019 Notes transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjItNS0xLTEtMA_ff272bdc-4af1-463a-a942-2208e258bcce">1,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjItMTItMS0xLTA_b65f9c5d-0a9f-46a1-a7d6-2ccd1b4c080b">1,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivative associated with 2023 Notes and Bond Hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjMtNS0xLTEtMA_12283259-75de-493d-8170-2c53a5318c35">1,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjMtMTItMS0xLTA_ad774514-10cf-400a-902f-0f3efe32e88a">1,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Warrant derivative  in connection with 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjQtNS0xLTEtMA_0ef35b4d-1678-4f04-93a5-b406a5e941e6">97,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjQtMTItMS0xLTA_423a343b-5ee9-4b71-a68a-a35cd7969232">97,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax effect for 2023 Notes transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjUtNS0xLTEtMA_c7da4880-5480-42c5-80c9-784e81467a66">3,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjUtMTItMS0xLTA_ead2955b-5493-4ffd-8c0e-035ec0c568e8">3,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjYtNy0xLTEtMA_081d10ac-195c-477b-9ecd-319d7bd08fd4">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjYtMTItMS0xLTA_5de819dc-cc33-4921-a982-3e471cab7c51">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctNS0xLTEtMA_79badb6d-de68-4ba5-8246-299fc4a462c2">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67458ea516e439bbc83b615b79b3518_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctOS0xLTEtMA_74e8608b-fc3d-4358-854f-8418e18c8155">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctMTItMS0xLTA_67fc0bf7-5221-48bc-bbea-30bda184a9db">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67458ea516e439bbc83b615b79b3518_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjgtOS0xLTEtMA_005fb4b4-e981-471f-aa73-c3bfb81229ab">143,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjgtMTItMS0xLTA_dcf28036-f449-41f6-8afe-0ed9366e2241">143,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf82073fee7b42059c5ceb699522c8e2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMS0xLTEtMA_f826254b-0c31-4d92-abef-5ecbac3dff5e">20,765,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf82073fee7b42059c5ceb699522c8e2_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMy0xLTEtMA_a70f36fc-b26e-44f0-96c7-d61658175288">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea39822ada3c494db6a1bf3fd99d48b2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktNS0xLTEtMA_042c29d8-b315-4b95-b098-18cdf40056a5">791,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i111967c6372740459aedf8ec7bb0ce69_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktNy0xLTEtMA_bb0fccbb-2f41-4dda-ac99-8838e8a42070">1,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f450afb88d04c82a9ea8a0fe0f120af_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktOS0xLTEtMA_dfe19006-5328-4b12-9f5f-c61a4fda90da">229,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMTItMS0xLTA_3b8af01a-080f-4b7e-b8a1-2a940bfd2be5">560,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMS0xLTEtMA_76aca2a8-4d72-4607-bea5-43b9acda1684">179,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtNS0xLTEtMA_b8f9366f-46a4-45a4-b7d9-6a988706a691">1,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMTItMS0xLTA_ddfb3e10-7fcd-4bd3-bc9b-5667fa795105">1,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtNS0xLTEtMA_bb04e3d7-649e-4ab2-9340-548c39fb89aa">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtMTItMS0xLTA_f51359b3-8406-48a4-af0c-f74fd47b8556">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMS0xLTEtMA_a2158653-a872-4490-932f-634acd5c1452">4,122,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMy0xLTEtMA_ad280bf6-8643-4b29-942d-ab6740533a43">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItNS0xLTEtMA_f8f2cc53-548e-49ab-82b3-36d444273253">448,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMTItMS0xLTA_8fcf2454-1383-44ee-8bb5-9fadb6ed5151">448,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net gain on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtNy0xLTEtMA_6997efd3-a547-40aa-a8d5-b2e42b7ed6a8">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtMTItMS0xLTA_dc7772a3-d059-42d5-9891-dedc4b72ff77">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtNy0xLTEtMA_aa8d42de-eb19-472f-9e9e-6b5b5cb16dda">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtMTItMS0xLTA_99c6ced1-f027-4c84-a600-8f76cdc5d4a1">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtNS0xLTEtMA_c1d1ae53-90d3-4bce-8f7f-fa66a528171d">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtMTItMS0xLTA_b38bbfc7-a27b-40ba-a07f-fd5b33d77572">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i651d151d6b5945ae854d15dfa48f1c67_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtMA_9e159baa-9101-4845-b6c5-a4b22dd390cf">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMTItMS0xLTA_339c1058-fd54-4156-b3f8-83c074d0e026">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59f3bec8971d4633aec80a74abc60a98_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMS0xLTEtMA_d3386b6b-ea78-45ba-a705-60e90a66647a">16,823,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f3bec8971d4633aec80a74abc60a98_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMy0xLTEtMA_2e51b44c-e887-480d-bccb-1c7f1d3549cd">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f9c1547a2345d6875efa9ab06fc528_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNS0xLTEtMA_f6ead11e-5858-4fb3-bc04-37fb3618a1c7">367,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ce61c0bc144472b7631a9d4df3f9f7_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNy0xLTEtMA_bb2ae411-412a-4a52-8c9d-8b50bc7c621b">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5781b4d9f661461796c8363bed666193_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctOS0xLTEtMA_aaf5d604-362f-47a9-aed4-d3548610123b">400,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMTItMS0xLTA_ce662199-412d-4ff2-888d-4e5ee3cfb6dd">767,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMS0xLTEtMTU4NQ_a7c96509-e8e8-4c0a-a20c-a321100beb7d">190,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtNS0xLTEtMTU5OA_163589b4-d70f-4d7c-bbcf-2088f2eb3773">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMTItMS0xLTQ5NDY_16351ffb-a0a7-4e04-afc7-07f1fd42356d">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtNS0xLTEtMTU5OA_57ec9d7b-a133-458b-a3ce-bbfbc43bf85e">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtMTItMS0xLTQ5NDg_1c5fca43-ff2f-4c68-b641-11f06ac66ddf">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMS0xLTEtMTU4OQ_0d6015f8-3583-47a4-9db0-9c81a81c395c">934,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMy0xLTEtMTY3MA_49db4d0c-d0c1-4a11-821a-43fb03d9e5d7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItNS0xLTEtMTU5OA_526de405-e486-4e9f-a8c5-92da9d68187e">77,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMTItMS0xLTQ5NTA_4ab8f732-fcc9-44d8-bb6d-cbab4ec0b414">77,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtNy0xLTEtMTYwOA_56c6dfed-0667-4f14-b75a-355e8e80f058">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtMTItMS0xLTQ5NTI_a473b3f4-0eb4-4767-819c-1baed5259371">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtNy0xLTEtMTYwOA_c80a7d3d-240a-4dff-95e3-f666907eea32">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtMTItMS0xLTQ5NTI_d1a368bb-61e9-4b71-9d8f-55d2ddca04e4">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reacquisition of equity due to 2023 debt extinguishment, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtNS0xLTEtMTYwMw_97ccb69d-f9b9-4f3d-945e-0bb17cfc649e">3,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtMTItMS0xLTQ5NjM_16487eb4-7b51-454f-823c-f3b21fb7c53e">3,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMC0xLTEtNDk2Ng_219e2ce5-02b5-469b-a2fa-1b0d64350836">Cumulative-effect adjustment from adoption of&#160;ASU 2016-13, net of tax</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f4968cadd8f471d9ce10c3dac04adeb_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtMTY2MA_cce559de-0a79-48bc-bebb-c16298fa5085">5,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic556fe238be54d7ea1cbe97cfc3b66cb_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMTItMS0xLTQ5NTU_8a6bc129-2a02-4aac-a1e5-9787c66b2278">5,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNS0xLTEtMTYxNA_621f28ea-1dc3-4aa3-a463-a1552cf669cf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMTItMS0xLTQ5NjE_f7d5fa44-49c5-459f-a015-05d6851ab218">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3886328178847949eca5c819b9d1a5f_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtNDc4_c56f54a2-d8f4-401c-bce2-fe03910d776a">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzgtMTItMS0xLTQ5NTc_9fbf8c41-f1b5-42b0-8bd3-3a2552af2c4d">2,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9438636ad1d45ac9d842c540b69c517_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMS0xLTEtNDk1OQ_ad21e7ff-91c7-4931-ba74-f11d0ac5d2b5">16,079,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9438636ad1d45ac9d842c540b69c517_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMy0xLTEtNDk1OQ_60087417-408e-4344-813b-37d5596a4fd3">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2a6466d039469193ef347cfe3c1115_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktNS0xLTEtNDk1OQ_6ba4f808-b774-4d9a-a7d7-ce0517ec7c49">318,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb83d5853ca34bfe8b02f1ad840f88e5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktNy0xLTEtNDk1OQ_16a601bb-3314-4ee8-b545-70039d715585">801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d45dbab0ab74a33aec9e7b5fc42b546_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktOS0xLTEtNDk1OQ_d00d9ff6-a8ea-4f4a-a97a-02ff65318be8">391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMTItMS0xLTQ5NTk_b79276a4-de65-492b-bcca-31c7021f9eaa">709,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy0xLTEtMS0w_909245d2-a065-46a6-b8eb-4870b0a3bb6e">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy0zLTEtMS0w_545cf2c5-9951-4f16-85ad-52044325af74">629,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy01LTEtMS0w_9e45b040-1732-4db6-b35e-af9e376ae8c7">143,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Promacta license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS0xLTEtMS0w_f172651e-23c1-450e-923a-7683c60f6304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS0zLTEtMS0w_47ac9ee7-5177-4d2b-922d-1b662c1fbb04">812,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS01LTEtMS0w_984b24a6-8841-4b85-b909-b973c7079c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNy0xLTEtMS02ODk1_d4c930da-84a6-4204-a61a-74e2606c23d4">17,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0zLTEtMS02OTM5_4f181f8d-f2f9-450f-bdb3-3d8235c7dd9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi01LTEtMS02OTM5_82576ef8-1e04-478f-b9ca-4ed226d7b268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0xLTEtMS0w_fe7cd832-cdea-4b2f-837a-c60bd1137cbd">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0zLTEtMS0w_84e65b07-be87-45fc-931d-5d1f8756d189">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi01LTEtMS0w_4d18e708-1ed2-4301-8021-7eba3d1d55c6">3,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC0xLTEtMS0w_9837d8ac-4d12-43b5-b571-6ef53b0ab019">25,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC0zLTEtMS0w_19c500d6-1de1-4a3f-8523-aa15b8918194">18,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC01LTEtMS0w_3a0c1d9a-c99c-4a7d-94bf-1a2daf877f45">12,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:GainLossOnShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS0xLTEtMS0w_af0fbb02-f5e6-4463-97eb-9da81aa85e71">16,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:GainLossOnShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS0zLTEtMS0w_bde0ec40-7bc6-49be-9289-e4dc2f981079">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:GainLossOnShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS01LTEtMS0w_b4f80856-0b03-44e7-9208-4bde38038189">50,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization/accretion of premium (discount) on investments, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtMS0xLTEtMA_eb38e01d-e574-4066-a929-42c8492320b3">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtMy0xLTEtMA_7f92b88a-537d-491d-a58c-c1a033247fc5">10,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtNS0xLTEtMA_6b85fb56-0acb-4acb-9084-a8e7f6b73abe">5,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtMS0xLTEtMA_9ad594d8-6dcd-493a-b58a-162f2cc54653">23,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtMy0xLTEtMA_bcf8a3af-1d9e-4188-989f-dc75d38662fc">29,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtNS0xLTEtMA_3f67fd62-6cb3-4912-ba89-9221f56192ab">43,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of commercial license and other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItMS0xLTEtMA_d07465b4-5534-4652-b470-a9c7fc73bfcf">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItMy0xLTEtMA_c7b98f9a-ee5a-44b8-bd1d-5d85097c8853">25,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItNS0xLTEtMA_caf33d48-3123-48bf-9094-c95fee76bf14">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtMS0xLTEtMA_aa5fa713-afb5-4b54-ab48-ec72491c208e">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtMy0xLTEtMA_d06eaaea-93b0-4091-b3e8-991bcc884de0">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtNS0xLTEtMA_d22be599-ca17-4e62-af9e-05317e63b1c9">20,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtMS0xLTEtMA_4984e573-d9ef-4e35-af57-6486d85ef032">19,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtMy0xLTEtMA_6a2603dc-beaa-4d9c-9e32-9485bcd23fd6">74,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtNS0xLTEtMA_bc6478d9-d537-4d2e-ac7e-a6e6fbb6471d">29,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties recorded in retained earnings upon adoption of ASC 606 </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtMS0xLTEtMA_79d002b8-e579-40fe-b52c-b3e97ee35ae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtMy0xLTEtMA_9bacd2be-2dbb-440d-979b-60894b9b4bf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtNS0xLTEtMA_47437a2d-9dd1-4edb-aade-2fe6e4b7ef8c">32,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtMS0xLTEtMA_4249b97f-6955-4f40-83af-047023d371f1">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtMy0xLTEtMA_3631559e-3ff0-4d37-95f0-1a3ef6dc89ce">3,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtNS0xLTEtMA_9f843340-32a5-4b20-a070-2cc552a031ff">2,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtMS0xLTEtMA_1975277c-12d6-404f-8c23-80a69373e08e">26,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtMy0xLTEtMA_0b3adf6b-89d2-4437-aa5e-c032bbf37a87">25,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtNS0xLTEtMA_2aa76fbf-3a2d-4127-853b-c65f865bfc00">29,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktMS0xLTEtMA_3017090a-68b5-4ca2-a824-01a243b73c41">17,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktMy0xLTEtMA_16eeea86-0bbd-4943-9a11-0175698ceb48">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktNS0xLTEtMA_a2558859-2dcb-4b0e-8fd9-c4a58f62c43b">2,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtMS0xLTEtMA_90f0746d-8595-4f14-be32-8d7e54b46260">1,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtMy0xLTEtMA_abfe2b41-76f0-47a3-8950-44fb7fadbb8b">6,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtNS0xLTEtMA_30b9c8f6-7112-48ab-8f6a-4fb8c6d86bc2">4,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtMS0xLTEtMA_7c96b014-2e32-4fec-b92c-8c3d3ae1877b">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtMy0xLTEtMA_aaab17d8-e80b-494a-abe9-538a6a038e6b">11,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtNS0xLTEtMA_73783323-9170-43c3-9225-40bb5c922e28">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItMS0xLTEtMA_d550a5f9-1fe2-4ac9-ae49-c71bbb20dc30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItMy0xLTEtMA_a54c6c98-04dc-46de-8a8d-0780b2218679">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItNS0xLTEtMA_200bfdec-437f-4b54-935e-397fd7ca1c80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMS0xLTEtMTIxNTg_691f46d6-49fb-4c97-9941-d5e0fde7669d">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMy0xLTEtMTIxNjc_6933426f-5cc3-4a69-b9b0-96c625a49ec2">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtNS0xLTEtMTIxNjI_fe2b55a8-25fc-4855-a010-7f6b53e3eac6">1,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMS0xLTEtMA_e887e9de-41b6-474a-90c3-dd44741a3eac">3,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMy0xLTEtMA_97eefbae-86ea-4868-8b0d-c0f9f2931029">3,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtNS0xLTEtMA_77d0e158-c5f2-4a92-b86d-2b0e8922eb08">4,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtMS0xLTEtMA_f6f86d4a-ed57-44dc-a93d-82fc62452078">54,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtMy0xLTEtMA_ff52b97f-6509-466a-907b-05b3c562ce02">29,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtNS0xLTEtMA_cde81a83-18d9-47ed-8cc2-a7320d3ce4c5">194,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of Promacta license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtMS0xLTEtMA_07be16e9-a7d4-46b1-bf75-580a1ba940e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtMy0xLTEtMA_fe4363f3-b1ad-4a8f-b179-ee5ac4ff613e">812,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtNS0xLTEtMA_13794dd2-4243-44c7-b80f-d438bd6ca302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of commercial license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctMS0xLTEtMA_de638754-7366-4915-a03a-df15b9a04d58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctMy0xLTEtMA_003dbe07-26e5-47b9-b501-80dceafd75e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctNS0xLTEtMA_37f7aed7-bd4a-49a3-bd1c-f3dc15202fa1">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash and restricted cash acquired</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtMS0xLTEtMA_b55c1f8e-bba3-4f4b-9768-17e655727407">404,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtMy0xLTEtMA_21c4dcc0-5bda-4ffe-87f1-d3215d4ac6da">11,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtNS0xLTEtMA_46d4d3a4-9259-458f-a79c-3b40a746e6ef">5,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktMS0xLTEtMA_c9284dde-245c-40cf-a463-4c644d6cb6f2">4,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktMy0xLTEtMA_d1eb2ee1-4dd9-4d18-910c-dc07946db60d">2,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktNS0xLTEtMA_cc0a7246-605e-4b11-b6b7-9f80516c1788">887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtMS0xLTEtMA_c1763e2d-37bd-4c86-be4f-654b33e16c3f">422,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtMy0xLTEtMA_a975da25-8340-4798-8871-cdb76ff92959">2,356,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtNS0xLTEtMA_b09944f5-ab37-439d-96d3-6974f60c156b">1,434,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from commercial license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzMtMS0xLTEtNjkxMQ_d702742f-538a-4d8c-b497-66e12a2d96f8">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMy0xLTEtNjk0NQ_ab2e754f-c97c-4319-bce8-1206aa81537d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItNS0xLTEtNjk0Nw_80b85cf6-6333-4835-ae64-2114c922b8d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtMS0xLTEtMA_de624c25-f415-4886-861f-bd40f3af6e1f">394,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtMy0xLTEtMA_bc39b759-f0f9-4774-a493-f1e42f35a750">535,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtNS0xLTEtMA_25973ca6-c875-45b9-aed4-128fc5340cc7">131,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMS0xLTEtMA_86c0f0f9-fb04-4a8f-85ec-bae7c888807d">644,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMy0xLTEtMA_8d91432c-f989-4cf1-8969-61c44bc36013">1,494,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItNS0xLTEtMA_3d009157-9274-4d6b-8dac-828bb3308749">892,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds received from repayment of Viking note receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtMS0xLTEtMA_d10dee03-4949-4e20-aae5-b988a132762b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtMy0xLTEtMA_ac27ad25-5090-4fa2-966b-2bde7b722e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtNS0xLTEtMA_dc78fe26-9e46-4e6b-ab7f-cd36481fb8e9">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtMS0xLTEtMA_6203f7d2-23eb-4ea4-9f76-b2a27106eb25">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtMy0xLTEtMA_3bd26bef-f6d4-4802-81d7-fe7ff14b12b7">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtNS0xLTEtMA_bf1ab145-acd4-4cb5-a109-e5f102142667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds on sale of Vernalis R&amp;D, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMS0xLTEtNjkyMQ_9ec27d89-3413-466f-8250-f463605cef29">22,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMy0xLTEtNjk0MQ_83762e07-efa6-45dd-9015-09a47099a6e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctNS0xLTEtNjk0MQ_c5c7a5c2-5a7b-4846-9c84-956497fcb46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtMS0xLTEtMA_fde80fff-083b-438d-ba33-1aed3d19f653">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtMy0xLTEtMA_8d246d0f-078a-42f2-8cfe-da890d273f02">4,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtNS0xLTEtMA_2879dd50-458e-4c61-a0c7-40f787db206d">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMS0xLTEtMA_1ebfb988-785c-4d07-9141-ed5c8753aa74">231,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMy0xLTEtMA_7701c1f2-0e35-40fe-9d7c-b2f99d63f62d">466,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctNS0xLTEtMA_11952258-782d-46f3-b954-141b46fe4241">423,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktMS0xLTEtMA_6ba7db55-9d96-4fb2-adc8-b2538e9bf79a">222,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktMy0xLTEtMA_d8881729-ad99-4711-8f9a-890bc4476bb7">27,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktNS0xLTEtMA_f7e42eb0-e63a-4f4a-ac7e-b2103ea950f1">217,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments under finance lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMS0xLTEtNjkzMQ_2b78340d-4ed5-42d3-9de4-7c215278cdde">9,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMy0xLTEtNjk1Mw_aca7664b-d4b1-4bad-ba4d-9b218b59d2ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItNS0xLTEtNjk1Mw_40410e0a-af6d-45fe-b854-9c77496e52dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross proceeds from issuance of 2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtMS0xLTEtMA_43de4e37-364a-4412-bd97-5dea35d1a9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtMy0xLTEtMA_65de2593-2ef2-4d89-ad47-72e2270880ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtNS0xLTEtMA_f30b4054-5778-4e19-be67-2ab2dd5739f0">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtMS0xLTEtMA_69de22a8-d984-4484-87d7-439b6dfa8f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtMy0xLTEtMA_f42e1cce-ba3a-4bfe-8429-64ec9ab6b078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtNS0xLTEtMA_0a1b0ba1-b731-43b5-99a4-ee1c507b1764">16,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMS0xLTEtMA_183443f1-39f1-4eab-9639-c42929451cdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMy0xLTEtMA_4241e480-fde0-4e84-ab62-5b487253098f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItNS0xLTEtMA_cefe6558-d51c-490a-a8fa-b0764c7ed331">90,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of convertible bond hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtMS0xLTEtMA_4b38601c-8a50-4136-a30c-1a912e54bd3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtMy0xLTEtMA_cf6f0638-69be-4bd8-950b-1edda54fbc68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtNS0xLTEtMA_cc56e9b7-fe52-42fb-9774-5bce0193c037">140,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from bond hedge settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtMS0xLTEtMA_116b14a0-24cc-44d2-862a-1e2d0b0cbef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtMy0xLTEtMA_1441911f-8ab5-4520-89ed-8940b88ecd3b">12,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtNS0xLTEtMA_bd14e999-3cf0-43d9-af5b-da400f384052">439,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to convert holders for bond conversion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtMS0xLTEtMA_9b57973c-0346-41b9-809b-d742aa6f2899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtMy0xLTEtMA_d5f47d7a-eaf6-473b-8637-b9b30836f891">12,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtNS0xLTEtMA_37533ca6-4c50-42b4-953c-10edf1500ab5">439,581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtMS0xLTEtMA_5f75f783-a68d-478d-bfa8-1fb15b71196f">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtMy0xLTEtMA_d8045596-3f06-4bd5-b94d-63eaaa785bbf">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtNS0xLTEtMA_0777cf79-d863-48fc-a754-4446234a66c2">20,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctMS0xLTEtMA_42227736-1aec-4cf9-9ee8-a30a3de1e114">1,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctMy0xLTEtMA_2ac55862-a86c-42f6-846c-bddb7230e1c8">4,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctNS0xLTEtMA_6fc54f9e-1855-4df4-aad2-c1140a3f258a">3,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtMS0xLTEtMA_6fd2267e-84ce-4429-9859-e382003ee44d">77,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtMy0xLTEtMA_85db8291-4822-4063-8ed2-69d0179bc18f">453,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtNS0xLTEtMA_cddcc1bb-3152-41de-a9e7-49b7171ce818">122,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktMS0xLTEtMA_f632509a-f464-4f75-a80b-9ae9bc1c7ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktMy0xLTEtMA_8edf8864-1310-49a3-be73-c10a249924d7">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktNS0xLTEtMA_27f233dd-ac6c-420a-bca8-587a4f8c2b9d">30,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtMS0xLTEtMA_7ea5e163-a39c-40b7-9556-8cafda8f7ba4">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtMy0xLTEtMA_1013797b-015b-497a-8991-5cc98f92eee9">3,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtNS0xLTEtMA_57b85d9d-f0db-4788-b4a9-ba413d6c4992">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtMS0xLTEtMA_78a945a7-aac2-46db-947a-376155a15415">310,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtMy0xLTEtMA_83e60163-97d3-41ba-a102-52a19526de07">485,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtNS0xLTEtMA_6a62b3b2-7e5a-4da1-a2c3-f7ceb59049c2">328,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItMS0xLTEtMA_e6cba2b7-c042-42a3-b25b-f00afe78e93f">24,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItMy0xLTEtMA_ddb0ecbe-26d6-47b0-98ca-d4aa2f043836">47,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItNS0xLTEtMA_1ea1cdb8-a9d2-4a7d-a642-7e565511ea0d">99,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtMS0xLTEtMA_5ed5cedd-c708-4b0a-b07d-6ba03a7e3b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtMy0xLTEtMA_64f7e6c7-ab26-45ea-9f83-0c073d7778af">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtNS0xLTEtMA_615b57b0-bc96-4bd1-b37b-24c7e3f9f2b9">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtMS0xLTEtMA_28fbc02e-909b-42d8-9b4e-0c5cd6c11b24">72,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtMy0xLTEtMA_06084afa-c034-4350-adb0-9bfea34e0a3a">119,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtNS0xLTEtMA_2a7e4af9-0998-4823-be50-9d2aa2f51db5">20,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtMS0xLTEtMA_b4d9fad8-7d4c-444b-8a07-8552ae895137">47,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtMy0xLTEtMA_9121c0c3-6527-4137-b8a6-11410d49e7fa">72,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtNS0xLTEtMA_4d275164-05d5-4541-8470-e24213a68387">119,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid during the year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtMS0xLTEtMA_237e27b4-c3f7-46ff-8ccd-5fe2b88a425d">4,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtMy0xLTEtMA_55882d65-788b-4ec2-8496-4e917cd3af3d">5,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtNS0xLTEtMA_c85a144f-652e-43d7-9cb9-e030b63da4b7">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktMS0xLTEtMA_648545ba-16b3-47cc-8a2d-4670da5632d9">2,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktMy0xLTEtMA_a2a9bd39-ba4a-4cd3-b343-449b0a705904">103,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktNS0xLTEtMA_eab6661d-3219-4819-a55f-db093f280759">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash in other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtMS0xLTEtMA_043b7dc4-57e6-4fc1-a56d-6f15c481a642">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtMy0xLTEtMA_76d2c531-b674-4d9a-89e0-aeedb17cbe7c">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtNS0xLTEtMA_5e1f1728-2543-4fbb-aaea-b4f73016be67">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItMS0xLTEtMA_d81b6c00-25eb-40a3-8e4e-1c7d3cf7e798">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItMy0xLTEtMA_617363f1-8d05-4ef4-922a-04579c91ab32">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItNS0xLTEtMA_891eb4dd-5421-44f5-bc09-b991bdf613fd">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (loss) gain on AFS investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtMS0xLTEtMA_ffbb6184-acf9-4cf3-aed1-5ce69fa8ff97">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtMy0xLTEtMA_52080f73-6f89-455e-a690-f1c8c0495e04">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtNS0xLTEtMA_2fe77905-4629-4d9d-903f-72948c16cdad">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of fixed assets recorded in accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtMS0xLTEtMA_52a2088c-ff34-46ac-ac06-5dc1b1883f77">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtMy0xLTEtMA_bcd3d947-de3d-40f3-9ef0-3d393c06f20c">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtNS0xLTEtMA_26aadedc-5aa5-4a69-bc63-1e0d90dfdb6b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_79"></div><div style="text-align:center"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_82"></div><div style="margin-top:14pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to &#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Ligand Pharmaceuticals Incorporated and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTc_f23885d2-5cfa-49ef-91c3-ccbce0ed71d4" continuedAt="ia1c227f9756342a1aaf6400f7748ca1d" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia1c227f9756342a1aaf6400f7748ca1d" continuedAt="i75c980d5f7ee481ba63786dbbf8aaa12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTM_5c0c64a4-d703-492e-8453-a4de71521470" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTg_abfe0ee3-7210-4fad-98a9-9d1cd08c2c3c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjE_30e7eedd-5c7e-411b-9ea1-3f853e2c36d0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking common stock and warrants was reclassified from &#8220;investment in Viking&#8221; to &#8220;short-term investments&#8221; in the audited consolidated balance sheet as of December 31, 2019. Additionally, &#8220;gain (loss) from</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">short-term investments&#8221; in the consolidated statements of operations include both the gain (loss) from investment in Viking and other short-term investments, which was previously included in &#8220;other income, net&#8221; for both the twelve months ended December&#160;31, 2019 and 2018.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDA_e8fb0bff-5d21-410c-9e40-861977b99c2e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTQ_8491760d-888a-40e9-b328-078344174e6c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDk_6854d0bf-1d80-4dbc-ac86-2f3cd6f749bc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c73811c3a6b413583f19b4f18914422_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi0xLTEtMS0w_2d9bd376-3e52-4b46-840e-666b26de52c8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ec746f5f2a1420e8b4a73e3b14f2911_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi0zLTEtMS0w_7ed9e830-19f9-42b2-ae3e-ac8ce070b009">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54f2cab9b1344c4ca4467e441c736d9d_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi01LTEtMS0w_78750b7b-de34-42b4-bbb2-eee637597326">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05df3adf0d3445b08cd69ac5d9c78c78_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy0xLTEtMS0w_9d21f6e9-fcb3-4af2-82c0-d2425f448871">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f7c735f7f3a43aab5151e4131cffac0_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy0zLTEtMS0w_2e2e6b62-3647-433a-98fd-e51b962b8f2c">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie64ebeef7e4d4fce822fce49568cde02_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy01LTEtMS0w_db4e66bf-8f08-4167-b8f1-daae37f51947">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dd5f6f2356147aaa9c76736d1bbfb27_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfNC01LTEtMS0w_5b2009db-143f-446b-9704-e033cda0f6fc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24pt"><span><br/></span></div><ix:continuation id="i75c980d5f7ee481ba63786dbbf8aaa12" continuedAt="i59feae412fbb4276abdd34b1e00babb4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDE_a93c0c7c-2164-4a89-9e82-060bcef3bab3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents &amp; Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of all investments with maturities of <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:durwordsen" name="lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjkxNQ_dd224f85-8b4b-43c4-ad17-2580774d96bb">three months</ix:nonNumeric> or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  We periodically review available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To date, we have not identified any other than temporary declines in fair value of its short-term investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDc_cedd8f07-c92f-42b6-8f50-b32df211cac1" escape="true"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2020, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:AccountsReceivableCreditLossExpenseReversalCOVID" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDk5NzUwNQ_7f744440-752c-4052-af02-52aad931e9bc">0.3</ix:nonFraction>&#160;million of allowance for credit losses as of December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0Mjk_6b0fa08a-8acc-412c-9b49-0ea35953ba9c" continuedAt="ia79f42b5e6584cedb82e92c47a3b5de4" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia79f42b5e6584cedb82e92c47a3b5de4">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_61c7065f-488f-4b65-829c-1c6d3751acd3"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_66d1155d-9a19-439a-a450-281a13eefac2"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_9a4141d1-c1d6-4a0b-acc9-815b435d153b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> write downs related to obsolete inventory recorded for the years ended December&#160;31, 2020, 2019 and 2018.  </span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTk_857710d2-2ab5-448d-a596-0baa49f83213" escape="true"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2">three</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1">ten</span> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTA_ed4bbb13-9c93-44d8-b6e9-8b0bf30f27f1" continuedAt="iae74ca86139a4baeb0f8e90cc3aed144" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i59feae412fbb4276abdd34b1e00babb4" continuedAt="i3b11f2796b564c5f85439c7520683241"><ix:continuation id="iae74ca86139a4baeb0f8e90cc3aed144" continuedAt="i4811fc37831f4869b9cb854498b40f67"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4811fc37831f4869b9cb854498b40f67">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</ix:continuation> </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Pfenex in October 2020, we will pay $<ix:nonFraction unitRef="usdPerShare" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfOTM0NTg0ODk0NTE5NA_8235ceb4-297a-4963-91e2-48aeb2a161f1">2.00</ix:nonFraction> per share or $<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfOTM0NTg0ODk0NTE3OA_ebf19fc5-d07e-4016-8c57-5066977dc841">77.8</ix:nonFraction>&#160;million as a CVR in the event a predefined regulatory milestone is achieved by December 31, 2021. The CVR Agreement provides that the required milestone will be achieved upon the receipt of a notice from the FDA that the teriparatide injection is therapeutically equivalent to FORTEO&#174; (teriparatide injection).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzM4ODc2NA_02e7ab58-a7df-4ff2-bddb-a09b3785afc9">25</ix:nonFraction>&#160;million of cash payments based on certain revenue achievements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="ia66f417c4e0546919bf13f281a215faa_I20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfODM1NQ_c50c769a-15f2-40dd-8f16-202f8b4c5623">10.5</ix:nonFraction> million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="right" contextRef="i5e2203c889594b6d90a943e1d333ba3a_I20100131" decimals="INF" format="ixt-sec:numwordsen" name="lgnd:NumberOfContingentValueRightsIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfODg4MQ_8c7de68f-6a9c-45ed-a95a-8f5cae01c0e4">four</ix:nonFraction> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDg_8aa8059e-6a1a-4095-a948-b8430b99fc7f" continuedAt="i80467c7269894c829789ef4ae9b644ca" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3b11f2796b564c5f85439c7520683241" continuedAt="id67df9e561314995ac7450e943f256a2"><ix:continuation id="i80467c7269894c829789ef4ae9b644ca"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2020, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2020.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:CommercialLicenseRightsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MzA_263700e3-26f2-4120-b0e1-33ec959ad9aa" continuedAt="i4967f1968d2a48d6b46742596ca55dcb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:ScheduleofCommercialLicenseRightsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTc_f5d0c5d1-e92a-4e7c-bff1-e52767c8a183" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0yLTEtMS0yMzY5_79b13149-a5a6-4316-9a79-49c76a248f14">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi00LTEtMS0yMzk4_795dc368-eb25-4dd5-baea-81b408a1e42a">9,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi02LTEtMS01MDY5_5caa54c1-db65-403e-997e-ee51c99e4a23">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi04LTEtMS0yMzQ1_fb2fafb0-e20b-4238-9411-b1a5459bbcf0">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0xMC0xLTEtMjM3OQ_c4730d42-39c2-40e5-bc4c-b23e9b81ae6f">5,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0xMi0xLTEtNTA3NQ_b54bb5e0-59f6-4f00-85f8-e03947525e57">12,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0yLTEtMS0yMzY5_55ec5f9a-42f4-4ba9-9c3b-1020428dea6b">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy00LTEtMS0yMzk4_a67f4bac-acc0-4f79-b138-99c9a199e560">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy02LTEtMS01MDY5_a4e67314-d298-44d9-b346-47348c4faab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy04LTEtMS0yMzQ4_4e35e545-afa2-4324-a65b-e1a25d5ec702">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0xMC0xLTEtMjM3OQ_74489b6b-2a28-4e50-9c8d-32e04fbf5938">7,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0xMi0xLTEtNTA3NQ_8854a8e1-3e9e-491c-85dd-b0fd2d27f4a7">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0yLTEtMS0yMzY5_2cf27f00-914e-4682-956a-a7ae076ea52d">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC00LTEtMS0yMzk4_469b1987-adf8-447c-841b-8e5fa1ec6aac">7,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC02LTEtMS01MDY5_63c3bdeb-b936-489f-90e6-ef36875910a3">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC04LTEtMS0yMzU1_da5aeff4-bed4-41cb-b6e1-864159d8d07c">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0xMC0xLTEtMjM3OQ_a4da72d0-f4b3-409b-a118-8fd96652efa9">5,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0xMi0xLTEtNTA3NQ_70793569-be52-4fe4-a89a-7964ba13efed">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0yLTEtMS01MDY1_20fc6f7c-d6f7-49de-a38f-a75a1c809647">38,298</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS00LTEtMS01MDY3_f3e099dd-5ca3-40e9-a5f5-63af28fb66ad">27,319</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS02LTEtMS01MDY5_1a409439-9cde-4d3c-a480-ef219b15c85e">10,979</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0edea451a947568476fa7759c97496_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS04LTEtMS01MDcx_125bff8d-1999-47e8-8570-66d35435a525">38,298</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f0edea451a947568476fa7759c97496_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0xMC0xLTEtNTA3Mg_bf250273-c070-4e04-bed7-d6615a663997">18,208</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0edea451a947568476fa7759c97496_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0xMi0xLTEtNTA3NQ_b8b434ec-8f47-41b1-bfa2-2a08dd809abf">20,090</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">1) Amounts represent accumulated amortization to principal or research and development expenses of  $<ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDkzMTUyNQ_f015141e-be51-457d-87aa-87e4be3124ca">21.3</ix:nonFraction> million and credit loss adjustments of $<ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDkzMTUxNg_63b0aa50-66b7-452c-91b9-41f178fa15c3">6.0</ix:nonFraction> million as of December&#160;31, 2020 . Of the $<ix:nonFraction unitRef="usd" contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NzI3OA_63b0aa50-66b7-452c-91b9-41f178fa15c3">6.0</ix:nonFraction> million credit loss adjustments as of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NzYyMw_0c4c5617-38b7-4f55-adcd-5b6d415ac747">5.5</ix:nonFraction> million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2020 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTMyNTY_474b559b-548c-413d-a3db-f176eb0cf1e3">12.0</ix:nonFraction> million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $<ix:nonFraction unitRef="usd" contextRef="id68885846d2347bdbc1bf3e58a6664b7_I20190531" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM0ODY_e6b3f538-77b3-4da9-9c73-a0ed2abe5136">20.0</ix:nonFraction> million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="id45ea6b88b7b4ce99056d77dfb9e072a_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM3Mjc_f8082a25-abd3-487c-bdb7-e5041b6c2c04">7.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iba869b10f43242e5b6c4fdd407e85a06_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM3MzM_1c889ba1-7cad-45b8-89a2-ad8f2625c2b2">10.0</ix:nonFraction>% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and reduce our asset as the funds are expended by Novan. As of December 31, 2019, Novan had used up the $<ix:nonFraction unitRef="usd" contextRef="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQxNDI_474b559b-548c-413d-a3db-f176eb0cf1e3">12.0</ix:nonFraction> million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id67df9e561314995ac7450e943f256a2" continuedAt="if6994ae4d1a247658e85d07155361319"><ix:continuation id="i4967f1968d2a48d6b46742596ca55dcb" continuedAt="ib7cab1800b644bc982ff1be36c689c5d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $<ix:nonFraction unitRef="usd" contextRef="i39c93e649e774e64b8ccfd071af32e96_I20191231" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ0MDk_9b5472b2-c2aa-45ad-94f6-24fafd87352a">8.0</ix:nonFraction> million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="i6bfcf4342f7f486e81aa9acfe6e847f3_I20191231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ2ODk_babdc1f3-5e4b-48da-99ee-48da2e86f585">5.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8cdf88f6a2da48ab9f7072c95808b688_I20191231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ2OTU_a01e4de5-4027-4e6c-b15f-9e0b87d97a1d">9.8</ix:nonFraction>% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5b43e6ec0024459cad6c7d3d2e8f6e3d_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ5MTM_9d278c0f-3100-41ec-a309-8f73bb472d99">10.0</ix:nonFraction> million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to <ix:nonFraction unitRef="usd" contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1ODE2NQ_57b6721d-e0e6-4dbe-9a42-b204a43a8388">zero</ix:nonFraction>, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ib8918e216e1f459c9ab0ac50491f1cf4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1ODE3NA_21abb091-f987-476b-8d66-e1301bffd0bb">3.0</ix:nonFraction> million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $<ix:nonFraction unitRef="usd" contextRef="idf035009648e4002a74fb15717a19c83_D20170531-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTU4NDI_b98867a5-6d63-417d-bba2-a445d19dde6b">10.0</ix:nonFraction> million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a <ix:nonFraction unitRef="number" contextRef="i3bc3b17ca38f450f93f33b56115ecdac_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTYxMTI_32390fc9-1507-4a30-ba31-5444f552d73e">5</ix:nonFraction>% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original <ix:nonFraction unitRef="number" contextRef="iefbf54fee39c450eaef1dc95742c7f6a_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTYyMDk_98f19dae-3686-4ecb-8f4d-9ec3d484c148">20</ix:nonFraction>% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="id0f6f413f8494ec9b556f99a873dab70_I20170531" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0MzY_52d5c7c1-213d-4b94-a459-64c00cb637e8">10.0</ix:nonFraction> million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of <ix:nonFraction unitRef="number" contextRef="idd2353e9253d4a1aa25a32912238e563_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTcxMzQ_c5c35940-1675-42fd-b701-3afb7b5459ee">5</ix:nonFraction>% on such pipeline products. The Amended Interest Purchase Agreement will terminate <ix:nonNumeric contextRef="i2d7158892fbf44ed81d8c9568292e404_D20170531-20170531" format="ixt-sec:duryear" name="lgnd:RoyaltyAgreementExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTcyMTk_7733a7b9-32c1-4f79-bd5f-4ea826cb26b2">10</ix:nonNumeric> years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2020 is <ix:nonFraction unitRef="number" contextRef="i569ef336eca149ea8ce1ab7ef2a48105_D20200101-20201231" decimals="2" name="lgnd:ForecastedCashFlowsEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTc3MTc_d27e9de0-58e3-4b93-967e-14b071d8f968">23</ix:nonFraction>%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2020 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if6994ae4d1a247658e85d07155361319" continuedAt="ia6bf82392401491facedc3518c0401b2"><ix:continuation id="ib7cab1800b644bc982ff1be36c689c5d"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU2MTExNA_0c4c5617-38b7-4f55-adcd-5b6d415ac747">5.5</ix:nonFraction> million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic and recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU2MTE3Ng_5d017edd-82bd-44b9-a5e9-47708b5e3fba">0.5</ix:nonFraction> million reserve for credit losses in other expense, net, in our consolidated statement of operations.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTg_ac869dc9-c171-462d-9267-b85b7bc4e128" continuedAt="ia2a0aca84aae4d93ae4952ebe9be98f3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard. See additional information in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsection below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we own. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Captisol Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when control of Captisol material is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. We have elected to recognize the cost of freight and shipping when or after control over Captisol material has transferred to the customer as an expense in cost of Captisol. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract revenue includes service revenue, license fees and future contingent milestone based payments. We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia6bf82392401491facedc3518c0401b2" continuedAt="i2830750d8c4849bc8cbf77bd65ad399b"><ix:continuation id="ia2a0aca84aae4d93ae4952ebe9be98f3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment.  These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjY3MTE_90376dd2-cae3-4f99-b380-7888f07b8d85">0.9</ix:nonFraction> million. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December 31, 2018 was $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjY4MTc_d42cc94a-22e8-43be-9203-13ce905eccc0">3.3</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjQ_6e43c2a5-36e8-4a1c-9cfa-d39dce5bb321" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib905672f26f34c6ca6ac51ce2c25db59_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC0yLTEtMS0w_1181baab-994f-4ce7-ab52-006804085805">25,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb8f7f86660458caf621f649275af47_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC00LTEtMS0w_db1e72c3-afec-477d-bff7-717f99519ec6">25,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida12bcf9ff53440e84c2633931d5fcca_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC02LTEtMS0w_8d781570-6bd4-4513-9bc2-e1c5c8544062">21,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17a6bd9499ad4be8b30f8a074e5a4747_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS0yLTEtMS0w_0e7b81eb-d03c-4a42-9423-22207350df9f">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib762c00218db440eabd64c06b5cbeb17_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS00LTEtMS0w_efdeb716-f4b1-4b8d-984d-bc151a381d77">5,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b26e3a5c35487591dbea42ea400987_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS02LTEtMS0w_d4b0610b-afec-4b07-ad5a-37eb146b7384">5,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12906a0a0841439f945d94aff020ae08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi0yLTEtMS0w_eeba7220-3223-469f-a944-8e98b916be67">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e03c8cbe544fe2b60dd5184c74c3fa_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi00LTEtMS0w_6d469aba-b124-4729-b62e-46a77771a290">2,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d572ef2b8494f9fa8c4e977a195c4f2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi02LTEtMS0w_2ee4b1ef-7a48-4402-a514-d1821a241ef7">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea7a020b78c4b429f74dae393a5908a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy00LTEtMS02MTY1_b53cc64b-c3b8-46a0-b8e5-55ad67ced83f">14,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74da4f182fe445218f31adabb243815c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy02LTEtMS02MTY1_28fff164-6c07-42d7-94a1-0c21120bd8f8">99,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy0yLTEtMS0w_7037656e-7942-43b3-862e-2e8afd6abf71">33,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy00LTEtMS0w_bbbbf573-e31f-4a9c-ac42-b03fed319328">46,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d16dd704b74221b973893e02cd3023_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy02LTEtMS0w_9b2c4715-5529-40a6-9d9c-25c8fd9f677a">128,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy0yLTEtMS0w_191a0c76-db11-4604-8fb4-67b4d733fdf4">109,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy00LTEtMS0w_5fd40edb-3761-4a52-8d8c-48d49dca4237">31,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy02LTEtMS0w_f6e6ef90-d6b9-45e4-8745-40a095d92fa4">29,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb20656a8d498d86e9974aeb28d3ba_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS0yLTEtMS0w_e46e4d6f-03ac-441f-afe9-49811cee2614">21,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31dbb0c91f244d82be41bfabf480335e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS00LTEtMS0w_39d5b461-4666-4252-9145-0d8af77c4959">16,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237f75928ac747deb799e5591927eeb2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS02LTEtMS0w_66c60cdb-13ec-4bd3-8f58-efe9d6485b75">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58de6fecf534ed0a1da850b2cff8a8b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi0yLTEtMS0w_2b0901dd-489f-4642-8fdc-df3f569b217f">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44536cfe5ccd4fd58d70bd6fa6a9bbe7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi00LTEtMS0w_b4c957ce-1a79-416f-baa4-1ccf547b6a91">6,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c1d00145a84fc9849e6e8261b1e931_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi02LTEtMS0w_771bb476-a3a5-416d-a7fd-b1e9257a97c5">78,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a84b0ab35142d58562b6af8b4ed5a7_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy0yLTEtMS00OTQy_6a71f701-91df-478d-b8fc-92848921b4db">11,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a2317a4d4b4c3e918e6cc04ab22e08_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy00LTEtMS00OTQy_7c6ef5b7-70c8-4b23-b830-45d964b51c17">17,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073f00141a744d8b9364ba86efafc46_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy02LTEtMS00OTQy_0eb6ad7c-8587-4412-b55a-be2e471f7f5a">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4954555f1f4c42a396f5d8999d8fa5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy0yLTEtMS0w_c9196b55-92ff-4a7a-96e6-3354b5a093cc">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c2c62904f340b6aa85bf2c884b4476_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy00LTEtMS0w_cc6be7b9-2016-44d3-adaa-846a8548bf5d">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8da33f34df41008bfe20ee259d58b6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy02LTEtMS0w_2b5c4c43-6316-44b9-801a-2aa3cb5475f1">4,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC0yLTEtMS0w_5d0073d0-707b-4a5a-9d9c-2a629e530f2c">42,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC00LTEtMS0w_387bad31-9116-4652-ba8d-29b385d0cab2">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC02LTEtMS0w_fac591fd-a8c3-4194-b663-33bcfbcc0a41">93,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2830750d8c4849bc8cbf77bd65ad399b" continuedAt="ie58321a83dd34e91a4f88038c7bf3b82"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTI_e8aa3e11-4fd5-432a-a287-d078d997a596" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjY_5c134508-ae80-44c6-8359-051bb5aeb5f1" continuedAt="i007e326cf66047529152269b41a9801c" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i007e326cf66047529152269b41a9801c">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjM_2928ca79-fb71-4b39-8401-c90aabe543c4" continuedAt="id0222d63752d438fb7b0779eb9af546c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction unitRef="number" contextRef="if7f17131fa164971b710daf95103fef2_I20201231" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzE3MjQ_7b3f1412-4098-40e1-8bd6-527ccdd53805">0</ix:nonFraction>% given that except for 2007, during which we declared a cash dividend on our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd93f549e0fa415b9e51a92f0daf7bb7_D20070101-20071231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzE4MTk_c2c9e48e-528d-4b62-842b-81037baf96f7">2.50</ix:nonFraction> per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2">six</span> month anniversary of the date of grant, and 1/48 each month thereafter for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124">forty-two</span> months. RSUs and PSUs granted to employees vest over <ix:nonNumeric contextRef="ia580ec3f4bff42659168b12a15f67809_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzM5NjA4Mg_24d30d6f-cf99-489e-937c-85360071485b">three years</ix:nonNumeric>. All option awards generally expire <ix:nonNumeric contextRef="ia4bc8d4c0ee94b9dba90c475ab5a47fd_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI2MjY_7b893787-3157-4a61-81cd-31a035b59697">ten years</ix:nonNumeric> from the date of grant.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0222d63752d438fb7b0779eb9af546c">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzMxNDc1OQ_c7a63a8c-4aa9-4839-a9bd-44d0df7e1af8" continuedAt="i98da04b0f93340088d22f6ec3ca7b639" escape="true">Derivatives</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie58321a83dd34e91a4f88038c7bf3b82" continuedAt="i5e73e0b9c6e544a28e62e6d86cb16718"><ix:continuation id="i98da04b0f93340088d22f6ec3ca7b639"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="i4236aad26ee440e0b4e5773018b84e4d_I20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI4Njk_ab26f839-b0a4-450b-9c7a-0cbbea9b9489">750.0</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i4236aad26ee440e0b4e5773018b84e4d_I20180531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5NDk_021138e9-ae87-4b42-b712-aa63f5a07f95">0.75</ix:nonFraction>% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $<ix:nonFraction unitRef="usd" contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzQyMTY_60703790-a792-4c4a-8595-62f5c0679b87">245.0</ix:nonFraction> million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to <ix:nonFraction unitRef="usd" contextRef="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzUwMjg_f82365ba-ccfd-4ebd-86d0-f1408ec5b764"><ix:nonFraction unitRef="usd" contextRef="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzUwMjg_fa5e3fb4-dd74-43e1-b314-ff99e72dfd27">zero</ix:nonFraction></ix:nonFraction>. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjA_21b2ba95-9a8f-435d-b4c4-135e7132b385" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTY_0f59f494-d890-4c71-832f-88ce6b7be3c7" continuedAt="i6196de525f4c45018d85ab7a3ce6d901" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2020, all of the <ix:nonFraction unitRef="shares" contextRef="ib0b6ced4e4e74197bd6f08f6e744dd49_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NTYyMQ_27877f7b-fbf3-4aff-b0c0-18dd997bebcc">0.6</ix:nonFraction> million weighted average shares of outstanding equity awards as of December&#160;31, 2020 were anti-dilutive due to the net loss for the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5e73e0b9c6e544a28e62e6d86cb16718" continuedAt="i69128545c0be4b9eac1ed3b4d9fa044a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i6196de525f4c45018d85ab7a3ce6d901">delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0Mjc_1f267137-e0a1-4058-b66f-6bbf3dcb6379" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi0xLTEtMS0w_89820d2b-1012-4df9-a58e-9ec15451ff6b">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi0zLTEtMS0w_46f82a12-1b2c-49dc-8a5c-ef236a6dfb26">18,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi01LTEtMS0w_aa63a3f9-e8de-4621-9f49-42f13e0b4002">21,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC0xLTEtMS0w_dff33504-1638-4a61-9887-3d1cecf2f98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC0zLTEtMS0w_1e126742-c394-46c0-aa2a-eff6b90e47df">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC01LTEtMS0w_20ba26b2-ed98-417b-8185-ad3003354aa0"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC01LTEtMS0w_7a71e8ef-2214-4a85-9ff4-10ca2d6ef491">72</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS0xLTEtMS0w_6d16df9d-c8f3-4790-bbae-d4a96f50b1fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS0zLTEtMS0w_2ee7db49-257c-4001-b4c4-cecba2e7aa15">719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS01LTEtMS0w_84f283f9-93c9-4d46-b6fd-119cb91a70f2"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS01LTEtMS0w_885f68d6-91cc-4319-96f9-af15e3dd1ed2">1,125</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi0xLTEtMS0w_655a7b22-5e20-4a3f-846b-bea193e81616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi0zLTEtMS0w_72c77f8a-2728-46d7-89b1-e8ecddeaeb47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi01LTEtMS0w_9d119449-865b-417f-9ec4-054d1eee1388">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy0xLTEtMS0w_1f7315df-ff59-41bd-9b43-8996a0b9fe17">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy0zLTEtMS0w_7823ef0e-b250-4b1b-b16f-2a2f7e921fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy01LTEtMS0w_9ac807a8-eb67-4c68-998d-42e37b16adc2"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy01LTEtMS0w_a6b07d5f-bdb1-4a15-a4dc-f297fa614c45">693</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC0xLTEtMS0w_5820134b-0214-40af-b2ff-4eadd1fbb09c">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC0zLTEtMS0w_7925833a-d28f-417d-83ff-568a0cb33ccb">19,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC01LTEtMS0w_a9b22807-198a-4332-bef8-6cf500ccd4e6">24,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS0xLTEtMS0w_33bb10ea-3d5d-4753-900a-63f4648595ab">8,458</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS0zLTEtMS0w_2f07f30d-f8cf-41c7-a213-6122c9d79ce2">8,926</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS01LTEtMS0w_3fbf5c3c-026a-4ce5-97a9-e000a4a6391c"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS01LTEtMS0w_d87946fa-fa03-4108-93fe-510f1d3d5aa7">2,845</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDQ_cfbc4141-ceee-4427-b9c4-fcd6f06befc5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTY_e2ab9503-c2b6-4d33-96f8-9e8f55af8d68" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees and partners, patients, communities and business operations, as well as the U.S. and global economy and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have restricted in-person access to our executive offices, our administrative employees are mostly working remotely, and we have limited the number of staff in our research and development laboratories and other facilities. The continued spread of the COVID-19 pandemic and the measures taken by the governments of countries have</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected, and could continue to affect, our business and the business of our partners, including future disruptions to our supply chain and the manufacture or shipment of drug substance and finished drug product for Captisol, delays by us or our partners in the initiation or enrollment of patients in clinical trials, discontinuations by patients enrolled in clinical trials, difficulties launching or commercializing products and other related activities, which could delay ongoing clinical trials, increase development costs, reduce royalty revenues and have a material adverse effect on our business, financial condition and results of operations. Several of our partners have reported that their operations have been impacted including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who have contracted the virus or to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevent the spread of the virus. This may lead to clinical trial protocol deviations or to discontinuation of treatment for patients who are currently enrolled in the clinical trials being conducted by us or our partners. In addition, certain of our partners have reported negative impacts on product sales which will impact our royalty revenues.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i69128545c0be4b9eac1ed3b4d9fa044a" continuedAt="ic3e9dd3369ac44909ea1b49e4ef10d19"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and Vernalis partners have initiated antibody discovery programs for the potential treatment of COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDU_0838ff63-a172-4aa5-9d60-aa41e46b025b" continuedAt="i2e37b98117834297a64cf01f008483dd" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We adopted ASU 2016-13 on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance sheet of retained earnings to be recognized on the date of adoption with prior periods not restated. The cumulative-effect adjustment, net of tax, recorded on January 1, 2020, is approximately $5.2 million. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under previously applicable accounting standards. See additional disclosure on credit losses under  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Accounts Receivable and Allowance for Credit Losses&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Commercial License and Other Economic Rights&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discussed above and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Short-term Investments&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (8), Balance Sheet Accent Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Test for Goodwill Impairment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the disclosure requirements on fair value measurements. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We adopted this standard on a prospective basis on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic3e9dd3369ac44909ea1b49e4ef10d19"><ix:continuation id="i2e37b98117834297a64cf01f008483dd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures. We intent to adopt this standard on January 1, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTQ0OQ_3a26745b-4486-4597-b985-6ffa7ee1e57a" continuedAt="i267428f196e645068eff1bdbc3f68956" escape="true">Sale of Vernalis R&amp;D and Promacta License</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i267428f196e645068eff1bdbc3f68956"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vernalis R&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited (the &#8220;Purchase and Sale Agreement&#8221;) with HitGen UK Ltd (&#8220;Buyer&#8221;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships.  On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $<ix:nonFraction unitRef="usd" contextRef="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg0Nw_cb21b75a-25b5-4124-a0c2-cc8253eeda26">26.7</ix:nonFraction>&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;D has the input, process and output elements defined in ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $<ix:nonFraction unitRef="usd" contextRef="ifea99838f3eb4029ace6787bc75b67d4_I20201201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg2Mg_54f6d31c-21d7-4cbb-9ece-e0fa45e68e3a">6.1</ix:nonFraction>&#160;million, goodwill allocated to the selling business that was written off was $<ix:nonFraction unitRef="usd" contextRef="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg4Nw_3b79df0f-4b8b-4ffe-ab16-070026823319">3.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i55f09740f6734811b4be02fd7bc044ad_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTA5OTUxMTYzMzIzOA_e2fca502-ef97-4791-a996-d26c828c12b4">17.1</ix:nonFraction> million gain from sale of Vernalis R&amp;D recorded to income from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Promacta License</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $<ix:nonFraction unitRef="usd" contextRef="i01ab621af16c4274a42e8324d4de973e_D20190306-20190306" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfOTQy_4e7039b1-2b69-44c9-baea-7eecf4241984">827.0</ix:nonFraction>&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was <ix:nonFraction unitRef="usd" contextRef="id0bbacdd5fd54f5989b4a62974637a61_I20190306" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTExNg_3511eb43-395a-493d-badb-0592d36446b4">zero</ix:nonFraction>. Of the total cash proceeds from the sale, $<ix:nonFraction unitRef="usd" contextRef="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTE2Mg_173018ea-0959-4e02-a304-3bda1d1cc1ae">14.2</ix:nonFraction>&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTI5Nw_888d6d2e-124f-452a-a0ca-3876b3837d36">812.8</ix:nonFraction>&#160;million was recorded to income from operations in accordance with ASC 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.</span></div></ix:continuation><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTY4OQ_4cd63f8b-31be-4eb8-be50-0e4a7d5e3fe8" continuedAt="ia8b652b54b384935b8624a6c030ec5c9" escape="true">Short-term Investments: Investment in Viking</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8b652b54b384935b8624a6c030ec5c9" continuedAt="i858f99ac67bc46258a1db68f1d5a6195">Our ownership in Viking was approximately <ix:nonFraction unitRef="number" contextRef="ie261b70fecc64fc3acc322f37f4fbb70_D20200101-20201231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfNzM_ac610598-fca6-485c-a5f8-24435d295499">9.8</ix:nonFraction>% as of December&#160;31, 2020, and we account for it as an investment in available-for-sale securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking.</ix:continuation></span></div><div><span><br/></span></div><div><ix:continuation id="i858f99ac67bc46258a1db68f1d5a6195" continuedAt="i0ad61414b4db4587a164b96276ed2812"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and December&#160;31, 2019, we recorded our common stock in Viking in "short-term investments" at fair value of $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTA1MQ_8442220d-0923-4f28-b5ed-b609bf8ea202">32.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTA1OA_b01f847e-271b-466b-8371-6e024877870c">48.4</ix:nonFraction> million, respectively. We also have outstanding warrants to purchase <ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTEyMg_764c170a-af85-42b7-a825-e2fa302a8fde">1.5</ix:nonFraction> million shares of Viking's common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i389fb553398f4fb5809d534052c56744_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTE4MQ_c5426890-0df2-44f3-8210-db9977987de4">1.50</ix:nonFraction> per share. We recorded the warrants in Viking in "short-term investments" in our consolidated balance sheets at fair value of $<ix:nonFraction unitRef="usd" contextRef="i3839777e750f48b3970c5b559eed73b8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTI5OA_b6a7bbed-c7d6-4662-bec9-c6d6e998d018">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3736760d3c7340649ea390cca0ce15fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTMwNQ_2f5e8485-423e-4f12-8e9e-db7add3e3822">9.9</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ad61414b4db4587a164b96276ed2812">&#8221;</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcxMw_56edba36-0122-42c0-b4a8-dfd4ef8842d4" continuedAt="ia41ec849521843e78ee036d5054dcf3d" escape="true">Acquisitions</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ia41ec849521843e78ee036d5054dcf3d" continuedAt="i3fbfcdff83d349c88736f4b8cb5437ee"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth below, we completed <ix:nonFraction unitRef="acquisition" contextRef="ic665f012e5c54711abae64ce09f53a48_D20180101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="lgnd:NumberOfAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjU_2e18ba92-ae1c-46fb-be04-ffd3da8c5d20">six</ix:nonFraction> acquisitions from January 1, 2018 through December 31, 2020, of which four (Pfenex, Icagen, Ab Initio and Vernalis) were accounted for as business combinations and two (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfenex Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preliminary purchase price of $<ix:nonFraction unitRef="usd" contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzM3Nw_6c11a62e-18b5-4d10-af4f-a90d3f7f3154">465.1</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzM5MA_1c9f55d8-93b4-4888-a316-a82bd6cb2367">429.6</ix:nonFraction> million cash consideration paid upon acquisition, and a contingent CVR payment of up to $<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzQxMQ_ebf19fc5-d07e-4016-8c57-5066977dc841">77.8</ix:nonFraction> million in cash based on a certain specified milestone with an estimated initial fair value of $<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-5" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzQwMQ_5f78a8bc-d53c-485e-9f60-5fcdef3b0913">37.0</ix:nonFraction> million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA3NDAyOA_25411368-0801-4483-8e51-06f483611d4f">1.5</ix:nonFraction>&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was <ix:nonFraction unitRef="pure" contextRef="id7ccafcd4382434aab44acf88304dbff_I20201001" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzMyMjQwMQ_1ca39e35-9612-4ae6-9467-6ee47e35d06d">7.1</ix:nonFraction>%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $<ix:nonFraction unitRef="usd" contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2NTE2Ng_35c0d188-8807-44f7-9b74-a4d76ea93f40">17.3</ix:nonFraction> million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $<ix:nonFraction unitRef="usd" contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfOTM0NTg0ODkwMjk1OA_1c9f55d8-93b4-4888-a316-a82bd6cb2367">429.6</ix:nonFraction> million. In addition, the fair value of equity compensation attributable to the post-combination service period was $<ix:nonFraction unitRef="usd" contextRef="i937655058f00466eb023f3a052a305a9_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2NTMxNA_738acab9-84f2-4125-a4f3-55dd5a230e74">8.7</ix:nonFraction> million.These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $<ix:nonFraction unitRef="usd" contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2MzMyMQ_853daaa4-9fb0-4a40-9151-d2d4b3d313f4">20.7</ix:nonFraction> million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. <ix:nonNumeric contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5MQ_d51ab565-c06b-4000-9113-2551fc318a48" continuedAt="i299a118516ca4690acf22c34cad5ba6f" escape="true">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i299a118516ca4690acf22c34cad5ba6f"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMS0xLTEtMS0zMzAy_047c588f-eb8c-4cd4-a255-2e124ef2d9ed">51,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMi0xLTEtMS0zMzAy_2175e933-7a6f-4556-886b-221d182c6c60">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMy0xLTEtMS0zMzAy_da713b0a-c180-4f88-b7db-f8dce20ab0f7">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNC0xLTEtMS0zMzAy_6fa1516c-8b8a-45eb-b599-485264a762e5">7,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNS0xLTEtMS0zMzAy_20bd78e0-3258-46d1-826d-a37e67e74840">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNi0xLTEtMS0zMzAy_ece548ec-e53a-43ce-9bc1-70a7d956d17a">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNy0xLTEtMS0zMzAy_093476e8-ffff-424f-932c-63c49a569073">385,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfOC0xLTEtMS05MjA4_cca0e2d6-a28c-4ade-bdf1-66c3c20f49ba">90,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTEtMS0xLTEtMzMwNg_3b23f132-606f-4404-8e86-9348a8700d01">6,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTItMS0xLTEtMzMwNg_90a82ac8-5835-4de1-9619-b665684ab223">7,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTMtMS0xLTEtMzMwNg_92479b2c-98c3-4043-aa3a-52952513c2a5">3,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTQtMS0xLTEtMzMwNg_df3d13eb-a461-4f8d-a610-3e497b0cc582">3,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTUtMS0xLTEtMzMwNg_68de82e4-b7cd-48d7-a794-1e3851843aff">1,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTYtMS0xLTEtMzMwNg_d51d7d46-b115-4c9c-9641-ec3a1483aeed">53,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTktMS0xLTEtMzMxNw_b7cddcbe-dc95-48ed-b0ac-96bee8c44c84">465,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjQxNQ_a61f57d4-c517-449c-b383-e551aed2eddb">None</ix:nonFraction> of the goodwill is expected to be deductible for tax purposes. <ix:nonNumeric contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5Mg_984516cc-7431-4af1-bfd5-7e9dddd86bce" continuedAt="i91e6d1f814c045648920953d03000b69" escape="true">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i3fbfcdff83d349c88736f4b8cb5437ee" continuedAt="i32315b8b2ce34908821811eaae105e5f"><div style="margin-bottom:6pt"><ix:continuation id="i91e6d1f814c045648920953d03000b69"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3722684bf7fe44dd891c916f6dafc459_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMi0xLTEtMS0zODI0_5e3022ee-004f-4c17-a979-c08110aa6dd5">114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0825ac3f9e433dbbbf222c70233130_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMi0yLTEtMS0zODI0_efeff7e6-4a5d-4efa-9309-e1c7b21117bf">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc05913ba57443492a26d3b59204160_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMy0xLTEtMS0zODI0_ad2ca0cb-4eb8-41d7-a118-27f0b9ac93c4">117,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90111327cda4413486d72b7e169d1885_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMy0yLTEtMS0zODI0_3c222c48-8b36-4395-a868-67f05f080bba">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203357e791ee4e05a98b8573e4a989e4_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNC0xLTEtMS0zODI0_35f77eaf-7131-4e8c-9df4-50bff48c16ae">80,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22ae29ffee0842cc89e6ee8c5f22ccd8_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNC0yLTEtMS0zODI0_8357f99d-db33-4aa0-a95b-e4d1111269f3">17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0bc7404b304067a3243b8534e113e2_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNS0xLTEtMS0zODI0_75ee2bd6-56ce-4694-a7f9-e198c14c4b12">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica518070bfb04532a62ae6496bac0810_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNS0yLTEtMS0zODI0_59085cde-92af-4c00-98f4-7ed20bcef806">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6809a505f14eb48603ff22d2339675_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNi0xLTEtMS0zODI0_f327aa54-c18f-414d-96ee-2559183b4a9b">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0e4a9163e7b41fe9f7db2ee091c394e_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNi0yLTEtMS0zODI0_402774eb-397c-4678-b662-70c9ca49dc0f">17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c5bd0218924d9ba52a0cf66da8376b_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0xLTEtMS0zODI0_6c5a2f40-f47b-4691-9ac9-e1adf0a37c1c">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e224ad1e1fc4df0a08700f496a00009_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0yLTEtMS0zODI0L3RleHRyZWdpb246N2IxNDEzNzgzZDBkNDNmODg3NGNmOTAxMzI5ZDM0YzFfMzI5ODUzNDg4MzM1Mg_cee49c3d-cc13-47ff-bb2f-741d858e7c06">10</ix:nonNumeric>-<ix:nonNumeric contextRef="i058f44a298dc4b5cba311ad359517ca8_D20201001-20201001" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0yLTEtMS0zODI0L3RleHRyZWdpb246N2IxNDEzNzgzZDBkNDNmODg3NGNmOTAxMzI5ZDM0YzFfMzI5ODUzNDg4MzM1OA_94417da1-aa8f-44c5-920e-8325967c9f31">19</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfOC0xLTEtMS01NDgz_b642d91d-5c4e-4a17-98c9-03876eae1f5d">385,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from <ix:nonFraction unitRef="number" contextRef="i386227a58a154f12b0c88d447866796f_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTY0OTI2NzQ5OTUyNQ_d198b1d6-b0fe-43de-a9ba-d3ec9425f9fd">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9d3e28c670344068a7dccc625bd2d1a3_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTY0OTI2NzQ5OTUyOA_83dd7607-3bf9-4725-a78d-922883d3b3e9">15</ix:nonFraction>%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately $<ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2MTMwMQ_50ed7da6-0c9e-44f0-b277-e43aacf0e684">2.0</ix:nonFraction> million of revenue and $<ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA2ODMwMQ_1810f148-6b4c-4679-9d72-477b041487ca">19.3</ix:nonFraction> million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December&#160;31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December&#160;31, 2020 and December&#160;31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $<ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA4OTAxMg_b313ea66-6e3d-4352-88d6-4513cda3ba76">7.1</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA4OTAzMg_3eb3d8f9-d842-4c82-87e1-e18b09421bd2">4.8</ix:nonFraction>&#160;million in 2019. <ix:nonNumeric contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5NQ_63c4097e-1597-44fe-bb8e-70aac1cc33d1" continuedAt="i95368398d52b432c8d8982754d737e97" escape="true">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):</ix:nonNumeric></span></div><ix:continuation id="i95368398d52b432c8d8982754d737e97"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMi0xLTEtMS0zODQw_1c2eadb8-6b4f-46f1-a0bd-53d20e98022b">189,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMi0zLTEtMS0zODUx_05d9154a-0e80-4e3d-a147-05a6c55c3238">170,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMy0xLTEtMS0zODQw_2b1165f0-eed0-45bb-bd7f-d7a9753aa19c">60,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMy0zLTEtMS0zODUx_22fc13b1-7a2e-4001-8d3a-5677e6195ead">594,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNS0xLTEtMS0zODQw_a7a346b9-e237-4c0f-aacc-bbb66257b532">3.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNS0zLTEtMS0zODUx_a77746b9-44fc-4645-a0a8-a5622e242253">31.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNi0xLTEtMS0zODQw_35e3ffd7-7745-4654-9695-22d729a07d75">3.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNi0zLTEtMS0zODUx_12d50937-4246-4dd2-98ce-b09c4a8e7725">30.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taurus Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of  $<ix:nonFraction unitRef="usd" contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc1NA_d03520b3-cb55-4603-8fa7-fb78b9f7aab6">5.1</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc3MA_d7399796-bb85-4d66-beb6-c3a668449fb5">4.6</ix:nonFraction> million in cash, and a $<ix:nonFraction unitRef="usd" contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909" decimals="-5" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationConsiderationTransferredHoldback" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc4Mg_6bd847d5-a35d-407d-9c58-4bc344813185">0.5</ix:nonFraction> million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $<ix:nonFraction unitRef="usd" contextRef="ib636b729155f4a749fd149d8b766cfd7_I20200909" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc5Ng_6be5b29d-d3d9-45d2-b1fb-15437bb3cce7">4.5</ix:nonFraction> million tied to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i32315b8b2ce34908821811eaae105e5f" continuedAt="i282a2a459595416d80f0ac51a100fef7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partnered and internal research and development and for up to $<ix:nonFraction unitRef="usd" contextRef="ia074696e58a149c1995c46517312190b_I20200909" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NjgwOA_efa4cd0b-32ee-4e45-b48e-586a4ef628b5">25.0</ix:nonFraction> million as a <ix:nonFraction unitRef="number" contextRef="ief985e0d5a6e476ca3e8f1deefd76040_D20200909-20200909" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NjgyMQ_ce586a06-f63f-48d4-8b94-4e626c290f1c">25</ix:nonFraction>% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8dc30f6eb26f47a0a96ce21282bdd8d4_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjI0MQ_58efb2a9-886d-419e-9790-ee800e9fcfe6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:78.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMC0xLTEtMS0xODA4_32eb6652-b960-4a9d-89b7-3110e673e681">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMS0xLTEtMS0xODE3_07019eba-dd21-44db-9fba-922c5af67e5f">5,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMi0xLTEtMS01NDIz_3281264a-fb87-412a-b689-73830f8e3fc9">5,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i1be13e965a8f4da5b69ebbcc4a009825_D20200909-20200909" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NzE2Ng_abab2d80-f757-4043-b187-e3f36cab4b55">10</ix:nonNumeric> years. We account for the CVRs in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. <ix:nonFraction unitRef="usd" contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjM4OA_03a43baa-0b59-4fcb-bbf4-9d246d7b8c3b">None</ix:nonFraction> of the CVRs are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">xCella Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#8217;s antibody discovery throughput and efficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid $<ix:nonFraction unitRef="usd" contextRef="i68f1407f97f14a568173adad6da04c53_D20200908-20200908" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzg5Ng_9ac4f3d5-3c81-4a70-b52f-80bfa43da87b">7.1</ix:nonFraction> million in cash (including a $<ix:nonFraction unitRef="usd" contextRef="i68f1407f97f14a568173adad6da04c53_D20200908-20200908" decimals="-5" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationConsiderationTransferredHoldback" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkwNw_0b54090a-deb0-4ed0-bda6-9b5cb002eb0f">0.5</ix:nonFraction> million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $<ix:nonFraction unitRef="usd" contextRef="i145875c08ac643eb987fa42283dc0c10_I20200908" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkxOA_6c3b839a-7d1b-4eb1-ab7f-ea38c8d459be">5.0</ix:nonFraction> million tied to our use of the xCella technology for partnered research and development and for up to $<ix:nonFraction unitRef="usd" contextRef="i7e76f65e64ab4ec5a35fb2b202c36fda_I20200908" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkyNQ_0730e2ca-b1fe-4833-8169-93d9bb3a497a">25.75</ix:nonFraction> million as a <ix:nonFraction unitRef="number" contextRef="i7e1fdefc6b2b422989b6e605a3d10f27_D20200908-20200908" decimals="INF" name="lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzk0Mw_56331d18-d4ce-4d06-8462-c0fcd046adab">25</ix:nonFraction>% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib48f53a633bb468199177a6ba86fca12_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjI4NQ_a2c2049a-3f0f-44d1-9f39-22c2fec7da1e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:78.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMC0xLTEtMS0xOTMw_3b84d61d-d661-4c1e-87ca-74bde365b456">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMS0xLTEtMS0xOTMw_57b8400f-d488-4634-bffc-280be2b50494">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMi0xLTEtMS0xOTMw_fd0dfa61-1b1d-4ab5-8318-9076071e4584">820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMy0xLTEtMS0xOTMw_cf957e94-eba1-4859-878c-63f53dc5db7a">7,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfNC0xLTEtMS01NDQ1_f02ab253-d384-48b6-b52d-ad0d4e34c1cd">7,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="if7ed9c03cb994049a1d3a5de61dbd7e8_D20200908-20200908" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNDQ4OA_648de516-0863-40b8-a0a2-7a87589ee287">15</ix:nonNumeric> years. We account for the earnout rights in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. <ix:nonFraction unitRef="usd" contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjQwMw_afeb7072-a9cf-415b-b174-3118d5592777">None</ix:nonFraction> of the earnout rights are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjM4OA_1aa37c3a-17b6-49a0-8ac5-9cce8df20311">19.9</ix:nonFraction>&#160;million included $<ix:nonFraction unitRef="usd" contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjM5NQ_28e81043-efd3-4aa1-baae-9ea42755b87b">15.1</ix:nonFraction> million cash consideration paid upon acquisition, and a CVR of up to $<ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjQxNQ_1b2722e9-f5c0-45aa-84a3-8a7b0f72894a">25.0</ix:nonFraction> million of cash payments based on certain revenue milestones with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-5" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjQyNw_7f4e0cc8-02cb-49c9-8b4e-ff2ff3eedd29">4.8</ix:nonFraction> million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was <ix:nonFraction unitRef="pure" contextRef="ie7604f5c2dda42bcadd9b8697034b298_I20200401" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzMyMjQwNw_2060495b-2ad8-4345-879b-fbfef7019e29">5.5</ix:nonFraction>%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i282a2a459595416d80f0ac51a100fef7" continuedAt="i9ecfb2e7360c4fb7b46e70218cc6e8f8"><ix:nonNumeric contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjMyOQ_273420c3-6376-4882-b801-c98b459585d6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMC0xLTEtMS0yMDU2_dc5351cf-ff5e-49e6-90bf-cc0cb867875e">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMS0xLTEtMS0yMDU2_f9865833-b36c-4b4e-933a-d29b48a1fdc1">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMi0xLTEtMS0yMDU2_8328726a-b9f4-4f4f-bd85-b5a6862933b1">812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMy0xLTEtMS0yMDU2_aeb4ffcb-31ff-46ae-861b-c3108f1a673b">3,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNC0xLTEtMS0yMTM2_263b586e-8ef7-4c4a-8758-6d2738b6eb5c">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNC0xLTEtMS0yMDU2_5a66a2c3-03c4-493f-96b2-c138958c824e">12,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNi0xLTEtMS0yMDU2_8551450b-4085-42a3-b1c8-c192b6624f43">9,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNy0xLTEtMS01NDQ4_3dfcd9ac-64d6-4e43-9c3c-c1e7cfa4744b">19,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $<ix:nonFraction unitRef="usd" contextRef="ie23c947370d64bf7b1e94889103679fd_I20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODc4OA_825c97b3-d315-4a34-b268-6a3d74376b3a">11.1</ix:nonFraction> million of customer relationships and $<ix:nonFraction unitRef="usd" contextRef="ieeed7ae64c0d4c0a83986dde7c9fa1d7_I20200401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgwMQ_29f882a7-8ea4-4da5-8f30-997fabcb5efd">1.7</ix:nonFraction> million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgxMQ_73aa8205-837c-4764-8662-38435bde0943">17</ix:nonFraction>%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of <ix:nonNumeric contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgxNw_a7a87373-ee7e-4a70-a20c-e1871fe1fa49">9.6</ix:nonNumeric> years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401" decimals="INF" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgyNg_73aa8205-837c-4764-8662-38435bde0943">17</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i96dc5cd222804e959a28968aa702662d_D20200401-20200401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgzNw_d2fd7f3b-dcb0-494e-a543-b575b79978be">10</ix:nonNumeric> years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgzMg_cd49380b-dfb2-4f6d-b255-9c55ebf32ee0">9.7</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ab Initio Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA4NA_a969273d-b763-4fbc-b51e-93e0646087ef">12.0</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTEwNA_a0fa25d1-290b-40dc-ae27-c919d4919da7">11.9</ix:nonFraction> million cash consideration paid upon acquisition, net of cash acquired, and $<ix:nonFraction unitRef="usd" contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723" decimals="-4" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTE4Mw_4aa9b8ce-7601-4bdc-903c-4a865017df36">0.15</ix:nonFraction> million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i91f10778634c436b8efd5b90ec1f5c3e_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcwNw_42bfdd1a-cbbd-4108-a801-d212e22a8860" continuedAt="ib21cb2e7ef3242698a91c7ce86357053" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMC0xLTEtMS0w_8ea9f65a-ca19-4fb6-a237-199dc93a0d93">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMS0xLTEtMS0w_1d01b18d-0de8-4a9d-b90b-f41551af8f9b">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMi0xLTEtMS0w_99597c43-555b-4c50-b7eb-6098b4944dd4">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMy0xLTEtMS0w_5416c6bc-572e-4180-b6b2-459a3d0a94cc">7,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfNC0xLTEtMS0w_cd021f42-c4df-46c2-9e98-541118c31c3a">4,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfNS0xLTEtMS0w_d75fa383-c85e-4d60-a4fc-2c5c9f3b30c5">12,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9ecfb2e7360c4fb7b46e70218cc6e8f8" continuedAt="ib3ac7636aab6464a96761d68bca63c1e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="ib21cb2e7ef3242698a91c7ce86357053">(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="iff99e585e3164b03a575580fc0b45900_I20190723" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTkxMg_35b5938e-9b4f-4282-9240-80ce86a073ca">12.0</ix:nonFraction>%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric contextRef="i3c19ea46b38444f6b60a4af0f07a64a5_D20190723-20190723" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjA2NQ_df00e907-6cd4-402a-9523-b45b5f6c8fcf">20</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vernalis Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we acquired Vernalis, a biotechnology company for $<ix:nonFraction unitRef="usd" contextRef="iba9013bb387c441fb61e592bae9e466f_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjU4MQ_bdc89b5e-4c90-48d1-a47b-ff6971d1948c">43.0</ix:nonFraction> million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i09c35816fc7c45c68db42cb9ad26c032_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcwOA_38ef745f-b71e-4d59-a43e-0fb75efbcf48" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:76.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMC0xLTEtMS0w_a44a386d-682f-4b29-8b8a-4d31dbc42643">34,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMS0xLTEtMS0w_d5b2b5c8-4db7-4948-8f09-55bd0e86d903">2,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMi0xLTEtMS0w_16cb9bc7-e70f-44eb-aca6-6c887f30e8db">6,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMy0xLTEtMS0w_6142c8bf-9a2a-4793-938b-f2c514e1bf3c">3,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and product reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNC0xLTEtMS0w_a1be74fd-4b42-4e6d-9da0-d19d027dd1dd">9,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNS0xLTEtMS0w_399c43c3-8aa8-4643-bd1c-9ea6882b37f5">746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNi0xLTEtMS0w_cd168e71-c3f4-4626-b4f7-c5742f02e807">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNy0xLTEtMS0w_a53265b2-9c60-4603-920a-2818fc8ba48f">5,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfOC0xLTEtMS0w_2f1f6836-3be7-4f7b-ac9a-21e1023b1e15">42,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><ix:continuation id="ib3ac7636aab6464a96761d68bca63c1e" continuedAt="i6a8811d5df304a5ab1ea2b61c0359ecd"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzMwOQ_534decf0-df0b-4bcf-be46-64e892f084ed">34.0</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric contextRef="ida6c60fab2814867a46699ae1d38afb9_D20181001-20181031" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzQ2MA_2dfacaa4-adbd-4a2e-8f06-241a42a258db">nine years</ix:nonNumeric>. We retained the core technology after the sale of Vernalis R&amp;D in December 2020. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a8811d5df304a5ab1ea2b61c0359ecd">&#8221;</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM3Nw_7187c5d3-f45e-4dc8-b48a-2ad61f8ea5b8" continuedAt="iee83fb8b2ccf45a9a1f09b4722aab3ce" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iee83fb8b2ccf45a9a1f09b4722aab3ce" continuedAt="ic509f09d2b0e404a98d204fa92de73f3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic509f09d2b0e404a98d204fa92de73f3" continuedAt="ic0e14fe1f9064a7ab57cba64e2a67c9f"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM4MA_b8393e04-0f66-4dc6-8634-1419630e5a14" continuedAt="i17f143cfe90b4ed695875b56894fe25f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c70e7e03138499ea135008f92ae636a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC0xLTEtMS0w_cd1eb3da-9baa-4deb-b264-12c7e9e9fc13">324,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b304285ad04468834c9942bcb940c3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC0zLTEtMS0w_839e062d-0944-4ed9-b85f-ec76a3d2388c">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e787593a0f4a95ae7e6faf6902fb14_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC01LTEtMS0w_5a5c8906-e8f0-40fa-8867-84e9f6ce32ee">320,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0b482524274e4f862807e22f04339d_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC03LTEtMS0w_f034107c-b5da-451e-9749-a2a129e1ee7a">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b897c6c62a4eb0b9c455c2a5e3c9c0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS0xLTEtMS0w_47d98db6-f2ef-49ec-856a-34603ad2d3db">32,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d7240c3b2641f7b93fefce9ba43997_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS0zLTEtMS0w_db0c08e9-7ffa-4140-af46-4db0bb3a0302">32,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c05d3e8a024a8480cfb6b10bc43054_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS01LTEtMS0w_7e411454-d49d-4457-a2a7-2ea821b7cdd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066e6e259ad14a0083f5921dcfe54962_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS03LTEtMS0w_e148163d-0f71-4c10-9b3b-ff27aa1904fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0128c7696ac747c0b7cb29daf26b7d23_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi0xLTEtMS0w_dd8019d1-3418-4b48-aef9-dc98b4d9a533">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib655d0debbde4feb93a3f225e8d31237_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi0zLTEtMS0w_d16bcd7b-03ea-4748-8be1-f8c2aa7444b4">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8884ec54ac6436b9f6405038ca8d51e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi01LTEtMS0w_adfc97dd-0ed7-48b5-a0e7-fe6930684d5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985674008c3e482dae7633f65d66191f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi03LTEtMS0w_f2de785f-d16a-4980-a0ef-6ac19284b302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c24d33a6514e0e90a361e94093f011_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy0xLTEtMS0w_d16b12e6-00b6-41c7-9fd5-be28ee704444">363,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325849b89a604daf9659e7cd5fca620c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy0zLTEtMS0w_78aca9b3-d679-4dbd-b3e0-80adaec6cb07">42,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8dc920224d41959a40fbf2fb518de0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy01LTEtMS0w_f7e84e69-17ae-4bfd-bd06-1c3920d166cd">320,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c7cd32e8b844f784308ca4fe584644_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy03LTEtMS0w_525ba619-cf72-4d20-bcff-3bae133a9bf5">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c86d7cd6446daa9d2bb7abb2b4ec3_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS0xLTEtMS0w_87d91351-a610-4b2e-bbc5-ea008030054b">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66b0db35db44f8c8369e77da14013ac_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS0zLTEtMS0w_30e31563-52bb-4473-8505-4f8fe914d07d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b6c6ceb9d7450496a7b9d016f7dbbb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS01LTEtMS0w_9879ddf0-21f8-41a2-99a3-64cd10a1ac52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c8f26d622543f39f164698f8b83b7e_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS03LTEtMS0w_c04529ab-3580-4f1e-baec-54892dd93841">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab0ec6924f4304a39b0bf8f5001c7b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtMS0xLTEtMA_e89448b4-2e9a-4149-a1d3-891905644ce0">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a70d84e512248ac9fba2353f9f99a60_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtMy0xLTEtMA_1415e90b-a4b0-477f-a7b7-8f4d83c05ae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1c28bffdd04f8392e2e09f40101997_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtNS0xLTEtMA_7c44bff9-4d35-4e15-97be-7b44ee127609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia485d5109cc4438e997246e17ebfc4ca_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtNy0xLTEtMA_95b9db5d-76f6-4c44-aee6-d6cbee103bbd">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8606ca98858540a5963136c5f3cd6569_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtMS0xLTEtMA_cd5484d1-818d-4517-adcc-f8698a9d0010">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98368e7d660497ca20cee33026379c1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtMy0xLTEtMA_f6ea6c42-fd3b-42e1-96ae-1147405e757b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fc9d0e319d49ed89ca0eebf9f35bff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtNS0xLTEtMA_404e0c49-3e73-4b3b-9a09-f543fddd722d">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5029c0e076064d15bcaaa31e3d8187fa_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtNy0xLTEtMA_7d7eb2a2-5b64-480d-815b-42cb8ae47b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f8caf1622a41fa91f4942f87f67bde_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMS0xLTEtODE1Mw_0812e350-4f10-4994-88ea-fd8fd4f42bf2">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac63a2559a74326abe6d930f6accfb4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMy0xLTEtNzYxNQ_81b6f724-8eb7-41cb-a3d4-d1185319bab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b487fdb37824d4f9ef1a0400ee9dccf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNS0xLTEtNzYxOQ_0d1511c0-8317-462a-9389-3f15222643ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1dd4fca49c48fb9be8bec85e267e45_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNy0xLTEtNzYwOA_cef98b10-859e-4253-8f01-3c7f7a3704bf">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033d9d285210428ca8efab5d8a1ee24d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMS0xLTEtODE1Mw_b98e7f28-8cc7-4f67-bd20-d206dc92ceac">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539792c492b3485dbdd59cf131d570cf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMy0xLTEtNzYxNQ_f72e965e-6a62-417a-a0d5-2822ee8d38f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb3f5f216147b0bc15b06e777edd38_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNS0xLTEtNzYxOQ_08246943-4b3f-4977-b10e-070bed45baa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09c77184f6647d4bfadfba8681652ae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNy0xLTEtNzYwOA_1b741af5-bbbb-4a64-adb6-1ec0d8dc0743">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d368fdfb8cc44779ec8d9c4b178bb55_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMS0xLTEtMA_d310ee0c-b30d-4c37-affd-42aa26aad342">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74f3ffda69b453e9607122edad77fdf_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMy0xLTEtMA_15224261-ecf3-4f44-8317-be01c90f3259">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100d3ad1f1d043d7ba7a409ef38f47a5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNS0xLTEtMA_f2f23985-46f9-4766-9827-144d01412f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92c7c3420a147f186540d32f570459b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNy0xLTEtMA_821b594a-668a-45f1-ba01-874c04003c8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c24d33a6514e0e90a361e94093f011_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMS0xLTEtMA_7c2add0b-9fe0-4e57-bd3b-dc06e9b57aec">49,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325849b89a604daf9659e7cd5fca620c_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMy0xLTEtMA_a74ebc2b-dc85-4f81-9d4b-150af7d05c5b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8dc920224d41959a40fbf2fb518de0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNS0xLTEtMA_5b051b35-217b-4de4-86a5-9e5ab4ce7f48">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c7cd32e8b844f784308ca4fe584644_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNy0xLTEtMA_9d0296ad-bcac-47dd-abaf-1d0726b5b71b">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bed8cb3b0ed4b978d1785374324f715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC0xLTEtMS0w_0109b73a-c068-44ff-9bab-264ab272a782">939,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0af1caad2ec4bb3b5063b4f40c26520_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC0zLTEtMS0w_780bbbce-351b-4352-af4a-eb8c042a1b54">3,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faaf97bade2466badfff2a3a6a9a037_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC01LTEtMS0w_42ca127d-094a-45a9-950a-d2c13797908e">936,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9480b683b415427882bd5e8708c90123_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC03LTEtMS0w_f52f096e-9f01-438d-9742-1105c4a95915">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044b313dd18245adafea8294b91bf524_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS0xLTEtMS0w_e968fb66-0c12-414a-8e2a-f06c16a663a5">48,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97080b1df6004dca997119afd07fb422_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS0zLTEtMS0w_2e6b0764-4b96-4de3-8bc3-130011dadb4e">48,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf5ad2f46ec4ee98ca750ce92cee1c0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS01LTEtMS0w_ac19774b-aefe-421d-aaad-a52fe22127ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb7ec904b154a24ac4500272466e24c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS03LTEtMS0w_e99c6a7b-f979-4946-b635-dc03deeae2c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3b19e4b35e406ebcd52022bb02eda0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi0xLTEtMS0w_be209d99-6da3-4fc2-a4f5-03d174865dea">9,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce9786861db4e7cab91a951db9a86ae_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi0zLTEtMS0w_617d8277-786c-4439-84a9-0614a7b54cbd">9,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21553bca1b1431b87f6ef73264c6a08_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi01LTEtMS0w_4da81fb5-9086-472b-9953-2a12c4c5e530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6055eb2a56ee4de58267511ac1b63e34_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi03LTEtMS0w_a4609a2c-cf0b-4788-a804-48e47c5411ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d83a1f143a24e3f875bf1146a570289_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy0xLTEtMS0w_760d2ecc-6890-4e67-84c7-b7e477c91109">998,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078cb5087cab4be7ba5189ff529510ac_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy0zLTEtMS0w_d0b1230b-8544-41dc-a808-df711a585abc">61,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a273d6b52d4ba48768b5519b0c3665_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy01LTEtMS0w_8fe2c85b-a638-4963-bac9-d756016c2593">936,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3bca9d1ae7450e90354484c1d5f005_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy03LTEtMS0w_b175cb4f-67a7-42ea-a987-31573854b540">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57d66428a1f493aa864bbf8e827485c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS0xLTEtMS0w_bd792633-ba92-4c2e-8351-48c0f92cf1d2">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5cf083ca134bf79668ec12b74a240c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS0zLTEtMS0w_0ef7e34c-1bc1-46e7-8a1b-f96e38dfd2c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfb0ea4403e4557afd920f82e95aaab_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS01LTEtMS0w_5eb33027-2bbb-4e95-aaeb-9c786673caed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5202115d56d44835a5e19d2567442658_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS03LTEtMS0w_c18d5d67-bdb7-49a9-b246-c9b71045a2b5">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13aae0d9ac5c46eda486f9147f718cc7_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtMS0xLTEtMA_7439e471-6f7d-4b23-bfe8-f518fe1b6b95">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35aa47334744f07856c9d53b543fcc1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtMy0xLTEtMA_dcd19468-1cf4-4698-b26d-03de2d2dfd1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b8c8ad9a5c4b95bcdd1ef1f93fd6cf_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtNS0xLTEtMA_56b144c1-4669-4423-8dd5-03b4782abdc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945a71f3ec5741968deafb92ba14c4d0_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtNy0xLTEtMA_7fdea6a8-0e5f-49d3-82b8-fde2d92b6813">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic218f09432544a61968a84902b4b6b12_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtMS0xLTEtMA_61a69bce-9672-4caa-8589-533548b93d82">5,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ebb572aba124b47ac39a33fd2538183_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtMy0xLTEtMA_062798ca-0f42-42e1-9d3d-2d41f0d05184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5a9499dd5044ea8aea5a77be53c4ab_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtNS0xLTEtMA_90a874c8-ab84-40fb-863c-30f287a0d702">5,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb7330e33f14407916171e7e0d390c9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtNy0xLTEtMA_4473e3f6-9d49-4ff9-8f55-a6dcea6ad496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020a06568fff458680224e0c17f7e1e9_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItMS0xLTEtMA_cea43929-d653-4b0e-9321-2b4191a664ba">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd39e73b51b426faf5d3000ec040cab_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItMy0xLTEtMA_f5338997-d1ee-4e82-ad93-bf896d4325a1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5f225519564e599eb1b5523a3a9fd0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItNS0xLTEtMA_051d09d6-c8eb-4546-95c8-a3bf413ece64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42909e8f9c30495abe5bb1c928de6828_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItNy0xLTEtMA_b72c0a33-0b91-4f16-a1ad-474501cf8c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d83a1f143a24e3f875bf1146a570289_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtMS0xLTEtMA_2a50e5d2-b41d-4796-ad7c-63d5fb214df8">9,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078cb5087cab4be7ba5189ff529510ac_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtMy0xLTEtMA_a63e60e2-4190-4848-adfb-7b27491efe15">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a273d6b52d4ba48768b5519b0c3665_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtNS0xLTEtMA_6c2a743a-a631-4a37-9b0b-0711d170241d">5,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3bca9d1ae7450e90354484c1d5f005_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtNy0xLTEtMA_bcb7f76d-202f-4e2f-92ca-d00c8bd90b9c">3,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic0e14fe1f9064a7ab57cba64e2a67c9f"><ix:continuation id="i17f143cfe90b4ed695875b56894fe25f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $<ix:nonFraction unitRef="usd" contextRef="i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfMTA5OTUxMTYzODIzMg_1256a06d-90e9-42c1-8cb9-88f59257f59a">1.8</ix:nonFraction> million contingent liability on development milestones to former Crystal shareholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $<ix:nonFraction unitRef="usd" contextRef="i546f06ef7f934d938a78d35cc7bd6f13_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNDM1Mw_6a4d48ac-57ce-4a14-a853-7f713936a71f">375.0</ix:nonFraction> million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $<ix:nonFraction unitRef="usd" contextRef="iee3c61a29b7d488e9481564d3568bfc8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNDQ2OA_679bc18c-9b4f-4092-8c8b-f4a158aa1080">10.0</ix:nonFraction> million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the third quarter of 2020, we paid a $<ix:nonFraction unitRef="usd" contextRef="i5c7e8aa3d64f4299bb8749e88d06bc86_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfMzI5ODUzNDg5MDQwOA_c62a2778-7347-43c2-8359-35a5b626b547">0.5</ix:nonFraction> million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM3Ng_c73ba17d-a063-4484-9e12-c263350268ae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2020 is as follows (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37b745566de4dda9b10c642d417c89d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMS0xLTEtMS0w_be4dc37e-b13e-493e-9765-cb462a782f64">3,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMi0xLTEtMS0w_20c65b84-024f-44e3-b815-5aef4e91f86d">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMy0xLTEtMS0w_feea78d8-0f58-4144-8a93-4f328f5e10a8">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities due to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfNC0xLTEtMS03NjY4_7e9d731e-4fac-4497-a541-fa21948630a7">41,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cc73ea0d9c420c800a11a503944b1d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfNC0xLTEtMS0w_f31b0740-4cdf-4afc-b44d-1aed7bf7f12b">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than a reduction in goodwill resulting from the sale of Vernalis R&amp;D disclosed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2),Sale of Vernalis R&amp;D and Promacta License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, there were <ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNTgzNw_4ceea7f7-f97f-46c7-bda8-88940c8b4182">no</ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information related to the fair value.</span></div></ix:continuation><div id="ib69a1c25a15148f9b95ad6e3392de608_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTI_a83eb8e8-dfd9-4947-8a19-e9826389c154" continuedAt="i0015528f99af495d82d49d8eb3b65cdb" escape="true"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTI_fb1617fa-bcf3-46ac-8355-e41474cc8b6b" continuedAt="iefda7ed3f80c491386ef435e591f26e2" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0015528f99af495d82d49d8eb3b65cdb" continuedAt="ic50d8dc7b7b745efb583248c331a7ea8"><ix:continuation id="iefda7ed3f80c491386ef435e591f26e2" continuedAt="ia3c7eb661b8d478da56eb23bf15c16f5">We lease certain office facilities and equipment primarily under various operating leases and one finance lease. Our operating leases have remaining contractual terms up to <ix:nonNumeric contextRef="i7fb52bcb659e47438837272f49d907bd_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzE1OA_5565397c-0fb0-4c9c-a17c-014ab57a1bcf">three years</ix:nonNumeric>, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="i7fb52bcb659e47438837272f49d907bd_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIyOQ_14ef5596-33b3-449d-8d96-b708695a475c">five years</ix:nonNumeric>. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial in prior years.</ix:continuation></ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic50d8dc7b7b745efb583248c331a7ea8" continuedAt="iecee8c6d63ca4b0ca4d834cd7ddd2625"><ix:continuation id="ia3c7eb661b8d478da56eb23bf15c16f5" continuedAt="if28726101a254e28981edceaf8fdc3ab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an agreement with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol. The agreement is considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. We allocated consideration in the agreement between lease and non-lease components using relative standalone prices. As of December 31, 2020, we have paid consideration of $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PurchaseCommitmentConsiderationPaidToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjY5OTI_6756af34-7826-494b-8866-e60919057ac5">35.3</ix:nonFraction>&#160;million and have total future commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMDc_e22766a5-b472-4795-b850-b34a54c10cce">24.1</ix:nonFraction>&#160;million through 2021. In October 2020, we determined the lease had commenced and recognized a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="i39e9c330c7d843a6b978f225237f75fe_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMjI_c0b9db46-b746-4b7c-8376-fd5e3597395f">16.1</ix:nonFraction>&#160;million. We allocated $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMzc_0027be0e-6f74-4885-9079-1531d8a57099">25.8</ix:nonFraction>&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and have a remaining lease liability of $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwNTI_e8dfd88a-f5c9-4c7d-b65c-a3e3eb7beba1">6.6</ix:nonFraction>&#160;million as of December 31, 2020. The right of use asset is to be amortized straight-line over the remaining <ix:nonNumeric contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzg3OTYwOTMwMzA0NTA_2124ef56-fed2-4392-8881-ddec6dd5ca99">8</ix:nonNumeric> year lease term.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTM_882d8b90-56ff-4801-87d5-79267ab2d444" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:53.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzEtMS0xLTEtMA_f65c1c06-fefa-4168-bfa0-0a1c9e010c3f">6,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzItMy0xLTEtNDMyNg_0f763f7e-2751-47d8-93fe-d68d137cd838">10,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMS0xLTEtNDM0Mg_8a572a1b-e736-44db-b664-9006e365b5c9">15,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMy0xLTEtNDMzOQ_3028c0b8-fc0c-4aeb-90de-330f1892f303">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMS0xLTEtNTIzOA_507c399c-7f3d-443c-9e7f-722f644f251c">22,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMy0xLTEtNTIzOA_63cfd995-fc38-455c-80d2-354bffd3a98b">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMS0xLTEtMA_3a17e475-b5bf-45de-8aeb-7268df1d06f7">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzYtMy0xLTEtNDQyMA_0e24c62b-5563-4d3d-af5e-6e6bdc06870c">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzctMS0xLTEtNDQxNw_edec4244-a7de-4570-a682-743a2396f1c3">6,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzctMy0xLTEtNDQyMA_4fb683ad-25c9-47f8-b86e-13daad49d24c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMS0xLTEtNTI0NQ_d339ca53-762a-40fe-954a-b50cfdd8a945">8,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMy0xLTEtNTI0NQ_27aaec7c-64cf-4d93-bbff-714115c18df3">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMS0xLTEtMA_87c28f49-8b8d-460d-a078-9d280dbcbc7c">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMy0xLTEtNDQzOA_e69094e5-9694-4fa1-9ff2-a8b316ef5fa2">9,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTEtMS0xLTU1MTY_09eef19b-1732-49d2-92e1-b4cf346b8970">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTMtMS0xLTU1MjU_52ba791f-6de0-488a-a9fe-afaf380d210f">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzUtMS0xLTEtMA_f839b2ed-e4a0-418e-9a97-4b3032a7245a">14,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTMtMS0xLTUyNDg_87d90a9a-7a40-4e43-93b2-4175d6f01863">11,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTQ_60cead37-8c90-4fd2-bf14-ca3d5470af83" escape="true"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTQ_b5881a71-4514-4501-b9e4-51a882dda66b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzEtMi0xLTEtMA_c0e034d3-e06e-47ea-815f-b4c4f1622439">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzEtNC0xLTEtNDc1MA_bf838af8-d482-4525-af04-690fb67383fc">6,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzItMi0xLTEtMA_9858fd8a-2eef-4da8-be4a-82dd3f282b05">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzItNC0xLTEtNDc1MA_04798266-b29a-4d9f-bc78-ae722a448996">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzMtMi0xLTEtMA_9aa73a86-ad7e-4acc-8474-43afc5a8983d">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzMtNC0xLTEtNDc1MA_a7fafd27-8c57-4089-8092-7631be2d49ed">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzQtMi0xLTEtMA_349769f9-f58f-4d24-bcfe-83d68c056ce5">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzQtNC0xLTEtNDc1MA_4afffcef-3ef8-4af4-ac54-5cbeb199c786">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzUtMi0xLTEtMA_2f473148-27bc-495b-a1b7-a91cd5e4d9f8">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzUtNC0xLTEtNDc1MA_539f8530-8a8e-4ee0-bf84-8a4a3181a438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzYtMi0xLTEtMA_4e30dbe6-b4b9-4fce-9e20-c6274db525c8">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzYtNC0xLTEtNDc1MA_7490469e-edc8-4714-a4dc-3391781ec7e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzctMi0xLTEtMA_350f04fc-6f24-4c1b-b988-a6a106aef6b7">8,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzctNC0xLTEtNTIzMg_1bacc059-2f9c-49a2-abec-9ee80d29cd1a">6,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzgtMi0xLTEtMA_feed1b18-c5e1-4b78-beab-18643e2dcded">1,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzgtNC0xLTEtNDc1NQ_d8f2b2b1-9273-4a14-a9a5-9a17f51bd46e">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzktMi0xLTEtMA_30ef6675-01e3-4f58-a0fa-1d53bdcbd622">7,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzktNC0xLTEtNTIzMg_e2eb251b-c5bb-4800-9053-866914a45a43">6,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iecee8c6d63ca4b0ca4d834cd7ddd2625"><ix:continuation id="if28726101a254e28981edceaf8fdc3ab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI1MDY_e3ebe87e-4355-453d-bfc1-78c05e01c388">4.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI1NTU_37a6dab2-a8b0-42a1-b3a3-79e3fd14938e">6</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI2NDQ_490609b8-805d-4449-97ad-d31ab0c0dde1">2.4</ix:nonFraction> million for the twelve months ended December&#160;31, 2020. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI2OTA_002c4a42-d194-49df-87a6-124acf777830">2.1</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3MjA_1d7c1775-b518-405d-b60c-97a162a86c06">0.3</ix:nonFraction> million) and $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzEwOTk1MTE2MzkzNTU_776330e4-b06e-4686-932d-ca8e43d1ba48">2.1</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzEwOTk1MTE2MzkzODk_16f366f9-5310-47ac-9618-5f45096071c0">0.7</ix:nonFraction> million) for the twelve months ended December&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNjM_0e3a5e31-42de-4620-b256-630c986103e5">7.9</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNjg_d43cdbb3-f837-4290-ba1e-b80402649d02">3.5</ix:nonFraction>%. Cash paid for amounts included in the measurement of finance lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzg3OTYwOTMwMjkzMDE_705f3291-6c64-4111-ba72-c502562fb1c9">9.7</ix:nonFraction>&#160;million for the twelve months ended December&#160;31, 2020. Finance lease expense, which was recorded in cost of Captisol, was $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNzQ_95b89e56-3951-4a98-862d-62b8b026dad6">0.2</ix:nonFraction> million for the twelve months ended December&#160;31, 2020.</span></div></ix:continuation></ix:continuation><div id="ib69a1c25a15148f9b95ad6e3392de608_103"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE2MjM1_57d0d2d4-8f2e-40c8-8f6c-40cf6e4ed2f3" continuedAt="iae8d144ba2a2476b95ccef3e8338d446" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iae8d144ba2a2476b95ccef3e8338d446" continuedAt="i4766c9baf8e74fa88ff970733bb03aa7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued $<ix:nonFraction unitRef="usd" contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwMQ_60703790-a792-4c4a-8595-62f5c0679b87">245.0</ix:nonFraction> million aggregate principal amount of 2019 Notes, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE3NQ_592b402f-de77-4e17-9e2d-7af2a29966ea">239.3</ix:nonFraction> million. The implied estimated effective rate of the liability component of the 2019 Notes was <ix:nonFraction unitRef="number" contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI2NQ_a559ea28-8377-4758-9cc2-41a10a5e6430">5.83</ix:nonFraction>%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzUxOA_205f01cf-1571-480e-9b94-cc2488c1955f">75.05</ix:nonFraction> per share of common stock. The notes bear cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU5MA_60d18702-39f3-4473-9cbb-4d6ee9e57bc8">0.75</ix:nonFraction>% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at least <ix:nonFraction unitRef="trading_day" contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk0MA_ebfc14bc-d1e9-4c5f-bf76-c9d6082384d7">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk5Ng_25fed931-a90b-4775-a800-38378c61ec11">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzExOTE_d9f715f6-3c8a-4427-8042-3a29ec455c61">130</ix:nonFraction>% of the conversion price on such trading day; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the <ix:nonFraction unitRef="day" contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNTY_56ab5464-b0ad-411e-a9ca-bc515c93bae2">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzMDU_3bc67613-0180-4885-887f-5086fea3fcb1">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0MTg_dbeda4c3-a704-40bd-b1fa-cd85de65a597">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $<ix:nonFraction unitRef="usd" contextRef="i034232aba8564ecda5fc7d8eb72396d9_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIxMzA_08720770-e902-419f-85ec-3c8ae59f714b">341.6</ix:nonFraction> million. In accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the derivative was adjusted to its fair value as of December 31, 2018 to $<ix:nonFraction unitRef="usd" contextRef="i28107efd47144a3abd7964318b557020_D20181231-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIyNjA_171f8f90-0aaa-46ff-8418-67869f4aec56">23.4</ix:nonFraction> million with the resulting $<ix:nonFraction unitRef="usd" contextRef="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIyODI_04504865-278b-4d1e-8d27-033e48505474">118.7</ix:nonFraction> million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI2Mjk_05612114-012a-46c8-9fe8-01607ea78ecf">21.8</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI4OTU_661adae6-f39d-47ae-b9d2-0a88cf080763">31.6</ix:nonFraction> million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI5OTg_cae367f9-a78d-4a62-9ce6-6037aa263cde">195.9</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $<ix:nonFraction unitRef="usd" contextRef="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzMxMTY_cb87298c-c822-4495-9ced-9912614e1029">195.9</ix:nonFraction> million principal amount and the excess of conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="i2f492ad4dfa64cb6b2319778404cfec8_D20181001-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzMyMDc_a95c4b10-4554-46ca-b46c-51d779a72b85">439.6</ix:nonFraction> million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzM1MjE_e75a6ce9-bc3a-40a1-95e2-692d2bb18a43">3.2</ix:nonFraction> million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4766c9baf8e74fa88ff970733bb03aa7" continuedAt="id4e3dede24e140059e5d44cc2ed3d8e9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQwMDc_17bedda3-4bbd-4a12-94a6-f06d6d7036e1">1.0</ix:nonFraction> million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $<ix:nonFraction unitRef="usd" contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQxNzI_e3811ac0-47ae-4a17-801b-73325624e292">1.0</ix:nonFraction> million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $<ix:nonFraction unitRef="usd" contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQyNzU_61e4f3fc-1467-49d1-9fb7-fa1d7204803d">0.5</ix:nonFraction> million in cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $<ix:nonFraction unitRef="usd" contextRef="i62894ef4375a4892a57a4a49a14e7ac1_D20190815-20190815" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQzNzY_15c072ec-3509-465c-a309-8485fb682102">26.3</ix:nonFraction> million principal amount and $<ix:nonFraction unitRef="usd" contextRef="if187349176e84ceda4964da4edd883be_I20190815" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQ0MDA_4d8a304a-cf83-46b9-96fb-3ad1173a17f9">11.9</ix:nonFraction> million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQ1NDQ_4ef766be-5d34-4adc-ae70-3e4366428b23">11.0</ix:nonFraction> million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU1MzE_aa34711d-610a-46b2-9599-c51a0e2fd313">3,264,643</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible bond hedges had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831" decimals="INF" name="lgnd:ExercisePriceofConvertibleBondHedge" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU4MDc_1b03cf72-5667-488a-a741-c4676124756d">75.05</ix:nonFraction> per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $<ix:nonFraction unitRef="usd" contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PaymentsforConvertibleBondHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzY2MTc_1433d5ce-75f6-4865-8473-8493d8a4caba">48.1</ix:nonFraction> million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $<ix:nonFraction unitRef="usd" contextRef="i220b0c6c496e42fc8ea7dccfde48d81d_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyMTE_41d8c6f7-afac-4631-9474-a051b089b5a5">340.0</ix:nonFraction> million and marked it to market as of December 31, 2018 to $<ix:nonFraction unitRef="usd" contextRef="ie35fa90cf89940babbfb526c040370f4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyNjU_288d1132-a24f-4803-959d-7bda680f5b38">22.6</ix:nonFraction> million with the resulting $<ix:nonFraction unitRef="usd" contextRef="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyODc_dda93f18-b768-4195-8269-2df59e19bedc">119.4</ix:nonFraction> million increase, net of $<ix:nonFraction unitRef="usd" contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzczMDc_16a763b2-e70f-49d0-b172-df79d10410b7">471.2</ix:nonFraction> million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $<ix:nonFraction unitRef="usd" contextRef="id18f5551b94641ff880e77978a598895_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc1MzQ_fb6f7dc3-1849-4ef2-8818-fde54632aa03">10.2</ix:nonFraction> million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire <ix:nonFraction unitRef="shares" contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc3ODI_54a4f0f7-2619-4d6d-8ec8-e8e9ae489f08">3,264,643</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc4MzQ_acfe6762-97a5-4c08-b6ba-490471fa4644">125.08</ix:nonFraction> per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $<ix:nonFraction unitRef="usd" contextRef="i5a15352b902e4da3bb0205dc843b9a3f_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzgxOTU_d994a092-3188-4cbd-9261-0bad12a00a07">11.6</ix:nonFraction> million for these warrants and recorded this amount to additional paid-in capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of <ix:nonFraction unitRef="shares" contextRef="i661dd10b9d474519ba9a2208b86c8de9_D20181101-20181130" decimals="INF" format="ixt:numdotdecimal" name="lgnd:WarrantsSettled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzg4MzU_c1379454-8b7c-4603-bdad-f5e03a6bf788">525,000</ix:nonFraction> warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#8217; equity to a derivative liability on the modification dates, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkwNTM_ce96b995-4002-4c74-a6f0-f9d18410cf68">28.3</ix:nonFraction> million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkxNjU_0cb76e94-bdc3-460e-accc-3b720ed63ca0">30.1</ix:nonFraction> million and recorded a $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkxODM_cbb9987c-c3f6-460f-a1d4-17e38dccd2bd">1.8</ix:nonFraction> million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December&#160;31, 2020, there are <ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIxOTkwMjMyNzk1MjY_d0cf7f96-0b40-471b-a806-be84d08a2a58">no</ix:nonFraction> warrants outstanding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk1NjY_06e54966-0f1d-40ae-8e87-927662d06592">750</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk2NDY_02273d25-6380-42c0-9b3e-ba42e7066fe5">0.75</ix:nonFraction>% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk4MDk_74694f1e-1ea6-47e8-9975-261d6410516d">733.1</ix:nonFraction> million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwMTMw_c9c8570a-27c6-4f96-9131-8e32170fc949">248.48</ix:nonFraction> per share.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4e3dede24e140059e5d44cc2ed3d8e9" continuedAt="i16fd755ba2304894999cabbf34b013b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least <ix:nonFraction unitRef="trading_day" contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNDYy_f2fc933b-89db-4db0-894e-5b7643d14340">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNTE4_66775c8f-89f2-4b5b-be7d-1aa8640ddbb2">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNzEz_f695ba15-dd1b-4f2b-9e6b-d35ffc70514c">130</ix:nonFraction>% of the conversion price on such trading day;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the <ix:nonFraction unitRef="trading_day" contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNzc3_6ee7e7d0-57a6-4d6e-a670-0d23ed2a2774">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwODI2_03e61605-2d49-43cf-9d8c-7f7125f7574b">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTM5_11032bef-8e3c-467f-81f1-ec3a35283d31">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $<ix:nonFraction unitRef="usd" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzExNzU0_c808867c-edf7-4280-8add-7875ade322fb">144.0</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $<ix:nonFraction unitRef="usd" contextRef="i323e527963b14f6ab5f0f11b66cf75a8_D20180522-20180619" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyMTc5_bdd284ea-fdf0-4f43-b4ad-e3d60fd731bb">13.5</ix:nonFraction> million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNTc2_7a395a67-e772-4af3-acc5-4a52a082d557">248.48</ix:nonFraction>. As of December&#160;31, 2020, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $<ix:nonFraction unitRef="usd" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNzQ5_afbfd354-5ec0-423e-96e0-2a5f20a4853b">16.9</ix:nonFraction> million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $<ix:nonFraction unitRef="usd" contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyOTIw_c749916a-1ba7-4a02-a7a6-27806111ad4b">3.2</ix:nonFraction> million was recorded as interest expense for the twelve months ended December&#160;31, 2019. The portion of these costs allocated to the liability component totaling $<ix:nonFraction unitRef="usd" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzMDQ0_5202db03-b660-43ff-a26d-14d667b45128">13.7</ix:nonFraction> million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i65069fa42dbc40d2941743d3f4afb5f7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0MjY_e46996dd-e66f-4d53-88dd-c4b3476664c2">254.7</ix:nonFraction> million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0NDc_1c740020-383e-4008-a26f-407e8b5be05d">222.8</ix:nonFraction> million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i65069fa42dbc40d2941743d3f4afb5f7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:DebtInstrumentAccruedInterestRepurchasedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0Njg_b3dcbd0e-09bd-4530-b1e0-099313320342">0.6</ix:nonFraction> million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $<ix:nonFraction unitRef="usd" contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnRepurchaseOfDebtInstrument" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0ODc_d2b4ffc7-82ce-4393-9390-b016a6fd6955">2.5</ix:nonFraction> million reflected in other income (expense), net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2020; (2) a $<ix:nonFraction unitRef="usd" contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseInDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc1MDY_b41296ad-3f80-45bf-8bde-21540a54a7a7">35.0</ix:nonFraction> million reduction in debt discount, and (3) a $<ix:nonFraction unitRef="usd" contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc1MjY_381d01f3-c8f8-4131-85ff-449b2224be03">3.2</ix:nonFraction> million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. After the repurchases, approximately $<ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3NjU_8af11274-c95b-4e02-992a-1419558704a6">495.3</ix:nonFraction> million in principal amount of the 2023 Notes remain outstanding. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzNTk3_4296bb73-e50f-4272-8243-1fa0ddebc77e">3,018,327</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzODcx_ed6b70a7-6752-4032-8d7b-a67fe5a01209">248.48</ix:nonFraction> per share and are exercisable when and if the 2023 Notes are converted. We paid $<ix:nonFraction unitRef="usd" contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PaymentsforConvertibleBondHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzOTU0_8f119635-21b3-462b-bccf-7d870b6b835e">140.3</ix:nonFraction> million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i16fd755ba2304894999cabbf34b013b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering <ix:nonFraction unitRef="shares" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0ODM5_735b48de-a612-4812-af81-1a48234eb889">3,018,327</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc84240a812d4182830716e5492a75f0_I20180522" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0ODkx_6f9d271b-a0df-4202-bf3d-75e0878e34a3">315.38</ix:nonFraction> per share, subject to certain adjustments. We received $<ix:nonFraction unitRef="usd" contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0OTQ5_9fb68440-1520-42ff-836a-80b93a53e338">90.0</ix:nonFraction> million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $<ix:nonFraction unitRef="usd" contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE1ODk1_70f51cc0-4e1d-47c2-ba01-d690506cd3bd">19.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE1OTAy_fb14aabc-9cd4-4a70-badc-9e91273b5414">7.5</ix:nonFraction> million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="if6c815b5da3a452d8a7e3e5be67a017e_I20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE2Njg_db4f3d42-6d66-41d1-a18c-66ea87a30dc5">234.4</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="ib69a1d348c964f9585625ef80a9b7fa8_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MDE_57e014c8-bdbd-4758-b58f-d1262215635b">203.8</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="if6c815b5da3a452d8a7e3e5be67a017e_I20200430" decimals="-5" format="ixt:numdotdecimal" name="lgnd:DebtInstrumentAccruedInterestRepurchasedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MjA_bbac8de1-1813-4085-a934-a8b767993e82">0.6</ix:nonFraction>&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 28, 2021, in connection with the repurchases of approximately $<ix:nonFraction unitRef="usd" contextRef="i50cd7daf68e54877a8d9e082be5523ad_I20210128" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3Mjc_c90e46a6-a1b5-4f5c-8090-7874ff71ad31">20.3</ix:nonFraction>&#160;million in principal of the 2023 Notes for approximately $<ix:nonFraction unitRef="usd" contextRef="i350edb2222fc4ac0a3c6507827c9b80d_D20210128-20210128" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MzQ_7947d6b4-5873-45de-9dd7-fdfaedb96a91">19.1</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i50cd7daf68e54877a8d9e082be5523ad_I20210128" decimals="-5" format="ixt:numdotdecimal" name="lgnd:DebtInstrumentAccruedInterestRepurchasedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3NDE_81468538-d775-45c5-9d60-d5b424e32b41">0.1</ix:nonFraction>&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE2MjM4_3f145ba8-afdd-4a67-9862-d56338abc650" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzUtMS0xLTEtMA_9739ef14-145a-498a-bdea-4b1ea91bb373">495,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzUtMy0xLTEtMA_f9768cb0-6ec6-4716-a62f-54d5c2f7dbdc">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzYtMS0xLTEtMA_187fdefa-d8c4-4cd4-8aa2-10f6efd0b6d7">52,987</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzYtMy0xLTEtMA_cd897c4c-4fbf-4001-8db0-a92dcf4007ac">111,041</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzctMS0xLTEtMA_a0d19246-6650-4de0-b437-2b57c7a0858b">442,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzctMy0xLTEtMA_fba76649-4e8a-4e76-a853-67441322c804">638,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzgtMS0xLTEtMA_7738e849-c9d2-4e30-a669-ca97ffadc8c4">48,397</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzgtMy0xLTEtMA_752f815f-c082-4ccf-8032-bdc1216b0e5a">101,422</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzktMS0xLTEtMA_884a6042-5269-49aa-b93e-981075e43d2a">466,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzktMy0xLTEtMA_4309b38e-0258-421c-987f-8ed8e9256918">647,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were no events of default or violation of any covenants under our financing obligations.</span></div></ix:continuation><div id="ib69a1c25a15148f9b95ad6e3392de608_109"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODM_1c40a2e7-d4b9-442e-9659-27bbae3578b1" continuedAt="iddf4efbcd77e4a19a45a5e33d101a5eb" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="iddf4efbcd77e4a19a45a5e33d101a5eb" continuedAt="ia60f83cd055e471aa60edf46d046c07f">Short-term Investments</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia60f83cd055e471aa60edf46d046c07f" continuedAt="i4c7ab4a36f564fc88093009bbef87f0e"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1NzY_92936957-174f-47f1-9243-62731672439e" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a4018efce8403baff24ddd52876e90_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMS0xLTEtODE1Nw_629185b3-d2b4-47d0-bb43-27f8ef4b726e">151,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a4018efce8403baff24ddd52876e90_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMy0xLTEtODE1Nw_c97528cc-051c-4427-95ed-b1bc5e0f76ef">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a4018efce8403baff24ddd52876e90_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNS0xLTEtODE1Nw_94d136f0-bc86-48af-9a7a-e6e26fd71fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a4018efce8403baff24ddd52876e90_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNy0xLTEtODE1Nw_93693e97-baa4-46cc-9bbf-b823098f5d5c">151,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMS0xLTEtMA_fd4d7a54-517a-406b-aabb-be2f0adc46b4">84,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMy0xLTEtMA_777a2b99-b996-47da-a1c8-88024d351a77">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNS0xLTEtMA_273ce77f-5f31-4a04-b74a-c41ed30ceddd">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNy0xLTEtMA_5a339a6b-002a-44c2-b4de-94dc4ea57537">84,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMS0xLTEtODE1OQ_edd1eb49-0205-4b36-a6d5-7990872647b1">45,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMy0xLTEtODE1OQ_06a86758-cd87-40a4-b868-5a5513d9d3b6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNS0xLTEtODE1OQ_79139193-9a49-42f4-9557-2994de0fab53">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNy0xLTEtODE1OQ_891a9107-259f-4fa9-9fce-29599d4cfa0f">45,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide70d0b7f442498693f401787562d65e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtMS0xLTEtMA_d725d49a-1fba-4327-9a24-f9df840e3cb6">30,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide70d0b7f442498693f401787562d65e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtMy0xLTEtMA_12cd4c88-d687-4182-92e3-03f5bc7a750d">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide70d0b7f442498693f401787562d65e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtNS0xLTEtMA_c81de1e2-740c-46cc-b95b-d206a9c72f47">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide70d0b7f442498693f401787562d65e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtNy0xLTEtMA_80a7462b-069c-44b2-832c-c9455094d0de">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882b43ad553b45d298444f65918a460d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMS0xLTEtODE2MQ_402b9c40-dbbd-4281-a3a7-d9663bc8e881">4,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882b43ad553b45d298444f65918a460d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMy0xLTEtODE2MQ_cec84587-b66e-4cc5-af91-7b204f2b1bf1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882b43ad553b45d298444f65918a460d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNS0xLTEtODE2MQ_51b11386-3ff4-4812-be88-c8210f844a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882b43ad553b45d298444f65918a460d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNy0xLTEtODE2MQ_40e53807-e08b-40b5-81d8-fc23ebc1d6fe">4,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b17149c809471b94d0d5841711e32b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMS0xLTEtMA_bef1eef3-4599-405e-a289-ff784bfce4b9">4,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b17149c809471b94d0d5841711e32b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMy0xLTEtMA_9d741ead-4715-4457-94bc-cb1ab7661039">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3b17149c809471b94d0d5841711e32b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNS0xLTEtMA_72e93d38-a3e4-403e-ac5b-80791ab3b062">1,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b17149c809471b94d0d5841711e32b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNy0xLTEtMA_4f2c89f9-3727-44ce-84e0-4df5df5a2c8e">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMS0xLTEtODE2Mw_bc4dc319-52e6-471b-a25b-79cff2203484">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMy0xLTEtODE2Mw_2b3f1b04-6064-4b84-9949-f8b6c7e1db41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNS0xLTEtODE2Mw_cb8daa5e-d87b-480a-8c52-3cce7d47f3b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNy0xLTEtODE2Mw_f678dd4d-d4b3-4be5-866d-7bce89103f78">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMS0xLTEtMA_97f0423d-eb34-44c9-aa6b-395048731697">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMy0xLTEtMA_5d54f4a7-670a-4e50-af30-4976a626f9a0">393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNS0xLTEtMA_6cca6809-b457-4342-b43d-33d80497ba15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNy0xLTEtMA_b358de91-2c54-4f22-8cf0-404278785379">393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMS0xLTEtMA_ccbb077f-b0dd-45e5-ac1f-8da9522c2cb9">324,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMy0xLTEtMA_4531ac0a-58ac-42ae-81f8-586c543d8173">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNS0xLTEtMA_dbfbc3d8-9c8d-459f-bbd0-bdc0de671785">1,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNy0xLTEtMA_d69d3ec4-4977-4fc7-bdfc-37e1e84a3dd7">324,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTEtMS0xLTA_4ead8c61-77fb-4bdb-b26f-a784582f9bb6">411,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTMtMS0xLTA_66121bed-114b-4204-89d4-f38e7dbad5e6">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTUtMS0xLTA_d63c7a6f-982d-4191-bf2f-e46818a9962d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTctMS0xLTA_f44ead00-49aa-4cc5-a0ca-b54d4958e63a">411,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTEtMS0xLTA_497c6664-a204-421f-a1ad-3e7611be0200">63,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTMtMS0xLTA_b37958cf-02e2-450e-8b1c-d916fb7a894f">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTUtMS0xLTA_09321964-7ba5-461e-b322-935982021fee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTctMS0xLTA_43485ba9-f4cd-4f85-be3d-fd5021c23731">63,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTEtMS0xLTA_8aeba9f5-8864-4dee-aaf4-25e028543204">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTMtMS0xLTA_26839c4f-5b68-4f9e-b1f0-07c66e8f8553">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTUtMS0xLTA_adb3e69c-ee2d-4d7d-a898-fc19f8fedcd0">1,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTctMS0xLTA_fd2e4c99-5080-4b44-aaa1-0fb465e73c32">3,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTEtMS0xLTA_2545362a-6d42-4b26-85c1-31fdbb22b51b">210,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTMtMS0xLTA_7f14e32b-88e6-450a-9afc-693b2936e10d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTUtMS0xLTA_607dff35-695d-4ff7-b3ef-78f51ac8377d">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTctMS0xLTA_e586d28b-40e3-4936-8a23-b063d2c5f645">210,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTEtMS0xLTA_eae87bcd-8de0-4b5c-924c-1bc4bcfa7e75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTMtMS0xLTA_c5bd3015-f83a-4f4d-a04e-dd9e52631276">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTUtMS0xLTA_d7a50d24-735b-4e17-94a2-b522d8ebfcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTctMS0xLTA_017be535-3c29-4f3f-b66e-5a4b8716a148">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual Fund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTEtMS0xLTA_183ddb34-7021-472f-8271-f539676b5fd1">250,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTMtMS0xLTA_a8f1d61e-a6f8-4ba6-a605-8514f0464db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTUtMS0xLTA_421cbb42-d258-47a9-946f-cbcde1ec8c5c">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTctMS0xLTA_3b2bb577-11f4-433e-bd5f-161cfc01c981">250,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTEtMS0xLTA_f82ec215-fafa-4ce5-9116-a63ae478b97b">941,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTMtMS0xLTA_1f936087-1d5c-49a9-bd25-a164ac112051">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTUtMS0xLTA_83fa4914-2f1c-4296-900e-e4ed9f63f0c4">2,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTctMS0xLTA_36d58f0c-62bc-41bd-a339-1283fa26221b">939,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of  December&#160;31, 2020 and December&#160;31, 2019, we recorded shares of Viking common stock we own at fair value of $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODEw_8442220d-0923-4f28-b5ed-b609bf8ea202">32.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODI0_b01f847e-271b-466b-8371-6e024877870c">48.4</ix:nonFraction> million, respectively, in &#8220;Short-term investments&#8221; in our consolidated balance sheets. We also own warrants to purchase up to <ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODQ2_764c170a-af85-42b7-a825-e2fa302a8fde">1.5</ix:nonFraction> million shares of Viking's common stock at an exercise price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODY4_ca1cbbed-f1df-4b81-b66b-121f2193bdea">1.50</ix:nonFraction> per share. We recorded the warrants in &#8220;Short-term investments&#8221; in our consolidated balance sheet at fair value of $<ix:nonFraction unitRef="usd" contextRef="i3839777e750f48b3970c5b559eed73b8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODgy_b6a7bbed-c7d6-4662-bec9-c6d6e998d018">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3736760d3c7340649ea390cca0ce15fd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODky_2f5e8485-423e-4f12-8e9e-db7add3e3822">9.9</ix:nonFraction> million at December&#160;31, 2020 and December&#160;31, 2019, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzIxOTkwMjMyNjg5OTA_28de4c27-0199-4253-8227-6cf795043c30" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzItMS0xLTEtOTM4OA_ab600148-cc33-448d-8ce0-26371879bec8">141,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzItMy0xLTEtOTM5Mg_e96a4c5f-10fe-4196-a64d-d16c56c8ddfe">141,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzMtMS0xLTEtOTM4OA_b3cc0f16-d782-4035-919c-baba6b6413cf">26,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzMtMy0xLTEtOTM5Mg_70bd0549-7ae2-45cb-b062-c11c5259f443">26,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzQtMS0xLTEtOTM4OA_be622a58-88a7-4d71-aa20-1cf6d8990b81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzQtMy0xLTEtOTM5Mg_7b09c8fa-6f2c-4bc5-be0e-b33e71d7cc2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzUtMS0xLTEtOTcxNA_671110f3-e5ae-4ae5-870e-ade6c9240181">168,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzUtMy0xLTEtOTcxNg_93dd0c90-1fb0-4ad9-ba90-4408f69d3531">168,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzIxOTkwMjMyNjg5ODk_8ecc4a24-16b6-4950-9f92-7df910ec992f" continuedAt="i69f414d89ccc4aabafbb28d0b7135f01" escape="true">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4c7ab4a36f564fc88093009bbef87f0e" continuedAt="i22ca5284922247a38ac8fa9ae89b6b1b"><div style="margin-bottom:6pt"><ix:continuation id="i69f414d89ccc4aabafbb28d0b7135f01"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMS0xLTEtOTQwNg_852be713-da9f-4aa9-b5cc-16c58e8d051b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMy0xLTEtOTQwMg_6c70969b-e1b6-40b6-adc4-43ddbed9edf4">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtNS0xLTEtOTcyOA_6b7afc57-0bbc-4cc7-934e-9362a7c78018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtNy0xLTEtOTcyOA_48109385-235a-4b23-a37b-c8bb7a98a22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtOS0xLTEtOTcyOA_e472c66c-e24b-431e-b7c1-b73e322cb49a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMTEtMS0xLTk3Mjg_8bab0536-7c13-484d-862a-51235b1f5faa">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMS0xLTEtOTQwNg_5fa3771a-cd79-4dbe-865a-ddd151d58f2a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMy0xLTEtOTQwMg_6f0e8b40-7465-4b27-bdb2-0cc4b7f8777c">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtNS0xLTEtOTcyOA_78f5f6f3-9f56-4a71-aedf-cf4fbc29a690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtNy0xLTEtOTcyOA_565977b4-839e-42ef-92d4-b54da41c4c84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtOS0xLTEtOTcyOA_742aecd7-25ba-4c2c-b028-afc8d4893f67">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMTEtMS0xLTk3Mjg_b2f17a22-7c87-4bbb-94c4-7521605c2f88">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMS0xLTEtOTQwNg_12f2fac8-5019-43af-9a69-5461ff4212d4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMy0xLTEtOTQwMg_b2c43263-9465-43c3-977d-fdc3e9f00d22">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtNS0xLTEtOTcyOA_815fdac0-c956-4089-91b9-5be11e3b2fba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtNy0xLTEtOTcyOA_81a95169-ca27-446b-be36-b2118d0cb917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtOS0xLTEtOTcyOA_a1046d27-5386-4e39-ae15-699122eb9d85">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMTEtMS0xLTk3Mjg_b062c989-9f94-4c32-b611-7f9b7b658950">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMS0xLTEtOTcyOA_52e963e7-a089-4bdd-95dc-649ba76a3716">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMy0xLTEtOTcyOA_bd3e7c2f-5f20-40d7-a4b2-7cae5f8a7b94">26,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtNS0xLTEtOTcyOA_146a0e36-7f1e-43d1-9319-51455bb87b80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtNy0xLTEtOTcyOA_ae497fab-5f22-49d2-babe-f2da33dc0b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtOS0xLTEtOTcyOA_9c859720-6cc7-4f17-9945-a5fcab611cf9">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMTEtMS0xLTk3Mjg_51595ed0-5d7b-48f2-bc83-875a616e719a">26,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMS0xLTEtOTQzNg_9ca897ef-6a57-4b7c-9344-c1d6425b94fb">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMy0xLTEtOTQxMA_1ca83e43-5120-44a1-a7e5-825170f3c1bc">58,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktNS0xLTEtOTcyOA_bfd264ff-4d4c-4cb5-987a-ca8d9460a93e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktNy0xLTEtOTcyOA_a0a8ab41-b79a-40a4-839b-0ba3b75b8d68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktOS0xLTEtOTcyOA_28b2ab59-9184-487b-91c1-2757dea42c30">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMTEtMS0xLTk3Mjg_10a48005-a0e7-4430-8371-51cef749c008">58,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTEtMS0xLTk0MzY_9ac8618b-373a-43f7-8764-420706a37cc1">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTMtMS0xLTk0MTA_a2f48fec-afd3-4d15-af4c-987ca7738762">79,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTUtMS0xLTk3Mjg_9ba5ab8e-d8fa-400d-8e8e-1b009de8620b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTctMS0xLTk3Mjg_01bdfba5-403a-443d-9736-c8d9af10fb79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTktMS0xLTk3Mjg_6c883876-5c10-48e3-945f-e87a714458ab">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTExLTEtMS05NzI4_c40d4cd0-878d-419d-8d82-eeb79ed86319">79,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTEtMS0xLTk3Mjg_cee3d1f8-90f4-486f-85f6-e131cd788a2b">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTMtMS0xLTk3Mjg_b240320e-654c-46c1-ac75-f0853a671d05">137,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTUtMS0xLTk3Mjg_2b17b7b0-3781-4ef8-9f47-8cdd9ab3c43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTctMS0xLTk3Mjg_aa325aba-90f7-4040-b584-c954df851ddb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTktMS0xLTk3Mjg_08fea67e-f98a-4114-80e0-fabcb36f7407">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTExLTEtMS05NzI4_4ef303f9-6460-4bb0-9769-96a516590cef">137,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzMyOTg1MzQ4OTY3NjE_8564d478-5128-44d5-8dc8-3669f89c8754">14</ix:nonFraction> positions which were in an unrealized loss position as of December&#160;31, 2020. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODU_f1fc3298-1bc0-4980-92e4-b54283355093" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a1b1bd10fa49dead7f5c9e02e131de_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzItMS0xLTEtMA_62b63f0b-3b9d-44c8-ba0d-802e42cb4ebb">14,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc43418c7cf4e05b0c7f76c2cc94620_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzItMy0xLTEtMA_1a9cc125-8f76-4904-be0c-d406f17d8ad2">6,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646d4825dcfe46109944de937f3380eb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzMtMS0xLTEtMA_d2c401f4-3a6d-4ca8-877e-2023d2623c45">3,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bf4f32a33946e492417f9d2dc73c52_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzMtMy0xLTEtMA_26291e0a-9b3a-4db5-b62d-50d076a16036">2,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453759ea8cff4f2ab3008749a56e3265_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzQtMS0xLTEtMA_0d448f96-a4b1-4b4f-869d-2deaaa88650b">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3ae4a6112a4341988947a8a9dd966c_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzQtMy0xLTEtMA_797c5631-d946-4dea-97a5-fdd8ba6aab1d">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzUtMS0xLTEtMA_d61b1a98-6c72-4cdf-ac34-529554b6fbec">19,241</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzUtMy0xLTEtMA_072af97d-ba18-4d84-8a4a-77234c1fa6a5">10,035</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzYtMS0xLTEtMA_61ad4df2-bf9e-498a-85b8-9795d8e76baa">4,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzYtMy0xLTEtMA_03251ea3-3010-4744-abe8-b61af945bbf9">2,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzctMS0xLTEtMA_0e37de04-7d8c-4994-b52d-4f7ba3bd18fd">14,434</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzctMy0xLTEtMA_ed9b5cc5-a07b-4737-af81-d2399c9dfd31">7,185</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4MQ_17ee1139-a959-4580-b6e3-e99ff17f0d7f">three</span> to <ix:nonNumeric contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4Nw_baf87db8-0366-4ed4-a97e-c5ab1f111c2b">ten years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU3NQ_5aded146-ea82-41ec-a6cd-77d78e80057a">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU3OQ_5af10020-3365-42c9-8c3e-93915532bac8">1.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU4Nw_efb2e2c6-2036-43c7-80fe-c974bf52a2c8">0.9</ix:nonFraction> million was recognized for the twelve months ended December&#160;31, 2020, 2019, and 2018, respectively, and was included in operating expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><ix:continuation id="i22ca5284922247a38ac8fa9ae89b6b1b" continuedAt="i20af23228e634df892e7dbbff5659166"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1Nzc_3c6984ff-c964-497d-8abc-84438577e37d" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzMtMS0xLTEtMA_3828f1ff-598b-4138-a6b7-23c2a85e1706">189,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzMtMy0xLTEtMA_22deb345-b375-4062-b2f0-278a2482d0b9">95,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9dc7611933a43fe92197068c75cff82_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzUtMS0xLTEtMA_9479fae1-805a-4fb1-919b-ca3cbc5b70b7">277,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d307d89e01d4dc1a92c17f8c98db873_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzUtMy0xLTEtMA_09671e3e-660e-4353-92d3-808b39462206">242,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9dc7611933a43fe92197068c75cff82_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzYtMS0xLTEtMA_54539e33-17f5-4e90-b3d5-a43d297131b1">63,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d307d89e01d4dc1a92c17f8c98db873_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzYtMy0xLTEtMA_a8d6fe63-c111-4919-a6fc-9e81cdb1ca6d">50,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc4e97847f9451da65751e2c293f78c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzctMS0xLTEtMA_8232f11f-343b-447d-a807-7db5a0aafa95">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81490ee5e44b6f8903898601190850_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzctMy0xLTEtMA_a79dcfd6-d5ab-4684-a571-62a729abf772">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc4e97847f9451da65751e2c293f78c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzgtMS0xLTEtMA_3b7a6c5b-d63e-4cb6-a168-14cca1dfef44">1,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81490ee5e44b6f8903898601190850_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzgtMy0xLTEtMA_a1f01cb5-b8c6-4aa6-8ad1-4acf80295064">1,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14712e5300454f86a3bed5deb1f6d271_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzktMS0xLTEtMA_e20d5c89-e84f-4d3c-a50d-4f3acd998fed">40,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4833f2fd94e489fb8b7467d472e39b6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzktMy0xLTEtMA_e3975623-be89-4e05-8ed7-728330eebe14">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14712e5300454f86a3bed5deb1f6d271_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEwLTEtMS0xLTA_5b9bb4e8-bc66-42a3-9fc7-3af5e2c874a1">15,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4833f2fd94e489fb8b7467d472e39b6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEwLTMtMS0xLTA_5990764a-ebe7-4abf-873d-a8a7f069ba30">13,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8faf4085074f419d9384b54bc96efbf6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTEtMS0xLTI3MDM_39489c8f-324f-4f4f-b48a-f2cac528d866">362,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8faf4085074f419d9384b54bc96efbf6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEyLTEtMS0xLTI3MTY_e4eba5e8-1bd1-4e6b-b0f2-baaee9506510">7,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1128ec95e7954d9c91d5362eeae281d0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEyLTMtMS0xLTI3NDQ_2809d71d-f059-476f-8d80-3daa40597396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTEtMS0xLTA_536c6dd9-9609-4a90-9423-1127b1a35a01">784,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTMtMS0xLTA_cb1e5c2c-745f-4985-a023-90103a5ed463">305,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExMTA_a2adf9ee-7333-4e8c-b6b8-d8dd9d65ea1b">20</ix:nonNumeric> years. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExMzg_7dde701b-e181-40a7-9531-542c067b493c">23.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExNDI_ef2cc15d-bfe3-4ca0-972a-811cc5d92db2">16.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExNTA_abf9c560-550c-418f-97f1-faea08a1e903">15.8</ix:nonFraction> million was recognized for the years ended December&#160;31, 2020 and 2019, and 2018, respectively. Estimated amortization expense for the years ending December&#160;31, 2021 through 2025 is $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_032cac24-afb8-4f99-b218-c5402abf596a"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_3250cfb7-acb5-42e1-9004-23d2cc76f61b"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_bb437583-d0cf-44aa-8dcf-622878ef8108"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_e219b290-c7a8-4564-aad3-80dfcc4e762d">47.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. For each of the years ended December&#160;31, 2020, 2019, and 2018, there was <ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_29ab127f-09d4-43fa-a479-ec95e21d7c66"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_859ef221-6930-4913-a727-943fcab247a7"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_9bdf792a-b77a-4c04-bfe7-9e572d66f95d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1Nzk_7bef97b8-a617-499c-a24f-a04c75fc4844" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzItMS0xLTEtMA_915c286f-11bf-4fa8-bbd4-35a8b587ce4b">8,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzItMy0xLTEtMA_8a676342-ef00-42d8-bd1b-ea931a625149">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzMtMS0xLTEtMA_350a0d4b-e2f4-48bd-9036-2f222c7a1471">977</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzMtMy0xLTEtMA_093efc37-e1a7-41a3-aa94-c3d460f16b97">1,135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzQtMS0xLTEtMA_3a0b6448-b194-40d8-83a8-aadf48a8080b">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzQtMy0xLTEtMA_4b4f8767-5bc6-4e78-8658-3ab3c1c09ed8">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzUtMS0xLTEtMA_1bee57a0-a353-4012-90e0-d423cbe649b5">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzUtMy0xLTEtMA_e2e863d4-653c-483e-9c5e-1f722bbf778d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="lgnd:AccruedSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMS0xLTEtMA_a3cb73bd-15de-49df-81ae-0dd05a00dbe9">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMy0xLTEtMA_7d53ceee-0a41-4f21-a149-65e5a57f8a13">3,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedAssetAcquisitionsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEwLTEtMS0xLTc3OTA_31bba73a-8993-42f5-ba94-e1dc04726521">1,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:AccruedAssetAcquisitionsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMy0xLTEtNzgzMA_75d0f7ef-769e-44a7-994b-c07b81436e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTEtMS0xLTc3OTQ_28eeb1a9-f594-405b-90e9-767aac0bf529">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:AccruedSubcontractorExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzktMy0xLTEtNzgzNA_5def315d-528a-4c80-9110-717d78a44ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTEtMS0xLTc3OTk_1a922803-a307-4630-a993-1c1fa6482483">604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEwLTMtMS0xLTc4Mzg_5ea0ac77-5e26-4c33-8a0c-bb5f6b03a9c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTEtMS0xLTA_a04e28ab-4a06-4a90-b7b1-35d8b499cebc">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTMtMS0xLTA_05db3f7d-9772-4797-81ea-7f1adfeb80fc">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTEtMS0xLTA_3b8bc6c9-8f59-47a7-b7e0-7cde894d16d8">18,530</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTMtMS0xLTA_41cbfa0a-e2ed-472b-b24f-c3f84a1f0784">8,581</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i20af23228e634df892e7dbbff5659166"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CVRs associated with the Pfenex and Icagen acquisitions, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="lgnd:ScheduleofContingentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODA_de5f3e4f-1b0c-4fa4-88aa-d215fb144540" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes rollfoward of contingent liabilities as of December 2020 and 2019 (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6602a2330fa646ef83a50932115be131_I20181231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMS0xLTEtMA_be7614fd-41af-4b82-bff2-ccbb8fef7885">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMi0xLTEtMA_d2de9b1c-9f8f-4749-a0a5-0547f7e33b0a">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMy0xLTEtMA_c6650b22-55e2-48e4-abf7-5e4d6ec53c71">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNi0xLTEtNTI3NQ_6f181470-7554-4474-a1f4-8bf7b3f33d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c6ced26abf49119a93a11e832e5a52_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNi0xLTEtMA_5fa7e205-0c7c-457c-96b0-e046f4381702">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOC0xLTEtNjk4Mg_adafe6ec-f37c-40bd-95c9-c488da605717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNy0xLTEtMA_6f11eda8-96a4-4dfa-bdd2-5142b1ccd22e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOC0xLTEtMA_eeac6c1f-0b8b-4968-a598-578c2189b057">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOS0xLTEtMA_bad9dd06-20f5-450f-b433-1fd9a77e3144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2153eb1062134c4caa172f7dd8ec0db3_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMTAtMS0xLTA_25ccc6d7-9bdb-4b81-951c-89f2a72a1deb">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5666f75fbad04ecc8c0e8a27df194c97_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMS0xLTEtMA_e49ec457-230d-4147-9bb5-8e1f00070cee">5,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMi0xLTEtMA_4a59c0c3-f134-4b9f-89a3-11afe90e0b1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMy0xLTEtMA_63fd7296-6f2a-4f63-b7d5-9ad82a0f161b">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNi0xLTEtNTI3NQ_100ba27e-2d7b-4dad-880d-8081bfba4864">520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b7e192f2c8428f85754de4b57ade3e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNi0xLTEtMA_c8c15b75-2473-4f53-8fc9-51b2cd4638e8">5,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOC0xLTEtNjk4Mg_06722bdc-fc62-4e62-bf02-32e46077f099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNy0xLTEtMA_05eb38b1-8902-4880-93be-e8f8d5c1f0a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOC0xLTEtMA_40d1f7c1-98fe-4214-b116-e65c3de93c30">1,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOS0xLTEtMA_acdf30dd-1e61-4536-8f43-bc8d18e9abba">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3791d21ca45848d09706bba5675782e8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMTAtMS0xLTA_0377c3d3-0031-4cca-bdc1-27868fc352d6">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f29ffa2d604282aa3977c1329d5123_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMS0xLTEtMA_464eab02-6c37-4514-91b2-f121e5d78794">6,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMi0xLTEtMA_bf3ff765-2902-4319-88e5-07541e6b6fe1">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMy0xLTEtMA_7b016b0d-69c2-4c62-9516-048c7fa54926">818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNi0xLTEtNTI3NQ_f24c5615-263c-4a8b-be0a-25125b8f763d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6420ef91bf1d4a1bba260796e56a4947_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNi0xLTEtMA_84936405-08fc-4797-943d-fa70befbbc57">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOC0xLTEtNjk4Mg_e5c29d0b-0181-4243-b500-3722cc53a4b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNy0xLTEtMA_8f694e23-1705-45a8-af0b-90bf1bc0ca23">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOC0xLTEtMA_08415f07-9de4-45b0-ac0e-ce9634a45e14">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOS0xLTEtMA_07de6480-6fc2-47f5-ba98-18e1ad96443e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fa7210a5ce4cf1a32446731c009ebf_I20201231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMTAtMS0xLTA_89a71d4c-6c56-4d7e-b250-0190142f6118">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ffb3aecca43f8bd0831902d08bf27_I20181231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMS0xLTEtNjk3OQ_dd3d4ee4-93a3-4da7-8b00-7818ccbc0978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMi0xLTEtNjk3OQ_79e42828-4468-441b-a01e-447926b62dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMy0xLTEtNjk3OQ_66885bf9-59da-4a45-b867-be90fbd0aff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtNjk3OQ_f7c2e700-44fc-4b50-b612-394d70235976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cc2ace08aa413b9bb245ce5edda280_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNy0xLTEtNjk3OQ_4e1ce5f5-7eba-425e-9177-05e916517270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOC0xLTEtNjk4Mg_dc8ee912-b14a-4944-bd17-7762d5774fd9">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOS0xLTEtNjk3OQ_914a8d5d-5444-4c3e-9746-577efe6e25f5">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTAtMS0xLTY5Nzk_b2c09296-8301-491a-bed2-e924a548cb05">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTEtMS0xLTY5Nzk_d7366115-efb9-4782-a4b9-343abe45bdcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4db53852ed4656a0f1f7d4738cf64b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTItMS0xLTY5Nzk_2233e163-3a5a-4cf2-9f86-a785373c28d0">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b713c7049f465f8770df03d4238b33_I20181231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMS0xLTEtNjk3OQ_b5d67f82-c7ec-4ee9-afb2-71c6c11fb4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMi0xLTEtNjk3OQ_df83fd94-0498-4c8a-94ee-8c70b090505b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMy0xLTEtNjk3OQ_5b9da0ae-a70c-4c35-ba08-6554186035a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtNi0xLTEtNjk3OQ_e401b850-e45e-4516-a36e-6a8776ad602b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie528dc87bee94f8caf3f8a1e273dd57e_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtNy0xLTEtNjk3OQ_a51640cc-1d16-4ecf-84dc-76fbb9d79a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtOC0xLTEtNjk4Mg_b82d5bda-c9e2-4278-ae47-a4fd19e18b05">37,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtOS0xLTEtNjk3OQ_f9dd4f54-5b17-4c76-8174-277cd02c60d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTAtMS0xLTY5Nzk_178d2c6a-88a9-4519-8724-1a6b53b30965">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTEtMS0xLTY5Nzk_d077d4ca-5df4-4818-a53d-03493e095985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82f7ae16d724ecc956f678166ebf230_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTItMS0xLTY5Nzk_877dd740-7f04-4786-bffd-fc2c523a450b">37,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMS0xLTEtMA_331c95bc-1256-437d-bb49-ab3c441b901a">12,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMi0xLTEtMA_076b40cd-f4ec-4b05-a547-80096309a0d2">3,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMy0xLTEtMA_5cf061a1-4f38-4944-bf38-53c237fd5256">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtNTI3NQ_958176f7-9d1d-4aaa-b31f-a18d8d359968">520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtMA_aa7a5650-da42-403e-9f9e-4a7576eaa320">8,942</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzYtOC0xLTEtNjk4Mg_86258e98-8bb9-4ba6-9a03-091804060193">41,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNy0xLTEtMA_5643398c-3e7c-4159-adbb-51145025812d">2,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOC0xLTEtMA_af74ed73-227a-43bb-af51-5d7f5f56dee7">963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOS0xLTEtMA_8ecb859e-9e01-4eec-9c24-279f83eda27d">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTAtMS0xLTA_6e7d6ab7-9f55-400c-845f-abad9a049971">49,133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_115"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTQ_6004a8fa-9fd7-4f71-96fe-81c92616149c" continuedAt="ic5f05ca9e7124b5ea807708bb6e196ee" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic5f05ca9e7124b5ea807708bb6e196ee" continuedAt="ie9603465f04e4f7b9c4f16df5f12ae55"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTU_7f70360b-4d7f-45ec-b572-ca2625d2f0b9" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2792a74cce448d9d3e648d7b956be5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtMS0xLTEtMA_2567f037-d919-4be1-b38a-a8859d17852e">13,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42695687f81e405c9d3cdbe7d31e2a8a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtMy0xLTEtMA_8d7a270e-ebcc-4350-bfd7-9c8ff4ac50d5">9,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a106a25b78411482849d23ad9a09e8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtNS0xLTEtMA_3e9b0b8f-8ba5-40fe-9bc4-41a5423fd974">8,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc06096f96b64e82ac914c97075da05d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtMS0xLTEtMA_94eae887-6818-4261-9c8c-91f56f335ec4">17,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0e4043c1aa44d99e0496901785ab2b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtMy0xLTEtMA_b29a8b22-364f-4c2b-8ac5-f18fed037808">14,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c0367d73764a1aa9aef7ba6ff77792_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtNS0xLTEtMA_3e89bd99-a735-4263-b751-dcdb894872be">12,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtMS0xLTEtMA_542ed660-f81b-4f44-885b-cf6d9df76660">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtMy0xLTEtMA_f7283bad-0354-4d3d-9291-2be45563c805">24,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtNS0xLTEtMA_518229fe-423c-43a3-a712-fd11efebd475">20,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="i953919e814ac433bba490fdfd486bf52_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMyOTg1MzQ4ODc1NTM_3bcd0b01-e794-4467-bed3-28a6a4ae0259">1.1</ix:nonFraction> million shares. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ic40ca45f254145e681e785bbb6305a78_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMwOA_c52db972-b955-47b0-9b1d-f132da5643b3">1.1</ix:nonFraction> million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie9603465f04e4f7b9c4f16df5f12ae55" continuedAt="ia09c7e063c984a4cb66d819002591414"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTY_33a22767-5b0f-49dc-8649-93e0f25cb770" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMS0xLTEtMTIzOTM_43123c02-3143-484d-bb6e-dfcd8316a104">1,876,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtMy0xLTEtMTI2MjI_16a504ca-9e4a-4b7a-be3a-faa095c8d0c0">53.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d99a0a13be944d08abee4b0e2287edd_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtNS0xLTEtMTI2MjI_53d8f60b-e7f2-4c51-b3e5-e4c3e7fcb68b">5.77</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtNy0xLTEtMTI2MjI_0bf717bd-e34a-4eb2-a1b3-5c4a0d0de09d">157,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMS0xLTEtMTIzOTM_90da0ff7-166c-4962-a40b-478c7b8bf8d1">228,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMy0xLTEtMTI2MjI_c8509cf9-bf5d-4d95-b7b2-c3160a9277e2">162.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMS0xLTEtMTIzOTM_fd0390b1-0f19-4b6c-ab4c-77d4c95d421c">358,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMy0xLTEtMTI2MjI_b30a410e-5360-44af-afae-eb01aeeee9ca">55.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMS0xLTEtMTIzOTM_014ad7be-e57b-4c61-bfb2-37d3ff341faa">10,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMy0xLTEtMTI2MjI_f8820e21-6ad1-4cbc-904f-27d2cf63be25">114.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMy0xLTEtMTI2MjI_07a827e1-80b6-48b1-a875-2b945ef9c3f0">66.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNS0xLTEtMTI2MjI_0d3f73fb-2cc4-45e4-a71b-f2b76d344533">5.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNy0xLTEtMTI2MjI_ce09dc83-6487-478b-8576-16756ee84966">125,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzktMS0xLTEtMTIzOTM_4100c24a-da47-43ca-abca-7bd3b2c6dec8">1,313,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMy0xLTEtMTI2MjI_080df20d-211f-4cf6-b49a-eedccfdc40a9">47.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNS0xLTEtMTI2MjI_b0ed6fff-c735-4ba6-8bb5-8d542b877b7d">4.56</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNy0xLTEtMTI2MjI_4741db96-1eb7-4cb0-a5cc-d21bfb3ee46c">117,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEwLTEtMS0xLTEyMzkz_1287ed8b-e57a-4d75-a80d-439d2c1dfdb1">1,736,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMy0xLTEtMTI2MjI_a25e134a-23ca-4ca0-a653-9b160f36a6b5">66.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNS0xLTEtMTI2MjI_db55aa04-f7c7-4c0c-a80f-a55eca0734fd">5.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNy0xLTEtMTI2MjI_29a236b5-f01c-4caa-987c-da97948bcf73">125,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTEtMS0xLTEyNDAz_c6065688-6f42-46af-8647-ed00d7b3c2f9">338,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEwLTMtMS0xLTEyNjI3_72a9f16d-561b-4a10-ae7b-09b151d7a46d">116.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTEtMS0xLTEyNDAz_fa80d4d5-3ea7-4ff7-825e-ab1a0a6f88b4">112,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzExLTMtMS0xLTEyNjI3_d0c5aa9f-c0dc-4f8a-bfd0-986a65151867">23.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTEtMS0xLTEyNDAz_cb08b64b-2860-459c-9644-f6e59d428eff">6,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEyLTMtMS0xLTEyNjI3_4b9a9cb1-4a42-4f9f-ad23-6d4285c44a3e">139.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE2LTEtMS0xLTEyNDAz_c5b165d0-22b6-470d-a27d-56c05dc48bc0">1,956,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTMtMS0xLTEyNjI3_db34e470-f7e2-41a6-9e3f-6892e057f753">77.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTUtMS0xLTEyNjI3_3a8a8858-b77e-41e2-8028-9213e5e31615">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTctMS0xLTEyNjI3_9d07ded3-5579-4d78-a1cb-a513809fdcc4">72,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE3LTEtMS0xLTEyNDAz_41b36487-66a1-45fd-b58d-4466ccf67926">1,454,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTMtMS0xLTEyNjI3_48b433d7-2d85-4913-b58e-3e62cafe1de2">61.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTUtMS0xLTEyNjI3_77a46015-1f87-4590-b55b-259df8244a74">4.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTctMS0xLTEyNjI3_99360e8d-c8fd-4a64-a772-88c8061f1b76">70,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE4LTEtMS0xLTEyNDAz_e23f4048-219e-4dfe-8f55-5305197e9de1">1,956,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTMtMS0xLTEyNjI3_eeb7d645-5ac3-45f2-b571-2a0db5b46b4b">77.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTUtMS0xLTEyNjI3_398b1733-0d72-45b9-9eed-b5e4e4195256">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTctMS0xLTEyNjI3_3842e43f-fb9b-4f18-9d44-39688958bd09">72,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMS0xLTEtMA_6e5c78d8-8af7-48da-9b1b-33fd3ef52659">806,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMy0xLTEtMA_29a11b3d-0e60-4e6a-bafa-1cbe0f31fd40">92.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMS0xLTEtMA_9c542a4a-8df1-4205-947a-5d9837b2019d">156,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMy0xLTEtMA_5efa489f-db95-475f-80fc-2bd0e0e3a3d5">21.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMS0xLTEtMA_1b36be94-41d4-4b28-97bd-c191c57aa78d">44,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMy0xLTEtMA_089c353a-5852-404c-98e1-2af4d41377cb">91.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMS0xLTEtMA_75837816-ac88-43a5-a5c2-9ad3a958aaf6">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMy0xLTEtMA_fd947631-ffec-4d43-bf08-682b4444142c">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNS0xLTEtMA_785626af-9108-46dc-99a5-c93f5df1614c">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNy0xLTEtMA_b369c25f-f80f-47ec-bb96-de0245fc7b74">59,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMS0xLTEtMA_57d88e08-ba67-460c-b981-3f84d70c6076">1,611,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMy0xLTEtMA_b85908b8-a21e-4fe0-986b-ec5c77176ed7">76.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNS0xLTEtMA_cdb14d04-a66d-41ae-9799-26395f9b8a9b">4.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNy0xLTEtMA_48b7e9f3-ac64-4e74-85af-985328cf1cc0">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMS0xLTEtMA_5bb4a45d-5fca-4999-b747-2bd44b3db83d">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMy0xLTEtMA_ba93a733-7aff-4287-acc3-8638fcb88c48">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNS0xLTEtMA_ba71b22d-50c3-4c53-81c1-9dd7620d0ac5">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNy0xLTEtMA_99ab1cd6-021f-4c65-97ba-ac4eebe4cabc">59,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU4NQ_60ca8f2a-dbc2-48d0-9d6f-d6417ac1e522">41.39</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU4OQ_ede0d3c2-d3ae-4202-9a88-f5349b03cbf4">48.65</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU5Ng_35ca9a8c-082e-40e2-82ea-46bd232912d2">58.85</ix:nonFraction> per share, respectively. The total intrinsic value of all options exercised during 2020, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcxNA_4480ea2e-1c15-48e0-a621-b56dd6ebaf52">11.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcxOA_e5868368-e4e6-4ab1-87d7-0d2cdc56bb70">10.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcyNQ_6c0d38a4-b347-41ac-ad94-31c77e99ad85">51.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgyMQ_e7671868-4c15-4087-be2c-b37ca1d9cad1">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgyNQ_0fd4bd90-a43d-4822-b6a7-b5e6770d8472">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgzMg_67f46715-3122-4f72-804c-79dbaf77a26c">19.8</ix:nonFraction> million, respectively. </span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTE_b2b64d7d-ea69-42e0-930f-80e4977132c3" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMC0xLTEtNTM2My90ZXh0cmVnaW9uOjM0NWFlYTFkMjc5YzRmMThiM2QyMmYwNDUwM2I1YjkzXzMyOTg1MzQ4ODMzNTM_f6432b27-4def-4a04-9f9d-f8e59093492e">10.05</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMC0xLTEtNTM2My90ZXh0cmVnaW9uOjM0NWFlYTFkMjc5YzRmMThiM2QyMmYwNDUwM2I1YjkzXzMyOTg1MzQ4ODMzOTA_42857bff-0d07-422f-a8f2-db12af70224a">14.47</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMS0xLTEtMA_ffb6d144-e9c3-4012-9021-4d927d6d6eee">284,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMy0xLTEtMA_7f79b69d-2c20-41f1-9f16-d34371463416">0.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtNS0xLTEtMA_68ac55cc-3906-40f0-8a3c-8feb1c43d03c">13.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtNy0xLTEtMA_d7f30b06-9d74-4f96-b308-887273301933">270,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtOS0xLTEtMA_93ac24fa-fd4a-406e-a9a7-2d3901861c48">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMC0xLTEtNTM2NC90ZXh0cmVnaW9uOjU2ZDU1YjA1OTc3NzRjODQ4ZTM0OTUzMWQ4MmZkZTQxXzMyOTg1MzQ4ODMzNjI_9100f8f7-6884-499b-80bf-0706016b2294">21.92</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMC0xLTEtNTM2NC90ZXh0cmVnaW9uOjU2ZDU1YjA1OTc3NzRjODQ4ZTM0OTUzMWQ4MmZkZTQxXzMyOTg1MzQ4ODMzNjY_b2489d09-3b73-4455-ab0e-2e9985de31ff">56.26</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMS0xLTEtMA_704fcd87-574e-4b47-8f95-33ddd7d742e2">344,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMy0xLTEtMA_38c452a5-5aec-442d-8c91-1522dd179932">2.88</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItNS0xLTEtMA_e22757a1-127d-49a9-a049-f7689776d801">35.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItNy0xLTEtMA_994ea3ba-3719-49ab-9db9-28d066bcb3ae">344,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItOS0xLTEtMA_4b454454-3bb3-4450-aa5c-7c3510e0f0e1">35.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMC0xLTEtNTM2Ni90ZXh0cmVnaW9uOjU2YzBkZWVmNjRhZjQwNzRiZTEzNGNkNDAyYTk5NjcxXzMyOTg1MzQ4ODMzNjI_9cf8db9d-9dea-4415-916e-d3930c30eb96">63.58</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMC0xLTEtNTM2Ni90ZXh0cmVnaW9uOjU2YzBkZWVmNjRhZjQwNzRiZTEzNGNkNDAyYTk5NjcxXzMyOTg1MzQ4ODMzNjY_b6173550-e57b-4e53-a024-fb33cff0ce05">74.42</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMS0xLTEtMA_c2bdd742-a80a-40f5-9c9b-38b7d568cb21">307,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMy0xLTEtMA_cf3f5587-49c0-43df-9fd9-51793d4693b5">5.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtNS0xLTEtMA_6c57af73-4be0-44ce-9816-39fefdd913bb">71.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtNy0xLTEtMA_c96423d6-b957-4013-8c73-5f7cc370e7d5">220,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtOS0xLTEtMA_539dc999-ea5a-461c-8ef1-005624abe651">73.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMC0xLTEtNTM2OC90ZXh0cmVnaW9uOmQ4NTFiN2UwYzUzMzRhOThiNmVlNjU4YjQ1YzZhMjI3XzMyOTg1MzQ4ODMzNjI_ad557723-1a08-45f5-96e5-c56e5e5dce6a">82.90</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMC0xLTEtNTM2OC90ZXh0cmVnaW9uOmQ4NTFiN2UwYzUzMzRhOThiNmVlNjU4YjQ1YzZhMjI3XzMyOTg1MzQ4ODMzNjY_552174e9-4308-4304-88d1-7b1db57cb9bf">95.35</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMS0xLTEtMA_e655b6e6-35aa-4dc6-97a0-4499bb96ce23">185,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMy0xLTEtMA_2eda93f5-b238-4471-9913-b3c20213282b">6.23</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtNS0xLTEtMA_a4113210-92df-41a7-89c9-d8aeb968fb17">86.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtNy0xLTEtMA_8913f69c-3811-44d1-9cb5-8dc3e6752cc2">140,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtOS0xLTEtMA_87f52432-3049-42e2-9b4e-dee361e57943">86.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMC0xLTEtNTM3MQ_b037a16d-df82-406b-8dc5-c173a79cb2ac"><ix:nonFraction unitRef="usdPerShare" contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMC0xLTEtNTM3MQ_fc9f6546-c355-470d-9aaa-014154ea9b06">95.68</ix:nonFraction></ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMS0xLTEtMA_b93a4b65-82a8-4307-a21c-4e93863f9b90">305,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMy0xLTEtMA_23afb9bd-0dd6-469f-ba94-b2719670335f">9.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtNS0xLTEtMA_a62451a9-7b5a-48ca-93fa-58b1ff5db47e">95.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtNy0xLTEtMA_dfc0bd19-3d04-4d0d-afaa-451cb0379330">63,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtOS0xLTEtMA_f5e67613-336c-4010-996e-25fcd34bb70b">95.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMC0xLTEtNTM3Mg_189cfd14-e7ef-4c1c-ad19-436792bbfff7"><ix:nonFraction unitRef="usdPerShare" contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMC0xLTEtNTM3Mg_4bc3ceec-588b-48d5-b2a9-458853cb5502">97.92</ix:nonFraction></ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMS0xLTEtMA_f9d9ad48-6a9e-4928-80a9-2d2acfabab7e">4,976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMy0xLTEtMA_a3c8c054-4d65-4b5e-a1c9-6ddc2725cae1">5.02</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtNS0xLTEtMA_7be5a151-151a-4f38-b814-8a61e89d59c3">97.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtNy0xLTEtMA_1af252a5-9b6c-4c37-b4ad-a5f3beed40ff">4,976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtOS0xLTEtMA_90af2ead-24d9-47ae-84d2-ba9285487268">97.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMC0xLTEtNTM3NQ_24bdf3b3-b807-4308-bece-152c183a1e72"><ix:nonFraction unitRef="usdPerShare" contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMC0xLTEtNTM3NQ_f7213bc2-1548-458b-ae24-68a7a0feb83c">98.20</ix:nonFraction></ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMS0xLTEtMA_38fbaebb-4691-4e77-9a32-6c066e534bab">270,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMy0xLTEtMA_3f529275-f85c-4008-841e-fb498469dd3c">9.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctNS0xLTEtMA_5f764228-9d79-4137-8c9a-3401215abbde">98.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctNy0xLTEtMA_9c5c661c-e3d1-419f-a754-cb8b1135d514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctOS0xLTEtMA_f3c450fa-c0d8-479f-b54c-6fca78135237">98.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMC0xLTEtNTM3Ny90ZXh0cmVnaW9uOjc5NDk2YTBhMmM5ZjQzN2I4ZTAwYjAxZTA1NjMxNzdlXzMyOTg1MzQ4ODMzNjY_8fdb1dd6-bccc-4a7c-bd4c-c7ebeb5f54dc">100.02</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMC0xLTEtNTM3Ny90ZXh0cmVnaW9uOjc5NDk2YTBhMmM5ZjQzN2I4ZTAwYjAxZTA1NjMxNzdlXzMyOTg1MzQ4ODMzNzA_ceb8061e-f07c-497a-9b6b-4574ebc5f508">113.76</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMS0xLTEtMA_5e38dd5c-fea0-427b-8dca-eb8f6ed34c53">257,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMy0xLTEtMA_2b60e2cc-4155-44d9-ab2a-428655372355">6.69</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtNS0xLTEtMA_58b81800-4618-4ebb-84eb-0c41785a0a70">104.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtNy0xLTEtMA_9947195f-0e08-4ea6-89df-570a2019cb6c">220,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtOS0xLTEtMA_6b6cbd93-a049-4289-927b-6ee193027f98">103.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMC0xLTEtNTM3OA_521d85f7-b18b-4461-baa3-4c0598ba4e52"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMC0xLTEtNTM3OA_7904fc5d-1c49-4f87-b823-60ebf93c0d31">117.58</ix:nonFraction></ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMS0xLTEtMA_f17c9848-b0e0-4f44-9d3e-0e72123295e8">19,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMy0xLTEtMA_8469c985-3ac7-4f56-ad5f-83521fabce60">9.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktNS0xLTEtMA_60721167-7b18-4e8f-ad12-14b1fc43e035">117.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktNy0xLTEtMA_292fe8b1-4736-4642-ba70-bcf18e261ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktOS0xLTEtMA_cddc6ef8-8956-465f-a654-9c8de3f7f7b8">117.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTAtMS0xLTUzODAvdGV4dHJlZ2lvbjowNTgyMDIzZDk5YTU0MGI3OTAzYzY4ZmU5OThlZDYyZV8zMjk4NTM0ODgzMzY2_262283a5-072e-49c2-b208-5869a691ec4c">117.97</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTAtMS0xLTUzODAvdGV4dHJlZ2lvbjowNTgyMDIzZDk5YTU0MGI3OTAzYzY4ZmU5OThlZDYyZV8zMjk4NTM0ODgzMzcw_9b6d739e-77d0-4ff9-83ef-dd620520bfdf">195.91</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTEtMS0xLTA_673a9646-0f6c-4c1c-bfa7-7804660d06f1">582,030</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTMtMS0xLTA_787373db-bdd9-4977-9738-623edd23062f">7.56</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTUtMS0xLTA_844b49a2-803a-43e2-8dcc-390368ab1a1d">137.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTctMS0xLTA_5c16b4b1-3dfc-4c6e-bb36-2834955671c2">347,840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTktMS0xLTA_474fd656-99b3-43c4-8a7c-879377d021c2">141.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTEtMS0xLTA_aee02545-599f-4e7e-9545-1365afcaed1c">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i28daf0e5db1049f18fd204ea459bc201_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTMtMS0xLTA_342c55bc-c340-4ec0-85fe-83ce6c7e11c5">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTUtMS0xLTA_ca3fffb9-81ce-4d0f-b5e5-699b1119539f">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTctMS0xLTA_121ac835-f76b-4fa2-bf22-7875b712c67f">1,611,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTktMS0xLTA_c3ff9b36-dd51-47ea-8eab-ff3b1a028a3c">76.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia09c7e063c984a4cb66d819002591414" continuedAt="i8127d49173714c0eb4ebc4e4fc393b8f"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTk_655437dd-2586-48c3-a597-80803d9f12ab" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMS0xLTEtMTE3NjYvdGV4dHJlZ2lvbjo4ZjhmZDkxNTllZjI0YzZhOWMyMTM4NzQwYTk2NmQzZV8zMjk4NTM0ODgzMzQ1_fff5db73-5664-4b3e-ac47-88f514e61f39">0.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMS0xLTEtMTE3NjYvdGV4dHJlZ2lvbjo4ZjhmZDkxNTllZjI0YzZhOWMyMTM4NzQwYTk2NmQzZV8zMjk4NTM0ODgzMzUy_eb77f249-f6b8-4e52-911f-db42afb55b9e">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMy0xLTEtMTE3NzIvdGV4dHJlZ2lvbjo2Nzg4ZTZlM2EyZDM0YWEyYmQ3MWYwODBhMmM0NzUyZF8zMjk4NTM0ODgzMzQ1_c5fb90d0-6565-4982-8f46-046135883421">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMy0xLTEtMTE3NzIvdGV4dHJlZ2lvbjo2Nzg4ZTZlM2EyZDM0YWEyYmQ3MWYwODBhMmM0NzUyZF8zMjk4NTM0ODgzMzUy_10244775-05a8-42a8-8fa3-cc115b11a757">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItNS0xLTEtMTE3NzgvdGV4dHJlZ2lvbjo2ZGMzY2VjYTAyNWM0ZWRjYTQzMmIyNGYyMjhlNDhiOF8zMjk4NTM0ODgzMzQ1_ffe5797a-752f-4c73-b8c1-9375d755d3a5">2.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItNS0xLTEtMTE3NzgvdGV4dHJlZ2lvbjo2ZGMzY2VjYTAyNWM0ZWRjYTQzMmIyNGYyMjhlNDhiOF8zMjk4NTM0ODgzMzUy_50da8c0b-0742-4896-a5d5-facbd826b9b4">3.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMS0xLTEtMTE3ODQvdGV4dHJlZ2lvbjo5YjhlMjk2NTIxMzE0YTQ5YTY4YzFjMDJhYjA1M2M0ZV8zMjk4NTM0ODgzMzQy_5d1ede26-77c5-4f56-8142-298e2cb1423f">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMS0xLTEtMTE3ODQvdGV4dHJlZ2lvbjo5YjhlMjk2NTIxMzE0YTQ5YTY4YzFjMDJhYjA1M2M0ZV8zMjk4NTM0ODgzMzQ4_d8adeb77-8087-451a-85c0-44aa8fcd1ae0">71</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMy0xLTEtMTE3OTAvdGV4dHJlZ2lvbjo3NDAxMDE0MDFkYTU0MmFhYjYyYTc5MjNmZjQzNzg5N18zMjk4NTM0ODgzMzQy_3783dba2-08de-415b-92bd-690b323e55ef">40</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMy0xLTEtMTE3OTAvdGV4dHJlZ2lvbjo3NDAxMDE0MDFkYTU0MmFhYjYyYTc5MjNmZjQzNzg5N18zMjk4NTM0ODgzMzQ4_0d3a57e3-5f63-4715-aa41-cb134e741a41">49</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtNS0xLTEtMTE3OTYvdGV4dHJlZ2lvbjphYTAxYTg5MTEyZmE0MDdmOTI3NDI3ODc0NDcwYThmZl8zMjk4NTM0ODgzMzQy_3dd5cf3e-f29c-429c-adb6-c8ae7aa6763d">33</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtNS0xLTEtMTE3OTYvdGV4dHJlZ2lvbjphYTAxYTg5MTEyZmE0MDdmOTI3NDI3ODc0NDcwYThmZl8zMjk4NTM0ODgzMzQ4_7656511b-8719-4bf7-ab26-85c1a48a217b">36</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMS0xLTEtMTE4MDIvdGV4dHJlZ2lvbjpmOGRlZWVkZDRlNDc0ZWRjOWVmYmNiZTU1MmFhY2I4NV8zMjk4NTM0ODgzMzUx_e52b88ec-0a79-40c2-99f4-80b4c7394985">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMS0xLTEtMTE4MDIvdGV4dHJlZ2lvbjpmOGRlZWVkZDRlNDc0ZWRjOWVmYmNiZTU1MmFhY2I4NV8zMjk4NTM0ODgzMzY0_8574aaad-aa45-469c-a458-7ac0f99e0cb6">5.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMy0xLTEtMTE4MTAvdGV4dHJlZ2lvbjplOThhYzE1ZGRmNjQ0NzQ3YmI4Y2E5ZDQzOWZiY2Y4NV8zMjk4NTM0ODgzMzUx_9c300ba7-2247-4521-b776-bbf2cb27cb84">4.6</ix:nonNumeric> to <ix:nonNumeric contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMy0xLTEtMTE4MTAvdGV4dHJlZ2lvbjplOThhYzE1ZGRmNjQ0NzQ3YmI4Y2E5ZDQzOWZiY2Y4NV8zMjk4NTM0ODgzMzYz_8bc2bee9-341a-4258-bc04-b6094d4ab2b8">5.9</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtNS0xLTEtMTE4MTcvdGV4dHJlZ2lvbjo0MWIyZjk0OTExOTA0ZGUyYmZhMjkxZGRhMjkyOTcyZF8zMjk4NTM0ODgzMzUx_4014b605-98a8-470b-9fee-c0fcb12f37e7">5.1</ix:nonNumeric> to <ix:nonNumeric contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtNS0xLTEtMTE4MTcvdGV4dHJlZ2lvbjo0MWIyZjk0OTExOTA0ZGUyYmZhMjkxZGRhMjkyOTcyZF8zMjk4NTM0ODgzMzYz_732a27ff-3737-4278-a2da-a30130f3c7bb">5.8</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="if56ecb42bfb845cdbf6b43bfa81634cd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzExMDc_58726873-ca1f-4d62-87bc-4fa39dd50d96">37.2</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzEyNjE_338f5bf2-70c4-4e23-bdba-3df6da129df3">2.9</ix:nonNumeric> years.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTc_385b257e-8e93-4a69-aed5-13d609c0e7e1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:69.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.578%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacd51de929754bda9511cd8c27350601_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMS0xLTEtMTI2NTY_16344d7c-f738-4a08-a3ee-fde54cea5aed">133,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iacd51de929754bda9511cd8c27350601_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMy0xLTEtMTI2NTY_7de9a49b-53b4-442e-acbd-78771dca2ccc">91.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMS0xLTEtMTI2NTY_4610a3c2-a551-4bc3-a68c-8bd1db6ea445">62,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMy0xLTEtMTI2NTY_1051f5e3-f4d7-48ac-8abe-c18fb4fa695f">169.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMS0xLTEtMTI2NTY_c9758824-0bd6-4cf5-b1e5-bef647e10ae8">61,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMy0xLTEtMTI2NTY_17b9980e-cc40-44d7-8a1d-55a1e896dbe7">86.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMS0xLTEtMTI2NTY_f7f6b88b-90a4-458a-b346-abb98b9c0467">1,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMy0xLTEtMTI2NTY_8634b96a-e139-4b7d-bfbd-a168c669e44a">125.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1115896595ee46f58722433b8bebfcc6_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzUtMy0xLTEtMTI2NTY_75eb1e0d-8b52-4df9-9172-a19fbf2ee333">130.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzYtMS0xLTEtMTI2NTY_ca957a71-c6d1-43e3-bc89-c9f75b9d2707">118,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzYtMy0xLTEtMTI2NTY_40768add-4a6b-42b7-a520-b9f7c1caa3e8">115.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzctMS0xLTEtMTI2NTY_90a08dcd-5061-4b09-8904-2c4e81f27848">102,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzctMy0xLTEtMTI2NTY_dd87cd66-013f-40f5-b5f6-ca46b337e00a">121.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzgtMS0xLTEtMTI2NTY_418355ff-c89f-48ea-a93e-225d26f7a76a">666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzgtMy0xLTEtMTI2NTY_d1f3571d-ac6a-4be5-9872-a195c12f78a3">134.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3b624942505415386809d9280250f36_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMy0xLTEtMA_9c3d2326-9ffa-4c81-baeb-2c9b10437a85">125.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMS0xLTEtMA_1692baab-7d24-40ad-816d-9055ceac3362">111,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMy0xLTEtMA_35d410aa-9949-4397-9c8b-6af9342bcd45">89.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMS0xLTEtMA_6b0a3547-5e38-4a19-a333-ba7f26a6768d">52,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMy0xLTEtMA_6db531b7-0b04-45fb-b6e5-d72104315dcc">121.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMS0xLTEtMA_d952f3c8-b119-4aac-b35d-590a85b7c80f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMy0xLTEtMA_ef88213d-a2c4-46dd-9db2-6fef45c51771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzUtMy0xLTEtMA_5d579b56-28b3-456c-9f24-8017688a791a">106.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, unrecognized compensation cost related to non-vested stock awards amounted to $<ix:nonFraction unitRef="usd" contextRef="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE0Njg_c070337b-281b-4497-9be5-e9b041da5f97">10.6</ix:nonFraction>&#160;million. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE1NDU_31a0a98a-bae0-46d8-839c-c082d7717c30">1.5</ix:nonNumeric> years.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="ia2c71624a82f425e97a2dd558100c435_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE1OTA_3b118ca1-c5d4-4aab-a83b-7ce57ab437d0">52,808</ix:nonFraction> shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to <ix:nonFraction unitRef="shares" contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE3NjU_4dfe7cc7-3e13-4f4b-b865-6b11050bd14c">1,250</ix:nonFraction> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="number" contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE5MjM_fa17ca29-30ae-4f65-ad3e-85c6f3d8d1f2">85</ix:nonFraction>% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were <ix:nonFraction unitRef="shares" contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNjQ_49910b67-d5e4-4899-9bde-b8c97faed3e3">6,455</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i26da0a13ba874bfeb0373d75e17b5d4f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNjg_99214687-ca08-4065-a940-63912f84a011">4,745</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0398cc7bf5994c79a7c821c2a8c34c80_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNzU_0817efc9-a63f-40f1-8deb-7c32725d93b4">3,386</ix:nonFraction> shares issued under the ESPP in 2020, 2019 and 2018, respectively. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased <ix:nonFraction unitRef="shares" contextRef="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIyMzk_52357342-db21-45cc-97ef-58cb1e622d65">260,000</ix:nonFraction> shares of our common stock at a cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIyODI_fe6f8516-8ef0-4e26-894c-0614924d22ad">191.14</ix:nonFraction> per share. In September 2018, the board of directors authorized us to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i304f82f2dad244e382a657b3d676fb43_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIzNzI_40bae01d-1af7-424f-8326-3521c3fdf519">200.0</ix:nonFraction> million of our common stock from time to time over a period of up to three years (the &#8220;Repurchase Program&#8221;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i931b931a1abf45438f4f158f651d36c0_I20190123" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzI2MTI_3da8be5a-5621-40a1-88a3-657c280610f6">350.0</ix:nonFraction> million of our outstanding common stock under the Repurchase Program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i0e34e1285b384e0d8ee4bc840f707708_I20190911" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzI3OTY_5abd90a1-4075-44f7-9920-8f85c898b064">500.0</ix:nonFraction> million of our common stock from time to time over the next <ix:nonNumeric contextRef="i6ab16e1f7dff4858bc4003f7815ab55f_D20190911-20190911" format="ixt-sec:durwordsen" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIxOTkwMjMyNTk5Mzc_7dbc95d2-98c7-476a-a45e-445f68f4ad3b">three years</ix:nonNumeric>. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8127d49173714c0eb4ebc4e4fc393b8f" continuedAt="if4a7428e9c714928b6ab2c6cf7850ff5">plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $<ix:nonFraction unitRef="usd" contextRef="i931b931a1abf45438f4f158f651d36c0_I20190123" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMyODQ_3da8be5a-5621-40a1-88a3-657c280610f6">350.0</ix:nonFraction> million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM0NDA_4f6f5e5a-0c32-471f-b424-16ba98a85afe">248.8</ix:nonFraction> million of our common stock remained available as of December&#160;31, 2020.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if4a7428e9c714928b6ab2c6cf7850ff5">During the twelve months ended December&#160;31, 2020, 2019 and 2018, we repurchased <ix:nonFraction unitRef="shares" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Mzc_bf0aabb4-4216-4c29-9bf4-9329775beed8">934,079</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1NTE_f2731d1c-d4dd-4086-87a2-0bddb9ffe139">78.0</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1NTU_ffa0f9ea-a003-4a70-9293-b7a60c109e1b">4,122,133</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Njk_6fff24af-d7c9-4145-bdc4-4803ef6346df">448.4</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Nzc_14463fbd-1530-4c72-a01a-85fb6b1a6cae">782,248</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1OTE_037cec8d-f554-4859-b4ba-f727c92c63c8">127.5</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_121"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzU2MDY_a6c33e28-8871-45fb-86fe-764f44e6f491" continuedAt="ic879dbde5bc848b1baacb59126b4827b" escape="true">Commitment and Contingencies: Legal Proceedings</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic879dbde5bc848b1baacb59126b4827b" continuedAt="ief2265b1ab4849e0be962537996f3d45"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 450, Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. On July 29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#8217;s counterclaims. On April 7, 2020, the Court ordered that the Scheduling Order be amended such that, inter alia, the fact discovery cut off occurred on November 2, 2020, the close of expert discovery was set for March 22, 2021, and that May 17, 2021 would remain the first day of a five-to-six-day bench trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all <ix:nonFraction unitRef="patent" contextRef="i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNTI_9064e0e7-ea6f-4d52-ae3d-7a6c19ec96d7">four</ix:nonFraction> patents and CyDex filed its answer to Lupin&#8217;s counterclaims on January 2, 2020. Fact discovery is ongoing. The Court&#8217;s scheduling order sets close of discovery on May 7, 2021 and a five day bench trial starting on December 13, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received <ix:nonFraction unitRef="civil_complaint" contextRef="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNjE_432e1e50-31e8-4e4e-b6b3-ccda0649e5b2">three</ix:nonFraction> civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the <ix:nonFraction unitRef="civil_complaint" contextRef="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNzI_f8cdcb7f-94c3-4139-a617-a0894dc35add">three</ix:nonFraction> complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and August of 2019, Pfenex Inc., which was acquired by us in October 2020, filed three petitions (IPR2019- 01027, IPR2019-01028 and IPR2019-01478) for inter partes review of U.S. Patent No. 9,422,345 (&#8220;the &#8216;345 patent&#8221;; entitled &#8220;Expression System&#8221;), which is owned by GlaxoSmithKline Biologicals S.A., with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) of the U.S. Patent and Trademark Office. In November 2019 and February 2020, the Board instituted trial on the invalidity grounds in IPR2019-01028, but exercised its discretion not to institute trial on IPR2019-01027 or IPR2019-01478. In May 2020, GlaxoSmithKline Biologicals S.A. (&#8220;GSK&#8221;) filed two petitions (IPR2020-00890 and IPR2020-00962) for inter partes review of U.S. Pat. No. 8,530,171 (&#8220;the &#8216;171 patent,&#8221; entitled &#8220;High Level Expression of Recombinant Toxin Proteins&#8221;), which is owned by Pfenex, with the PTAB of the U.S. Patent and Trademark Office. On June 29, 2020, GSK filed a motion to withdraw IPR2020-00890, which was granted on August 28, 2020. In October 2020, Pfenex and GSK executed a confidential settlement agreement agreeing to terminate the proceedings before the PTAB resolving these issues. Pfenex and GSK filed a joint motion to terminate IPR2019-01028 and IPR2020-00962 on October 30, 2020, and an amended joint motion to terminate on November 4, 2020. A decision granting the parties&#8217; joint motion to terminate in IPR2019-01028 was issued on November 12, 2020. The PTAB subsequently granted the parties&#8217; joint motion to terminate in IPR2020-00962 on December 30, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ief2265b1ab4849e0be962537996f3d45">On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claims that the Company is in violation of the assignment provision of that certain Commercial Platform License and Services Agreement, dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We allege that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#8217;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims are deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it seeks to dismiss its claim without prejudice. The arbitration will be conducted by a three arbitrator panel, who have not yet been appointed. The parties must each appoint one arbitrator by February 26, 2021, and the two arbitrators will then appoint a third arbitrator. We intend to vigorously defend ourselves against this action.</ix:continuation></span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_124"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTc_01ee6f1e-107d-4c66-9105-2f09fac3cae7" continuedAt="i2f3b172195014536b50edf5a4cfc30c8" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2f3b172195014536b50edf5a4cfc30c8" continuedAt="i4cf8b2c37bca4ed98d85fad297ff42ea"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTM_0489c6df-d5a2-48a8-a222-ace8457e201c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:66.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtMS0xLTEtMA_fc617999-1ed8-4155-b2c1-bb4d5bceffae">10,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtMy0xLTEtMA_7e58e716-165c-47c0-81cf-48a44cef2a69">89,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtNS0xLTEtMA_615165d2-e944-41fa-8510-0e4e3511c276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtMS0xLTEtMA_d187d0a1-3bb0-487a-ac9a-4a9fd94155c8">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtMy0xLTEtMA_c2477fdf-6d70-478d-bbc5-34cf4269cb6e">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtNS0xLTEtMA_80af975b-cd17-496e-a9a8-902fbb0bbc55">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtMS0xLTEtMA_e4adf8a2-fe2b-44fa-964d-129085c7aab7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtMy0xLTEtMA_9cfa0ada-21e1-402e-bc6b-429a3d621784">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtNS0xLTEtMA_4bbb3750-d0c4-4e89-a8f3-7580825b3cd7">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtMS0xLTEtMA_241a96ff-16c1-46bb-b5d9-0c66c335416f">11,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtMy0xLTEtMA_6a1d67ce-8c67-485e-a144-c89dfb0ac3fe">92,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtNS0xLTEtMA_b5c35ade-d336-41f6-829e-247b4f1e88bd">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtMS0xLTEtMA_7be9e7dc-393e-4a6f-91e5-dd9c9a1f6f74">15,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtMy0xLTEtMA_5915e411-e5e6-4f56-915c-3c989178ac0b">74,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtNS0xLTEtMA_6c580ca0-2f3b-4e53-9211-fd1c3c9cf785">29,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktMS0xLTEtMA_bee2db2b-5469-45e4-9299-7c8793aa1db4">3,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktMy0xLTEtMA_42e97419-4fa1-438f-9232-11bd375e728a">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktNS0xLTEtMA_20715175-eff9-4ca2-89a0-57d9927ef4bb">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTEtMS0xLTA_92235b64-590c-4145-a463-d8eefc234593">7,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTMtMS0xLTA_38f2a6f3-2241-4c70-8587-e1ca45d95f09">167,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTUtMS0xLTA_74cf0014-f6da-4ed2-9fb0-742b633f565c">30,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNjI_9e7513d9-1c73-4ebb-aaa9-9b1f34c1d32c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItMS0xLTEtMA_fd62cdfd-dbca-43d7-b568-5101c616c680">2,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItMy0xLTEtMA_413f2d7a-7f8a-47ec-aa2a-904006d92ea4">167,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItNS0xLTEtMA_f7cf42ba-e5c4-4710-99e6-44eaae4ab872">36,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtMS0xLTEtMA_8debbde2-56c7-4628-b89c-e8b8c1807e94">1,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtMy0xLTEtMA_219fdb91-72dc-4fd1-92bf-c06c96ceeb1b">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtNS0xLTEtMA_2856c82e-ca5a-42c1-8621-c433754d0fd8">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtMS0xLTEtMA_c492dcfa-9440-4d1f-a4ee-e58f8dce5e0e">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtMy0xLTEtMA_5141ccb9-716c-4c14-82e5-33e712de1354">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtNS0xLTEtMA_e6a74e86-bed4-45a9-a69c-dcb990dcb95b">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtMS0xLTEtMA_2549c0ad-f7f6-406f-b916-fd0dafbd32e3">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtMy0xLTEtMA_daa0614d-4c87-4c53-a6df-bfd749bf05f2">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtNS0xLTEtMA_48c86cb7-2852-4eed-b4cd-4a93444fac03">8,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtMS0xLTEtMA_7cf84da1-c5c4-49c1-b17b-c397d88edf6a">1,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtMy0xLTEtMA_19c944a4-e6e9-4151-9717-2cf3a735719a">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtNS0xLTEtMA_286777f7-a304-498b-91c6-e6fd8ee55a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctMS0xLTEtMA_2a4da8bf-a527-4094-a673-b28b56641b1a">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctMy0xLTEtMA_e1da89d6-005d-443e-b07f-a8c9b0ad7efe">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctNS0xLTEtMA_79c4d6de-7fbe-4eb8-8387-58ea462bb39e">2,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtMS0xLTEtMA_aaf84a23-5bc4-495c-bb6f-f1ac09dd33bc">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtMy0xLTEtMA_5717a24e-37a9-4018-b10c-86dfd0b62d5a">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtNS0xLTEtMA_2743b473-acf9-4463-afc1-a9f8b8b768e0">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktMS0xLTEtMA_85ea9879-0a48-401f-9df2-4ccfbbd0cf1f">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktMy0xLTEtMA_78b4262e-2f5e-4be6-b296-34be0fa40f41">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktNS0xLTEtMA_172c33e5-c901-4367-84f9-d3fc5b760cc8">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTEtMS0xLTk1ODY_32fbc2b5-fa7d-4ac9-9f06-a29069a392d2">4,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTMtMS0xLTk2MDU_fb1a6db8-5900-4de5-a121-b7817fcbbf41">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTUtMS0xLTk2MTE_8052db8b-c3b1-4c60-905f-99c32bbba7bc">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTk2MTg_9ad73547-42c6-4f17-9142-4bf7f4d3683c">3,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTk2MTQ_4d24123a-e6e0-45d6-8a3a-3aaf5bfbb73e">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTk2MjM_5ccd19e1-3b09-423d-92c2-7908d34bd223">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTEtMS0xLTA_64116801-0660-4a15-be2e-4d66a69a3bcf">121,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTMtMS0xLTA_e2521004-6fda-49ef-853d-8ae74b531e92">1,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTUtMS0xLTA_ebcc0938-e3e4-4fa4-9fe1-e3e8a9a2a207">4,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTg5ODU_4ac9ab06-175a-4c33-bfd9-9ef4fb7d92b0">127,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTkwODQ_42ca5001-06b2-471b-bcd4-3c487a78763b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTkwODQ_550cb15c-fabd-4de9-92fe-67c066337cd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTA_5e3ccd08-ee57-46a7-995e-1be3f2d22f76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTA_f0e2be30-23d4-4c08-8682-a61af20b9058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTA_ab99bb5b-ad20-473f-873f-1a354e96a1c0">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTEtMS0xLTA_85e59159-906e-4e42-b42c-3fdd134e5ac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTMtMS0xLTA_60e49dc8-2815-4918-8c8c-40bc266bc71f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTUtMS0xLTA_77ac3b6c-5d32-486c-95c0-657bb5cce774">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTEtMS0xLTA_42748256-b489-4421-a81f-27eb4208865f">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTMtMS0xLTA_32375db7-5631-4c37-a9f6-d0845567f8cf">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTUtMS0xLTA_cfbf6dde-62dd-49f9-abd3-c26bef0f2e28">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTEtMS0xLTA_5841c629-058c-4f8a-b772-152756ccafe7">7,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTMtMS0xLTA_614c6f84-8ead-4429-86ff-3b670f59ef34">167,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTUtMS0xLTA_ad7b9e6b-ff51-4066-918b-ba2f32a2be38">30,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i4cf8b2c37bca4ed98d85fad297ff42ea" continuedAt="i313f3b9a4ef04ec097a288572763eaf5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2020, 2019 and 2018. The valuation allowance decreased $<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE1NjM_aff4b494-21d0-44b4-95e1-db6eda152f33">116.5</ix:nonFraction> million in 2020, increased $<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE1ODU_05ee012a-e5e4-4c06-b867-60bca66a79a7">136.9</ix:nonFraction> million in 2019 and decreased $<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2MTA_2cae04a8-bb5d-4eb2-bf7e-c55e92bcdf32">2.5</ix:nonFraction> million in 2018.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTU_6b81c1e1-9191-4971-94b6-cbf093c69b98" continuedAt="i9e6d08a86d6340639adcbea01cfa2dda" escape="true">Deferred tax assets (liabilities) are comprised of the following:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i9e6d08a86d6340639adcbea01cfa2dda"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:76.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzQtMS0xLTEtMA_3a77938d-5048-410d-8b3b-5f9a646e5db9">64,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzQtMy0xLTEtMA_67b22dda-d548-4135-9fb8-17bcea75bef5">150,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzUtMS0xLTEtMA_47a98a53-be1a-4441-ac50-b28318f6c7fc">19,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzUtMy0xLTEtMA_dcff8cd3-2566-41f8-b11b-fd141b81f6a4">14,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzYtMS0xLTEtOTY0Mw_6142489d-b007-4135-91ea-523414889cb6">11,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzYtMy0xLTEtOTY0Nw_9a9b62c4-da7f-4834-8459-344f51d3ec94">9,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzktMS0xLTEtMA_2052798e-eb70-405e-896e-2be944493a03">13,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzktMy0xLTEtMA_d9845875-8673-4bce-8aa8-a399fba0178b">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEwLTEtMS0xLTA_7c550865-c68f-439d-9f5b-35c1e6f8573d">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEwLTMtMS0xLTA_75ee4258-2a2b-494f-a8b4-c76adb5cc7fb">185,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzExLTEtMS0xLTA_53d4bc63-78ae-445e-b562-0f89b248d9fd">24,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzExLTMtMS0xLTA_70c7a353-c3b6-4070-976c-ea388a5337a2">141,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEyLTEtMS0xLTA_33aae867-1d9b-4005-ad57-210e0fcb48e7">84,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEyLTMtMS0xLTA_761aebf8-ec60-4722-a0dd-cf1403cecb79">44,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzE3LTEtMS0xLTA_7b039c40-670a-4460-a924-52e2e659c204">119,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzE3LTMtMS0xLTA_bb7fb947-3faa-4898-8085-9fd75110fc87">40,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIxLTEtMS0xLTA_51543795-99b1-480f-8a8c-2f5281c322ef">4,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIxLTMtMS0xLTA_c812d3ad-a394-4759-a5d0-0262fcd657a9">10,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIyLTEtMS0xLTA_2cbd7904-be13-45e2-9c89-9220062ee196">124,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIyLTMtMS0xLTA_4d9b8f17-aa96-4b7c-8835-93de446629d1">51,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzI0LTEtMS0xLTA_53744c2b-336d-45ab-8502-b0f0f12e1868">40,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzI0LTMtMS0xLTA_634b4503-e83b-4ada-bbcf-8d222d526718">7,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="i338fe8a7f9a14546aadd061a86a8794a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIwMTU_30e05718-d543-4546-a50c-c11d932fb4d9">162.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if9dac967dc794fbabfc9e438958fbe78_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIwMjI_9da76dce-0d03-4e80-8d74-154ad60e1498">129.3</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2031. We also have $<ix:nonFraction unitRef="usd" contextRef="i8e7f6ee2f38047f4bf987be2ec85087b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIxMDg_3e740191-a89c-468d-a78d-72e57fbb367f">9.2</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2040. We have $<ix:nonFraction unitRef="usd" contextRef="i20cb5a20013b480c8b516e20e1aace66_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIyMDI_beac6dfb-73c1-4099-a434-9b000db6e03b">23.1</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="i6df4a7ca341f4c80b8357649cb1d8155_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIzMzA_57a6c011-1ff0-48f0-be3e-b4ed52b63fda">110.1</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="i3c7d29ba6dd34ca2ac02b4e24d20ead9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIzOTM_ade50f64-314e-4781-9b96-183e8f7fa498">17.6</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019 we had approximately $<ix:nonFraction unitRef="usd" contextRef="i0176de2e50c3447c864e3818f9715431_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2NDkyNjc0NDk4NTA_537bc941-ad07-4520-95da-85ffb6db61bb">713.8</ix:nonFraction>&#160;million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="i00351799e1f0421bb7f825c963509503_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2NDkyNjc0NDk4NzA_fbcf0c03-1841-41a2-b16b-f7a0447aaf21">14.6</ix:nonFraction>&#160;million of non-U.S. capital loss carryovers. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License."</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2020 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTY_baf278cb-4e1d-4a20-a9e6-75b2a0f38b62" continuedAt="i0cbef269fdb546a8836674a0604b08e6" escape="true">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i313f3b9a4ef04ec097a288572763eaf5"><div style="margin-bottom:6pt"><ix:continuation id="i0cbef269fdb546a8836674a0604b08e6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:66.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItMS0xLTEtMA_8f2d0796-eeb0-4ec3-8b96-62b4eedbdf9b">28,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItMy0xLTEtMA_9a735ec6-1499-4fde-82a6-95f62684862c">30,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItNS0xLTEtMA_6f5a6e14-beab-4220-b0e1-30fe39da5efb">29,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtMS0xLTEtMA_89c196ed-f42d-4f8d-9565-198b8b61b8a0">3,911</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtMy0xLTEtMA_dc222be6-12fe-4286-8355-6f482668f688">543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtNS0xLTEtMA_df955716-3603-4622-8896-a57a7ea0a55b">1,247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtMS0xLTEtMA_7334d3ec-ea05-4d9e-bae8-a36ea2724e1c">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtMy0xLTEtMA_fa09b8ba-79e2-4c92-9206-1bca0f096a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtNS0xLTEtMA_06547469-2d28-4fc6-b2ef-266447056511">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtMS0xLTEtMA_dc572bc9-dbc0-4faf-b45b-51792ace9d20">955</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtMy0xLTEtMA_49afb90e-fe69-4a15-8446-87e433a176c4">2,096</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtNS0xLTEtMA_c6deed97-91b6-4761-b777-6da2e21a9978">657</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtMS0xLTEtMA_68270f3e-1638-4d16-8e53-0a42c518522a">31,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7153cd81712409ba213861c38901324_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtMy0xLTEtMA_76e3dc5a-c096-42c0-ae4d-31d6a421fae5">28,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtNS0xLTEtMA_e1a49a54-29a7-4e65-81dc-f2bcdeaeceec">30,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2020 is $<ix:nonFraction unitRef="usd" contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzM3Mjc_e2edb0a3-c2e4-4b75-b5cb-f84d8aaef7b7">30.2</ix:nonFraction> million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2020 and December&#160;31, 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2017 tax year to the present.&#160;The state income tax returns generally remain open for the 2016 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2020, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2016 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div></ix:continuation><div id="ib69a1c25a15148f9b95ad6e3392de608_127"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90ZXh0cmVnaW9uOjA0MTlmNDNjZmNmNTQ5YTU5ZWZlNjE0MDkyMTAwNTAwXzM2Ng_e94fcdab-30f5-415e-aa2d-f638e5dc2ff8" continuedAt="i908e3afb5e334a76a6d7e222b5120dd3" escape="true">Summary of Unaudited Quarterly Financial Information</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i908e3afb5e334a76a6d7e222b5120dd3" continuedAt="iafee60ad13f94fa9a9c164251d76d27d"><ix:nonNumeric contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90ZXh0cmVnaW9uOjA0MTlmNDNjZmNmNTQ5YTU5ZWZlNjE0MDkyMTAwNTAwXzM2NA_f963d125-3e90-4048-bdde-7fedaefe3996" continuedAt="i1afbbc94228e4dcaa4cea3a90ed6eb01" escape="true">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share amounts):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="iafee60ad13f94fa9a9c164251d76d27d"><ix:continuation id="i1afbbc94228e4dcaa4cea3a90ed6eb01"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItMS0xLTEtMA_90e43bf0-2640-4f57-8144-de8cd6641097">33,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItMy0xLTEtMA_371db142-373a-487b-bddc-50a9cf984665">41,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItNS0xLTEtMA_ed6fb089-8dd6-4dba-bdef-40f06f4c7c80">41,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItNy0xLTEtMA_8a042e1a-2792-44df-a496-f7c8f5eb6e01">69,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtMS0xLTEtMA_36524197-b45f-4a02-a850-f67f3362f208">29,373</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtMy0xLTEtMA_e9292aa5-052f-4743-a572-b87db7814180">34,320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtNS0xLTEtMA_fc1fdc28-32e9-4bf9-8370-78bf7cc04674">38,101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtNy0xLTEtMA_7ddaa3ad-f659-42bc-ac46-2f3756b5d7ba">75,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtMS0xLTEtMA_7b9638dc-72eb-42ad-9fc9-fac5f59b7a73">6,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtMy0xLTEtMA_f4df870e-46ee-488c-8f3d-35c9f23d5fe2">6,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtNS0xLTEtMA_1835339b-138e-4048-92e3-087a263199dc">4,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtNy0xLTEtMA_aedfe795-f75a-454a-8413-d275bf448498">2,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtMS0xLTEtMA_9858aac2-8dd6-4d6a-a9d8-922b1593d265">24,131</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtMy0xLTEtMA_25d04a03-3e90-48a5-a9ac-2ef9f5cf5c48">22,086</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtNS0xLTEtMA_55e39db7-a94a-4cf6-bb20-87f8568dba08">6,701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtNy0xLTEtMA_97aca354-ce08-4bf7-9920-97c0b122c5da">5,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctMS0xLTEtMA_df076092-5cbd-4f95-9622-eb4fb7f9e169">1.46</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctMy0xLTEtMA_1ab85048-580d-40a9-901d-7a530fbcba21">1.38</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctNS0xLTEtMA_48115b26-bae1-4e3d-89f9-e2c25e415897">0.42</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctNy0xLTEtMA_aa62a8ae-7a08-4087-bbe6-1c8f14b7159f">0.36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktMS0xLTEtMA_01023afe-4e84-4eaf-8f33-888721abf59a">1.46</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktMy0xLTEtMA_e69120d4-5db8-41ed-b564-ec4d977ce31b">1.32</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktNS0xLTEtMA_5d9d4b7f-9e5e-4db1-a413-e7f73f22a593">0.42</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktNy0xLTEtMA_f82a7f8c-4b55-44f5-8a99-642ea0c50d3f">0.35</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTEtMS0xLTA_c3d5e758-0f33-4c63-88d4-99e065f9b100">16,529</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTMtMS0xLTA_ad5237fb-3d75-46dc-9122-e1c7b841958a">16,055</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTUtMS0xLTA_3da7496d-f420-4441-b31b-6ebb12ee5e98">16,082</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTctMS0xLTA_3ec3dcca-41c2-4127-bd21-7154a6bed6ef">16,077</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTEtMS0xLTA_6b0eaf0a-7477-4c97-a668-f1bc32568322">16,529</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTMtMS0xLTA_aa4aa99c-845f-4a4c-97d9-37b5915447e9">16,694</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTUtMS0xLTA_a4afeb02-5b00-4b80-8971-3e32bd609ffa">16,082</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTctMS0xLTA_460d6da4-951e-4176-950b-d893c557d5f2">16,684</ix:nonFraction></span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTEtMS0xLTA_0fdbe555-10c6-4180-aa74-071a542fd4c1">43,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTMtMS0xLTA_2842b913-7c99-420e-ad05-4230b3fbffa6">24,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTUtMS0xLTA_3e5d1269-71e2-4cab-a8fe-b9e923960d12">24,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTctMS0xLTA_6d3071f0-8fdb-496e-98c5-f0fe5f05d488">27,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTEtMS0xLTA_f4b748a8-5c13-4b5d-af1f-73ff8ef15faf">29,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTMtMS0xLTA_94d41dd4-8013-49e6-ae92-3070bdef8a80">29,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTUtMS0xLTA_786e3412-65ee-4236-a353-692b138b12ee">29,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTctMS0xLTA_684c824b-51ac-4e98-9da7-1b308a146f67">37,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTEtMS0xLTA_e7c81b1b-06e5-43b5-8da4-02b4a920c3b5">176,376</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTMtMS0xLTA_c96c7353-e984-4c9b-a414-ccf3c37eb52a">3,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTUtMS0xLTA_386dbadc-31dc-4438-9aa3-1a48af25def8">4,620</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTctMS0xLTA_eea32adc-6cdb-4ad7-b5e5-5d61465159c5">810</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTEtMS0xLTA_a93c9057-8c9a-4820-ad12-b460eb9a75e8">666,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTMtMS0xLTA_7df25211-da1c-4c62-8462-2efac77ae8f9">14,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTUtMS0xLTA_f196cbcc-08ff-427f-8d5a-3dd6c7175a43">15,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTctMS0xLTA_3172a00c-9211-433a-bd68-d4158ef0aee4">7,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTEtMS0xLTA_e15d0454-6bea-45d5-a5d8-d423698097db">32.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTMtMS0xLTA_12b8747c-1117-4e4c-8e1e-7a128309806f">0.74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTUtMS0xLTA_895804f2-f559-4434-911d-76f81f8392f0">0.81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTctMS0xLTA_b66c28fa-cc55-469d-8fe2-8438e7fe6c34">0.43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTEtMS0xLTA_dc264408-2f08-4fe3-9552-e50a6392eead">31.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTMtMS0xLTA_66f0e53a-6c4d-45c1-9e47-40f16654c6b9">0.74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTUtMS0xLTA_3ae22609-1a01-450a-9f19-63a31c508081">0.81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTctMS0xLTA_1305ba65-b98e-4505-99c9-a01a14b2bb68">0.43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTEtMS0xLTA_d305ceaf-61b5-460a-b509-893f3abbbd24">20,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTMtMS0xLTA_16ab3b8b-24dc-4d23-a9a5-c1524f0d7c90">19,558</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTUtMS0xLTA_ce5f12aa-5d69-4db9-a2ac-3da796cf80bc">18,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTctMS0xLTA_729297c4-4440-4caf-a575-686a6a1fae03">17,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTEtMS0xLTA_d8472c5a-3b66-4d08-8fb0-8fbe675e992f">21,277</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTMtMS0xLTA_da7ae80a-735f-410a-a38b-fec7c2194b9c">19,558</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTUtMS0xLTA_0942fa34-3fb8-4144-b904-d3f32c59fb89">18,770</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTctMS0xLTA_1bafc6d2-fca8-448d-b56d-7aa8bbd4ea23">17,243</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Includes pre-tax gain from sale of Promacta license of $<ix:nonFraction unitRef="usd" contextRef="ic55d7c252e32432b8ac5deb25dbbe252_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTAtMS0xLTUyOTkvdGV4dHJlZ2lvbjoyMTQ5NWQ3OGE1ZWQ0ODEzYWVjOGE2OTIwOGU2M2U5MV8xMDk5NTExNjI3ODUx_1f6ea604-ffa3-428c-b1ec-fb844de8a9fe">812,797</ix:nonFraction>.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_133"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_136"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2020.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - Integrated Framework, management concluded that our internal controls over financial reporting were effective as of December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A registrant may omit an assessment of an acquired business&#8217;s internal control over financial reporting from the registrant&#8217;s assessment of its internal control; however, such an exclusion may not extend beyond one year from the date of the acquisition, nor may such assessment be omitted from more than one annual management report on internal control over financial reporting. We acquired Pfenex in October 2020, and we  excluded from the assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2020, the acquired entity&#8217;s internal control over financial reporting associated with total assets of $14.2 million (exclusive of net intangible assets and goodwill of $468.1 million), total revenue of $2.0 million and net loss of $19.3 million included in our consolidated financial statements as of and for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, has audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Ligand Pharmaceuticals Incorporated&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Ligand Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Pfenex Inc., which is included in the 2020 consolidated financial statements of the Company and constituted $14.2 million of assets (exclusive of goodwill and intangibles), as of December 31, 2020 and $2 million and $19.3 million of revenues and net loss, respectively, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Pfenex Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes and our report dated February&#160;24, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="ib69a1c25a15148f9b95ad6e3392de608_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:28.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_142"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_145"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a Code of Conduct and Ethics Policy (&#8220;Code of Conduct&#8221;) that applies to all officers, directors and employees. The Company will promptly disclose (1) the nature of any amendment to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our Code of Conduct that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information under Item&#160;10 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2020.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_148"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Compensation</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;11 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_151"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;12 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_154"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;13 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_157"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Accountant Fees and Services</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;14 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="ib69a1c25a15148f9b95ad6e3392de608_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_163"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits and Financial Statement Schedule</span></td></tr></table></div><div style="-sec-extract:summary;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Financial statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_58">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_58">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_61">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_67">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_70">Consolidated Statements of Comprehensive Income </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_70">(Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_70">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_73">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_73">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_76">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib69a1c25a15148f9b95ad6e3392de608_79">62</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Filing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000115/exhibit21-rule27announcment.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000115/exhibit21-rule27announcment.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rule 2.7 Announcement issued by Ligand Holdings UK Ltd., dated August 9, 2018 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000043/ex218k3519.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000043/ex218k3519.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Financial Trust</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 5, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/exhibit21assetpurchase.htm">2.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among Ligand Pharmaceuticals Incorporated, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera Discovery, Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312520215346/d79922dex21.htm">2.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of August 10, 2020, by and among Pfenex Inc., Ligand Pharmaceuticals Incorporated and Pelican Acquisition Sub, Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 11, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a101ligandxcellaagreem.htm">2.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated September 8, 2020, among Ligand Pharmaceuticals Incorporated, xCella Biosciences, Inc. and Eton Venture Services, Ltd. Co., as stockholders&#8217; representative</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a102ligandtaurusagreem.htm">2.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated September 9, 2020, among Ligand Pharmaceuticals Incorporated, Taurus Biosciences, LLC and the other signatories listed therein</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000108/exhibit21vineyard-spae.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited, dated as of October 11, 2020, by and among Ligand Pharmaceuticals Incorporated, Vernalis Limited, HitGen UK Ltd and HitGen Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 13, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/0000936392-98-001000.txt">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of the Company. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-58823</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 9, 1998</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616301000008/0000886163-01-000008-0002.txt">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2001</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616304000015/ex3-6.txt">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2004</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November&#160;19, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000157/exhibit36.htm">3.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certification of Incorporation of the Company, dated June 19, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-233130</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000116/exhibit31-ligandxfourt.htm">3.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth Amended and Restated Bylaws of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgndexhibi41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specimen stock certificate for shares of the common stock of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/exhibit41.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indenture, dated as of May 22, 2018, between the Company and Wilmington Trust, National Association, as trustee, including the form of 0.75% Convertible Senior Notes due 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit43_ligand-descripti.htm">4.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description of Registered Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_ligand-2002stoc.htm">10.1#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Stock Incentive Plan (as amended and restated effective December 15, 2020)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000063/lgnd-2019annualmeetingproxy.htm#sb6e62536bc644ccb9ea4178e9b4c6808">10.2#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Employee Stock Purchase Plan (as amended and restated effective June 6, 2019)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 24, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix B</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000031/lgnd-ex105_optionagreement.htm">10.3#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000095013706000420/a16037orexv10w289.txt">10.4#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Issuance Agreement for non-employee directors under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-131029</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;13, 2006</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.289</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">10.5#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">10.6#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan - Performance-Based RSU Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">10.7#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Executive Officer Change in Control Severance Agreement </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August&#160;22, 2007</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312508260208/dex102.htm">10.8#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Severance Plan, dated December 20, 2008</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;24, 2008</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000025/exhibit109final.htm">10.9#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm">10.11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Glucagon Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">10.12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">10.13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;31, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">10.14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">10.15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of TR Beta Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit25ligand-cvragr.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit25ligand-cvragr.htm">16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent Value Rights Agreement, dated as of September 30, 2020, by and between Ligand Pharmaceuticals Incorporated and American Stock Transfer &amp; Trust Company, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol&#174; Supply Agreement, dated December&#160;20, 2002, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1st Amendment to Captisol&#174; Supply Agreement, dated July&#160;29, 2005, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.101</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2nd&#160;Amendment to Captisol&#174; Supply Agreement, dated March&#160;1, 2007, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.102</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3rd&#160;Amendment to Captisol&#174; Supply Agreement, dated January&#160;25, 2008, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.103</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4th&#160;Amendment to Captisol&#174; Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.104</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, dated September&#160;3, 1993, between CyDex L.C. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.105</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.106</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.107</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.111</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exclusive License Agreement, dated June&#160;4, 1996, between Pfizer,&#160;Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.108</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum to Nonexclusive License Agreement, dated December&#160;11, 2001, between CyDex, Inc. and Pfizer,&#160;Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment to License Agreement, dated May 12, 2006, between CyDex, Inc. and Prism Pharmaceuticals, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.113</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Agreement, dated March 5, 2007, between CyDex, Inc. and Prism Pharmaceuticals, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.114</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License and Supply Agreement, dated October 12, 2005, between CyDex Pharmaceuticals, Inc. and Proteolix, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">000-28298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 23, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">10.31&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">10.32&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">10.33&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">10.34&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex102.htm">10.35</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 12, 2014, between Bank of America, N.A. and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex104.htm">10.36</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 12, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">10.37</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 14, 2014, between Bank of America, N.A. and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex108.htm">10.38</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of August 14, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 18, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">10.39&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 31, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">10.40&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">10.41&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000025/lgnd123119exhibit1042n.htm">10.42&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated March 20, 2018.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 27, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">10.43&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease, dated November 3, 2015, between the Company and 3911/3931 SVB, LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 10, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">10.44&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 9, 2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">10.45</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-033093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">49</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Warrant Transaction </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-00393</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a101redlineplatformlicen.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a101redlineplatformlicen.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform License Agreement, dated March 23, 2015, by and between Open Monoclonal Technology, Inc. and WuXi AppTec Biopharmaceuticals Co., Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1014redlineamendmentnum.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1014redlineamendmentnum.htm">59</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment Number 1 to Platform License Agreement, dated June 11, 2017, by and between Open Monoclonal Technology, Inc. and WuXi Biologics (Hong Kong) Limited (as successor-in-interest to WuXi AppTec Biopharmaceuticals Co., Ltd.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1015redlineamendmentnum.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1015redlineamendmentnum.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment Number 2 to Platform License Agreement, dated June 25, 2018, by and between Open Monoclonal Technology, Inc. and WuXi Biologics Ireland Limited (as successor-in-interest to WuXi Biologics (Hong Kong) Limited).</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit101tofor.htm">10.64</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Barclays Bank PLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit102tofor.htm">10.65</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000061/ligand-exhibit103tofor.htm">10.66</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Goldman Sachs &amp; Co. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1067_bondhedgexbarc.htm">10.67</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Barclays Bank PLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1068.htm">10.68</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ligand-ex1069xbondhedgeame.htm">10.69</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Goldman Sachs &amp; Co. LLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a103ligandtauruscvragr.htm">10.70</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent Value Rights Agreement, dated September 9, 2020, between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members' Representative (regarding Taurus Biosciences, LLC acquisition) (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2020)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a104ligandtaurusminota.htm">10.7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000101/a104ligandtaurusminota.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial License Agreement, dated September 9, 2020, between Taurus Biosciences, LLC and Minotaur Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2020)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ligandcydexex1072_gileadsu.htm">10.72</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply agreement, dated December 22, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit102ligandcydexg.htm">10.7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616320000122/exhibit102ligandcydexg.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment to Supply Agreement, dated September 21, 2020, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc., which amends that certain Supply Agreement, dated December 2, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123120xexhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subsidiaries of the Company </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123120xexhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123120xexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123120xexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123120xexhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Comprehensive Income, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicates management contract or compensatory plan.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*&#160;&#160;&#160;&#160;Certain schedules and annexes have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the U.S. Securities and Exchange Commission upon request.</span></div><div style="padding-left:72pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_166"></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.198%"><tr><td style="width:1.0%"></td><td style="width:28.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-K Summary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="ib69a1c25a15148f9b95ad6e3392de608_169"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.695%"><tr><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIGAND&#160;PHARMACEUTICALS&#160;INCORPORATED</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IGGINS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. Higgins,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;24, 2021 </span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IGGINS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. Higgins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; MATTHEW KORENBERG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Matthew Korenberg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN W. KOZARICH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John W. Kozarich</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JASON M. ARYEH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason M. Aryeh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SARAH BOYCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sarah Boyce</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;TODD C. DAVIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;NANCY R. GRAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nancy R. Gray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN L. LAMATTINA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. LaMattina</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SUNIL PATEL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sunil Patel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;STEPHEN L. SABBA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stephen L. Sabba</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>exhibit43_ligand-descripti.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if07ccd87cd644f5fa76f5e93aebdc813_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Ligand Pharmaceuticals Incorporated (&#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221;) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended&#58; our common stock. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Description of Common Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following summary of the terms of our common stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;certificate of incorporation&#8221;), and the Amended and Restated Bylaws, as amended (the &#8220;bylaws&#8221;), which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under our certificate of incorporation, the total number of shares of all classes of stock that we have authority to issue is 65,000,000, consisting of 5,000,000 shares of preferred stock, par value $0.001 per share, and 60,000,000 shares of common stock, par value $0.001 per share.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Dividends</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to limitations under Delaware law and preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by our board of directors out of legally available funds. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Liquidation </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities of our company, subject to the prior rights of any preferred stock then outstanding. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Rights and Preferences</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Fully Paid and Nonassessable</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All outstanding shares of our common stock are fully paid and nonassessable and the shares of common stock offered hereby will be fully paid and nonassessable. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and Delaware Law </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult&#58; acquisition of us by means of a tender offer&#59; acquisition of us by means of a proxy contest or otherwise&#59; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price of our shares. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Undesignated Preferred Stock </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Requirements for Advance Notification of Stockholder Nominations and Proposals </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.  These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;121351065.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Elimination of Stockholder Action by Written Consent </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our bylaws state that a special meeting of the stockholders may be called by our president and shall be called by our president or secretary upon written request from our board of directors or upon a written request from stockholders owning at least 10% of the entire capital stock of the company issued and outstanding and entitled to vote. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Delaware Anti-Takeover Statute </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We are subject to Section 203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder, unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">prior to the date of the transaction, the Board approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">on or subsequent to the date of the transaction, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&#160;2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 203 defines a business combination to include&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;121351065.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Forum Selection</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine.  To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Fair Market Value Provision </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our certificate of incorporation contains a fair market value provision that requires the approval of the holders of 66 2&#47;3% of our outstanding voting stock as a condition to a merger or certain other business transactions with, or proposed by, any person that beneficially owns, directly or indirectly, 15% or more of our voting stock (an &#8220;Interested Stockholder&#8221;), except in cases where a majority of the Continuing Directors (as defined below) approve the transaction or certain minimum price criteria and other procedural requirements are met. A &#8220;Continuing Director&#8221; is (i) a director who was originally elected upon incorporation of Ligand, (ii)&#160;a director who is not an Interested Stockholder or affiliated with an Interested Stockholder, or (iii)&#160;a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;121351065.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">director whose nomination or election to our board of directors is recommended or approved by a majority of the Continuing Directors. The minimum price criteria are recommended or approved by a majority of the Continuing Directors. The minimum price criteria generally require that, in a transaction in which stockholders are to receive payments, holders of our common stock must receive, on the consummation date of the transaction, a value equal to the higher of (A) the highest price paid by the Interested Stockholder for common stock during the prior two years and (B) the highest closing sale price of common stock during the 30-day period before (1) the announcement of the transaction or (2) the date on which the Interested Stockholder became an Interested Stockholder, whichever is higher.  In addition, such payment must be made in cash or in the type of consideration paid by the Interested Stockholder for the greatest portion of its shares. Our board of directors believes that this fair market value provision helps assure that all our stockholders will be treated similarly if certain kinds of business transactions are effected. However, this fair market value provision may make it more difficult to accomplish certain transactions that are opposed by the incumbent board of directors and that could be beneficial to stockholders.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Amendment of Charter Provisions </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least 66 2&#47;3% of our then outstanding common stock. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Amendment of Bylaws</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The affirmative vote of the holders of at least the majority of the total voting power of all outstanding shares of our voting stock is required for stockholders to amend our bylaws. This provision makes it more difficult to circumvent the anti-takeover provisions of our bylaws. Our board of directors is authorized to make, amend, supplement or repeal our bylaws&#59; provided that no amendment or supplement to the bylaws adopted by the board of directors may vary or conflict with any amendment or supplement duly adopted by the stockholders. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Listing</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our common stock is listed for trading on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;121351065.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The transfer agent and registrar for our common stock is Computershare Trust Company N.A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;121351065.2&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exhibit101_ligand-2002stoc.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i664c1cf448764a67a9d84958fcbe1361_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2002 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(AS AMENDED AND RESTATED EFFECTIVE DECEMBER 15, 2020)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE ONE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GENERAL PROVISIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.    PURPOSE OF THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            This 2002 Stock Incentive Plan is intended to promote the interests of Ligand Pharmaceuticals Incorporated, a Delaware corporation, by providing eligible persons in the Corporation&#8217;s and its Subsidiaries&#8217; service with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Corporation as an incentive for them to remain in such service. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Capitalized terms shall have the meanings assigned to such terms in the attached Appendix.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">II.   &#160;&#160;&#160;&#160;STRUCTURE OF THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            A. &#160;&#160;&#160;&#160;The Plan shall be divided into three separate equity incentives programs&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;1.     &#160;&#160;&#160;&#160;the Discretionary Option Grant Program under which eligible persons may, at the discretion of the Plan Administrator, be granted options to purchase shares of Common Stock,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;2.     &#160;&#160;&#160;&#160;the Stock Issuance Program under which eligible persons may, at the discretion of the Plan Administrator, be issued shares of Common Stock, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;the Other Stock Award Program under which eligible persons may, at the discretion of the Plan Administrator, be granted restricted stock units, stock appreciation rights and dividend equivalents. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            B. &#160;&#160;&#160;&#160;The provisions of Articles One, Five and Six shall apply to all equity programs under the Plan and shall govern the interests of all persons under the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">III.  &#160;&#160;&#160;&#160;ADMINISTRATION OF THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            A. &#160;&#160;&#160;&#160;The Primary Committee shall have sole and exclusive authority to administer the Plan with respect to Section 16 Insiders (other than non-employee Board members, whose Awards shall be administered by the full Board, as provided below). Administration of the Plan with respect to all other persons eligible to participate in those programs may, at the Board&#8217;s discretion, be vested in the Primary Committee or a Secondary Committee, or the Board may retain the power to administer those programs with respect to all such persons. However, any discretionary Awards for members of the Primary Committee must be authorized by a disinterested majority of the Board. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            B. &#160;&#160;&#160;&#160;Members of the Primary Committee or any Secondary Committee shall serve for such period of time as the Board may determine and may be removed by the Board at any time. The Board may also at any time terminate the functions of any Secondary Committee and reassume all powers and authority previously delegated to such committee.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            C. &#160;&#160;&#160;&#160;Each Plan Administrator shall, within the scope of its administrative functions under the Plan, have full power and authority (subject to the provisions of the Plan) to establish such rules and regulations as it may deem appropriate for proper administration of the Plan and to make such determinations under, and issue such interpretations of, the provisions of those programs and any outstanding Awards thereunder as it may deem necessary or advisable. Decisions of the Plan Administrator within the scope of its administrative functions under the Plan shall be final and binding on all parties who have an interest in the equity incentive programs under its jurisdiction or any Award thereunder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            D. &#160;&#160;&#160;&#160;Service on the Primary Committee or the Secondary Committee shall constitute service as a Board member, and members of each such committee shall accordingly be entitled to full indemnification and reimbursement as Board members for their service on such committee. No member of the Primary Committee or the Secondary Committee shall be liable for any act or omission made in good faith with respect to the Plan or any Awards under the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            E. &#160;&#160;&#160;&#160;Notwithstanding the foregoing, the full Board shall administer the Plan with respect to any Awards to the non-employee members of the Board.  In addition, in its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Primary Committee or any Secondary Committee under the Plan except with respect to matters which under Rule 16b3 under the Exchange Act, or any regulations or rules issued thereunder, are required to be determined in the sole discretion of the Primary Committee.  Should any Awards made under the Plan prior to November 2, 2017, be intended to qualify as Qualified Performance-Based Compensation within the meaning of Section 162(m)(4)(C) of the Code prior to its repeal, then all such determinations regarding such Awards will be made solely by the Primary Committee comprised solely of two of more &#8220;outside directors&#8221; within the meaning of Section 162(m) of the Code.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV.   &#160;&#160;&#160;&#160;ELIGIBILITY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;The persons eligible to participate in the Discretionary Option Grant, Stock Issuance and Other Stock Award Programs are as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        (i) &#160;&#160;&#160;&#160;Employees,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        (ii) &#160;&#160;&#160;&#160;non-employee members of the Board or the board of directors of any Parent or Subsidiary, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        (iii) &#160;&#160;&#160;&#160;consultants and other independent advisors who provide services to the Corporation (or any Parent or Subsidiary). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;Each Plan Administrator shall, within the scope of its administrative jurisdiction under the Plan, have full authority to determine, (i) with respect to the option grants under the Discretionary Option Grant Program, which eligible persons are to receive such grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the status of the granted option as either an Incentive Option or a Non-Statutory Option, the time or times when each option is to become exercisable, the vesting schedule (if any) applicable to the option shares, the maximum term for which the option is to remain outstanding and such other terms and conditions of such option as the Plan Administrator determines are appropriate, (ii) with respect to stock issuances under the Stock Issuance Program, which eligible persons are to receive such issuances, the time or times when the issuances are to be made, the number of shares to be issued to each Participant, the vesting schedule (if any) applicable to the issued shares, the purchase price, if any, and consideration for such shares and such other terms and conditions of such issued shares as the Plan Administrator determines are appropriate, and (iii) with respect to other Awards under the Other Stock Awards Program, which eligible persons are to receive such Awards, the type of Award, the time or times when the issuances are to be made, the number of shares subject to such Award to be issued to each Participant, the vesting schedule (if any) applicable to </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Awards, the consideration for such Awards and such other terms and conditions of such Awards as the Plan Administrator determines are appropriate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">V.    &#160;&#160;&#160;&#160;STOCK SUBJECT TO THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;Subject to adjustment pursuant to this Section V, the number of shares of Common Stock which may be issued or transferred pursuant to Awards under the Plan is 7,413,754 shares, which number shall be reduced at any time by (i) one share for each share subject to any outstanding Award that is not a Full Value Award, and (ii) 1.5 shares for each share subject to any outstanding Award that is a Full Value Award.  Notwithstanding anything in this Section V.A. to the contrary, the number of shares of Common Stock that may be issued or transferred pursuant to Incentive Stock Options under the Plan shall not exceed an aggregate of 7,413,754 shares, subject to adjustment pursuant to this Section V.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            B. &#160;&#160;&#160;&#160;No one person participating in the Plan may receive Awards for more than 1,000,000 shares of Common Stock in the aggregate per calendar year.  In addition, notwithstanding any provision to the contrary in the Plan,  the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee member of the Board as compensation for services as a non-employee member of the Board during any calendar year of the Corporation may not exceed $550,000, increased to $850,000 in the calendar year of his or her initial service as a non-employee member of the Board.  The Plan Administrator may make exceptions to this limit for individual non-employee members of the Board in extraordinary circumstances, as the Plan Administrator may determine in its discretion, provided that the non-employee member of the Board receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee members of the Board.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.92pt">To the extent all or a portion of an Award is forfeited, expires or such Award or portion thereof is settled for cash (in whole or in part), the shares of Common Stock subject to such Award or portion thereof, shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards under the Plan in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A above.  Notwithstanding anything to the contrary contained herein, the following shares of Common Stock shall not be added to the shares of Common Stock authorized for grant under Section V.A and will not be available for future grants of Awards&#58; (i) shares of Common Stock tendered by an Optionee or withheld by the Corporation in payment of the exercise price of an option&#59; (ii) shares of Common Stock tendered by the Optionee or Participant or withheld by the Corporation to satisfy any tax withholding obligation with respect to an option or stock appreciation right&#59; (iii) shares of Common Stock subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof&#59; and (iv) shares of Common Stock purchased on the open market with the cash proceeds from the exercise of options.  Shares of Common Stock tendered by the Participant or withheld by the Corporation to satisfy any tax withholding obligation with respect to a Full Value Award shall be available for future grants of Awards under the Plan in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A. above&#59; provided, however, that, notwithstanding the foregoing, in the event shares subject to a Full Value Award are delivered by a Participant or withheld by the Company to satisfy any Withholding Taxes at a tax withholding rate in excess of the minimum statutory withholding rates, such shares tendered or withheld to satisfy the Withholding Taxes at a rate in excess of the minimum statutory withholding rates shall not be available for future grants of Awards under the Plan and shall continue to be counted against the share reserve in an amount corresponding to the reduction in the share reserve previously made in accordance with Section V.A. above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any shares of Common Stock forfeited by the Participant or repurchased by the Corporation under Article Three, Section I.C at a price not greater than the price originally paid by the Participant so that such shares are returned to the Corporation will again be available for Awards in an amount </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">corresponding to the reduction in the share reserve previously made in accordance with Section V.A. above.  The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not be counted against the shares available for issuance under the Plan.  Notwithstanding the provisions of this Section V.C, no shares of Common Stock may again be optioned, granted or awarded if such action would cause an Incentive Option to fail to qualify as an incentive stock option under Section 422 of the Code. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">           D. &#160;&#160;&#160;&#160;If any change is made to the Common Stock by reason of any stock split, stock or cash dividend (other than normal cash dividends), recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation&#8217;s receipt of consideration, equitable adjustments shall be made by the Plan Administrator to (i) the maximum number and&#47;or class of securities issuable under the Plan or with respect to Incentive Stock Options under the Plan, (ii) the maximum number and&#47;or class of securities for which any one person may be granted Awards under the Plan per calendar year, (iii) the number and&#47;or class of securities for which grants are subsequently to be made under the Automatic Option Grant Program to new and continuing non-employee Board members, (iv) the number and&#47;or class of securities and the exercise or purchase price per share in effect under each outstanding Award under the Plan, and (v) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto). Such adjustments to the outstanding Awards are to be effected in a manner which shall preclude the enlargement or dilution of rights and benefits under such Awards. The adjustments determined by the Plan Administrator shall be final, binding and conclusive.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;Subject to Article Two, Section III, Article Three, Section II and Article Four, Section V, in the event of any transaction or event described in Section V.D or any unusual or nonrecurring transactions or events affecting the Corporation, any affiliate of the Corporation, or the financial statements of the Corporation or any affiliate, or of changes in applicable laws, regulations or accounting principles, including, without limitation, a Change in Control or a Hostile Take-Over, the Plan Administrator, in its sole and absolute discretion, and on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Optionee&#8217;s or Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Plan Administrator determines that such action is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;To provide for either (A) termination of any such Award in exchange for an amount of cash, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Optionee&#8217;s or Participant&#8217;s rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section V.E the Plan Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Optionee&#8217;s or Participant&#8217;s rights, then such Award may be terminated by the Corporation without payment) or (B) the replacement of such Award with other rights or property selected by the Plan Administrator in its sole discretion&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar Awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices&#59; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards, and in the number and&#47;or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;To provide that such Award shall be exercisable or payable or fully vested with respect to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;To provide that the Award cannot vest, be exercised or become payable after such event.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;F.&#160;&#160;&#160;&#160;In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Corporation assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, for reasons of administrative convenience, the Corporation in its sole discretion may refuse to permit the exercise of any Award during a period of thirty (30) days prior to the consummation of any such transaction.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE TWO</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DISCRETIONARY OPTION GRANT PROGRAM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.   &#160;&#160;&#160;&#160;OPTION TERMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            Each option shall be evidenced by one or more documents in the form approved by the Plan Administrator&#59; provided, however, that each such document shall comply with the terms specified below. Each document evidencing an Incentive Option shall, in addition, be subject to the provisions of the Plan applicable to such options.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            A. &#160;&#160;&#160;&#160;EXERCISE PRICE.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;1. &#160;&#160;&#160;&#160;The exercise price per share shall be fixed by the Plan Administrator but shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the option grant date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;2. &#160;&#160;&#160;&#160;The exercise price shall become immediately due upon exercise of the option and shall, subject to the provisions of the documents evidencing the option, be payable in one or more of the forms specified below&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;cash or check made payable to the Corporation, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;shares of Common Stock held by the Optionee or otherwise issuable upon exercise of the option and valued at Fair Market Value on the Exercise Date, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iii) &#160;&#160;&#160;&#160;to the extent the option is exercised for vested shares, through a special sale and remittance procedure pursuant to which the Optionee shall concurrently provide irrevocable instructions to (a) a Corporation-designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Corporation by reason of such exercise and (b) the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale, or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iv)&#160;&#160;&#160;&#160;with the consent of the Plan Administrator, a promissory note bearing interest at no less than such rate as shall then preclude the imputation of interest under the Code.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            Except to the extent such sale and remittance procedure is utilized, payment of the exercise price for the purchased shares must be made on the Exercise Date.  Notwithstanding any other provision of the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Plan to the contrary, no Optionee who is a member of the Board or an &#8220;executive officer&#8221; of the Corporation within the meaning of Section 13(k) of the Exchange Act shall be permitted to pay the exercise price of an option, or continue any extension of credit with respect to the exercise of an option, with a loan from the Corporation or a loan arranged by the Corporation in violation of Section 13(k) of the Exchange Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            B. &#160;&#160;&#160;&#160;EXERCISE AND TERM OF OPTIONS. Each option shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the option. However, no option shall have a term in excess of ten (10) years measured from the option grant date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            C. &#160;&#160;&#160;&#160;EFFECT OF TERMINATION OF SERVICE.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;1. &#160;&#160;&#160;&#160;The following provisions shall govern the exercise of any options held by the Optionee at the time of cessation of Service or death&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;Any option outstanding at the time of the Optionee&#8217;s cessation of Service for any reason shall remain exercisable for such period of time thereafter as shall be determined by the Plan Administrator and set forth in the documents evidencing the option, but no such option shall be exercisable after the expiration of the option term. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;Any option held by the Optionee at the time of death and exercisable in whole or in part at that time may be subsequently exercised by the personal representative of the Optionee&#8217;s estate or by the person or persons to whom the option is transferred pursuant to the Optionee&#8217;s will or the laws of inheritance or by the Optionee&#8217;s designated beneficiary or beneficiaries of that option. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iii) &#160;&#160;&#160;&#160;During the applicable post-Service exercise period, the option may not be exercised in the aggregate for more than the number of vested shares for which the option is exercisable on the date of the Optionee&#8217;s cessation of Service. Upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the option term, the option shall terminate and cease to be outstanding for any vested shares for which the option has not been exercised. However, the option shall, immediately upon the Optionee&#8217;s cessation of Service, terminate and cease to be outstanding to the extent the option is not otherwise at that time exercisable for vested shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;2. &#160;&#160;&#160;&#160;The Plan Administrator shall have complete discretion, exercisable either at the time an option is granted or at any time while the option remains outstanding, to&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;extend the period of time for which the option is to remain exercisable following the Optionee&#8217;s cessation of Service from the limited exercise period otherwise in effect for that option to such greater period of time as the Plan Administrator shall deem appropriate, but in no event beyond the expiration of the option term, and&#47;or </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;                        (ii) &#160;&#160;&#160;&#160;permit the option to be exercised, during the applicable post-Service exercise period, not only with respect to the number of vested shares of Common Stock for which such option is exercisable at the time of the Optionee&#8217;s cessation of Service but also with respect to one or more additional installments in which the Optionee would have vested had the Optionee continued in Service. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;D. &#160;&#160;&#160;&#160;STOCKHOLDER RIGHTS. The holder of an option shall have no stockholder rights with respect to the shares subject to the option until such person shall have exercised the option, paid the exercise price and become a holder of record of the purchased shares.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;E. &#160;&#160;&#160;&#160;REPURCHASE RIGHTS. The Plan Administrator shall have the discretion to grant options which are exercisable for unvested shares of Common Stock. Should the Optionee cease Service while holding such unvested shares, the Corporation shall have the right to repurchase any or all of those unvested shares. The terms upon which such repurchase right shall be exercisable (including the period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Plan Administrator and set forth in the document evidencing such repurchase right. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            F. &#160;&#160;&#160;&#160;LIMITED TRANSFERABILITY OF OPTIONS. During the lifetime of the Optionee, Incentive Options shall be exercisable only by the Optionee and shall not be assignable or transferable other than by will or the laws of inheritance following the Optionee&#8217;s death. Non-Statutory Options shall be subject to the same restriction, except that a Non-Statutory Option may be assigned in whole or in part during the Optionee&#8217;s lifetime to one or more members of the Optionee&#8217;s family or to a trust established exclusively for one or more such family members or to Optionee&#8217;s former spouse, to the extent such assignment is in connection with the Optionee&#8217;s estate plan or pursuant to a domestic relations order. The assigned portion may only be exercised by the person or persons who acquire a proprietary interest in the option pursuant to the assignment. The terms applicable to the assigned portion shall be the same as those in effect for the option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate. Notwithstanding the foregoing, the Optionee may also designate one or more persons as the beneficiary or beneficiaries of his or her outstanding options under this Article Two, and those options shall, in accordance with such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee&#8217;s death while holding those options. Such beneficiary or beneficiaries shall take the transferred options subject to all the terms and conditions of the applicable agreement evidencing each such transferred option, including (without limitation) the limited time period during which the option may be exercised following the Optionee&#8217;s death.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">II.   &#160;&#160;&#160;&#160;INCENTIVE OPTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            The terms specified below shall be applicable to all Incentive Options. Except as modified by the provisions of this Section II, all the provisions of Articles One, Five and Six shall be applicable to Incentive Options.  To the extent an option which is designated as an Incentive Option fails to meet the requirements of Section 422 of the Code, then such option shall be treated as a Non-Statutory Option.  Options which are specifically designated as Non-Statutory Options when issued under the Plan shall not be subject to the terms of this Section II.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            A. &#160;&#160;&#160;&#160;ELIGIBILITY. Incentive Options may only be granted to Employees. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            B. &#160;&#160;&#160;&#160;DOLLAR LIMITATION. The aggregate Fair Market Value of the shares of Common Stock (determined as of the respective date or dates of grant) for which one or more options granted to any Employee under the Plan (or any other option plan of the Corporation or any Parent or Subsidiary) may for the first time become exercisable as Incentive Options during any one calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000). To the extent the Employee holds two (2) or more such options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options as Incentive Options shall be applied on the basis of the order in which such options are granted.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            C. &#160;&#160;&#160;&#160;10% STOCKHOLDER. If any Employee to whom an Incentive Option is granted is a 10% Stockholder, then the exercise price per share shall not be less than one hundred ten percent (110%) of the Fair Market Value per share of Common Stock on the option grant date, and the option term shall not exceed five (5) years measured from the option grant date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">III.  &#160;&#160;&#160;&#160;CHANGE IN CONTROL&#47;HOSTILE TAKE-OVER</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">           A. &#160;&#160;&#160;&#160;In the event of a Change in Control, each outstanding option under the Discretionary Option Grant Program shall automatically accelerate so that each such option shall, immediately prior to the effective date of that Change in Control, become exercisable for all the shares of Common Stock at the time subject to such option and may be exercised for any or all of those shares as fully vested shares of Common Stock. However, an outstanding option shall NOT become exercisable on such an accelerated basis if and to the extent&#58; (i) such option is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing at the time of the Change in Control on any shares for which the option is not otherwise at that time exercisable and provides for subsequent payout of that spread in accordance with the same exercise&#47;vesting schedule applicable to those option shares or (iii) the acceleration of such option is subject to other limitations imposed by the Plan Administrator at the time of the option grant. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;All outstanding repurchase rights under the Discretionary Option Grant Program shall automatically terminate, and the shares of Common Stock subject to those terminated rights shall immediately vest in full, in the event of a Change in Control, except to the extent&#58; (i) those repurchase rights are to be assigned to the successor corporation (or parent thereof) or are otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed by the Plan Administrator at the time the repurchase right is issued. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;C. &#160;&#160;&#160;&#160;Immediately following the consummation of the Change in Control, all outstanding options under the Discretionary Option Grant Program shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;D. &#160;&#160;&#160;&#160;Each option which is assumed in connection with a Change in Control or otherwise continued in effect shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to the Optionee in consummation of such Change in Control had the option been exercised immediately prior to such Change in Control. Appropriate adjustments shall also be made to the exercise price payable per share under each outstanding option, provided the aggregate exercise price payable for such securities shall remain the same (subject only to reduction by reason of rounding). To the extent the actual holders of the Corporation&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption of the outstanding options under the Discretionary Option Grant Program, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;E. &#160;&#160;&#160;&#160;The Plan Administrator shall have the discretionary authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall, immediately prior to the effective date of a Change in Control, become exercisable for all the shares of Common Stock at the time subject to those options and may be exercised for any or all of those shares as fully vested shares of Common Stock, whether or not those options are to be assumed in the Change in Control transaction or otherwise continued in effect. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Discretionary Option Grant Program so that those rights shall immediately terminate upon the consummation of the Change in Control transaction, and the shares subject to those terminated rights shall thereupon vest in full. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;F. &#160;&#160;&#160;&#160;The Plan Administrator shall have full power and authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall become exercisable for all the shares of Common Stock at the time subject to those options in the event the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Optionee&#8217;s Service is subsequently terminated by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those options do not otherwise accelerate. In addition, the Plan Administrator may structure one or more of the Corporation&#8217;s repurchase rights so that those rights shall immediately terminate with respect to any shares held by the Optionee at the time of such Involuntary Termination, and the shares subject to those terminated repurchase rights shall accordingly vest in full at that time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;G. &#160;&#160;&#160;&#160;The Plan Administrator shall have the discretionary authority to structure one or more outstanding options under the Discretionary Option Grant Program so that those options shall, immediately prior to the effective date of a Hostile Take-Over, become exercisable for all the shares of Common Stock at the time subject to those options and may be exercised for any or all of those shares as fully vested shares of Common Stock. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Discretionary Option Grant Program so that those rights shall terminate automatically upon the consummation of such Hostile Take-Over, and the shares subject to those terminated rights shall thereupon vest in full. Alternatively, the Plan Administrator may condition the automatic acceleration of one or more outstanding options under the Discretionary Option Grant Program and the termination of one or more of the Corporation&#8217;s outstanding repurchase rights under such program upon the subsequent termination of the Optionee&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of such Hostile Take-Over.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;H. &#160;&#160;&#160;&#160;The portion of any Incentive Option accelerated in connection with a Change in Control or Hostile Take-Over shall remain exercisable as an Incentive Option only to the extent the applicable One Hundred Thousand Dollar ($100,000) limitation is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be exercisable as a Nonstatutory Option under the Federal tax laws.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;I. &#160;&#160;&#160;&#160;The outstanding options shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE THREE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STOCK ISSUANCE PROGRAM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.    &#160;&#160;&#160;&#160;STOCK ISSUANCE TERMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            Shares of Common Stock may be issued under the Stock Issuance Program through direct and immediate issuances without any intervening option grants. Each such stock issuance shall be evidenced by a Stock Issuance Agreement which complies with the terms specified below. Shares of Common Stock may also be issued under the Stock Issuance Program pursuant to share right awards which entitle the recipients to receive those shares upon the attainment of designated performance goals or the satisfaction of specified Service requirements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;PURCHASE PRICE.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;1. &#160;&#160;&#160;&#160;The purchase price per share, if any, shall be fixed by the Plan Administrator. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;2. &#160;&#160;&#160;&#160;Shares of Common Stock may be issued under the Stock Issuance Program for any form of consideration as the Plan Administrator may deem appropriate in each individual instance, including, without limitation&#58;</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;cash or check made payable to the Corporation, or </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;past services rendered to the Corporation (or any Parent or Subsidiary), or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iii) &#160;&#160;&#160;&#160;future services to be rendered to the Corporation (or any Parent or Subsidiary). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;RESTRICTIONS.  Shares of Common Stock issued under this Stock Issuance Program shall be subject to such restrictions on transferability and other restrictions as the Plan Administrator may impose (including, without limitation, limitations on the right to vote such shares or the right to receive dividends on such shares).  These restrictions may lapse separately or in combination at such times, pursuant to such circumstances, in such installments, or otherwise, as the Plan Administrator determines at the time of the grant of the shares or thereafter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, with respect to shares of Common Stock issued under this Stock Issuance Program subject to vesting, dividends which are paid prior to vesting shall only be paid out to the Participant to the extent that the vesting conditions are subsequently satisfied and the share vests.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;Forfeiture.  Except as otherwise determined by the Plan Administrator at the time of the grant of the shares or thereafter, upon termination of employment or service during the applicable restriction period, shares of Common Stock issued under this Stock Issuance Program that are at that time subject to restrictions shall be forfeited&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, the Plan Administrator may (a) provide in any award agreement that restrictions or forfeiture conditions relating to such shares will be waived in whole or in part in the event of terminations resulting from specified causes, and (b) in other cases waive in whole or in part restrictions or forfeiture conditions relating to such shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">II.   CHANGE IN CONTROL&#47;HOSTILE TAKE-OVER</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;All of the Corporation&#8217;s outstanding forfeiture restrictions or repurchase rights on any shares of Common Stock issued under the Stock Issuance Program shall terminate automatically, and all the shares of Common Stock subject to those terminated rights shall immediately vest in full, in the event of any Change in Control, except to the extent (i) those forfeiture restrictions or repurchase rights are to be assigned to the successor corporation (or parent thereof) or are otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed in the Stock Issuance Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;The Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s forfeiture restrictions or repurchase rights under the Stock Issuance Program so that those rights shall automatically terminate in whole or in part, and the shares of Common Stock subject to those terminated rights shall immediately vest, in the event the Participant&#8217;s Service should subsequently terminate by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those forfeiture restrictions or repurchase rights are assigned to the successor corporation (or parent thereof) or are otherwise continued in effect. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;C. &#160;&#160;&#160;&#160;The Plan Administrator shall also have the discretionary authority to structure one or more of the Corporation&#8217;s forfeiture restrictions or repurchase rights under the Stock Issuance Program so that those rights shall automatically terminate in whole or in part, and the shares of Common Stock subject to those terminated rights shall immediately vest, either upon the occurrence of a Hostile Take-Over or upon the subsequent termination of the Participant&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of that Hostile Take-Over.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">III.  &#160;&#160;&#160;&#160;SHARE ESCROW&#47;LEGENDS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Unvested shares may, in the Plan Administrator&#8217;s discretion, be held in escrow by the Corporation until the Participant&#8217;s interest in such shares vests or may be issued directly to the Participant with restrictive legends on the certificates evidencing those unvested shares. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE FOUR</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OTHER STOCK AWARDS PROGRAM</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;STOCK APPRECIATION RIGHTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;A stock appreciation right may be granted to any eligible person selected by the Plan Administrator.  A stock appreciation right shall be subject to such terms and conditions not inconsistent with the Plan as the Plan Administrator shall impose and shall be evidenced by a stock appreciation right agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;A stock appreciation right shall entitle the Participant (or other person entitled to exercise the stock appreciation right pursuant to the Plan) to exercise all or a specified portion of the stock appreciation right (to the extent then exercisable pursuant to its terms) and to receive from the Corporation an amount equal to the product of (i) the excess of (A) the Fair Market Value of the Common Stock on the date the stock appreciation right is exercised over (B) the Fair Market Value of the Common Stock on the date the stock appreciation right was granted and (ii) the number of shares of Common Stock with respect to which the stock appreciation right is exercised, subject to any limitations the Plan Administrator may impose.  The exercise or base price per share of a stock appreciation right shall be fixed by the Plan Administrator but shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the date the stock appreciation right was granted. </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;Subject to Section I.B above, payment of the amounts determined under Sections I.B. above shall be in cash, in Common Stock (based on its Fair Market Value as of the date the stock appreciation right is exercised) or a combination of both, as determined by the Plan Administrator.  To the extent any payment is effected in Stock, it shall be made subject to satisfaction of all provisions of Article Two above pertaining to options.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;Each stock appreciation right shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the stock appreciation right. However, no stock appreciation right shall have a term in excess of ten (10) years measured from the date the stock appreciation right was granted.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;Dividend Equivalents</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any eligible person selected by the Plan Administrator may be granted dividend equivalents based on the dividends declared on the shares of Common Stock that are subject to any Award, to be credited as of dividend payment dates, during the period between the date the Award is granted and the date the Award is exercised, vests or expires, as determined by the Plan Administrator.  Such dividend equivalents shall be converted to cash or additional shares of Common Stock by such formula and at such time and subject to such limitations as may be determined by the Plan Administrator.  Notwithstanding anything to the contrary, dividends or dividend equivalents with respect to an Award that is subject to vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the extent that the vesting conditions are subsequently satisfied and the Award vests. In addition, notwithstanding anything to the contrary, no dividend equivalents shall be payable with respect to options or stock appreciation rights. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;Restricted Stock Units</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Plan Administrator is authorized to make Awards of restricted stock units (a right to shares of Common Stock deliverable in the future) to any eligible person selected by the Plan Administrator in such amounts and subject to such terms and conditions as determined by the Plan Administrator.  At the time of grant, the Plan Administrator shall specify the date or dates on which the restricted stock units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as it deems appropriate.  At the time of grant, the Plan Administrator shall specify the maturity date applicable to each grant of restricted stock units which shall be no earlier than the vesting date or dates of the Award and may be determined at the election of the grantee.  On the maturity date, the Corporation shall, subject to Article Six, Section V,  transfer to the Participant one unrestricted, fully transferable share of Common Stock for each restricted stock unit scheduled to be paid out on such date and not previously forfeited.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;OTHER TERMS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the term of any award of stock appreciation rights, dividend equivalents or restricted stock units shall be set by the Plan Administrator in its discretion.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;Except as otherwise provided herein, the Plan Administrator may establish the exercise or purchase price, if any, of any award of stock appreciation rights, dividend equivalents or restricted stock units.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;An award of stock appreciation rights, dividend equivalents or restricted stock units shall only be exercisable or payable prior to the Participant&#8217;s termination of Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Plan Administrator in its sole and absolute discretion may provide that an award of stock appreciation rights, dividend equivalents or restricted stock units may be exercised or paid subsequent to a termination of Service, as applicable, or following a Change in Control of the Corporation, or because of the Participant&#8217;s retirement, death or disability, or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Payments with respect to any Awards granted under this Article Four shall be made in cash, in Stock or a combination of both, as determined by the Committee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;All Awards under this Article Four shall be subject to such additional terms and conditions as determined by the Plan Administrator and shall be evidenced by an award agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">V.  &#160;&#160;&#160;&#160;CHANGE IN CONTROL&#47;HOSTILE TAKE-OVER</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;In the event of a Change in Control, each outstanding Award under the Other Stock Award Program shall automatically accelerate so that each such Award shall, immediately prior to the effective date of that Change in Control, become vested and exercisable and&#47;or payable with respect to all the shares of Common Stock at the time subject to such Award and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock. However, an outstanding Award shall NOT become vested and exercisable and&#47;or payable on such an accelerated basis if and to the extent&#58; (i) such Award is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such Award is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing at the time of the Change in Control on any shares for which the Award is not otherwise at that time vested, exercisable or payable and provides for subsequent payout of that spread in accordance with the same exercise&#47;vesting&#47;payment schedule applicable to those Award shares or (iii) the acceleration of such Award is subject to other limitations imposed by the Plan Administrator at the time of the Award grant. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;Immediately following the consummation of the Change in Control, all outstanding Awards under the Other Stock Award Program shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;C. &#160;&#160;&#160;&#160;Each Award which is assumed in connection with a Change in Control or otherwise continued in effect shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to the Participant in consummation of such Change in Control had the Award been exercised or paid immediately prior to such Change in Control. Appropriate adjustments shall also be made to the exercise or purchase price payable per share under each outstanding Award, provided the aggregate exercise or purchase price payable for such securities shall remain the same. To the extent the actual holders of the Corporation&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption of the outstanding Awards under the Other Stock Award Program, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;D. &#160;&#160;&#160;&#160;The Plan Administrator shall have the discretionary authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall, immediately prior to the effective date of a Change in Control, become vested and exercisable and&#47;or payable exercisable for all the shares of Common Stock at the time subject to those Awards and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock, whether or not those Awards are to be assumed in the Change in Control transaction or otherwise continued in effect. In addition, the Plan Administrator shall have the discretionary authority to structure one or more of the Corporation&#8217;s repurchase rights under the Other Stock Award Program so that those rights shall immediately terminate upon the consummation of the Change in Control transaction, and the shares subject to those terminated rights shall thereupon vest in full. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;E. &#160;&#160;&#160;&#160;The Plan Administrator shall have full power and authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall become vested and exercisable and&#47;or payable for all the shares of Common Stock at the time subject to those Awards in the event the Participant&#8217;s Service is subsequently terminated by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control transaction in which those Awards do not otherwise accelerate. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;F. &#160;&#160;&#160;&#160;The Plan Administrator shall have the discretionary authority to structure one or more outstanding Awards under the Other Stock Award Program so that those Awards shall, immediately prior to the effective date of a Hostile Take-Over, become vested and exercisable and&#47;or payable for all the shares of Common Stock at the time subject to those Awards and may be exercised or paid for any or all of those shares as fully vested shares of Common Stock. Alternatively, the Plan Administrator may condition the automatic acceleration of one or more outstanding Awards under the Other Stock Award Program upon the subsequent termination of the Optionee&#8217;s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of such Hostile Take-Over.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            G. &#160;&#160;&#160;&#160;The outstanding Awards shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE FIVE</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PERFORMANCE-BASED AWARDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding any other provision of the Plan or any Award, with respect to any Award which is intended to continue to qualify as Qualified Performance-Based Compensation (as described in Section 162(m)(4)(C) of the Code prior to its repeal) pursuant to the transition relief rules in the Tax Cuts and Jobs Act of 2017, to the extent any of the provisions of the Plan or any Award (or any amendments hereto pursuant to this amendment and restatement of the Plan) would cause such Awards to fail to so qualify, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any such provisions shall not apply to such Awards to the extent necessary to ensure the such Awards continue to so qualify.  In addition, any Award which is intended to continue to qualify as Qualified Performance-Based Compensation (as described in Section 162(m)(4)(C) of the Code prior to its repeal) pursuant to the transition relief rules in the Tax Cuts and Jobs Act of 2017 shall be subject to any additional limitations as the Primary Committee determines necessary for such Award to continue to so qualify. To the extent permitted by applicable law, and the Plan and any such Awards shall be deemed amended to the extent necessary to conform to such requirements.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE SIX</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.   &#160;&#160;&#160;&#160;TAX WITHHOLDING</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;The Corporation&#8217;s obligation to deliver shares of Common Stock upon the exercise, vesting or payment of Awards under the Plan shall be subject to the satisfaction of all applicable income and employment tax withholding requirements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;The Plan Administrator may, in its discretion, provide any or all holders of Awards under the Plan with the right to use shares of Common Stock in satisfaction of all or part of the Withholding Taxes to which such holders may become subject in connection with the exercise, vesting or payment of their Awards. Such right may be provided to any such holder in either or both of the following formats&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;Stock Withholding&#58; The election to have the Corporation withhold, from the shares of Common Stock otherwise issuable upon the exercise, vesting or payment of such Award, a portion of those shares with an aggregate Fair Market Value equal to the minimum required percentage of the Withholding Taxes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;Stock Delivery&#58; The election to deliver to the Corporation, at the time the Award is exercised, vests or is paid, one or more shares of Common Stock previously acquired by such holder (other than in connection with the exercise, vesting or payment triggering the Withholding Taxes) and held for at least six (6) months (or such other period determined by the Plan Administrator) with an aggregate Fair Market Value equal to the percentage of the Withholding Taxes (not to exceed one hundred percent (100%)) designated by the holder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;Notwithstanding any other provision of the Plan, the number of shares of Common Stock which may be withheld or delivered by the Participant in order to satisfy the Withholding Taxes with respect to the exercise, vesting or payment of an Award shall be limited to the number of shares of Common Stock which have a Fair Market Value on the date of withholding or delivery equal to the aggregate amount of such Withholding Taxes based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income or such higher rate as may approved by the Administrator (which rates shall in no event exceed the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America))&#59; provided, however, unless otherwise approved by the Administrator, to the extent such shares of Common Stock were acquired by the Participant from the Company as compensation, the shares of Common Stock must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#8217;s earnings for financial reporting purposes&#59; provided, further, that the number of shares of Common Stock withheld or delivered shall be rounded up to the nearest whole share sufficient to cover the Withholding Taxes to the extent rounding up to the nearest whole share does not result in the liability classification of the applicable Award under generally accepted accounting principles in the United States of America.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">II.  &#160;&#160;&#160;&#160;EFFECTIVE DATE AND TERM OF THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;This Plan constitutes an amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan most recently adopted by the Board on March 28, 2019, and approved by the Corporation&#8217;s stockholders on June 6, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  This amended and restated Plan was adopted by the Board on October 26, 2020, and will become effective on the Restatement Effective Date.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;The Plan shall terminate upon the earliest to occur of (i) October 25, 2030, or (ii) the termination of all outstanding options in connection with a Change in Control. In the event of the termination of the Plan, then all option grants and unvested stock issuances outstanding at that time shall continue to have force and effect in accordance with the provisions of the documents evidencing such grants or issuances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;This amended and restated Plan shall be submitted for the approval of the Company&#8217;s stockholders within 12 months after the date of the Board&#8217;s adoption of this amended and restated Plan.  If this amended and restated Plan is not approved by the Company&#8217;s stockholders, this amended and restated Plan shall not become effective and the Existing Plan shall continue in full force and effect in accordance with its terms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">III.   &#160;&#160;&#160;&#160;AMENDMENT OF THE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;The Board shall have complete and exclusive power and authority to amend or modify the Plan in any or all respects. However, no such amendment or modification shall adversely affect the rights and obligations with respect to Awards at the time outstanding under the Plan unless the Optionee or the Participant consents to such amendment or modification. In addition, certain amendments may require stockholder approval pursuant to applicable laws or regulations.  Except as permitted by Article One, Section V, Article Two, Section III or Article Four, Section V in connection with a transaction specified in Article One, Section V.D or V.E (including, without limitation, any Change in Control, Hostile Take-Over, stock dividend, stock split, extraordinary cash dividend, recapitalization, combination of shares or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price of outstanding Options or stock appreciation rights or cancel, exchange, substitute, buyout or surrender outstanding Options or stock appreciation rights in exchange for cash, other Awards or Options or stock appreciation rights with an exercise price that is less than the exercise price of the original Options or stock appreciation rights without stockholder approval.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV.    &#160;&#160;&#160;&#160;USE OF PROCEEDS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Any cash proceeds received by the Corporation from the sale of shares of Common Stock under the Plan shall be used for general corporate purposes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">V.   &#160;&#160;&#160;&#160;REGULATORY APPROVALS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;The implementation of the Plan, the granting of any Award under the Plan and the issuance of any shares of Common Stock under the Plan shall be subject to the Corporation&#8217;s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards granted under it and the shares of Common Stock issued pursuant to it. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;No shares of Common Stock or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of applicable securities laws, including the filing and effectiveness of the Form S-8 registration statement for the shares of Common Stock issuable under the Plan, and all applicable listing requirements of any stock exchange (or the Nasdaq Global Market, if applicable) on which Common Stock is then listed for trading.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;All stock certificates delivered pursuant to the Plan are subject to any stop-transfer orders and other restrictions as the Plan Administrator deems necessary or advisable to comply with federal, state, or foreign jurisdiction, securities or other laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted, or traded.  The Plan Administrator may place legends on any stock certificate to reference restrictions applicable to the Common Stock.  In addition to the terms and conditions provided herein, the Board may require that an Optionee or Participant make such reasonable covenants, agreements, and representations as the Board, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements. The Plan Administrator shall have the right to require any Optionee or Participant to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Plan Administrator.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Notwithstanding any other provision of the Plan, unless otherwise determined by the Plan Administrator or required by any applicable law, rule or regulation, the Corporation shall not deliver to any Optionee or Participant certificates evidencing shares of Common Stock issued in connection with any award and instead such shares of Common Stock shall be recorded in the books of the Corporation (or, as applicable, its transfer agent or stock plan administrator).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E.&#160;&#160;&#160;&#160;In the event that the Corporation establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by an Optionee or a Participant may be permitted through the use of such an automated system.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VI.  &#160;&#160;&#160;&#160;NO EMPLOYMENT&#47;SERVICE RIGHTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Nothing in the Plan shall confer upon the Optionee or the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining such person) or of the Optionee or the Participant, which rights are hereby expressly reserved by each, to terminate such person&#8217;s Service at any time for any reason, with or without cause.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;COMPLIANCE WITH SECTION 409A OF THE CODE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the extent that the Plan Administrator determines that any Award granted under the Plan is subject to Section 409A of the Code, the agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A of the Code.  To the extent applicable, the Plan and Award agreements shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the adoption of the Plan.  Notwithstanding any provision of the Plan to the contrary, in the event that following the adoption of the Plan the Plan Administrator determines that any Award may be subject to Section 409A of the Code and related Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the adoption of the Plan), the Plan Administrator may adopt such amendments to the Plan and the applicable Award agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Plan Administrator determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and&#47;or preserve the intended tax treatment of the benefits provided with respect to the Award, or (b) comply with the requirements of Section 409A of the Code and related Department of Treasury guidance.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;FORFEITURE AND CLAW-BACK PROVISIONS</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;Pursuant to its general authority to determine the terms and conditions applicable to Awards under the Plan, the Plan Administrator shall have the right to provide, in the terms of Awards made under the Plan, or to require a participant to agree by separate written or electronic instrument, that&#58; (1) any proceeds, gains or other economic benefit actually or constructively received by the participant upon any receipt or exercise of the Award, or upon the receipt or resale of any shares underlying the Award, must be paid to the Corporation, and (2) the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be forfeited, if (i) a termination of Service occurs prior to a specified date, or within a specified time period following receipt or exercise of the Award, (ii) the participant at any time, or during a specified time period, engages in any activity in competition with the Corporation, or which is inimical, contrary or harmful to the interests of the Corporation, as further defined by the Plan Administrator or (iii) the participant incurs a termination of Service for Misconduct&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;All Awards (including any proceeds, gains or other economic benefit actually or constructively received by a participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares underlying the Award) shall be subject to the applicable provisions of any claw-back policy implemented by the Corporation, whether implemented prior to or after the grant of such Award, including without limitation, any claw-back policy adopted to comply with the requirements of applicable law, including without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such claw-back policy and&#47;or in the applicable Award agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i664c1cf448764a67a9d84958fcbe1361_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APPENDIX</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following definitions shall be in effect under the Plan&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A. &#160;&#160;&#160;&#160;AWARD shall mean an option, stock issuance award, stock appreciation right award, restricted stock unit award or dividend equivalent award granted pursuant to the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;BOARD shall mean the Corporation&#8217;s Board of Directors. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;C. &#160;&#160;&#160;&#160;CHANGE IN CONTROL shall mean a change in ownership or control of the Corporation effected through any of the following transactions&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;a merger, consolidation or other reorganization approved by the Corporation&#8217;s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation&#8217;s outstanding voting securities immediately prior to such transaction, or </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;the sale, transfer or other disposition of all or substantially all of the Corporation&#8217;s assets in complete liquidation or dissolution of the Corporation, or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(iii) &#160;&#160;&#160;&#160;the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation&#8217;s stockholders. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D. &#160;&#160;&#160;&#160;CODE shall mean the Internal Revenue Code of 1986, as amended. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;E. &#160;&#160;&#160;&#160;COMMON STOCK shall mean the Corporation&#8217;s common stock. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;F. &#160;&#160;&#160;&#160;CORPORATION shall mean Ligand Pharmaceuticals Incorporated, a Delaware corporation, and any corporate successor to all or substantially all of the assets or voting stock of Ligand Pharmaceuticals Incorporated which shall by appropriate action adopt the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">           &#160;&#160;&#160;&#160;G. &#160;&#160;&#160;&#160;DISCRETIONARY OPTION GRANT PROGRAM shall mean the discretionary option grant program in effect under Article Two of the Plan. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">             H. &#160;&#160;&#160;&#160;EMPLOYEE shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;I. &#160;&#160;&#160;&#160;EXERCISE DATE shall mean the date on which the Corporation shall have received written notice of the option exercise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;J. &#160;&#160;&#160;&#160;FAIR MARKET VALUE per share of Common Stock on any relevant date shall be determined in accordance with the following provisions&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;If the Common Stock is at the time traded on the Nasdaq Global Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is       reported by the National Association of Securities Dealers on the Nasdaq Global Market and published in The Wall Street Journal. If there is no closing selling price for the Common </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange     determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;K. &#160;&#160;&#160;&#160;Full Value Award shall mean any Award other than an option or a stock appreciation right and that is settled by the issuance of shares of Common Stock.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">L.&#160;&#160;&#160;&#160;HOSTILE TAKE-OVER shall mean a change in ownership or control of the Corporation effected through either of the following transactions&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination, or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(ii)  &#160;&#160;&#160;&#160;a Hostile Tender-Offer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;M. &#160;&#160;&#160;&#160;HOSTILE TENDER-OFFER shall mean the acquisition, directly or indirectly, by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation) of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation&#8217;s stockholders which the Board does not recommend such stockholders to accept.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;N. &#160;&#160;&#160;&#160;INCENTIVE OPTION shall mean an option which satisfies the requirements of Code Section 422.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">           &#160;&#160;&#160;&#160;O. &#160;&#160;&#160;&#160;INVOLUNTARY TERMINATION shall mean the termination of the Service of any individual which occurs by reason of&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;such individual&#8217;s involuntary dismissal or discharge by the Corporation for reasons other than Misconduct, or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                  &#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;such individual&#8217;s voluntary resignation following (A) a change in his or her position with the Corporation which materially reduces his or her duties and responsibilities or the level of management to which he or she reports, (B) a reduction in his or her level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs) by more than fifteen percent (15%) or (C) a relocation of such individual&#8217;s place of employment by more than fifty (50) miles, provided and only if such change, reduction or relocation is effected by the Corporation without the individual&#8217;s consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;P. &#160;&#160;&#160;&#160;MISCONDUCT shall mean the commission of any act of fraud, embezzlement or dishonesty by the Optionee or Participant, any unauthorized use or disclosure by such person of </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by such person adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or dismiss any Optionee, Participant or other person in the Service of the Corporation (or any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan, to constitute grounds for termination for Misconduct. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Q. &#160;&#160;&#160;&#160;1934 ACT shall mean the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;R. &#160;&#160;&#160;&#160;NON-STATUTORY OPTION shall mean an option not intended to satisfy the requirements of Code Section 422.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;S. &#160;&#160;&#160;&#160;OPTIONEE shall mean any person to whom an option is granted under the Discretionary Option Grant Program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;T.&#160;&#160;&#160;&#160;OTHER STOCK AWARD PROGRAM shall mean the discretionary stock award grant program in effect under Article Four of the Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;U. &#160;&#160;&#160;&#160;PARENT shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;V. &#160;&#160;&#160;&#160;PARTICIPANT shall mean any person who is issued an Award under the Plan other than an option.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;W.&#160;&#160;&#160;&#160;Performance Criteria shall mean the criteria that the Primary Committee selects for purposes of establishing the Performance Goal or Performance Goals for a Participant for a Performance Period, determined as follows&#58;  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;The Performance Criteria that will be used to establish Performance Goals shall be determined by the Plan Administrator.  Such criteria may include, but are not limited to, one or more of the following&#58; net earnings (either before or after interest, taxes, depreciation and amortization), gross or net sales or revenue, adjusted net income, operating earnings or profit, cash flow (including, but not limited to, operating cash flow and free cash flow), return on assets, return on capital, return on stockholders&#8217; equity, total stockholder return, return on sales, gross or net profit or operating margin, expenses, working capital, earnings per share, adjusted earnings per share, price per share of Stock, regulatory body approval for commercialization of a product, implementation or completion of critical projects, and market share, any of which may be measured either in absolute terms or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices.    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;The Plan Administrator may, in its sole discretion, provide that one or more adjustments shall be made to one or more of the Performance Goals.  Such adjustments may include, but are not limited to, one or more of the following&#58; items related to a change in accounting principle, items relating to financing activities, expenses for restructuring or productivity initiatives, other non-operating items, items related to acquisitions, items attributable to the business operations of any entity acquired by us during the performance period, items related to the disposal of a business or segment of a business, items related to discontinued operations that do not qualify as a segment of a business under applicable accounting standards, items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the performance period, other items of significant income or expense which are determined to be appropriate adjustments, items relating to unusual or extraordinary corporate transactions, events or developments, items related to amortization of acquired intangible assets, items </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that are outside the scope of our core, on-going business activities, items related to acquired in-process research and development, items relating to changes in tax laws, items relating to major licensing or partnership arrangements, items relating to asset impairment charges, items relating to gains or losses for litigation, arbitration and contractual settlements, or items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions.  </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;X.&#160;&#160;&#160;&#160;Performance Goals shall mean, for a Performance Period, the goals established in writing by the Plan Administrator for the Performance Period. Performance Goals may be expressed in terms of overall Corporation performance or the performance of a division, business unit, or an individual.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Y.&#160;&#160;&#160;&#160;Performance Period shall mean the one or more periods of time, which may be of varying and overlapping durations, as the Plan Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to, and the payment of, an Award.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;Z. &#160;&#160;&#160;&#160;PERMANENT DISABILITY OR PERMANENTLY DISABLED shall mean the inability of the Optionee or the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more. However, solely for purposes of the Awards granted to non-employee Board members, Permanent Disability or Permanently Disabled shall mean the inability of the non-employee Board member to perform his or her usual duties as a Board member by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;AA. &#160;&#160;&#160;&#160;PLAN shall mean the Corporation&#8217;s 2002 Stock Incentive Plan, as amended and restated and set forth in this document.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;BB. &#160;&#160;&#160;&#160;PLAN ADMINISTRATOR shall mean the particular entity, whether the Primary Committee, the Board or the Secondary Committee, which is authorized to administer the Plan with respect to one or more classes of eligible persons, to the extent such entity is carrying out its administrative functions under those programs with respect to the persons under its jurisdiction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">             CC. &#160;&#160;&#160;&#160;PRIMARY COMMITTEE shall mean the committee of two (2) or more non-employee Board members appointed by the Board to administer the Discretionary Option Grant and Stock Issuance Programs with respect to Section 16 Insiders.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;DD.&#160;&#160;&#160;&#160;Qualified Performance-Based Compensation means any compensation granted under the Plan prior to November 2, 2017 that is intended to qualify as &#8220;qualified performance-based compensation&#8221; as described in Section&#160;162(m)(4)(C) of the Code prior to its repeal. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;EE. &#160;&#160;&#160;&#160;RESTATEMENT EFFECTIVE DATE shall mean the date the Plan shall become effective and shall be coincident with the approval of the Plan at the special meeting of the Corporation&#8217;s stockholders scheduled to take place on December 15, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;FF.&#160;&#160;&#160;&#160;SECONDARY COMMITTEE shall mean a committee of one or more Board members appointed by the Board to administer the Discretionary Option Grant, Stock Issuance and Other Stock Award Programs with respect to eligible persons other than Section 16 Insiders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;GG. &#160;&#160;&#160;&#160;SECTION 16 INSIDER shall mean an officer or director of the Corporation subject to the short-swing profit liabilities of Section 16 of the 1934 Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;HH. &#160;&#160;&#160;&#160;SERVICE shall mean the performance of services for the Corporation (or any Parent or Subsidiary) by a person in the capacity of an Employee, a non-employee member of the board of directors </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or a consultant or independent advisor, except to the extent otherwise specifically provided in the documents evidencing the option grant or stock issuance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;II. &#160;&#160;&#160;&#160;STOCK EXCHANGE shall mean either the American Stock Exchange or the New York Stock Exchange.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;JJ. &#160;&#160;&#160;&#160;STOCK ISSUANCE AGREEMENT shall mean the agreement entered into by the Corporation and the Participant at the time of issuance of shares of Common Stock under the Stock Issuance Program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;KK. &#160;&#160;&#160;&#160;STOCK ISSUANCE PROGRAM shall mean the stock issuance program in effect under Article Three of the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;LL. &#160;&#160;&#160;&#160;SUBSIDIARY shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;MM. &#160;&#160;&#160;&#160;10% STOCKHOLDER shall mean the owner of stock (as determined under Code Section 424(d)) possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Corporation (or any Parent or Subsidiary).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;NN. &#160;&#160;&#160;&#160;WITHHOLDING TAXES shall mean the applicable income and employment withholding taxes to which the holder of Non-Statutory Options or unvested shares of Common Stock may become subject in connection with the exercise of those options or the vesting of those shares.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.67
<SEQUENCE>4
<FILENAME>exhibit1067_bondhedgexbarc.htm
<DESCRIPTION>EX-10.67
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i411ea96789e24cc8a9db4febdba8fffe_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.67</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND CALL OPTION AMENDMENT AGREEMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">dated as of January 28, 2021</font></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Between LIGAND PHARMACEUTICALS INCORPORATED and BARCLAYS BANK PLC</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font><br></font></div><div id="i411ea96789e24cc8a9db4febdba8fffe_4"></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Barclays Bank PLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company issued $650,000,000 principal amount of 0.75% Convertible Senior Notes due 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an Indenture dated as of May 22, 2018 between Company and Wilmington Trust, National Association as trustee&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the pricing of the Convertible Notes, Company and Dealer entered into a Base Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 17, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 650,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 40% applicable to Dealer&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the exercise of the over-allotment option by the initial purchasers of the Convertible Notes, Company and Dealer entered into an Additional Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Transaction, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 18, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 100,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Confirmation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 40% applicable to Dealer&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company and Dealer entered into that certain Call Option Amendment Agreement, dated as of April 6, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Call Option Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to, among other things, amend certain terms of the Call Option Confirmations&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with a repurchase by Company of $20,280,000 aggregate principal amount of Convertible Notes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 2021 Repurchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company has requested and the Dealer has agreed to make certain amendments to the Call Option Confirmations for the Options relating to such repurchased Convertible Notes to remain outstanding until a later exercise, notwithstanding the repurchase of the corresponding Convertible Notes&#59;</font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of their mutual covenants herein contained, the parties hereto, intending to be legally bound, hereby mutually covenant and agree as follows&#58;</font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any capitalized term not otherwise defined herein shall have the meaning set forth for such term in the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  (a) Each of the Call Option Confirmations shall be amended by adding the sentence &#8220;Notwithstanding anything to the contrary herein, the January 2021 Repurchase shall not constitute a Repayment Event&#8221; to the end of Section 8(a)(iii).</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b) For the avoidance of doubt, the amendments set forth in Sections 2(ii) through (vi) of the First Call Option Amendment shall apply to each of the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company represents and warrants to Dealer on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law))&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e) it is not in possession of any material nonpublic information regarding Company or the Shares&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)  it is not entering into this Agreement to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise in violation of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) the execution, delivery and performance of this Agreement do not violate or conflict with any applicable law or regulation promulgated under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or the Federal Reserve Act, as amended, to the extent applicable to the Company and which may require the Company, as a condition of a loan, loan guarantee, direct loan (as that term is defined in the CARES Act) or any other investment, or any financial assistance or relief under any program or facility, to comply with a requirement not to, or otherwise agree, attest, certify or warrant that it has not, as of the date specified in such condition, repurchased, or will not repurchase, any equity security of the Company, and that it has not, as of the date specified in the condition, made a capital distribution or will make a capital distribution.</font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Dealer represents and warrants to Company on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; and</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law)).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement and any dispute arising hereunder shall be governed by and construed in accordance with the laws of the State of New York (without reference to choice of law doctrine).</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all of the signatures thereto and hereto were upon the same instrument.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Reliance, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company confirms that it has relied on the advice of its own counsel and other advisors (to the extent it deems appropriate) with respect to any legal, tax, accounting, or regulatory consequences of this Agreement, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that it has not relied on Dealer or its affiliates in any respect in connection therewith, and that it will not hold Dealer or its affiliates accountable for any such consequences.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as expressly set forth herein, all of the terms and conditions of the Call Option Confirmations (as amended by the First Call Option Amendment) shall remain in full force and effect and are hereby confirmed in all respects.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><div id="i411ea96789e24cc8a9db4febdba8fffe_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Barclays Bank PLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Faiz Khan&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Faiz Khan</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div style="padding-right:-1pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:20pt"><font><br></font></div><div style="margin-bottom:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ligand Pharmaceuticals Incorporated</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#160;&#160;&#47;s&#47; Matthew Korenberg                                            </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Name&#58; Matthew Korenberg</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Title&#58; EVP, CFO</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.68
<SEQUENCE>5
<FILENAME>exhibit1068.htm
<DESCRIPTION>EX-10.68
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4388dbfa21584100b3e1f75520ddf3e3_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.68</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND CALL OPTION AMENDMENT AGREEMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">dated as of January 28, 2021</font></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Between LIGAND PHARMACEUTICALS INCORPORATED and DEUTSCHE BANK AG, LONDON BRANCH</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font><br></font></div><div id="i4388dbfa21584100b3e1f75520ddf3e3_4"></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Deutsche Bank AG, London Branch (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company issued $650,000,000 principal amount of 0.75% Convertible Senior Notes due 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an Indenture dated as of May 22, 2018 between Company and Wilmington Trust, National Association as trustee&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the pricing of the Convertible Notes, Company and Dealer entered into a Base Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 17, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 650,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 20% applicable to Dealer&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the exercise of the over-allotment option by the initial purchasers of the Convertible Notes, Company and Dealer entered into an Additional Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Transaction, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 18, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 100,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Confirmation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 20% applicable to Dealer&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company and Dealer entered into that certain Call Option Amendment Agreement, dated as of April 6, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Call Option Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to, among other things, amend certain terms of the Call Option Confirmations&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with a repurchase by Company of $20,280,000 aggregate principal amount of Convertible Notes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 2021 Repurchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company has requested and the Dealer has agreed to make certain amendments to the Call Option Confirmations for the Options relating to such repurchased Convertible Notes to remain outstanding until a later exercise, notwithstanding the repurchase of the corresponding Convertible Notes&#59;</font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of their mutual covenants herein contained, the parties hereto, intending to be legally bound, hereby mutually covenant and agree as follows&#58;</font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any capitalized term not otherwise defined herein shall have the meaning set forth for such term in the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  (a) Each of the Call Option Confirmations shall be amended by adding the sentence &#8220;Notwithstanding anything to the contrary herein, the January 2021 Repurchase shall not constitute a Repayment Event&#8221; to the end of Section 8(a)(iii).</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b) For the avoidance of doubt, the amendments set forth in Sections 2(ii) through (vi) of the First Call Option Amendment shall apply to each of the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company represents and warrants to Dealer on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law))&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e) it is not in possession of any material nonpublic information regarding Company or the Shares&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)  it is not entering into this Agreement to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise in violation of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; and </font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) the execution, delivery and performance of this Agreement do not violate or conflict with any applicable law or regulation promulgated under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or the Federal Reserve Act, as amended, to the extent applicable to the Company and which may require the Company, as a condition of a loan, loan guarantee, direct loan (as that term is defined in the CARES Act) or any other investment, or any financial assistance or relief under any program or facility, to comply with a requirement not to, or otherwise agree, attest, certify or warrant that it has not, as of the date specified in such condition, repurchased, or will not repurchase, any equity security of the Company, and that it has not, as of the date specified in the condition, made a capital distribution or will make a capital distribution.                </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Dealer represents and warrants to Company on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; and</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law)).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement and any dispute arising hereunder shall be governed by and construed in accordance with the laws of the State of New York (without reference to choice of law doctrine).</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all of the signatures thereto and hereto were upon the same instrument.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Reliance, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company confirms that it has relied on the advice of its own counsel and other advisors (to the extent it deems appropriate) with respect to any legal, tax, accounting, or regulatory consequences of this Agreement, that it has not relied on Dealer or its affiliates in any respect in connection therewith, and that it will not hold Dealer or its affiliates accountable for any such consequences.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as expressly set forth herein, all of the terms and conditions of the Call Option Confirmations (as amended by the First Call Option Amendment) shall remain in full force and effect and are hereby confirmed in all respects.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Stay Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties agree that (i) to the extent that prior to the date hereof both parties have adhered to the 2018 ISDA U.S. Resolution Stay Protocol (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the terms of the Protocol are incorporated into and form a part of this Agreement and the Call Option Confirmations, and for such purposes each of this Agreement and the Call Option Confirmations shall be deemed a Protocol Covered Agreement and each party shall be deemed to have the same status as &#8220;Regulated Entity&#8221; and&#47;or &#8220;Adhering Party&#8221; as applicable to it under the Protocol&#59; (ii) to the extent that prior to the date hereof the parties have executed a separate agreement the effect of which is to amend the qualified financial contracts between them to conform with the requirements of the QFC Stay Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bilateral Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the terms of the Bilateral Agreement are incorporated into and form a part of this Agreement and the Call Option Confirmations and each party shall be deemed to have the status of &#8220;Covered Entity&#8221; or &#8220;Counterparty Entity&#8221; (or other similar term) as applicable to it under the Bilateral Agreement&#59; or (iii) if clause (i) and clause (ii) do not apply, the terms of Section 1 and Section 2 and the related defined terms (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bilateral Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the form of bilateral template entitled &#8220;Full- Length Omnibus (for use between U.S. G-SIBs and Corporate Groups)&#8221; published by ISDA on November 2, 2018 (currently available on the 2018 ISDA U.S. Resolution Stay Protocol page at www.isda.org and, a copy of which is available upon request), the effect of which is to amend the qualified financial contracts between the parties thereto to conform with the requirements of the QFC Stay Rules, are hereby incorporated into and form a part of this Agreement and the Call Option Confirmations, and for such purposes each of this Agreement and the Call Option Confirmations shall be deemed a &#8220;Covered Agreement,&#8221; Dealer shall be deemed a &#8220;Covered Entity&#8221; and Company shall be deemed a &#8220;Counterparty Entity.&#8221; In the event that, after the date of this Agreement, both parties hereto become adhering parties to the Protocol, the terms of the Protocol will replace the terms of this paragraph. In the event of any inconsistencies between this Agreement and the terms of the Protocol, the Bilateral Agreement or the Bilateral Terms (each, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QFC Stay Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as applicable, the QFC Stay Terms will govern. Terms used in this paragraph without definition shall have the meanings assigned to them under the QFC Stay Rules. For purposes of this paragraph, references to &#8220;this Agreement and the Call Option Confirmations&#8221; include any related credit enhancements entered into between the parties or provided by one to the other. In addition, the parties agree that the terms of this paragraph shall be incorporated into any related covered affiliate credit enhancements, with all references to Dealer replaced by references to the covered affiliate support provider.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QFC Stay Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the regulations codified at 12 C.F.R. 252.2, 252.81&#8211;8, 12 C.F.R. 382.1-7 and 12 C.F.R. 47.1-8, which, subject to limited exceptions, require an express recognition of the stay-and-transfer powers of the FDIC under the Federal Deposit Insurance Act and the Orderly Liquidation Authority under Title II of the Dodd Frank Wall Street Reform and Consumer Protection Act and the override of default rights related directly or indirectly to the entry of an affiliate into certain insolvency proceedings and any restrictions on the transfer of any covered affiliate credit enhancements.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><div id="i4388dbfa21584100b3e1f75520ddf3e3_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deutsche Bank AG, London Branch</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Andrew Yaeger&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Andrew Yaeger</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;   Managing Director</font></div><div style="padding-right:-1pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Stowell&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Paul Stowell</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;   Managing Director</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deutsche Bank Securities Inc., acting solely as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agent in connection with the Call Option Confirmations</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Andrew Yaeger&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Andrew Yaeger</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;   Managing Director</font></div><div style="padding-right:-1pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Stowell&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Paul Stowell</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;   Managing Director</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:20pt"><font><br></font></div><div style="margin-bottom:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ligand Pharmaceuticals Incorporated</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Matthew Korenberg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Name&#58; Matthew Korenberg</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Title&#58; EVP, CFO</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.69
<SEQUENCE>6
<FILENAME>ligand-ex1069xbondhedgeame.htm
<DESCRIPTION>EX-10.69
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic7676310eecd44e8a4863ea8b30f77cc_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.69</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND CALL OPTION AMENDMENT AGREEMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">dated as of January 28, 2021</font></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Between LIGAND PHARMACEUTICALS INCORPORATED and GOLDMAN SACHS &#38; CO. LLC</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font><br></font></div><div id="ic7676310eecd44e8a4863ea8b30f77cc_4"></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Goldman Sachs &#38; Co. LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company issued $650,000,000 principal amount of 0.75% Convertible Senior Notes due 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an Indenture dated as of May 22, 2018 between Company and Wilmington Trust, National Association as trustee&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the pricing of the Convertible Notes, Company and Dealer entered into a Base Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 17, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 650,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 40% applicable to Dealer&#59; </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with the exercise of the over-allotment option by the initial purchasers of the Convertible Notes, Company and Dealer entered into an Additional Call Option Transaction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Transaction, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to an ISDA confirmation dated as of May 18, 2018, which supplements, forms a part of, and is subject to an agreement in the form of the 2002 ISDA Master Agreement, pursuant to which Company purchased from Dealer 100,000 call options (as amended, modified, terminated or unwound from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Call Option Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with the Base Call Option Confirmation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Call Option Confirmations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with an Applicable Percentage of 40% applicable to Dealer&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Company and Dealer entered into that certain Call Option Amendment Agreement, dated as of April 6, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Call Option Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to, among other things, amend certain terms of the Call Option Confirmations&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in connection with a repurchase by Company of $20,280,000 aggregate principal amount of Convertible Notes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 2021 Repurchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company has requested and the Dealer has agreed to make certain amendments to the Call Option Confirmations for the Options relating to such repurchased Convertible Notes to remain outstanding until a later exercise, notwithstanding the repurchase of the corresponding Convertible Notes&#59;</font></div><div style="margin-bottom:10pt;padding-right:-1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of their mutual covenants herein contained, the parties hereto, intending to be legally bound, hereby mutually covenant and agree as follows&#58;</font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any capitalized term not otherwise defined herein shall have the meaning set forth for such term in the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  (a) Each of the Call Option Confirmations shall be amended by adding the sentence &#8220;Notwithstanding anything to the contrary herein, the January 2021 Repurchase shall not constitute a Repayment Event&#8221; to the end of Section 8(a)(iii).</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:-1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b) For the avoidance of doubt, the amendments set forth in Sections 2(ii) through (vi) of the First Call Option Amendment shall apply to each of the Call Option Confirmations.</font></div><div style="padding-right:-1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company represents and warrants to Dealer on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law))&#59; </font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e) it is not in possession of any material nonpublic information regarding Company or the Shares&#59; and</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)  it is not entering into this Agreement to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise in violation of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) it and any of its subsidiaries has not applied, and shall not, until after the first date on which no portion of the Call Option Transaction remains outstanding following any final exercise and settlement, cancellation or early termination of the Call Option Transaction, apply, for a loan, loan guarantee, direct loan (as that term is defined in the Coronavirus Aid, Relief and Economic Security Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) or other investment, or to receive any financial assistance or relief under any program or facility (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that (a) is established under applicable law (whether in existence as of the Trade Date or subsequently enacted, adopted or amended), including without limitation the CARES Act and the Federal Reserve Act, as amended, and (b) (i) requires under applicable law (or any regulation, guidance, interpretation or other pronouncement of a governmental authority with jurisdiction for such program or facility) as a condition of such Financial Assistance, that the Counterparty comply with any requirement not to, or otherwise agree, attest, certify or warrant that it has not, as of the date specified in such condition, repurchased, or will not repurchase, any equity security of Counterparty, and that Counterparty has not, as of the date specified in the condition, made a capital distribution or will make a capital distribution, or (ii) where the terms of the Transaction would cause Counterparty to fail to satisfy any condition for application for or receipt or retention of the Financial Assistance (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Financial Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that Counterparty or any of its subsidiaries may apply for Restricted Financial Assistance if Counterparty either (a) determines based on the advice of outside counsel of national standing that the terms of the Transaction would not cause Counterparty or any of its subsidiaries to fail to satisfy any condition for application for or receipt or retention of such Financial Assistance based on the terms of the program or facility as of the date of such advice or (b) delivers to Dealer evidence or other guidance from a governmental authority with jurisdiction for such program or facility that the Transaction is permitted under such program or facility (either by specific reference to the Transaction or by general reference to transactions with the attributes of the Transaction in all relevant respects).</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties of Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Dealer represents and warrants to Company on the date hereof that&#58;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)  it has the power to execute this Agreement and any other documentation relating to this Agreement to which it is a party, to deliver this Agreement and to perform its obligations under this Agreement and has taken all necessary action to authorize such execution, delivery and performance&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)  such execution, delivery and performance do not violate or conflict with any law applicable to it, any provision of its constitutional documents, any order or judgment of any court or other agency of government applicable to it or any of its assets or any material contractual restriction binding on or affecting it or any of its assets&#59;</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)  all governmental and other consents that are required to have been obtained by it with respect to this Agreement have been obtained and are in full force and effect and all conditions of any such consents have been complied with&#59; and</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)  its obligations under this Agreement constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws affecting creditors&#8217; rights generally and subject, as to enforceability, to equitable principles of general application (regardless of whether enforcement is sought in a proceeding in equity or at law)).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement and any dispute arising hereunder shall be governed by and construed in accordance with the laws of the State of New York (without reference to choice of law doctrine).</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all of the signatures thereto and hereto were upon the same instrument.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Reliance, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Company confirms that it has relied on the advice of its own counsel and other advisors (to the extent it deems appropriate) with respect to any legal, tax, accounting, or regulatory consequences of this Agreement, that it has not relied on Dealer or its affiliates in any respect in connection therewith, and that it will not hold Dealer or its affiliates accountable for any such consequences.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as expressly set forth herein, all of the terms and conditions of the Call Option Confirmations (as amended by the First Call Option Amendment) shall remain in full force and effect and are hereby confirmed in all respects.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Resolution Stay Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Recognition of the U.S. Special Resolution Regimes.</font></div><div style="padding-right:1pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) In the event that Dealer becomes subject to a proceeding under (x) the Federal Deposit Insurance Act and the regulations promulgated thereunder or (y) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Special Resolution Regime</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the transfer from Dealer of this Agreement and the Call Option Confirmations,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any interest and obligation in or under, and any property securing, this Agreement and the Call Option Confirmations, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if each of this Agreement, the Call Option Confirmations, and any interest and obligation in or under, and any property securing, this Agreement or the Call Option Confirmations were governed by the laws of the United States or a state of the United States.</font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) In the event that Dealer or an Affiliate becomes subject to a proceeding under a U.S. Special Resolution Regime, any Default Rights (as defined in 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Default Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) under this Agreement or the Call Option Confirmations that may be exercised against Dealer are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement or the Call Option Confirmations, as applicable, were governed by the laws of the United States or a state of the United States.</font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Limitation on Exercise of Certain Default Rights Related to an Affiliate&#8217;s Entry Into Insolvency Proceedings.  Notwithstanding anything to the contrary in this Agreement or either of the Call Option Confirmations, the parties expressly acknowledge and agree that&#58;</font></div><div style="padding-left:72pt;padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i) The Company shall not be permitted to exercise any Default Right with respect to this Agreement or either Call Option Confirmation or any Affiliate Credit Enhancement that is related, directly or indirectly, to an Affiliate of Dealer becoming subject to receivership, insolvency, liquidation, resolution, or similar proceeding (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insolvency Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), except to the extent that the exercise of such Default Right would be permitted under the provisions of 12 C.F.R. 252.84, 12 C.F.R. 47.5 or 12 C.F.R. 382.4, as applicable&#59; and</font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii) Nothing in this Agreement or any Call Option Confirmation shall prohibit the transfer of any Affiliate Credit Enhancement, any interest or obligation in or under such Affiliate Credit Enhancement, or any property securing such Affiliate Credit Enhancement, to a transferee upon or following an Affiliate of Dealer becoming subject to an Insolvency Proceeding, unless the transfer would result in the Company being the beneficiary of such Affiliate Credit Enhancement in violation of any law applicable to the Company.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the purpose of this paragraph, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k) and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Enhancement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any credit enhancement or credit support arrangement in support of the obligations of Dealer under or with respect to this Agreement or any Call Option Confirmation, including any guarantee, collateral arrangement (including any pledge, charge, mortgage or other security interest in collateral or title transfer arrangement), trust or similar arrangement, letter of credit, transfer of margin or any similar arrangement.</font></div><div style="padding-left:108pt;padding-right:1pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) U.S. Protocol.  If</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has previously adhered to, or subsequently adheres to, the ISDA 2018 U.S. Resolution Stay Protocol as published by the International Swaps and Derivatives Association, Inc. as of July 31, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISDA U.S. Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the terms of such protocol shall be incorporated into and form a part of this Agreement and each Call Option Confirmation and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the terms of the ISDA U.S. Protocol shall supersede and replace the terms of this section. For purposes of incorporating the ISDA U.S. Protocol, Dealer shall be deemed to be a Regulated Entity, the Company shall be deemed to be an Adhering Party, and this Agreement and each Call Option Confirmation shall each be deemed to be a Protocol Covered Agreement. Capitalized terms used but not defined in this paragraph shall have the meanings given to them in the ISDA U.S. Protocol.</font></div><div style="padding-left:72pt;padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Pre-existing In-Scope Agreements.  Dealer and the Company agree that to the extent there are any outstanding &#8220;in-scope QFCs,&#8221; as defined in 12 C.F.R. &#167; 252.82(d), that are not excluded under 12 C.F.R. &#167; 252.88, between Dealer and the Company that do not otherwise comply with the requirements of 12 C.F.R. &#167; 252.2, 252.81&#8211;8 (each such agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preexisting In-Scope Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then each such Preexisting In-Scope Agreement is hereby amended to include the foregoing provisions in this section, with references to &#8220;this Confirmation and each Call Option Confirmation&#8221; being understood to be references to the applicable Preexisting In-Scope Agreement.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><div id="ic7676310eecd44e8a4863ea8b30f77cc_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goldman Sachs &#38; Co. LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Josh Murray&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Josh Murray</font></div><div style="padding-right:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div style="padding-right:-1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-right:-1pt"><font><br></font></div><div style="padding-right:-1pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:20pt"><font><br></font></div><div style="margin-bottom:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ligand Pharmaceuticals Incorporated</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#47;s&#47; Matthew Korenberg                                    </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Name&#58; Matthew Korenberg</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Title&#58; EVP, CFO</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Call Option Amendment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.72
<SEQUENCE>7
<FILENAME>ligandcydexex1072_gileadsu.htm
<DESCRIPTION>EX-10.72
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie0752179b337449fb4ea5969e2182b45_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.72</font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE LIGAND PHARMACEUTICALS INCORPORATED HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIGAND PHARMACEUTICALS INCORPORATED IF PUBLICLY DISCLOSED. </font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUPPLY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This SUPPLY AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is effective December 22, 2015 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by and between CyDex Pharmaceuticals, Inc., a Delaware corporation with principal offices at 11119 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYDEX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Gilead Sciences, Inc., a Delaware corporation with principal offices at 333&#160;Lakeside Drive, Foster City, California 94404 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX and Gilead are sometimes referred to individually as &#8220;Party&#8221; or collectively as the &#8220;Parties.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead and its Affiliates (as defined below) wish to purchase the product listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to this Agreement from CYDEX (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may be amended from time to time in writing by the Parties&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX is ready, willing and able to supply Product to Gilead and Gilead&#8217;s Affiliates subject to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in consideration of the foregoing and the covenants and other agreements contained herein, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Purchase and Sale</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">CYDEX agrees to sell Product to Gilead and its Affiliates based on orders placed under this Agreement pursuant to a Purchase Order (as defined below). In addition, CYDEX agrees to sell Product to Gilead&#8217;s Affiliates based on orders placed under this Agreement pursuant to a Purchase Order (as defined below)&#59; provided, that Gilead shall be jointly and severally obligated to pay for all Product purchased by its Affiliates and shall be responsible to CYDEX for any actions or inactions by an Affiliate which, if they had been done by Gilead, would constitute a breach of this Agreement. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any (A) entity that, directly or indirectly, Controls, is Controlled by, or is under common Control with, Gilead and (B) any third party contract manufacturers of Gilead that may have purchase Product on Gilead&#8217;s behalf for the manufacture of the Licensed Products (as defined below). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (i) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether by the ownership of stock, by contract, or otherwise, and&#47;or (ii) ownership or direct or indirect control of at least fifty percent (50%) of the voting stock of an entity. Gilead shall from time to time provide CYDEX a list of Gilead&#8217;s Affiliates&#59; CYDEX shall have no obligation to deal with an Affiliate which is not included on the most recent such list.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">This Agreement and the Purchase Orders accepted under it comprise the Parties&#8217; entire agreement and understanding with respect to Product. In the event of a conflict between any provision of this Agreement and any provision of the Purchase Order Terms and Conditions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the provision of this Agreement shall control. For avoidance of doubt&#58; the Parties confirm that the first sentence of Section 2 of the Purchase Order Terms and Conditions constitutes such a conflict. It is the Parties&#8217; express intent that no other document may supplement or vary the terms hereof absent a written amendment duly executed by both Parties and expressly referencing this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Supply</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.36pt">Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead or its Affiliates shall issue a Purchase Order for Product ordered under this Agreement in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purchase Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX shall have three (3) business days after the date of receipt of a Purchase Order to either&#58; (i) provide written notice of its acceptance&#59; or (ii) present Gilead or its Affiliates with a Purchase Order for Gilead consideration and acceptance. CYDEX shall supply the Product to Gilead or its Affiliate in accordance with each Purchase Order and the terms of this Agreement, and shall cause each delivery to made strictly in accordance with the delivery dates and locations specified in the Purchase Order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">Forecasting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On at least an annual basis during the Term, Gilead (on behalf of itself and its Affiliates) shall provide to CYDEX a non-binding rolling forecast detailing the quantities for the delivery of Product for the next twelve (12) calendar months of the Term (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead shall have the right to update a Forecast at any time. CYDEX shall supply Product in a quantity up to a maximum of 150% of the quantity specified in the Forecast and shall utilize commercially reasonable efforts to supply such additional Product in excess of those quantities in the timeline requested by Gilead.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">Minimum Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise agreed to by the Parties, CYDEX shall maintain a minimum stock of the Product at all times in order to satisfy the quantities set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.36pt">Delay and Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If delivery of any quantity of Product is delayed after CYDEX has accepted a Purchase Order, through no fault of Gilead and not due to a Force Majeure Event (as defined in Section 23), by more than thirty (30) days beyond the delivery date set forth in the Purchase Order (but subject to the delivery windows specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the quantity shall be considered a shortfall (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon a Shortfall, or indication from CYDEX that a Shortfall is to occur, Gilead or its Affiliates shall have the right, in its discretion, to cancel the applicable Purchase Order without liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.69pt">Minimum Shelf Life</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX warrants that the Product supplied by CYDEX at the time of delivery to Gilead shall have a minimum shelf life as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During such Product&#8217;s shelf life, the Product shall conform to the Specifications (as defined below) and be consistent with and in compliance with the Product Warranty (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Commercialization Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX hereby grants to Gilead a non-exclusive, worldwide, royalty-free license under CYDEX Intellectual Property to use and incorporate the Product in and sell (and have sold) any Licensed Product for any and all human diseases and conditions which are identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for such Licensed Product. No license is granted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for making (or having made) the Product or for selling (or having sold) the Product other than for Licensed Products. For purposes of this Section, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYDEX Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean (i)&#160;any and all know-how owned or controlled by CYDEX that relates to the use of the Product, and (ii) any and all patents owned or controlled by CYDEX that claims the Product or use thereof. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a pharmaceutical composition comprising as the active pharmaceutical ingredient the compound identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(as such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may be amended from time to time in writing by the Parties) prepared or combined with or formulated using the Product. For avoidance of doubt&#58; because only CYDEX-supplied material is &#8220;Product,&#8221; such a composition which is prepared or combined with or formulated using non-CYDEX-supplied cyclodextrin material is not a &#8220;Licensed Product.&#8221; Similarly, a pharmaceutical composition comprising as an active pharmaceutical ingredient a compound not identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(as such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may be amended from time to time in writing by the Parties) prepared or combined with or formulated using the (CYDEX-supplied) Product is not a &#8220;Licensed Product.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.36pt">DMF Reference Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead shall pay CYDEX a one-time DMF Reference Fee of &#91;***&#93; in exchange for the right of Gilead and its Affiliates to reference, in its regulatory filings for and to the extent regarding Licensed Products, CYDEX&#8217;s Type III, IV and V Drug Master Files (DMF) for the Product. CYDEX shall invoice this amount within 15 days after the Effective Date. For avoidance of doubt, Gilead shall not be obligated to pay any royalties or other milestones other than the one-time DMF Reference Fee payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.36pt">Purchase Order Quantities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead shall order a minimum of &#91;***&#93; of Product on or before December 28, 2015 and the delivery time for such initial order shall be &#8220;January 5, 2016 or such sooner time as CYDEX is able to deliver.&#8221; There is no annual minimum Product purchase quantity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead covenants and agrees that it shall not, and it shall cause its Affiliates not to, resell or transfer (other than in or for Licensed Products) any quantity of the Product, or use any of the Product for anything other than for a Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Price</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">The prices of the Product as of the Effective Date are as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">attached hereto. Such prices shall be fixed during the Term unless otherwise agreed to by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">To the extent applicable, CYDEX shall calculate and charge Gilead or its Affiliates for applicable sales, GST or VAT imposed by any federal, state, provincial, local, or other governmental entity for Product provided under this Agreement, excluding taxes based solely on CYDEX&#8217;s net income or arising from the employment relationship between CYDEX and its personnel. Gilead and its Affiliates shall have no liability for taxes billed later than one hundred eighty (180) days after their due date. CYDEX shall hold Gilead and its Affiliates harmless from all claims and liability arising from CYDEX&#8217;s failure to calculate or charge any such taxes or similar charges.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">All items ordered by Gilead can be delayed for shipment up to &#91;***&#93; from date of original requested ship date at no charge to Gilead. Gilead shall pay a warehouse charge to CYDEX at a rate to be agreed to by the Parties on &#91;***&#93; after the original requested ship date. CYDEX may invoice in full the total cost of the Product on the original requested ship date notwithstanding Gilead&#8217;s request to delay shipment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Payment</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Invoices for Product shipped to Gilead or its Affiliates and for the DMF Reference Fee are due and payable net thirty (30) days from the date of receipt of invoice by Gilead. CYDEX shall submit invoices referencing the applicable Purchase Order or DMF Reference Fee to Gilead at the following address&#58;</font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. </font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ATTN&#58; Accounts Payable</font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.O. Box 5469 </font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">San Mateo, CA 94402 </font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; apinvoices&#64;gilead.com</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Delivery&#59; Risk of Loss</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise agreed to by the Parties in writing, CYDEX shall deliver all shipments of Product to Gilead DDP (Incoterms 2010) to the facility designated in the accepted Purchase Order. Title and risk of loss, damage or destruction to the Product shall remain with CYDEX until final delivery of the Product to Gilead at the named place of destination on the accepted Purchase Order. CYDEX shall package and label the Product for delivery in accordance with Gilead&#8217;s packaging and labeling requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Product</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">CYDEX shall supply the Product (i) in conformance with the specifications (including for the Product and any raw materials or components) set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which may be modified from time to time by mutual agreement of the Parties (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">CYDEX shall notify Gilead within two (2) business days of any information of which CYDEX becomes aware of any deviations of the Product from the Specifications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">From time to time, Gilead may request, and CYDEX shall promptly provide, sales reports detailing the purchase of Product under this Agreement, including a list of all Affiliates who have purchased Product.</font></div><div id="ie0752179b337449fb4ea5969e2182b45_7"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Warranties and Remedies</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">CYDEX warrants that all Product shall be consistent with and in compliance with the Specifications, this Agreement, any Quality Agreement entered into by the Parties, all </font></div><div id="ie0752179b337449fb4ea5969e2182b45_10"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applicable laws and current good manufacturing practices as established by the United States Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">Each Party represents and warrants to the other Party that it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder without the consent of any third party and without breach of any agreements with or obligations to any third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">CYDEX warrants that any Product it delivers to Gilead and its Affiliates is free and clear of any liens, security interests or encumbrances of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">CYDEX represents and warrants that neither CYDEX, nor any of its subsidiaries, nor any of their respective directors, officers, employees or agents has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended (such act, including the rules and regulations thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the U.K. Bribery Act 2010 (as amended from time to time and including the rules and regulations thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Bribery Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions adopted by the Negotiating Conference of the Organisation for Economic Co-operation and Development on 21 November 1997 (such convention, including the rules and regulations thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OECD Convention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or any other applicable anticorruption laws, rules or regulations (collectively with the FCPA, the U.K. Bribery Act and OECD Convention, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anticorruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX shall ensure that it, its employees, any permitted subcontractor or agent and&#47;or affiliates shall comply with the Anticorruption Laws at all times. CYDEX represents and warrants that it and, to its knowledge, its affiliates, have conducted their businesses in compliance with the Anticorruption Laws and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. Specifically but without limiting CYDEX&#8217;s obligation to comply with all applicable laws, CYDEX shall comply with laws prohibiting human trafficking, slavery and child labor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.69pt">Notwithstanding the representations and warranties set forth in this Agreement, Gilead acknowledges and accepts the risks inherent in attempting to develop and commercialize any pharmaceutical product. There is no implied representation that any Licensed Products can be successfully developed or commercialized. The express warranties set forth in Section 2 and this Section 8 are provided in lieu of, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> NEITHER PARTY PROVIDES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ANY WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> WHETHER WRITTEN OR ORAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EXPRESS OR IMPLIED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> AND EACH PARTY HEREBY DISCLAIMS ALL OTHER WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> WHETHER WRITTEN OR ORAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EXPRESS AND IMPLIED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party&#8217;s representations and&#47;or warranties under this Agreement are solely for the benefit of the other Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and may be asserted only by the other Party. Each Party shall be solely responsible for all representations and warranties that it or its Affiliates make to any customer (or other third party</font></div><div id="ie0752179b337449fb4ea5969e2182b45_16"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Limitation of Liability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Indemnity</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Each Party shall indemnify, and at the other Party&#8217;s request, defend, and hold the other Party, its affiliates, and its and their respective officers, directors, employees, stockholders and agents harmless from and against any and all losses, settlements, liabilities, damages and expenses (including reasonable attorneys&#8217; fees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">resulting from any third party claims, demands, suits or proceedings (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the extent arising out of or relating to (i) a breach by the indemnifying Party of any of its representations, warranties or covenants set forth in this Agreement, or any other material breach of this Agreement or of any applicable laws by such Party or (ii) &#91;***&#93;&#59; except to the extent any such Loss(es) is covered by indemnification obligations of the indemnified Party hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">Each Party shall notify the other Party promptly upon learning of a Claim that is subject to indemnification pursuant to this Section 10, and if so requested by the indemnified Party, the indemnifying Party shall control defense and settlement thereof diligently, in good faith, and using reasonably experienced counsel with expertise in the relevant field&#59; provided, however, that the indemnifying Party shall make no settlement of any such Claim which is binding upon the indemnified Party or admitting fault on behalf of the indemnified Party, in each case without first receiving the indemnified Party&#8217;s consent thereto, which consent shall not unreasonably be withheld or delayed. The indemnified Party shall reasonably cooperate in such defense and&#47;or settlement and may participate at its own expense using its own counsel.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Records</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">CYDEX shall prepare and maintain complete and accurate records and data for the Product and shall maintain such records and data with respect to the Product (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gilead Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for five (5) years after termination or expiration of this Agreement or such longer period of time as may be required by applicable laws. Upon Gilead&#8217;s request, CYDEX shall provide copies of all such Gilead Data to Gilead (as Confidential Information of CYDEX). If CYDEX wants to destroy Gilead Data as it is no longer required to maintain such Gilead Data as required by this Agreement or applicable laws, it shall offer to provide all such Gilead Data to Gilead (as Confidential Information of CYDEX) prior to its destruction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">CYDEX shall maintain the Drug Master File for the Product. At Gilead&#8217;s request and upon Gilead&#8217;s payment of the one-time payment set forth in Section 2(g), CYDEX shall provide a letter of authorization to Gilead permitting Gilead to refer to CYDEX&#8217;s Drug Master File in connection with any regulatory filings for Gilead&#8217;s (and&#47;or Gilead&#8217;s Affiliates&#8217;) Licensed Products. In addition, upon request, CYDEX shall provide to Gilead all documents and information related to the Product necessary for Gilead to submit in connection with any regulatory filing for Gilead&#8217;s (and&#47;or Gilead&#8217;s Affiliates&#8217;) Licensed Products.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.74</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Inspection&#59; Release&#59; Latent Defects</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Gilead or its Affiliate shall examine each shipment of Product upon its arrival at the destination specified in this Agreement and shall promptly notify CYDEX in writing of any shortage, loss or damage apparent under reasonable examination within &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inspection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If such shipment is not expressly rejected by the end of the Inspection Period, it shall be deemed to have been accepted (in each case within the meaning of the Uniform Commercial Code). CYDEX shall provide Gilead with a written response within five (5) business days of being notified in writing, of the discovery of a Product that does not conform to the Product Warranty (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Defective Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX&#8217;s written response shall acknowledge receipt and planned investigation. A follow up CYDEX&#8217;s written response within thirty (30) days shall include at a minimum, the root cause of the defect and CYDEX&#8217;s corrective actions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">If after actual or deemed acceptance of a shipment of Product, Gilead or its Affiliate concludes that such Product nonetheless is (or has become) Defective Product is discovered, Gilead shall notify CYDEX and the provisions in the last three sentences of Section 12(a) above and Section 12(c)-(e) below shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">In the event of any Defective Product, CYDEX shall, at Gilead&#8217;s sole option, either (i) replace the Defective Product at no additional charge to Gilead, or (ii) provide Gilead with a full refund for any Defective Product. Return freight and any other costs incurred by Gilead, including the cost of destruction, for Defective Product shall be borne by CYDEX.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">In the event the Parties disagree with respect to whether or not the Product is Defective Product, the Product in question shall be submitted to a third party laboratory agreeable to both Parties for further testing. The Parties further agree that the determination of the third party laboratory as to whether or not the Product is Defective Product shall be binding on both Parties, and the costs associated with such testing shall be borne by the Party whose position is not supported by the findings of the third party laboratory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.69pt">Gilead and CYDEX agree to work together rapidly, with time being of the essence, to resolve any quality issues relating to the Product, which may include holding quality improvement meetings to be scheduled at mutually agreeable times.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">In the event either Party believes it may be necessary to conduct a recall with respect to any quantity of the Product(s) which were sold by CYDEX to Gilead or its Affiliates under this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX and Gilead shall consult with each other as to how best to proceed, it being understood and agreed that the final decision as to any Recall of any quantity of the Product shall be made by Gilead&#59; provided, however, that CYDEX shall not be prohibited hereunder from taking any action that it is required to take by applicable law. Any Recall required primarily because of the failure of the Product(s) to conform to the Product Warranty or other breach of this Agreement by CYDEX, shall be conducted by Gilead at CYDEX&#8217;s expense.</font></div><div id="ie0752179b337449fb4ea5969e2182b45_22"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Confidentiality</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Each respective Party agrees not to use or disclose any Confidential Information (as defined below) which it may receive from the other Party for any purpose other than the purchase of Product under this Agreement. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the Party that releases or discloses Confidential Information and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the Party that receives the Confidential Information from the Disclosing Party. No Party shall disclose or permit disclosure of any Confidential Information to any person other than officers, employees and agents of the Receiving Party who have a bona fide need to know such Confidential Information and who are bound by obligations of confidentiality and non-use at least as protective as those of this Agreement. Each Party agrees that it shall take all reasonable measures to protect and avoid disclosure or use of the Confidential Information contrary to the terms of this Agreement. Such measures shall include, but not be limited to, employing the same degree of care that the Receiving Party utilizes to protect its own Confidential Information of a similar nature, which in no event shall be less than a reasonable degree of care. Each Party agrees to promptly notify the other in writing of any actual or suspected misuse, misappropriation or unauthorized disclosure of the Confidential Information which may come to the Receiving Party&#8217;s attention. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all non-public proprietary or confidential information disclosed by the Disclosing Party to the Receiving Party under this Agreement. Confidential Information shall also include confidential findings and observations obtained during visits and&#47;or demonstrations in research and development laboratories or production facilities of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">The confidentiality obligations set forth in this Section 13 shall not apply to information that&#58; (i) was in the possession or control of the Receiving Party (with no duty of confidentiality) prior to its receipt from the Disclosing Party, as demonstrated by written records&#59; (ii) was or thereafter becomes part of the public domain through no fault of the Receiving Party or of persons for whom the Receiving Party is responsible&#59; (iii) was rightfully obtained by the Receiving Party from a third party with no obligation of confidentiality to or for the benefit of the Disclosing Party&#59; (iv) the Disclosing Party gives prior written approval for the Receiving Party to disclose onward free of confidentiality obligations&#59; or (v) the Receiving Party independently developed without use or reference to the Confidential Information, as demonstrated by written records contemporaneous with such development.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Notwithstanding the above, nothing herein shall be construed to limit disclosure of Confidential Information pursuant to the order, rule or requirement of a court, administrative agency or other governmental body with proper jurisdiction (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided, however, that the Receiving Party, to the extent allowed by law, shall promptly notify the Disclosing Party of such Order and shall reasonably cooperate with the Disclosing Party in its efforts to seek a protective order or other limitations or exemptions from such Order. Nothing in this Agreement shall be construed as authorizing the Receiving Party to use or disclose Confidential Information beyond the scope of any protective order or other limitation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.69pt">The Receiving Party agrees that it shall not attempt to reverse engineer or otherwise analyze any Disclosing Party Confidential Information for purposes of determining the </font></div><div id="ie0752179b337449fb4ea5969e2182b45_28"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">composition, chemical structure, chemical pretreatments or other properties, attributes, or characteristics of such Confidential Information. In addition, whether or not the Product constitutes Confidential Information, Gilead shall not attempt to reverse engineer, deconstruct or otherwise analyze the Product for purposes of determining the composition, chemical structure, chemical pretreatments or other properties, attributes, or characteristics of the Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Upon the first of expiration or termination of this Agreement, or at Disclosing Party&#8217;s written request, the Receiving Party agrees to promptly destroy all of the Disclosing Party&#8217;s Confidential Information, except one copy which may be retained in its legal archives for the sole purpose of monitoring the Receiving Party&#8217;s surviving obligations under this Agreement. The Receiving Party agrees to promptly destroy any and all materials to the extent that they are synthesized or otherwise contain Confidential Information in their synthesis or production. Upon request of the Disclosing Party, the Receiving Party shall provide written confirmation of such destruction. Each Party&#8217;s obligations of confidentiality and non-use shall survive the expiration or termination of this Agreement for a period of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The validity and interpretation of this Agreement and the legal relations of the Parties to it shall be governed by the internal substantive laws of the state of California, excluding that state&#8217;s conflicts of law provisions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Term</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall have a term of five (5) years following the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Termination</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Gilead may terminate this Agreement (and&#47;or, subject to the following sentence, any Purchase Order) without cause by providing thirty (30) days prior written notice to CYDEX. Termination or expiration of this Agreement without cause shall not relieve the Parties of their rights and responsibilities under any accepted Purchase Order which is outstanding as of the effective date of such termination or expiration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">In the event of a material breach of this Agreement, the Party in such breach shall be provided with written notification of the breach by the other Party. The Party in such breach shall have thirty (30) days to cure the breach (to the extent the breach is of a type that can be cured in 30 days). If the breach is not cured within thirty (30) days following notice or if the breach is not of the type that can be cured in 30 days, then this Agreement shall automatically terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">In the event of a Party&#8217;s voluntary bankruptcy petition&#59; liquidation, winding up or similar proceeding&#59; or appointment of a receiver, trustee or manager for the benefit of creditors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(which is not dismissed within 60 days)&#59; or the filing of an involuntary bankruptcy petition against a Party (which is not dismissed within 60 days), then the other Party shall be entitled immediately to terminate this Agreement and any accepted Purchase Orders without notice or liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Expiration or termination of this Agreement shall not affect accrued rights or obligations of the Parties. Sections 2(i), 9, 10, 11(a), 12, 13, 16, 17, 22, 25, 26 and 29 shall survive termination or expiration of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Intellectual Property Rights</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party shall retain all proprietary rights in and to its respective Confidential Information including, but not limited to, that related to patent, copyright, trademark, and trade secrets. Except as expressly set forth herein, no license in or to any proprietary right is granted or implied by conveying Confidential Information hereunder. Indeed, except as expressly set forth herein, no license in or to any intellectual property or other proprietary right is granted or implied by virtue of entering into or operating under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Insurance</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Each Party shall maintain in full force and effect during the term of this Agreement, the following insurance coverages, with limits of liability not less than those specified below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:24.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Commercial General Liability with limits of $5 million, including coverage for premises liability, personal and advertising injury, products and completed operations liability, broad form property damage and blanket contractual liability. Such insurance may be provided on a claims-made basis, however, such insurance shall have a retroactive date prior to the date that any work will be performed pursuant to the Agreement, and shall be maintained (or shall have an extended reporting period) of at least 5 years after the termination of this Agreement. The use of primary and excess limits to achieve the total required limits is acceptable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">With respect to CYDEX only,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:21.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) Workers&#8217; compensation insurance pursuant to all applicable laws, covering CYDEX employees (including principals) and contractors engaged in providing services under this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)Employer&#8217;s liability insurance with a minimum limit of $5,000,000 bodily injury - each accident, $5,000,000 disease - each employee, $5,000,000 disease - policy limit. The use of primary and excess limits to achieve the total required limits is acceptable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">All insurance programs provided by an outside insurance carrier required to be maintained hereunder shall be from insurers having an A.M. Best rating of A VIII or better, or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">equivalent, and shall be from insurance carriers and in a form reasonably acceptable to the other Party. Gilead may self-insure for the above coverages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">To the extent requested by the other Party, each Party shall provide the other with written evidence of self-insurance and&#47;or an original certificate of insurance evidencing that (A) all such insurance coverages are in effect, and (B) none of the required policies of insurance shall be terminated, canceled or materially modified by insurers except upon at least thirty (30) days written notice to the other Party. Any failure to maintain the insurance coverage required by this Section 18 shall be a material breach which may be cured only by restoring such coverage retroactive to the date of lapse of the prior coverage.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Successors and Assigns</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The terms and provisions of this Agreement shall be binding upon and inure to the benefit of any successor of a Party. Neither this Agreement, nor the Parties rights or duties hereunder, may be assigned or delegated without the express, written consent of the other Party, which consent may be withheld for any reason, except that Gilead may assign this Agreement to an Affiliate without CYDEX&#8217;s consent, and either Party may without the other Party&#8217;s consent assign this Agreement in connection with such (first) Party (or its parent company) being acquired.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Notices</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All notices under this Agreement shall be in writing and shall be deemed given upon personal delivery, facsimile transmission with electronic confirmation of transmission, delivery by internationally- or nationally-recognized courier service, or three (3) days after sending by certified or registered mail, postage prepaid and return receipt requested, to the following addresses or facsimile numbers of the respective Parties or such other address or facsimile number as given by notice under this Section 20&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead&#58;&#160;&#160;&#160;&#160;Gilead Sciences, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;333 Lakeside Drive </font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foster City, CA 94404 </font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attention&#58; Rob Silber</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:0.72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Copy to&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:36pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">333 Lakeside Drive </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Foster City, CA 94404 </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; General Counsel </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fax No.&#58; (650) 522-5771</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX&#160;&#160;&#160;&#160;CyDex Pharmaceuticals, Inc.</font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;c&#47;o Ligand Pharmaceuticals Incorporated </font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;11119 North Torrey Pines Road, Suite 200 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;La Jolla, CA 92037 </font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Attention&#58; Vice President and Secretary</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:0.72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Copy to&#58;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ligand Pharmaceuticals Incorporated </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11119 North Torrey Pines Road, Suite 200 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">La Jolla, CA 92037 </font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Severability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is severable. The invalidity, illegality or unenforceability (to any extent) of any provision of this Agreement shall not affect the validity, legality, or enforceability of the remaining provisions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Use of Name</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As between CYDEX and Gilead, Gilead shall have the sole authority to select trademarks for Licensed Products and shall own all such trademarks. Neither Party grants the other the right to use any of its or its Affiliates&#8217; logos, trademarks or trade names. Under no circumstances shall CYDEX use the Gilead trademark or corporate logo or name any of its personnel in promotional materials, literature, press releases, advertising or any other public announcement without Gilead&#8217;s prior written permission and approval on each occurrence.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Force Majeure</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither Party shall be liable for any delay in performing or for failing to perform its obligations under this Agreement where such failure or delay results from any force majeure cause beyond its reasonable control including, without limitation, acts of God&#59; earthquakes&#59; severe weather conditions such as hurricanes, tornadoes, ice storms or blizzards&#59; epidemics or quarantines&#59; fire&#59; explosions&#59; floods&#59; sabotage&#59; destruction of production facilities&#59; general shortages of specified raw materials, power or fuel&#59; war&#59; acts of domestic or international terrorism&#59; transportation accidents&#59; riots or civil disturbances&#59; insurrection&#59; embargo&#59; and acts of government or governmental agencies including changes in law or regulations that materially and adversely impact the Party or its obligations under this Agreement (individually and collectively a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that the affected Party promptly notifies (within ten (10) business days or as soon as practicable after discovery of the event) the other Party of the event. If the delays caused by the Force Majeure Event are not cured within sixty (60) calendar days following passage of the Force Majeure Event, then either Party may immediately terminate this Agreement upon written notice to the other Party. A Force Majeure Event shall not include labor disputes or strikes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Entire Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement sets forth the entire understanding and agreement between the Parties as to the subject matter herein. This Agreement replaces and supersedes any previously existing understandings or agreements between the Parties as to the subject matter herein&#59; provided, that any prior nondisclosure&#47;nonuse agreement is not superseded and shall remain in full force and effect in addition to this Agreement. None of the terms of this Agreement shall be amended or modified or waived except in writing, signed by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Export Control</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In handling Confidential Information provided or received hereunder the Parties shall adhere to all applicable United States export laws and regulations, and shall not knowingly export or re-export (directly or indirectly) any of the Confidential Information or any product, process, or service resulting directly therefrom to any restricted country without first obtaining any and all required government authorizations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Relationship of Parties</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither Party is the agent or legal representative of the other Party. Nothing contained in this Agreement shall be deemed to create the relationship of partner, principal and agent, or joint venture between the Parties. Neither Party has the right or authority to incur obligations of any kind in the name of or for the other Party, and each Party agrees not to purport to do so.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Further Assurances</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and instruments and take any such other action as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">No Guaranty of Favorable Outcomes</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CYDEX does not warrant that Gilead&#8217;s clinical studies (if any) will produce any particular results or any favorable results, or that Licensed Products can ever be successfully or profitably commercialized.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Patent Marking</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead agrees (for itself and its Affiliates) that with respect to each unit or package of Licensed Products sold in a given country, Gilead (or its Affiliate) shall comply with the customary patent marking laws and practices.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">In Vivo Studies</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Gilead wishes to conduct any in vivo study (preclinical or clinical, in animals or in humans, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of a Licensed Product, the following provisions shall apply&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.36pt">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead represents and warrants that each Study shall be performed in accordance with all applicable laws, regulations and requirements. Gilead shall provide or cause to be provided all appropriate information and warnings to participants enrolled in each Study and obtain or cause to be obtained appropriate documentation of informed consent from all participants in each such Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gilead has the freedom to design each Study, and (as between Gilead and CYDEX) Gilead is solely responsible for executing each Study&#59; and so it is reasonable that, and the parties agree that, Gilead shall be solely responsible therefor and for any effects or consequences of the design and execution of each Study, except to the extent any such effects or consequences arise out of or result from the actions of CYDEX.</font></div><div style="margin-bottom:12pt;padding-left:20.35pt;padding-right:20.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;The remainder of this page has intentionally been left blank.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;14</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WITNESSETH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Parties execute and deliver this Supply Agreement on and as of the Effective Date. By signing this Supply Agreement, the Parties agree to all terms and conditions set forth herein as of the Effective Date, and warrant and represent that the individuals signing below are authorized to make such commitments on behalf of their respective organizations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CyDex Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Matthew W. Foehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:0.72pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Printed Name&#58;&#160;&#160;&#160;&#160;MATTHEW W. FOEHR</font></div><div style="margin-bottom:0.12pt;padding-left:0.72pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;PRESIDENT&#47;COO</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gilead Sciences, Inc.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Reza Olivai&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:0.72pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Printed Name&#58;&#160;&#160;&#160;&#160;Reza Oliyai</font></div><div style="margin-bottom:0.12pt;padding-left:0.72pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;VP, PDCS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;15</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product&#58; Captisol&#174; sulfobutylether &#223;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(beta) cyclodextrin, sodium salt (Clinical Grade or Commercial Grade, as specified for Gilead&#8217;s proposed use and supplied by CYDEX) </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specifications&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:190.65pt;padding-right:147.25pt;text-align:justify;text-indent:54.95pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:190.65pt;padding-right:147.25pt;text-align:justify;text-indent:54.95pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:190.65pt;padding-right:147.25pt;text-align:justify;text-indent:54.95pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-2 </font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Provisions</font></div><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The price for all Product ordered shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Safety Stock&#58; &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minimum Shelf Life&#58; &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Forecasting Mechanism&#58; Non-binding annual forecast as provided in Section 2(b). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Delivery&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:36.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Days after Purchase Order</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Minimum Monthly Delivery Quantity</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A-3 </font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Products</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Active Pharmaceutical Ingredient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Indications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All indications except (a) ocular treatment of any disease or condition with a formulation including a hormone&#59; (b) topical ocular treatment of inflammatory conditions&#59; (c) treatment and prophylaxis of fungal infections in humans&#59; and (d) any ocular treatment for retinal degeneration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:22.32pt;padding-right:22.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font></div><div style="margin-bottom:12pt;padding-left:22pt;padding-right:22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Purchase Order</font></div><div style="margin-bottom:12pt;padding-left:51.9pt;padding-right:5.95pt;text-align:justify;text-indent:1.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:22.32pt;padding-right:22.32pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="ie0752179b337449fb4ea5969e2182b45_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*** Certain Confidential Information Omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>lgnd_123120xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icc2f9829e09b4e908b305a6c83a62d2d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:49.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ab Initio Biotherapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergan Ligand Retinoid Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cita NeuroPharmaceuticals Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystal Bioscience, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glycomed Incorporated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Icagen, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Biopharmaceuticals Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand JVR, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals (Canada) Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurogen Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OMT I, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OMT II, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OMT, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open Monoclonal Technology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfenex Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacopeia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Technology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Taurus Biosciences, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis (Canada II) Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis (Canada) Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Development Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis plc</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Research Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">xCella Biosciences, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>lgnd_123120xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i658bee461a174786aacaec0103a74e02_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statement (Form S-8 No. 333-252480) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated&#59; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;24, 2021, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December&#160;31, 2020.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2021</font></div><div><font><br></font></div><div style="height:130.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>lgnd_123120xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2cf9d8bd8a674ee4a2c3521fcc2d7f02_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, John L. Higgins, certify that&#58;</font></div><div style="margin-bottom:7pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:11.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;24, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>lgnd_123120xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9ea59a3e3c6b4076af265745caf37748_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Matthew Korenberg, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February&#160;24, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>lgnd_123120xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib8fa0170eee3450e9e30cff0322d6f0c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John L. Higgins, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John L. Higgins</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr><tr style="height:13pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Korenberg</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>lgnd-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails">
        <link:definition>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
        <link:definition>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails">
        <link:definition>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
        <link:definition>2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofVernalisRDandPromactaLicense" roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense">
        <link:definition>2110102 - Disclosure - Sale of Vernalis R&amp;D and Promacta License</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofVernalisRDandPromactaLicenseNarrativeDetails" roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails">
        <link:definition>2411407 - Disclosure - Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsInvestmentinViking" roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking">
        <link:definition>2112103 - Disclosure - Short-term Investments: Investment in Viking</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsInvestmentinVikingNarrativeDetails" roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails">
        <link:definition>2413408 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.ligand.com/role/Acquisitions">
        <link:definition>2114104 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.ligand.com/role/AcquisitionsTables">
        <link:definition>2315302 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2416409 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2417410 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails">
        <link:definition>2418411 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaFinancialInformationDetails" roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails">
        <link:definition>2419412 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAllocationofConsiderationDetails" roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails">
        <link:definition>2420413 - Disclosure - Acquisitions - Allocation of Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.ligand.com/role/FairValueMeasurement">
        <link:definition>2121105 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.ligand.com/role/FairValueMeasurementTables">
        <link:definition>2322303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2423414 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>2424415 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2425416 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ligand.com/role/Leases">
        <link:definition>2126106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ligand.com/role/LeasesTables">
        <link:definition>2327304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ligand.com/role/LeasesNarrativeDetails">
        <link:definition>2428417 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails">
        <link:definition>2429418 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>2430419 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>2430419 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes">
        <link:definition>2131107 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2332305 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails">
        <link:definition>2433420 - Disclosure - Convertible Senior Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails">
        <link:definition>2434421 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails">
        <link:definition>2135108 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>2336306 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInvestmentCategoriesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails">
        <link:definition>2437422 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>2438423 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>2440425 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsPropertyandEquipmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails">
        <link:definition>2441426 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>2442427 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAccruedLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails">
        <link:definition>2443428 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsContingentLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails">
        <link:definition>2444429 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ligand.com/role/StockholdersEquity">
        <link:definition>2145109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ligand.com/role/StockholdersEquityTables">
        <link:definition>2346307 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareBasedCompensationDetails" roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails">
        <link:definition>2447430 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2448431 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionPlanActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails">
        <link:definition>2449432 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityBreakdownofOptionsOutstandingDetails" roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails">
        <link:definition>2450433 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsDetails" roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails">
        <link:definition>2451434 - Disclosure - Stockholders' Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>2452435 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedings" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings">
        <link:definition>2153110 - Disclosure - Commitment and Contingencies: Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedingsNarrativeDetails" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails">
        <link:definition>2454436 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ligand.com/role/IncomeTaxes">
        <link:definition>2155111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ligand.com/role/IncomeTaxesTables">
        <link:definition>2356308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2457437 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2458438 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails">
        <link:definition>2459439 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>2460440 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2461441 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformation" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation">
        <link:definition>2162112 - Disclosure - Summary of Unaudited Quarterly Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformationTables" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables">
        <link:definition>2363309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails">
        <link:definition>2464442 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lgnd_WarrantsSettled" abstract="false" name="WarrantsSettled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_AccruedInventoryPurchases" abstract="false" name="AccruedInventoryPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" abstract="true" name="CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CydexPharmaceuticalsIncMember" abstract="true" name="CydexPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" abstract="true" name="LiabilityForContingentValueRightsCompanyMetabasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_CorporateShareRepurchaseAbstract" abstract="true" name="CorporateShareRepurchaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" abstract="false" name="PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSupplierExpensesCurrent" abstract="false" name="AccruedSupplierExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSubcontractorExpensesCurrent" abstract="false" name="AccruedSubcontractorExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_TwoThousandTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceofConvertibleBondHedge" abstract="false" name="ExercisePriceofConvertibleBondHedge" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" abstract="false" name="NonCashChangeInEstimatedFairValueOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NovanMolluscumProductsMember" abstract="true" name="NovanMolluscumProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AccruedSalesReturns" abstract="false" name="AccruedSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" abstract="false" name="DebtInstrumentAccruedInterestRepurchasedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsPolicyTextBlock" abstract="false" name="CommercialLicenseRightsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRights" abstract="false" name="LiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_XCellaBiosciencesIncMember" abstract="true" name="XCellaBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PurchaseforCommercialLicenseRights" abstract="false" name="PurchaseforCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EmployeeStockPurchasePlanAbstract" abstract="true" name="EmployeeStockPurchasePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHolders" abstract="false" name="PaymentsToContingentValueRightHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolMember" abstract="true" name="MaterialSalesCaptisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" abstract="false" name="FiniteLivedIntangibleAssetsCreditLossAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" abstract="false" name="RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PromactaMember" abstract="true" name="PromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" abstract="true" name="LiabilityForContingentValueRightsCompanyIcagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodOneMember" abstract="true" name="VestingPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInOtherEconomicRights" abstract="false" name="IncreaseDecreaseInOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationContingentValueRights" abstract="false" name="IncomeTaxReconciliationContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AbInitioMember" abstract="true" name="AbInitioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodTwoMember" abstract="true" name="VestingPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" abstract="false" name="MaturityPeriodOfHighlyLiquidSecuritiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_ProductRoyaltyPercentage" abstract="false" name="ProductRoyaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" abstract="true" name="LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_MilestonePaymentsMember" abstract="true" name="MilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" abstract="false" name="AccountsReceivableCreditLossExpenseReversalCOVID" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyEvomelaMember" abstract="true" name="RoyaltyEvomelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_MilestoneMember" abstract="true" name="MilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" abstract="false" name="AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsSIIMember" abstract="true" name="ContractualRelationshipsSIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PfenexMember" abstract="true" name="PfenexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsAlvogenMember" abstract="true" name="ContractualRelationshipsAlvogenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VernalisMember" abstract="true" name="VernalisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotes2019Member" abstract="true" name="ConvertibleSeniorNotes2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationConsiderationTransferredHoldback" abstract="false" name="BusinessCombinationConsiderationTransferredHoldback" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CorMatrixMember" abstract="true" name="CorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityAmountPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" abstract="false" name="AmortizationOfCommercialLicenseAndOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_GainLossOnShortTermInvestments" abstract="false" name="GainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsforConvertibleBondHedges" abstract="false" name="PaymentsforConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsJazzMember" abstract="true" name="ContractualRelationshipsJazzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_TaurusBiosciencesLLCMember" abstract="true" name="TaurusBiosciencesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" abstract="false" name="AccountsReceivableCreditLossExpenseReversalCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" abstract="false" name="DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_PalvellaTherapeuticsIncMember" abstract="true" name="PalvellaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" abstract="false" name="PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LupinPatentInfringementMember" abstract="true" name="LupinPatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsArcellxMember" abstract="true" name="ContractualRelationshipsArcellxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AziyoMember" abstract="true" name="AziyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyOtherMember" abstract="true" name="RoyaltyOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseRights" abstract="false" name="CommercialLicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" abstract="false" name="BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedAssetAcquisitionsCurrent" abstract="false" name="AccruedAssetAcquisitionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInDebtDiscount" abstract="false" name="IncreaseDecreaseInDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContractRevenueMember" abstract="true" name="ContractRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AmendedESPPMember" abstract="true" name="AmendedESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_CurrentPortionOfLiabilityForContingentValueRights" abstract="false" name="CurrentPortionOfLiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LicenseUpfrontPayment" abstract="false" name="LicenseUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IcagenMember" abstract="true" name="IcagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyAgreementExpirationPeriod" abstract="false" name="RoyaltyAgreementExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_AziyoandCorMatrixMember" abstract="true" name="AziyoandCorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ScheduleofContingentLiabilitiesTableTextBlock" abstract="false" name="ScheduleofContingentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" abstract="false" name="PurchaseCommitmentConsiderationPaidAllocatedToInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentValueRightOnProductRevenuesMember" abstract="true" name="ContingentValueRightOnProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_MetabasisTherapeuticsMember" abstract="true" name="MetabasisTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" abstract="true" name="USDistrictCourtForTheNorthernDistrictOfOhioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ContractualRelationshipsMerckMember" abstract="true" name="ContractualRelationshipsMerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidToDate" abstract="false" name="PurchaseCommitmentConsiderationPaidToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_SelexisAndDianomiMember" abstract="true" name="SelexisAndDianomiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ContingentLiabilityRollForward" abstract="true" name="ContingentLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" abstract="true" name="DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" abstract="true" name="EarnoutRightsForPartnerResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyPromactaMember" abstract="true" name="RoyaltyPromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" abstract="true" name="LiabilityForContingentValueRightsCompanyPfenexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeElevenMember" abstract="true" name="ExercisePriceRangeElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" abstract="false" name="ScheduleofCommercialLicenseRightsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_Phase3ClinicalTrialMember" abstract="true" name="Phase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ProceedsFromCommercialLicenseRights" abstract="false" name="ProceedsFromCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" abstract="true" name="LicenseFeesMilestonesAndOtherProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PurchaseOfConvertibleBondHedge" abstract="false" name="PurchaseOfConvertibleBondHedge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" abstract="false" name="BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_NumberOfAcquisitions" abstract="false" name="NumberOfAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotes2023Member" abstract="true" name="ConvertibleSeniorNotes2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsIssued" abstract="false" name="NumberOfContingentValueRightsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" abstract="true" name="ContingentValueRightForInternalResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCydexMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCydexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" abstract="false" name="ForecastedCashFlowsEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" abstract="false" name="DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VikingTherapeuticsInc.Member" abstract="true" name="VikingTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_InvestmentInVikingCurrent" abstract="false" name="InvestmentInVikingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CrystalMember" abstract="true" name="CrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyKyprolisMember" abstract="true" name="RoyaltyKyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>lgnd-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7ecf66f-fb1d-4843-ae41-6a06ac503950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a18ac4b-e30e-4a21-9abd-ca83c0133fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7ecf66f-fb1d-4843-ae41-6a06ac503950" xlink:to="loc_us-gaap_Liabilities_9a18ac4b-e30e-4a21-9abd-ca83c0133fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4878bbbd-89bc-4b20-be1e-2f60abdca121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7ecf66f-fb1d-4843-ae41-6a06ac503950" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4878bbbd-89bc-4b20-be1e-2f60abdca121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3daed4bb-8d85-45ab-86d4-52b23038ddac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7ecf66f-fb1d-4843-ae41-6a06ac503950" xlink:to="loc_us-gaap_StockholdersEquity_3daed4bb-8d85-45ab-86d4-52b23038ddac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d92e497d-571e-41d2-9ba1-5a5d77d085b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:to="loc_us-gaap_PreferredStockValue_d92e497d-571e-41d2-9ba1-5a5d77d085b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d0ee6d2c-3bb6-458d-8f6e-0a47bbd20b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:to="loc_us-gaap_CommonStockValue_d0ee6d2c-3bb6-458d-8f6e-0a47bbd20b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_59e15a30-4a71-4940-b52c-f1275eb86f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_59e15a30-4a71-4940-b52c-f1275eb86f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10685430-4d92-4dc8-a0ae-661be97cea42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10685430-4d92-4dc8-a0ae-661be97cea42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31ab44d6-7e74-4e57-a400-9a318167ee7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59d347a6-d108-4f04-b3a2-2b54fa2b2fe1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31ab44d6-7e74-4e57-a400-9a318167ee7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_290efdf3-cadb-4a6e-bdac-2b428ad7d7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_us-gaap_LiabilitiesCurrent_290efdf3-cadb-4a6e-bdac-2b428ad7d7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3b27a9ae-78f8-47f6-ab7a-466202af9597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_3b27a9ae-78f8-47f6-ab7a-466202af9597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_f593828e-0345-4894-9b17-c833fd49ceb4" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_lgnd_LiabilityForContingentValueRights_f593828e-0345-4894-9b17-c833fd49ceb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7a4a8045-66b8-492d-8456-6892d1d397c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7a4a8045-66b8-492d-8456-6892d1d397c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cb49f80-b964-4d75-b095-7f8ceaec8727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cb49f80-b964-4d75-b095-7f8ceaec8727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5f8cbb2c-aab4-4fff-929a-63327c37ab22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d61baa7d-5463-4b21-a018-505d28bb8f09" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5f8cbb2c-aab4-4fff-929a-63327c37ab22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1dbd73d9-4c57-4860-831a-984833368551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_us-gaap_AccountsPayableCurrent_1dbd73d9-4c57-4860-831a-984833368551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a3d70459-dd6c-4766-aafd-0c12f037af8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a3d70459-dd6c-4766-aafd-0c12f037af8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_3a1a5667-2e4b-4ab3-9c03-d339f2c0c821" xlink:href="lgnd-20201231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_3a1a5667-2e4b-4ab3-9c03-d339f2c0c821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c2163186-c333-410f-ac36-24ecd58908cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c2163186-c333-410f-ac36-24ecd58908cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e6473722-c444-4668-96bd-eb8551b1c93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e6473722-c444-4668-96bd-eb8551b1c93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_43d2666c-e702-4552-adff-3c1c859962cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4cf7e610-dfe3-4512-b0b6-4dd05e55bfa7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_43d2666c-e702-4552-adff-3c1c859962cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f67cd05-2307-4f06-a428-2d064abd3899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f67cd05-2307-4f06-a428-2d064abd3899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_4db1c959-8557-4d22-8e47-b8d4f6847500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_ShortTermInvestments_4db1c959-8557-4d22-8e47-b8d4f6847500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_edf02e6b-1a64-4df8-a01b-4e0733d20c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_edf02e6b-1a64-4df8-a01b-4e0733d20c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0838130-b1ad-4af7-ba89-ea473dfac72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_InventoryNet_e0838130-b1ad-4af7-ba89-ea473dfac72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_65df17a8-6062-4fe7-97a3-d614c8aa43e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_IncomeTaxesReceivable_65df17a8-6062-4fe7-97a3-d614c8aa43e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_342b119b-33db-41bf-b9b1-7ec32ab519bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cf083015-200d-4a8d-a7c1-b605042e040b" xlink:to="loc_us-gaap_OtherAssetsCurrent_342b119b-33db-41bf-b9b1-7ec32ab519bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9dd9af81-ef44-4c8f-b663-aadd3ecef9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_AssetsCurrent_9dd9af81-ef44-4c8f-b663-aadd3ecef9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c41babc1-3e06-435e-9794-deb6624cdc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c41babc1-3e06-435e-9794-deb6624cdc1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1dc7de0c-7dba-4b1d-86e5-60779846fd43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1dc7de0c-7dba-4b1d-86e5-60779846fd43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_af65d065-3b7e-4574-9ebd-98922eec9423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_Goodwill_af65d065-3b7e-4574-9ebd-98922eec9423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_17ebb4fd-1c40-451b-a6d9-4e92a40bcb48" xlink:href="lgnd-20201231.xsd#lgnd_CommercialLicenseRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_lgnd_CommercialLicenseRights_17ebb4fd-1c40-451b-a6d9-4e92a40bcb48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6d08b4ac-1d2f-447a-8ee8-65ef1d4cbb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6d08b4ac-1d2f-447a-8ee8-65ef1d4cbb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8caaa1b5-26d3-4749-8666-1a79e05bce4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8caaa1b5-26d3-4749-8666-1a79e05bce4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c6830402-fd61-404d-af53-bfeddc4ee35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c6830402-fd61-404d-af53-bfeddc4ee35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e0c4634-25ee-43ce-9b50-731b7e195cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_605d5db3-0b7f-4136-8030-90afbcae113b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e0c4634-25ee-43ce-9b50-731b7e195cee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf6527fe-2bbb-4910-b3c3-1f37e13110af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cd37d6f1-e885-4ba1-90e0-8a0661d98b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bf6527fe-2bbb-4910-b3c3-1f37e13110af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cd37d6f1-e885-4ba1-90e0-8a0661d98b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2ed73631-6de6-4e77-90be-a8504e5ee9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bf6527fe-2bbb-4910-b3c3-1f37e13110af" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2ed73631-6de6-4e77-90be-a8504e5ee9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c17b024f-b5e3-42e0-822f-6fd9822490e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bf6527fe-2bbb-4910-b3c3-1f37e13110af" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c17b024f-b5e3-42e0-822f-6fd9822490e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bfaa7231-1b83-4784-bed0-bbbe1bb05930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_26f4d92e-e04c-4e84-9b56-ec0513c6dda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bfaa7231-1b83-4784-bed0-bbbe1bb05930" xlink:to="loc_us-gaap_OperatingIncomeLoss_26f4d92e-e04c-4e84-9b56-ec0513c6dda3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3d606cd9-03b5-4482-a44e-8d8aa0abec4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bfaa7231-1b83-4784-bed0-bbbe1bb05930" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3d606cd9-03b5-4482-a44e-8d8aa0abec4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc800c79-704b-42b6-a35d-d86d5f36168d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b15ab02e-1d4c-4f98-9084-44ba3eb68d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fc800c79-704b-42b6-a35d-d86d5f36168d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b15ab02e-1d4c-4f98-9084-44ba3eb68d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_797b82e1-a18d-45b5-82e5-6abbd61a3a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fc800c79-704b-42b6-a35d-d86d5f36168d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_797b82e1-a18d-45b5-82e5-6abbd61a3a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4d52851e-71cb-440e-9580-2a81554d8025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7449cf88-ace0-4547-a274-801b29b2d09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d52851e-71cb-440e-9580-2a81554d8025" xlink:to="loc_us-gaap_GainLossOnInvestments_7449cf88-ace0-4547-a274-801b29b2d09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_62ebeaea-31ae-4b33-9f35-c4b90c56fbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d52851e-71cb-440e-9580-2a81554d8025" xlink:to="loc_us-gaap_InvestmentIncomeInterest_62ebeaea-31ae-4b33-9f35-c4b90c56fbf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e031fb08-74aa-4c4a-856e-b5259c65fcae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d52851e-71cb-440e-9580-2a81554d8025" xlink:to="loc_us-gaap_InterestExpense_e031fb08-74aa-4c4a-856e-b5259c65fcae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0fec6651-d9aa-46cd-8e75-9aa401977fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d52851e-71cb-440e-9580-2a81554d8025" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0fec6651-d9aa-46cd-8e75-9aa401977fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_52f104fd-f50c-46e8-b0f4-afcfcaabad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_b250f2ca-6f3c-4772-baeb-75fc7a30f9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_52f104fd-f50c-46e8-b0f4-afcfcaabad3d" xlink:to="loc_us-gaap_CostDirectMaterial_b250f2ca-6f3c-4772-baeb-75fc7a30f9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_274dffcd-6628-4bae-8de2-4ac77e8b1d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_52f104fd-f50c-46e8-b0f4-afcfcaabad3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_274dffcd-6628-4bae-8de2-4ac77e8b1d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_24730559-a8ed-4131-ac43-6ed1a3c1bd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_52f104fd-f50c-46e8-b0f4-afcfcaabad3d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_24730559-a8ed-4131-ac43-6ed1a3c1bd46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1f5c9615-67cc-43c1-bef4-7ec47f69ec8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_52f104fd-f50c-46e8-b0f4-afcfcaabad3d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1f5c9615-67cc-43c1-bef4-7ec47f69ec8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b781a409-8c8f-40a8-8040-268faaec3925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dedc4705-4eff-43b7-b53d-65a335c77ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b781a409-8c8f-40a8-8040-268faaec3925" xlink:to="loc_us-gaap_NetIncomeLoss_dedc4705-4eff-43b7-b53d-65a335c77ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2885711b-185e-48ed-9ce8-489e5719ecab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b781a409-8c8f-40a8-8040-268faaec3925" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2885711b-185e-48ed-9ce8-489e5719ecab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49281e76-9055-42e3-a9e7-9de08f29fcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b781a409-8c8f-40a8-8040-268faaec3925" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49281e76-9055-42e3-a9e7-9de08f29fcca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5c68f7bf-cd88-4c39-a7ca-0ab6a6a1ad06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5c68f7bf-cd88-4c39-a7ca-0ab6a6a1ad06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_0ab623b9-4dd8-453d-a2c4-b8e6824af086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_0ab623b9-4dd8-453d-a2c4-b8e6824af086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_ff4d0d2b-e983-458d-aa0b-fefa80dd0129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_ff4d0d2b-e983-458d-aa0b-fefa80dd0129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_c73f88fa-1810-4f9d-bd60-4c07d09697fe" xlink:href="lgnd-20201231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_c73f88fa-1810-4f9d-bd60-4c07d09697fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea752075-14d2-4c9a-b4bf-f535c9413657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea752075-14d2-4c9a-b4bf-f535c9413657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_002fd675-2148-430a-b562-a780879878b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_002fd675-2148-430a-b562-a780879878b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8904f528-222c-4ba6-8dc5-5e5d32576b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8904f528-222c-4ba6-8dc5-5e5d32576b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_7bf5e817-a722-4a4d-8c5a-122998e0ab6d" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_7bf5e817-a722-4a4d-8c5a-122998e0ab6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_64093d2b-9bbb-45a9-a970-31f55397a63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_64093d2b-9bbb-45a9-a970-31f55397a63e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5c3a835e-5552-4aa7-bd01-3c63bf614890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5c3a835e-5552-4aa7-bd01-3c63bf614890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f874228a-ed4a-4420-92bb-cd556aecd99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f874228a-ed4a-4420-92bb-cd556aecd99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4ccbf454-926e-4b71-906e-9b4fdc897666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84ab4f74-c717-4643-9ec3-09ee00fad9d9" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4ccbf454-926e-4b71-906e-9b4fdc897666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_56f9636e-dfa5-475d-848e-a1f4b13d38d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_56f9636e-dfa5-475d-848e-a1f4b13d38d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3c8583ba-d401-445f-bc13-a8432cb25bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3c8583ba-d401-445f-bc13-a8432cb25bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_aab15e70-6edc-48ea-9320-298e62bfff87" xlink:href="lgnd-20201231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_aab15e70-6edc-48ea-9320-298e62bfff87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_144d68a7-2bce-4319-8cdb-ee717ae697b4" xlink:href="lgnd-20201231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_144d68a7-2bce-4319-8cdb-ee717ae697b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_407cacec-e8ba-44dd-9e5b-eac5287854b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_407cacec-e8ba-44dd-9e5b-eac5287854b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0c70ca59-981b-4c55-81ae-f4f9cb2b6f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0c70ca59-981b-4c55-81ae-f4f9cb2b6f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_c306bc17-fe60-4c0a-b8e2-a1d4c6145d78" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_c306bc17-fe60-4c0a-b8e2-a1d4c6145d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_42da8f88-3fdc-466b-81ad-e3af61099bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_42da8f88-3fdc-466b-81ad-e3af61099bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e717da9-9e43-430d-bdb8-2cf668016ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e717da9-9e43-430d-bdb8-2cf668016ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5c6117f9-754b-4bb0-bf20-4f702fbb7164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5c6117f9-754b-4bb0-bf20-4f702fbb7164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b1934b23-27e8-4569-8312-b32a4c53040d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b1934b23-27e8-4569-8312-b32a4c53040d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_395928e5-1308-44c2-b0be-c8754104c249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_395928e5-1308-44c2-b0be-c8754104c249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cb0155bd-16a3-416e-b82a-d00496f4189f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_ShareBasedCompensation_cb0155bd-16a3-416e-b82a-d00496f4189f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4d01265a-0819-4221-bbbb-35e2f30f524a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4d01265a-0819-4221-bbbb-35e2f30f524a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_b33c0770-2cc7-4c30-9a4d-c9c36e8986c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_b33c0770-2cc7-4c30-9a4d-c9c36e8986c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_5ab2239b-0c99-437f-9d67-be21e4956f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_5ab2239b-0c99-437f-9d67-be21e4956f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_ff82956d-7940-4733-99c1-bfb22e246bac" xlink:href="lgnd-20201231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_ff82956d-7940-4733-99c1-bfb22e246bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_72e89a09-7f10-41f6-8e16-eff6a599f524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_ProfitLoss_72e89a09-7f10-41f6-8e16-eff6a599f524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7d54b731-894b-4ff5-901b-1e0df91dacff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7d54b731-894b-4ff5-901b-1e0df91dacff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_8f8e2a97-7723-41bd-b178-3d155296006f" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d64c8c3-cc1f-47dc-832a-13ff5a166696" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_8f8e2a97-7723-41bd-b178-3d155296006f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_935bec60-c80f-4630-9b59-278502c68524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_935bec60-c80f-4630-9b59-278502c68524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0bc3ded6-0270-400d-82b9-5748325c5026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0bc3ded6-0270-400d-82b9-5748325c5026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60e22aee-c4b7-4692-8f60-c04766222bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60e22aee-c4b7-4692-8f60-c04766222bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge_8a17243b-acd4-4c1f-8333-c36b0283c283" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_lgnd_PurchaseOfConvertibleBondHedge_8a17243b-acd4-4c1f-8333-c36b0283c283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_3428964f-7ef9-44b1-b59c-ec7e80291ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_3428964f-7ef9-44b1-b59c-ec7e80291ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_57d874e7-8e60-4c5b-b41a-124742feb9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_57d874e7-8e60-4c5b-b41a-124742feb9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_e60986d8-ea4f-422e-887c-0a2d3829ae85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_e60986d8-ea4f-422e-887c-0a2d3829ae85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7d702f09-293e-4f0d-ad19-9e09f0d218bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7d702f09-293e-4f0d-ad19-9e09f0d218bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_18214e18-45cb-43e7-af10-03350124a25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_18214e18-45cb-43e7-af10-03350124a25c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_c5ecf405-f835-454d-a250-6b516ba1c99c" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_c5ecf405-f835-454d-a250-6b516ba1c99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_d08458ea-9df4-4f2e-878b-b743b88eb20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_d08458ea-9df4-4f2e-878b-b743b88eb20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c93c062-7e0e-4293-9889-7699fce85d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c93c062-7e0e-4293-9889-7699fce85d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1fcd35b9-0f95-413a-a39b-1ddd16bd7222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4bc87782-9c13-44ee-9314-8fb4d460a66e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1fcd35b9-0f95-413a-a39b-1ddd16bd7222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c3132009-0d30-4182-8c8f-8666552eca48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8e4bb8b-bfd0-496d-ad2a-d30921bcf14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c3132009-0d30-4182-8c8f-8666552eca48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8e4bb8b-bfd0-496d-ad2a-d30921bcf14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34e816cd-90fd-4be1-b22b-2ab936e11135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c3132009-0d30-4182-8c8f-8666552eca48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34e816cd-90fd-4be1-b22b-2ab936e11135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475e6370-32d6-4c2e-b62e-dbc769e6cd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c3132009-0d30-4182-8c8f-8666552eca48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475e6370-32d6-4c2e-b62e-dbc769e6cd9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8f900f65-7bd3-46c2-bc04-9c723a4cb5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_891418c1-7fa0-4d9c-8b27-6ca4a5afb260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8f900f65-7bd3-46c2-bc04-9c723a4cb5a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_891418c1-7fa0-4d9c-8b27-6ca4a5afb260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_84631b1a-c457-4218-948d-786c8cbdbe32" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8f900f65-7bd3-46c2-bc04-9c723a4cb5a7" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_84631b1a-c457-4218-948d-786c8cbdbe32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a1d425b7-9330-4e0e-9d10-5f6a0f1c7bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a1d425b7-9330-4e0e-9d10-5f6a0f1c7bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_fe98b644-1c5d-4f69-9ebd-2bc04ae6fa7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_fe98b644-1c5d-4f69-9ebd-2bc04ae6fa7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_27bd3585-2147-4642-949f-444783443b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_27bd3585-2147-4642-949f-444783443b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15042563-1631-4e17-a00b-c3efd25a0c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15042563-1631-4e17-a00b-c3efd25a0c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_38e3b48d-a8a6-401b-9fe9-e0a130aa73e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8cefe823-34ac-429e-89f9-5ca8560ce59b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_38e3b48d-a8a6-401b-9fe9-e0a130aa73e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicense"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicenseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinViking"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinVikingNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisitions" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_61467198-4d40-41f1-825b-ea13c587f4ef" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_61467198-4d40-41f1-825b-ea13c587f4ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_09d7ab23-e7c4-4bda-a7f5-7500bc5ca212" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_09d7ab23-e7c4-4bda-a7f5-7500bc5ca212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e29818c3-bbfe-4e40-81b2-f7c91c009906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e29818c3-bbfe-4e40-81b2-f7c91c009906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d8138f7-74f1-4fad-91da-c655ede4b77e" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d8138f7-74f1-4fad-91da-c655ede4b77e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_80cd340a-0e54-4d92-9a93-65cd432db2a2" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_80cd340a-0e54-4d92-9a93-65cd432db2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b5526ce-77bf-4062-9f2b-b9800d48b770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b5526ce-77bf-4062-9f2b-b9800d48b770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2df8e034-19fc-4a20-bae5-4fafd613630a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2df8e034-19fc-4a20-bae5-4fafd613630a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4b351e27-abc9-4f51-a1c9-035d5f32b5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4b351e27-abc9-4f51-a1c9-035d5f32b5a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_73d5b949-2419-4681-869b-bc6964a9dd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_73d5b949-2419-4681-869b-bc6964a9dd40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d967cd8-0cba-4de1-a79d-4c3f2fb26082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d967cd8-0cba-4de1-a79d-4c3f2fb26082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c7e73ee3-4329-4c12-bbb3-b06c0f70dc90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c7e73ee3-4329-4c12-bbb3-b06c0f70dc90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c9628723-7f59-4c1b-8a74-49b6824f1e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_Goodwill_c9628723-7f59-4c1b-8a74-49b6824f1e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6af3d490-708e-4308-8909-499aab763650" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6af3d490-708e-4308-8909-499aab763650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b89bcabe-f705-4a16-b42c-6a75736ad156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_33a21347-d65e-46e0-a207-978eb75f85ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b89bcabe-f705-4a16-b42c-6a75736ad156" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsProFormaFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAllocationofConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_851ecc6b-181f-46c7-be50-583a1585b09d" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_049148c6-f795-4d4d-a0f1-174f8b51aa33" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_851ecc6b-181f-46c7-be50-583a1585b09d" xlink:to="loc_lgnd_LeaseLiabilityCurrent_049148c6-f795-4d4d-a0f1-174f8b51aa33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_203f1f2e-b5a5-4cad-886d-94e2d8dd9ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_851ecc6b-181f-46c7-be50-583a1585b09d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_203f1f2e-b5a5-4cad-886d-94e2d8dd9ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7dd4f73f-af27-4fba-bfa3-894102231a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_851ecc6b-181f-46c7-be50-583a1585b09d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7dd4f73f-af27-4fba-bfa3-894102231a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_03424cb0-1fbc-461b-8148-daaa75d8458d" xlink:href="lgnd-20201231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c44dca53-9b7d-4425-8271-25a6f342a618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_03424cb0-1fbc-461b-8148-daaa75d8458d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c44dca53-9b7d-4425-8271-25a6f342a618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c6fc269f-3d6a-45e1-a7bd-f679019a1184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_03424cb0-1fbc-461b-8148-daaa75d8458d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c6fc269f-3d6a-45e1-a7bd-f679019a1184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_ee087a89-462a-48fe-9ed1-aa6fb89dbd3d" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_598223e2-012f-4a57-b711-77655a27ea96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_ee087a89-462a-48fe-9ed1-aa6fb89dbd3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_598223e2-012f-4a57-b711-77655a27ea96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ad2e624a-797d-456d-97aa-3ac801534a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_ee087a89-462a-48fe-9ed1-aa6fb89dbd3d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ad2e624a-797d-456d-97aa-3ac801534a67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6a024fd0-c2f8-44e1-8419-341dd8accd43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6a024fd0-c2f8-44e1-8419-341dd8accd43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e1b92bf5-c16e-4c68-b796-b4b9d7e0cedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e1b92bf5-c16e-4c68-b796-b4b9d7e0cedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cca5ff7d-4588-4954-b2c6-bd0844ed4018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cca5ff7d-4588-4954-b2c6-bd0844ed4018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_097ab669-d9b9-49ac-af38-4f10ebd972b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_097ab669-d9b9-49ac-af38-4f10ebd972b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_81be073d-ca87-4c15-a801-f554aa3a23a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_81be073d-ca87-4c15-a801-f554aa3a23a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b698cded-42eb-4cc7-8175-08b77b278773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_198cf99e-c535-4a91-91ae-26097f1effae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b698cded-42eb-4cc7-8175-08b77b278773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45d954bf-523a-46e5-9a47-86d4c2e82313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45d954bf-523a-46e5-9a47-86d4c2e82313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4f53b72-d919-49ac-ada6-67f93c27b3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4f53b72-d919-49ac-ada6-67f93c27b3c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef04d812-3de6-45df-bb12-e69079896ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef04d812-3de6-45df-bb12-e69079896ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1958250a-e873-463a-9519-483caff6e17b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1958250a-e873-463a-9519-483caff6e17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e5c5b0a4-d146-4009-bce8-7540f72f2cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e5c5b0a4-d146-4009-bce8-7540f72f2cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b268e21-849a-4a1d-afa1-15de2947c82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e05ac547-6eca-43e8-b76e-55bafe78ff24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b268e21-849a-4a1d-afa1-15de2947c82b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ea26164a-e15b-405a-8353-cd4445d045ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_431f49b7-3ab7-4ba7-991d-1d7c36085229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ea26164a-e15b-405a-8353-cd4445d045ba" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_431f49b7-3ab7-4ba7-991d-1d7c36085229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_c095201a-eb2f-4750-abc3-15112c859ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ea26164a-e15b-405a-8353-cd4445d045ba" xlink:to="loc_us-gaap_FinanceLeaseLiability_c095201a-eb2f-4750-abc3-15112c859ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_514e9b75-3950-4aaa-bdf8-186a572ca071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ac5848ff-eab8-4ecb-b05e-4a856ca62019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_514e9b75-3950-4aaa-bdf8-186a572ca071" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ac5848ff-eab8-4ecb-b05e-4a856ca62019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bba9c905-08f6-43eb-8af8-e5176a2d8e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_514e9b75-3950-4aaa-bdf8-186a572ca071" xlink:to="loc_us-gaap_OperatingLeaseLiability_bba9c905-08f6-43eb-8af8-e5176a2d8e27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ddcd40a9-fa06-4bbf-97b6-dc6c6738023c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1cdceeeb-a3fb-4f91-9763-15780eacf30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ddcd40a9-fa06-4bbf-97b6-dc6c6738023c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1cdceeeb-a3fb-4f91-9763-15780eacf30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6afa7fc1-2ae2-4109-8a19-fbbdd48d3c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ddcd40a9-fa06-4bbf-97b6-dc6c6738023c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6afa7fc1-2ae2-4109-8a19-fbbdd48d3c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e0f7d2-0467-4d10-bd06-141c11680424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ddcd40a9-fa06-4bbf-97b6-dc6c6738023c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e0f7d2-0467-4d10-bd06-141c11680424" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_03c72f87-a8b0-4942-b784-bb26376d41e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2fc8f5d3-5ca0-43a6-a911-1b16c4f820d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_03c72f87-a8b0-4942-b784-bb26376d41e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2fc8f5d3-5ca0-43a6-a911-1b16c4f820d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_75627a7a-cc44-4334-9416-a4ce858e222a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_03c72f87-a8b0-4942-b784-bb26376d41e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_75627a7a-cc44-4334-9416-a4ce858e222a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_d884e4d7-fccf-43b6-b31d-7fdc493b7a98" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_03c72f87-a8b0-4942-b784-bb26376d41e2" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_d884e4d7-fccf-43b6-b31d-7fdc493b7a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8fc62787-401f-4f0f-9590-d5727a2d432f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_699653af-bbdd-43c1-bae3-ef8e1d7fff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8fc62787-401f-4f0f-9590-d5727a2d432f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_699653af-bbdd-43c1-bae3-ef8e1d7fff20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_3f8e33cd-a9aa-40ff-82c4-dd22acf6a73e" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8fc62787-401f-4f0f-9590-d5727a2d432f" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_3f8e33cd-a9aa-40ff-82c4-dd22acf6a73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04911506-cfeb-4305-8a37-39fbb1c5e2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8fc62787-401f-4f0f-9590-d5727a2d432f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04911506-cfeb-4305-8a37-39fbb1c5e2a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_678ea61c-ad3c-406d-b835-ad3373ed7c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_04508175-1041-47e1-a4b7-a0a55779409f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_678ea61c-ad3c-406d-b835-ad3373ed7c3d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_04508175-1041-47e1-a4b7-a0a55779409f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1b45e713-373b-4c9f-93f7-184852f8832a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_678ea61c-ad3c-406d-b835-ad3373ed7c3d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1b45e713-373b-4c9f-93f7-184852f8832a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3138b10a-0522-4cd8-9bbd-bbde63544ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_246516f5-0e71-476e-9944-8af6dad6d28c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3138b10a-0522-4cd8-9bbd-bbde63544ff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_246516f5-0e71-476e-9944-8af6dad6d28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_edb3366b-3746-414b-9cc2-357f4db190f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3138b10a-0522-4cd8-9bbd-bbde63544ff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_edb3366b-3746-414b-9cc2-357f4db190f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0daa05f1-5f46-43e1-8f9e-feb05e45cf2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7baa50e5-f7d3-4ab2-90e2-c86d45b4138b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0daa05f1-5f46-43e1-8f9e-feb05e45cf2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7baa50e5-f7d3-4ab2-90e2-c86d45b4138b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2854d7bf-daf5-4f0f-b779-47279cf9cdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0daa05f1-5f46-43e1-8f9e-feb05e45cf2c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2854d7bf-daf5-4f0f-b779-47279cf9cdf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_803529d6-d990-4522-a108-521550d90520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8e9d695f-23c5-494c-aa3d-87ba9250dc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_803529d6-d990-4522-a108-521550d90520" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8e9d695f-23c5-494c-aa3d-87ba9250dc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf2300dd-346b-43a5-9e23-72928aa76b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_803529d6-d990-4522-a108-521550d90520" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf2300dd-346b-43a5-9e23-72928aa76b5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f04d74ab-e863-44c3-909f-f33c4bbf8988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f04d74ab-e863-44c3-909f-f33c4bbf8988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_cf10a414-1980-4b5d-844a-6353efd54556" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSalesReturns"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_lgnd_AccruedSalesReturns_cf10a414-1980-4b5d-844a-6353efd54556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_d3b0936f-56bc-4fbe-922d-a287eb52fce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_d3b0936f-56bc-4fbe-922d-a287eb52fce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent_d34a34a8-6be9-48d8-a954-75c3d5fa2d11" xlink:href="lgnd-20201231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_lgnd_AccruedAssetAcquisitionsCurrent_d34a34a8-6be9-48d8-a954-75c3d5fa2d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_12d7e223-73be-4335-a556-6ac27da7f07f" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_12d7e223-73be-4335-a556-6ac27da7f07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_08414e5b-85da-4612-ad42-88944749aa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_08414e5b-85da-4612-ad42-88944749aa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_c9f88b3d-001b-4ac3-b902-7b1d22d6875a" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_c9f88b3d-001b-4ac3-b902-7b1d22d6875a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_7b88e3a7-8ce6-4f9c-8039-147f7c65ecaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_7b88e3a7-8ce6-4f9c-8039-147f7c65ecaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_98255b88-2556-46a5-bf27-4d22f157c7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_19560911-e3f4-411c-85b1-37f03034b3c3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_98255b88-2556-46a5-bf27-4d22f157c7df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_39bba428-5344-4935-878c-b172e127246d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27fb903a-bdb0-49e7-9112-f5fbd20b5671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_39bba428-5344-4935-878c-b172e127246d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27fb903a-bdb0-49e7-9112-f5fbd20b5671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4d45c5eb-d1f1-4cd6-85db-f4c136947fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_39bba428-5344-4935-878c-b172e127246d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4d45c5eb-d1f1-4cd6-85db-f4c136947fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_066c5466-5267-4643-a36f-77f2a85fc1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_39bba428-5344-4935-878c-b172e127246d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_066c5466-5267-4643-a36f-77f2a85fc1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19abad39-ea3b-4e18-8c27-525b6c90a66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b7ecb8d1-b35e-493c-8923-99fe06fed51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19abad39-ea3b-4e18-8c27-525b6c90a66c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b7ecb8d1-b35e-493c-8923-99fe06fed51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e16a2b7c-16b6-4e94-9eaa-38d78286e095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19abad39-ea3b-4e18-8c27-525b6c90a66c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e16a2b7c-16b6-4e94-9eaa-38d78286e095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cb8542cc-86ee-44ca-bc7b-21b544bb39bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19abad39-ea3b-4e18-8c27-525b6c90a66c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cb8542cc-86ee-44ca-bc7b-21b544bb39bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_86545957-26c6-4232-9196-d1db9ceec80e" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_86545957-26c6-4232-9196-d1db9ceec80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_e346c53b-500f-4fe4-a616-ff6865a3f175" xlink:href="lgnd-20201231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_e346c53b-500f-4fe4-a616-ff6865a3f175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7209d07d-f4e8-4d5d-b5db-1886bdf81479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7209d07d-f4e8-4d5d-b5db-1886bdf81479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9d6757e7-2c6f-473b-93b8-721d32b400eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9d6757e7-2c6f-473b-93b8-721d32b400eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_814f355f-7a05-40ea-a153-8cd3f0ccf283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_814f355f-7a05-40ea-a153-8cd3f0ccf283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_3bb5c12f-7c0a-4475-a306-98a3d7d4f428" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_3bb5c12f-7c0a-4475-a306-98a3d7d4f428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_af66ec05-7ab3-40a1-a43b-ae256b53b9a3" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_af66ec05-7ab3-40a1-a43b-ae256b53b9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e7d5383b-63b5-493d-a942-6ce0e1fd7bc3" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e7d5383b-63b5-493d-a942-6ce0e1fd7bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a5489a46-d0cf-4830-9d2b-f77a3618e44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a5489a46-d0cf-4830-9d2b-f77a3618e44e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_41b9ee0e-9d59-4f69-8fbf-ff20672e4245" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_41b9ee0e-9d59-4f69-8fbf-ff20672e4245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_786522fb-8bdf-483d-ae36-a29f161c8ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_786522fb-8bdf-483d-ae36-a29f161c8ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d398a0db-2e59-4068-9f6e-8d7cb25f121a" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d398a0db-2e59-4068-9f6e-8d7cb25f121a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_645d4e43-aad4-4a65-8bf0-1887af275698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_645d4e43-aad4-4a65-8bf0-1887af275698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9affb555-539b-4944-a676-38bbd0f7d842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9affb555-539b-4944-a676-38bbd0f7d842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_8b79b80c-8168-40d4-9590-5c9e50a30646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cd48fe2-b1b8-4e8d-9a60-b9cceaec9936" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_8b79b80c-8168-40d4-9590-5c9e50a30646" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_36e7eec6-4492-4bca-bdaa-49cf55b17023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a4d2054d-8802-48a5-bc82-4f95c22cb6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_36e7eec6-4492-4bca-bdaa-49cf55b17023" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a4d2054d-8802-48a5-bc82-4f95c22cb6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_798e1cb9-3480-482c-958c-402b960b6b66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_36e7eec6-4492-4bca-bdaa-49cf55b17023" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_798e1cb9-3480-482c-958c-402b960b6b66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d4d0f541-de7b-4a29-9734-39fb3756a642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_cb0600a6-c7d3-4da6-ba7f-1798236a2be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0f541-de7b-4a29-9734-39fb3756a642" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_cb0600a6-c7d3-4da6-ba7f-1798236a2be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6134283e-de0e-451f-9932-b78e889cc42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0f541-de7b-4a29-9734-39fb3756a642" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6134283e-de0e-451f-9932-b78e889cc42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723e79e9-41a3-4379-af98-28d527ca40f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0f541-de7b-4a29-9734-39fb3756a642" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723e79e9-41a3-4379-af98-28d527ca40f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852e63c0-d7e5-4ff6-9a6b-c73f20d1fdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0f541-de7b-4a29-9734-39fb3756a642" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852e63c0-d7e5-4ff6-9a6b-c73f20d1fdc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a5efd397-c81b-4a2d-bfdc-86c0a22c57c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e2f3595d-4e03-4368-854b-5d657b23d60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a5efd397-c81b-4a2d-bfdc-86c0a22c57c7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e2f3595d-4e03-4368-854b-5d657b23d60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e861a7b-8d71-4cfa-b31f-eefa0c625ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a5efd397-c81b-4a2d-bfdc-86c0a22c57c7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e861a7b-8d71-4cfa-b31f-eefa0c625ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7aae0166-322b-4c4d-bc30-4190c195731d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_604b3bf9-f57b-4e53-87a1-521ca8f71ea4" xlink:href="lgnd-20201231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7aae0166-322b-4c4d-bc30-4190c195731d" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_604b3bf9-f57b-4e53-87a1-521ca8f71ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_882f66b4-a9ff-4282-9b37-06f2d7a78236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7aae0166-322b-4c4d-bc30-4190c195731d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_882f66b4-a9ff-4282-9b37-06f2d7a78236" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>lgnd-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended" id="i7fdd1299a58f4edda63b76aac0246734_CoverPage"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i6bccaa1549e64f6a8437607c936e9482_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i982b835e454b41c7b159bca7085d5e38_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="if89048a1c4044b269debf7131ea24523_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_379790ed-32a9-4065-98b6-b03189fad7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_379790ed-32a9-4065-98b6-b03189fad7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_9f05b362-0d83-4e12-9c1a-62e52ddc6473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_CostDirectMaterial_9f05b362-0d83-4e12-9c1a-62e52ddc6473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_c95ff4e3-8ce9-4b08-83d9-d38ef88c68c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_c95ff4e3-8ce9-4b08-83d9-d38ef88c68c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3679ce53-7606-41fe-8ae7-daa8aafcfe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3679ce53-7606-41fe-8ae7-daa8aafcfe54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_751ccd8a-c4a5-4f28-a73d-71e787bf054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_751ccd8a-c4a5-4f28-a73d-71e787bf054a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_61441d2c-86ab-4a8c-94a5-833b0c691e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_61441d2c-86ab-4a8c-94a5-833b0c691e7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c2d96c8b-905c-4266-9e3b-409d477f82ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c2d96c8b-905c-4266-9e3b-409d477f82ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29a6e20f-a452-4706-9a02-2b31c037e0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_29a6e20f-a452-4706-9a02-2b31c037e0f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d30b18d1-8168-4a2f-8a1f-af1b7915d147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_GainLossOnInvestments_d30b18d1-8168-4a2f-8a1f-af1b7915d147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6c4f64f6-588d-44b5-a948-ff9a260d95b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6c4f64f6-588d-44b5-a948-ff9a260d95b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8a3872b4-5015-4cea-9b42-8051029471b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_InterestExpense_8a3872b4-5015-4cea-9b42-8051029471b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7afd6e80-5d9d-4b10-9961-3f40774bb305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7afd6e80-5d9d-4b10-9961-3f40774bb305" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3996cc21-4c00-4e66-9830-047f4168dfc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3996cc21-4c00-4e66-9830-047f4168dfc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d56b4b79-57e6-4b9f-8737-4ff3172da820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d56b4b79-57e6-4b9f-8737-4ff3172da820" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0afb3af8-f662-4459-a4bb-bd22fcf8fef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0afb3af8-f662-4459-a4bb-bd22fcf8fef9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92562afb-1ff2-40d0-9d51-f7f515bd2315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_NetIncomeLoss_92562afb-1ff2-40d0-9d51-f7f515bd2315" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e082183e-bfa0-4700-a88d-4385727dc20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_EarningsPerShareBasic_e082183e-bfa0-4700-a88d-4385727dc20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f9278d4-5204-433b-88b3-7c496cc390c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f9278d4-5204-433b-88b3-7c496cc390c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aadfcf85-928a-4601-92d6-a102a69c112f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aadfcf85-928a-4601-92d6-a102a69c112f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6b72b9-c82e-4656-9788-c55298fb6002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6b72b9-c82e-4656-9788-c55298fb6002" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:to="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17d47941-9377-40ad-a0c9-03e5245388b0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:to="loc_srt_ProductsAndServicesDomain_17d47941-9377-40ad-a0c9-03e5245388b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:to="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4949a949-93aa-4052-a7c3-0e91aeafa7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_us-gaap_RoyaltyMember_4949a949-93aa-4052-a7c3-0e91aeafa7df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_079e6c87-7b0c-4df0-816b-2d3b395dedfd" xlink:href="lgnd-20201231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_079e6c87-7b0c-4df0-816b-2d3b395dedfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_828084d3-0ba6-4c90-b97a-233dc3a691b2" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_ContractRevenueMember_828084d3-0ba6-4c90-b97a-233dc3a691b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_9296ad74-5897-4252-b401-34237d8b446f" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_VernalisMember_9296ad74-5897-4252-b401-34237d8b446f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_9e4e3644-7066-49f5-b347-cc5900fa5d6b" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_PromactaMember_9e4e3644-7066-49f5-b347-cc5900fa5d6b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="i11dd339923304f4f94ffc9353db251be_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i49e7c4d2c5884c239a1b7783d7637fcc_CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d71c5cb3-56f4-4006-8385-d08c794f1fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d71c5cb3-56f4-4006-8385-d08c794f1fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3dec75da-7e62-4485-bf39-25841657fb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_SharesOutstanding_3dec75da-7e62-4485-bf39-25841657fb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cf2457-11af-4095-b82c-c1a4dfc827ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cf2457-11af-4095-b82c-c1a4dfc827ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0b97be1a-4eed-4c2f-8f9e-364845ae37aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0b97be1a-4eed-4c2f-8f9e-364845ae37aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b396177-5c59-438c-ba57-1cada06d6452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b396177-5c59-438c-ba57-1cada06d6452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_94e5fcab-86cc-4f2f-bcc7-42ace00918e1" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_94e5fcab-86cc-4f2f-bcc7-42ace00918e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dfc0ebea-dc78-408a-85ab-b1a3dad8560b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dfc0ebea-dc78-408a-85ab-b1a3dad8560b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_430ef1b7-9cfe-4229-99b8-cacdaa3943a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_430ef1b7-9cfe-4229-99b8-cacdaa3943a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b14c0741-3fb7-43db-887b-ff76ce630fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b14c0741-3fb7-43db-887b-ff76ce630fc4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_099ef6d5-8409-453a-880a-a174fbd3c9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_099ef6d5-8409-453a-880a-a174fbd3c9c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_e43a4e2d-dff4-40c6-b39c-273adec16b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_e43a4e2d-dff4-40c6-b39c-273adec16b6e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_102d051c-a27d-413b-831a-d9448a95c264" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_102d051c-a27d-413b-831a-d9448a95c264" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_eaddd76a-c50f-4da6-90c4-060c36a988a0" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_eaddd76a-c50f-4da6-90c4-060c36a988a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_712ccc9d-8b70-4b20-a669-58c9c4a60b5a" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_712ccc9d-8b70-4b20-a669-58c9c4a60b5a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_0db1c792-71c0-42a9-9440-36b8b2f8d554" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_0db1c792-71c0-42a9-9440-36b8b2f8d554" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_efcbbe5c-ea2d-4be0-a02f-64ba54134b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_efcbbe5c-ea2d-4be0-a02f-64ba54134b64" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d028d65e-5e93-40fa-93c0-3f3d62fe9e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d028d65e-5e93-40fa-93c0-3f3d62fe9e8a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be698e6a-d776-4ecb-a04e-8bac2c1c83e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be698e6a-d776-4ecb-a04e-8bac2c1c83e2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_4b06f093-2f61-403e-8a92-f250da51d8da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_4b06f093-2f61-403e-8a92-f250da51d8da" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_7f77d69d-aa53-416f-bfe1-b39123012087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_7f77d69d-aa53-416f-bfe1-b39123012087" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f245eed3-c10e-4f0d-b21f-77fb4066f62b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_NetIncomeLoss_f245eed3-c10e-4f0d-b21f-77fb4066f62b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6231936-5580-4ae3-9d66-890661057d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_460a81fc-01b8-4fc9-a9df-7ffd105fe0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:to="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c803def8-07eb-4b49-ac93-7caf995ddf6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:to="loc_us-gaap_EquityComponentDomain_c803def8-07eb-4b49-ac93-7caf995ddf6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:to="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd60f04a-2ccc-4f02-86a3-71da4d5ac1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_CommonStockMember_cd60f04a-2ccc-4f02-86a3-71da4d5ac1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee1f0fe7-4aab-453d-a6c8-ada3d9d9d45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee1f0fe7-4aab-453d-a6c8-ada3d9d9d45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2c86ab59-f0b7-4a8d-ac9e-004cf4601bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2c86ab59-f0b7-4a8d-ac9e-004cf4601bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d6bf2e44-d720-4be6-8934-eb5729f39db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_RetainedEarningsMember_d6bf2e44-d720-4be6-8934-eb5729f39db8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_625d1623-8ee5-4d86-9f5d-705d1875afc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_625d1623-8ee5-4d86-9f5d-705d1875afc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_813e6f72-a7a8-4d08-a0e8-15bd92f2d29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_813e6f72-a7a8-4d08-a0e8-15bd92f2d29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_740570e8-712c-4d02-b5d9-a91b4d932e47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_740570e8-712c-4d02-b5d9-a91b4d932e47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_e50f9212-c28e-4bff-8486-564b9833c7a6" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_e50f9212-c28e-4bff-8486-564b9833c7a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_c69b9497-c353-4fa8-a163-23310e9f466f" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_c69b9497-c353-4fa8-a163-23310e9f466f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b45c0301-65a1-40cc-a599-50675553ad1f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b45c0301-65a1-40cc-a599-50675553ad1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_461bf83a-2ddb-4f95-8c8e-975c015157f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_461bf83a-2ddb-4f95-8c8e-975c015157f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ia6d3e6970c894fd9b82aea9bb46a1924_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i674776d30300461b86db7893da5d1dca_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ie23950c1e820403fa6f19c2fae8ee033_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i3a730047e1394d5ba9829101d00cee53_BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i4ea317de173d4a2c81b3017a37ff31d3_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_38823419-bdbd-44ba-9de6-d4a19a0da3f3" xlink:href="lgnd-20201231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_38823419-bdbd-44ba-9de6-d4a19a0da3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_5060d26f-8bb9-4224-b04a-0949a6574ee5" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_5060d26f-8bb9-4224-b04a-0949a6574ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ac636f82-faf8-4551-baac-df849da48034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_InventoryWriteDown_ac636f82-faf8-4551-baac-df849da48034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0692d07d-9f6d-426a-bf73-357fcc5f23ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0692d07d-9f6d-426a-bf73-357fcc5f23ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_cd2175c1-0879-46cf-b82f-7bd7b31cf653" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_cd2175c1-0879-46cf-b82f-7bd7b31cf653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3640b53-fceb-48ef-bd75-9f39848fe4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3640b53-fceb-48ef-bd75-9f39848fe4f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_489937e1-48d9-4df6-955d-e33c3588fc56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_489937e1-48d9-4df6-955d-e33c3588fc56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_11041127-cac4-4573-897f-3ccf99a88600" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_11041127-cac4-4573-897f-3ccf99a88600" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_70cf0e65-3c3d-4649-9d71-b8ea6be21cce" xlink:href="lgnd-20201231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_LicenseUpfrontPayment_70cf0e65-3c3d-4649-9d71-b8ea6be21cce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_3f79c539-e3d9-4a5a-954c-1d270c4a207a" xlink:href="lgnd-20201231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_3f79c539-e3d9-4a5a-954c-1d270c4a207a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_c5879273-7401-451d-9128-02fd5350cbaa" xlink:href="lgnd-20201231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_ProductRoyaltyPercentage_c5879273-7401-451d-9128-02fd5350cbaa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5455e7d4-f1b3-4bb5-a699-705e78a7fc5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5455e7d4-f1b3-4bb5-a699-705e78a7fc5c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0741f3e6-3085-426e-904d-6a9046cbe81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0741f3e6-3085-426e-904d-6a9046cbe81d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_8cce8f84-866e-4f17-9e1d-72517a191d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_8cce8f84-866e-4f17-9e1d-72517a191d3f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_c8aa7aa9-258c-44cc-8b43-8c101b96393e" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_c8aa7aa9-258c-44cc-8b43-8c101b96393e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_2a9e954d-7b13-45fa-a925-2e6d8ffef416" xlink:href="lgnd-20201231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_2a9e954d-7b13-45fa-a925-2e6d8ffef416" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_3ed23079-e8ac-4399-aec2-22594acd1cad" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_3ed23079-e8ac-4399-aec2-22594acd1cad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d8dbe74-73e2-444e-9d3b-d8c9ec2ed9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d8dbe74-73e2-444e-9d3b-d8c9ec2ed9bd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_b47bd078-5d60-4b92-a466-d40ec9e237aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_b47bd078-5d60-4b92-a466-d40ec9e237aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c20ad436-b5d3-441e-845c-ab63f74332ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c20ad436-b5d3-441e-845c-ab63f74332ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23c9beab-4dbc-4e8d-afe6-3a8d28a977ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23c9beab-4dbc-4e8d-afe6-3a8d28a977ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7956f7cc-1f8b-47f4-b149-c8828b59e4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7956f7cc-1f8b-47f4-b149-c8828b59e4e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1afc9222-b71c-42e3-a943-dcb2dfaebc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1afc9222-b71c-42e3-a943-dcb2dfaebc41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d25ed38b-7989-4174-934f-60c98e6fa308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d25ed38b-7989-4174-934f-60c98e6fa308" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7f801f6-0a87-43c3-911e-66bc068178a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7f801f6-0a87-43c3-911e-66bc068178a2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7167b12e-4538-441f-9da0-540e1f51094d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DerivativeAssets_7167b12e-4538-441f-9da0-540e1f51094d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9c0c8350-066f-4011-bb7f-ae131f2106ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DerivativeLiabilities_9c0c8350-066f-4011-bb7f-ae131f2106ef" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9129490b-af26-44ab-9e04-04d641916bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9129490b-af26-44ab-9e04-04d641916bc4" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_39711941-f352-423a-94a0-03ff529d105c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_39711941-f352-423a-94a0-03ff529d105c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d28f542c-f33b-4bea-92b0-69427c794b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_OperatingLeaseLiability_d28f542c-f33b-4bea-92b0-69427c794b93" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4cea7b2b-15d4-47a4-9696-f89579585282_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4cea7b2b-15d4-47a4-9696-f89579585282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_abfa3cad-e4e2-4098-a3e8-bee70f54e2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_abfa3cad-e4e2-4098-a3e8-bee70f54e2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84be2b29-0c51-44ef-9b2c-74c047075e88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84be2b29-0c51-44ef-9b2c-74c047075e88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_6dc53eca-8dbe-42cf-97a3-edd2e6c2fb36" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_6dc53eca-8dbe-42cf-97a3-edd2e6c2fb36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_7fd4415c-44b3-4aaf-b828-9bf39e3e5d01" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_7fd4415c-44b3-4aaf-b828-9bf39e3e5d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1421e150-31e6-4d09-8874-2cd5d3ca66de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:to="loc_us-gaap_SeniorNotesMember_1421e150-31e6-4d09-8874-2cd5d3ca66de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_ce90a2f7-da40-42da-a27e-f033547b4ef1" xlink:href="lgnd-20201231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_NovanMolluscumProductsMember_ce90a2f7-da40-42da-a27e-f033547b4ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_b1d57648-3def-4a0f-9e6c-f137b8aec398" xlink:href="lgnd-20201231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_b1d57648-3def-4a0f-9e6c-f137b8aec398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_e0f17464-6a34-43d8-8fe7-59b4203e856d" xlink:href="lgnd-20201231.xsd#lgnd_AziyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_AziyoMember_e0f17464-6a34-43d8-8fe7-59b4203e856d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_d389efb1-fc3a-4b64-ae43-86e8b9b74bf0" xlink:href="lgnd-20201231.xsd#lgnd_CorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_CorMatrixMember_d389efb1-fc3a-4b64-ae43-86e8b9b74bf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_494cd437-0ecc-4af0-90bb-755bde13cdf7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_494cd437-0ecc-4af0-90bb-755bde13cdf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_d5a4ee0a-794c-4e26-89e2-1d96716ea104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_d5a4ee0a-794c-4e26-89e2-1d96716ea104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_569e68ad-8e0a-42fc-a10f-abd48efa77bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:to="loc_us-gaap_LicensingAgreementsMember_569e68ad-8e0a-42fc-a10f-abd48efa77bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d58e921f-07af-45b2-b368-69701b2e3252_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d58e921f-07af-45b2-b368-69701b2e3252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_3876cc35-9353-4866-b5a5-61d6cd2a3034" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_PfenexMember_3876cc35-9353-4866-b5a5-61d6cd2a3034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_df83475c-b297-4c08-a6ed-9749ac40611c" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_IcagenMember_df83475c-b297-4c08-a6ed-9749ac40611c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_cc887ac0-f9eb-49df-a0b1-eb4772614124" xlink:href="lgnd-20201231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_CrystalMember_cc887ac0-f9eb-49df-a0b1-eb4772614124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_4f70dcba-4d1d-44c4-9083-de52c64806c4" xlink:href="lgnd-20201231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_4f70dcba-4d1d-44c4-9083-de52c64806c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d8c2fc8-1b51-48d4-a37f-12fadba041b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:to="loc_srt_RangeMember_1d8c2fc8-1b51-48d4-a37f-12fadba041b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:to="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc935c85-4a5a-4eae-88d9-ab54ad6ee36d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:to="loc_srt_MinimumMember_fc935c85-4a5a-4eae-88d9-ab54ad6ee36d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d569d60-72eb-484d-bf54-491b24482b53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:to="loc_srt_MaximumMember_7d569d60-72eb-484d-bf54-491b24482b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3bc88b4-4ab6-4a25-9533-eae583df230d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3bc88b4-4ab6-4a25-9533-eae583df230d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a1d7cd7-aa6d-4a82-8f10-ee3a10dd6631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a1d7cd7-aa6d-4a82-8f10-ee3a10dd6631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_8b3c4b8e-4ed6-4a7e-8049-d53a9174a7a7" xlink:href="lgnd-20201231.xsd#lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_8b3c4b8e-4ed6-4a7e-8049-d53a9174a7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_22ce83bb-e4e7-469e-9518-8268df3bbea5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:to="loc_us-gaap_VestingDomain_22ce83bb-e4e7-469e-9518-8268df3bbea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:to="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_0ffa378b-c2e5-40f1-9f4b-a3cfd5ceab1c" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:to="loc_lgnd_VestingPeriodOneMember_0ffa378b-c2e5-40f1-9f4b-a3cfd5ceab1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_6953e60d-c9ff-4bff-85bf-dcd68402354d" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:to="loc_lgnd_VestingPeriodTwoMember_6953e60d-c9ff-4bff-85bf-dcd68402354d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76eb5eab-5567-4dad-9e3f-8836e5c507bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:to="loc_us-gaap_PlanNameDomain_76eb5eab-5567-4dad-9e3f-8836e5c507bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:to="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_250ea5b2-38ea-4368-87af-ccc1938f95e7" xlink:href="lgnd-20201231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_250ea5b2-38ea-4368-87af-ccc1938f95e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_14d4d36e-7b05-479c-8407-eaa751d02075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:to="loc_us-gaap_StockCompensationPlanMember_14d4d36e-7b05-479c-8407-eaa751d02075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de3ca2a5-80b9-4b81-a2f1-0e43657a9512_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:to="loc_srt_ProductsAndServicesDomain_de3ca2a5-80b9-4b81-a2f1-0e43657a9512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:to="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_b0c0a103-9bdc-40dd-914c-bcab77fdc299" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:to="loc_lgnd_ContractRevenueMember_b0c0a103-9bdc-40dd-914c-bcab77fdc299" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended" id="i8b8a124b64494c478669ae62844e5082_BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d569151a-b0d2-41b0-9339-4f29439bd51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d569151a-b0d2-41b0-9339-4f29439bd51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a8ffca0-d62a-4a55-868b-a3b13ad9a5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a8ffca0-d62a-4a55-868b-a3b13ad9a5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_465ede22-deb6-409d-9d68-a01a9007df5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_465ede22-deb6-409d-9d68-a01a9007df5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_76fc3296-c99d-4a7f-9438-91ee92b2c3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_76fc3296-c99d-4a7f-9438-91ee92b2c3c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9678ef30-47c1-46bc-b635-5876acb3266c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9678ef30-47c1-46bc-b635-5876acb3266c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_19ada8ce-4d4c-423d-95b7-32a5a6ed3e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:to="loc_us-gaap_SalesRevenueNetMember_19ada8ce-4d4c-423d-95b7-32a5a6ed3e3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fba7759e-2f3d-4937-b3d6-437065204911_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:to="loc_srt_NameOfMajorCustomerDomain_fba7759e-2f3d-4937-b3d6-437065204911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_2a9bf1bb-0e38-443a-bcd1-32394f2b3c77" xlink:href="lgnd-20201231.xsd#lgnd_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerAMember_2a9bf1bb-0e38-443a-bcd1-32394f2b3c77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_776bde77-5b0b-47cf-99d3-f76ed11c3dee" xlink:href="lgnd-20201231.xsd#lgnd_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerBMember_776bde77-5b0b-47cf-99d3-f76ed11c3dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_4867d72b-83c1-4a2f-b82d-6684e9dfc17f" xlink:href="lgnd-20201231.xsd#lgnd_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerCMember_4867d72b-83c1-4a2f-b82d-6684e9dfc17f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended" id="i45b55edc31ad4661aafa541d3f5a6ab8_BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e77027f1-435a-4028-8927-bb8aacbe0464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e77027f1-435a-4028-8927-bb8aacbe0464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_22d1ca33-fb58-4366-b0b2-13cd5a3cf09d" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_22d1ca33-fb58-4366-b0b2-13cd5a3cf09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9fcea85-4d3c-4696-ae83-520d79cc425c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9fcea85-4d3c-4696-ae83-520d79cc425c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_3a3b03e0-186c-47e5-9bcf-c8d0fd51bc1b" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_3a3b03e0-186c-47e5-9bcf-c8d0fd51bc1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_6e8bde22-1a57-4dd3-84da-e177728e27f0" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_6e8bde22-1a57-4dd3-84da-e177728e27f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d83f4d9-838f-4d76-9a3f-1d7769a0c878_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d83f4d9-838f-4d76-9a3f-1d7769a0c878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b1dae0c3-9e22-4c70-a3e4-bb9ad0caf898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:to="loc_us-gaap_LicensingAgreementsMember_b1dae0c3-9e22-4c70-a3e4-bb9ad0caf898" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e708c533-ed71-4949-964e-fea18d84e4ed_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e708c533-ed71-4949-964e-fea18d84e4ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_6aef7bfd-e67f-4b17-9c3c-81963505b802" xlink:href="lgnd-20201231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_AziyoandCorMatrixMember_6aef7bfd-e67f-4b17-9c3c-81963505b802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_a26f81ad-6c7d-4602-b898-75f506a31c88" xlink:href="lgnd-20201231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_a26f81ad-6c7d-4602-b898-75f506a31c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_3435d456-fc94-4016-aed4-6fe5c9602bd9" xlink:href="lgnd-20201231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_SelexisAndDianomiMember_3435d456-fc94-4016-aed4-6fe5c9602bd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:to="loc_us-gaap_TypeOfAdoptionMember_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_577d7501-7497-4740-a252-7c723b776a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_577d7501-7497-4740-a252-7c723b776a6b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended" id="i0525de8521a74e8c8e7e9e5800898ac9_BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f376f4e4-0c25-41b3-9e0f-2953df07e3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f376f4e4-0c25-41b3-9e0f-2953df07e3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:to="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:to="loc_srt_ProductsAndServicesDomain_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:to="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:to="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_e6292e75-6627-4d56-88f7-918302296981" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyKyprolisMember_e6292e75-6627-4d56-88f7-918302296981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_cfa5103d-99fd-46a4-8f9b-41c14482c7cc" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyEvomelaMember_cfa5103d-99fd-46a4-8f9b-41c14482c7cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_44a9d707-43b3-46b0-bb1a-5fd7215ac337" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyOtherMember_44a9d707-43b3-46b0-bb1a-5fd7215ac337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_14369e6f-1c52-44dd-8757-7f90342d0144" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyPromactaMember_14369e6f-1c52-44dd-8757-7f90342d0144" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended" id="i90b96e3d58784101a3d4c2c5a52b3557_BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6efca74a-923a-4bf2-b119-330bac325a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6efca74a-923a-4bf2-b119-330bac325a9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:to="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03ef94bb-2a76-408d-8f2c-e5427551dc65_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:to="loc_srt_ProductsAndServicesDomain_03ef94bb-2a76-408d-8f2c-e5427551dc65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:to="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_b17cfef4-b6b0-489f-ba1f-7032955c38e6" xlink:href="lgnd-20201231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_b17cfef4-b6b0-489f-ba1f-7032955c38e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:to="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_5786ce37-335f-4641-8d30-8522faaff749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_us-gaap_ServiceMember_5786ce37-335f-4641-8d30-8522faaff749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_48653fc3-ecf7-47b5-932d-0a0d56541e86" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_LicenseFeesMember_48653fc3-ecf7-47b5-932d-0a0d56541e86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_7a4cfa0c-f5cb-4d0b-81fc-00966fe84d72" xlink:href="lgnd-20201231.xsd#lgnd_MilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_MilestoneMember_7a4cfa0c-f5cb-4d0b-81fc-00966fe84d72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_eea3d35c-c32c-437d-8cf2-ae57e0092a5d" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_eea3d35c-c32c-437d-8cf2-ae57e0092a5d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended" id="i9510c9868b2e469caf23c0d1549c4557_BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicense"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="extended" id="id16a425132cd4e57bdaeedb7821f3ae8_SaleofVernalisRDandPromactaLicense"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicenseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="extended" id="iba09796b6a794f258b17063eb4d55038_SaleofVernalisRDandPromactaLicenseNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2a6ad9c1-2622-4819-8d31-39fcb4b72c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2a6ad9c1-2622-4819-8d31-39fcb4b72c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e001460b-d807-45e2-8221-5a91403bc8fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e001460b-d807-45e2-8221-5a91403bc8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_02a10366-c587-417e-a374-5329f641563e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_02a10366-c587-417e-a374-5329f641563e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5a4cf94a-08d4-4345-8eb1-e07de55308e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5a4cf94a-08d4-4345-8eb1-e07de55308e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd6f7cf2-4f11-4b52-ad89-b53751a9bf98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd6f7cf2-4f11-4b52-ad89-b53751a9bf98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e4093c93-eed2-44c5-b46e-c3eb73cceab6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e4093c93-eed2-44c5-b46e-c3eb73cceab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_00c5c4dd-bfc5-4b88-b478-984a1a0aeec9" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:to="loc_lgnd_VernalisMember_00c5c4dd-bfc5-4b88-b478-984a1a0aeec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_e73b68b0-e5dd-44ae-9296-30991c3152a7" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:to="loc_lgnd_PromactaMember_e73b68b0-e5dd-44ae-9296-30991c3152a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908648f7-5f3f-4973-92b4-091148e145d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_908648f7-5f3f-4973-92b4-091148e145d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_de18d962-ac63-4edd-93be-c274a226986c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_de18d962-ac63-4edd-93be-c274a226986c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_aa57ab57-a3f0-413d-bbe1-925dffeefe78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_aa57ab57-a3f0-413d-bbe1-925dffeefe78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_f2d5bec4-4ec9-4b53-9a9f-b6a6af39fe22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_f2d5bec4-4ec9-4b53-9a9f-b6a6af39fe22" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinViking"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="extended" id="i27ee69778ca54a5a9a8d78429202d86a_ShorttermInvestmentsInvestmentinViking"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinVikingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="extended" id="i30c8f38bbd3848e988cd2acbb69b7180_ShorttermInvestmentsInvestmentinVikingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_e56b7160-6834-4a1e-8dbd-8f62ae762480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_e56b7160-6834-4a1e-8dbd-8f62ae762480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f0e6b921-1f07-4dec-98bb-1cf8234d5a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f0e6b921-1f07-4dec-98bb-1cf8234d5a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a6cf72f9-a80a-4db6-b957-f04b345c5dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a6cf72f9-a80a-4db6-b957-f04b345c5dbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f588c4d5-38a1-46ae-87a8-e6d5651af2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f588c4d5-38a1-46ae-87a8-e6d5651af2ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_307427f3-225e-441a-b6e8-7bf319b4d5f0" xlink:href="lgnd-20201231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_lgnd_InvestmentInVikingCurrent_307427f3-225e-441a-b6e8-7bf319b4d5f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_30f4b1e3-5f23-413d-8c58-cae5deab66ae_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:to="loc_srt_OwnershipDomain_30f4b1e3-5f23-413d-8c58-cae5deab66ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:to="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_4e3c8871-8627-4609-a2f8-77c75d46bbda" xlink:href="lgnd-20201231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_4e3c8871-8627-4609-a2f8-77c75d46bbda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_aa01ba21-70a6-4b8b-baf9-828ff81a03fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:to="loc_us-gaap_WarrantMember_aa01ba21-70a6-4b8b-baf9-828ff81a03fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d6446103-4b25-49a1-a01f-f1e351428921_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:to="loc_us-gaap_RelatedPartyDomain_d6446103-4b25-49a1-a01f-f1e351428921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:to="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_32f8b9ab-c43a-473f-91bc-d094a8097523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_32f8b9ab-c43a-473f-91bc-d094a8097523" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisitions" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/Acquisitions" xlink:type="extended" id="i6071dd8cc2fa4d01b986d7c0db08c847_Acquisitions"/>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended" id="i680976e924b54a18ac717ec408ef3a39_AcquisitionsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e6b734cd-aebf-47e1-895e-a4c8c7e2d8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e6b734cd-aebf-47e1-895e-a4c8c7e2d8c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_669ae15a-0f46-4a09-b546-64326f591fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_669ae15a-0f46-4a09-b546-64326f591fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_37edafa4-5ad8-47b0-aa1c-6ef77ee01189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_37edafa4-5ad8-47b0-aa1c-6ef77ee01189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed23745c-a816-405e-9917-e914bd0a1902_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed23745c-a816-405e-9917-e914bd0a1902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_fd39575d-4149-4033-8b44-23d571215ecb" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_PfenexMember_fd39575d-4149-4033-8b44-23d571215ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_395319ec-f0a6-40d9-b9d4-8f42296e570a" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_395319ec-f0a6-40d9-b9d4-8f42296e570a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_3a457372-2ca4-4533-a4f6-f8ba11f00d67" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_3a457372-2ca4-4533-a4f6-f8ba11f00d67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_134d2aa8-ea76-4679-a2b5-37ce2b6758cb" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_IcagenMember_134d2aa8-ea76-4679-a2b5-37ce2b6758cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_221b8b7b-495d-4c30-83c0-84953e3e5b01" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_AbInitioMember_221b8b7b-495d-4c30-83c0-84953e3e5b01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_cf7d22cd-2641-487a-b269-961f2c8e47d5" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_VernalisMember_cf7d22cd-2641-487a-b269-961f2c8e47d5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i2924594d103d4aeda70f9349ab8fef5c_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_65593005-a91b-4e8a-9c1b-5485d39bb7a4" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_NumberOfAcquisitions_65593005-a91b-4e8a-9c1b-5485d39bb7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_422a8a61-4778-4c6e-9b5e-c385b257bbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_422a8a61-4778-4c6e-9b5e-c385b257bbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_761744d6-6a15-4edc-b5e4-c07cc7efa589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_761744d6-6a15-4edc-b5e4-c07cc7efa589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b4ca4c6-73d8-4e54-ab05-702932d6adba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b4ca4c6-73d8-4e54-ab05-702932d6adba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d69fd87a-585e-4595-9685-5c53f3f6da46" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d69fd87a-585e-4595-9685-5c53f3f6da46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_810462dd-7128-40fe-aa0b-fc7580b227e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_810462dd-7128-40fe-aa0b-fc7580b227e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8ac29cca-66e9-4c14-825b-65ce65ff0f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8ac29cca-66e9-4c14-825b-65ce65ff0f7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_60faecfd-3566-45e5-a480-f9571fbc4d67" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_60faecfd-3566-45e5-a480-f9571fbc4d67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_76dc3c4b-18f8-47ed-933c-2a642206266a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_76dc3c4b-18f8-47ed-933c-2a642206266a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e64102a-20c0-43b0-a97a-77f8b23e2474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e64102a-20c0-43b0-a97a-77f8b23e2474" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_c78b4115-341e-4c91-a018-97f9e42beb9d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_c78b4115-341e-4c91-a018-97f9e42beb9d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_8121f473-10ff-4c03-8a70-09e3a125bd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_8121f473-10ff-4c03-8a70-09e3a125bd71" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_11e03b2b-8234-4f95-bd0c-931fcfa0aec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_11e03b2b-8234-4f95-bd0c-931fcfa0aec6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_7d28d7d8-3ae5-4cbd-96e7-53c3bbc85d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_7d28d7d8-3ae5-4cbd-96e7-53c3bbc85d2f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_64dcecb8-a015-4426-b682-4d211adcc946" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_64dcecb8-a015-4426-b682-4d211adcc946" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_37f7720f-5071-473d-b2d9-6796f5a3fc13" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_37f7720f-5071-473d-b2d9-6796f5a3fc13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_771762f0-95be-4889-ba4a-3c4b7fc9dfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_771762f0-95be-4889-ba4a-3c4b7fc9dfd3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f583a44-aa4d-4629-9c5c-b3ea8f783bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f583a44-aa4d-4629-9c5c-b3ea8f783bfb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_3da75c40-4ea8-4d20-a6e0-ff48c49a5776" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_3da75c40-4ea8-4d20-a6e0-ff48c49a5776" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_aa940d77-58b1-4704-a204-90db6cb07943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_aa940d77-58b1-4704-a204-90db6cb07943" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_acc4bf8e-2ca4-4d60-9ebc-0a61781c928d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_acc4bf8e-2ca4-4d60-9ebc-0a61781c928d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_61ab86b8-16af-4037-800f-40f0820d2a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_61ab86b8-16af-4037-800f-40f0820d2a99" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_182becc8-5add-4de2-850f-118dc934b830_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_182becc8-5add-4de2-850f-118dc934b830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_cac06a5a-abc1-439f-8ac8-f03a11b6867f" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_PfenexMember_cac06a5a-abc1-439f-8ac8-f03a11b6867f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_34bb390e-23dc-4075-8c57-3dd1370d6ff1" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_34bb390e-23dc-4075-8c57-3dd1370d6ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_8bfe3fdc-377b-4889-8cbc-ae26c1d98912" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_8bfe3fdc-377b-4889-8cbc-ae26c1d98912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_5cac76c6-6a3d-4bbd-895f-ac66a9654bee" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_IcagenMember_5cac76c6-6a3d-4bbd-895f-ac66a9654bee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_5dbc64a5-5c1b-4451-8c31-da6efa2407b8" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_AbInitioMember_5dbc64a5-5c1b-4451-8c31-da6efa2407b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_1b866082-fab4-4f55-b704-1d03279c707b" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_VernalisMember_1b866082-fab4-4f55-b704-1d03279c707b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58148ca3-a062-446a-bff7-4dd3f10a4405_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58148ca3-a062-446a-bff7-4dd3f10a4405_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7cfed40-4154-4999-80e1-fc880917faaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7cfed40-4154-4999-80e1-fc880917faaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7c5c0a4f-929a-44c6-955d-aa5b49fe6d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7c5c0a4f-929a-44c6-955d-aa5b49fe6d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c72ce55a-0edc-48dd-9009-8af72864f0db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c72ce55a-0edc-48dd-9009-8af72864f0db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_3b05c41a-5c01-4540-beb1-52ec74d63908" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_3b05c41a-5c01-4540-beb1-52ec74d63908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember_87067a73-37e5-4a09-a18e-bd575148bd22" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_ContingentValueRightOnProductRevenuesMember_87067a73-37e5-4a09-a18e-bd575148bd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_4c2333c1-f504-4b46-b5f3-75796d8b7aef" xlink:href="lgnd-20201231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_4c2333c1-f504-4b46-b5f3-75796d8b7aef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember_ed3e712b-2607-411c-b71f-623f271e4cf6" xlink:href="lgnd-20201231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_MilestonePaymentsMember_ed3e712b-2607-411c-b71f-623f271e4cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:to="loc_srt_RangeMember_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:to="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_679dbc04-a874-43dc-a437-f190f12472ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:to="loc_srt_MinimumMember_679dbc04-a874-43dc-a437-f190f12472ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f44dcc26-a80c-4b3a-8b6f-d4ce6ed22cb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:to="loc_srt_MaximumMember_f44dcc26-a80c-4b3a-8b6f-d4ce6ed22cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_95c15562-77aa-4fa8-bb71-c934283f9982_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_95c15562-77aa-4fa8-bb71-c934283f9982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3f80e13e-3320-4a8e-a63e-f44e721cfc0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3f80e13e-3320-4a8e-a63e-f44e721cfc0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i066d4605264d4543a0a02d8776198919_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa65ed10-78ab-4441-8550-1d6bf1393142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa65ed10-78ab-4441-8550-1d6bf1393142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_700415e4-d677-496e-b458-4eb939e4893c" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_700415e4-d677-496e-b458-4eb939e4893c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_040e2509-35d8-499b-ab21-4c09fca792f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_040e2509-35d8-499b-ab21-4c09fca792f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9c6dd839-7d0d-4e4f-b9ef-94888556f1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9c6dd839-7d0d-4e4f-b9ef-94888556f1d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2b12c50d-12bc-4266-b708-9226ba43d78b" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2b12c50d-12bc-4266-b708-9226ba43d78b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cd4673f6-2704-4cdc-81d9-cb3ade8c0af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cd4673f6-2704-4cdc-81d9-cb3ade8c0af1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_ea5c2c6b-0ee2-46c2-8aff-44a006da983f" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_ea5c2c6b-0ee2-46c2-8aff-44a006da983f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_66bd10b6-1b84-4e36-aabd-f9a83e637185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_Goodwill_66bd10b6-1b84-4e36-aabd-f9a83e637185" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0caefd2d-8b8f-472e-8762-fc0a4088962a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0caefd2d-8b8f-472e-8762-fc0a4088962a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_cb09cd96-924f-43dd-b8cf-eb35c6c1f069" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_cb09cd96-924f-43dd-b8cf-eb35c6c1f069" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d65ed9f4-fc96-4221-9cc3-460d34eea929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d65ed9f4-fc96-4221-9cc3-460d34eea929" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_cc437316-fcfe-4cf2-a0aa-7753dac7bc19" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_cc437316-fcfe-4cf2-a0aa-7753dac7bc19" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_73cf0fba-4922-4fa7-9485-68b5c3c3c566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_73cf0fba-4922-4fa7-9485-68b5c3c3c566" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d8d374e5-2f5b-4998-8cc3-04dc239e9b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d8d374e5-2f5b-4998-8cc3-04dc239e9b0d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cce442be-2e70-4a42-a1cd-ed4970bd753d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cce442be-2e70-4a42-a1cd-ed4970bd753d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c782c87-8ffc-48c9-854a-ae8269e1224b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c782c87-8ffc-48c9-854a-ae8269e1224b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_9646468e-b9c7-4021-88db-e2f609168bb9" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:to="loc_lgnd_PfenexMember_9646468e-b9c7-4021-88db-e2f609168bb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="extended" id="i2a8fee6364fb4160a52e4e5aee910d23_AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_61a8737b-d385-408c-be4b-03e31c4a3f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_61a8737b-d385-408c-be4b-03e31c4a3f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c1c31d60-d6cc-446d-9f82-3c43e97c9ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c1c31d60-d6cc-446d-9f82-3c43e97c9ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c2cb0c6d-4442-4578-89e2-7277f7e4eecc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c2cb0c6d-4442-4578-89e2-7277f7e4eecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_4a5c34ff-597c-4da3-9cb3-92cd2594eb30" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:to="loc_lgnd_PfenexMember_4a5c34ff-597c-4da3-9cb3-92cd2594eb30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:to="loc_srt_RangeMember_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:to="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dc5191ad-1a4a-4ac9-b7a2-036ca3e1e145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:to="loc_srt_MinimumMember_dc5191ad-1a4a-4ac9-b7a2-036ca3e1e145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5fbb003c-7f1d-4b14-8059-b79174ad5f19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:to="loc_srt_MaximumMember_5fbb003c-7f1d-4b14-8059-b79174ad5f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6db2d74-2daf-4796-a409-bbbea7021848_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6db2d74-2daf-4796-a409-bbbea7021848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember_5b27f0fb-9008-4ee4-9173-fea6d019ba43" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsAlvogenMember_5b27f0fb-9008-4ee4-9173-fea6d019ba43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember_f0d390e7-a7d3-4fa1-97cb-84c9932aca0f" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsMerckMember_f0d390e7-a7d3-4fa1-97cb-84c9932aca0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember_6263fe02-63ac-41da-ad96-a7794e8204ae" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsJazzMember_6263fe02-63ac-41da-ad96-a7794e8204ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember_32763941-9816-469f-80d1-b3fc9ad66c19" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsSIIMember_32763941-9816-469f-80d1-b3fc9ad66c19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember_6cabe614-942d-459a-acb9-f8fb241a52cc" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsArcellxMember_6cabe614-942d-459a-acb9-f8fb241a52cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2564886c-0271-4a4e-acac-7a5b2db72888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2564886c-0271-4a4e-acac-7a5b2db72888" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="extended" id="i7af0a284edba4ab0a26a8ee1dc23ab74_AcquisitionsProFormaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_18e022fc-2ff6-42e2-85a6-58861150acc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_18e022fc-2ff6-42e2-85a6-58861150acc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2e0cddc1-4669-4ecd-a1d4-5e795a26b2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2e0cddc1-4669-4ecd-a1d4-5e795a26b2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_474a7c4d-4848-4036-946a-63e404c31bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_474a7c4d-4848-4036-946a-63e404c31bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8b4cd922-4dca-4443-81bf-afed0a12a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8b4cd922-4dca-4443-81bf-afed0a12a6cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd3b5388-d934-4735-b160-eb2f8711143a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd3b5388-d934-4735-b160-eb2f8711143a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_caf0aa12-ff1a-4bb4-a572-6a5b50493267" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:to="loc_lgnd_PfenexMember_caf0aa12-ff1a-4bb4-a572-6a5b50493267" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAllocationofConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="extended" id="i5f793006d9e04129a3522cbb3cb003d2_AcquisitionsAllocationofConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cd6043a0-20a7-429d-ba57-9117eb23ecec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cd6043a0-20a7-429d-ba57-9117eb23ecec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_86ffbfe5-6a21-4210-b84b-c613f0feebad" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_86ffbfe5-6a21-4210-b84b-c613f0feebad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_635145e7-7a12-4bd5-9dfa-96ec2db63db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_635145e7-7a12-4bd5-9dfa-96ec2db63db8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_8e5fefdf-2c66-4ded-9dbd-29f02bedd28a" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_8e5fefdf-2c66-4ded-9dbd-29f02bedd28a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_954e942b-f017-4f3f-8817-70b939f7335d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_954e942b-f017-4f3f-8817-70b939f7335d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0268baf-a0ba-42e5-808f-f8def74d6218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0268baf-a0ba-42e5-808f-f8def74d6218" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6936b257-d562-450d-acec-d3fafc6cbe44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6936b257-d562-450d-acec-d3fafc6cbe44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9a57aaed-6d4c-4201-af30-9d569533d620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9a57aaed-6d4c-4201-af30-9d569533d620" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6cc8d47d-8a8a-4c8b-8a12-1b5569395a55" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6cc8d47d-8a8a-4c8b-8a12-1b5569395a55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a93f83de-3654-4919-ae33-ec56016ebebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a93f83de-3654-4919-ae33-ec56016ebebd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_eca56d39-cac5-4c0b-b721-70677013e351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_RestructuringReserve_eca56d39-cac5-4c0b-b721-70677013e351" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8f7455ad-4e94-439f-9332-61e1d6346b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8f7455ad-4e94-439f-9332-61e1d6346b0a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_13148b9b-c23e-49d2-a87f-797270403576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_13148b9b-c23e-49d2-a87f-797270403576" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3768c0b2-3799-428e-8230-0bbe5a5a871f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3768c0b2-3799-428e-8230-0bbe5a5a871f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_6c24cfc7-343f-44da-b312-59dcf5a80a27" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_6c24cfc7-343f-44da-b312-59dcf5a80a27" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22bdc073-f6d5-4dc5-8687-7f58ca785f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_Goodwill_22bdc073-f6d5-4dc5-8687-7f58ca785f6c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_47d2924a-33de-4751-9e7c-4ca8bc901531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_47d2924a-33de-4751-9e7c-4ca8bc901531" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b168de8e-1020-43b5-9151-aa40abddf097_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b168de8e-1020-43b5-9151-aa40abddf097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_903f5d24-ee3a-4c0d-aa93-ecd9475242cf" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_903f5d24-ee3a-4c0d-aa93-ecd9475242cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_3f8df6b6-f75c-432b-96e8-4e03c127813a" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_3f8df6b6-f75c-432b-96e8-4e03c127813a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_bab66745-f751-4fa3-afee-4f8cd978ffd9" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_IcagenMember_bab66745-f751-4fa3-afee-4f8cd978ffd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_3b516375-4ea6-4f32-b648-b5191320c9f2" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_AbInitioMember_3b516375-4ea6-4f32-b648-b5191320c9f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_7344499b-967c-42e9-8c20-f0a1bb5b1e18" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_VernalisMember_7344499b-967c-42e9-8c20-f0a1bb5b1e18" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended" id="i468a55117a8945f5a97bdd5c49f277e1_FairValueMeasurement"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended" id="i869f8972e07549b289c72bbda3668ac5_FairValueMeasurementTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i9633ea43742f475fa289c6a61be49ccd_FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_047ab297-6c1e-4ad0-bc98-2f0b469ba64e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_047ab297-6c1e-4ad0-bc98-2f0b469ba64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fff91859-e98d-473c-888f-af084246892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fff91859-e98d-473c-888f-af084246892d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_eb0d005a-7953-434e-9832-a3a62e879250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_eb0d005a-7953-434e-9832-a3a62e879250" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_1602046b-3ba6-44c8-a7d1-b060cc716cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_1602046b-3ba6-44c8-a7d1-b060cc716cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:to="loc_srt_RangeMember_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:to="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_588efe48-4278-4c12-b9a6-d8b65205ff47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:to="loc_srt_MaximumMember_588efe48-4278-4c12-b9a6-d8b65205ff47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0779642a-45dc-4c55-b610-229b546e3b85_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0779642a-45dc-4c55-b610-229b546e3b85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_c8ca5fc3-a080-4e46-ae8d-96aed2ae3151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:to="loc_us-gaap_TransferredOverTimeMember_c8ca5fc3-a080-4e46-ae8d-96aed2ae3151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5fbb55ed-a7c0-46af-b268-7d26138b65e5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:to="loc_srt_ProductsAndServicesDomain_5fbb55ed-a7c0-46af-b268-7d26138b65e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:to="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_599f3210-db5d-426a-a53b-de009035d8bd" xlink:href="lgnd-20201231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_599f3210-db5d-426a-a53b-de009035d8bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_f95add7b-a077-4158-a901-8fdf26bf89a9" xlink:href="lgnd-20201231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_f95add7b-a077-4158-a901-8fdf26bf89a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1e138eb6-1d83-44af-8871-528b0ef0bfd3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1e138eb6-1d83-44af-8871-528b0ef0bfd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_76fce8ae-53f9-4e40-8d11-afe2e0d132e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_76fce8ae-53f9-4e40-8d11-afe2e0d132e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5490350a-b97f-4c5d-92de-8a1c21309fba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5490350a-b97f-4c5d-92de-8a1c21309fba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fc62b77d-f35a-4a7e-9fa7-69d6d4e90b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fc62b77d-f35a-4a7e-9fa7-69d6d4e90b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e76986fe-7d55-4c05-8fc9-42f9f918e3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e76986fe-7d55-4c05-8fc9-42f9f918e3f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bb23519-3009-4a55-b6f0-0ac7a85a49fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bb23519-3009-4a55-b6f0-0ac7a85a49fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d4650ddd-7b55-457a-b91c-bb9c472b5345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d4650ddd-7b55-457a-b91c-bb9c472b5345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_16cffc87-3398-4e30-8d04-7b7c003d755a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_EquitySecuritiesMember_16cffc87-3398-4e30-8d04-7b7c003d755a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b66f8740-69b6-47c7-93c3-4681d6d0e68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_WarrantMember_b66f8740-69b6-47c7-93c3-4681d6d0e68c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a6de73de-6bd1-41cc-8b84-b95165e65d05_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a6de73de-6bd1-41cc-8b84-b95165e65d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_2485be0a-4caf-4ca0-b1f4-66e454ae4334" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_2485be0a-4caf-4ca0-b1f4-66e454ae4334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_fd62ecf6-1071-496e-a3aa-590a4fded1b4" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_fd62ecf6-1071-496e-a3aa-590a4fded1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_15393677-6cc0-40ad-8fe0-a4c3ea35465b" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_15393677-6cc0-40ad-8fe0-a4c3ea35465b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_238b53c7-03dd-45f8-9116-a222c2bccd00" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_238b53c7-03dd-45f8-9116-a222c2bccd00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_413e94e2-7355-4afb-aed4-0f2302748695" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_413e94e2-7355-4afb-aed4-0f2302748695" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_24efec19-be09-4658-8453-d1873bf8eed5" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_24efec19-be09-4658-8453-d1873bf8eed5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i43fddd8adeab406d988e6788f994fb08_FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5dbf45de-ec20-4e00-bd73-6070dfa74429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5dbf45de-ec20-4e00-bd73-6070dfa74429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c9735ae7-7913-43fd-ba24-9900a647add3" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c9735ae7-7913-43fd-ba24-9900a647add3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_31b9ed9c-b833-4dd1-b548-8a68365aa9d2" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_31b9ed9c-b833-4dd1-b548-8a68365aa9d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_7d29d649-d47b-458e-b4bd-587b5f7fb798" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_7d29d649-d47b-458e-b4bd-587b5f7fb798" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a1c4bd20-f5ea-46bf-ae79-4cf0abcb1caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db47d3f4-b647-4850-9b96-633b0bd24f57_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db47d3f4-b647-4850-9b96-633b0bd24f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e02895d5-1e99-40fd-9bc0-e1adac2e453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e02895d5-1e99-40fd-9bc0-e1adac2e453f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="iacaecd44d7af445d950578c4f351614b_FairValueMeasurementsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended" id="iae4367f32116484589b752c01da1afd3_Leases"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended" id="ie4533662450a495e880c05ff19e8d37f_LeasesTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i6d8c4258c53e473385d9306c133ad2b6_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_35369513-9128-4053-b20b-092109ce02a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_35369513-9128-4053-b20b-092109ce02a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c71b2a67-6387-422e-896c-88984a0d990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c71b2a67-6387-422e-896c-88984a0d990b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_f6d6eee8-c0c9-4080-bfe1-726df76e34aa" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_f6d6eee8-c0c9-4080-bfe1-726df76e34aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_adaa42ae-f9cc-43a5-8644-28a0d672c2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_adaa42ae-f9cc-43a5-8644-28a0d672c2b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0587f5a6-070d-4315-8471-1ae0d407388c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0587f5a6-070d-4315-8471-1ae0d407388c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ee3f3480-8fd8-44fd-8cbd-35c13459ac9c" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ee3f3480-8fd8-44fd-8cbd-35c13459ac9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d0ceb86-177f-4096-90da-b7f7c70d6f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d0ceb86-177f-4096-90da-b7f7c70d6f48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_53e8106a-071b-406a-ad1e-beb850ffc5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_53e8106a-071b-406a-ad1e-beb850ffc5c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786ba695-a2fc-4df8-888f-270aeba7b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786ba695-a2fc-4df8-888f-270aeba7b10b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08eff9cc-9051-4ef1-8527-b62e94a26d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08eff9cc-9051-4ef1-8527-b62e94a26d30" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cb58e4bc-4c41-4d38-834e-e294eea3d745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeasePayments_cb58e4bc-4c41-4d38-834e-e294eea3d745" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_5b2cc961-c616-4fe4-9973-a4f444239869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseExpense_5b2cc961-c616-4fe4-9973-a4f444239869" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_cf2c713d-23dd-415e-acb8-9249b79a1850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_SubleaseIncome_cf2c713d-23dd-415e-acb8-9249b79a1850" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c1c1beb3-76d0-451d-b97e-cce2d20ea03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c1c1beb3-76d0-451d-b97e-cce2d20ea03d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c45588fd-ee40-44ad-ae5c-a2aba91a3050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c45588fd-ee40-44ad-ae5c-a2aba91a3050" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_229b4e0d-219c-4ffe-aa7b-91cd112e5b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_229b4e0d-219c-4ffe-aa7b-91cd112e5b0f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8f7b6bb5-5d63-4c9e-bc03-b132291bfba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8f7b6bb5-5d63-4c9e-bc03-b132291bfba9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:to="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2792daa2-8087-445c-b573-96b36f704d0a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:to="loc_srt_RangeMember_2792daa2-8087-445c-b573-96b36f704d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:to="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a568483-0997-414b-8cf4-ff331edddfda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:to="loc_srt_MaximumMember_0a568483-0997-414b-8cf4-ff331edddfda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="i46d91c0b245941c793bd2613f4ca49d4_LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended" id="icf15d87f29894cc88bb53fb06225d51b_LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended" id="i5bf43543eaca4d858ef08cb3a0e6697d_ConvertibleSeniorNotes"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" id="id5d7e6b9a2074eef96dc6e9e732e4aef_ConvertibleSeniorNotesTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" id="i2c7cd66c2b464d3d92c2bb735803c22c_ConvertibleSeniorNotesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_10cfeba4-05a5-4fce-974e-f6e5c47c75d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_10cfeba4-05a5-4fce-974e-f6e5c47c75d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b096eaf7-24df-4ed1-af60-e4b32c4b1aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b096eaf7-24df-4ed1-af60-e4b32c4b1aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_421cce49-931f-4803-be87-42608bfaf162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_421cce49-931f-4803-be87-42608bfaf162" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_93ffe69d-49d9-48ee-9713-37513d97d305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_93ffe69d-49d9-48ee-9713-37513d97d305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c8608303-4e09-4ec9-9459-96bccd557bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c8608303-4e09-4ec9-9459-96bccd557bf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8ac7f776-4fe0-4208-b299-53385d2835b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8ac7f776-4fe0-4208-b299-53385d2835b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7d65bec-0217-4e34-ba1f-57e5138293f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7d65bec-0217-4e34-ba1f-57e5138293f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3ff292a3-20bd-42cd-8d1a-ca355a23e533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3ff292a3-20bd-42cd-8d1a-ca355a23e533" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3c4e165-a160-48c5-9bd0-edc539a66c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3c4e165-a160-48c5-9bd0-edc539a66c5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_939ed0d3-9661-4988-9e55-831871ac80f3" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_939ed0d3-9661-4988-9e55-831871ac80f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c2745e76-790b-44cd-bcf0-fdc9a80ff31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c2745e76-790b-44cd-bcf0-fdc9a80ff31f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_0d2d3354-fc42-40c3-9ec8-764da32fbcb4" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_0d2d3354-fc42-40c3-9ec8-764da32fbcb4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86b8100b-5545-4925-bba4-3c9f1aa7acf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86b8100b-5545-4925-bba4-3c9f1aa7acf5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_9b951ac9-a45f-46e0-b644-cf155652e1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_9b951ac9-a45f-46e0-b644-cf155652e1cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7adc35f2-b455-486f-b56f-2a34c48a688a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7adc35f2-b455-486f-b56f-2a34c48a688a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_30de1e67-742b-436d-b2b8-502b41826fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_30de1e67-742b-436d-b2b8-502b41826fca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_e60e2e86-5ef5-42ba-8245-6b8bd7ddafd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_e60e2e86-5ef5-42ba-8245-6b8bd7ddafd1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a4a2e98-3b2b-43bc-aad3-428258a0e188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a4a2e98-3b2b-43bc-aad3-428258a0e188" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80e484a8-ca69-4682-bf8e-c29f565721d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80e484a8-ca69-4682-bf8e-c29f565721d8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_146d6afb-b9bc-4e82-be2b-ff696330b78f" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_146d6afb-b9bc-4e82-be2b-ff696330b78f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_5bda1333-5be3-4e9c-b3eb-1c1292086f7f" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_5bda1333-5be3-4e9c-b3eb-1c1292086f7f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_e252ccd9-c77a-4383-b052-21d563078ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_e252ccd9-c77a-4383-b052-21d563078ea1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c2f8bc6d-dfe7-4a04-a407-35c835c3eabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_675e0842-8c71-4487-8a3c-9cb71a9d0ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_675e0842-8c71-4487-8a3c-9cb71a9d0ad6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ae2d52e-8138-4d91-bc3e-884578a16ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ae2d52e-8138-4d91-bc3e-884578a16ec2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8313a964-ad99-4903-aeaf-b4e54cb0a523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8313a964-ad99-4903-aeaf-b4e54cb0a523" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled_d2b4605a-39ca-46dc-8823-cc4513abb3cb" xlink:href="lgnd-20201231.xsd#lgnd_WarrantsSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_WarrantsSettled_d2b4605a-39ca-46dc-8823-cc4513abb3cb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_2f6c4b09-be7f-4776-af12-748c5c80fcdf" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_2f6c4b09-be7f-4776-af12-748c5c80fcdf" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8251d5cc-8966-4bb3-9f69-bc9073f2c8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8251d5cc-8966-4bb3-9f69-bc9073f2c8b0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_fc2a3348-ad63-47c1-a30b-9527d4773b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_fc2a3348-ad63-47c1-a30b-9527d4773b84" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_dcfc7a8d-ad1a-4e21-aca7-b114704fc4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_dcfc7a8d-ad1a-4e21-aca7-b114704fc4e7" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5ae02c8b-d2f0-4aec-a17a-ca00c418598a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5ae02c8b-d2f0-4aec-a17a-ca00c418598a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_448c2bd6-e5b1-40d5-9ea8-cdf68444a6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_448c2bd6-e5b1-40d5-9ea8-cdf68444a6ad" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_37961c7c-e261-4571-b0ab-f711f93819d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_37961c7c-e261-4571-b0ab-f711f93819d3" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_6ec2abf1-3cb2-4f6d-83b5-0ff3eb2aa6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_6ec2abf1-3cb2-4f6d-83b5-0ff3eb2aa6f5" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_51c953ef-1fe6-4f40-8df5-f24a64f36a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_51c953ef-1fe6-4f40-8df5-f24a64f36a12" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_2a20aaee-0f3d-4797-a81a-296889f12b2f" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentAccruedInterestRepurchasedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_2a20aaee-0f3d-4797-a81a-296889f12b2f" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument_61d73e71-6df8-4fcd-99f0-b7878f13c2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument_61d73e71-6df8-4fcd-99f0-b7878f13c2eb" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_238dd143-5f05-41c0-93c7-a90d83baacf7" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_238dd143-5f05-41c0-93c7-a90d83baacf7" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_06165085-80bc-46de-b0d8-860483184a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_LongTermNotesPayable_06165085-80bc-46de-b0d8-860483184a9c" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_7ccca382-5ab4-4e20-847d-9824a342d5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_7ccca382-5ab4-4e20-847d-9824a342d5a7" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_c1ba55e8-535e-4f6c-b7a2-0dce46db3f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:to="loc_us-gaap_OtherExpenseMember_c1ba55e8-535e-4f6c-b7a2-0dce46db3f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_beeeffd2-2ce4-4466-bfab-bf4d67383989_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_beeeffd2-2ce4-4466-bfab-bf4d67383989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_55a4b761-6e46-4a62-aa13-fcb9e0438a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_55a4b761-6e46-4a62-aa13-fcb9e0438a9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21c6408a-e76b-49a9-8b34-3cf6bdd60006_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21c6408a-e76b-49a9-8b34-3cf6bdd60006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_549ff301-4df2-4cf7-9fe3-b7d80de83c10" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_549ff301-4df2-4cf7-9fe3-b7d80de83c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_4ce712c9-5e97-4f54-af24-24dd0eff8b1f" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_4ce712c9-5e97-4f54-af24-24dd0eff8b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bc49929b-2e12-4afe-8c9c-54a8b21807d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bc49929b-2e12-4afe-8c9c-54a8b21807d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_08894554-e393-4b58-86f3-04ec948f7fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_08894554-e393-4b58-86f3-04ec948f7fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_255e55a6-e454-4303-bcca-69289780967e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_255e55a6-e454-4303-bcca-69289780967e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b6838513-b434-46cf-9ab8-d64b8640aae4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b6838513-b434-46cf-9ab8-d64b8640aae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_02c508d1-eb25-45de-b8a2-6d5f45750af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:to="loc_us-gaap_SubsequentEventMember_02c508d1-eb25-45de-b8a2-6d5f45750af3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended" id="i126bf57c8b2740b285b46373ade18312_ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ed86373-dafd-434d-8e0d-e43fe603a37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ed86373-dafd-434d-8e0d-e43fe603a37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5890eea6-016f-4432-b2e4-ae78600796a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5890eea6-016f-4432-b2e4-ae78600796a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_322fbb1c-dad8-4e80-a6d2-a1835a035d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_LongTermNotesPayable_322fbb1c-dad8-4e80-a6d2-a1835a035d82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a75f74c-0217-4d22-878b-4da0612721a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a75f74c-0217-4d22-878b-4da0612721a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_e8e70ff7-a197-4260-8eeb-2ddb707c2bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_e8e70ff7-a197-4260-8eeb-2ddb707c2bf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_a1a36b4f-45b8-4a40-813f-2447469ea384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_a1a36b4f-45b8-4a40-813f-2447469ea384" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended" id="i532fec0fdeb947fea5a92c68e87c0a4f_BalanceSheetAccountDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended" id="icb6b077ed73240c6af872df7cd796544_BalanceSheetAccountDetailsTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended" id="ifbb2ef7a2daf481ea22d8b57e1dd2713_BalanceSheetAccountDetailsInvestmentCategoriesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a3ac5832-dc6f-4e44-9209-0bd982417195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a3ac5832-dc6f-4e44-9209-0bd982417195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f5f8243-d779-468a-a4ce-397a97e10ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f5f8243-d779-468a-a4ce-397a97e10ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c642920d-d6a4-4699-ad42-4c6972890b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c642920d-d6a4-4699-ad42-4c6972890b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fc9e6e4-a34b-475b-99d9-0b74e3d5732c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fc9e6e4-a34b-475b-99d9-0b74e3d5732c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:to="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_588ba3b8-051c-4074-96f8-d914954fcdb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_588ba3b8-051c-4074-96f8-d914954fcdb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_191629a4-89f7-4f71-9d7b-e4464390945b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_MutualFundMember_191629a4-89f7-4f71-9d7b-e4464390945b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_8f7007e8-8a56-4614-adf2-01ed1101c85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_DemandDepositsMember_8f7007e8-8a56-4614-adf2-01ed1101c85d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2e7885d0-8ee1-453c-9fe7-1d01475e179b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_CommercialPaperMember_2e7885d0-8ee1-453c-9fe7-1d01475e179b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_61ffcd58-56c3-4d2e-b6ab-5d48d847af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_61ffcd58-56c3-4d2e-b6ab-5d48d847af49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_4b7dcb32-0c15-48ba-a9f2-328552a785d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_AgencySecuritiesMember_4b7dcb32-0c15-48ba-a9f2-328552a785d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a5b8a410-7639-402f-83b0-9ec1f4c791e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_a5b8a410-7639-402f-83b0-9ec1f4c791e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5b8bc5f9-e99e-4034-bcde-1a21c69dccd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5b8bc5f9-e99e-4034-bcde-1a21c69dccd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_359a9ade-933e-4f98-88c4-a8ecade8cd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_WarrantMember_359a9ade-933e-4f98-88c4-a8ecade8cd14" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended" id="i11ff04ddd1e94ac5a197ab13b2f1b96f_BalanceSheetAccountDetailsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_20dfe7fc-ab46-41df-be82-cad9be1cc20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_20dfe7fc-ab46-41df-be82-cad9be1cc20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5b788723-edff-4339-8ef7-eb5d8ced08d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5b788723-edff-4339-8ef7-eb5d8ced08d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8709c1d-1453-4b63-9b0e-f0867c1c21d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8709c1d-1453-4b63-9b0e-f0867c1c21d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_979a1ede-8826-41f9-b939-33836ddde3eb" xlink:href="lgnd-20201231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_lgnd_InvestmentInVikingCurrent_979a1ede-8826-41f9-b939-33836ddde3eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a9f42999-742c-4a0d-8fb0-ca788f864f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a9f42999-742c-4a0d-8fb0-ca788f864f51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_15186b95-78c3-4308-96e0-7c7f5ca39bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:to="loc_us-gaap_WarrantMember_15186b95-78c3-4308-96e0-7c7f5ca39bca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended" id="icca32bfa104947d994089a658c602a1b_BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended" id="ia6ca4465a20c42ab8b28f034d68e2509_BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_50f8fbda-bfa4-46ad-b97b-1c5f15c7063b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_50f8fbda-bfa4-46ad-b97b-1c5f15c7063b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1501b3ed-c197-490b-a95b-6ab2eabed2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1501b3ed-c197-490b-a95b-6ab2eabed2b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_29bc3d86-83e5-43f9-80bc-d3a1aacae4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_29bc3d86-83e5-43f9-80bc-d3a1aacae4e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7493c142-dac0-4e7b-bf24-4b90f93d4948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7493c142-dac0-4e7b-bf24-4b90f93d4948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_91cf0e3f-3584-41fa-bd17-220e6ad9a004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_91cf0e3f-3584-41fa-bd17-220e6ad9a004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7fb82eab-381a-4081-a91a-d1c01632ea2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7fb82eab-381a-4081-a91a-d1c01632ea2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:to="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_065b6bbd-68df-4014-8c3d-42084291d923_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_065b6bbd-68df-4014-8c3d-42084291d923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_4cbd2e9b-755c-4a0e-ade0-8c5f278fd828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_DemandDepositsMember_4cbd2e9b-755c-4a0e-ade0-8c5f278fd828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ce140a75-0c92-4391-8646-dd6ea4fcb062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ce140a75-0c92-4391-8646-dd6ea4fcb062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_56b66a63-282f-43d3-bbcb-43fd366f2b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_CommercialPaperMember_56b66a63-282f-43d3-bbcb-43fd366f2b5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended" id="idccf2e6810e84fcb9ce5e92da2ba22db_BalanceSheetAccountDetailsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5e5971dc-fa8e-4124-8a99-4f4757e7b701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5e5971dc-fa8e-4124-8a99-4f4757e7b701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b9c04229-1d8a-4300-971f-bd3b93556e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b9c04229-1d8a-4300-971f-bd3b93556e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44a25167-9d43-4102-8e6b-646e3e6ead35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44a25167-9d43-4102-8e6b-646e3e6ead35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6165c8b0-88c7-4d64-8d4c-51265b5ecdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6165c8b0-88c7-4d64-8d4c-51265b5ecdec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c8a84e8a-4f77-4dc6-9f31-55fb2af5cdf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_Depreciation_c8a84e8a-4f77-4dc6-9f31-55fb2af5cdf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:to="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e25cac48-6aca-4d86-9346-f61597169af5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:to="loc_srt_RangeMember_e25cac48-6aca-4d86-9346-f61597169af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:to="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_18a0fee9-4f87-4ce8-a2dc-b0d97a3a3bbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:to="loc_srt_MinimumMember_18a0fee9-4f87-4ce8-a2dc-b0d97a3a3bbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ba26362-a334-4c41-ae6a-00a08d8896f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:to="loc_srt_MaximumMember_7ba26362-a334-4c41-ae6a-00a08d8896f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fa01455-eca3-425b-9743-fe534179f921_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fa01455-eca3-425b-9743-fe534179f921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_31615181-8465-4937-89cb-b78871edcda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_us-gaap_OfficeEquipmentMember_31615181-8465-4937-89cb-b78871edcda8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_328ccf2c-ab27-4ad1-91ee-be92769309b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_328ccf2c-ab27-4ad1-91ee-be92769309b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_bb32da0a-9a70-400c-afe7-48f5aa102794" xlink:href="lgnd-20201231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_bb32da0a-9a70-400c-afe7-48f5aa102794" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended" id="i1d3842eb00fa4bfba7c809dee4c1dcce_BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22178c01-9e7d-4c8b-a1c4-f2675d48d6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_Goodwill_22178c01-9e7d-4c8b-a1c4-f2675d48d6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d346a1e3-9936-40e5-826b-10093379d341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d346a1e3-9936-40e5-826b-10093379d341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0d463c7-3d18-47b1-ac8f-fdeb9351ce29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0d463c7-3d18-47b1-ac8f-fdeb9351ce29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b99ddc2-4ff7-4456-818f-ac79b2de572c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b99ddc2-4ff7-4456-818f-ac79b2de572c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9daf4242-4727-4607-b195-797f91f5cf26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9daf4242-4727-4607-b195-797f91f5cf26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8a83f97e-e44f-4eee-bf75-7a1a0f631066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8a83f97e-e44f-4eee-bf75-7a1a0f631066" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85cf79db-4905-47f0-a013-1197da4f25f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85cf79db-4905-47f0-a013-1197da4f25f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4b2a94cb-49e3-4dcf-bcb8-19519fe2a4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4b2a94cb-49e3-4dcf-bcb8-19519fe2a4a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_02e4a22b-1b51-47f2-8ad2-5e74189694d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_02e4a22b-1b51-47f2-8ad2-5e74189694d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636aff5b-7327-4f5d-93ee-b9313cf05fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636aff5b-7327-4f5d-93ee-b9313cf05fc5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_25819476-f562-44e6-baaf-05734af6013b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_25819476-f562-44e6-baaf-05734af6013b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44ed71a8-795f-4a8b-9956-9d11162b9004_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44ed71a8-795f-4a8b-9956-9d11162b9004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_6cd645e2-d459-476a-85a9-29a1beb7182c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_PatentedTechnologyMember_6cd645e2-d459-476a-85a9-29a1beb7182c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_74d44cf4-df70-4616-b3c5-304f8720c3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_TradeNamesMember_74d44cf4-df70-4616-b3c5-304f8720c3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_ed2d8968-1866-42a0-a5f4-5505d1b895e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_CustomerRelationshipsMember_ed2d8968-1866-42a0-a5f4-5505d1b895e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_20e163a3-d661-427f-a054-ff49bd62f7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_ContractualRightsMember_20e163a3-d661-427f-a054-ff49bd62f7b5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended" id="ib3026322c87a493fb59042f5fbdcb41b_BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended" id="i10ae374738b54bcb87ec373781686e4a_BalanceSheetAccountDetailsContingentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_b5fc7d42-3ac1-4ee8-be21-38ca4f7f8da8" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_b5fc7d42-3ac1-4ee8-be21-38ca4f7f8da8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a9d21be-eef2-4647-a478-221179c0ad5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a9d21be-eef2-4647-a478-221179c0ad5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:href="lgnd-20201231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e9e30389-6c95-4ba7-b55b-f7277f5f614d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e9e30389-6c95-4ba7-b55b-f7277f5f614d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_f091145e-491b-4523-ba03-92fc087d6815" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_f091145e-491b-4523-ba03-92fc087d6815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_21adf5cd-d58d-446d-b152-b5e351be484c" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_21adf5cd-d58d-446d-b152-b5e351be484c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_96b21123-2efe-4074-be9f-a72992b4a01b" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_96b21123-2efe-4074-be9f-a72992b4a01b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3bf833ad-9b7b-4242-86df-86423258cadd" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3bf833ad-9b7b-4242-86df-86423258cadd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_edc51aae-6e07-4082-893e-688dc0bf02a1" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b9684ef-736c-4914-9541-2661525e95e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b9684ef-736c-4914-9541-2661525e95e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_f9886b68-e998-4838-90cd-8141f4df706f" xlink:href="lgnd-20201231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_f9886b68-e998-4838-90cd-8141f4df706f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_f6f80a4c-d0e3-49ad-9c61-807810b08b3a" xlink:href="lgnd-20201231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_f6f80a4c-d0e3-49ad-9c61-807810b08b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_550729a8-c81b-4e73-ac49-981c64ecdf23" xlink:href="lgnd-20201231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_CrystalMember_550729a8-c81b-4e73-ac49-981c64ecdf23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_5406428a-4c78-4050-ae95-af53d5beb09d" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_IcagenMember_5406428a-4c78-4050-ae95-af53d5beb09d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_a7353d2c-9eee-47a4-bce9-c45544958a35" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_PfenexMember_a7353d2c-9eee-47a4-bce9-c45544958a35" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended" id="i7654d99ffd1f4f3ab406d4002a1f2cf7_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended" id="i8c732547ab8e49b085f43ddb68fb9233_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended" id="i3aa272e95ed643dd9b90cef8392cc249_StockholdersEquityShareBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_3d6c64f1-23ef-4d7f-9434-434e1283c208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_3d6c64f1-23ef-4d7f-9434-434e1283c208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb767e36-c1b0-4f60-8eb8-58a05053529c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb767e36-c1b0-4f60-8eb8-58a05053529c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_990583f3-2fdf-4d28-9b3d-7b5094c868a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_990583f3-2fdf-4d28-9b3d-7b5094c868a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1cbabf63-2973-48fb-a654-dca59461eab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1cbabf63-2973-48fb-a654-dca59461eab0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i645d4249df7f4fc7ba00044ad520b860_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_107eab9f-5deb-45f0-b7d9-52ecb6e35812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_107eab9f-5deb-45f0-b7d9-52ecb6e35812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d53ebb1f-c003-4144-81d4-7141e348de2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d53ebb1f-c003-4144-81d4-7141e348de2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da7f74c3-3da1-409b-a3a2-6620cea91446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da7f74c3-3da1-409b-a3a2-6620cea91446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b50723b-8a24-42d1-ae64-a2487b543583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b50723b-8a24-42d1-ae64-a2487b543583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_33efac59-5746-4fca-91ef-f13f281d3e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_33efac59-5746-4fca-91ef-f13f281d3e22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f7004d-21a6-4096-b0b1-1328314bb2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f7004d-21a6-4096-b0b1-1328314bb2c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5721a0c1-4365-4b2e-a48c-e4432fc68afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5721a0c1-4365-4b2e-a48c-e4432fc68afa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eba379ab-41dc-48c8-8c00-81671dbf9e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eba379ab-41dc-48c8-8c00-81671dbf9e34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f70f49dc-e158-4c84-b30c-e76001574bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f70f49dc-e158-4c84-b30c-e76001574bca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:href="lgnd-20201231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_940f22f1-34a0-4e9e-805c-76c52ed3eb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_940f22f1-34a0-4e9e-805c-76c52ed3eb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_222bde9e-670e-4d16-a8b8-9591e2a33df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_222bde9e-670e-4d16-a8b8-9591e2a33df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3e8abfea-e24a-4c30-897a-1ac48e55602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3e8abfea-e24a-4c30-897a-1ac48e55602a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:href="lgnd-20201231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb872da9-63db-4061-b452-f6476892fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb872da9-63db-4061-b452-f6476892fc31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_ba001309-3d38-4daf-a48c-4cf97747402f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_ba001309-3d38-4daf-a48c-4cf97747402f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4985af66-41eb-458e-a337-920600d05642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4985af66-41eb-458e-a337-920600d05642" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_f22a52f2-9c64-441b-89c7-1d9cb9421da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_f22a52f2-9c64-441b-89c7-1d9cb9421da7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_926bf364-d379-44b6-8383-e61772eabefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_926bf364-d379-44b6-8383-e61772eabefe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_acea497f-a413-4665-a0f8-2299825238dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_acea497f-a413-4665-a0f8-2299825238dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_19b685f8-2869-4738-a9af-c25f7e7a781c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:to="loc_us-gaap_PlanNameDomain_19b685f8-2869-4738-a9af-c25f7e7a781c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:to="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_776a4550-3088-4ace-9f70-fa81711b0649" xlink:href="lgnd-20201231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_776a4550-3088-4ace-9f70-fa81711b0649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_2e44140d-13d6-4ddc-9369-8c2a500b6572" xlink:href="lgnd-20201231.xsd#lgnd_AmendedESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:to="loc_lgnd_AmendedESPPMember_2e44140d-13d6-4ddc-9369-8c2a500b6572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd4d6b4-934b-4a9a-b801-23ae056b0174_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd4d6b4-934b-4a9a-b801-23ae056b0174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93d34d98-ebab-4bcc-909e-0c37948ac81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93d34d98-ebab-4bcc-909e-0c37948ac81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16be9dde-2425-45c4-aba2-1bfb5c654a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:to="loc_us-gaap_RestrictedStockMember_16be9dde-2425-45c4-aba2-1bfb5c654a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d8de7eee-909c-441f-b62a-e94e1b078f11_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d8de7eee-909c-441f-b62a-e94e1b078f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_8a5184be-0833-4a48-9e5e-5a5b1a806d0a" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:to="loc_lgnd_PfenexMember_8a5184be-0833-4a48-9e5e-5a5b1a806d0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended" id="ia9403116b72c40c092137dca78c9226e_StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended" id="i92ac7b578f3e403db0ae79d6c92592a8_StockholdersEquityBreakdownofOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0a0845a-d725-4cdd-b5cc-454b9f11603a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0a0845a-d725-4cdd-b5cc-454b9f11603a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e29703e-a993-4a2e-8830-6ef6d19903d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e29703e-a993-4a2e-8830-6ef6d19903d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_b7af8774-44fc-4694-9322-54aaad5ab322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_b7af8774-44fc-4694-9322-54aaad5ab322" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_71815445-42c9-4f64-b69e-82bedc430bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_71815445-42c9-4f64-b69e-82bedc430bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_eec74e30-caf3-4255-89c6-34d24a75ec53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_eec74e30-caf3-4255-89c6-34d24a75ec53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fdca390-c939-4852-96ee-e607bb1b0813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fdca390-c939-4852-96ee-e607bb1b0813" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_a37268e4-1f45-4fdd-aea7-1faee15a02ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_a37268e4-1f45-4fdd-aea7-1faee15a02ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_9cbeb9f8-5756-4f71-9496-88f9ed1e5d8a" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_9cbeb9f8-5756-4f71-9496-88f9ed1e5d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_cd2257da-bf36-4fb0-bc45-d122b8677edb" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_cd2257da-bf36-4fb0-bc45-d122b8677edb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_1884c51d-a210-4777-8c49-e1bd526a1ac1" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_1884c51d-a210-4777-8c49-e1bd526a1ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_0da43c49-0e0a-4d2b-88c6-a186a513bdac" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_0da43c49-0e0a-4d2b-88c6-a186a513bdac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_ee7100e9-b731-4b7a-88dc-03df4476d381" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_ee7100e9-b731-4b7a-88dc-03df4476d381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_69e7ff0b-0864-452e-9729-acaf31b707a0" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_69e7ff0b-0864-452e-9729-acaf31b707a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_c25ba81f-7993-4b97-ad8f-7ef0114005ac" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_c25ba81f-7993-4b97-ad8f-7ef0114005ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_d6284e58-9c80-4578-a6f3-24e8c2462b62" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_d6284e58-9c80-4578-a6f3-24e8c2462b62" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_cc27eb7d-4ee6-4350-b921-f528993f810e" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_cc27eb7d-4ee6-4350-b921-f528993f810e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_b5073c3f-269e-495d-9995-01a203e54902" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_b5073c3f-269e-495d-9995-01a203e54902" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended" id="iccc8e06c685347069dfe91bb13ac7f35_StockholdersEquityAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_507d0bf8-4d62-4123-9043-08f0f07de242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_507d0bf8-4d62-4123-9043-08f0f07de242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18cdf3bf-b591-4b7b-842a-d77ded997683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18cdf3bf-b591-4b7b-842a-d77ded997683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f8cbd8-f1f5-4438-b209-9355a8ea5b66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f8cbd8-f1f5-4438-b209-9355a8ea5b66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:to="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:to="loc_srt_RangeMember_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:to="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d72339e3-b2ab-4f1d-ba1c-6bc878b5e065" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:to="loc_srt_MinimumMember_d72339e3-b2ab-4f1d-ba1c-6bc878b5e065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c4a5763-75dc-4622-8800-97902466ca14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:to="loc_srt_MaximumMember_2c4a5763-75dc-4622-8800-97902466ca14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended" id="ibe2f07cf2110471c975a9a816a30d9e6_StockholdersEquityRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec5a5705-3b49-4999-adb2-2327fcd5fb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec5a5705-3b49-4999-adb2-2327fcd5fb1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438972d1-1d34-4d9b-9d7c-a38870dbaa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438972d1-1d34-4d9b-9d7c-a38870dbaa95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b6e12192-f53b-4a8e-b268-4ef3f9e21835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b6e12192-f53b-4a8e-b268-4ef3f9e21835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30955c21-fc30-4cbc-b197-4fe7b68f0e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30955c21-fc30-4cbc-b197-4fe7b68f0e55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29b17a9f-a541-4a41-bb83-57c36d8bbf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2f9af14-1049-4533-85ee-eea631bda78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2f9af14-1049-4533-85ee-eea631bda78c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c57063eb-dcf7-4032-89a6-fe521358ddde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c57063eb-dcf7-4032-89a6-fe521358ddde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe16ed8d-d119-4569-894a-23431a453cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe16ed8d-d119-4569-894a-23431a453cfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a0adcb8a-b2a0-4d1f-81a1-e4b9f60a4c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a0adcb8a-b2a0-4d1f-81a1-e4b9f60a4c6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_67d4191a-c0ac-4b31-bf7a-7b95715502a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:to="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1ee6e3c4-40ec-49c8-a2e1-bae773d0bdde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:to="loc_us-gaap_RestrictedStockMember_1ee6e3c4-40ec-49c8-a2e1-bae773d0bdde" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended" id="if66ff81c394e427fa0c3468efcbf71b8_CommitmentandContingenciesLegalProceedings"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended" id="i37ffb341ccf34cb8adff22edf463e127_CommitmentandContingenciesLegalProceedingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_74d13f61-2402-49eb-be20-903f01e36090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_74d13f61-2402-49eb-be20-903f01e36090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_5d01632c-578a-4dc5-bdf3-0ed1065697d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_5d01632c-578a-4dc5-bdf3-0ed1065697d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:to="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:to="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c130baf5-09c7-41e5-b762-bb48b3455f5c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:to="loc_srt_LitigationCaseTypeDomain_c130baf5-09c7-41e5-b762-bb48b3455f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:to="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember_866ab513-d5f0-40cf-ad8b-decd33cf1e07" xlink:href="lgnd-20201231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:to="loc_lgnd_LupinPatentInfringementMember_866ab513-d5f0-40cf-ad8b-decd33cf1e07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_0ae2d6ba-6b4b-42c4-9679-5286d7bfefb9" xlink:href="lgnd-20201231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_0ae2d6ba-6b4b-42c4-9679-5286d7bfefb9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended" id="i14e32e56291f4b39ae4e45b2c92101c1_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended" id="i3b61d6f5818a4fbbb9280b14e84814c0_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i04fb4373915143d1a4558e58b6e5421c_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a00ab2fd-8f6f-4ad9-9689-1ec461e82276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a00ab2fd-8f6f-4ad9-9689-1ec461e82276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e7193ed2-508b-43ad-83bd-a343f7c921ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e7193ed2-508b-43ad-83bd-a343f7c921ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_bbb9fe1a-bf64-4e5d-a988-4d2c1b01240e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_bbb9fe1a-bf64-4e5d-a988-4d2c1b01240e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_90eaf7f5-ddb0-4325-b339-112c23dd6879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_90eaf7f5-ddb0-4325-b339-112c23dd6879" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a5a8ca22-a48e-4879-a7bd-57623e504d04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a5a8ca22-a48e-4879-a7bd-57623e504d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_07dbe186-87f5-463a-81b5-921ab8d1c9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_07dbe186-87f5-463a-81b5-921ab8d1c9b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7b5dfbd9-bcb1-489d-a19b-1281c9a48a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7b5dfbd9-bcb1-489d-a19b-1281c9a48a60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_20996ac0-bdbf-454d-ba20-9d78a4f05add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_ForeignCountryMember_20996ac0-bdbf-454d-ba20-9d78a4f05add" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_04223aba-aafa-4c83-bdfb-fe9ba0bb0751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_us-gaap_ResearchMember_04223aba-aafa-4c83-bdfb-fe9ba0bb0751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_351f6262-8643-40ce-9fd5-65a363751fc3" xlink:href="lgnd-20201231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_351f6262-8643-40ce-9fd5-65a363751fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_01653786-eae8-4b0e-be10-f1f0c71b9989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_01653786-eae8-4b0e-be10-f1f0c71b9989" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="ia59807e7331a44b5936afcfa591ce89c_IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="i3a88b6a96b394b88aa5517620932f1b3_IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended" id="i46f3d42817924f20a4f4aaa1a77087af_IncomeTaxesDeferredTaxesDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i5ee059b540a24769be3b4decace09ccd_IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended" id="if050948750774b23bb2e0b546a9108a8_SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended" id="i3c760d30e2e74b3981db494a88cffeea_SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended" id="i7dd03a11c58b49b7952a778b0082a818_SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b8a40b4-fe37-4994-bdcc-953b4923bcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b8a40b4-fe37-4994-bdcc-953b4923bcaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_c892227d-ee52-4691-82b5-9fddccd82436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_c892227d-ee52-4691-82b5-9fddccd82436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dae17f9f-717b-46df-9d71-21f895ef78d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dae17f9f-717b-46df-9d71-21f895ef78d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7009be47-8587-4d0b-89ac-9f160c64ecb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_NetIncomeLoss_7009be47-8587-4d0b-89ac-9f160c64ecb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6625f3e3-a945-4f44-a7a1-9d1bdcff7d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:to="loc_us-gaap_EarningsPerShareBasic_6625f3e3-a945-4f44-a7a1-9d1bdcff7d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_661ab8fe-e668-43e9-ba5f-8564ef48fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_661ab8fe-e668-43e9-ba5f-8564ef48fa4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfcf5e2d-ca12-4e32-a928-e4b130ab73f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfcf5e2d-ca12-4e32-a928-e4b130ab73f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3a84034-72a6-46e2-bf01-40e98d0ded69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3a84034-72a6-46e2-bf01-40e98d0ded69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af3eb100-9533-4d1a-8a75-6317916704b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af3eb100-9533-4d1a-8a75-6317916704b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:to="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c483f889-a1d7-4c20-974c-2d94359267ef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:to="loc_srt_ProductsAndServicesDomain_c483f889-a1d7-4c20-974c-2d94359267ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:to="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_7f8023a1-6911-47b5-8735-a73f0acfc7e4" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:to="loc_lgnd_PromactaMember_7f8023a1-6911-47b5-8735-a73f0acfc7e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>lgnd-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0a26a662-b308-4dd0-a657-b3da494e93a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8596e7ad-bb3f-4103-96b9-000af3a1398f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2270e01e-2d94-4af6-9d4a-84b7e4e3a268_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies: Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_39d286ec-06b3-4fbc-8d52-31cadf096c7d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_9f170db5-af85-43ba-a392-e18720d45bcb_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$117.97-$195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTenMember" xlink:to="lab_lgnd_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_97583cb2-d0f1-481e-826d-eef41252309f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a12328d0-91b3-4279-a847-82063929d0c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_e0826f7f-9f1a-4a0a-a84e-ac9bc0ba9af4_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2d66a602-3dd2-4edc-a49b-8be6f583650f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_e81ee77b-934b-4a32-b2f5-48dc02793972_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the conversion option derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_8f30ac90-b8f7-44bb-bef8-ffed800498c9_periodStartLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at beginning of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_86154e65-4083-4f06-91a9-4ca4dc3b2f86_periodEndLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at end of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_7305b1d7-378c-40df-a628-113b09c0bbf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate change for changes in federal or state law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_d4a50e10-0b60-4731-85f0-1acc6c6d29fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_09e0f1b4-9248-4b7e-8d41-9af55a8cb265_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsAlvogenMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Alvogen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsAlvogenMember" xlink:to="lab_lgnd_ContractualRelationshipsAlvogenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PromactaMember_c92e9580-51aa-4c84-be58-955f833c7e1a_terseLabel_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:label id="lab_lgnd_PromactaMember_label_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta [Member]</link:label>
    <link:label id="lab_lgnd_PromactaMember_documentation_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PromactaMember" xlink:to="lab_lgnd_PromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7c16a46b-9c88-4a44-821c-ec5308e362e4_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f0207f5d-679c-403c-ab3e-36d77615befa_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_015a972d-bb6f-43c1-9eef-1c7d97f3e09f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5be67546-2f54-4b4b-a622-f7c166a5e32c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_8e2b9370-d4fb-46b3-b0dd-4c3588be3295_terseLabel_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_label_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products [Member]</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_documentation_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember" xlink:href="lgnd-20201231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NovanMolluscumProductsMember" xlink:to="lab_lgnd_NovanMolluscumProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_7ea61551-5e52-49f2-923e-23e6fd655d28_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquisition of equity due to 2023 debt extinguishment, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_b8498b6a-5251-40e4-8934-9f4a9de052e4_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cb0aa3ad-e1ae-4cfd-bdd4-6d68cdd126fc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_7163e177-1b38-44a6-a0a4-b2cd6fe359f7_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross payments to acquire business attributable to vested portion of stock options</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_label_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_documentation_en-US" xlink:label="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:to="lab_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_4a09d217-4155-45d6-8d97-4970deb9d0ed_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3643335d-87c7-4821-97f0-3008905a0395_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_124b41c2-e969-4448-89ee-8ed417689b63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_eee98071-e0f1-4e33-80b3-b4147e8fc0e7_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3bbb40ec-cd86-4203-a7b6-6b7c947d6edf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_371883df-02ed-428a-91f2-353831f044a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_6f6b3579-8c7b-44b0-b974-be54fa96f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_06a157ab-e346-4190-ac6a-b1a6dfa432ab_terseLabel_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_label_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_documentation_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:href="lgnd-20201231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:to="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_03cd2f2f-2f59-444c-9297-5abed787a950_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cf187744-a9ad-4c60-941b-672bd21582f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_fcbf0552-b092-4427-b92a-b9fc8deb24b7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_977fa88f-96e9-43be-a4e7-b70a9396bea1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_2bdab82e-5977-4ce2-96d8-7b5847e4ee1e_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of milestone payments (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_1064e69c-d822-4217-8c74-69ee4330ad1a_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a18d7e08-1bc7-4cae-b3d6-1f5b4b7a98ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0a6c2146-ffc3-4d52-b472-4d52ded38898_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_d09c02a4-eb07-4f3f-b4ed-5b7395701e07_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_4f2362d8-35bd-479a-9d3f-372617392018_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement of Notes</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5ff0325e-73eb-47ba-b629-c730adac7456_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average useful lives of acquired finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a896f85e-f604-4f54-9341-9c29962e6b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74f09245-ceda-475a-9e08-0b4116a1d8c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93727758-bf98-4466-b1c5-e5912e1176dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5de60b1b-c5f7-4f25-accd-a1b3ea3a09ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_02aaf2ff-6466-4495-9dd6-0d45d66d1a91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_333bda35-02d9-4a69-887f-e3bd12bccee8_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:to="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_816fff20-342a-4428-837f-348fe1753bf9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares allowed to purchase in employee stock purchase plan per employee (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_550f4024-87de-4115-a34d-297f529807b8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_7f3f4896-9613-41d7-a6a1-6fed04d59adb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_b6c76afe-ebb8-47c7-8106-bb10bbce97b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_e8f37912-3456-455c-b27d-5006fd17afa1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_615d4b06-923b-443e-9289-7780511e1c08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b7da272d-be28-4f39-b1e8-301559605898_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_5ff86950-3916-4ab9-a2ff-b7b00e492dc0_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$100.02-$113.76</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeEightMember" xlink:to="lab_lgnd_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4231e845-7169-4930-bc77-b30ac25e8674_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9149b00b-cb88-42bf-8018-94a47be1c9ff_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_cc45ed84-0cf2-4ef4-a794-3572e42792f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_adf9af3f-456b-4c6b-9c7a-cbcd62421310_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_d55257a4-1f64-4c63-9801-c9b4a808637c_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_eb598c22-277d-4e6d-9f6b-d66fa0a131da_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$21.92-$56.26</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTwoMember" xlink:to="lab_lgnd_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2af0748-3950-4455-b774-f17c0f18106e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e4ff2a2a-89ca-4276-9e0b-fcd5ceddb3e7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_92b6e897-d577-4ab8-b7fc-e8d69fc44a42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8b6ba95c-64d5-4ac5-823f-3145f649d6c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerBMember_395eaa38-42a2-4f97-a478-5eda9fe8f342_terseLabel_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_lgnd_PartnerBMember_label_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_lgnd_PartnerBMember_documentation_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember" xlink:href="lgnd-20201231.xsd#lgnd_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerBMember" xlink:to="lab_lgnd_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_005a5341-ea44-4ea9-be26-0ba3bdf07227_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3fd4d7a6-b089-4cb2-86e7-30e04e65870a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d0a5e255-0d2f-4d17-8b08-811f6057b965_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_df4b47ab-86c0-411b-9706-a96bb56274d6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_09da3e11-61b0-4bd1-9478-b1c2c3cdc9dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7f56609c-3a86-4bd9-a860-17b13b1aba50_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_bd81a5f9-eda4-4591-9b79-9c7824cb335d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f449f85-79d5-432a-9b7c-78dab9c8a679_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2e9fbaf9-2aad-45c0-9f08-f5dae9f3eaed_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f66bf619-4cac-4bf0-bab9-c712d71d4a4b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_e6e80aee-ce54-444c-b29d-74d8484786b4_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Icagen</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Icagen [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Icagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_971cace2-eec1-4ea6-8ae1-54e456b20b12_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_01fff6b9-694f-43d3-b187-beff8891ddef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2ff6e8d-0696-4f6e-aeb3-9645ca01e378_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodOneMember_8e05a837-1d02-489e-9fc9-2d577f56a6e7_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/8 on the six month anniversary of the date of grant</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodOneMember" xlink:to="lab_lgnd_VestingPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3d3e7ad5-78ed-4da0-9cec-2465e2225442_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2936e937-bfe1-4cae-a0e4-9b7de507e081_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1c35cf6-e046-42ce-9d90-64447c278513_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb13a4e5-09f2-4be2-9b88-b58933d4a828_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_edc5a666-efdd-4d8f-87a2-cc1968ed0aea_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_6426ca9c-a525-49d5-bac1-cb57d052984c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share consideration</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_b51d0822-14fe-44d0-87a0-a52930f000ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_71367883-1fce-46de-a826-e1a22ea3575e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future option grants (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_31549d39-e32b-45a8-bcd7-9c52b4015be3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_a405f76a-0122-46e9-9fe9-183c179acf3b_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future commitments through 2021</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_3a18d300-d7c2-426e-aa60-7a43f89de79b_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_207e687a-adaa-432b-87d8-03671daf4624_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">97.92</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSixMember" xlink:to="lab_lgnd_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_96209d68-e423-4a12-be52-cb0144e0685e_terseLabel_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_label_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi [Member]</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_documentation_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember" xlink:href="lgnd-20201231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisAndDianomiMember" xlink:to="lab_lgnd_SelexisAndDianomiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8f97b36d-6265-4c40-b3f1-14bb1559080d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_51f107d9-2a91-4f8f-8fee-1e312d9be00c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_85e7ac28-e87e-4fb7-bece-23db28402ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_e18f9313-0d35-4e90-a86a-cf4d10f31e91_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts owed to former licensees</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99419d46-3596-48fe-a0de-3ed2f92133a4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_ee35e17d-6ce7-43b0-bc9c-ab21c6ed6d45_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_fd6cce61-5236-4efa-9a0c-d3335f146089_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_80380562-c834-4748-9336-ee4424f35e73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_e14dcbb2-a125-4b0b-b700-df7dc2ba3dac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f3d10d56-c674-4d14-9ad7-6f845666cd49_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets recorded in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_0f614e7e-4f06-4ae1-adc8-f0793f833860_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:href="lgnd-20201231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_799a9465-dd22-47e7-9125-59b1390d197f_verboseLabel_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:href="lgnd-20201231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3506c0e3-a627-4905-970b-1d5ffe79bcf0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under amended ESSP (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_653337ec-2cf6-409c-a2a1-31a28fe38c6b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_791d9211-ca78-40cc-9be0-9412bd2f4d41_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_c472cc88-b446-4a91-a8d7-ec00eb40d93d_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from commercial license rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:href="lgnd-20201231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:to="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_96c416cd-fdcc-4341-a81a-ca525f565e23_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2b8c3c84-a7d6-4d62-ab24-add9fc4d1972_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a79509d5-cd14-4ea0-87ad-c84926982b63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_563e55f9-ace1-4479-9fc3-723472a09734_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_e6f0db83-252a-4429-80a7-4c903f2b1c08_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f612e0f6-739d-4832-8f4c-b5b33d321c52_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_7a5934ef-b028-4aea-bba4-d1dbc917127c_negatedLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDII</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_2e829e74-09a6-4242-a42c-bcf26cb42b68_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_edcec729-49ff-4bb2-b86c-c302552013e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5b6f9753-78ee-4af8-8d8c-3dd734385a72_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4bfdd2dc-fb34-4e6d-8ac6-0ecd394ac237_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_3fd51aa6-8ab5-43b3-bb27-04d6b5d11f91_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_f7b4ef14-7a9d-4523-9c36-07c24a31d629_negatedLabel_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_label_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_documentation_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:to="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_5b8f0d80-32bf-4a42-9f24-8e52f0b58f50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notices for conversion</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_e7903012-af1e-4196-b651-f7bbabd24d0f_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles acquired</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_059f6012-32f1-465d-96ca-6e05194c6943_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a6488be9-9489-45cf-9059-2348bc80a96f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1598f390-2e1b-498c-ae48-d44ef5ce970b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_a19053eb-3df1-4954-88b8-e79c2e8e289f_terseLabel_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella</link:label>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_label_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_XCellaBiosciencesIncMember_documentation_en-US" xlink:label="lab_lgnd_XCellaBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xCella Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_XCellaBiosciencesIncMember" xlink:to="lab_lgnd_XCellaBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_12ec1cd7-ee46-4181-b212-27eeb7cebdd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_9781611f-69ae-4209-837b-72cbae3eb27d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ef40456-71ae-41ca-af34-bdae5362b29a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62bee1fc-5670-4390-a0a0-646a5aceb289_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a0d95aa6-6187-4674-b74f-047061bfb798_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bc860a60-01c3-40b0-9ed2-a4a70e1e4d0a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95c8d686-3408-421f-a603-d85ff7d7bfd3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_6e2c9c58-50a7-4478-9a6b-fd39d881cf32_terseLabel_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:href="lgnd-20201231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:to="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2bafd1da-047f-4790-bb66-93e3d743e008_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_91c45238-58c9-4e11-a819-77ac4b7bec6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_3b49436b-1c54-4590-8b9d-52885c8beb20_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_98a00fad-7e7f-4d7e-901e-845ab4430acb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f7f47169-65ed-4d2b-84d7-9a6fa6b17939_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_daf6c83e-087c-461a-b378-25c79fc7648b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_03f8211c-41c4-4644-b477-e050ffec8ec6_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share of shares repurchased (USD per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35b36d13-40d6-4906-b7cb-9a72b10c30e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_be3f8b89-e1cd-455e-9ecb-e27d49f8be7a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5b4c645e-5d0b-4f6c-8ec8-a91e29188e0a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dca8eda2-aa5d-4ad3-b71c-b7d832de62af_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_3696957e-00b2-47ee-b120-a8c44c2d652b_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other economic rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:to="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_34ff7e53-9770-4f3f-8b59-4c8626a55412_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_68a321f9-c21d-4804-a73d-978d0c2c6ab1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_4d2a4b58-793d-4e02-b2bb-92463b490890_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of convertible bond hedge (USD per share)</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_label_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:to="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_dc01dd03-40e3-4678-8fb2-6ba94f566b38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9df2c378-bdcf-4223-8b9c-de535c482cdb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4b16edf9-0212-472f-a1b3-b91ecb005ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, change in amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7f6dea27-eada-40ce-a9d3-42f4bd301f8e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_ad689d96-ca05-4773-b122-31f4c0335d85_terseLabel_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_label_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Share Units [Member]</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_documentation_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Share Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:href="lgnd-20201231.xsd#lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:to="lab_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_62fe3b13-9944-4f62-a97d-7f244380f16d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8b34b2b5-350f-49d6-8a08-0ddce20405bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_9f30a6d8-ae94-4fd0-bfae-f09615abf8a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_7e76bb6f-0369-4c04-9205-19695f166375_terseLabel_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement</link:label>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_label_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement [Member]</link:label>
    <link:label id="lab_lgnd_LupinPatentInfringementMember_documentation_en-US" xlink:label="lab_lgnd_LupinPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember" xlink:href="lgnd-20201231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LupinPatentInfringementMember" xlink:to="lab_lgnd_LupinPatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8d64604e-d633-4ecb-b8b9-0f2585370fbf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AbInitioMember_846a373c-a25c-48ea-a664-5be18e5ff19d_terseLabel_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:label id="lab_lgnd_AbInitioMember_label_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio [Member]</link:label>
    <link:label id="lab_lgnd_AbInitioMember_documentation_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AbInitioMember" xlink:to="lab_lgnd_AbInitioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_fb394f17-b430-4b36-8c49-96c75c516bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_80f28d75-3e22-4f0f-baac-2e8d17a8ac3e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments: Investment in Viking</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_911a8418-aa7d-4e50-9e77-b3b8ad8d2df7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11fa4533-0d0d-4e13-b897-0226f50e2ae0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f540fb32-341a-4a26-9b81-fe75d712fc19_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_6fe01c3d-6034-4912-81c3-4e17390a5fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7408615f-41be-49ad-a27c-a4af3a10fba9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition, net of cash and restricted cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5c29dcec-9c84-44f9-b7f6-61886659e55a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0b43dfc5-03f1-4960-b1de-b2e8cc56ebbe_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment , gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3fc23869-20e4-47ef-b3e3-f63e7cbad612_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_33df3a12-3d18-4b33-9ad2-6d66f374764f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_32bdf384-0374-4be5-853e-d659c6f3030e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_e75a5b16-c717-45d8-85b1-8553ae513d75_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for restricted investments owed to former licensees</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_label_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:to="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_17198315-8ff6-4e22-9d87-405ba7b0b5c2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VernalisMember_ec69b4fe-b819-4b43-a976-54b543de7511_terseLabel_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:label id="lab_lgnd_VernalisMember_label_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis [Member]</link:label>
    <link:label id="lab_lgnd_VernalisMember_documentation_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VernalisMember" xlink:to="lab_lgnd_VernalisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_00cf6b81-77c9-435b-a8ba-bf5010bec535_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_07c00a53-89e3-4265-9b3d-7c67b9f8f1a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_288605c3-662e-4580-887d-fc1f070c18d4_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of royalty agreement</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_label_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_documentation_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:to="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_555ac5ea-5b3a-40c0-a7d2-964bcbb8a86a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_c86a9f84-9a9c-4e77-be30-1a4aa5af4f47_terseLabel_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2002 Stock Incentive Plan</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand two Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:href="lgnd-20201231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:to="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_091b9637-4079-436d-8186-75f6d7350f66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_57f6a819-cd90-48da-bb57-297d3d05c22d_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_2aba7e4b-1c8c-4072-a38d-3a3ff992dbab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangibles Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_b464c7b4-680d-488e-adea-649a6198725d_negatedTerseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in debt discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:to="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_186738c8-cf52-4b58-bdca-0d579e8196fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Vernalis R&amp;D</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e80fc007-7b23-43d6-98de-699108203549_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_285c7ca1-d5e7-45f1-8d45-213545e7a127_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_a2a4905d-4955-4b3b-ad10-093b593a0aca_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earn-out payment</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1ce9d797-9b26-4d24-9fe6-673e45ff7e6a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31fd294c-9d86-45be-9212-6e3e335e067f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_2f1e7aec-c2b9-4376-81aa-6a50f629e35a_terseLabel_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contingent liabilities</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Portion of Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:href="lgnd-20201231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:to="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_12ec0cc4-64e0-4628-993b-3e0c8c0cc1d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_d9a72008-d956-46f5-b6ce-8b9aa20cc2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond hedge settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_23e708c3-7d90-4867-b220-706d8100fd79_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_d1dd1848-106a-4748-b136-421cfbf94281_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_edcdc5d9-4d06-45df-bfc8-b16fbddffd71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_2b99e20c-c717-4bcb-b0f9-0efd27d9f754_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6fb54af6-efda-4727-9aaa-de0068078528_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_bb8cfdd3-99f4-442e-abd7-53fb49f87b53_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_423522a0-c6d9-41d5-ace5-83090239e225_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision to return adjustments</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_f708d657-4dae-4ff8-be1f-a38b44d618f5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_c3c72699-5c8f-46e2-9dc1-6a1237d11a26_terseLabel_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating and Finance Lease Assets and Liabilities</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5aa2f94a-8ef7-4f51-ac33-2fb9a66366a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_8dbd17f2-ce25-4729-98af-027e5493a122_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If-converted value in excess of principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5a573af7-574c-4abe-acf5-121ab5e0158e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_e1fec448-1e0f-4080-8e17-dfaf89121542_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Unaudited Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_5aa87e89-32a1-4bac-a747-39e342109235_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$82.90-$95.35</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFourMember" xlink:to="lab_lgnd_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c86da270-0255-47df-bccc-fb48c02ba97f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f77d67ff-1627-445c-affc-e6cf3f28050f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_0aa9b5d4-dcc1-4fd1-924e-dd53b7925d2a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9d78c0a-50a1-4640-bb70-f2839daa9a78_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_c45145d5-8c06-4804-9c1b-cd63010d4327_terseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to allowance for credit losses related to COVID</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_label_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:to="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b00bbf5e-fbf6-4929-94dd-929dffe79bb9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_d051b995-862a-4825-9cec-d5f19878a67c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and unbilled receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_57c6d135-7a55-4e07-bcfb-45f28bc7e2dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased face amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_d3f5e02a-401f-416c-b21b-70a439a5f460_negatedLabel_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of commercial license rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:to="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a375d122-8767-4f42-8952-fde110da5103_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_21f578b2-85d8-40f5-9855-60344e033948_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset recognized</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ea908eca-774b-42d5-9df4-c3760c7193ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_390523a8-fefe-4703-aea0-6926b50fbc63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_603001ba-1b0b-4c30-8d99-1f0372048452_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_45624512-d790-458e-88d9-b483922cce28_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_56884fb1-283f-460e-87d2-51b153778846_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2c3b2dcb-084c-4bff-b558-9a05b12d714b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1c7c1607-c8f7-4961-b86d-7b49ddc0d3a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_54a187f2-697a-439f-8dc2-70b816ae80e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_8d8f0fdd-3083-4d0c-8bfa-06fbc818b9c7_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsMerckMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsMerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsMerckMember" xlink:to="lab_lgnd_ContractualRelationshipsMerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b92fe07c-0963-4eb0-a202-712c869dc07a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_11fa00d6-55ad-4739-874a-6131e3f99ab7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_2ef8bc09-c660-4e56-aa8d-1721686b99a8_terseLabel_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year:</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year [Abstract]</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:href="lgnd-20201231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:to="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50bfb185-e88d-4713-af94-74bfbc6703ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e3adf56b-cd18-4e7f-9e0c-ae39d628f9a8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_cbaf378b-43c6-42fa-986b-b7cc414a853d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_WarrantsSettled_5b2ea467-f2fc-45ab-93b6-e9c4b8dc5d0e_terseLabel_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants settled (shares)</link:label>
    <link:label id="lab_lgnd_WarrantsSettled_label_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Settled</link:label>
    <link:label id="lab_lgnd_WarrantsSettled_documentation_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled" xlink:href="lgnd-20201231.xsd#lgnd_WarrantsSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_WarrantsSettled" xlink:to="lab_lgnd_WarrantsSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerCMember_6ade2ea5-3c8b-4ad3-9054-c3347e2b267c_terseLabel_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_lgnd_PartnerCMember_label_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_lgnd_PartnerCMember_documentation_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember" xlink:href="lgnd-20201231.xsd#lgnd_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerCMember" xlink:to="lab_lgnd_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_71256b21-96b4-4f45-89ba-cf4f55ab8e60_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_cde2832c-c567-4c42-ada3-bbba78b4ddcf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aed2e6a2-948b-4106-9446-97f9a5a47c1f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_10d07d7b-f506-48fb-8d80-5ef79179f737_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and product reserves</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b8f4bbd6-2ca0-418b-9a15-41ca2be93a36_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_056cf840-8a3d-493d-9bac-5aa082085938_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">117.58</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeNineMember" xlink:to="lab_lgnd_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7abfd6e0-017c-47b1-910f-56209d665904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_df2360ae-bda2-42b9-ad08-bc73746d5887_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Crystal</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_9b2ad538-b666-4e7a-a512-a31d743c81cb_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/48 each month for forty-two months</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodTwoMember" xlink:to="lab_lgnd_VestingPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_485e678f-7e4a-4ceb-9167-8b5c52e6615a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_894a999a-eb80-40c0-a8ad-032ba3566bdc_negatedLabel_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of contingent liabilities</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_label_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash change in estimated fair value of contingent value rights</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash change in estimated fair value of contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:href="lgnd-20201231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:to="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_3b608dee-7940-4e44-a70f-e253c2973480_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_72e27d59-1cc6-4463-b315-1c78d5191f61_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_0c92750b-18d1-41d1-9d7f-7d5dd8b6d371_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_290faa25-e977-44c3-b5ec-b4c52afdc3f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_847ac98d-dad2-405e-9c26-00a237258f11_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_0416061b-13ac-47b8-8bb2-f0e5e52538cd_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:href="lgnd-20201231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:to="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2e1451d8-5eb0-48dc-93e3-cdd720ef61e9_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_11774405-ab5a-4a2e-a012-2314f8b06d23_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3805ab41-e0bf-48a8-9537-3600623456a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_b285a977-be36-428b-bec4-bd589c4aeb24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_5f254149-b82d-4aa2-9c55-45f0be745dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_e5a60b98-b2e8-4150-8eb6-16cc9d1bd5a0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-combination expense</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_ed539c93-17b6-482e-aa55-ca7bc53827a9_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_041c0b04-21b0-4b56-b2dc-0734a65c198c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_186a6517-124c-4f2a-a85b-67a80e77dbe9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1a32bbbf-41b6-4adc-9675-93685a5a1524_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_c59e63e6-3ef9-4afa-94aa-d5f7f16c19e2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to convert holders for bond conversion</link:label>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_88fe7b92-aabf-4058-a24f-4ca6ba2772bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_644901f0-8b20-4b4c-8915-2dae2dcfb847_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of 2023 Notes outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_eaff0f25-2dd3-4bf2-bdf2-8e762a7dce79_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_9c67ecdc-055c-4e97-a51a-e3c20334f381_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a03507d3-b588-45f5-ba4c-cd1c3d244fc1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2237150a-ae61-435d-b931-c04687225722_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4ab50c8d-45ec-40ab-bec9-8c4101cf6001_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cc70851e-f222-4ac5-971e-f11a59881f65_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e77cf8cc-df90-446e-9699-784a36f59d73_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Vernalis R&amp;D and Promacta License</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e4631bd-7fda-475d-8a28-afc7e54353fa_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_a78304ed-4101-4a9c-a422-111fc52b5655_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6b2edb0c-0540-4a3d-8b4b-b8ba34ce7ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_d5c9c501-6056-4da8-aea5-b3ecdfdc0b9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7a132638-e144-4d2d-9c0c-ffc8cb43dcf8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5bb8791a-c865-4d4b-a767-ea2a2dc2948c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_c54674b3-3cd3-46fd-9ff1-a12e380b1029_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization and credit loss adjustments on finite-lived intangible assets</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_label_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization &amp; Credit Loss Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_documentation_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization &amp; Credit Loss Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:to="lab_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34523a72-f407-42fe-b9ab-a6a06dc25a28_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84140aad-5d8f-4fd1-8a05-fcd319bd54e6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted income per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39545d4d-7681-4382-9659-b8eebd9e5577_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares&#8212;diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_ff9a9fe8-2af1-4caf-badc-15b830ac7bb5_terseLabel_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_label_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_documentation_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:to="lab_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_782273ff-c0f1-4a04-ba17-77ad32b232f4_terseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities due to acquisitions</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Acquisition, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Acquisition, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_edb95708-ec28-4fb5-9977-86bc28605daa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fb5946e9-33d6-4160-858b-561856f2c31a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2cbd691-abc3-42a1-9f7d-f44ac4bda17d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssets_d4f18c4b-b47b-45ac-9e07-3ce02b8bd868_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in derivative assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263268-111a-42f7-aa3e-81ef173f64e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_380e510d-356c-4da5-800a-5d8ebc660dc3_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0542f551-3c59-48d9-8f24-5317a962fa2e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1bf739f4-0bc4-47b7-a6c4-9832b3d443d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of warrants issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9044b52c-7ff9-41fa-b693-e60adcae8acd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3f96eade-f1e5-4418-b5d8-953773153e9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3dafb345-1fab-4f0b-a150-b2bcdfe1f624_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_14434d57-e61b-4cca-af77-fd49e5bf0871_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d8b9ff18-6529-4239-a38e-f413f007dd98_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1c71986d-1210-4151-861a-f0681083ecb9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 60,000 shares authorized; 16,080 and 16,823 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_293d1e67-b9f5-4324-bca0-daa7b997dec3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bd4e53b4-d317-4f32-bb65-71b00ca7831e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_b64566aa-95bc-4e46-a116-6c646c5112dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_93450064-6ace-4ea3-a52c-778017ffa1d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_2c38eafc-5a7b-4861-b266-5ec87e26d2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f6555d7c-c6fe-432e-bc8c-51d882f04307_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_b7f6a9f0-615e-4958-aaca-bde75ee8f5d1_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and other identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_5fcfda8b-e1c7-4ebc-bd9a-830dd25606a1_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:to="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_8682b457-7882-45b0-bc84-649ae5f74280_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Net Operating Losses and Credits, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Net Operating Losses and Credits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d26cc9b5-ddca-4c15-a884-1658e8523a63_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc771641-9049-42af-be2b-28d02eb36a16_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting right (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5574d53e-9daa-4cc0-adb9-95474d342ca9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_20725730-05dc-4518-aa80-6bf90b1e78f3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_9ea32022-1e60-447a-becc-bf35ec1c8ae5_terseLabel_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of forecasted cash flows (as a percent)</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_label_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:href="lgnd-20201231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:to="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9fb90ea2-5856-4da1-b417-7fb179bf8a78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_710d7287-42e8-4b22-9e98-6c35600df92b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d55629e8-b9b2-4839-b4a5-c289106e661f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_e83b84e6-7e0f-4f4d-b860-fc36ede15ed7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d0269db8-da41-4fb5-b5f8-794176bdcecc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_21eb2895-7e61-41da-a2eb-45627d3b4700_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_53fc5dad-d360-4971-af1d-8b182810909e_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_label_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyKyprolisMember" xlink:to="lab_lgnd_RoyaltyKyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_68dac7cb-5aa0-4f16-80ca-05fe1aeeff84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax differential on income/loss of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5cd36b52-f50c-4c06-9652-2536b891240c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8ec9e13d-29b3-405d-8fdc-60bd0cd28e10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_338b726a-3694-4f46-8b5b-6f540940adf3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_35477b74-2a4b-406b-8cfd-077d62eefcad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_b0ed9f83-3a03-428a-88b5-b4dfc502f8d3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent</link:label>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:to="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5b997cd9-0efc-423d-a592-844a6248551f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b4d02c9b-81a5-4794-a551-5f977c18c434_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnRepurchaseOfDebtInstrument_6ac5d8da-47ec-47a4-8ce1-2159df7a083a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repurchase of debt instrument</link:label>
    <link:label id="lab_us-gaap_GainLossOnRepurchaseOfDebtInstrument_label_en-US" xlink:label="lab_us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Repurchase of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:to="lab_us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_a8f209e1-20f7-4afb-b85e-10fcea39619e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerAMember_0aeb11e5-0d76-4ce5-ad42-5fc0500e6887_terseLabel_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_lgnd_PartnerAMember_label_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_lgnd_PartnerAMember_documentation_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember" xlink:href="lgnd-20201231.xsd#lgnd_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerAMember" xlink:to="lab_lgnd_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_7bb9b92c-af43-48dd-9ead-bed720ca294b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_8fe5fc31-6e14-4415-b6a2-9bd41ca983c8_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7ed5d76d-ebbc-42d7-81de-dd24cb8d6533_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1d196f49-ee16-4fc0-b691-be923e1f0895_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_caf3abd6-0a3e-432c-b7c0-fe52274a5801_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_bc4cea9a-d3fd-4b89-b1b9-bf88ade2d642_terseLabel_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus</link:label>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_label_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus Biosciences, LLC [Member]</link:label>
    <link:label id="lab_lgnd_TaurusBiosciencesLLCMember_documentation_en-US" xlink:label="lab_lgnd_TaurusBiosciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taurus Biosciences, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TaurusBiosciencesLLCMember" xlink:to="lab_lgnd_TaurusBiosciencesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_89581be1-e9b1-4fe9-ba5e-96ef66513319_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_2eca499f-e75c-4352-88f4-c0636194d65c_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reserve for credit losses due to COVID-19</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_label_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</link:label>
    <link:label id="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:to="lab_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c0bc00e9-8bc1-4eb0-9422-1187826d762a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_7fd2e6a8-9ec9-448c-a25a-2cfd5bb94597_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_9ce9feae-94ff-43e5-a95d-fb67cf01761e_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsSIIMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsSIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - SII</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsSIIMember" xlink:to="lab_lgnd_ContractualRelationshipsSIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:to="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0821526-4605-4da6-aea0-370aa7ed1634_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_efbdb404-498f-4eed-9aa1-895973196fb8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6a256d31-7762-4733-9ec2-8c26570870e5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2ec7849f-2b7d-464e-ad37-6103eab7a960_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_908d2e32-8c2a-4055-bc02-4f26942fe4d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_bdd13f2c-847d-4970-a95b-2bb56a0ce017_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_910a76c2-04cc-4917-8d38-cf67301fe0d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_659b9e4d-1efe-4d54-b875-ac88b6f7377d_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties recorded in retained earnings upon adoption of ASC 606</link:label>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_label_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Recorded upon Adoption of New Accounting Pronouncement</link:label>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_documentation_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Recorded upon Adoption of New Accounting Pronouncement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:to="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_b8cd6d2e-ae78-43e5-aa32-562c0d651ad9_terseLabel_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_label_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio [Member]</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_documentation_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:href="lgnd-20201231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:to="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_0ef66ec7-45f0-4180-a308-e31ba4a77451_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Vernalis R&amp;D</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41855d2a-1665-4eb5-b89e-0f8c4d4dc158_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_61b7813b-eb59-454c-8eec-1afe8d291419_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_4bd4e8d0-87c8-414a-b585-e2089b46371d_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability per share (USD per share)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Amount per Share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Amount per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1982c67b-18e4-4bbb-8cf6-f0f4879afb74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_1930fef5-4aee-41e4-a739-b66e8f7a3896_negatedLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant repurchase</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Repurchased</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_c7b9ecbe-f367-4898-9deb-88eef84f31c0_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:to="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ea80d207-c40f-4806-aa91-c9a5c9bb1ae4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3158e1f3-dcc7-4ad1-b4a0-c4d08349b082_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_955655e4-d0e0-4c6b-a7f6-aa9f8b14f16b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4f656f51-ec06-49eb-9215-91f4eb987512_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_42c14666-b537-4b74-875a-6bdf7d6bed1b_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Metabasis</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_75b6600b-dbda-4db3-a91e-4c21dc54022c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of finance leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_7c921369-969c-4f0c-83a0-6b0c505e8c86_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_80d63f70-8230-48d7-aae6-243fafca9025_verboseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Technologies</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_524ce91d-8dfa-4fd1-a180-6e6afdb44309_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cc1d9866-90ca-49b4-86cd-3b9d7cf69a94_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f689b00d-2af5-479f-9514-50503c043953_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_39ad7aab-3148-4c88-82d7-effc3c38c34f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on debt instrument (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_cf59c1e9-5d31-4d3e-a44c-66d4d60c5da5_terseLabel_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_label_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_documentation_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:href="lgnd-20201231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:to="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_75d92dd3-9803-42b1-9d64-d7869f70d8fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_6f609bd4-da6f-4853-8a8f-cb78875066f5_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2019 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotes2019Member" xlink:to="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_66acb3af-fb4e-4e0e-9d2a-8443f526d1b5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted per share amounts:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationTable_c16d5180-85df-47a7-8676-04ee606cb4c9_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationTable" xlink:to="lab_lgnd_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1196ab83-f381-43b0-8192-347743878905_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b079a771-797e-43f5-a73e-12902d3817e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_956b1684-ec4f-4968-94d9-b9aa43f0b5d1_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRights_4eeceff5-a2a1-4266-91a2-023834b8d562_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights" xlink:href="lgnd-20201231.xsd#lgnd_CommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRights" xlink:to="lab_lgnd_CommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_2f8f4a25-76c1-4190-907f-3ccb30568590_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deduction to additional paid-in-capital for warrants settled</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Settled</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_be614936-941b-440b-b822-c05aa6b488bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_07d7c903-d560-487c-a18b-3cebe181cbaf_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_c1e3b7ec-d1de-4849-ac91-c9d7eed44584_terseLabel_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_label_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_documentation_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:to="lab_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_21c564ce-e213-44b2-b9d1-a96fc0b3f557_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_59e59798-8218-45d7-9b36-fef24766fcdb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash to settle unvested stock options recognized as share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_03965747-5964-4c46-bb76-148c97ac38f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0f74125d-ae50-46e2-ad30-ef16bf704ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_eb6f0843-4423-49cb-92f7-b7b399fecf83_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR holders and other contingency payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_8031a674-8f94-4d0b-aff8-f69b3e750b1e_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to contingent value right holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:to="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_82c089ee-4753-47be-b690-f7ef6fb50801_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_9d459692-f8e7-4064-a69e-ca488e8b9de5_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_418f7597-da7d-4175-9631-04155ef594e1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_47586436-052d-490a-8a09-f406f856c1e9_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_0616c36f-a719-4ed2-9f85-3d85a1157557_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_label_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward" xlink:href="lgnd-20201231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilityRollForward" xlink:to="lab_lgnd_ContingentLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78ec6d88-8ae4-40a8-bfb7-e1b98e9b0cd9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa9a5d7a-c5e3-4e16-b088-d34c3d228b9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_29952098-e2d1-4599-9a4e-2c6f61f87206_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_886b369f-8640-49d6-b5ab-373751b31958_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_b46b2b76-c78a-47dd-b9ba-c6480eed96a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds on sale of Vernalis R&amp;D, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_dbb8d99a-f747-4b1a-af50-5727262fef8e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_edcda99e-f247-4156-ae02-29094bffa22e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_96de3985-f445-4333-bebe-39a0cc483134_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c06ca3cd-b2b4-4360-bb0d-653b5d4a4d21_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_41b96603-1d44-4075-8846-703fd532bfe8_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2976e265-a713-4f0c-b51d-49449198271f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) - Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_902fd397-4339-4558-aed5-f0800ff2ea3a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_2299b977-9b1a-4523-812e-de6eea5da0bf_negatedTerseLabel_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) short-term investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments" xlink:href="lgnd-20201231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_GainLossOnShortTermInvestments" xlink:to="lab_lgnd_GainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_4514ba19-7f65-4e5d-9880-df45481e928f_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete technology</link:label>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentedTechnologyMember" xlink:to="lab_us-gaap_PatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_bf6374b4-dcd9-4f1e-9de7-c55e52e90773_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity and Liability Components of the Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6d716402-198d-4e3f-a6d3-d72f4f7bb6f4_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019869c5-00e6-4187-8ae3-db1fd6682278_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9adc66dc-0bae-4ada-8730-c686dd6dd9cf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_4ddef489-21d2-41e3-bb9b-22ffe9263db3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5606705d-8366-42b0-ae64-86a8409a2e6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_4a689724-a3c3-496c-a3c3-eec9b3df2082_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Pfenex</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Pfenex [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Pfenex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_0de71762-180c-4afb-8c0e-e4c1fb6c48fc_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in if-converted value in excess of principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:to="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1ea53b76-98a1-4dea-b9d1-9b382a1c7ef7_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9bcb69bd-561b-4f7c-b418-b973a8c6d73c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_fd4b7eda-d967-46cf-946b-241f9c20b11d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_ec93b4f9-45f0-4523-bcc5-b323a3c1d2b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5f4f3c61-c529-4ac9-860b-c6b9510da452_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1af6bd34-0ace-4bc1-b717-3f5b384a4bb9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_fde8f3b0-c0e2-4cde-ac50-470dbf8d6e12_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4c884e51-0dfa-4af5-9465-a54612cebf87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_440311c2-7048-4e30-9ddb-5314d0f2f9d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9118150b-124e-4555-9734-84a3e6526397_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5e1bf83-6132-481e-9af0-a3598cad4916_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_bcca47a9-fb6e-49a6-b548-9b688bc52087_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_b5043a5b-17e7-4d00-bcc7-882c3849c840_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_135718bd-6324-4bf1-a9e1-e1b79a2c08cd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_266f82bf-1c98-42a2-a3c4-051879dd7e52_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_6f809be1-00f1-4cb4-af6e-b49390008420_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$10.05 &#8211; $195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember" xlink:to="lab_lgnd_ExercisePriceRangeElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_d5a5a746-3128-4d96-8041-ac7de480b96e_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on repurchased debt</link:label>
    <link:label id="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_label_en-US" xlink:label="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest, Repurchased Amount</link:label>
    <link:label id="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest, Repurchased Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentAccruedInterestRepurchasedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:to="lab_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_26dc08b0-d01d-4251-90ce-138024cd9f52_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5d64b99a-30c4-4b86-a63b-e94876596edf_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiability_719017f4-bdb4-46c3-8731-ecac7c42a426_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiability_label_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_lgnd_LeaseLiability_documentation_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiability" xlink:to="lab_lgnd_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44e47df7-215f-4641-8514-7ae74346a2df_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestonePaymentsMember_c67b01f9-dfe2-4794-a4da-8baa5ca09b80_terseLabel_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_lgnd_MilestonePaymentsMember_label_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_lgnd_MilestonePaymentsMember_documentation_en-US" xlink:label="lab_lgnd_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember" xlink:href="lgnd-20201231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestonePaymentsMember" xlink:to="lab_lgnd_MilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8865ec0d-48af-4595-8db3-c4423b1e40d3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ef2ce35d-5c1f-4e42-bbb9-78f5d868a409_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_42f14a25-7f85-4227-a9e0-e30abfdd0181_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_de4323b4-c85c-4b04-821d-986c2d0c43a1_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableTable_6d3d92e1-e9e9-4a4d-bf13-01f63295f8db_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Table]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableTable_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableTable" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_d24bf041-e88b-42e9-a716-5a893a9cea59_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cab7e967-eafd-4bae-8f45-6dc865c0d889_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b30694ae-07dc-4b2a-ab2f-009cc9ce6086_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_96efe88f-3216-4069-9709-24b869530384_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14e1c843-fb4c-4666-ae8d-987f69ffd2ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_547eb717-f8c4-446d-94dd-021cdb100931_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsJazzMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsJazzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Jazz</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsJazzMember" xlink:to="lab_lgnd_ContractualRelationshipsJazzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dcaa4b6d-874e-4948-a2a7-569484486774_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_2ecac73e-aaf3-4a25-84c3-4f75dbaf3a27_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ffb27b8a-ffd0-45e4-a7f8-78c99a9e2230_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40534333-a87b-4105-8dff-f8883106a069_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_b9354be0-8135-425d-8c84-9e21ca3c3420_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_ce7168d5-150a-4d71-8cc2-c045cadb923e_terseLabel_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of cash and cash equivalents, maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_label_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Period Of Highly Liquid Securities Maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_documentation_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of highly liquid securities maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:href="lgnd-20201231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:to="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0c0e99d6-ce1d-43b4-9bec-e4b0023320d9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_159f1ac0-80eb-4cda-a3a0-d905f088b6ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_634aaf33-cacc-4a76-b407-391086833269_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs related to obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_d6a73be1-ccfb-4535-b3d7-90468979e0dc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a251ed00-4de1-48f9-87c8-5ebe411225b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_3b291d11-a407-4baf-919a-c422da51a224_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f21048c6-2aa3-420e-b0ed-d10e306ab0e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_385c9645-154a-4cfc-b9f4-f9dcbecc268f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfAcquisitions_0c7ea635-d00f-4709-9ebc-333f38999268_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_label_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_documentation_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfAcquisitions" xlink:to="lab_lgnd_NumberOfAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b18d746c-acf6-48d1-af11-a9a53522b9c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_58c8318c-435a-4872-a0a2-a74f86f4a8b0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e620f7cc-d6dc-417e-bfd5-87739f77f39e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_8cc613a4-8baf-4759-af88-595bfb42e16d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_c08e376a-b62d-4c80-9850-4ed4d9ed3732_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_12906b05-6df1-4f21-b048-0e1512605491_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1167db8a-d0bf-4d6d-80ef-a45abbcbd8ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c3a9df07-769d-4df6-b6ef-8178a4003c26_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_ae868b55-48cb-4279-be32-ab8a1d4e93ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion value over the principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_836c2bfe-9492-4ce5-a145-77b8782f1598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ddf96cc2-434d-4375-b2ff-a4d477c8df81_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_02a66bd5-bd81-4e36-8f83-1b7dc43b597f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2cedf011-a460-4cb5-9dbc-e84d9b9c6675_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e4cd10f5-b75e-479a-adfc-708097a73130_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_270ef6a9-57e7-41fd-a3d3-9f7d442f7d71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9ee71d69-80d4-4216-8c4c-42e68b2c0c80_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d383eb1c-7438-437d-881e-f644ac624a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f989c908-227f-4612-9114-d224277102ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_6693c9ef-51d0-4aa2-aeda-bd9ddc442726_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_501aee80-37f0-4162-a9e4-2ecb523bf7ea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e6fc0915-8a66-4eef-9c4d-0ca0591e758d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_749923f8-cca4-44d6-8b24-f99f02be804e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_90d57377-3a8a-41db-938f-0ed1501de8c6_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2023 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotes2023Member" xlink:to="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4041d6a1-b9be-4787-91c4-43df8da1e90d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount (including unamortized debt issuance cost)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_76c005c5-94a1-4370-b54d-d097fc9ada84_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_668b4b75-770a-4255-820e-3eb864cebbdb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseMember_4431488c-e36d-4eb2-af8b-97ecdb838938_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense</link:label>
    <link:label id="lab_us-gaap_OtherExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseMember" xlink:to="lab_us-gaap_OtherExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_100a2b97-a127-4b6d-a072-ff788f01c3b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2971cf3f-0112-43e0-98cb-dc7c047882fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_38a3f51f-93e0-4a8f-a2d0-fce7dc10c0c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_42ea08ee-892e-4cbc-8d2f-95e5af8a3fd0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d6ede8b0-8ca3-4f7d-bb81-16e6fde65a5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_884bca1f-3cbc-41e6-89e2-f15a042b5a8c_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:to="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_4e1836d4-51da-496b-b015-d454f8002b89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_68cecd29-eea0-4f2c-a0a8-b77ed79ad648_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_449ea98d-e871-44eb-a2b3-eda392074981_totalLabel_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset" xlink:href="lgnd-20201231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseRightOfUseAsset" xlink:to="lab_lgnd_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_509076ec-6605-4232-8611-7b7dc2e84947_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_7dc36251-697c-4e29-bfa9-b53e1e8e78f1_terseLabel_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related liabilities</link:label>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_label_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Asset Acquisitions, Current</link:label>
    <link:label id="lab_lgnd_AccruedAssetAcquisitionsCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Asset Acquisitions, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent" xlink:href="lgnd-20201231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedAssetAcquisitionsCurrent" xlink:to="lab_lgnd_AccruedAssetAcquisitionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_94419510-8270-4e54-98fc-97ded75c45d4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_6da3aeac-d93d-4fd5-8f59-cb0aa56fe9e0_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repurchase of warrants</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c7c48d4-5c36-4946-95d2-9bdf9049d836_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_61def762-51f6-448e-8caf-bc39a70fa6dd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_5675be42-fcc5-4881-9c6c-50ddfd1860fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_943aaa89-13cc-4748-ac14-999e27baaf47_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_00a99010-1a9f-4d86-827d-80cc49fe6241_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period in force</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f15782b-9e3b-48fe-a16c-0bd67a0971b6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_9b27094d-11cd-40c6-80ac-a1c26d1c5917_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_d3752d91-3a77-40cb-80a5-55f340eb7a55_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate used to value intangible assets acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1fade4c3-11e8-437f-aff8-bbe6ed9460d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ce87aa79-4495-4b56-94e2-70f056efee3e_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_dee6422e-0179-4e73-ba24-62872698ae6a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_d20dc0b9-2cba-4e74-97fc-7c50894ce933_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:to="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_feb0bf14-cb85-4c12-8e9d-4100d6f4eba9_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationLineItems" xlink:to="lab_lgnd_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_95639ca5-c479-42a7-81c2-f4427db3ba60_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_911cf1ef-a4aa-42dc-8a6b-5ca7e9d93ec3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_942e48bf-a879-4843-993f-33d59361be9c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on AFS investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9bb802e5-7a81-4464-a0c6-6ba08a6d5859_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3a5831bc-5119-425d-836a-3678981853c6_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fa909bbf-46f8-4759-8d75-8caf706e7826_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b87471ac-26ef-4f96-b253-855af6ac74b1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b85301d2-ef5e-4a37-a962-d35299232ca8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_63a26887-4ae8-4727-9176-fd6566dcf224_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible bond hedge and warrant transactions, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_0ceb2a12-59e6-4f2a-9f76-c532cbee5831_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_380248c5-ef4a-4809-921b-c827217bf5ce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_d053d6c9-30fc-4372-9cb6-9ce957155731_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6705fb6-798b-45e1-9c30-2ef256c38a6a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddfa280c-70ae-4361-a7bc-513b2e9a21e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorMatrixMember_beb5294e-08b8-4d7a-984c-535c77f1c0ad_terseLabel_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_label_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember" xlink:href="lgnd-20201231.xsd#lgnd_CorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorMatrixMember" xlink:to="lab_lgnd_CorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_437b290d-8b3f-4c8b-b87e-c889233784f7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_a6b2876f-aa27-4ae4-8f29-7587c486dddc_terseLabel_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc.</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_label_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member" xlink:href="lgnd-20201231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingTherapeuticsInc.Member" xlink:to="lab_lgnd_VikingTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2aaa4695-3a79-46a3-83fb-01aaedf37cf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4fc3ff55-3e6c-41e4-8632-c16ffd0ef0eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_2efc8a32-23d1-434b-b36a-ff406a6a0af1_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_d38786a1-06dd-401e-897f-399d5e344e2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ec00f594-6a25-4108-b041-9a4eedb90b19_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ca320cb2-9989-4a90-aa29-a1348008b1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_230f4c2e-02ba-49ed-86f9-a03698e42985_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_72d0a8a6-e467-4786-bdf8-859f9cdc18ed_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_747ef0f7-143c-44eb-9cd1-11e333bee5fa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e8572fad-de80-4c59-bf81-1a76109804b7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_69b30826-fb32-46be-bee5-85583ee901ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Senior Notes (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f8cdba3-73b9-43df-af75-d2a87aceb155_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_01688024-00da-403c-9587-e5da2598657b_terseLabel_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development</link:label>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_label_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development [Member]</link:label>
    <link:label id="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right for Internal Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:to="lab_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_cba79ef6-8ffb-49da-947c-cdf7f3d385e6_terseLabel_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_label_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_documentation_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases" xlink:href="lgnd-20201231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedInventoryPurchases" xlink:to="lab_lgnd_AccruedInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_78f2a202-933c-457b-a901-383c531067e6_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_fe6e1ffe-704d-424e-83a8-d14f23d61ecd_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of equity component of currently redeemable convertible notes</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification of Equity Component of Convertible Debt</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification of Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_534e9bdd-177a-4fdf-b21b-44fe9fc36897_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4d31d0da-7231-40f1-b3db-7d97da50711d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_21438c7c-1209-4b7d-9f7f-1e1db5eeb97c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8822899d-6003-46e1-be7e-67efb6058a5a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_72e4e581-a744-470b-913e-ef352b0f3b9f_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_label_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:href="lgnd-20201231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:to="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_de2c44db-4c34-4469-a469-90c4c553a1eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cfa733f4-4ac2-4248-b00b-6a1b16afbef4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a87842b3-aff4-444d-9021-4c365677b109_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7b337690-dac6-4990-9408-0ebe706afec6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_da342974-6f41-4062-85c1-627b4708df1e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_e1af4a26-5cb9-454b-9c1b-bc6385293fca_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_865f069a-26ea-46d4-bed0-fcde97af1798_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b4337b0e-543f-4c6d-a668-aeadd5d16d0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties owed to third parties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_29eb7053-907a-4f97-83a8-f2bcc9194024_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price trigger to classify convertible debt as current (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_0f3d3a11-fe6f-454e-9a73-07626b6705a7_negatedLabel_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible bond hedge</link:label>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_label_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Convertible Bond Hedge</link:label>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_documentation_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Convertible Bond Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseOfConvertibleBondHedge" xlink:to="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_02f9f55e-9c63-43ae-bfc5-2a73f101b2b7_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">95.68</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFiveMember" xlink:to="lab_lgnd_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_5e1bd964-ee68-4782-b8a3-f7b6f6728cdf_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_d4c492d9-01cc-4ba4-9b1b-00fa3f134544_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractRevenueMember_3178ac0b-03ee-4857-8a32-8440083f6619_terseLabel_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_label_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_documentation_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractRevenueMember" xlink:to="lab_lgnd_ContractRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0d7822ce-af88-40f3-bf11-97f703ff9257_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_56cbe271-a9a8-4545-82a9-758faa377608_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f7a2833e-4dc7-4115-8321-85d7131010f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_8b1669d4-0e45-4429-a812-2d2530aac242_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum threshold of debt trading price trigger (as a percent)</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:to="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f4eb49ef-5fdb-45b6-a271-17de6e214366_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f71cf757-abb4-4ae1-826b-f200e89e3997_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_933c32b5-2d6e-4fc4-80b8-9ad675055821_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share of stock options (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_130defb2-69ad-4f6a-b61a-ba7ce1faa831_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_ecc3c989-7135-444d-a7c2-0fafb7a66c92_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyPromactaMember" xlink:to="lab_lgnd_RoyaltyPromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_e125a080-6f37-4fb5-b7e8-446476f567ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_95e83da4-3c11-4315-9861-cd21b972ca59_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSalesReturns_fce5b965-2f4a-422a-b38b-e1385d8305d2_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return reserve</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_label_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_documentation_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSalesReturns" xlink:to="lab_lgnd_AccruedSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e405a8e9-5b8c-4bb4-8a4b-f7c40102b336_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6c5d3fdf-9f20-46ca-a5e9-bc299de6b2f6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_8445080e-6384-4bba-9b2e-0282b085e27f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_473064df-d7f8-4679-8fbe-4586c3cbbb8f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_a04ced2b-0702-4bf0-b2a4-dbc306a8a082_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_578e770b-e333-4a7f-9ec3-20e21ff2c991_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4a5e241b-a01a-4dc0-adaf-af3d5ac94da0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4df2644f-2700-4bf9-8b3a-d1e84c0bf397_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmendedESPPMember_9ef17c74-451b-4aec-856e-94803ebc6182_terseLabel_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_label_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_documentation_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember" xlink:href="lgnd-20201231.xsd#lgnd_AmendedESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmendedESPPMember" xlink:to="lab_lgnd_AmendedESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_cd5588b3-0136-4e61-a59d-79f5a84e1586_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_614f13b9-4cd0-49c7-a38f-c88727a9d494_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period in which cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b039aa57-389f-4418-842b-62887ce9c2c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_154cf739-9fda-435c-82e3-8e1f710fc883_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_43454c2c-96d8-4311-9f91-524157a777c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of 2023 Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_14d96b64-9155-4384-8f30-a00801f6cffb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_4ef2d1fc-8c12-42d1-9792-b77f86970e3e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ab9eaa7e-aca6-4306-ab97-7e9e96595de5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_109afc06-54e1-4f78-83c6-0ae5806d172a_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0453508c-0e33-4971-9235-3ea6c3b9d1e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_609c94d6-32ac-4fa0-9d0d-a086efc9537f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_17d945cb-9177-417c-bf2d-ec82054fb5f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_b48f4ed3-bbf5-4a3f-8d60-465630c0739d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a8ccea1e-8b75-450a-9106-b6469ac538ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_515811d6-7d65-4bef-837e-15c3e27517ad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a0840a7-a8a9-4ad2-90e2-519abd2ec10b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_15cfecc8-de0f-41f0-a51e-a3294ca244f8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_0d7f03a2-0b6f-4f80-b535-64f058d39acc_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible senior notes outstanding (Level 2)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_104a1e75-ff76-43f6-b28b-232891a10d02_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_c99bfbae-75db-448f-ab41-06ad546cfc31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_e8a4870e-d066-481a-b1af-fb422646adc7_terseLabel_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals</link:label>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:to="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d52c2c14-bb16-4aab-86b2-0dc4b4d8a478_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cb7a0f1a-ab31-4770-9f3d-da9bbc760d7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4d66fc2d-83a1-4376-9d81-3ac09d02aa45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_707a97de-4e26-4c3d-9be7-eef3cce8b18b_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_9bdc4d5f-c870-4c77-87c3-9ba0b2b2f6f2_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_79b8c86c-f69a-42eb-a930-ad3026d9547d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_3d38cd05-956c-4d0d-b007-760afabf71f1_terseLabel_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development</link:label>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_label_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development [Member]</link:label>
    <link:label id="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Rights for Partner Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:href="lgnd-20201231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:to="lab_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_20f04085-92b7-45bc-8e1c-87e4c3492799_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_53651611-2247-4b4e-af31-1c087ee86672_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3befb1de-2103-41b0-8cd7-89166e4ad616_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c20d6aa8-5dfa-42b3-8f35-ecab75307a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6c6c96f4-23b8-46c1-a14c-291aec1bd9a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset with finite life - core technology</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_88e0122d-c885-4835-83eb-08c28a4a3f24_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_625c7217-2ca6-4cfa-9b55-76a406c89cc1_negatedLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c6776ee5-1a9c-4bfb-8961-8fed20f528e1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_301844af-79e3-4a5a-b348-44d2d915e6e9_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:to="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_15fc08b7-ec79-4c3a-91b1-ff4541cc562f_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - CyDex</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c59c9d81-aa81-4ca2-a944-87f11ad3837f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired that is expected to be deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b7145e7f-299f-4cbf-b65d-725cf848fc5f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4f47f8e2-eb32-4d74-9e01-fceeea9583b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_54d97927-c637-4e50-aa83-3968dc29ecf6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9d00c286-3964-4542-85d1-b8b70bf4ef7b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyOtherMember_8cd371e0-039d-403b-b359-e769d5f3d9c5_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_label_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyOtherMember" xlink:to="lab_lgnd_RoyaltyOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_dadab319-219d-4bd5-b6f2-e3514bfb47f3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9b250fba-5357-494e-aa43-d72d8a2c03fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_fc047cda-d832-44c5-9ac6-89dafba791c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from derivative instrument</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ab3a7684-1adc-4ea0-876c-7989a37fecd7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_247961db-ebec-4df4-a93c-f616233c8049_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f09c56a0-fb6e-40a5-9482-68ed53cbbd9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_87823f71-048f-4bea-8a83-f4f977b465ec_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_8f19fd9b-df9d-48c5-b3cf-97327617ed24_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$63.58-$74.42</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeThreeMember" xlink:to="lab_lgnd_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4b963753-3f6f-46c7-b836-064769580d60_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_74e0fb0c-0f53-4ee8-a58d-134bb5828773_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_label_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:href="lgnd-20201231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:to="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d91f7db2-83ff-42fb-b151-4a4da949c749_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableLineItems_039d953d-9fd9-4707-98a1-da7008b960cb_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Line Items]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableLineItems_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_617c45e9-7ade-4b14-9dcc-848947a13de1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_889085b5-ac3f-433c-9f73-4920a2c6bcc7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_06938db7-1d76-4e5e-83ca-4d7dd19d0dbd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_dc35c7bc-f8f2-4774-bae9-e3681d52fe11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d4be09ff-6f6d-4928-b4bd-f97206de3fc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareProFormaAbstract_c17e3587-e903-4405-a034-7544cd8af4a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareProFormaAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Pro Forma [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract" xlink:to="lab_us-gaap_EarningsPerShareProFormaAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f4e5cc74-9044-488d-9e14-e09c9bb116cf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2309e6d5-0412-4042-955e-d31f4a6dbc81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d66b0691-ac8d-45bc-8551-9e6098654b93_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_1d04a192-6eec-41fa-a4db-32afac3aa5c0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_0c402d6e-bd46-41af-9616-dcf18edfacf3_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivatives</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Derivatives</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e4b1af2b-0b6f-417c-8288-7b44de2854cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c2057ec6-38b1-420c-a821-950a7ff5f0f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ce67046a-eeca-4b51-92f7-6afb9d16eb3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of premium (discount) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_b485ff0f-bda5-43e6-b4aa-5da4618f793c_terseLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment Additions</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_11258c00-9a10-460f-891b-5305c0500128_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_bbba8513-f3e6-47d6-94e9-43b5f2c8443f_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_15417f45-a23a-444b-80a4-c07625de77fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_749278d8-189a-4ffa-bf47-491d08c7ac0e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_7ff4ab29-de69-4394-b0bf-1bcbb531708d_terseLabel_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product royalty (as a percent)</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_label_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_documentation_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage" xlink:href="lgnd-20201231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProductRoyaltyPercentage" xlink:to="lab_lgnd_ProductRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0ea7a6cd-afdb-436c-a9a6-2510535ff4a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1a5ba7d6-76b8-43e8-8df0-66ac15657b83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_bb429fcf-d1b4-4b8c-a47d-9dbab12ef98f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0117a6b4-c015-48d9-8866-527882e5aa76_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_f1bce3ae-6e9e-4b77-9410-e8959a93d2aa_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$10.05-$14.47</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeOneMember" xlink:to="lab_lgnd_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_2df2b6eb-c175-4c91-a121-8cdefa8c100f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c88a203b-9979-4325-aeb9-c45ed703db81_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_d3921220-0bbc-4014-80f5-f9a4f8ebb983_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual relationships</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IcagenMember_df9eb240-2a25-4ca3-88e9-bc9b69da6b7d_terseLabel_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen</link:label>
    <link:label id="lab_lgnd_IcagenMember_label_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen [Member]</link:label>
    <link:label id="lab_lgnd_IcagenMember_documentation_en-US" xlink:label="lab_lgnd_IcagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Icagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IcagenMember" xlink:to="lab_lgnd_IcagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_4be2a6dc-ade9-4aab-b54e-af083dfc9cf4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b8d1274d-c055-45b9-8b36-b653461b10c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e49e0d32-39c2-4dc4-817f-317b04f756f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_72563dca-68f5-46e6-854f-4516d01e23f7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_51724c7c-6177-4b4b-9995-35df5f4fa18e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3bc8c110-bd1b-4f6f-9ff4-923e98505c49_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_387b0f29-abfc-40d5-966a-465d8ca68859_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_4b22f04f-0da2-49f0-8ffa-732091fad68b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_15af067e-b5e1-448f-a21e-ce3886b3a096_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_80055765-5f72-43e5-b5ef-fe72d48387bc_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_ee4c7906-fba2-4219-aac7-989f1054c0ca_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_262c9385-d1bf-4bf3-b3fc-ddedb77936b0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_6e4a3df1-bae7-48aa-9959-85f1c7595518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_07f91c8a-180c-4215-b9ca-73cad63b734d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe837100-20a8-4dd0-88c9-5b1ee4ef463e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_28f9eb97-80dc-4a42-9fd3-92a423119f5f_negatedLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a3751795-031e-46e9-88b5-2b4e25ca8d8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoMember_a24603c7-c080-4dbf-ae71-447b0b34d576_terseLabel_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo</link:label>
    <link:label id="lab_lgnd_AziyoMember_label_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:label id="lab_lgnd_AziyoMember_documentation_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember" xlink:href="lgnd-20201231.xsd#lgnd_AziyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoMember" xlink:to="lab_lgnd_AziyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b04b7719-b07f-4410-8381-a605f31f6afb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5bef3ee0-1552-4908-97c6-bbdbc8a580bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_04143232-fd25-4840-b7a3-e8629a05b9d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c542e171-58eb-42df-a4fe-23a3b5cd5cf5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a498b211-fc13-4a2e-b5a3-7956a6d4990c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_cfe92386-a864-4774-8e75-d59c9d9dc25e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8880feba-270c-4c7f-952d-f63ce0eb1e6f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_a08c4495-33a3-4ea5-8695-93f83d8fc446_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d58adc1e-4a04-4f5f-921e-2640db01e036_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_dedb84ce-812d-4103-85f0-5b8985c69126_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of consideration allocated to inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_93886453-b99c-491a-8193-6b9371087568_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ff31b2a0-dd69-4dd5-a77a-189527bfdd53_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c062597b-a50d-4e3b-9532-c590a3eb8bb7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_a112b2e5-42ea-4963-b8c1-348a718573b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_56ce9b56-4449-4940-aef9-a7d542827a67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5f3d6b60-2bc5-4646-96a3-bb76cc217312_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_3cb06dd0-cabf-4c82-94a3-b8c91e470985_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent liabilities</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRights" xlink:to="lab_lgnd_LiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b643fe8c-f82e-45b1-9cce-12103200c489_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_3343ce93-3fde-4ded-a4f5-354655f12085_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6658a8e2-5914-41a7-b3d5-8ad03b5fdc1d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_338dfd35-83ae-4c44-bd19-86ac4051460e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_71ff956a-3750-43f6-9dfb-551ac3fecb07_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiabilityCurrent" xlink:to="lab_lgnd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_5dc00dcb-7ee8-4431-a759-b3d653a1a62c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CrystalMember_d6275fca-01e7-453a-a8e2-f28311d6ef65_terseLabel_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal</link:label>
    <link:label id="lab_lgnd_CrystalMember_label_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:label id="lab_lgnd_CrystalMember_documentation_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember" xlink:href="lgnd-20201231.xsd#lgnd_CrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CrystalMember" xlink:to="lab_lgnd_CrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_250445a6-de4e-46ff-9cd3-416b5ae80b5a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6bcdef60-26aa-4ff6-8587-a7e6902df972_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_846820a3-fffa-4fe0-a2ae-8e0469ae1a30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion price per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_f7a093db-5aa9-488b-a71d-b48e59d69b4e_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual fund</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_fdc5a352-23ef-4d4e-859d-7f5ddedbc997_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_099c1b2e-0692-424a-b526-58344ccfdf16_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and other assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f7cfb0a1-3336-4e68-af34-4a5938afb7e7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_46be0f2b-1fc5-4c4d-a7fb-cc48e27edb80_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) - Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3a58108b-4cb2-4947-be37-2527ad0d6c37_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd3849c4-01a8-470a-adbb-69677f070b31_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_c88d83cb-fc33-4b59-8251-5aa9275ce1cb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3b06b011-878f-4406-bac2-2414f34a64f9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b8a482e6-0775-4541-b8db-4ce61cfc843c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_e1c2ad3b-9dc3-4a07-a117-32532bf45516_terseLabel_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_label_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember" xlink:href="lgnd-20201231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_Phase3ClinicalTrialMember" xlink:to="lab_lgnd_Phase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_aafea42b-d463-4c11-90ae-4391371f6c78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_498493bc-2ce9-4797-8ce2-dc61917a0aad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18e042a7-3c8d-49c3-a067-73899101689f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e28d6c09-bbbe-480c-b477-e64abcc6a571_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets with finite lives</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_1f327158-614a-4a31-8d16-fb8abe698e7a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_04f80808-1d03-4e39-b385-16c00f1081a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_006d85fc-3dce-4c27-be9e-1f0935971d7a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_98580596-04eb-446f-bcc8-c9334cdeb49b_verboseLabel_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants investments in Viking</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_label_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_documentation_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent" xlink:href="lgnd-20201231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InvestmentInVikingCurrent" xlink:to="lab_lgnd_InvestmentInVikingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_e21a3a32-5ab1-44b0-9098-30b0d76d548d_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Captisol</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_bf9f23a3-05a0-450c-92a1-869a04a00faa_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_02619a92-ea27-4286-9ec6-aa1ecad011bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0250fea1-a8f3-4721-bb12-a6d1c3b3d12b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_032c4a8b-55cd-4d16-91e0-487c2bb343d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6426ee69-0dff-4f6c-89e2-5cc8153a3fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae6333c2-7538-4b06-92c4-a05294ffc407_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_1dd6bc68-054a-46a2-bc2e-56c0c524bcb3_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:to="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_c390ee74-bcb4-4a74-8084-bb08868d90ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_f9635043-cd18-4e96-a41d-41d012af97c4_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captisol</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember" xlink:href="lgnd-20201231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolMember" xlink:to="lab_lgnd_MaterialSalesCaptisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_d3dfb4fb-e307-4673-840b-c421f30cd8ed_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9675221-6be3-4835-9a8c-811c240c7fdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_486727b2-2d16-41b0-95cd-a61f6298883b_verboseLabel_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:href="lgnd-20201231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:to="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5e1fe80f-50c4-4d76-b007-de484c5f2ad1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_4094b004-e097-4a03-988a-688a445157d6_terseLabel_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_label_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx [Member]</link:label>
    <link:label id="lab_lgnd_ContractualRelationshipsArcellxMember_documentation_en-US" xlink:label="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Relationships - Arcellx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractualRelationshipsArcellxMember" xlink:to="lab_lgnd_ContractualRelationshipsArcellxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_757c1001-98dd-4cb6-a161-b81b3a09246d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_541d0576-a0f7-4ca1-bbee-b17be134f412_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_2c1cadba-1725-4974-b47f-5d0db8699160_verboseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember" xlink:href="lgnd-20201231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisTherapeuticsMember" xlink:to="lab_lgnd_MetabasisTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9ff3faf4-be4e-4fb0-bc78-a26d8440819e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_914471b2-ca56-4592-82b8-c823b4a3d541_negatedLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect for Notes transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_c40d26ec-97b1-466e-a2db-1865c7ca507b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc327994-9324-4340-8c37-5d94cf93331b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d5e58211-779e-49f8-8d2f-4776a6062f9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_bb8fe411-e1b0-4707-95a1-1aeb9fa66edd_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d7f41629-d5cf-4dff-894f-afcc77b90e19_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Significant Partners</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f5df9d3c-3370-496b-9691-ad04070c8f1b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_ed4fb486-bc16-4e79-9655-93c14fdd46b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1051bf9-b6c2-456c-bb7c-4f5f69107978_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_ade9dc4a-b7e5-4808-a822-df9914574bfc_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cd15b9d8-3824-433c-a69f-b9d1ed216657_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_23a8ca22-b82f-4c4c-855a-075f25f30236_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Categories</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a84c4e01-f067-4d74-8247-1cdc83991fa3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_30c03ea7-25ad-4184-88b9-61919d808a03_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b25d574d-ddd9-466c-b052-1565feb99f9a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9c7aa149-4592-44cb-8649-62e041f90cd7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_efb9a825-2e43-4ad7-9327-f8c360103f7e_terseLabel_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_label_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember" xlink:href="lgnd-20201231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoandCorMatrixMember" xlink:to="lab_lgnd_AziyoandCorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aa38fc85-fa9f-45b9-84b9-f221247c2f92_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain on available-for-sale securities, net of deferred tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_c0e1e757-48dc-4100-8997-ee47e7b7081e_terseLabel_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_label_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_documentation_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:href="lgnd-20201231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:to="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_16cd4319-cec6-4199-958b-ad629a45f565_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_596dadba-483c-486f-8c05-16264feb8fbd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b0b26950-cf25-43f7-bbc4-2aebebdd93c8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0ced84d3-9d40-419e-bf1b-7b3e748b47a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c81aea41-e32f-4def-9af9-bdc0c0401a2e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ef83305e-2545-46e6-a2e2-ba789d1f52b2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_59d34975-56a0-45fe-92d2-89ca5376abb0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_c8b42935-0d88-4e70-a840-0a62329a4bdd_terseLabel_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments</link:label>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bd500c2-c393-4a21-8088-de25c832340e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisition:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_65a49299-8e3e-4228-ab25-85d7701e180d_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity component of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_571746ab-4f04-4f3b-9822-c83290156814_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_b01b2e06-eb37-49f0-905d-8a3f3b1cb0be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the liability component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_90a02282-5bcd-4552-958c-8dc261b06396_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b1a89f3a-0f3d-4a69-8e0b-7fa0279519ba_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_4938761d-569b-4bd6-ad8d-ec549e8a4ed8_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank deposits</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b5554030-fa5c-4de1-800d-1b8b3076d411_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_6dc8d079-2320-4719-9dbb-7771b70c29e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_c9179e9c-8f83-439c-aa36-b5a8f4847fed_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3ba06f6e-9ccf-47ca-86ff-349943ca5be2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2478ad84-cc68-411c-a1c7-6c0d92fb52ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in public offering (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ee62834e-f7ba-4067-a1c7-d431c720ee05_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b55c826-493e-4cbe-85b2-7c93143d81b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_a84f635b-2163-4d7e-93a6-dae6d1d8ac3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_9f145ac8-4fd2-4882-a98f-40782d428184_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">98.2</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSevenMember" xlink:to="lab_lgnd_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f3da8339-5d31-43df-a7fe-afe1ed35a5d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_eb7d1a6b-7918-4908-9eae-feb030715803_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected cash flow discount rate (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_35ca8156-2cb9-45f9-83a8-3810f6442743_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_3af74d8b-cabb-450a-ac89-ba2d2123c709_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_aa684658-51f9-41f1-a1a5-5e145ab52700_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from repayment of Viking note receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6a5ed97a-7db3-4e92-b867-c26290169ddf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMember_09f8fa63-7491-4947-beea-9321653e76b1_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMember" xlink:to="lab_lgnd_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_292e47bc-cd40-4cb2-ae3f-80f2464c396b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_879da847-5f18-4cc1-8b97-b33cc5eb0bab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_847fe2e3-968d-4c4c-8a37-83c947299336_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_3ae17399-4e3a-4cde-a5b2-8afda9e73606_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury bill</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_d7a7ee91-d7ce-455b-8a57-2b93c78abeb4_terseLabel_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:href="lgnd-20201231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:to="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e18ea651-1848-46bb-8ae9-de4a56a3de92_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_78a40d75-144d-4785-b3e3-7c9d5ff09c4d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_390126a1-a6bf-4382-9e30-1e0c41f1fe1c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1f5a432e-7f92-4502-8963-aa0e92bd9c5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0e4753c-ebd4-4bd7-b9d1-6bee4df08bb2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_441557b6-a13f-48c6-9cea-35ff79c5be24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_51f2cfd4-fcc7-47fb-b26a-d0f57504e5cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2cc6cd64-e115-4391-9154-92dcfbb3707e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_f5f779f7-61c0-44d8-9614-8c99a2b21d00_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42d9a6f3-bd32-4d64-a040-ca14004312bd_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_f9c8173d-5fcf-42b8-ba26-2ab8941d0c18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d52f6545-e0a1-40f0-9b2d-5c8066c9e6c1_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bdb077b7-e66f-42ee-a3b5-ef54cdd73e21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_46da86ec-d2bd-4ab0-abb2-8213ab4d6b2c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares&#8212;basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9e008345-16f3-4967-a81d-a50781f42727_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b454061d-1f1c-4dc9-b061-e17ddea798c4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_af65bfd9-656c-4e45-b1e6-8a0abd4a0dcd_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneMember_dfef062e-6c7b-4169-931e-fca8c1b708ab_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:label id="lab_lgnd_MilestoneMember_label_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Member]</link:label>
    <link:label id="lab_lgnd_MilestoneMember_documentation_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember" xlink:href="lgnd-20201231.xsd#lgnd_MilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneMember" xlink:to="lab_lgnd_MilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_805237cb-ebae-4e05-b09f-0677f8395879_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PfenexMember_aeaae712-ba01-4aff-b0e7-125714541a65_terseLabel_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex</link:label>
    <link:label id="lab_lgnd_PfenexMember_label_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex [Member]</link:label>
    <link:label id="lab_lgnd_PfenexMember_documentation_en-US" xlink:label="lab_lgnd_PfenexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfenex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PfenexMember" xlink:to="lab_lgnd_PfenexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5afe0d51-041b-460e-a8cd-df4fe59ef0fb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-Known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_65e8df8d-c4c3-4ead-961e-16dc10c3874c_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash holdback for potential indemnification claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_label_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:to="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_04ecd608-4275-4d2e-a47a-b53ea2cdd201_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_08dec68a-a18f-446b-a41a-3835044cb328_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_3578e0b7-ff5a-4e69-918c-cb08cf4df9e4_terseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to contingent liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_36e3c195-8d2a-4542-9fc8-5bdfd289a985_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2d77b55e-212c-4882-bf90-67fe66d1a428_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fbcf9e38-a182-4a10-ae4e-513a93ea7a97_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a3c45775-d00c-470a-ad3c-b04e8d47e3ec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e42927ff-bcd9-49ed-8f44-ca27cd319ef3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_5c28c718-1b6a-4944-899e-75a6cc7943bd_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit loss adjustments on finite-lived intangible assets</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_label_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Credit Loss Adjustments</link:label>
    <link:label id="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_documentation_en-US" xlink:label="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Credit Loss Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:to="lab_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db4d3011-dafc-46bc-8205-6939dc80ecb6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19fbcf33-304b-4b40-8071-22ffa69b21ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b6faf814-eeb8-4c0f-9691-65f280f8a52d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_d3dde1cd-f616-4656-8388-54fac364d3a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_4c792ca0-e051-4f06-9ff8-dc3c2232d296_verboseLabel_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents &amp; Short Term Investments</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:href="lgnd-20201231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:to="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b2fadff6-3aca-495f-a6fb-a6754b2caf7c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_2685a8b8-22f5-4006-a0ac-801557a61b7c_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_38473c72-44dc-4594-8b2b-88606875e660_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5e5d21af-16a8-4f12-9cd6-127c740ff7f0_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_29af39aa-0e0c-4332-83a7-b24bbf9fe98b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_71afd856-a365-4482-b669-57df6d656dd8_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyEvomelaMember" xlink:to="lab_lgnd_RoyaltyEvomelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_8acfba65-bdcf-4eb6-aadd-2d39dfeae2b0_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_72eba06c-3d27-4b60-a5cb-c586d4396bd8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f01fed03-33c1-4249-9bd3-2660ca8d5486_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree since acquisition date included in comprehensive income</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_9c2cd0bd-21d1-4f7b-89ba-399d18b7d60a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_caae558f-02ef-490b-a521-f8a961f3f1cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_631d5fa5-7125-4dd8-b54b-a9165a00cab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_9636e8ac-b51c-45b6-a66e-337aef0813e7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83706d5f-a2a2-476c-9aab-7eb1d5edb1f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_cd2e77a0-5ea2-4a31-b31e-b870cace765c_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_72bbf1b8-d188-4575-b78d-808bd12e09fe_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_75526289-6818-4e21-a4fa-0f8a080d562e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_15dbc0cd-bb29-4cdd-a34b-6932dc16a24a_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for convertible bond hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:to="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_1d670de6-8fc3-4894-b660-5fb70afd5125_terseLabel_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues</link:label>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_label_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues [Member]</link:label>
    <link:label id="lab_lgnd_ContingentValueRightOnProductRevenuesMember_documentation_en-US" xlink:label="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Right on Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:to="lab_lgnd_ContingentValueRightOnProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a4e3746c-93d1-47d8-84c4-7821ad7e411d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7a8fa296-f216-4202-9e75-b9d05978f56b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_d42f010c-d8f6-4f6a-a92f-18c4d10461cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill written off</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ce496a62-5a94-4ab5-995e-7a74722312d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_1ffc9029-5573-42eb-bcf4-b63e8c0b475e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of civil complaints filed against entity</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_66051072-a779-4bf1-a064-57ab1e6f5fa8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_134b86f1-49a9-4107-999b-3ea787266230_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_2ee4a379-dcb8-478a-a398-e54f3030574d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18816e1-93ed-45fd-9780-60e74ade4880_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e1726c55-f61f-40d6-ae34-0499fd2ebed6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1d60aaa7-4a81-43b3-87b2-aa56046144e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_3e97f578-d69f-45c3-b1b0-69d619fdec1f_terseLabel_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for license</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_label_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_documentation_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment" xlink:href="lgnd-20201231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseUpfrontPayment" xlink:to="lab_lgnd_LicenseUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_57725760-dd74-43a5-bd3a-c0cde1c2556e_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_e99f42dc-fc29-46fe-a2ba-2194e5a0f63e_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback from acquisition</link:label>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_label_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Holdback</link:label>
    <link:label id="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Holdback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:to="lab_lgnd_BusinessCombinationConsiderationTransferredHoldback" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_071ab97d-97a7-4bd3-ab88-02995da9657e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fccac2cd-d869-4e56-96da-3f5b94c133bd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_ad963040-f7f8-48c3-b306-9862fc48fe35_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid to date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_01928040-5e80-4e19-9464-0d37c4f4fad0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_50b04da9-c67f-4968-a696-ad6ec9ec7acd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_37f6f71d-f59d-4e9c-a703-105c37785ac4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8c34e358-3ab8-43f8-9969-bfbc4c1a3d4d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_df8f753a-ff07-4d01-8511-730d9aae8692_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic per share amounts:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_7fefa227-fa34-42b4-8086-326a43c7cfeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>lgnd-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df8541e0-03a2-4cf0-afef-5d57e839fea7,g:c05e0910-d9c8-4292-8e3b-91706b854e69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_089fc66b-eeb6-4332-a35a-164c6801340d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_AmendmentFlag_089fc66b-eeb6-4332-a35a-164c6801340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1fa5fb8e-8c77-4088-b429-7cb22e58d10c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentFiscalYearFocus_1fa5fb8e-8c77-4088-b429-7cb22e58d10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_70c2d512-3be7-4588-8267-862f9afe1925" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_70c2d512-3be7-4588-8267-862f9afe1925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_33913122-55dc-4d39-8119-2b0335484b84" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityCentralIndexKey_33913122-55dc-4d39-8119-2b0335484b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_51ce3d06-5565-410a-b1bd-c7b43a4fcd06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_CurrentFiscalYearEndDate_51ce3d06-5565-410a-b1bd-c7b43a4fcd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_06af6a88-391e-4f42-ae5c-8039b5e6e00b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentType_06af6a88-391e-4f42-ae5c-8039b5e6e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e1eb3cb6-69ed-4ad7-b11a-2ab3967400aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentAnnualReport_e1eb3cb6-69ed-4ad7-b11a-2ab3967400aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_89835add-4f7c-450e-a3a5-dd5e6dcec157" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentPeriodEndDate_89835add-4f7c-450e-a3a5-dd5e6dcec157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6b212c90-6667-4623-9803-821893f9aa13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_DocumentTransitionReport_6b212c90-6667-4623-9803-821893f9aa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b9bfdf91-1f24-42e9-a88a-f55d37e2ab43" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityFileNumber_b9bfdf91-1f24-42e9-a88a-f55d37e2ab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fc0b9c48-6ffc-404b-ad57-ecdc3407a2e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityRegistrantName_fc0b9c48-6ffc-404b-ad57-ecdc3407a2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1e90901e-3838-4f36-afde-022bf4294eac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1e90901e-3838-4f36-afde-022bf4294eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8cb1c517-ad60-49dd-a2d0-f0fc9fd8a801" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityTaxIdentificationNumber_8cb1c517-ad60-49dd-a2d0-f0fc9fd8a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f4b90bc-56f0-47b9-9087-3c1f570ed2b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityAddressAddressLine1_6f4b90bc-56f0-47b9-9087-3c1f570ed2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e27ed483-9a56-42c7-bde5-5165d5d3bb80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityAddressCityOrTown_e27ed483-9a56-42c7-bde5-5165d5d3bb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_92d358ed-8119-46c1-a2be-85cb7e85cad4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityAddressStateOrProvince_92d358ed-8119-46c1-a2be-85cb7e85cad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_16e2da00-dd2e-410b-b466-0884e7084e4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityAddressPostalZipCode_16e2da00-dd2e-410b-b466-0884e7084e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_988555a0-df35-4291-a329-775b99219157" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_CityAreaCode_988555a0-df35-4291-a329-775b99219157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ca91825c-6fdf-437b-aacd-d7423dfde9be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_LocalPhoneNumber_ca91825c-6fdf-437b-aacd-d7423dfde9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a58d8dd-95e7-4ff3-9db7-c45c2f4d60cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_Security12bTitle_5a58d8dd-95e7-4ff3-9db7-c45c2f4d60cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ab0ba4a4-d84e-48b7-9827-1e61ddc4b74a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_TradingSymbol_ab0ba4a4-d84e-48b7-9827-1e61ddc4b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d023779c-b06f-4e38-a5a5-3c3aa94076b4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_SecurityExchangeName_d023779c-b06f-4e38-a5a5-3c3aa94076b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_978a80eb-fb3b-4435-92ff-fda56fc2385b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_978a80eb-fb3b-4435-92ff-fda56fc2385b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a70a4af6-e00e-412e-8c81-6129acbf555b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityVoluntaryFilers_a70a4af6-e00e-412e-8c81-6129acbf555b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a6a8e39e-78b3-4773-98d2-74893eea27a0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityCurrentReportingStatus_a6a8e39e-78b3-4773-98d2-74893eea27a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_850f499a-bb1c-43f8-b00a-9c51732b12c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityInteractiveDataCurrent_850f499a-bb1c-43f8-b00a-9c51732b12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2c47c778-6dac-4dd3-9495-cadf88a18d97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityFilerCategory_2c47c778-6dac-4dd3-9495-cadf88a18d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e41e0264-2af2-4153-b9e2-ad6df8316bb8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntitySmallBusiness_e41e0264-2af2-4153-b9e2-ad6df8316bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b4e2dfdf-195c-46a3-a26d-8fda300fc9f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityEmergingGrowthCompany_b4e2dfdf-195c-46a3-a26d-8fda300fc9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4c74a96b-3215-492d-adcf-7bd69cb977d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4c74a96b-3215-492d-adcf-7bd69cb977d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8cdaee5d-3599-448d-b955-5cd0abed9a7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityShellCompany_8cdaee5d-3599-448d-b955-5cd0abed9a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_673c3692-0281-4bb3-894e-02722e2b50fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityPublicFloat_673c3692-0281-4bb3-894e-02722e2b50fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8194c25a-c2f9-4d6a-a85d-369d251b2df7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56d0bfec-6ce0-4fab-b195-9b6ba8b39f8b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8194c25a-c2f9-4d6a-a85d-369d251b2df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0d41f319-dfc6-4b2d-988e-91d62bf190e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d41f319-dfc6-4b2d-988e-91d62bf190e0" xlink:to="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fecdca9e-0f0a-47f7-bc1b-460872f24de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fecdca9e-0f0a-47f7-bc1b-460872f24de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2de7ef4f-6394-40a2-b218-91e918019d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_ShortTermInvestments_2de7ef4f-6394-40a2-b218-91e918019d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_850c0dc9-903f-4a1c-9649-055469c5e019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_850c0dc9-903f-4a1c-9649-055469c5e019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f46fb541-f19e-468f-8b63-cec7191ef1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_InventoryNet_f46fb541-f19e-468f-8b63-cec7191ef1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_b64f7493-389d-41b8-a808-e85c71bb1992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_IncomeTaxesReceivable_b64f7493-389d-41b8-a808-e85c71bb1992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_00c59bba-ad04-4d68-ab42-d0b38b104303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_OtherAssetsCurrent_00c59bba-ad04-4d68-ab42-d0b38b104303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ab66600-351b-4da6-a4e4-7c36f34e9d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d8dbba0-da9a-4305-8c3c-8335d824b808" xlink:to="loc_us-gaap_AssetsCurrent_2ab66600-351b-4da6-a4e4-7c36f34e9d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_839233c8-60dd-444d-811a-5a9399aa891b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_839233c8-60dd-444d-811a-5a9399aa891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93cde266-69c7-43de-a938-43a9ea311fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93cde266-69c7-43de-a938-43a9ea311fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_06064eb9-fb44-43f6-885c-aad61c89cd52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_Goodwill_06064eb9-fb44-43f6-885c-aad61c89cd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_948da9f0-80ef-40d3-bc3e-156971f4f0e4" xlink:href="lgnd-20201231.xsd#lgnd_CommercialLicenseRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_lgnd_CommercialLicenseRights_948da9f0-80ef-40d3-bc3e-156971f4f0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_024bfa28-f16c-4fdd-9d25-978993867d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_024bfa28-f16c-4fdd-9d25-978993867d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7e8a4fc5-60bc-420f-93d8-2d9e3693415a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7e8a4fc5-60bc-420f-93d8-2d9e3693415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b8261227-db62-47b8-83e3-ca968636a847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b8261227-db62-47b8-83e3-ca968636a847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5c509252-0020-4660-bfd3-ddff35e5cee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5c509252-0020-4660-bfd3-ddff35e5cee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1019ec1b-8373-491c-9278-231828ef9f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5e794f4e-53d9-4282-acf1-7fb03a7200b8" xlink:to="loc_us-gaap_Assets_1019ec1b-8373-491c-9278-231828ef9f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d41f319-dfc6-4b2d-988e-91d62bf190e0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:to="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c806fe23-ba00-4678-ba94-2878b7a379d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_AccountsPayableCurrent_c806fe23-ba00-4678-ba94-2878b7a379d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_baaa4ad4-3d98-452f-8fc0-b461d683a7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_baaa4ad4-3d98-452f-8fc0-b461d683a7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_4f388862-a256-4f0b-88d7-542b6b0e2099" xlink:href="lgnd-20201231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_4f388862-a256-4f0b-88d7-542b6b0e2099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_837c3d10-ca03-4d54-af61-40187f4c90b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_837c3d10-ca03-4d54-af61-40187f4c90b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1499bca8-e1e2-4100-843b-2845c919d5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1499bca8-e1e2-4100-843b-2845c919d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9e28920e-4568-4253-abba-2fc895eb0f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9e28920e-4568-4253-abba-2fc895eb0f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ff7ab29-511d-4e0a-870f-18ad53c9113d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4fbcc5bc-758f-4109-b1d2-166b11cf6bb7" xlink:to="loc_us-gaap_LiabilitiesCurrent_3ff7ab29-511d-4e0a-870f-18ad53c9113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_02626378-f45f-4472-b4d9-d3ca8f6e44ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_02626378-f45f-4472-b4d9-d3ca8f6e44ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_72a25f20-3b19-490f-94cb-6c38fee6a83d" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_lgnd_LiabilityForContingentValueRights_72a25f20-3b19-490f-94cb-6c38fee6a83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1b11d39e-98f0-4402-a390-77fea9c44ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1b11d39e-98f0-4402-a390-77fea9c44ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_66145111-4683-4bbe-a3b3-8d36450c4cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_66145111-4683-4bbe-a3b3-8d36450c4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1acb52dc-14a0-4758-879a-c6c26dcf93a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1acb52dc-14a0-4758-879a-c6c26dcf93a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9f7c3d3-8009-4fb1-b984-cea0c724d9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4f832342-d8b1-40bc-8a6c-11f7b7dea10f" xlink:to="loc_us-gaap_Liabilities_d9f7c3d3-8009-4fb1-b984-cea0c724d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10c5bb1d-fe99-4ab2-808c-3a3b717387f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:to="loc_us-gaap_CommitmentsAndContingencies_10c5bb1d-fe99-4ab2-808c-3a3b717387f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:to="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4da63459-08f3-4cb0-937e-a56fba6fef08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_PreferredStockValue_4da63459-08f3-4cb0-937e-a56fba6fef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7b75e138-664c-40da-b4c9-66ee1dbe9d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_CommonStockValue_7b75e138-664c-40da-b4c9-66ee1dbe9d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7d759be9-be45-4264-8d44-04e4e9c98e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7d759be9-be45-4264-8d44-04e4e9c98e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48b4a3c7-3b2f-433f-a8a8-840c5baf25bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48b4a3c7-3b2f-433f-a8a8-840c5baf25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9490b151-7a22-4221-ad65-89c051580abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9490b151-7a22-4221-ad65-89c051580abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a950d4c5-c289-4a76-a3e8-03f2820e34fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10dd65e3-8bfd-4ab9-a1bf-af7a4cf2f845" xlink:to="loc_us-gaap_StockholdersEquity_a950d4c5-c289-4a76-a3e8-03f2820e34fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9433d92-d95d-4f2a-9816-c282aa1124a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19b7a635-3dc0-412b-a3a6-b09490c24a83" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9433d92-d95d-4f2a-9816-c282aa1124a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_df2d3acf-a9d8-41cf-b4d6-736dae0a2f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_df2d3acf-a9d8-41cf-b4d6-736dae0a2f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9e46e78c-e213-455d-a5d3-8859a9ed0a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9e46e78c-e213-455d-a5d3-8859a9ed0a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2fb2a876-550e-47bb-90fa-6d4fb1b13e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2fb2a876-550e-47bb-90fa-6d4fb1b13e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e90fde02-95bc-4f5c-84cd-ab09d21bfb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e90fde02-95bc-4f5c-84cd-ab09d21bfb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d802394e-aabb-4d84-b1ba-052c66cd9865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d802394e-aabb-4d84-b1ba-052c66cd9865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_53bbf00d-770a-4792-bf24-482ec4db68fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_53bbf00d-770a-4792-bf24-482ec4db68fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34c4062d-f790-4d93-995a-c502c1a654c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_CommonStockSharesIssued_34c4062d-f790-4d93-995a-c502c1a654c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_edf4ee4a-8d9f-4e6f-97c7-417a13f93dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32f7c920-255d-4d8a-a593-53dba5235746" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_edf4ee4a-8d9f-4e6f-97c7-417a13f93dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8164cd3b-c40d-4f73-81cd-9a315da47228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8164cd3b-c40d-4f73-81cd-9a315da47228" xlink:to="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:to="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_17d47941-9377-40ad-a0c9-03e5245388b0" xlink:to="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4949a949-93aa-4052-a7c3-0e91aeafa7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_us-gaap_RoyaltyMember_4949a949-93aa-4052-a7c3-0e91aeafa7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_079e6c87-7b0c-4df0-816b-2d3b395dedfd" xlink:href="lgnd-20201231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_079e6c87-7b0c-4df0-816b-2d3b395dedfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_828084d3-0ba6-4c90-b97a-233dc3a691b2" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_ContractRevenueMember_828084d3-0ba6-4c90-b97a-233dc3a691b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_9296ad74-5897-4252-b401-34237d8b446f" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_VernalisMember_9296ad74-5897-4252-b401-34237d8b446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_9e4e3644-7066-49f5-b347-cc5900fa5d6b" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fe43329-821a-495f-a86b-fca62e765d41" xlink:to="loc_lgnd_PromactaMember_9e4e3644-7066-49f5-b347-cc5900fa5d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_489644fc-3a75-4000-b209-0c5c5e3c3bca" xlink:to="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_379790ed-32a9-4065-98b6-b03189fad7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0b5adf44-1d9c-4e4d-a5ae-1e1158909dc6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_379790ed-32a9-4065-98b6-b03189fad7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_9f05b362-0d83-4e12-9c1a-62e52ddc6473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_CostDirectMaterial_9f05b362-0d83-4e12-9c1a-62e52ddc6473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_c95ff4e3-8ce9-4b08-83d9-d38ef88c68c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_c95ff4e3-8ce9-4b08-83d9-d38ef88c68c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3679ce53-7606-41fe-8ae7-daa8aafcfe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3679ce53-7606-41fe-8ae7-daa8aafcfe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_751ccd8a-c4a5-4f28-a73d-71e787bf054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_751ccd8a-c4a5-4f28-a73d-71e787bf054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_61441d2c-86ab-4a8c-94a5-833b0c691e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_4e2d34b7-8b27-4c9b-a46c-449073ffe8d0" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_61441d2c-86ab-4a8c-94a5-833b0c691e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c2d96c8b-905c-4266-9e3b-409d477f82ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c2d96c8b-905c-4266-9e3b-409d477f82ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29a6e20f-a452-4706-9a02-2b31c037e0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_29a6e20f-a452-4706-9a02-2b31c037e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d30b18d1-8168-4a2f-8a1f-af1b7915d147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_GainLossOnInvestments_d30b18d1-8168-4a2f-8a1f-af1b7915d147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6c4f64f6-588d-44b5-a948-ff9a260d95b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6c4f64f6-588d-44b5-a948-ff9a260d95b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8a3872b4-5015-4cea-9b42-8051029471b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_InterestExpense_8a3872b4-5015-4cea-9b42-8051029471b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7afd6e80-5d9d-4b10-9961-3f40774bb305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7afd6e80-5d9d-4b10-9961-3f40774bb305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3996cc21-4c00-4e66-9830-047f4168dfc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_070022e1-9b0f-4507-a4e2-c095da09395c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3996cc21-4c00-4e66-9830-047f4168dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d56b4b79-57e6-4b9f-8737-4ff3172da820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d56b4b79-57e6-4b9f-8737-4ff3172da820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0afb3af8-f662-4459-a4bb-bd22fcf8fef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0afb3af8-f662-4459-a4bb-bd22fcf8fef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92562afb-1ff2-40d0-9d51-f7f515bd2315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_NetIncomeLoss_92562afb-1ff2-40d0-9d51-f7f515bd2315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4536c5aa-fa14-4abe-be87-8149549d35ac" xlink:to="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e082183e-bfa0-4700-a88d-4385727dc20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_EarningsPerShareBasic_e082183e-bfa0-4700-a88d-4385727dc20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f9278d4-5204-433b-88b3-7c496cc390c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f9278d4-5204-433b-88b3-7c496cc390c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aadfcf85-928a-4601-92d6-a102a69c112f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aadfcf85-928a-4601-92d6-a102a69c112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6b72b9-c82e-4656-9788-c55298fb6002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_799b3b32-a965-4071-a2db-efe034142449" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6b72b9-c82e-4656-9788-c55298fb6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e75c636b-8db6-4b0c-a813-df3066fbc924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8eca356-d80e-44d2-852d-8f0dfdd2effb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e75c636b-8db6-4b0c-a813-df3066fbc924" xlink:to="loc_us-gaap_NetIncomeLoss_b8eca356-d80e-44d2-852d-8f0dfdd2effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2fd7c3aa-6005-4746-a3b6-2c54c157dfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e75c636b-8db6-4b0c-a813-df3066fbc924" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2fd7c3aa-6005-4746-a3b6-2c54c157dfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0b12220e-34fc-4be6-952d-bb08fed8705f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e75c636b-8db6-4b0c-a813-df3066fbc924" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0b12220e-34fc-4be6-952d-bb08fed8705f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_48e69b94-1d4a-4e24-9c13-cabfb6fd93d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e75c636b-8db6-4b0c-a813-df3066fbc924" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_48e69b94-1d4a-4e24-9c13-cabfb6fd93d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a998f5d9-8625-4b9e-a29a-8fc40b48cffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a998f5d9-8625-4b9e-a29a-8fc40b48cffa" xlink:to="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c803def8-07eb-4b49-ac93-7caf995ddf6f" xlink:to="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd60f04a-2ccc-4f02-86a3-71da4d5ac1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_CommonStockMember_cd60f04a-2ccc-4f02-86a3-71da4d5ac1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee1f0fe7-4aab-453d-a6c8-ada3d9d9d45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee1f0fe7-4aab-453d-a6c8-ada3d9d9d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2c86ab59-f0b7-4a8d-ac9e-004cf4601bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2c86ab59-f0b7-4a8d-ac9e-004cf4601bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d6bf2e44-d720-4be6-8934-eb5729f39db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_758df215-2a6c-478d-a344-0d45b994101e" xlink:to="loc_us-gaap_RetainedEarningsMember_d6bf2e44-d720-4be6-8934-eb5729f39db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7f2301ff-5406-43ff-b2df-34ccf8eb4cdd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_625d1623-8ee5-4d86-9f5d-705d1875afc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_625d1623-8ee5-4d86-9f5d-705d1875afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_813e6f72-a7a8-4d08-a0e8-15bd92f2d29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_3be2a6f5-04c1-4d5b-9f8c-f5f52832b243" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_813e6f72-a7a8-4d08-a0e8-15bd92f2d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_740570e8-712c-4d02-b5d9-a91b4d932e47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_e50f9212-c28e-4bff-8486-564b9833c7a6" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_e50f9212-c28e-4bff-8486-564b9833c7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_c69b9497-c353-4fa8-a163-23310e9f466f" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ba49d3f7-0152-4b14-bce8-fa6a48388cb7" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_c69b9497-c353-4fa8-a163-23310e9f466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b45c0301-65a1-40cc-a599-50675553ad1f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_461bf83a-2ddb-4f95-8c8e-975c015157f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8c6b83a-adf3-4008-b284-5b595cf80e72" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_461bf83a-2ddb-4f95-8c8e-975c015157f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254951e0-6cb1-4bda-a660-6d43ce887ad7" xlink:to="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d71c5cb3-56f4-4006-8385-d08c794f1fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d71c5cb3-56f4-4006-8385-d08c794f1fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fbf774de-99b8-4084-9a36-58ff2654f901" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3dec75da-7e62-4485-bf39-25841657fb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_SharesOutstanding_3dec75da-7e62-4485-bf39-25841657fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cf2457-11af-4095-b82c-c1a4dfc827ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cf2457-11af-4095-b82c-c1a4dfc827ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0b97be1a-4eed-4c2f-8f9e-364845ae37aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0b97be1a-4eed-4c2f-8f9e-364845ae37aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b396177-5c59-438c-ba57-1cada06d6452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b396177-5c59-438c-ba57-1cada06d6452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_94e5fcab-86cc-4f2f-bcc7-42ace00918e1" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt_94e5fcab-86cc-4f2f-bcc7-42ace00918e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dfc0ebea-dc78-408a-85ab-b1a3dad8560b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dfc0ebea-dc78-408a-85ab-b1a3dad8560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_430ef1b7-9cfe-4229-99b8-cacdaa3943a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_430ef1b7-9cfe-4229-99b8-cacdaa3943a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b14c0741-3fb7-43db-887b-ff76ce630fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b14c0741-3fb7-43db-887b-ff76ce630fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_099ef6d5-8409-453a-880a-a174fbd3c9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_099ef6d5-8409-453a-880a-a174fbd3c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_e43a4e2d-dff4-40c6-b39c-273adec16b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_e43a4e2d-dff4-40c6-b39c-273adec16b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_102d051c-a27d-413b-831a-d9448a95c264" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_102d051c-a27d-413b-831a-d9448a95c264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_eaddd76a-c50f-4da6-90c4-060c36a988a0" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_eaddd76a-c50f-4da6-90c4-060c36a988a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_712ccc9d-8b70-4b20-a669-58c9c4a60b5a" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_712ccc9d-8b70-4b20-a669-58c9c4a60b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_0db1c792-71c0-42a9-9440-36b8b2f8d554" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_0db1c792-71c0-42a9-9440-36b8b2f8d554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_efcbbe5c-ea2d-4be0-a02f-64ba54134b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_efcbbe5c-ea2d-4be0-a02f-64ba54134b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d028d65e-5e93-40fa-93c0-3f3d62fe9e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d028d65e-5e93-40fa-93c0-3f3d62fe9e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be698e6a-d776-4ecb-a04e-8bac2c1c83e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be698e6a-d776-4ecb-a04e-8bac2c1c83e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_4b06f093-2f61-403e-8a92-f250da51d8da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_4b06f093-2f61-403e-8a92-f250da51d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_7f77d69d-aa53-416f-bfe1-b39123012087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_7f77d69d-aa53-416f-bfe1-b39123012087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f245eed3-c10e-4f0d-b21f-77fb4066f62b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_NetIncomeLoss_f245eed3-c10e-4f0d-b21f-77fb4066f62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6231936-5580-4ae3-9d66-890661057d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_SharesOutstanding_c6231936-5580-4ae3-9d66-890661057d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_460a81fc-01b8-4fc9-a9df-7ffd105fe0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1b416780-071f-443f-b719-23c4d3856000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_460a81fc-01b8-4fc9-a9df-7ffd105fe0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be9f8eeb-af39-4292-9c27-21a8e03af298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be9f8eeb-af39-4292-9c27-21a8e03af298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c58ba063-58f3-4d43-952d-6dabc48d9a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be9f8eeb-af39-4292-9c27-21a8e03af298" xlink:to="loc_us-gaap_ProfitLoss_c58ba063-58f3-4d43-952d-6dabc48d9a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be9f8eeb-af39-4292-9c27-21a8e03af298" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_1004add0-fe1c-45a2-b7ab-e3c2cdad4d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_1004add0-fe1c-45a2-b7ab-e3c2cdad4d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c143f526-9f43-4b5e-b305-85a275d67e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c143f526-9f43-4b5e-b305-85a275d67e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_6f637a7f-b36f-4ec9-b4b8-a0d9ae3740ca" xlink:href="lgnd-20201231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_6f637a7f-b36f-4ec9-b4b8-a0d9ae3740ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1fe9a044-80fb-4244-9cd4-cf70a3fc68d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1fe9a044-80fb-4244-9cd4-cf70a3fc68d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_4632d696-2d94-44e0-b729-bcff224ef8a0" xlink:href="lgnd-20201231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_4632d696-2d94-44e0-b729-bcff224ef8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b1f4bb2a-631b-4f04-83b8-ecc033384bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b1f4bb2a-631b-4f04-83b8-ecc033384bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb977ccd-5737-4e4b-94ce-f1680de91690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb977ccd-5737-4e4b-94ce-f1680de91690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_1ccdea35-de9e-4e1c-9ca9-203365e376ed" xlink:href="lgnd-20201231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_1ccdea35-de9e-4e1c-9ca9-203365e376ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_08d57a2f-4467-4779-80a5-7506e4068df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_ShareBasedCompensation_08d57a2f-4467-4779-80a5-7506e4068df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ce059647-5af1-4747-9c26-613fde106683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ce059647-5af1-4747-9c26-613fde106683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_4d39f01e-c009-43da-bbbe-829c964cf1fd" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_4d39f01e-c009-43da-bbbe-829c964cf1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_91d45869-81e8-4e98-a9b0-789cfe53e4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aee79385-c73c-4037-bc22-27e1e7709b24" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_91d45869-81e8-4e98-a9b0-789cfe53e4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be9f8eeb-af39-4292-9c27-21a8e03af298" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_856772cc-6191-40b9-bd72-03da95d74970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_856772cc-6191-40b9-bd72-03da95d74970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a7fbdd7b-c506-4e41-a10f-eb9cd8dbffcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a7fbdd7b-c506-4e41-a10f-eb9cd8dbffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb3bd2e8-c2ac-4dc4-b00c-f73eb1c1eb19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb3bd2e8-c2ac-4dc4-b00c-f73eb1c1eb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_d1175c17-4285-48d0-8599-b2835927ff65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_d1175c17-4285-48d0-8599-b2835927ff65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_f34e7052-9b48-4ed8-ac7d-fce2530fa236" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_f34e7052-9b48-4ed8-ac7d-fce2530fa236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdbf93c2-3ac2-46b0-a249-0600c7366ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdbf93c2-3ac2-46b0-a249-0600c7366ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_c7068835-afa5-435e-ac36-e46a1fac8215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_c7068835-afa5-435e-ac36-e46a1fac8215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3046d8f9-a4fa-420a-a25b-49292c335d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12fe44a9-3aac-4f32-802e-55915b0ecf3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3046d8f9-a4fa-420a-a25b-49292c335d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_c2f3c2f3-52ad-4d6d-89dd-ec13fc3605c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_c2f3c2f3-52ad-4d6d-89dd-ec13fc3605c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_02c97f0c-06cf-48d9-a75f-4261ccae592a" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_02c97f0c-06cf-48d9-a75f-4261ccae592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_78edfeef-2c22-4b3f-8f76-bd1142ba5a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_78edfeef-2c22-4b3f-8f76-bd1142ba5a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f2521822-7aca-470b-901f-2de79a5f649a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f2521822-7aca-470b-901f-2de79a5f649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9ca7e68e-c2c0-4ed3-9860-7536d096f236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9ca7e68e-c2c0-4ed3-9860-7536d096f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_79692b6e-7547-4c27-b394-9cba15f4a55e" xlink:href="lgnd-20201231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_79692b6e-7547-4c27-b394-9cba15f4a55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1f7aaf5b-6404-49d0-923f-e2fe64de765d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1f7aaf5b-6404-49d0-923f-e2fe64de765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_3e22d112-c89c-4bdd-a3c7-b8a94f0c6f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_3e22d112-c89c-4bdd-a3c7-b8a94f0c6f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_6780b36f-0723-492a-9c21-07354a26e11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_6780b36f-0723-492a-9c21-07354a26e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_70d8ac81-1e2e-47d9-8a87-dbd25baa935e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_70d8ac81-1e2e-47d9-8a87-dbd25baa935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9b0919e1-086d-4666-b8b5-0636165d0d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_9b0919e1-086d-4666-b8b5-0636165d0d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2e62d2b1-2230-474b-a8bf-6974ff984e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2e62d2b1-2230-474b-a8bf-6974ff984e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb9c8613-179b-4576-9560-102b632076f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e1c3b85-ec06-43d4-ba89-abc87f23e545" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb9c8613-179b-4576-9560-102b632076f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d441d578-283e-4ace-8b12-df4489bdbaca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d441d578-283e-4ace-8b12-df4489bdbaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a850b789-7c90-4360-bcfc-be2c776c4554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a850b789-7c90-4360-bcfc-be2c776c4554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_c8813c60-2e44-49c9-944c-83b3cff4c4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_c8813c60-2e44-49c9-944c-83b3cff4c4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b4886161-7d6d-4753-9a50-a54385bab352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b4886161-7d6d-4753-9a50-a54385bab352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_0bba748a-c860-4165-9394-efb4ec9b6dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_0bba748a-c860-4165-9394-efb4ec9b6dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge_0dc4ad59-f971-434c-aa1a-f663a7bc8de1" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_lgnd_PurchaseOfConvertibleBondHedge_0dc4ad59-f971-434c-aa1a-f663a7bc8de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_ca0793d8-c0c9-499a-9bee-108dff194b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_ca0793d8-c0c9-499a-9bee-108dff194b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_c0ec8154-e869-4f4d-b016-77bd58d06ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_c0ec8154-e869-4f4d-b016-77bd58d06ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a7647d2d-4cdd-4326-b733-6d20e88cc783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a7647d2d-4cdd-4326-b733-6d20e88cc783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_85304be7-9618-480a-9afa-4f51c0d7be8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_85304be7-9618-480a-9afa-4f51c0d7be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_06bac7cd-5b81-4138-bd4b-e3631f03b180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_06bac7cd-5b81-4138-bd4b-e3631f03b180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_6c5a4546-04ff-43d2-8089-a7cde320fdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_6c5a4546-04ff-43d2-8089-a7cde320fdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_36b4f506-93a6-46dc-a45b-0aac6cfa871e" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_36b4f506-93a6-46dc-a45b-0aac6cfa871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f9fdd8e-0f88-4d9f-b9e7-85db86cc4732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9e7764f7-401c-4053-882c-84d92633dd41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f9fdd8e-0f88-4d9f-b9e7-85db86cc4732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dcac2cf8-2000-4f71-bcd6-9fb0f20c5bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dcac2cf8-2000-4f71-bcd6-9fb0f20c5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f254feb-5b77-4a9b-b568-e1de5127636d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f254feb-5b77-4a9b-b568-e1de5127636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c9d809f-6630-4a63-a956-bdc9a90e8a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c9d809f-6630-4a63-a956-bdc9a90e8a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1501c5d-5aa5-4366-adba-c834936e97ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1501c5d-5aa5-4366-adba-c834936e97ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e5f896e-9a8f-46a9-ad99-0dbf708b94b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e5f896e-9a8f-46a9-ad99-0dbf708b94b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract_33b8eb8c-50bb-4500-997b-d41f09fc0c37" xlink:href="lgnd-20201231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e5f896e-9a8f-46a9-ad99-0dbf708b94b9" xlink:to="loc_lgnd_CashPaidDuringTheYearAbstract_33b8eb8c-50bb-4500-997b-d41f09fc0c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3e6e18c7-9727-43db-b18c-663ed6a4bd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_33b8eb8c-50bb-4500-997b-d41f09fc0c37" xlink:to="loc_us-gaap_InterestPaidNet_3e6e18c7-9727-43db-b18c-663ed6a4bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_741d6793-d2b5-4d3a-b556-a71cbfe25613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_33b8eb8c-50bb-4500-997b-d41f09fc0c37" xlink:to="loc_us-gaap_IncomeTaxesPaid_741d6793-d2b5-4d3a-b556-a71cbfe25613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4aa61a0a-e0bf-4935-b603-ef5dd9c2ae1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_33b8eb8c-50bb-4500-997b-d41f09fc0c37" xlink:to="loc_us-gaap_RestrictedCashCurrent_4aa61a0a-e0bf-4935-b603-ef5dd9c2ae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d4e2ce9-22a7-4d11-b937-00f29c9c9a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192b32a0-c242-4ce6-9b88-fe2d24c4cf06" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d4e2ce9-22a7-4d11-b937-00f29c9c9a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases_b692fbcb-9b82-4bce-8252-9aca07361c38" xlink:href="lgnd-20201231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d4e2ce9-22a7-4d11-b937-00f29c9c9a9f" xlink:to="loc_lgnd_AccruedInventoryPurchases_b692fbcb-9b82-4bce-8252-9aca07361c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_37b1be89-aa18-4287-9116-ef26f2897ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d4e2ce9-22a7-4d11-b937-00f29c9c9a9f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_37b1be89-aa18-4287-9116-ef26f2897ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d2b4d760-44a3-4829-9036-9ef6af9d8e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1d4e2ce9-22a7-4d11-b937-00f29c9c9a9f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d2b4d760-44a3-4829-9036-9ef6af9d8e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b29f93b4-d499-4161-910c-727094d2de7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4500cdbf-282d-4104-879c-01bb949fa9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b29f93b4-d499-4161-910c-727094d2de7b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4500cdbf-282d-4104-879c-01bb949fa9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_60f528cb-8af3-4937-9bea-f39a00f07e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_60f528cb-8af3-4937-9bea-f39a00f07e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03175bc0-6b49-4ae7-af89-fc2d477ee9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_03175bc0-6b49-4ae7-af89-fc2d477ee9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2c06583e-ea7e-4cdb-ba56-3aa4195968b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2c06583e-ea7e-4cdb-ba56-3aa4195968b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c06862dd-940e-48ad-90e2-e837b1c9017e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_UseOfEstimates_c06862dd-940e-48ad-90e2-e837b1c9017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e520a965-342c-42d4-a127-a448211e4419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e520a965-342c-42d4-a127-a448211e4419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_efc76dbf-c208-4d09-b255-dc89e6291e2a" xlink:href="lgnd-20201231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_efc76dbf-c208-4d09-b255-dc89e6291e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_44ea61a9-ac4a-42e2-8a3c-1c2f0703bec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_44ea61a9-ac4a-42e2-8a3c-1c2f0703bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c2c0632d-eac1-4deb-9b37-6a5e1f7083d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c2c0632d-eac1-4deb-9b37-6a5e1f7083d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8e1e3eb2-7601-4148-b21c-f0b33fc04995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8e1e3eb2-7601-4148-b21c-f0b33fc04995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2f5d3756-54d3-418a-a29e-c2e2e83e35ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2f5d3756-54d3-418a-a29e-c2e2e83e35ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7b00c113-e807-403f-95a0-04ed1b29a373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7b00c113-e807-403f-95a0-04ed1b29a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_1dffe9f5-54a6-42b2-bed7-21d1057476da" xlink:href="lgnd-20201231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_1dffe9f5-54a6-42b2-bed7-21d1057476da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_52cdd016-8981-46e5-9819-c507c7043748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_52cdd016-8981-46e5-9819-c507c7043748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_a0710827-fdf1-4886-b9db-68750cdda213" xlink:href="lgnd-20201231.xsd#lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_a0710827-fdf1-4886-b9db-68750cdda213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_533e6aff-4c19-4dde-9be1-3ac3d02d7a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_533e6aff-4c19-4dde-9be1-3ac3d02d7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f24d91f8-71d5-41e2-8571-6e7f7c716ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f24d91f8-71d5-41e2-8571-6e7f7c716ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6c8bd60a-67ac-4425-82b8-2620b1d74303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6c8bd60a-67ac-4425-82b8-2620b1d74303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ccf4d2d2-9381-4435-938b-228cd37f62b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ccf4d2d2-9381-4435-938b-228cd37f62b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_46e6a15c-16de-4ae4-94f7-256634bc1359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_46e6a15c-16de-4ae4-94f7-256634bc1359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e1886cf6-c5de-497e-85a5-224b206466a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e1886cf6-c5de-497e-85a5-224b206466a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e41c9f1f-6c6a-40b2-8cb0-b3355befb376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e41c9f1f-6c6a-40b2-8cb0-b3355befb376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf31f27f-527e-40d3-83c4-ba422aa6171e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ba1713-51fc-4d85-9f6d-d2927f5b0470" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf31f27f-527e-40d3-83c4-ba422aa6171e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_693e4ac3-42b2-4abf-8588-f520c5f19d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c54fc6ba-4d12-4a49-ac11-df00cc769d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_693e4ac3-42b2-4abf-8588-f520c5f19d2f" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c54fc6ba-4d12-4a49-ac11-df00cc769d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_32ddd12d-d8c1-458b-98b2-a63b029a32fb" xlink:href="lgnd-20201231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_693e4ac3-42b2-4abf-8588-f520c5f19d2f" xlink:to="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_32ddd12d-d8c1-458b-98b2-a63b029a32fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_12e18c18-576f-4488-a03c-f397f8bef469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_693e4ac3-42b2-4abf-8588-f520c5f19d2f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_12e18c18-576f-4488-a03c-f397f8bef469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84fc29db-8375-42b4-a3c7-f7a00f187349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_693e4ac3-42b2-4abf-8588-f520c5f19d2f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84fc29db-8375-42b4-a3c7-f7a00f187349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e26e4035-0f71-4ed9-bc3c-49b40e1cda9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e26e4035-0f71-4ed9-bc3c-49b40e1cda9f" xlink:to="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cea7b2b-15d4-47a4-9696-f89579585282" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_abfa3cad-e4e2-4098-a3e8-bee70f54e2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f9216d13-561d-4704-a6a8-deeacca09ce7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_abfa3cad-e4e2-4098-a3e8-bee70f54e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_84be2b29-0c51-44ef-9b2c-74c047075e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_6dc53eca-8dbe-42cf-97a3-edd2e6c2fb36" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_6dc53eca-8dbe-42cf-97a3-edd2e6c2fb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_7fd4415c-44b3-4aaf-b828-9bf39e3e5d01" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5330784f-39d7-41a9-ac6d-3d5b8a6a036f" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_7fd4415c-44b3-4aaf-b828-9bf39e3e5d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5087e3e6-b62f-4b2c-ac2d-0da97fcd74c4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1421e150-31e6-4d09-8874-2cd5d3ca66de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a5b47a3-9948-4d0e-abc3-6e6bb18f9c41" xlink:to="loc_us-gaap_SeniorNotesMember_1421e150-31e6-4d09-8874-2cd5d3ca66de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_42dd0a83-73dd-4bba-95f1-dc8bfeeae3d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_ce90a2f7-da40-42da-a27e-f033547b4ef1" xlink:href="lgnd-20201231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_NovanMolluscumProductsMember_ce90a2f7-da40-42da-a27e-f033547b4ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_b1d57648-3def-4a0f-9e6c-f137b8aec398" xlink:href="lgnd-20201231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_b1d57648-3def-4a0f-9e6c-f137b8aec398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_e0f17464-6a34-43d8-8fe7-59b4203e856d" xlink:href="lgnd-20201231.xsd#lgnd_AziyoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_AziyoMember_e0f17464-6a34-43d8-8fe7-59b4203e856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_d389efb1-fc3a-4b64-ae43-86e8b9b74bf0" xlink:href="lgnd-20201231.xsd#lgnd_CorMatrixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2185a5f3-db45-48a9-ace0-f0bca66d87e2" xlink:to="loc_lgnd_CorMatrixMember_d389efb1-fc3a-4b64-ae43-86e8b9b74bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_494cd437-0ecc-4af0-90bb-755bde13cdf7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_d5a4ee0a-794c-4e26-89e2-1d96716ea104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_d5a4ee0a-794c-4e26-89e2-1d96716ea104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_569e68ad-8e0a-42fc-a10f-abd48efa77bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e436613-c76f-48cd-b891-c4ec7865a851" xlink:to="loc_us-gaap_LicensingAgreementsMember_569e68ad-8e0a-42fc-a10f-abd48efa77bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58e921f-07af-45b2-b368-69701b2e3252" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_3876cc35-9353-4866-b5a5-61d6cd2a3034" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_PfenexMember_3876cc35-9353-4866-b5a5-61d6cd2a3034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_df83475c-b297-4c08-a6ed-9749ac40611c" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_IcagenMember_df83475c-b297-4c08-a6ed-9749ac40611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_cc887ac0-f9eb-49df-a0b1-eb4772614124" xlink:href="lgnd-20201231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_CrystalMember_cc887ac0-f9eb-49df-a0b1-eb4772614124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_4f70dcba-4d1d-44c4-9083-de52c64806c4" xlink:href="lgnd-20201231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c616500d-64ae-49ab-90a1-92bcadabefc8" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_4f70dcba-4d1d-44c4-9083-de52c64806c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d8c2fc8-1b51-48d4-a37f-12fadba041b8" xlink:to="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc935c85-4a5a-4eae-88d9-ab54ad6ee36d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:to="loc_srt_MinimumMember_fc935c85-4a5a-4eae-88d9-ab54ad6ee36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d569d60-72eb-484d-bf54-491b24482b53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a19c98c6-50c7-4589-9381-fe32ce09ffa3" xlink:to="loc_srt_MaximumMember_7d569d60-72eb-484d-bf54-491b24482b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e3bc88b4-4ab6-4a25-9533-eae583df230d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a1d7cd7-aa6d-4a82-8f10-ee3a10dd6631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a1d7cd7-aa6d-4a82-8f10-ee3a10dd6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_8b3c4b8e-4ed6-4a7e-8049-d53a9174a7a7" xlink:href="lgnd-20201231.xsd#lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f1c3c62-437b-4496-b389-c1ea6e4350ba" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember_8b3c4b8e-4ed6-4a7e-8049-d53a9174a7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_22ce83bb-e4e7-469e-9518-8268df3bbea5" xlink:to="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_0ffa378b-c2e5-40f1-9f4b-a3cfd5ceab1c" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:to="loc_lgnd_VestingPeriodOneMember_0ffa378b-c2e5-40f1-9f4b-a3cfd5ceab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_6953e60d-c9ff-4bff-85bf-dcd68402354d" xlink:href="lgnd-20201231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b9162c04-9e78-4e07-b2c0-a2755a160437" xlink:to="loc_lgnd_VestingPeriodTwoMember_6953e60d-c9ff-4bff-85bf-dcd68402354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_76eb5eab-5567-4dad-9e3f-8836e5c507bf" xlink:to="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_250ea5b2-38ea-4368-87af-ccc1938f95e7" xlink:href="lgnd-20201231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_53cc4618-202f-4988-8873-f4e1a9cb916c" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_250ea5b2-38ea-4368-87af-ccc1938f95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cf7eb6f-e30b-43bb-8c32-460a34e17e8b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_14d4d36e-7b05-479c-8407-eaa751d02075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec163d8a-f861-40da-8afd-7ddb80f361c7" xlink:to="loc_us-gaap_StockCompensationPlanMember_14d4d36e-7b05-479c-8407-eaa751d02075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_de3ca2a5-80b9-4b81-a2f1-0e43657a9512" xlink:to="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_b0c0a103-9bdc-40dd-914c-bcab77fdc299" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_efbb2566-250a-4d02-8d86-5f336cfde1db" xlink:to="loc_lgnd_ContractRevenueMember_b0c0a103-9bdc-40dd-914c-bcab77fdc299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:href="lgnd-20201231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d0ed823e-e82e-4a3f-809d-c23adfc93744" xlink:to="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_38823419-bdbd-44ba-9de6-d4a19a0da3f3" xlink:href="lgnd-20201231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_38823419-bdbd-44ba-9de6-d4a19a0da3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_5060d26f-8bb9-4224-b04a-0949a6574ee5" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID_5060d26f-8bb9-4224-b04a-0949a6574ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ac636f82-faf8-4551-baac-df849da48034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_InventoryWriteDown_ac636f82-faf8-4551-baac-df849da48034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0692d07d-9f6d-426a-bf73-357fcc5f23ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0692d07d-9f6d-426a-bf73-357fcc5f23ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_cd2175c1-0879-46cf-b82f-7bd7b31cf653" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_cd2175c1-0879-46cf-b82f-7bd7b31cf653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3640b53-fceb-48ef-bd75-9f39848fe4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3640b53-fceb-48ef-bd75-9f39848fe4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_489937e1-48d9-4df6-955d-e33c3588fc56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_489937e1-48d9-4df6-955d-e33c3588fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_11041127-cac4-4573-897f-3ccf99a88600" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_11041127-cac4-4573-897f-3ccf99a88600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_70cf0e65-3c3d-4649-9d71-b8ea6be21cce" xlink:href="lgnd-20201231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_LicenseUpfrontPayment_70cf0e65-3c3d-4649-9d71-b8ea6be21cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_3f79c539-e3d9-4a5a-954c-1d270c4a207a" xlink:href="lgnd-20201231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_3f79c539-e3d9-4a5a-954c-1d270c4a207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_c5879273-7401-451d-9128-02fd5350cbaa" xlink:href="lgnd-20201231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_ProductRoyaltyPercentage_c5879273-7401-451d-9128-02fd5350cbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5455e7d4-f1b3-4bb5-a699-705e78a7fc5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5455e7d4-f1b3-4bb5-a699-705e78a7fc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0741f3e6-3085-426e-904d-6a9046cbe81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0741f3e6-3085-426e-904d-6a9046cbe81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_8cce8f84-866e-4f17-9e1d-72517a191d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_8cce8f84-866e-4f17-9e1d-72517a191d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_c8aa7aa9-258c-44cc-8b43-8c101b96393e" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_c8aa7aa9-258c-44cc-8b43-8c101b96393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_2a9e954d-7b13-45fa-a925-2e6d8ffef416" xlink:href="lgnd-20201231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_2a9e954d-7b13-45fa-a925-2e6d8ffef416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_3ed23079-e8ac-4399-aec2-22594acd1cad" xlink:href="lgnd-20201231.xsd#lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19_3ed23079-e8ac-4399-aec2-22594acd1cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d8dbe74-73e2-444e-9d3b-d8c9ec2ed9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d8dbe74-73e2-444e-9d3b-d8c9ec2ed9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_b47bd078-5d60-4b92-a466-d40ec9e237aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_b47bd078-5d60-4b92-a466-d40ec9e237aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c20ad436-b5d3-441e-845c-ab63f74332ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c20ad436-b5d3-441e-845c-ab63f74332ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23c9beab-4dbc-4e8d-afe6-3a8d28a977ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23c9beab-4dbc-4e8d-afe6-3a8d28a977ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7956f7cc-1f8b-47f4-b149-c8828b59e4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7956f7cc-1f8b-47f4-b149-c8828b59e4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1afc9222-b71c-42e3-a943-dcb2dfaebc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_cfa19b6f-f5fd-45cf-b1c2-73d89b1bf65a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1afc9222-b71c-42e3-a943-dcb2dfaebc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d25ed38b-7989-4174-934f-60c98e6fa308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d25ed38b-7989-4174-934f-60c98e6fa308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7f801f6-0a87-43c3-911e-66bc068178a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7f801f6-0a87-43c3-911e-66bc068178a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7167b12e-4538-441f-9da0-540e1f51094d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DerivativeAssets_7167b12e-4538-441f-9da0-540e1f51094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9c0c8350-066f-4011-bb7f-ae131f2106ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_DerivativeLiabilities_9c0c8350-066f-4011-bb7f-ae131f2106ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9129490b-af26-44ab-9e04-04d641916bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9129490b-af26-44ab-9e04-04d641916bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_39711941-f352-423a-94a0-03ff529d105c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_39711941-f352-423a-94a0-03ff529d105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d28f542c-f33b-4bea-92b0-69427c794b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_d71fd20f-e4c4-41aa-98b1-62a2aa54cc8f" xlink:to="loc_us-gaap_OperatingLeaseLiability_d28f542c-f33b-4bea-92b0-69427c794b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95f4ab3f-d1d0-444b-b189-3d4d2694f8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95f4ab3f-d1d0-444b-b189-3d4d2694f8ad" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_465ede22-deb6-409d-9d68-a01a9007df5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_76fc3296-c99d-4a7f-9438-91ee92b2c3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_059ac201-5a73-49c6-a5ab-ac2ddf4f98a4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_76fc3296-c99d-4a7f-9438-91ee92b2c3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9678ef30-47c1-46bc-b635-5876acb3266c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_19ada8ce-4d4c-423d-95b7-32a5a6ed3e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b180dab-f118-4a5b-840d-9ff92508b109" xlink:to="loc_us-gaap_SalesRevenueNetMember_19ada8ce-4d4c-423d-95b7-32a5a6ed3e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fba7759e-2f3d-4937-b3d6-437065204911" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_2a9bf1bb-0e38-443a-bcd1-32394f2b3c77" xlink:href="lgnd-20201231.xsd#lgnd_PartnerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerAMember_2a9bf1bb-0e38-443a-bcd1-32394f2b3c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_776bde77-5b0b-47cf-99d3-f76ed11c3dee" xlink:href="lgnd-20201231.xsd#lgnd_PartnerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerBMember_776bde77-5b0b-47cf-99d3-f76ed11c3dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_4867d72b-83c1-4a2f-b82d-6684e9dfc17f" xlink:href="lgnd-20201231.xsd#lgnd_PartnerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d04eb06-8749-44fa-8b44-07232e65e7cf" xlink:to="loc_lgnd_PartnerCMember_4867d72b-83c1-4a2f-b82d-6684e9dfc17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7a23e180-a640-418e-aea9-dab1bec4a320" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d569151a-b0d2-41b0-9339-4f29439bd51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d569151a-b0d2-41b0-9339-4f29439bd51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a8ffca0-d62a-4a55-868b-a3b13ad9a5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6aa3cf0b-eac2-4527-beb3-602672bd8d41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a8ffca0-d62a-4a55-868b-a3b13ad9a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b25c2f5a-29dd-4410-a03c-daef3610769e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b25c2f5a-29dd-4410-a03c-daef3610769e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8d83f4d9-838f-4d76-9a3f-1d7769a0c878" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b1dae0c3-9e22-4c70-a3e4-bb9ad0caf898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_02791d6a-88b3-4411-80fc-5f788cbd4437" xlink:to="loc_us-gaap_LicensingAgreementsMember_b1dae0c3-9e22-4c70-a3e4-bb9ad0caf898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e708c533-ed71-4949-964e-fea18d84e4ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_6aef7bfd-e67f-4b17-9c3c-81963505b802" xlink:href="lgnd-20201231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_AziyoandCorMatrixMember_6aef7bfd-e67f-4b17-9c3c-81963505b802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_a26f81ad-6c7d-4602-b898-75f506a31c88" xlink:href="lgnd-20201231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_a26f81ad-6c7d-4602-b898-75f506a31c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_3435d456-fc94-4016-aed4-6fe5c9602bd9" xlink:href="lgnd-20201231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32947dd4-84d3-4ed6-b125-0318177ca270" xlink:to="loc_lgnd_SelexisAndDianomiMember_3435d456-fc94-4016-aed4-6fe5c9602bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45a3d0bb-33d1-4e78-92c2-99cf13b5fe73" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_577d7501-7497-4740-a252-7c723b776a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad64e221-2959-4588-9023-69a60cce05e1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_577d7501-7497-4740-a252-7c723b776a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6ca67504-22df-43c9-ae47-580af5ffb5a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e77027f1-435a-4028-8927-bb8aacbe0464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e77027f1-435a-4028-8927-bb8aacbe0464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_22d1ca33-fb58-4366-b0b2-13cd5a3cf09d" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments_22d1ca33-fb58-4366-b0b2-13cd5a3cf09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9fcea85-4d3c-4696-ae83-520d79cc425c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9fcea85-4d3c-4696-ae83-520d79cc425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_3a3b03e0-186c-47e5-9bcf-c8d0fd51bc1b" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments_3a3b03e0-186c-47e5-9bcf-c8d0fd51bc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_6e8bde22-1a57-4dd3-84da-e177728e27f0" xlink:href="lgnd-20201231.xsd#lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ee31ce08-3b4d-4d35-9456-ecf57a9ddc47" xlink:to="loc_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments_6e8bde22-1a57-4dd3-84da-e177728e27f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_852d078f-9b3b-44ee-ad67-5c9a38c252be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_852d078f-9b3b-44ee-ad67-5c9a38c252be" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:to="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9a68b74f-7d6e-4afb-8bef-e07d3bf82b50" xlink:to="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01a90dd7-c625-4969-82f0-4b63f8e6a111" xlink:to="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_e6292e75-6627-4d56-88f7-918302296981" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyKyprolisMember_e6292e75-6627-4d56-88f7-918302296981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_cfa5103d-99fd-46a4-8f9b-41c14482c7cc" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyEvomelaMember_cfa5103d-99fd-46a4-8f9b-41c14482c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_44a9d707-43b3-46b0-bb1a-5fd7215ac337" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyOtherMember_44a9d707-43b3-46b0-bb1a-5fd7215ac337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_14369e6f-1c52-44dd-8757-7f90342d0144" xlink:href="lgnd-20201231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_869b8cff-4c8e-4186-a826-338444ac402c" xlink:to="loc_lgnd_RoyaltyPromactaMember_14369e6f-1c52-44dd-8757-7f90342d0144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c39fba7d-dc87-4c2a-9d8a-905e3a73f306" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f376f4e4-0c25-41b3-9e0f-2953df07e3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1365d0b-f7e6-48b7-a578-3117d9caeaaf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f376f4e4-0c25-41b3-9e0f-2953df07e3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfdf1a80-9360-4b0e-9fde-dbf82f94b9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfdf1a80-9360-4b0e-9fde-dbf82f94b9bd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:to="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_03ef94bb-2a76-408d-8f2c-e5427551dc65" xlink:to="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_b17cfef4-b6b0-489f-ba1f-7032955c38e6" xlink:href="lgnd-20201231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_b17cfef4-b6b0-489f-ba1f-7032955c38e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:href="lgnd-20201231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2c1e007-2457-4c0a-88cf-a8d214bc544f" xlink:to="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_5786ce37-335f-4641-8d30-8522faaff749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_us-gaap_ServiceMember_5786ce37-335f-4641-8d30-8522faaff749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_48653fc3-ecf7-47b5-932d-0a0d56541e86" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_LicenseFeesMember_48653fc3-ecf7-47b5-932d-0a0d56541e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_7a4cfa0c-f5cb-4d0b-81fc-00966fe84d72" xlink:href="lgnd-20201231.xsd#lgnd_MilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_MilestoneMember_7a4cfa0c-f5cb-4d0b-81fc-00966fe84d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_eea3d35c-c32c-437d-8cf2-ae57e0092a5d" xlink:href="lgnd-20201231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_b9464bda-bbae-418c-885b-a9e512296593" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_eea3d35c-c32c-437d-8cf2-ae57e0092a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_14fa0f84-c723-4453-9549-9eb7ed4501a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6efca74a-923a-4bf2-b119-330bac325a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c93b842c-79d5-499b-ad28-6860e2907f2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6efca74a-923a-4bf2-b119-330bac325a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece30a15-2839-4ab0-ba1c-adbe01dfd415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ee67f9d-0828-44e5-85cc-f0695c6e3d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece30a15-2839-4ab0-ba1c-adbe01dfd415" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ee67f9d-0828-44e5-85cc-f0695c6e3d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece30a15-2839-4ab0-ba1c-adbe01dfd415" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_dffaf5b1-9b46-4a9c-bd21-f0567351d083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_dffaf5b1-9b46-4a9c-bd21-f0567351d083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5fa81059-2cf0-47d0-b323-791bcc40b306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5fa81059-2cf0-47d0-b323-791bcc40b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_cdb9eb58-5e1c-4476-8980-ba5fbc73290e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_cdb9eb58-5e1c-4476-8980-ba5fbc73290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_fa784332-a9ca-4e5a-b8f9-ad191fddc385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_fa784332-a9ca-4e5a-b8f9-ad191fddc385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed3c01d0-5668-47eb-b159-4ab532f3f528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_99e59acf-a795-4cfd-a600-c2d157bbd5a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed3c01d0-5668-47eb-b159-4ab532f3f528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3271a42-082c-4cda-85b4-52ca52025a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ece30a15-2839-4ab0-ba1c-adbe01dfd415" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3271a42-082c-4cda-85b4-52ca52025a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicense"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ac5bf258-e400-40ac-8a1b-0df7f8853f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f5f6c2a4-029e-4c5d-99b2-6f872df607af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ac5bf258-e400-40ac-8a1b-0df7f8853f34" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f5f6c2a4-029e-4c5d-99b2-6f872df607af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SaleofVernalisRDandPromactaLicenseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2cd3a8b9-f422-4559-a790-72331d24c5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2cd3a8b9-f422-4559-a790-72331d24c5f6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4093c93-eed2-44c5-b46e-c3eb73cceab6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_00c5c4dd-bfc5-4b88-b478-984a1a0aeec9" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:to="loc_lgnd_VernalisMember_00c5c4dd-bfc5-4b88-b478-984a1a0aeec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_e73b68b0-e5dd-44ae-9296-30991c3152a7" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6d113566-ed4e-426c-ad34-69abf3fe586a" xlink:to="loc_lgnd_PromactaMember_e73b68b0-e5dd-44ae-9296-30991c3152a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_908648f7-5f3f-4973-92b4-091148e145d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_de18d962-ac63-4edd-93be-c274a226986c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8225e105-52e1-4352-ba88-9fe42c2fcbe1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_de18d962-ac63-4edd-93be-c274a226986c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_aa57ab57-a3f0-413d-bbe1-925dffeefe78" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_f2d5bec4-4ec9-4b53-9a9f-b6a6af39fe22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2a0d53d0-9f65-4959-af5c-11efc731a200" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_f2d5bec4-4ec9-4b53-9a9f-b6a6af39fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0904e10c-898c-4816-bbfc-01831b9166dc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2a6ad9c1-2622-4819-8d31-39fcb4b72c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2a6ad9c1-2622-4819-8d31-39fcb4b72c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e001460b-d807-45e2-8221-5a91403bc8fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e001460b-d807-45e2-8221-5a91403bc8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_02a10366-c587-417e-a374-5329f641563e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_02a10366-c587-417e-a374-5329f641563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5a4cf94a-08d4-4345-8eb1-e07de55308e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5a4cf94a-08d4-4345-8eb1-e07de55308e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd6f7cf2-4f11-4b52-ad89-b53751a9bf98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b357cc19-966b-4f2e-848f-2a33d591ebb9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd6f7cf2-4f11-4b52-ad89-b53751a9bf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinViking"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7b7a2d4-4670-4b2f-a2a6-40f9a290edec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2258f7a9-9781-495f-9613-f7bd5fd53e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7b7a2d4-4670-4b2f-a2a6-40f9a290edec" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2258f7a9-9781-495f-9613-f7bd5fd53e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ShorttermInvestmentsInvestmentinVikingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe804719-5e22-47eb-946f-125c419a713f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe804719-5e22-47eb-946f-125c419a713f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_30f4b1e3-5f23-413d-8c58-cae5deab66ae" xlink:to="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_4e3c8871-8627-4609-a2f8-77c75d46bbda" xlink:href="lgnd-20201231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_619e3a29-36ce-46af-ae84-c5e9dfd6eae5" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_4e3c8871-8627-4609-a2f8-77c75d46bbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6178aca9-d9f6-41cd-a70c-bb7fc0ba70ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_aa01ba21-70a6-4b8b-baf9-828ff81a03fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ea37a90-c8df-47f9-9380-28a8a7e6cda9" xlink:to="loc_us-gaap_WarrantMember_aa01ba21-70a6-4b8b-baf9-828ff81a03fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6446103-4b25-49a1-a01f-f1e351428921" xlink:to="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_32f8b9ab-c43a-473f-91bc-d094a8097523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b6cbedb7-31ae-4a20-8fe5-100d4c5e05f6" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_32f8b9ab-c43a-473f-91bc-d094a8097523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_02f36d2c-27a4-41f1-9443-115528ffa0cb" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_e56b7160-6834-4a1e-8dbd-8f62ae762480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_e56b7160-6834-4a1e-8dbd-8f62ae762480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f0e6b921-1f07-4dec-98bb-1cf8234d5a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f0e6b921-1f07-4dec-98bb-1cf8234d5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a6cf72f9-a80a-4db6-b957-f04b345c5dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a6cf72f9-a80a-4db6-b957-f04b345c5dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f588c4d5-38a1-46ae-87a8-e6d5651af2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f588c4d5-38a1-46ae-87a8-e6d5651af2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_307427f3-225e-441a-b6e8-7bf319b4d5f0" xlink:href="lgnd-20201231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dc851f74-0a05-40df-997b-d0a3d3327f04" xlink:to="loc_lgnd_InvestmentInVikingCurrent_307427f3-225e-441a-b6e8-7bf319b4d5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisitions" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e9b7f069-9215-4c41-bf39-b743011e36f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1ef82bab-deef-4766-b1be-795198d08acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e9b7f069-9215-4c41-bf39-b743011e36f2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1ef82bab-deef-4766-b1be-795198d08acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2dd18f9d-3022-4583-b32b-7e95d8eb96e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2dd18f9d-3022-4583-b32b-7e95d8eb96e1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed23745c-a816-405e-9917-e914bd0a1902" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_fd39575d-4149-4033-8b44-23d571215ecb" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_PfenexMember_fd39575d-4149-4033-8b44-23d571215ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_395319ec-f0a6-40d9-b9d4-8f42296e570a" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_395319ec-f0a6-40d9-b9d4-8f42296e570a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_3a457372-2ca4-4533-a4f6-f8ba11f00d67" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_3a457372-2ca4-4533-a4f6-f8ba11f00d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_134d2aa8-ea76-4679-a2b5-37ce2b6758cb" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_IcagenMember_134d2aa8-ea76-4679-a2b5-37ce2b6758cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_221b8b7b-495d-4c30-83c0-84953e3e5b01" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_AbInitioMember_221b8b7b-495d-4c30-83c0-84953e3e5b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_cf7d22cd-2641-487a-b269-961f2c8e47d5" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14fba9aa-c123-462a-8954-1a384c3eaa98" xlink:to="loc_lgnd_VernalisMember_cf7d22cd-2641-487a-b269-961f2c8e47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92551872-5267-40fa-ad3b-e70094e5e033" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e6b734cd-aebf-47e1-895e-a4c8c7e2d8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e6b734cd-aebf-47e1-895e-a4c8c7e2d8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_669ae15a-0f46-4a09-b546-64326f591fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_669ae15a-0f46-4a09-b546-64326f591fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_37edafa4-5ad8-47b0-aa1c-6ef77ee01189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_03955d2b-9826-444f-b3ba-9ac8e1d2f0ff" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_37edafa4-5ad8-47b0-aa1c-6ef77ee01189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_16f36700-d7f1-496f-97d4-8445ebdf9bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_16f36700-d7f1-496f-97d4-8445ebdf9bd4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_182becc8-5add-4de2-850f-118dc934b830" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_cac06a5a-abc1-439f-8ac8-f03a11b6867f" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_PfenexMember_cac06a5a-abc1-439f-8ac8-f03a11b6867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_34bb390e-23dc-4075-8c57-3dd1370d6ff1" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_34bb390e-23dc-4075-8c57-3dd1370d6ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_8bfe3fdc-377b-4889-8cbc-ae26c1d98912" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_8bfe3fdc-377b-4889-8cbc-ae26c1d98912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_5cac76c6-6a3d-4bbd-895f-ac66a9654bee" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_IcagenMember_5cac76c6-6a3d-4bbd-895f-ac66a9654bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_5dbc64a5-5c1b-4451-8c31-da6efa2407b8" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_AbInitioMember_5dbc64a5-5c1b-4451-8c31-da6efa2407b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_1b866082-fab4-4f55-b704-1d03279c707b" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e672349d-2874-433d-85d0-ef792bdab575" xlink:to="loc_lgnd_VernalisMember_1b866082-fab4-4f55-b704-1d03279c707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58148ca3-a062-446a-bff7-4dd3f10a4405" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7cfed40-4154-4999-80e1-fc880917faaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7cfed40-4154-4999-80e1-fc880917faaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7c5c0a4f-929a-44c6-955d-aa5b49fe6d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7641394d-f31e-4ca0-96f3-c719dac46694" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7c5c0a4f-929a-44c6-955d-aa5b49fe6d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c72ce55a-0edc-48dd-9009-8af72864f0db" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_3b05c41a-5c01-4540-beb1-52ec74d63908" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember_3b05c41a-5c01-4540-beb1-52ec74d63908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentValueRightOnProductRevenuesMember_87067a73-37e5-4a09-a18e-bd575148bd22" xlink:href="lgnd-20201231.xsd#lgnd_ContingentValueRightOnProductRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_ContingentValueRightOnProductRevenuesMember_87067a73-37e5-4a09-a18e-bd575148bd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_4c2333c1-f504-4b46-b5f3-75796d8b7aef" xlink:href="lgnd-20201231.xsd#lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember_4c2333c1-f504-4b46-b5f3-75796d8b7aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestonePaymentsMember_ed3e712b-2607-411c-b71f-623f271e4cf6" xlink:href="lgnd-20201231.xsd#lgnd_MilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f955100-cbff-4650-91b7-85308d6d8d2f" xlink:to="loc_lgnd_MilestonePaymentsMember_ed3e712b-2607-411c-b71f-623f271e4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_23ec3c65-ca4a-4d7a-81d5-5173ac97e77f" xlink:to="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_679dbc04-a874-43dc-a437-f190f12472ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:to="loc_srt_MinimumMember_679dbc04-a874-43dc-a437-f190f12472ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f44dcc26-a80c-4b3a-8b6f-d4ce6ed22cb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_341976e5-89e6-4f39-b8e4-9bdd0e05f5d8" xlink:to="loc_srt_MaximumMember_f44dcc26-a80c-4b3a-8b6f-d4ce6ed22cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95c15562-77aa-4fa8-bb71-c934283f9982" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3f80e13e-3320-4a8e-a63e-f44e721cfc0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d491cacb-1fe1-4d94-8193-7e3352d6ed78" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3f80e13e-3320-4a8e-a63e-f44e721cfc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45b9b717-4e4f-4606-a8dc-8fce2836c6e7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_65593005-a91b-4e8a-9c1b-5485d39bb7a4" xlink:href="lgnd-20201231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_NumberOfAcquisitions_65593005-a91b-4e8a-9c1b-5485d39bb7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_422a8a61-4778-4c6e-9b5e-c385b257bbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_422a8a61-4778-4c6e-9b5e-c385b257bbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_761744d6-6a15-4edc-b5e4-c07cc7efa589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_761744d6-6a15-4edc-b5e4-c07cc7efa589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b4ca4c6-73d8-4e54-ab05-702932d6adba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b4ca4c6-73d8-4e54-ab05-702932d6adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d69fd87a-585e-4595-9685-5c53f3f6da46" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_d69fd87a-585e-4595-9685-5c53f3f6da46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_810462dd-7128-40fe-aa0b-fc7580b227e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_810462dd-7128-40fe-aa0b-fc7580b227e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8ac29cca-66e9-4c14-825b-65ce65ff0f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8ac29cca-66e9-4c14-825b-65ce65ff0f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_60faecfd-3566-45e5-a480-f9571fbc4d67" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions_60faecfd-3566-45e5-a480-f9571fbc4d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_76dc3c4b-18f8-47ed-933c-2a642206266a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_76dc3c4b-18f8-47ed-933c-2a642206266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e64102a-20c0-43b0-a97a-77f8b23e2474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e64102a-20c0-43b0-a97a-77f8b23e2474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_c78b4115-341e-4c91-a018-97f9e42beb9d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_c78b4115-341e-4c91-a018-97f9e42beb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_8121f473-10ff-4c03-8a70-09e3a125bd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_8121f473-10ff-4c03-8a70-09e3a125bd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_11e03b2b-8234-4f95-bd0c-931fcfa0aec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_11e03b2b-8234-4f95-bd0c-931fcfa0aec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_7d28d7d8-3ae5-4cbd-96e7-53c3bbc85d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_7d28d7d8-3ae5-4cbd-96e7-53c3bbc85d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_64dcecb8-a015-4426-b682-4d211adcc946" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationConsiderationTransferredHoldback"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationConsiderationTransferredHoldback_64dcecb8-a015-4426-b682-4d211adcc946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_37f7720f-5071-473d-b2d9-6796f5a3fc13" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues_37f7720f-5071-473d-b2d9-6796f5a3fc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_771762f0-95be-4889-ba4a-3c4b7fc9dfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_771762f0-95be-4889-ba4a-3c4b7fc9dfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f583a44-aa4d-4629-9c5c-b3ea8f783bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f583a44-aa4d-4629-9c5c-b3ea8f783bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_3da75c40-4ea8-4d20-a6e0-ff48c49a5776" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_3da75c40-4ea8-4d20-a6e0-ff48c49a5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_aa940d77-58b1-4704-a204-90db6cb07943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_aa940d77-58b1-4704-a204-90db6cb07943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_acc4bf8e-2ca4-4d60-9ebc-0a61781c928d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_acc4bf8e-2ca4-4d60-9ebc-0a61781c928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_61ab86b8-16af-4037-800f-40f0820d2a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe940169-f34a-46a0-9471-c013e89cd6e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_61ab86b8-16af-4037-800f-40f0820d2a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3d1a62c7-f124-4202-8852-fa32d554fcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3d1a62c7-f124-4202-8852-fa32d554fcfe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c782c87-8ffc-48c9-854a-ae8269e1224b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_9646468e-b9c7-4021-88db-e2f609168bb9" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4242a78-3822-4dbc-b78b-554b6d29e81a" xlink:to="loc_lgnd_PfenexMember_9646468e-b9c7-4021-88db-e2f609168bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0a5ad5b4-a0c3-4ecc-a5e8-85ea21c3b3af" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa65ed10-78ab-4441-8550-1d6bf1393142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa65ed10-78ab-4441-8550-1d6bf1393142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_700415e4-d677-496e-b458-4eb939e4893c" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_700415e4-d677-496e-b458-4eb939e4893c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_040e2509-35d8-499b-ab21-4c09fca792f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_040e2509-35d8-499b-ab21-4c09fca792f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9c6dd839-7d0d-4e4f-b9ef-94888556f1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9c6dd839-7d0d-4e4f-b9ef-94888556f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2b12c50d-12bc-4266-b708-9226ba43d78b" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2b12c50d-12bc-4266-b708-9226ba43d78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cd4673f6-2704-4cdc-81d9-cb3ade8c0af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cd4673f6-2704-4cdc-81d9-cb3ade8c0af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_ea5c2c6b-0ee2-46c2-8aff-44a006da983f" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_ea5c2c6b-0ee2-46c2-8aff-44a006da983f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_66bd10b6-1b84-4e36-aabd-f9a83e637185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_Goodwill_66bd10b6-1b84-4e36-aabd-f9a83e637185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0caefd2d-8b8f-472e-8762-fc0a4088962a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0caefd2d-8b8f-472e-8762-fc0a4088962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_cb09cd96-924f-43dd-b8cf-eb35c6c1f069" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_cb09cd96-924f-43dd-b8cf-eb35c6c1f069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d65ed9f4-fc96-4221-9cc3-460d34eea929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d65ed9f4-fc96-4221-9cc3-460d34eea929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_cc437316-fcfe-4cf2-a0aa-7753dac7bc19" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_cc437316-fcfe-4cf2-a0aa-7753dac7bc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_73cf0fba-4922-4fa7-9485-68b5c3c3c566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_73cf0fba-4922-4fa7-9485-68b5c3c3c566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d8d374e5-2f5b-4998-8cc3-04dc239e9b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d8d374e5-2f5b-4998-8cc3-04dc239e9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cce442be-2e70-4a42-a1cd-ed4970bd753d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5fabc691-08ff-4ede-b00c-85bb79144527" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cce442be-2e70-4a42-a1cd-ed4970bd753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_589ae453-4cc9-4835-8a7b-844960f6c089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_589ae453-4cc9-4835-8a7b-844960f6c089" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cb0c6d-4442-4578-89e2-7277f7e4eecc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_4a5c34ff-597c-4da3-9cb3-92cd2594eb30" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d25dd0c5-3b70-44db-951d-b46a31fed99f" xlink:to="loc_lgnd_PfenexMember_4a5c34ff-597c-4da3-9cb3-92cd2594eb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df4f6a7a-1f03-44c8-b997-ed3d53e9b2f3" xlink:to="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dc5191ad-1a4a-4ac9-b7a2-036ca3e1e145" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:to="loc_srt_MinimumMember_dc5191ad-1a4a-4ac9-b7a2-036ca3e1e145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5fbb003c-7f1d-4b14-8059-b79174ad5f19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5459910-a164-4e23-bde8-3d6157ffaf8f" xlink:to="loc_srt_MaximumMember_5fbb003c-7f1d-4b14-8059-b79174ad5f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6db2d74-2daf-4796-a409-bbbea7021848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsAlvogenMember_5b27f0fb-9008-4ee4-9173-fea6d019ba43" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsAlvogenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsAlvogenMember_5b27f0fb-9008-4ee4-9173-fea6d019ba43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsMerckMember_f0d390e7-a7d3-4fa1-97cb-84c9932aca0f" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsMerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsMerckMember_f0d390e7-a7d3-4fa1-97cb-84c9932aca0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsJazzMember_6263fe02-63ac-41da-ad96-a7794e8204ae" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsJazzMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsJazzMember_6263fe02-63ac-41da-ad96-a7794e8204ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsSIIMember_32763941-9816-469f-80d1-b3fc9ad66c19" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsSIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsSIIMember_32763941-9816-469f-80d1-b3fc9ad66c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractualRelationshipsArcellxMember_6cabe614-942d-459a-acb9-f8fb241a52cc" xlink:href="lgnd-20201231.xsd#lgnd_ContractualRelationshipsArcellxMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_lgnd_ContractualRelationshipsArcellxMember_6cabe614-942d-459a-acb9-f8fb241a52cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2564886c-0271-4a4e-acac-7a5b2db72888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2936107-fa02-4951-8378-76f5fa4f2714" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2564886c-0271-4a4e-acac-7a5b2db72888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dbce77d0-a920-456c-87f5-e176dcf45f6c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_61a8737b-d385-408c-be4b-03e31c4a3f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_61a8737b-d385-408c-be4b-03e31c4a3f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c1c31d60-d6cc-446d-9f82-3c43e97c9ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ce52ec9-8178-44f8-9ae5-1e0731877253" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c1c31d60-d6cc-446d-9f82-3c43e97c9ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d7f4b60a-75c3-48af-aec6-a2945b0f795a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d7f4b60a-75c3-48af-aec6-a2945b0f795a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fd3b5388-d934-4735-b160-eb2f8711143a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_caf0aa12-ff1a-4bb4-a572-6a5b50493267" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7be37fa6-b284-4038-9d60-e912981db2e7" xlink:to="loc_lgnd_PfenexMember_caf0aa12-ff1a-4bb4-a572-6a5b50493267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6543ee86-f977-4ba4-ae96-b0bc4ddfbe97" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_18e022fc-2ff6-42e2-85a6-58861150acc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_18e022fc-2ff6-42e2-85a6-58861150acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2e0cddc1-4669-4ecd-a1d4-5e795a26b2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2e0cddc1-4669-4ecd-a1d4-5e795a26b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareProFormaAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ea7112d-d6b5-49f0-9614-70cdd6c35132" xlink:to="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_474a7c4d-4848-4036-946a-63e404c31bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_474a7c4d-4848-4036-946a-63e404c31bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8b4cd922-4dca-4443-81bf-afed0a12a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareProFormaAbstract_f2171f51-4689-484a-8c4f-4bb0df420b3c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8b4cd922-4dca-4443-81bf-afed0a12a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#AcquisitionsAllocationofConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3dd64d4c-ed1c-400d-83ad-17ead2b17505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3dd64d4c-ed1c-400d-83ad-17ead2b17505" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b168de8e-1020-43b5-9151-aa40abddf097" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TaurusBiosciencesLLCMember_903f5d24-ee3a-4c0d-aa93-ecd9475242cf" xlink:href="lgnd-20201231.xsd#lgnd_TaurusBiosciencesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_TaurusBiosciencesLLCMember_903f5d24-ee3a-4c0d-aa93-ecd9475242cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_XCellaBiosciencesIncMember_3f8df6b6-f75c-432b-96e8-4e03c127813a" xlink:href="lgnd-20201231.xsd#lgnd_XCellaBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_XCellaBiosciencesIncMember_3f8df6b6-f75c-432b-96e8-4e03c127813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_bab66745-f751-4fa3-afee-4f8cd978ffd9" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_IcagenMember_bab66745-f751-4fa3-afee-4f8cd978ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_3b516375-4ea6-4f32-b648-b5191320c9f2" xlink:href="lgnd-20201231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_AbInitioMember_3b516375-4ea6-4f32-b648-b5191320c9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_7344499b-967c-42e9-8c20-f0a1bb5b1e18" xlink:href="lgnd-20201231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4364365d-f042-4c35-a88a-2b19b879d837" xlink:to="loc_lgnd_VernalisMember_7344499b-967c-42e9-8c20-f0a1bb5b1e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04889dc9-9fc2-4e4d-b0d5-ea96f3481fd0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cd6043a0-20a7-429d-ba57-9117eb23ecec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cd6043a0-20a7-429d-ba57-9117eb23ecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_86ffbfe5-6a21-4210-b84b-c613f0feebad" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_86ffbfe5-6a21-4210-b84b-c613f0feebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_635145e7-7a12-4bd5-9dfa-96ec2db63db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_635145e7-7a12-4bd5-9dfa-96ec2db63db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_8e5fefdf-2c66-4ded-9dbd-29f02bedd28a" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther_8e5fefdf-2c66-4ded-9dbd-29f02bedd28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_954e942b-f017-4f3f-8817-70b939f7335d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_954e942b-f017-4f3f-8817-70b939f7335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0268baf-a0ba-42e5-808f-f8def74d6218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0268baf-a0ba-42e5-808f-f8def74d6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6936b257-d562-450d-acec-d3fafc6cbe44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6936b257-d562-450d-acec-d3fafc6cbe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9a57aaed-6d4c-4201-af30-9d569533d620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9a57aaed-6d4c-4201-af30-9d569533d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6cc8d47d-8a8a-4c8b-8a12-1b5569395a55" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent_6cc8d47d-8a8a-4c8b-8a12-1b5569395a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a93f83de-3654-4919-ae33-ec56016ebebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a93f83de-3654-4919-ae33-ec56016ebebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_eca56d39-cac5-4c0b-b721-70677013e351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_RestructuringReserve_eca56d39-cac5-4c0b-b721-70677013e351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8f7455ad-4e94-439f-9332-61e1d6346b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8f7455ad-4e94-439f-9332-61e1d6346b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_13148b9b-c23e-49d2-a87f-797270403576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_13148b9b-c23e-49d2-a87f-797270403576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3768c0b2-3799-428e-8230-0bbe5a5a871f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3768c0b2-3799-428e-8230-0bbe5a5a871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_6c24cfc7-343f-44da-b312-59dcf5a80a27" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets_6c24cfc7-343f-44da-b312-59dcf5a80a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22bdc073-f6d5-4dc5-8687-7f58ca785f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_Goodwill_22bdc073-f6d5-4dc5-8687-7f58ca785f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_47d2924a-33de-4751-9e7c-4ca8bc901531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b421e31d-14bb-40be-b201-387d9c4e4abe" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_47d2924a-33de-4751-9e7c-4ca8bc901531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b2301d19-9824-4b21-94e0-9ef8e59bcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f6f25dfa-88e1-4915-9415-295f16098ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2301d19-9824-4b21-94e0-9ef8e59bcd78" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f6f25dfa-88e1-4915-9415-295f16098ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d7ed0c77-8f34-4146-9aee-1bf855e20361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8d877539-3e08-4b20-a1f3-ae3f310dd7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7ed0c77-8f34-4146-9aee-1bf855e20361" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8d877539-3e08-4b20-a1f3-ae3f310dd7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_5179c00e-6319-4d96-aa9c-46460ed792ad" xlink:href="lgnd-20201231.xsd#lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7ed0c77-8f34-4146-9aee-1bf855e20361" xlink:to="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_5179c00e-6319-4d96-aa9c-46460ed792ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8a98a146-0f41-438d-9d79-b68ff1f7ff22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8a98a146-0f41-438d-9d79-b68ff1f7ff22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c1258e2-f3b1-4a3c-a1ef-d6795134b6a2" xlink:to="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_588efe48-4278-4c12-b9a6-d8b65205ff47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9f83c1a-e644-476b-98c0-b0bee468f210" xlink:to="loc_srt_MaximumMember_588efe48-4278-4c12-b9a6-d8b65205ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0779642a-45dc-4c55-b610-229b546e3b85" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_c8ca5fc3-a080-4e46-ae8d-96aed2ae3151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a4e5471b-980d-4355-918b-ab825fcca4c4" xlink:to="loc_us-gaap_TransferredOverTimeMember_c8ca5fc3-a080-4e46-ae8d-96aed2ae3151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5fbb55ed-a7c0-46af-b268-7d26138b65e5" xlink:to="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_599f3210-db5d-426a-a53b-de009035d8bd" xlink:href="lgnd-20201231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_599f3210-db5d-426a-a53b-de009035d8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_f95add7b-a077-4158-a901-8fdf26bf89a9" xlink:href="lgnd-20201231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10ea05d1-819c-45e8-bfc0-38ad3ceddbad" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_f95add7b-a077-4158-a901-8fdf26bf89a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1e138eb6-1d83-44af-8871-528b0ef0bfd3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_76fce8ae-53f9-4e40-8d11-afe2e0d132e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c53c827-b1cd-43de-b21c-d0b583752847" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_76fce8ae-53f9-4e40-8d11-afe2e0d132e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5490350a-b97f-4c5d-92de-8a1c21309fba" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fc62b77d-f35a-4a7e-9fa7-69d6d4e90b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fc62b77d-f35a-4a7e-9fa7-69d6d4e90b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e76986fe-7d55-4c05-8fc9-42f9f918e3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e76986fe-7d55-4c05-8fc9-42f9f918e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bb23519-3009-4a55-b6f0-0ac7a85a49fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14516006-2772-40c1-aa18-6830284f3d1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bb23519-3009-4a55-b6f0-0ac7a85a49fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_16b7fbe6-a9ea-42e6-9d95-ca6bb39d8c10" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d4650ddd-7b55-457a-b91c-bb9c472b5345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d4650ddd-7b55-457a-b91c-bb9c472b5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_16cffc87-3398-4e30-8d04-7b7c003d755a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_EquitySecuritiesMember_16cffc87-3398-4e30-8d04-7b7c003d755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b66f8740-69b6-47c7-93c3-4681d6d0e68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1bb1cdda-81e7-42ce-8344-d08f27d0a638" xlink:to="loc_us-gaap_WarrantMember_b66f8740-69b6-47c7-93c3-4681d6d0e68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a6de73de-6bd1-41cc-8b84-b95165e65d05" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_2485be0a-4caf-4ca0-b1f4-66e454ae4334" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_2485be0a-4caf-4ca0-b1f4-66e454ae4334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_fd62ecf6-1071-496e-a3aa-590a4fded1b4" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_fd62ecf6-1071-496e-a3aa-590a4fded1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_15393677-6cc0-40ad-8fe0-a4c3ea35465b" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_15393677-6cc0-40ad-8fe0-a4c3ea35465b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_238b53c7-03dd-45f8-9116-a222c2bccd00" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyIcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyIcagenMember_238b53c7-03dd-45f8-9116-a222c2bccd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_413e94e2-7355-4afb-aed4-0f2302748695" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForContingentValueRightsCompanyPfenexMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyPfenexMember_413e94e2-7355-4afb-aed4-0f2302748695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_24efec19-be09-4658-8453-d1873bf8eed5" xlink:href="lgnd-20201231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18e4b02c-1863-425d-a2c9-3649a99fc4cd" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_24efec19-be09-4658-8453-d1873bf8eed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c969e85e-4fe1-4693-bcf8-7390c9488b57" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_047ab297-6c1e-4ad0-bc98-2f0b469ba64e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_047ab297-6c1e-4ad0-bc98-2f0b469ba64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fff91859-e98d-473c-888f-af084246892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fff91859-e98d-473c-888f-af084246892d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_eb0d005a-7953-434e-9832-a3a62e879250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_eb0d005a-7953-434e-9832-a3a62e879250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_1602046b-3ba6-44c8-a7d1-b060cc716cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fb6f6f09-f3b7-48ef-9f90-de46c39ec06d" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_1602046b-3ba6-44c8-a7d1-b060cc716cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9aa5c2bb-2742-4b74-ad77-4bfbd81ee9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9aa5c2bb-2742-4b74-ad77-4bfbd81ee9d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db47d3f4-b647-4850-9b96-633b0bd24f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e02895d5-1e99-40fd-9bc0-e1adac2e453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e084ef7e-0780-46a4-92a7-d8971313097a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e02895d5-1e99-40fd-9bc0-e1adac2e453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3abfc835-850a-49b4-9fac-b38e1c61d331" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6680bdfc-edc1-440a-9d56-bb076edf3948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5dbf45de-ec20-4e00-bd73-6070dfa74429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5dbf45de-ec20-4e00-bd73-6070dfa74429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c9735ae7-7913-43fd-ba24-9900a647add3" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c9735ae7-7913-43fd-ba24-9900a647add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_31b9ed9c-b833-4dd1-b548-8a68365aa9d2" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_31b9ed9c-b833-4dd1-b548-8a68365aa9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_7d29d649-d47b-458e-b4bd-587b5f7fb798" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities_7d29d649-d47b-458e-b4bd-587b5f7fb798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a1c4bd20-f5ea-46bf-ae79-4cf0abcb1caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7728c13-5c94-4cd2-98d5-905658199684" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a1c4bd20-f5ea-46bf-ae79-4cf0abcb1caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_8bbb8729-1dec-4efb-9e21-6ef9cb9e7369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0d33af32-2c3f-4006-8f4d-99853e790841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8bbb8729-1dec-4efb-9e21-6ef9cb9e7369" xlink:to="loc_us-gaap_AssetImpairmentCharges_0d33af32-2c3f-4006-8f4d-99853e790841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d2b93773-1b59-4ba0-a509-d4c38f7a63e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4b5167a9-858a-4912-b65f-b020e9b5b779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d2b93773-1b59-4ba0-a509-d4c38f7a63e1" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4b5167a9-858a-4912-b65f-b020e9b5b779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_ef3aee5f-0a18-4f86-9589-4d5af365a107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d2b93773-1b59-4ba0-a509-d4c38f7a63e1" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_ef3aee5f-0a18-4f86-9589-4d5af365a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_21b80610-3e65-4f73-98ed-ed0ae2241bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_f115bbe7-292e-45ad-b585-934606633aad" xlink:href="lgnd-20201231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21b80610-3e65-4f73-98ed-ed0ae2241bd1" xlink:to="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_f115bbe7-292e-45ad-b585-934606633aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ac84247e-22a8-4fd5-94a9-76e584da6ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21b80610-3e65-4f73-98ed-ed0ae2241bd1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ac84247e-22a8-4fd5-94a9-76e584da6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4a725801-d556-44ba-9d54-075c085491d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21b80610-3e65-4f73-98ed-ed0ae2241bd1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4a725801-d556-44ba-9d54-075c085491d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bde945a0-1d3c-4c1b-a3e4-53fae8cdeb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bde945a0-1d3c-4c1b-a3e4-53fae8cdeb2d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:to="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2792daa2-8087-445c-b573-96b36f704d0a" xlink:to="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a568483-0997-414b-8cf4-ff331edddfda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6cdfaf50-3763-4f5c-94bc-dfc9c8addde8" xlink:to="loc_srt_MaximumMember_0a568483-0997-414b-8cf4-ff331edddfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b9191efd-0dc2-43df-8828-85ae0d7f96c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_35369513-9128-4053-b20b-092109ce02a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_35369513-9128-4053-b20b-092109ce02a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c71b2a67-6387-422e-896c-88984a0d990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c71b2a67-6387-422e-896c-88984a0d990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_f6d6eee8-c0c9-4080-bfe1-726df76e34aa" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_f6d6eee8-c0c9-4080-bfe1-726df76e34aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_adaa42ae-f9cc-43a5-8644-28a0d672c2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_adaa42ae-f9cc-43a5-8644-28a0d672c2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0587f5a6-070d-4315-8471-1ae0d407388c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_0587f5a6-070d-4315-8471-1ae0d407388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ee3f3480-8fd8-44fd-8cbd-35c13459ac9c" xlink:href="lgnd-20201231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ee3f3480-8fd8-44fd-8cbd-35c13459ac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d0ceb86-177f-4096-90da-b7f7c70d6f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d0ceb86-177f-4096-90da-b7f7c70d6f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_53e8106a-071b-406a-ad1e-beb850ffc5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_53e8106a-071b-406a-ad1e-beb850ffc5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786ba695-a2fc-4df8-888f-270aeba7b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786ba695-a2fc-4df8-888f-270aeba7b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08eff9cc-9051-4ef1-8527-b62e94a26d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08eff9cc-9051-4ef1-8527-b62e94a26d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cb58e4bc-4c41-4d38-834e-e294eea3d745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeasePayments_cb58e4bc-4c41-4d38-834e-e294eea3d745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_5b2cc961-c616-4fe4-9973-a4f444239869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_OperatingLeaseExpense_5b2cc961-c616-4fe4-9973-a4f444239869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_cf2c713d-23dd-415e-acb8-9249b79a1850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_SubleaseIncome_cf2c713d-23dd-415e-acb8-9249b79a1850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c1c1beb3-76d0-451d-b97e-cce2d20ea03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c1c1beb3-76d0-451d-b97e-cce2d20ea03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c45588fd-ee40-44ad-ae5c-a2aba91a3050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c45588fd-ee40-44ad-ae5c-a2aba91a3050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_229b4e0d-219c-4ffe-aa7b-91cd112e5b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_229b4e0d-219c-4ffe-aa7b-91cd112e5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8f7b6bb5-5d63-4c9e-bc03-b132291bfba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_075e5820-548b-41d0-9d46-b4ee841eb455" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8f7b6bb5-5d63-4c9e-bc03-b132291bfba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d94f78f9-05af-478f-bcec-e3a7e011e3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9c65f264-5a7f-477d-bcd5-a2eaea1bbbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d94f78f9-05af-478f-bcec-e3a7e011e3a5" xlink:to="loc_us-gaap_AssetsAbstract_9c65f264-5a7f-477d-bcd5-a2eaea1bbbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e403893f-333c-4147-aabd-942d49f3f99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c65f264-5a7f-477d-bcd5-a2eaea1bbbe9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e403893f-333c-4147-aabd-942d49f3f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_9b552b65-e038-4a06-8fd6-02b28d39d232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c65f264-5a7f-477d-bcd5-a2eaea1bbbe9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_9b552b65-e038-4a06-8fd6-02b28d39d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_e0a36c8a-f3e0-4786-90e4-c12fe6f79143" xlink:href="lgnd-20201231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c65f264-5a7f-477d-bcd5-a2eaea1bbbe9" xlink:to="loc_lgnd_LeaseRightOfUseAsset_e0a36c8a-f3e0-4786-90e4-c12fe6f79143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d94f78f9-05af-478f-bcec-e3a7e011e3a5" xlink:to="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_df564050-4f7d-4dd4-823a-6eb6f8b92831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_df564050-4f7d-4dd4-823a-6eb6f8b92831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7041e385-b4eb-4cf9-a1ba-bff6f444ae03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7041e385-b4eb-4cf9-a1ba-bff6f444ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_23489c9d-a16d-494c-b0cf-8131a7767e04" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_lgnd_LeaseLiabilityCurrent_23489c9d-a16d-494c-b0cf-8131a7767e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_29b72b65-f1ee-47f6-a8bc-8c17977b9839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_29b72b65-f1ee-47f6-a8bc-8c17977b9839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e387aa01-f1b5-411e-9692-c52785ac3c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e387aa01-f1b5-411e-9692-c52785ac3c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_7c62433e-f40f-470c-97f3-bfc1b1087f48" xlink:href="lgnd-20201231.xsd#lgnd_LeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cd47f744-8b12-4c82-8408-e5e341a4c560" xlink:to="loc_lgnd_LeaseLiability_7c62433e-f40f-470c-97f3-bfc1b1087f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c94e71ae-af29-4e49-b099-3a3d2926efbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c94e71ae-af29-4e49-b099-3a3d2926efbe" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d599cb9f-8ce5-4e3d-a4c0-574be6050a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d599cb9f-8ce5-4e3d-a4c0-574be6050a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_41b710b6-366e-4791-a71a-2bb1b829ca6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_41b710b6-366e-4791-a71a-2bb1b829ca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90732740-f63a-4766-876e-08610f7e4197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90732740-f63a-4766-876e-08610f7e4197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_32d6ac8c-c03b-4f73-b693-787aa2cef5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_32d6ac8c-c03b-4f73-b693-787aa2cef5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0250df63-49de-4eb9-acca-3ec6c8ca9e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0250df63-49de-4eb9-acca-3ec6c8ca9e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_875906cc-37a3-41af-8834-9a596ebd598e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_875906cc-37a3-41af-8834-9a596ebd598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_77baf426-17c5-4a25-aed0-5ec26842b11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_77baf426-17c5-4a25-aed0-5ec26842b11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a91ceaf5-643a-4c5a-bc89-9197afa05c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a91ceaf5-643a-4c5a-bc89-9197afa05c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fe015b31-cbf4-4f16-8a02-2c7880beba5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4698ccc7-5418-4e37-ba10-0f83cff56f83" xlink:to="loc_us-gaap_OperatingLeaseLiability_fe015b31-cbf4-4f16-8a02-2c7880beba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c94e71ae-af29-4e49-b099-3a3d2926efbe" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4f358ba7-2b6c-4c07-9e69-ff43543d525d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4f358ba7-2b6c-4c07-9e69-ff43543d525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8859ad6f-2dc0-4df9-8667-52ef8a36f955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8859ad6f-2dc0-4df9-8667-52ef8a36f955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9254f219-55c7-4fd1-97a4-a2c42e5da2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9254f219-55c7-4fd1-97a4-a2c42e5da2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_10ecfa76-e549-4920-9d99-96c0548c474f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_10ecfa76-e549-4920-9d99-96c0548c474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8a08fedb-dd2b-4acf-b7c2-9697d8f57663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8a08fedb-dd2b-4acf-b7c2-9697d8f57663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_af18459b-c444-4073-970c-4759d4f518ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_af18459b-c444-4073-970c-4759d4f518ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc721e5a-10e6-493e-b051-7b8eae6c95ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc721e5a-10e6-493e-b051-7b8eae6c95ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4ba93489-661b-4ce7-8885-80b3bc4b0db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4ba93489-661b-4ce7-8885-80b3bc4b0db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_56e3a7e4-6bc9-42e1-9168-24a3a1fc1a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_711e9197-1b06-4dba-b2fb-7700cc0c90de" xlink:to="loc_us-gaap_FinanceLeaseLiability_56e3a7e4-6bc9-42e1-9168-24a3a1fc1a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20201231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_66b7b252-2852-4006-8980-f0ab2c46fe25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cf50508f-6bd1-47b6-824e-dd548efbce13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66b7b252-2852-4006-8980-f0ab2c46fe25" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cf50508f-6bd1-47b6-824e-dd548efbce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_536e96e0-fd16-4c99-86e8-2798ae30a8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1f0df2b9-36ca-42b9-8d1e-f376e7956bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_536e96e0-fd16-4c99-86e8-2798ae30a8f1" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1f0df2b9-36ca-42b9-8d1e-f376e7956bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6a233cb2-0934-469b-aba6-6c49949eb9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a233cb2-0934-469b-aba6-6c49949eb9dd" xlink:to="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c1c59cc-d25a-4a86-bdaa-0c5d72ea0d62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_c1ba55e8-535e-4f6c-b7a2-0dce46db3f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_09d5a056-c310-4996-8645-b0219187b26a" xlink:to="loc_us-gaap_OtherExpenseMember_c1ba55e8-535e-4f6c-b7a2-0dce46db3f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beeeffd2-2ce4-4466-bfab-bf4d67383989" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_55a4b761-6e46-4a62-aa13-fcb9e0438a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8dcbdc83-1148-4fa0-b13f-3290818f7de9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_55a4b761-6e46-4a62-aa13-fcb9e0438a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_21c6408a-e76b-49a9-8b34-3cf6bdd60006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_549ff301-4df2-4cf7-9fe3-b7d80de83c10" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_549ff301-4df2-4cf7-9fe3-b7d80de83c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_4ce712c9-5e97-4f54-af24-24dd0eff8b1f" xlink:href="lgnd-20201231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e1b949-d007-4041-a573-bed57819cba9" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_4ce712c9-5e97-4f54-af24-24dd0eff8b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bc49929b-2e12-4afe-8c9c-54a8b21807d7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_08894554-e393-4b58-86f3-04ec948f7fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_08894554-e393-4b58-86f3-04ec948f7fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_255e55a6-e454-4303-bcca-69289780967e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2915aac7-880f-4074-9f1b-4abe705605eb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_255e55a6-e454-4303-bcca-69289780967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6838513-b434-46cf-9ab8-d64b8640aae4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_02c508d1-eb25-45de-b8a2-6d5f45750af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a7341d3d-5d59-423c-ae45-e8a9fa202685" xlink:to="loc_us-gaap_SubsequentEventMember_02c508d1-eb25-45de-b8a2-6d5f45750af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ce3a261-5dd6-43f0-b95c-4f52ee589737" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_10cfeba4-05a5-4fce-974e-f6e5c47c75d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_10cfeba4-05a5-4fce-974e-f6e5c47c75d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b096eaf7-24df-4ed1-af60-e4b32c4b1aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b096eaf7-24df-4ed1-af60-e4b32c4b1aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_421cce49-931f-4803-be87-42608bfaf162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_421cce49-931f-4803-be87-42608bfaf162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_93ffe69d-49d9-48ee-9713-37513d97d305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_93ffe69d-49d9-48ee-9713-37513d97d305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c8608303-4e09-4ec9-9459-96bccd557bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c8608303-4e09-4ec9-9459-96bccd557bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8ac7f776-4fe0-4208-b299-53385d2835b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8ac7f776-4fe0-4208-b299-53385d2835b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7d65bec-0217-4e34-ba1f-57e5138293f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7d65bec-0217-4e34-ba1f-57e5138293f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3ff292a3-20bd-42cd-8d1a-ca355a23e533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3ff292a3-20bd-42cd-8d1a-ca355a23e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3c4e165-a160-48c5-9bd0-edc539a66c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3c4e165-a160-48c5-9bd0-edc539a66c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_939ed0d3-9661-4988-9e55-831871ac80f3" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_939ed0d3-9661-4988-9e55-831871ac80f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c2745e76-790b-44cd-bcf0-fdc9a80ff31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c2745e76-790b-44cd-bcf0-fdc9a80ff31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_0d2d3354-fc42-40c3-9ec8-764da32fbcb4" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_0d2d3354-fc42-40c3-9ec8-764da32fbcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86b8100b-5545-4925-bba4-3c9f1aa7acf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_86b8100b-5545-4925-bba4-3c9f1aa7acf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_9b951ac9-a45f-46e0-b644-cf155652e1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_9b951ac9-a45f-46e0-b644-cf155652e1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7adc35f2-b455-486f-b56f-2a34c48a688a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7adc35f2-b455-486f-b56f-2a34c48a688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_30de1e67-742b-436d-b2b8-502b41826fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_30de1e67-742b-436d-b2b8-502b41826fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_e60e2e86-5ef5-42ba-8245-6b8bd7ddafd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_e60e2e86-5ef5-42ba-8245-6b8bd7ddafd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a4a2e98-3b2b-43bc-aad3-428258a0e188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a4a2e98-3b2b-43bc-aad3-428258a0e188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80e484a8-ca69-4682-bf8e-c29f565721d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80e484a8-ca69-4682-bf8e-c29f565721d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_146d6afb-b9bc-4e82-be2b-ff696330b78f" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_146d6afb-b9bc-4e82-be2b-ff696330b78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_5bda1333-5be3-4e9c-b3eb-1c1292086f7f" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_5bda1333-5be3-4e9c-b3eb-1c1292086f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_e252ccd9-c77a-4383-b052-21d563078ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_e252ccd9-c77a-4383-b052-21d563078ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c2f8bc6d-dfe7-4a04-a407-35c835c3eabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c2f8bc6d-dfe7-4a04-a407-35c835c3eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_675e0842-8c71-4487-8a3c-9cb71a9d0ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_675e0842-8c71-4487-8a3c-9cb71a9d0ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ae2d52e-8138-4d91-bc3e-884578a16ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ae2d52e-8138-4d91-bc3e-884578a16ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8313a964-ad99-4903-aeaf-b4e54cb0a523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8313a964-ad99-4903-aeaf-b4e54cb0a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled_d2b4605a-39ca-46dc-8823-cc4513abb3cb" xlink:href="lgnd-20201231.xsd#lgnd_WarrantsSettled"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_WarrantsSettled_d2b4605a-39ca-46dc-8823-cc4513abb3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_2f6c4b09-be7f-4776-af12-748c5c80fcdf" xlink:href="lgnd-20201231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_2f6c4b09-be7f-4776-af12-748c5c80fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8251d5cc-8966-4bb3-9f69-bc9073f2c8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8251d5cc-8966-4bb3-9f69-bc9073f2c8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_fc2a3348-ad63-47c1-a30b-9527d4773b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_fc2a3348-ad63-47c1-a30b-9527d4773b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_dcfc7a8d-ad1a-4e21-aca7-b114704fc4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_dcfc7a8d-ad1a-4e21-aca7-b114704fc4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5ae02c8b-d2f0-4aec-a17a-ca00c418598a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5ae02c8b-d2f0-4aec-a17a-ca00c418598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_448c2bd6-e5b1-40d5-9ea8-cdf68444a6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_448c2bd6-e5b1-40d5-9ea8-cdf68444a6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_37961c7c-e261-4571-b0ab-f711f93819d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_37961c7c-e261-4571-b0ab-f711f93819d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_6ec2abf1-3cb2-4f6d-83b5-0ff3eb2aa6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_6ec2abf1-3cb2-4f6d-83b5-0ff3eb2aa6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_51c953ef-1fe6-4f40-8df5-f24a64f36a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_51c953ef-1fe6-4f40-8df5-f24a64f36a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_2a20aaee-0f3d-4797-a81a-296889f12b2f" xlink:href="lgnd-20201231.xsd#lgnd_DebtInstrumentAccruedInterestRepurchasedAmount"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount_2a20aaee-0f3d-4797-a81a-296889f12b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument_61d73e71-6df8-4fcd-99f0-b7878f13c2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_GainLossOnRepurchaseOfDebtInstrument_61d73e71-6df8-4fcd-99f0-b7878f13c2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_238dd143-5f05-41c0-93c7-a90d83baacf7" xlink:href="lgnd-20201231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_238dd143-5f05-41c0-93c7-a90d83baacf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_06165085-80bc-46de-b0d8-860483184a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_LongTermNotesPayable_06165085-80bc-46de-b0d8-860483184a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_7ccca382-5ab4-4e20-847d-9824a342d5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1bc41039-2840-49c8-9cd5-675a2ebf7bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_7ccca382-5ab4-4e20-847d-9824a342d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_829a2264-d9c2-446f-8d00-878c3e536a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_829a2264-d9c2-446f-8d00-878c3e536a7f" xlink:to="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bcb7e8eb-9ec4-4a8b-8682-dbc9c9c5285f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_a1a36b4f-45b8-4a40-813f-2447469ea384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab23998b-eb99-47fc-ad88-d8d73c7d4ba2" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_a1a36b4f-45b8-4a40-813f-2447469ea384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dc42fb49-2a97-4d69-9a3c-3e9c8d81a5da" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ed86373-dafd-434d-8e0d-e43fe603a37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ed86373-dafd-434d-8e0d-e43fe603a37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5890eea6-016f-4432-b2e4-ae78600796a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5890eea6-016f-4432-b2e4-ae78600796a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_322fbb1c-dad8-4e80-a6d2-a1835a035d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_7882ee96-b66c-41d1-a516-ec0e4876580b" xlink:to="loc_us-gaap_LongTermNotesPayable_322fbb1c-dad8-4e80-a6d2-a1835a035d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a75f74c-0217-4d22-878b-4da0612721a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a75f74c-0217-4d22-878b-4da0612721a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_e8e70ff7-a197-4260-8eeb-2ddb707c2bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9de04396-cccb-47ed-a55e-7427b1e56e50" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_e8e70ff7-a197-4260-8eeb-2ddb707c2bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_2783c760-0bc4-4d43-9b3e-c35ff4f6504f" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_49f15013-b506-4547-b4b3-bba6dc7a1795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_2783c760-0bc4-4d43-9b3e-c35ff4f6504f" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_49f15013-b506-4547-b4b3-bba6dc7a1795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_684084f1-6666-4b0e-be58-e9d83cd9f514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_684084f1-6666-4b0e-be58-e9d83cd9f514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_825d313a-993d-4ecf-a1b7-8c7480bfa899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_825d313a-993d-4ecf-a1b7-8c7480bfa899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_904bc4f5-1e37-46e9-9f77-96eb08e673e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_904bc4f5-1e37-46e9-9f77-96eb08e673e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6ef67a37-25bd-4b5e-8b81-42c5a8803920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6ef67a37-25bd-4b5e-8b81-42c5a8803920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_cef1e7d9-6411-43ab-9de4-cc09b050ead2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_cef1e7d9-6411-43ab-9de4-cc09b050ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8369e195-bb45-46df-9185-8898f000ddf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8369e195-bb45-46df-9185-8898f000ddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_903fd9f5-9783-4218-b2f0-50ea7da4ad87" xlink:href="lgnd-20201231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c7e03dca-25eb-453f-ba0d-7280fa00455e" xlink:to="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_903fd9f5-9783-4218-b2f0-50ea7da4ad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_d20847aa-8a87-4200-8717-f8ff93c96830" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d20847aa-8a87-4200-8717-f8ff93c96830" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:to="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_588ba3b8-051c-4074-96f8-d914954fcdb0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cdb76e61-c429-4638-b4e7-f577ced11f59" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_191629a4-89f7-4f71-9d7b-e4464390945b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_MutualFundMember_191629a4-89f7-4f71-9d7b-e4464390945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_8f7007e8-8a56-4614-adf2-01ed1101c85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_DemandDepositsMember_8f7007e8-8a56-4614-adf2-01ed1101c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2e7885d0-8ee1-453c-9fe7-1d01475e179b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_CommercialPaperMember_2e7885d0-8ee1-453c-9fe7-1d01475e179b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_61ffcd58-56c3-4d2e-b6ab-5d48d847af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_61ffcd58-56c3-4d2e-b6ab-5d48d847af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_4b7dcb32-0c15-48ba-a9f2-328552a785d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_AgencySecuritiesMember_4b7dcb32-0c15-48ba-a9f2-328552a785d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a5b8a410-7639-402f-83b0-9ec1f4c791e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_a5b8a410-7639-402f-83b0-9ec1f4c791e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5b8bc5f9-e99e-4034-bcde-1a21c69dccd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5b8bc5f9-e99e-4034-bcde-1a21c69dccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_359a9ade-933e-4f98-88c4-a8ecade8cd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_b6d13ccc-d9f0-40fa-b5af-ed80057e15ee" xlink:to="loc_us-gaap_WarrantMember_359a9ade-933e-4f98-88c4-a8ecade8cd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_58332003-ce74-4f72-aec0-b88dbef14b6e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a3ac5832-dc6f-4e44-9209-0bd982417195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a3ac5832-dc6f-4e44-9209-0bd982417195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f5f8243-d779-468a-a4ce-397a97e10ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f5f8243-d779-468a-a4ce-397a97e10ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c642920d-d6a4-4699-ad42-4c6972890b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c642920d-d6a4-4699-ad42-4c6972890b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fc9e6e4-a34b-475b-99d9-0b74e3d5732c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96429c98-658a-40c8-8319-49262dcc839a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2fc9e6e4-a34b-475b-99d9-0b74e3d5732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_cad2673e-3c55-411d-a9a0-d8bab806b139" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cad2673e-3c55-411d-a9a0-d8bab806b139" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c76dbfb3-3dd4-45ec-b456-0aabb649dfaa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_15186b95-78c3-4308-96e0-7c7f5ca39bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbfcc331-9161-4fae-987e-9746c02ca383" xlink:to="loc_us-gaap_WarrantMember_15186b95-78c3-4308-96e0-7c7f5ca39bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_8af167e1-ac10-49b6-a3e1-b9500a754738" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_20dfe7fc-ab46-41df-be82-cad9be1cc20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_20dfe7fc-ab46-41df-be82-cad9be1cc20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5b788723-edff-4339-8ef7-eb5d8ced08d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5b788723-edff-4339-8ef7-eb5d8ced08d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8709c1d-1453-4b63-9b0e-f0867c1c21d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8709c1d-1453-4b63-9b0e-f0867c1c21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_979a1ede-8826-41f9-b939-33836ddde3eb" xlink:href="lgnd-20201231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_lgnd_InvestmentInVikingCurrent_979a1ede-8826-41f9-b939-33836ddde3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a9f42999-742c-4a0d-8fb0-ca788f864f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2299e48c-3b54-40ba-b94f-51c5aca8e204" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a9f42999-742c-4a0d-8fb0-ca788f864f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_0163e2be-95d5-45c7-8798-29018209d9c7" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_0163e2be-95d5-45c7-8798-29018209d9c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_219514c0-69bb-4113-8ebf-52fbabcf3ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_219514c0-69bb-4113-8ebf-52fbabcf3ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_029caf1f-0b9e-4d2f-8ec4-79b1f8e190f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_029caf1f-0b9e-4d2f-8ec4-79b1f8e190f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_f262f3c5-c07d-479e-b4a5-c960c8be9d2f" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive_f262f3c5-c07d-479e-b4a5-c960c8be9d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_5102f15c-7c94-41c1-99b3-db205df6978a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_9f76f7fa-1321-4c27-8b12-9f4e75206770" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_5102f15c-7c94-41c1-99b3-db205df6978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_0163e2be-95d5-45c7-8798-29018209d9c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_32640856-6e65-4ba2-94ef-3d3e539cd44c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_32640856-6e65-4ba2-94ef-3d3e539cd44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_68c741e0-350b-43c9-8a04-177c3ea56682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_68c741e0-350b-43c9-8a04-177c3ea56682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_61200017-2d65-4dfe-a5c5-c3bf5793163a" xlink:href="lgnd-20201231.xsd#lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive_61200017-2d65-4dfe-a5c5-c3bf5793163a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9220edac-bd5f-47f4-a146-154f7706476c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cc805e96-61c2-494d-8b5c-e1a5826edb64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9220edac-bd5f-47f4-a146-154f7706476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_ff5c2121-1f51-4912-986f-2ccda08b5f2b" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_ff5c2121-1f51-4912-986f-2ccda08b5f2b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:to="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_065b6bbd-68df-4014-8c3d-42084291d923" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_4cbd2e9b-755c-4a0e-ade0-8c5f278fd828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_DemandDepositsMember_4cbd2e9b-755c-4a0e-ade0-8c5f278fd828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ce140a75-0c92-4391-8646-dd6ea4fcb062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ce140a75-0c92-4391-8646-dd6ea4fcb062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_56b66a63-282f-43d3-bbcb-43fd366f2b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c430c3cf-f5fc-4f3f-8389-82b470602b7d" xlink:to="loc_us-gaap_CommercialPaperMember_56b66a63-282f-43d3-bbcb-43fd366f2b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e07ff147-c143-48c9-a478-00b056bab171" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_50f8fbda-bfa4-46ad-b97b-1c5f15c7063b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_50f8fbda-bfa4-46ad-b97b-1c5f15c7063b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1501b3ed-c197-490b-a95b-6ab2eabed2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1501b3ed-c197-490b-a95b-6ab2eabed2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_29bc3d86-83e5-43f9-80bc-d3a1aacae4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ef834de7-a70f-4f6c-9427-eb532968154e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_29bc3d86-83e5-43f9-80bc-d3a1aacae4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_a7cadd67-cd12-4ffc-a28a-b9f319b041ee" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7493c142-dac0-4e7b-bf24-4b90f93d4948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7493c142-dac0-4e7b-bf24-4b90f93d4948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_91cf0e3f-3584-41fa-bd17-220e6ad9a004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_91cf0e3f-3584-41fa-bd17-220e6ad9a004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7fb82eab-381a-4081-a91a-d1c01632ea2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_d2b93343-81a8-493c-b9fe-7af3a4ae252a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7fb82eab-381a-4081-a91a-d1c01632ea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_ce33db22-f5a2-4cf6-834f-5f9935f0bddb" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_ce33db22-f5a2-4cf6-834f-5f9935f0bddb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:to="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e25cac48-6aca-4d86-9346-f61597169af5" xlink:to="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_18a0fee9-4f87-4ce8-a2dc-b0d97a3a3bbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:to="loc_srt_MinimumMember_18a0fee9-4f87-4ce8-a2dc-b0d97a3a3bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ba26362-a334-4c41-ae6a-00a08d8896f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6b149f9-06cb-489a-be55-daae1dbec89d" xlink:to="loc_srt_MaximumMember_7ba26362-a334-4c41-ae6a-00a08d8896f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2fa01455-eca3-425b-9743-fe534179f921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_31615181-8465-4937-89cb-b78871edcda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_us-gaap_OfficeEquipmentMember_31615181-8465-4937-89cb-b78871edcda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_328ccf2c-ab27-4ad1-91ee-be92769309b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_328ccf2c-ab27-4ad1-91ee-be92769309b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_bb32da0a-9a70-400c-afe7-48f5aa102794" xlink:href="lgnd-20201231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b80c751f-0ba8-49af-9df7-ef7af50a75db" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_bb32da0a-9a70-400c-afe7-48f5aa102794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fc552a4-6c45-4c4b-9a30-be3f74ae355f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5e5971dc-fa8e-4124-8a99-4f4757e7b701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5e5971dc-fa8e-4124-8a99-4f4757e7b701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b9c04229-1d8a-4300-971f-bd3b93556e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b9c04229-1d8a-4300-971f-bd3b93556e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44a25167-9d43-4102-8e6b-646e3e6ead35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44a25167-9d43-4102-8e6b-646e3e6ead35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6165c8b0-88c7-4d64-8d4c-51265b5ecdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6165c8b0-88c7-4d64-8d4c-51265b5ecdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c8a84e8a-4f77-4dc6-9f31-55fb2af5cdf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3427fa1e-a3a1-4487-8ccf-99dbe5ead3c4" xlink:to="loc_us-gaap_Depreciation_c8a84e8a-4f77-4dc6-9f31-55fb2af5cdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_25541cba-480e-4e2f-bde9-c3b3b39eeb9e" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_25541cba-480e-4e2f-bde9-c3b3b39eeb9e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44ed71a8-795f-4a8b-9956-9d11162b9004" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_6cd645e2-d459-476a-85a9-29a1beb7182c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_PatentedTechnologyMember_6cd645e2-d459-476a-85a9-29a1beb7182c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_74d44cf4-df70-4616-b3c5-304f8720c3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_TradeNamesMember_74d44cf4-df70-4616-b3c5-304f8720c3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_ed2d8968-1866-42a0-a5f4-5505d1b895e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_CustomerRelationshipsMember_ed2d8968-1866-42a0-a5f4-5505d1b895e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_20e163a3-d661-427f-a054-ff49bd62f7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce230e38-fe78-4c14-8c29-b01e9523f7ed" xlink:to="loc_us-gaap_ContractualRightsMember_20e163a3-d661-427f-a054-ff49bd62f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73d26887-9947-4db1-86cb-6fd62ede7b36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22178c01-9e7d-4c8b-a1c4-f2675d48d6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_Goodwill_22178c01-9e7d-4c8b-a1c4-f2675d48d6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d346a1e3-9936-40e5-826b-10093379d341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d346a1e3-9936-40e5-826b-10093379d341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0d463c7-3d18-47b1-ac8f-fdeb9351ce29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0d463c7-3d18-47b1-ac8f-fdeb9351ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b99ddc2-4ff7-4456-818f-ac79b2de572c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b99ddc2-4ff7-4456-818f-ac79b2de572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9daf4242-4727-4607-b195-797f91f5cf26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9daf4242-4727-4607-b195-797f91f5cf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8a83f97e-e44f-4eee-bf75-7a1a0f631066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8a83f97e-e44f-4eee-bf75-7a1a0f631066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85cf79db-4905-47f0-a013-1197da4f25f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85cf79db-4905-47f0-a013-1197da4f25f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4b2a94cb-49e3-4dcf-bcb8-19519fe2a4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4b2a94cb-49e3-4dcf-bcb8-19519fe2a4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_02e4a22b-1b51-47f2-8ad2-5e74189694d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_02e4a22b-1b51-47f2-8ad2-5e74189694d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636aff5b-7327-4f5d-93ee-b9313cf05fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636aff5b-7327-4f5d-93ee-b9313cf05fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_25819476-f562-44e6-baaf-05734af6013b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_63300bef-abea-4da8-bf5d-63ad7604c485" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_25819476-f562-44e6-baaf-05734af6013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0e4effec-6296-4bb0-b6cc-4d2902cd6414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0e4effec-6296-4bb0-b6cc-4d2902cd6414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_27f8bf74-4dfd-4a4d-93b9-b1f1eb477faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_27f8bf74-4dfd-4a4d-93b9-b1f1eb477faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_54117b85-7267-466d-9d87-671fe6cd5735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_54117b85-7267-466d-9d87-671fe6cd5735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9f884bbd-a8c9-4bf7-bf4b-737da528d9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9f884bbd-a8c9-4bf7-bf4b-737da528d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_cfca152b-f925-4761-818d-fb67bdbc6335" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSalesReturns"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_lgnd_AccruedSalesReturns_cfca152b-f925-4761-818d-fb67bdbc6335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedAssetAcquisitionsCurrent_cb8198e9-1645-40be-baa5-2074977e723e" xlink:href="lgnd-20201231.xsd#lgnd_AccruedAssetAcquisitionsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_lgnd_AccruedAssetAcquisitionsCurrent_cb8198e9-1645-40be-baa5-2074977e723e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_c101d8d3-cb1b-44cc-894c-989009261e66" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_c101d8d3-cb1b-44cc-894c-989009261e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_1cb1b3a3-c61b-4e40-a250-6da02a1dcb39" xlink:href="lgnd-20201231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_1cb1b3a3-c61b-4e40-a250-6da02a1dcb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba1e1c96-093e-497b-8c12-f0016023f2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba1e1c96-093e-497b-8c12-f0016023f2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f3b04570-cce8-47de-94cb-ec1a23e57cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_75ca0fe8-bd57-49f4-9c2e-f526797c103b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f3b04570-cce8-47de-94cb-ec1a23e57cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_95154a16-c002-42f7-a7ca-ee385bc4a0af" xlink:href="lgnd-20201231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_95154a16-c002-42f7-a7ca-ee385bc4a0af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9b9684ef-736c-4914-9541-2661525e95e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_f9886b68-e998-4838-90cd-8141f4df706f" xlink:href="lgnd-20201231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_f9886b68-e998-4838-90cd-8141f4df706f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_f6f80a4c-d0e3-49ad-9c61-807810b08b3a" xlink:href="lgnd-20201231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_f6f80a4c-d0e3-49ad-9c61-807810b08b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_550729a8-c81b-4e73-ac49-981c64ecdf23" xlink:href="lgnd-20201231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_CrystalMember_550729a8-c81b-4e73-ac49-981c64ecdf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IcagenMember_5406428a-4c78-4050-ae95-af53d5beb09d" xlink:href="lgnd-20201231.xsd#lgnd_IcagenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_IcagenMember_5406428a-4c78-4050-ae95-af53d5beb09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_a7353d2c-9eee-47a4-bce9-c45544958a35" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65bc97b5-739a-4316-b099-a4e5c1d65633" xlink:to="loc_lgnd_PfenexMember_a7353d2c-9eee-47a4-bce9-c45544958a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7c7e5da3-65fc-4453-ace2-3c8c54e1495f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_b5fc7d42-3ac1-4ee8-be21-38ca4f7f8da8" xlink:href="lgnd-20201231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare_b5fc7d42-3ac1-4ee8-be21-38ca4f7f8da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a9d21be-eef2-4647-a478-221179c0ad5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a9d21be-eef2-4647-a478-221179c0ad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:href="lgnd-20201231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12fb3a1b-5a45-4aca-91ad-538d25d270b6" xlink:to="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e9e30389-6c95-4ba7-b55b-f7277f5f614d" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e9e30389-6c95-4ba7-b55b-f7277f5f614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_f091145e-491b-4523-ba03-92fc087d6815" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions_f091145e-491b-4523-ba03-92fc087d6815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_21adf5cd-d58d-446d-b152-b5e351be484c" xlink:href="lgnd-20201231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_21adf5cd-d58d-446d-b152-b5e351be484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_96b21123-2efe-4074-be9f-a72992b4a01b" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_96b21123-2efe-4074-be9f-a72992b4a01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3bf833ad-9b7b-4242-86df-86423258cadd" xlink:href="lgnd-20201231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3bf833ad-9b7b-4242-86df-86423258cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_edc51aae-6e07-4082-893e-688dc0bf02a1" xlink:href="lgnd-20201231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_14b6c258-e7b8-4848-a016-a9a5e94bb550" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_edc51aae-6e07-4082-893e-688dc0bf02a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b91f34fa-61fd-48c1-b2ca-26cd996f1745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82575bef-9d88-4d64-a7e5-b562a9429ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b91f34fa-61fd-48c1-b2ca-26cd996f1745" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82575bef-9d88-4d64-a7e5-b562a9429ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_102cb8c6-7d0a-4e58-b562-0fc57a323b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_102cb8c6-7d0a-4e58-b562-0fc57a323b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fad9a6d6-bc55-496c-b6ae-20803acebf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fad9a6d6-bc55-496c-b6ae-20803acebf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_4cbfc919-9208-4b78-bced-4c8f67fc9509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_4cbfc919-9208-4b78-bced-4c8f67fc9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72441115-6128-432b-a1a9-7e89aff2ac3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72441115-6128-432b-a1a9-7e89aff2ac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8736b064-ffc5-4f50-88cc-8969e1a9261b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5243752-54c4-4f9f-b4f1-8b0bcf903dfe" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8736b064-ffc5-4f50-88cc-8969e1a9261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edfd0a-59de-41c3-a6e6-01e005409af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edfd0a-59de-41c3-a6e6-01e005409af4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb767e36-c1b0-4f60-8eb8-58a05053529c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_990583f3-2fdf-4d28-9b3d-7b5094c868a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_990583f3-2fdf-4d28-9b3d-7b5094c868a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1cbabf63-2973-48fb-a654-dca59461eab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a74a09d4-d00b-4359-8224-2416ec039492" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1cbabf63-2973-48fb-a654-dca59461eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c1bbeafa-5476-48d9-85ff-3fc69a00df91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_3d6c64f1-23ef-4d7f-9434-434e1283c208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_404f6822-9bd3-4183-b6f2-fe5c8aa5f7e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_3d6c64f1-23ef-4d7f-9434-434e1283c208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3fc7bc8c-e13e-41bb-aced-5f88dcd0d5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3fc7bc8c-e13e-41bb-aced-5f88dcd0d5aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_19b685f8-2869-4738-a9af-c25f7e7a781c" xlink:to="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_776a4550-3088-4ace-9f70-fa81711b0649" xlink:href="lgnd-20201231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_776a4550-3088-4ace-9f70-fa81711b0649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_2e44140d-13d6-4ddc-9369-8c2a500b6572" xlink:href="lgnd-20201231.xsd#lgnd_AmendedESPPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a5255a19-1389-4fcf-9d61-91bbf7656730" xlink:to="loc_lgnd_AmendedESPPMember_2e44140d-13d6-4ddc-9369-8c2a500b6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ffd4d6b4-934b-4a9a-b801-23ae056b0174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93d34d98-ebab-4bcc-909e-0c37948ac81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93d34d98-ebab-4bcc-909e-0c37948ac81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16be9dde-2425-45c4-aba2-1bfb5c654a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e0156ed-1e58-4816-8397-acdbe1616408" xlink:to="loc_us-gaap_RestrictedStockMember_16be9dde-2425-45c4-aba2-1bfb5c654a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8de7eee-909c-441f-b62a-e94e1b078f11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PfenexMember_8a5184be-0833-4a48-9e5e-5a5b1a806d0a" xlink:href="lgnd-20201231.xsd#lgnd_PfenexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c6ab6be-129b-4eaa-b0ca-56e548e71ddf" xlink:to="loc_lgnd_PfenexMember_8a5184be-0833-4a48-9e5e-5a5b1a806d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fd47b8c-8886-4126-8572-30687e9012e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_107eab9f-5deb-45f0-b7d9-52ecb6e35812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_107eab9f-5deb-45f0-b7d9-52ecb6e35812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d53ebb1f-c003-4144-81d4-7141e348de2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d53ebb1f-c003-4144-81d4-7141e348de2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da7f74c3-3da1-409b-a3a2-6620cea91446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da7f74c3-3da1-409b-a3a2-6620cea91446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b50723b-8a24-42d1-ae64-a2487b543583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b50723b-8a24-42d1-ae64-a2487b543583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_33efac59-5746-4fca-91ef-f13f281d3e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_33efac59-5746-4fca-91ef-f13f281d3e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f7004d-21a6-4096-b0b1-1328314bb2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f7004d-21a6-4096-b0b1-1328314bb2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5721a0c1-4365-4b2e-a48c-e4432fc68afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5721a0c1-4365-4b2e-a48c-e4432fc68afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eba379ab-41dc-48c8-8c00-81671dbf9e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eba379ab-41dc-48c8-8c00-81671dbf9e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f70f49dc-e158-4c84-b30c-e76001574bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f70f49dc-e158-4c84-b30c-e76001574bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:href="lgnd-20201231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_940f22f1-34a0-4e9e-805c-76c52ed3eb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_940f22f1-34a0-4e9e-805c-76c52ed3eb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_222bde9e-670e-4d16-a8b8-9591e2a33df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_222bde9e-670e-4d16-a8b8-9591e2a33df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3e8abfea-e24a-4c30-897a-1ac48e55602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_9dbde942-dae1-4b9f-abc5-6c6bb708996e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3e8abfea-e24a-4c30-897a-1ac48e55602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:href="lgnd-20201231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9076a1ee-62e4-4ca7-a19b-e5fe5627df4f" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb872da9-63db-4061-b452-f6476892fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb872da9-63db-4061-b452-f6476892fc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_ba001309-3d38-4daf-a48c-4cf97747402f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_ba001309-3d38-4daf-a48c-4cf97747402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4985af66-41eb-458e-a337-920600d05642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4985af66-41eb-458e-a337-920600d05642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_f22a52f2-9c64-441b-89c7-1d9cb9421da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_f22a52f2-9c64-441b-89c7-1d9cb9421da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_926bf364-d379-44b6-8383-e61772eabefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_926bf364-d379-44b6-8383-e61772eabefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_acea497f-a413-4665-a0f8-2299825238dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_089f540a-2c11-4480-8e33-9f97294ec4c8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_acea497f-a413-4665-a0f8-2299825238dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9989c8f7-696d-46dc-89f6-c09fd4741005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9989c8f7-696d-46dc-89f6-c09fd4741005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5dcb3055-562a-4924-b493-c2fb1a2a63ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5dcb3055-562a-4924-b493-c2fb1a2a63ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec9f6d02-5add-41b2-9cce-7b75b477347a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec9f6d02-5add-41b2-9cce-7b75b477347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2567f9bb-3aa6-456a-ba50-9b924c063672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2567f9bb-3aa6-456a-ba50-9b924c063672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c3b355a6-b0aa-4104-a9a6-92b6b5668752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c446ad-a3f2-4f79-addb-941d8e0731e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c3b355a6-b0aa-4104-a9a6-92b6b5668752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a824d028-935e-4d29-aa3f-f221bdc1829b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a824d028-935e-4d29-aa3f-f221bdc1829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41749ab7-16d1-4a58-9f9e-bab5a0e22e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41749ab7-16d1-4a58-9f9e-bab5a0e22e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a9eb94b-5912-47d4-a590-a76100f5b5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a9eb94b-5912-47d4-a590-a76100f5b5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f0822087-765b-43d4-ba63-85856b03b543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f0822087-765b-43d4-ba63-85856b03b543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53873990-b8e2-406e-a64e-649e46549725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53873990-b8e2-406e-a64e-649e46549725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3b44d174-46c2-42e1-bee0-96d91b917a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3b44d174-46c2-42e1-bee0-96d91b917a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e116c586-a022-4e4b-bc68-f0f19b2e3a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e26ef91-3489-4458-9236-b61ce3d1a58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e116c586-a022-4e4b-bc68-f0f19b2e3a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50f99846-7758-4423-8180-35e8a392c74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50f99846-7758-4423-8180-35e8a392c74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_64b563bf-b552-4137-9647-7e35a9ac68cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_64b563bf-b552-4137-9647-7e35a9ac68cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e0167f51-313e-4fda-bc38-9023a20fdbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e0167f51-313e-4fda-bc38-9023a20fdbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cbbe5a19-c57e-4666-acb4-537f50a9db89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cbbe5a19-c57e-4666-acb4-537f50a9db89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9b0ff749-7148-44d5-910c-ba51bd0efac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9b0ff749-7148-44d5-910c-ba51bd0efac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eb1ea7e3-361b-4779-b3d2-f40bf13fb870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eb1ea7e3-361b-4779-b3d2-f40bf13fb870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0f74071f-dff9-41ee-bb8b-419c4cf3abd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0f74071f-dff9-41ee-bb8b-419c4cf3abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38c79059-f9d5-4e6d-8ff5-3888e37ea7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f32b4d2f-c33b-4553-b370-12ba8a5c8afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38c79059-f9d5-4e6d-8ff5-3888e37ea7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_65c6ffbb-b50c-46b8-892e-69d743d9c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65c6ffbb-b50c-46b8-892e-69d743d9c1bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2b2ae9c8-c57c-4dcb-ba87-b902b1b9c47c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_100afbb2-cb17-4587-95e2-b646a6628e27" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_9cbeb9f8-5756-4f71-9496-88f9ed1e5d8a" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_9cbeb9f8-5756-4f71-9496-88f9ed1e5d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_cd2257da-bf36-4fb0-bc45-d122b8677edb" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_cd2257da-bf36-4fb0-bc45-d122b8677edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_1884c51d-a210-4777-8c49-e1bd526a1ac1" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_1884c51d-a210-4777-8c49-e1bd526a1ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_0da43c49-0e0a-4d2b-88c6-a186a513bdac" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_0da43c49-0e0a-4d2b-88c6-a186a513bdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_ee7100e9-b731-4b7a-88dc-03df4476d381" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_ee7100e9-b731-4b7a-88dc-03df4476d381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_69e7ff0b-0864-452e-9729-acaf31b707a0" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_69e7ff0b-0864-452e-9729-acaf31b707a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_c25ba81f-7993-4b97-ad8f-7ef0114005ac" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_c25ba81f-7993-4b97-ad8f-7ef0114005ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_d6284e58-9c80-4578-a6f3-24e8c2462b62" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_d6284e58-9c80-4578-a6f3-24e8c2462b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_cc27eb7d-4ee6-4350-b921-f528993f810e" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_cc27eb7d-4ee6-4350-b921-f528993f810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_b5073c3f-269e-495d-9995-01a203e54902" xlink:href="lgnd-20201231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_e4f78be3-c7c1-4eee-aeff-14917d3dac17" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_b5073c3f-269e-495d-9995-01a203e54902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_186e0fbf-035c-4200-901f-8392b23c69cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0a0845a-d725-4cdd-b5cc-454b9f11603a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a0a0845a-d725-4cdd-b5cc-454b9f11603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e29703e-a993-4a2e-8830-6ef6d19903d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1e29703e-a993-4a2e-8830-6ef6d19903d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_b7af8774-44fc-4694-9322-54aaad5ab322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_b7af8774-44fc-4694-9322-54aaad5ab322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_71815445-42c9-4f64-b69e-82bedc430bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_71815445-42c9-4f64-b69e-82bedc430bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_eec74e30-caf3-4255-89c6-34d24a75ec53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_eec74e30-caf3-4255-89c6-34d24a75ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fdca390-c939-4852-96ee-e607bb1b0813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6fdca390-c939-4852-96ee-e607bb1b0813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_a37268e4-1f45-4fdd-aea7-1faee15a02ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eac34f16-6265-46b2-831e-8e5a665a26aa" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_a37268e4-1f45-4fdd-aea7-1faee15a02ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf674509-13e8-4948-af88-d194d335be5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf674509-13e8-4948-af88-d194d335be5c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:to="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba6c9175-829b-42a3-aab0-2fafd9b5d8cb" xlink:to="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d72339e3-b2ab-4f1d-ba1c-6bc878b5e065" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:to="loc_srt_MinimumMember_d72339e3-b2ab-4f1d-ba1c-6bc878b5e065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c4a5763-75dc-4622-8800-97902466ca14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61c736b7-595d-488f-8e8d-62bd764d0021" xlink:to="loc_srt_MaximumMember_2c4a5763-75dc-4622-8800-97902466ca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a862dd2a-a78c-4c84-9077-e9dd09bfc9b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_507d0bf8-4d62-4123-9043-08f0f07de242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_507d0bf8-4d62-4123-9043-08f0f07de242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18cdf3bf-b591-4b7b-842a-d77ded997683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18cdf3bf-b591-4b7b-842a-d77ded997683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f8cbd8-f1f5-4438-b209-9355a8ea5b66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f3175e-7b6a-46a5-967f-cf1fa12541bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f8cbd8-f1f5-4438-b209-9355a8ea5b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6520fe68-21ed-4817-9630-618129bf6e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6520fe68-21ed-4817-9630-618129bf6e07" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:to="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f9f66d6a-1a5c-4f8d-9e61-8139d3d06e5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1ee6e3c4-40ec-49c8-a2e1-bae773d0bdde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebcf72e4-92c8-4cdb-93e9-770e0535ecd8" xlink:to="loc_us-gaap_RestrictedStockMember_1ee6e3c4-40ec-49c8-a2e1-bae773d0bdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_365b1446-11df-4574-8862-d6a981d08705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec5a5705-3b49-4999-adb2-2327fcd5fb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec5a5705-3b49-4999-adb2-2327fcd5fb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438972d1-1d34-4d9b-9d7c-a38870dbaa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438972d1-1d34-4d9b-9d7c-a38870dbaa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b6e12192-f53b-4a8e-b268-4ef3f9e21835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b6e12192-f53b-4a8e-b268-4ef3f9e21835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30955c21-fc30-4cbc-b197-4fe7b68f0e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30955c21-fc30-4cbc-b197-4fe7b68f0e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29b17a9f-a541-4a41-bb83-57c36d8bbf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ce54dd0-755c-4e47-a1df-c4a80d438093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29b17a9f-a541-4a41-bb83-57c36d8bbf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb5b1d03-7ed1-416d-8432-543e7129b9fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2f9af14-1049-4533-85ee-eea631bda78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2f9af14-1049-4533-85ee-eea631bda78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c57063eb-dcf7-4032-89a6-fe521358ddde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c57063eb-dcf7-4032-89a6-fe521358ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe16ed8d-d119-4569-894a-23431a453cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe16ed8d-d119-4569-894a-23431a453cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a0adcb8a-b2a0-4d1f-81a1-e4b9f60a4c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a0adcb8a-b2a0-4d1f-81a1-e4b9f60a4c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_67d4191a-c0ac-4b31-bf7a-7b95715502a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60941776-b031-4e0c-ac30-e9556904be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_67d4191a-c0ac-4b31-bf7a-7b95715502a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3c51742-29a9-4f34-a8bc-c16a4f603a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7841422e-849f-4833-8795-072c8aa6ed32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3c51742-29a9-4f34-a8bc-c16a4f603a7a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7841422e-849f-4833-8795-072c8aa6ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e2abc24-80c5-4c92-b0d3-0927ffa8d117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e2abc24-80c5-4c92-b0d3-0927ffa8d117" xlink:to="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:to="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c130baf5-09c7-41e5-b762-bb48b3455f5c" xlink:to="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LupinPatentInfringementMember_866ab513-d5f0-40cf-ad8b-decd33cf1e07" xlink:href="lgnd-20201231.xsd#lgnd_LupinPatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:to="loc_lgnd_LupinPatentInfringementMember_866ab513-d5f0-40cf-ad8b-decd33cf1e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_0ae2d6ba-6b4b-42c4-9679-5286d7bfefb9" xlink:href="lgnd-20201231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f462b4ae-4960-40e3-8fd0-028c51662561" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_0ae2d6ba-6b4b-42c4-9679-5286d7bfefb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_a7067f5a-605c-44b5-9ec5-6e5641f4a693" xlink:to="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_74d13f61-2402-49eb-be20-903f01e36090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_74d13f61-2402-49eb-be20-903f01e36090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_5d01632c-578a-4dc5-bdf3-0ed1065697d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_4b28a2c6-f5b1-4642-99f6-2779f761cd23" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_5d01632c-578a-4dc5-bdf3-0ed1065697d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0020a7c3-75cf-45ea-b4dd-f26e19ea99e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8422fd29-55e5-46b5-8bd2-81ce477b5820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0020a7c3-75cf-45ea-b4dd-f26e19ea99e5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8422fd29-55e5-46b5-8bd2-81ce477b5820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_523b9a4b-fb6f-4a05-b3b0-20959de8d499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7f1d454c-6c42-42be-97be-b66455c0c675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_523b9a4b-fb6f-4a05-b3b0-20959de8d499" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7f1d454c-6c42-42be-97be-b66455c0c675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_681e52a7-aa26-4b26-a479-fcad993eec40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_523b9a4b-fb6f-4a05-b3b0-20959de8d499" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_681e52a7-aa26-4b26-a479-fcad993eec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d81ee922-6712-4135-ac45-33f4ab39d2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_523b9a4b-fb6f-4a05-b3b0-20959de8d499" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d81ee922-6712-4135-ac45-33f4ab39d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_5cde7cd3-fe25-4c4a-81f9-03d2e7178aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_523b9a4b-fb6f-4a05-b3b0-20959de8d499" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_5cde7cd3-fe25-4c4a-81f9-03d2e7178aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0b4a6969-e0a1-4101-95ae-322d2af312a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0b4a6969-e0a1-4101-95ae-322d2af312a1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a5a8ca22-a48e-4879-a7bd-57623e504d04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_07dbe186-87f5-463a-81b5-921ab8d1c9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_07dbe186-87f5-463a-81b5-921ab8d1c9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7b5dfbd9-bcb1-489d-a19b-1281c9a48a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7b5dfbd9-bcb1-489d-a19b-1281c9a48a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_20996ac0-bdbf-454d-ba20-9d78a4f05add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_042f4f95-1b17-4241-99ef-3375eff523f9" xlink:to="loc_us-gaap_ForeignCountryMember_20996ac0-bdbf-454d-ba20-9d78a4f05add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ae2e9fe3-0f1c-42aa-9074-c6e4bed716fa" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_04223aba-aafa-4c83-bdfb-fe9ba0bb0751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_us-gaap_ResearchMember_04223aba-aafa-4c83-bdfb-fe9ba0bb0751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_351f6262-8643-40ce-9fd5-65a363751fc3" xlink:href="lgnd-20201231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_351f6262-8643-40ce-9fd5-65a363751fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_01653786-eae8-4b0e-be10-f1f0c71b9989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1edcb4-529d-4d58-b245-ee3d4f781053" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_01653786-eae8-4b0e-be10-f1f0c71b9989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_681acd35-8032-4bb1-ba44-3382bb33bf5f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a00ab2fd-8f6f-4ad9-9689-1ec461e82276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a00ab2fd-8f6f-4ad9-9689-1ec461e82276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e7193ed2-508b-43ad-83bd-a343f7c921ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e7193ed2-508b-43ad-83bd-a343f7c921ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_bbb9fe1a-bf64-4e5d-a988-4d2c1b01240e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_bbb9fe1a-bf64-4e5d-a988-4d2c1b01240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_90eaf7f5-ddb0-4325-b339-112c23dd6879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_dfe198b4-4f93-4ad1-a92e-e145e5125f7f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_90eaf7f5-ddb0-4325-b339-112c23dd6879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0690ed9f-e5c9-4339-9029-277fe71315da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0690ed9f-e5c9-4339-9029-277fe71315da" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1fca61b-a32e-4dd7-8ba5-4e7aeec5a7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c1fca61b-a32e-4dd7-8ba5-4e7aeec5a7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_db6117c4-1444-42f8-b02e-7ea9cf340f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_db6117c4-1444-42f8-b02e-7ea9cf340f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9e9637aa-2f23-433f-a3ad-e7d06140f74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9e9637aa-2f23-433f-a3ad-e7d06140f74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27930159-e8e8-476b-a5d5-26a4c081cb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a0668bd4-13b1-4b56-966e-e03d92618960" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27930159-e8e8-476b-a5d5-26a4c081cb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82ef52ca-adfd-4188-be3f-29e4ea1bc292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0690ed9f-e5c9-4339-9029-277fe71315da" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82ef52ca-adfd-4188-be3f-29e4ea1bc292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_855ddd6c-e121-407b-b2cb-64c36f211989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82ef52ca-adfd-4188-be3f-29e4ea1bc292" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_855ddd6c-e121-407b-b2cb-64c36f211989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d6128eb3-a8a5-4fa5-a798-a079115c0e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82ef52ca-adfd-4188-be3f-29e4ea1bc292" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d6128eb3-a8a5-4fa5-a798-a079115c0e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53f24612-625e-4ec4-a078-82162b43915f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0690ed9f-e5c9-4339-9029-277fe71315da" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53f24612-625e-4ec4-a078-82162b43915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_15be097b-edf6-4978-b9e2-346b3ffa4636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15be097b-edf6-4978-b9e2-346b3ffa4636" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8168d192-0cc2-4d15-9cec-4c45322bbe3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8168d192-0cc2-4d15-9cec-4c45322bbe3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_39035548-03aa-4358-873e-133d4d776b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_39035548-03aa-4358-873e-133d4d776b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_cda40717-e67f-4b24-b3e9-b7b0476684bd" xlink:href="lgnd-20201231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_cda40717-e67f-4b24-b3e9-b7b0476684bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_99d405a0-2a38-41ee-8e05-02e812b64f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_99d405a0-2a38-41ee-8e05-02e812b64f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_c9d5e665-512e-44f3-a922-e2e4744c27e4" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_c9d5e665-512e-44f3-a922-e2e4744c27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_289de037-4e37-4a8f-b59d-40f9df0353d0" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_289de037-4e37-4a8f-b59d-40f9df0353d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d84e60dd-f1de-4fe6-b796-63e9102e2044" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_d84e60dd-f1de-4fe6-b796-63e9102e2044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5f89561f-0035-4ad4-804f-d559bc1282d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5f89561f-0035-4ad4-804f-d559bc1282d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e89ce95e-9ec3-4e3e-b8b6-5649e0f0869d" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e89ce95e-9ec3-4e3e-b8b6-5649e0f0869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a1b99cd5-bd8f-4a44-a1fb-2b7b4a91a2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a1b99cd5-bd8f-4a44-a1fb-2b7b4a91a2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_65f6779f-63ad-407f-bb13-5de66c1c3d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_65f6779f-63ad-407f-bb13-5de66c1c3d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_495fea66-ab87-47ba-bba4-9e0c221d67cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_495fea66-ab87-47ba-bba4-9e0c221d67cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_237d4380-be60-42b0-b0c9-658d29b19f98" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount_237d4380-be60-42b0-b0c9-658d29b19f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_defd3219-2f83-4fc2-8f34-abc34f5f4f12" xlink:href="lgnd-20201231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_defd3219-2f83-4fc2-8f34-abc34f5f4f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e4adf712-43d7-4a0a-a505-8aacd695223b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e4adf712-43d7-4a0a-a505-8aacd695223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17806687-54fc-48d2-bd7f-c5d8a3766c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_161fea1e-3a9f-4272-9ac3-17a3fe9bd831" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17806687-54fc-48d2-bd7f-c5d8a3766c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0f553ed9-d0ba-49f6-91ee-98b6cb57db55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f553ed9-d0ba-49f6-91ee-98b6cb57db55" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1b1d7b4a-08be-40b4-8aa7-c52d7c96002d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1b1d7b4a-08be-40b4-8aa7-c52d7c96002d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2cb001da-c87e-460b-a2a5-7acc1bd22122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2cb001da-c87e-460b-a2a5-7acc1bd22122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_465ee5e7-1ab0-4a4f-92d1-716d93d7dd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_465ee5e7-1ab0-4a4f-92d1-716d93d7dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7280f796-b4fb-4437-9c56-2896f111de3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7280f796-b4fb-4437-9c56-2896f111de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_af3930cc-fb1b-4c33-9bb5-b7ca901048df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_af3930cc-fb1b-4c33-9bb5-b7ca901048df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d183f29b-766b-4804-a94b-ca89f93aec90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d183f29b-766b-4804-a94b-ca89f93aec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e60b7671-f579-463a-93b8-1ddd7a8c87dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_f9bfca0c-04b1-462e-ae60-31cd3935ba2d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e60b7671-f579-463a-93b8-1ddd7a8c87dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f553ed9-d0ba-49f6-91ee-98b6cb57db55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_5fae1bf7-e522-4256-b656-9bc2d907c4ad" xlink:href="lgnd-20201231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_5fae1bf7-e522-4256-b656-9bc2d907c4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_356c3ec9-f0fe-4fa7-9ccf-b51584240eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_356c3ec9-f0fe-4fa7-9ccf-b51584240eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7845abe0-4700-4191-8355-aaa63a70150e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7845abe0-4700-4191-8355-aaa63a70150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9ab95e5d-e891-43e3-9811-4658e423d8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b3f8a4f-4c14-4753-a349-5abdfaf6ca5d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_9ab95e5d-e891-43e3-9811-4658e423d8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b69eb95-af3f-4776-91eb-c0412ce1a83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b69eb95-af3f-4776-91eb-c0412ce1a83c" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_bb075ed5-c2c2-4ef3-b8be-6fd0456b4080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_bb075ed5-c2c2-4ef3-b8be-6fd0456b4080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d8d1d8d3-7b01-4636-b87f-c71d45d6c3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d8d1d8d3-7b01-4636-b87f-c71d45d6c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a91810a4-6bda-42ed-b5ce-7977f81878a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a91810a4-6bda-42ed-b5ce-7977f81878a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2e1b1980-b90f-4324-9729-9074f71c880e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2e1b1980-b90f-4324-9729-9074f71c880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8e1d82b5-a411-4391-bad1-99746cdcffe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8de58485-5ff8-4a7d-ad6a-4b4cff9806de" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8e1d82b5-a411-4391-bad1-99746cdcffe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4a3e8802-aa88-4798-9ddb-614b16b89dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_9572f567-fc56-4be3-a18a-e1e85f3cbf25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4a3e8802-aa88-4798-9ddb-614b16b89dce" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_9572f567-fc56-4be3-a18a-e1e85f3cbf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9f92f080-851e-4c86-ba35-50d9b4ad758a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_c88d8430-9098-4708-b034-85a009c4eda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9f92f080-851e-4c86-ba35-50d9b4ad758a" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_c88d8430-9098-4708-b034-85a009c4eda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20201231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b5f7ba10-790c-410b-b5b1-ee90b326c15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b5f7ba10-790c-410b-b5b1-ee90b326c15e" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:to="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c483f889-a1d7-4c20-974c-2d94359267ef" xlink:to="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_7f8023a1-6911-47b5-8735-a73f0acfc7e4" xlink:href="lgnd-20201231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_90a228d3-a707-43f4-a279-13906e3ea6dd" xlink:to="loc_lgnd_PromactaMember_7f8023a1-6911-47b5-8735-a73f0acfc7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableTable_3cecc06a-ace5-495f-82c9-704d0018af85" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b8a40b4-fe37-4994-bdcc-953b4923bcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b8a40b4-fe37-4994-bdcc-953b4923bcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_c892227d-ee52-4691-82b5-9fddccd82436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_c892227d-ee52-4691-82b5-9fddccd82436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dae17f9f-717b-46df-9d71-21f895ef78d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dae17f9f-717b-46df-9d71-21f895ef78d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7009be47-8587-4d0b-89ac-9f160c64ecb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_NetIncomeLoss_7009be47-8587-4d0b-89ac-9f160c64ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6625f3e3-a945-4f44-a7a1-9d1bdcff7d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6bfe2935-ff2b-44f5-b855-d030fa705606" xlink:to="loc_us-gaap_EarningsPerShareBasic_6625f3e3-a945-4f44-a7a1-9d1bdcff7d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_661ab8fe-e668-43e9-ba5f-8564ef48fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_aeb7e2d2-c2fe-47d0-98a1-85f4f976cbf3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_661ab8fe-e668-43e9-ba5f-8564ef48fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfcf5e2d-ca12-4e32-a928-e4b130ab73f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfcf5e2d-ca12-4e32-a928-e4b130ab73f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3a84034-72a6-46e2-bf01-40e98d0ded69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3a84034-72a6-46e2-bf01-40e98d0ded69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af3eb100-9533-4d1a-8a75-6317916704b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableLineItems_6642dca8-2d0e-4874-a57a-2ace835e59d7" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af3eb100-9533-4d1a-8a75-6317916704b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>lgnd-20201231_g1.jpg
<TEXT>
begin 644 lgnd-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)O8F)Y+E9I
M9V%R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S$S  "2
MD@ "     S$S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(P.C Q.C,P(#$S.C(V.C,U #(P,C Z,#$Z
M,S @,3,Z,C8Z,S4   !" &\ 8@!B 'D +@!6 &D 9P!A '( <P   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(P+3 Q+3,P5#$S.C(V.C,U+C$R
M-CPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y";V)B>2Y6:6=A<G,\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@!,P*Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HIKR)$A>5U11U+' %4_[;TK_H)V
M?_@0O^- %ZBH;>[MKM=UK<13#UC<-_*IJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O#/BA_R/ES_P!<H_\ T$5[G7AGQ0_Y'RY_ZY1_^@B@#D*FL_\
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M0#+P/\LB?4?U&10!L5X9\4/^1\N?^N4?_H(KW.O#/BA_R/ES_P!<H_\ T$4
M<A4UG_Q_V_\ UU7^=0U-9_\ '_;_ /75?YTQGTY1112$%%%% !1110 4444
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M0!\P45[KJ?PS\.:BQ=+:2R<]6M7VC_ODY'Y"L"?X-6[-_HVLRQCTDMP_\F%
M'E-%>I)\&5##?KI*]P+3!_\ 0ZT[/X1:)"P:[N;NY(_AW!%/Y#/ZT >-HC2.
M$12S,<  9)KO/"_PPO\ 4W2YUP/8VG7RB,2R#Z?P_CS[5ZEI7AO1]$_Y!FGP
MP/C'F;=SG_@1R?UK3H$06-C;:;91VEC"L$$8PJ(.!4]%%( J.XN(K2UEN+AP
MD4*%W8]%4#)-25R/Q-OVL?!%PJ-M:ZD2 $>AY(_)2* /'_$6N3^(=<GU"XR
MYQ$A/^K0?=7_ #W)K+HHIC);:VFO+J.WM8FEFE8*B(,EC7KOACX6V%C$EQKX
M%Y=$9\G/[N/V_P!H_I[5F?"#18Y&O-9F4,T;?9X2?X3C+'ZX*C\Z]3H C@@A
MMH5BMHDBC7[J1J% _ 5)112$%%%% '.^/O\ D0]4_P"N0_\ 0A7S_7T!X^_Y
M$/5/^N0_]"%?/],85Z[\'?\ D"ZC_P!?"_\ H->15Z[\'?\ D"ZC_P!?"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (+NQM+^'RKZUAN8_P"[+&&'ZUS5[\-/#-X2RV;V
MS'O!*1^AR/TKK** /.YO@[I;9^SZE=Q^GF!6_D!51_@RI8^7KI5>P:TR?SWB
MO3Z* /+O^%,>NO?^2?\ ]G5N'X.:<I_?ZI=./]A%7^>:]&HH X^S^%_AFTP9
M+>:[([SS'^2X%=-8Z98Z9%Y>G6<%LG<11A<_7'6K5% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lgnd-20201231_g2.jpg
<TEXT>
begin 644 lgnd-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )^!+ # 2(  A$! Q$!_\0
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MN@/-B#KDHV"1D'(XXXKKZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O*?VL?^36?C)_V)FL_P#I#-7JU>4_
MM8_\FL_&3_L3-9_](9J #]D[_DUGX-_]B9HW_I##7JU>4_LG?\FL_!O_ +$S
M1O\ TAAKU:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_B]\,Q\5/"MO80:A_8NL:;J
M%MJ^DZH;<3BUO+>0/$[1DKO0X*LH92R.P#*3D<9=^&?C%\1K[P]9>)KCP_X%
MT#3[N*_U*;P?KEY=7NK-$RLML&>VM_LL#L"9,-*S*/+X#,U>WT4 ?,OB#X!_
M$"/PS\0OAUX=N/#L'@3QI>7EU)K=Y=7"ZGI27S%KV)+58FCN22TAC<SQ;?,
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MBOKJ\N;'XUZHDPU&V6UNU$D.I31M-;A(Q"SQR))L"(/GX4=*^[O%7_(L:O\
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M:W>-)YK>:*=3(ZRQK+*P$B&2+=L)^W** /SP\>>+-._X17QN+W0K+X=WNO\
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MDFK-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E/[6/_)K/QD_[$S6?_2&:O5J\I_:
MQ_Y-9^,G_8F:S_Z0S4 '[)W_ ":S\&_^Q,T;_P!(8:]6KRG]D[_DUGX-_P#8
MF:-_Z0PUZM0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG)XKNDN?&_Q$\-6/A+4-<.I>,O!<^@M97]JJLD!F^PVD3Q3JS8 1G0Q'YF#
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M_P!#+_Y(77_QJC_AJ+X9?]#+_P"2%U_\:KU6B@#RK_AJ+X9?]#+_ .2%U_\
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M (:B^&7_ $,O_DA=?_&J/^&HOAE_T,O_ )(77_QJO5:* /*O^&HOAE_T,O\
MY(77_P :H_X:B^&7_0R_^2%U_P#&J]5HH \J_P"&HOAE_P!#+_Y(77_QJC_A
MJ+X9?]#+_P"2%U_\:KU6B@#RK_AJ+X9?]#+_ .2%U_\ &J/^&HOAE_T,O_DA
M=?\ QJO5:* /*O\ AJ+X9?\ 0R_^2%U_\:H_X:B^&7_0R_\ DA=?_&J]5HH
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M:KU6B@#RK_AJ+X9?]#+_ .2%U_\ &J/^&HOAE_T,O_DA=?\ QJO5:* /*O\
MAJ+X9?\ 0R_^2%U_\:H_X:B^&7_0R_\ DA=?_&J]5HH \J_X:B^&7_0R_P#D
MA=?_ !JC_AJ+X9?]#+_Y(77_ ,:KU6B@#RK_ (:B^&7_ $,O_DA=?_&J/^&H
MOAE_T,O_ )(77_QJO5:* /*O^&HOAE_T,O\ Y(77_P :H_X:B^&7_0R_^2%U
M_P#&J]5HH \J_P"&HOAE_P!#+_Y(77_QJC_AJ+X9?]#+_P"2%U_\:KU6B@#R
MK_AJ+X9?]#+_ .2%U_\ &J/^&HOAE_T,O_DA=?\ QJO5:* /*O\ AJ+X9?\
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M&HOAE_T,O_DA=?\ QJO5:* /*O\ AJ+X9?\ 0R_^2%U_\:H_X:B^&7_0R_\
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M:]6KRG]D[_DUGX-_]B9HW_I##7JU !1110 4444 %%%% 'S_ /LH_P#(Q?M
M_P#93+W_ --VG5] 5\__ +*/_(Q?M _]E,O?_3=IU?0% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1124 +1110 4444 %%%% !1110 5Y5_P W3?\
M<F?^WU>JUY5_S=-_W)G_ +?4 >JUY3^UC_R:S\9/^Q,UG_TAFKU:O*?VL?\
MDUGXR?\ 8F:S_P"D,U !^R=_R:S\&_\ L3-&_P#2&&O5J\I_9._Y-9^#?_8F
M:-_Z0PUZM0 4444 %%%% !1110!\_P#[*/\ R,7[0/\ V4R]_P#3=IU?0%?/
M_P"RC_R,7[0/_93+W_TW:=7T!0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 E)
MNYQD9H;.#ZXK\W/BI\5/&MC\3O%MO;^+=<MK>#5[N&*&'4IDC1%F<*JJ&P
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M0!\__LH_\C%^T#_V4R]_]-VG5] 5\_\ [*/_ ",7[0/_ &4R]_\ 3=IU?0%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_#<>(?_ )!H_P"&EO"7_0'^('_AN/$/_P @T >K45Y3_P -+>$O^@/\0/\
MPW'B'_Y!H_X:6\)?] ?X@?\ AN/$/_R#0!ZM17E/_#2WA+_H#_$#_P -QXA_
M^0:/^&EO"7_0'^('_AN/$/\ \@T >K45Y3_PTMX2_P"@/\0/_#<>(?\ Y!H_
MX:6\)?\ 0'^('_AN/$/_ ,@T >K45Y3_ ,-+>$O^@/\ $#_PW'B'_P"0:/\
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M/\0/_#<>(?\ Y!H_X:6\)?\ 0'^('_AN/$/_ ,@T >K45Y3_ ,-+>$O^@/\
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M/_R#0!ZM17E/_#2WA+_H#_$#_P -QXA_^0:/^&EO"7_0'^('_AN/$/\ \@T
M>K45Y3_PTMX2_P"@/\0/_#<>(?\ Y!H_X:6\)?\ 0'^('_AN/$/_ ,@T >K4
M5Y3_ ,-+>$O^@/\ $#_PW'B'_P"0:/\ AI;PE_T!_B!_X;CQ#_\ (- 'JU%>
M4_\ #2WA+_H#_$#_ ,-QXA_^0:/^&EO"7_0'^('_ (;CQ#_\@T >K45Y3_PT
MMX2_Z _Q _\ #<>(?_D&C_AI;PE_T!_B!_X;CQ#_ /(- 'JU%>4_\-+>$O\
MH#_$#_PW'B'_ .0:/^&EO"7_ $!_B!_X;CQ#_P#(- 'JU%>4_P##2WA+_H#_
M ! _\-QXA_\ D&C_ (:6\)?] ?X@?^&X\0__ "#0!ZM17E/_  TMX2_Z _Q
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MQ\^IW7PV\0;E/<1+]A(C'TR>>2:XO:5*VE+1=_\ (^CC@\+EJY\<^:?2"?\
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MB_:!_P"RF7O_ *;M.KZ KY__ &4?^1B_:!_[*9>_^F[3J^@* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*2B@!
MN:AN+F*SA>::188D!9I)"%50.223T%<'\5/CAX8^$MCYFKW@EOY%W0:=;X::
M3WQ_"O\ M-@<'&3Q7S0]S\4/VNM0*0C_ (1OP4KX/+" X/<\&=QZ<*"!]WK7
M-4KJ+Y(J\NQ[.$RR>(C[:J^2FMY/]%U9WGQ8_:\AAO#X>^'=M_;VLS-Y*WR1
MF2)7/&(D',K>_P!WI]ZLGX=?LIZQXSU7_A*/BIJ%Q>7DQ$@TWS=SL.PE<?=
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M_P#3=IU?0%?/_P"RC_R,7[0/_93+W_TW:=7T!0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCJ^-ES5I7MLNB]$+2T45L< 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7E7_-TW_<F?^WU>JUY5_S=-_W)G_M]0!ZK7E/[6/\ R:S\9/\ L3-9
M_P#2&:O5J\I_:Q_Y-9^,G_8F:S_Z0S4 '[)W_)K/P;_[$S1O_2&&O5J\I_9.
M_P"36?@W_P!B9HW_ *0PUZM0 4444 %%%% !1110!\__ +*/_(Q?M _]E,O?
M_3=IU?0%?/\ ^RC_ ,C%^T#_ -E,O?\ TW:=7T!0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 444F>] #>>E9?B#Q)IGA739M0U:^ATZ
MQA&7GN'"*/;)ZD]@.37E7QD_:?\ #7PM2:PMF&N>(5ROV&WD&V%O^FK\[?\
M=&6]AUKQ?0/A/\1?VF]5M]?\<W\VC>&\[X+=5V$H>T,1^Z"/^6CY)&#\U<<Z
M]GR4U=_UN>[ALK<H?6,5+DI]WN_1=34\>?M/>)_BEK#>%?A5IUR3+E6U'R\3
M.O0LH/$*?[;<\C[IKK?A#^R%IOA^X36_&TR^(]=D;S3;2$O;QN3DEMW,K>[<
M=>#UKV?P'\.?#_PUTA=-\/Z='9P\&1P,R3-_>=SRQ^O3M@5U-$:',^>J[O\
M!&E?-(TX/#X"/)#J_M2]7T]$)'&L:A54*JC  & !Z5)1178?/!1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* #BDZ=::2, ]J\
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M?%/P9;;TT+PIXLDL-'MSG9:6DEG:W*V\9).$C>XD55'")L4   #U/QAXTL/
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M/_#2WA+_ * _Q _\-QXA_P#D&C_AI;PE_P! ?X@?^&X\0_\ R#7JU% 'E/\
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M ,-+>$O^@/\ $#_PW'B'_P"0:/\ AI;PE_T!_B!_X;CQ#_\ (->K44 >4_\
M#2WA+_H#_$#_ ,-QXA_^0:/^&EO"7_0'^('_ (;CQ#_\@UZM10!Y3_PTMX2_
MZ _Q _\ #<>(?_D&C_AI;PE_T!_B!_X;CQ#_ /(->K44 >4_\-+>$O\ H#_$
M#_PW'B'_ .0:/^&EO"7_ $!_B!_X;CQ#_P#(->K44 >4_P##2WA+_H#_ ! _
M\-QXA_\ D&C_ (:6\)?] ?X@?^&X\0__ "#7JU% 'E/_  TMX2_Z _Q _P##
M<>(?_D&C_AI;PE_T!_B!_P"&X\0__(->K44 >4_\-+>$O^@/\0/_  W'B'_Y
M!H_X:6\)?] ?X@?^&X\0_P#R#7JU% 'E/_#2WA+_ * _Q _\-QXA_P#D&C_A
MI;PE_P! ?X@?^&X\0_\ R#7JU% 'E/\ PTMX2_Z _P 0/_#<>(?_ )!H_P"&
MEO"7_0'^('_AN/$/_P @UZM10!Y3_P -+>$O^@/\0/\ PW'B'_Y!H_X:6\)?
M] ?X@?\ AN/$/_R#7JU% 'E/_#2WA+_H#_$#_P -QXA_^0:/^&EO"7_0'^('
M_AN/$/\ \@UZM10!Y3_PTMX2_P"@/\0/_#<>(?\ Y!H_X:6\)?\ 0'^('_AN
M/$/_ ,@UZM10!Y3_ ,-+>$O^@/\ $#_PW'B'_P"0:/\ AI;PE_T!_B!_X;CQ
M#_\ (->K44 >4_\ #2WA+_H#_$#_ ,-QXA_^0:/^&EO"7_0'^('_ (;CQ#_\
M@UZM10!Y3_PTMX2_Z _Q _\ #<>(?_D&C_AI;PE_T!_B!_X;CQ#_ /(->K44
M >4_\-+>$O\ H#_$#_PW'B'_ .0:/^&EO"7_ $!_B!_X;CQ#_P#(->K44 >4
M_P##2WA+_H#_ ! _\-QXA_\ D&C_ (:6\)?] ?X@?^&X\0__ "#7JU% 'E/_
M  TMX2_Z _Q _P##<>(?_D&C_AI;PE_T!_B!_P"&X\0__(->K44 >4_\-+>$
MO^@/\0/_  W'B'_Y!H_X:6\)?] ?X@?^&X\0_P#R#7JU% 'E/_#2WA+_ * _
MQ _\-QXA_P#D&C_AI;PE_P! ?X@?^&X\0_\ R#7JU% 'E/\ PTMX2_Z _P 0
M/_#<>(?_ )!H_P"&EO"7_0'^('_AN/$/_P @UZM44DJ0QEW8(JC)9C@ >IH
M\M_X:4\)?] CQ_\ ^&Y\0_\ R#6;JG[6OP^T/RUU#_A*=,EF5C"NJ^#=8L%E
M*C)59+BUC3/U8=:Y+XN?M?:?HMP^A>!(5\1:Y(WDBZC4R01N> $"\RMZ8^7I
MR>E<OX!_9=\1_$G5QXJ^*VHW+O*0XTWS/WK+U"N1Q$O^PG//\)KCE7<GR4E=
M_@CZ&CE<:=-8C'RY(=%]J7HNGJSBOB=^T-XW^,K2V/AO2=<TWPBTPMYI='TB
M]U";!!YG-I%*ZJ1_ JX[$M7;_!RU^%GPK6&]FT7Q]K7B%>?M]Q\-O$&V,_\
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M ,@UZM10!Y3_ ,-+>$O^@/\ $#_PW'B'_P"0:/\ AI;PE_T!_B!_X;CQ#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^D,->K4 %%%% !1110 4444 ?/\ ^RC_ ,C%^T#_ -E,O?\ TW:=7T!7S_\
MLH_\C%^T#_V4R]_]-VG5] 4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGMMVM,J;I7'HTC98_B:ZRD_6MJ=&%/X5J>=BLRQ6+TJS?+V6B^Y#J6BBMSS
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MG_A<GB[_ *(3\0/_  .\/?\ RUH_X7)XN_Z(3\0/_ [P]_\ +6@#U:BO*?\
MA<GB[_HA/Q _\#O#W_RUH_X7)XN_Z(3\0/\ P.\/?_+6@#U:BO*?^%R>+O\
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MQ _\#O#W_P M: /5J*\I_P"%R>+O^B$_$#_P.\/?_+6C_A<GB[_HA/Q _P#
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MA[_Y:T?\+D\7?]$)^('_ ('>'O\ Y:T >K45Y3_PN3Q=_P!$)^('_@=X>_\
MEK1_PN3Q=_T0GX@?^!WA[_Y:T >K45Y3_P +D\7?]$)^('_@=X>_^6M'_"Y/
M%W_1"?B!_P"!WA[_ .6M 'JU%>4_\+D\7?\ 1"?B!_X'>'O_ ):T?\+D\7?]
M$)^('_@=X>_^6M 'JU%>4_\ "Y/%W_1"?B!_X'>'O_EK1_PN3Q=_T0GX@?\
M@=X>_P#EK0!ZM17E/_"Y/%W_ $0GX@?^!WA[_P"6M'_"Y/%W_1"?B!_X'>'O
M_EK0!ZM17E/_  N3Q=_T0GX@?^!WA[_Y:T?\+D\7?]$)^('_ ('>'O\ Y:T
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M,NIEC!/H,GD^PYKXL\!?%[XT>-/"MCX=\*6EU?2P!UFUR93-*Y+LWSS2G8N
MP4?Q87K7:^'/V-=:\57PU7XB^*[B\N6^_!:RM-(>^#-(./H%(]#5+$.HOW4&
M_71&,\GI823^O5U%+HM9/Y=+^9O>./VW/#^FLUGX4TRY\17C'8DT@,$!8\#
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M2XJ3_AL'X8?]!JX_\ )O_B:/JM?^1_<+DEV/:?PH_"O%O^&P/AA_T&KC_P
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MPM/V=.]O,N,5%60M%%%=A04444 %%%% !1110 5Y5_S=-_W)G_M]7JM>5?\
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M_P!:C+X(M_(]7^Q*E/7%5(T_5Z_<CZJ\1>./#WA*/S-:UO3]+7&0+JX2,GZ
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M4/E65I!:1_W((E0?D!5VDS[UZ-/#4:/\."7HBE%+9"TM%%=10E+110 4444
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MJHRC-7B[H52G.C+EJ)I]FK#J*3-&X>HJC,6BF[U_O#\ZCDN(HD9GD1%7J6;
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MA>-]*\56=UXGU:;6M$02>?8PVEM$\A,;!,,J*1A]I//0'KTJ;XD?LA^,-/\
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M'^!/!NQM+\+Z?%+']V>:+SY1]'DW,/P-=R%'8 4>VP]/X*=_5_H'-!;(^/\
M_A1/QO\ B5\WBWQ=_9=K)_K+5[LMU_Z8P_NS^8KKO#'[#?A33=DFM:MJ.M2K
MUCCVVT3?4#<WY-7TE2GZU,L;5:M%\J\E87M)=-#B?"_P7\#^#=C:3X7TZ"5/
MNSR0^=,/^VC[F_6NWQBCZTM<<I2F[R=S-MO<****0@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *2EHH ADA2XC:.1%=&&&5AD$>A%<)XB^ _@#Q3N.H>%--,C?>EMXO
ML\A]RT>TD_C7H-)51G*+O%V&FT?-OB3]AOP=J6Y](U/5-'D/1&99XA^! ;_Q
MZN0_X9<^*G@/YO!_C@2P)TA6YFM"WMY?S(?Q-?8&*6NN.,K)6;NO,T521\>M
M\2OVB/AUQK/AYM=@CZR-9+<#;Z[[8C'U;\:U-$_;JMX9C;^)/"=W92H<2-93
M!V_[]R!<?]]5]6_E65K?A31?$T/E:OI-CJD>,!;RV24#Z;@:OZQ2G_$IKY:#
MYXO='FWAW]JSX:^(=B_V]_9LS?\ ++4('BQ]6P4_\>KTW1_$>E>(H//TK4[/
M4X?^>EG<)*OYJ37EGB3]DGX;>(M[1Z/)I$[=9=.G:/'T1MR#_OFO,]:_88^Q
MW'VKPQXPN+.9.46]A^8?]M8RN/\ OFCDPM3X9N/JK_D%H/9V/K 48KX_;P/^
MT=\._P#D&:V_B&V3G"W:77R^FVX ;\%J2W_:I^)W@V9+?Q=X!:3'&\6\UH[^
M^XAU/X#%1+"V5XSBUZ_YB]GV=SZ]H^E>&^$_VK-$UX(NHZ!K6B2'[S31(\0_
M$,&_\=K;U#]HSPS:DBVAOKT]FCB"+^;,#^E>)6QF&H.U2HD_6_Y&$I*.[/5_
MPI.:\*E_:,U'4G,6C^&6ED[%I&E)_P" JH_G3/\ A+/BWXA_X\](_LX'I_HR
MQ?\ HXFN'^UL.]*:E+T3)]HNFI[QFJMYJ5KI\>^ZN8;=/[TKA1^IKQ#_ (5Q
M\3-?P=1\0_9$;[T?VMQ_X[&-I_.I%_9O?R9KF]UJ:_N A80P1!6=@.%WNQZ]
M,D5/U[%37[K#OYM+\!<\ND2[\1OC5%I'B31XM&O([RRMW\Z\:V<.LJGC8"#C
M@9/U*^E6-5_:1T2UR+&PO+Y^QDVQ(?QY/Z5Y:?@?XUR<:)Q_U]0?_%U['\&O
M!EWH&CR0:YH%M9WT,O[JZQ#))(AYP64DY!SU[$>E>-A:^9XBO*+3@I:W:;2M
MT5S.,JDGV.5_X6WX^\3\:'X<\F%NDRP/+C_@;87]*;_P@_Q1\5<ZIK1T^,_>
MC-QLR/\ =A&#]#7O>T#H**]K^S95'^_K2EY7LON1KR7W9XIIG[--IN+ZIK5Q
M<N>2+>,1\_[S;L_E79Z3\%_".DE672H[F0?Q7;-*#_P$G;^E=S^-%=-/+<)2
M^&FOGK^8*G%="M9:=:Z=#Y5M;0VT?]R&,(/R%6:6BO2C%15D:!1115 %%%%
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M^U-8R*%87:(/732&]B3AC3^J+I4C]X>S_O(]D_X23XW_ /1/?A__ .%W??\
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MX?\ 1//A_P#^%Y??_*:O5J* /*?^$C^.'_1//A__ .%Y??\ RFH_X2/XX?\
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M]YKR+_?M_P# FKT7QT\&2==5:,YQ\]M+_1:WCF&$EM47WE<T>YE?\)%\;_\
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M#_\ \+R^_P#E-7JN1ZU5N]1M=/CWW5S#;I_>ED"#]34.48J[ \T_X2+XW_\
M1//A_P#^%Y??_*:C_A)/C?\ ]$]^'_\ X7=]_P#*:NFU#XL>$M+SYVNVK_\
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M?_*:O&?^&3OB=9_+9?$8JC<M_I=U'S]!FFG]F_XX6_[NU^)6(%^Z/[;OD^O
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MD/[>UQ;YCN/ FV=>&!U4I^A@.*/J&(Z1_%?YA[*?8]G_ .$C^.'_ $3WX?\
M_A>7W_RFH_X2/XX?]$]^'_\ X7E]_P#*:O)8_P!O:PR/,\'W*CC=MOE./7'[
ML9J]!^WAX=:0"7PUJB1]V22-C^1(_G2^HXC^7\@]G/L>F?\ "2?'#_HGGP__
M /"\OO\ Y34G_"2?&_\ Z)[\/_\ PO+[_P"4U<##^W9X+;/G:'KR>GEQ0-_.
M45=M_P!N+P#,A9[+7(.<;9+:(GZ_+*:CZG77V&+V<NQV7_"2?&__ *)Y\/\
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MX?\ _A>7W_RFH_X2/XX?]$\^'_\ X7E]_P#*:O5J* /*?^$C^.'_ $3SX?\
M_A>7W_RFKG?!=]XJOOVCY7\7:/H^AZD/"A6.WT35I=2A:+[8N',DEK;D-N+C
M;L(  .XY('O%>5?\W3?]R9_[?4 >JUY3^UC_ ,FL_&3_ +$S6?\ TAFKU:O*
M?VL?^36?C)_V)FL_^D,U !^R=_R:S\&_^Q,T;_TAAKU:O*?V3O\ DUGX-_\
M8F:-_P"D,->K4 %%%% !1110 4444 ?/_P"RC_R,7[0/_93+W_TW:=7T!7S_
M /LH_P#(Q?M _P#93+W_ --VG5] 4 %%%% !1110 4444 %%%% "44M% !11
M10 4444 %%%% $<D:R*590P/4$9%86H^ _#NIY-UHEC*Q_B^SJ&_[Z S704V
ML9TH5%[T4_45D]SSN^^ GA"^7]W9363>L$[?R8L*YK4/V9;!\FPUNYMSV^T1
M++^H*U[92?C7!4RO!U-Z:^6GY$.G%]#P4_!_Q[H?_((\3[XEZ1_:I8L^GRX*
M_F:/MGQ@\/\ ^LA.HQ+T^2&7./\ =PWYU[SCWH_6N?\ LJ$?X524?1_YAR=F
M>#CX[^*M$_Y#7A;:HZGRY;?_ -"#5JV/[2NC3*!>:5>VS'KY)20#\RO\J]CP
M/05CZAX1T35B3>:197+?WI+=&/YXS2^JXVG_  Z]_)I?F+EDMF<WI_QO\':A
M@?VI]G<_PW$+K^N,?K72Z?XLT75L"RU>QNC_ '8KA&/Y US.H? [P?J&3_9?
MV9S_ !6\SK^F<?I7,:A^S3H\H)L]5O+9NWG*D@'Y!?YT>TS*G\4(R]';\PO-
M=+GL>?<45X3_ ,**\6:)_P @7Q3@+]T>9+;_ **6%-^Q_&'0.$E.HPKU^:&7
M/_?6&I_VC6I_Q:$EZ:_D'.^J/>?UH_"O!A\8O'>A_P#(7\,%HUX,GV:6+/\
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M2@&!Q:G\>,&O=:7-+^RH_9JS7S%R>;/"?^$P^+5CGS=$$^./^/8-^/R-2?\
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MHH IW&G6UY-;23VT,\EM)YD+R1AFB;:5W*3]TX)&1V)%7*** "BBB@ HHHH
M**** $HI:* $P/2C:/2EHH 3:/2C:/2EHH SY-#T^9662QMG5AA@T*D'Z\51
MF\#^'+F,I+H.F2)_=>SC(_5:W<T<4^:7<=V<G<_"GP7=8$_A#0I@O3S--A;'
MYK5.;X(_#^X8,_@O0AQCY-/B7^2BNXVT8I^TFMI,?,^YYU)^SS\.)I"[>#]-
M!//RQE1^0.*SY?V7?A?(C*?"EN PP=MQ.I_ A^*]5YHQ6GMZRVF_O8<S[GCD
MO[)'PLECVKX;>(_WEO[DG]9"*IW'[&_PTFQLTV\@Q_SSOI#G_OHFO;^:,U7U
MJLOMO[Q\\NYX#/\ L4_#N9MRG5H1C&U+L$?7E#7FGQB_8Q30O#[:IX'EU#4;
MB EI]-NF621T]8MJJ21_=.2>W/!^R:3Z5K#&UX24N:_J4JDUU/ ?V:_V<8OA
MC:Q:_KB+/XIN(\*N<K9(PY0'NY'#-^ XR3[_ -:.M%<U:K*M-SF]2)2<G=BT
M445F2%%%% !1110 4444 %>5?\W3?]R9_P"WU>JUY5_S=-_W)G_M]0!ZK7E/
M[6/_ ":S\9/^Q,UG_P!(9J]6KRG]K'_DUGXR?]B9K/\ Z0S4 '[)W_)K/P;_
M .Q,T;_TAAKU:O*?V3O^36?@W_V)FC?^D,->K4 %%%% !1110 4444 ?/_[*
M/_(Q?M _]E,O?_3=IU?0%?/_ .RC_P C%^T#_P!E,O?_ $W:=7T!0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E
M+10 4444 )@>E9VH>']-U9<7VG6MW_U\0+)_,5I4E9RA&2M)7 XC4/@UX/U+
M+/HT4+>MN[Q8_!2!^E<U??LVZ!< M:WU]:-V!974?@5!_6O6Z7(KAGE^$J?%
M37Y?D0X1?0^3OB-X';X:S6]E#KDEVUVK.UNB&+:F< L-Q!SR/^ FJ?P_TO4?
M&&HIH4&O3:;&4:2.(R.48CE@%!QG&3^!KZ0\0?"_PUXGU)K_ %/3FN;IU"F0
MW,J\ 8  5@!^ J#2_A%X3T74+>^LM+:&ZMV#QNMS,<$>Q?!^AKYJ61U?K//%
MI4[[7=[&'L7S76QP=I^S+;[MU[K\T[$Y;R8 A_,L?>MZS_9V\+6O^M>^NSW\
MV8 ?^.J*]1%+7OPRK!PVIKYW?YFRIQ70XNR^#_@^PP8]#@<C_GLSR_\ H1-;
M]EX7T;3<?9-)LK;_ *XVZ+_(5J_A25W0PU&G\$$ODB^5=$+M'H**6BNFR&%%
M%%, I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J
M*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J
M*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J
M*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ /5J*\I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M /5J\J_YNF_[DS_V^I/^$C^.'_1//A__ .%Y??\ RFKG?!=]XJOOVCY7\7:/
MH^AZD/"A6.WT35I=2A:+[8N',DEK;D-N+C;L(  .XY( ![Q7E/[6/_)K/QD_
M[$S6?_2&:O5J\I_:Q_Y-9^,G_8F:S_Z0S4 '[)W_ ":S\&_^Q,T;_P!(8:]6
MKRG]D[_DUGX-_P#8F:-_Z0PUZM0 5Y!\2/V6/AY\4_%":_K6F7L.H2$?;_[*
MU2YL8]4002P*EVD,BK.!',ZY8;MOR;O++(WK]% ' ^*/@GX1\62:9)/97NDS
M:9;?8;2X\.ZM>:--';<8M_,LY8F,0*J1&25! ( -.\0?!?P=XF\-:3H-UI#6
MNGZ/,+C36TJ[GT^XLI0&4O#<6[I+&S!W#%7!8.P;.XY[RB@#GO!?@O1?A[X=
MM=#\/V"V&G0%G$>]Y'=W8L\DDCDO)([%F:1R69F)8DDFNAHHH ^?_P!E'_D8
MOV@?^RF7O_INTZOH"OG_ /91_P"1B_:!_P"RF7O_ *;M.KZ H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRK_FZ;
M_N3/_;ZO5:\J_P";IO\ N3/_ &^H ]5KRG]K'_DUGXR?]B9K/_I#-7JU>4_M
M8_\ )K/QD_[$S6?_ $AFH /V3O\ DUGX-_\ 8F:-_P"D,->K5Y3^R=_R:S\&
M_P#L3-&_](8:]6H **** "BBB@ HHHH ^?\ ]E'_ )&+]H'_ +*9>_\ INTZ
MOH"OG_\ 91_Y&+]H'_LIE[_Z;M.KZ H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&MW+&\T=N7 D=$*AV"]2%+H">@+KGJ* +=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 454N+ZWM;BUBFN(X9;F0Q0)(X5I7
M",Y5 ?O':CM@<X5CT!JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%5+Z^M]+L[F\N[B.TM+>-IIKB9PD<:*"69F/   ))/
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M_P#AO$_^3Z/^%5_M#?\ 1??#_P#X;Q/_ )/KZ HH ^?_ /A5?[0W_1??#_\
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M_P#X57^T-_T7WP__ .&\3_Y/H_X57^T-_P!%]\/_ /AO$_\ D^OH"B@#Y_\
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MZ?>:9;L/A^H00W,EM)*"OV[D[K.'![8/K7TY10!\_P#_  JO]H;_ *+[X?\
M_#>)_P#)]'_"J_VAO^B^^'__  WB?_)]?0%% 'S_ /\ "J_VAO\ HOOA_P#\
M-XG_ ,GT?\*K_:&_Z+[X?_\ #>)_\GU] 44 ?/\ _P *K_:&_P"B^^'_ /PW
MB?\ R?1_PJO]H;_HOOA__P -XG_R?7T!10!\_P#_  JO]H;_ *+[X?\ _#>)
M_P#)]'_"J_VAO^B^^'__  WB?_)]?0%% 'S_ /\ "J_VAO\ HOOA_P#\-XG_
M ,GT?\*K_:&_Z+[X?_\ #>)_\GU] 44 ?/\ _P *K_:&_P"B^^'_ /PWB?\
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MU4"9K6XM26'V[YAY5U+QZD'M6Y_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\
MPJO]H;_HOOA__P -XG_R?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]
MH;_HOOA__P -XG_R?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_H
MOOA__P -XG_R?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA_
M_P -XG_R?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -
MXG_R?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R
M?1_PJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R?1_P
MJO\ :&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R?1_PJO\
M:&_Z+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R?1_PJO\ :&_Z
M+[X?_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R?1_PJO\ :&_Z+[X?
M_P##>)_\GU] 44 ?/_\ PJO]H;_HOOA__P -XG_R?6'XX_9\^.GQ \%Z_P"%
MM7^/6AOI6MZ?<:9>+#X 5',,T;1R!6^W<':QP>U?3E% 'S__ ,*K_:&_Z+[X
M?_\ #>)_\GT?\*K_ &AO^B^^'_\ PWB?_)]?0%% 'S__ ,*K_:&_Z+[X?_\
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M=GHGQ8^&H^)WAW2=+74/[*%AKFF:R)!!YN_['=Q7/E8W+C?Y6W=GY<YP<8H
M\*^)C:G\5_VEO$?@R3X?Z'\1=&\-^'M.NXM+\77BP:/#<7,MSYD[#[/<LUR5
MBC2,B$A4%QETW 2>I_LO7>E3?!G1[71IM8:TTNXO-+>UUZZ2YN[&6"YEBDM6
ME4 .D3*8XSU,:QDDU>\8?"_7)/'4OC3P1X@T_P .>([RPBTO4?[8TF34K.[M
MXGDDA)BCN+=EE1I9 '\PC;(P*GY2N]\+?AW:?"[P=!H-M=3:A)]HN+VZOK@
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MJ[E;W7]H30_AU;?"O5/&OC[P/X?\9Q^&=)FN[:/6]+@O'SL!$41E1MID=47
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M-%$"QD"A4 51EB0#UBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_#C^(?_ ).H ]6HKRG_ (9I\)?]!CX@?^''\0__ "=1_P ,T^$O^@Q\0/\
MPX_B'_Y.H ]6HKRG_AFGPE_T&/B!_P"''\0__)U'_#-/A+_H,?$#_P ./XA_
M^3J /5J*\I_X9I\)?]!CX@?^''\0_P#R=1_PS3X2_P"@Q\0/_#C^(?\ Y.H
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M(?\ Y.H ]6HKRG_AFGPE_P!!CX@?^''\0_\ R=1_PS3X2_Z#'Q _\./XA_\
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M/XA_^3J /5J*\I_X9I\)?]!CX@?^''\0_P#R=1_PS3X2_P"@Q\0/_#C^(?\
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M('_AQ_$/_P G4?\ #-/A+_H,?$#_ ,./XA_^3J /5J*\I_X9I\)?]!CX@?\
MAQ_$/_R=1_PS3X2_Z#'Q _\ #C^(?_DZ@#U:BO*?^&:?"7_08^('_AQ_$/\
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M'Q _\./XA_\ DZ@#U:BO*?\ AFGPE_T&/B!_X<?Q#_\ )U'_  S3X2_Z#'Q
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M"7_08^('_AQ_$/\ \G4?\,T^$O\ H,?$#_PX_B'_ .3J /5J*\I_X9I\)?\
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M\F5(8 U?"O[1/BKX]:UH>G?#--%\.PW'A.Q\5ZAJ?B2TEU$1?;#(L%G'!#/
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MJO?#5[K&O:%=:IH7B#2-(N+>V@GMVC2:&XM)+N1Y /.B=729-PW*0A 8]?\
M$+X,V/Q'^$Z>"+_4KJS\B.T:VU2Q"I/;7-L\<D%P@;<,K)$K;3D'D5C>#_@O
MKB_$VW\?>._%5GXI\0V&E2:/ID6D:0VEV=K#*Z//(8WN)W>9S'&"WF!0JX"
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MN&U&YCN8%2)VM8%=K,,8BRB8KY0,8E96S0![IX-^(^L>-/C-XYT.TBL3X/\
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M<X!)QZGK5JJ>GQ7<-C:I?3QW5ZL2K//!$8HY) !N94+,5!.2%+-C.,GK5R@
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MX?\ _A>7W_RFH_X2/XX?]$\^'_\ X7E]_P#*:O5J* /*?^$C^.'_ $3SX?\
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M'_\ X7E]_P#*:O5J* /*?^$C^.'_ $3SX?\ _A>7W_RFH_X2/XX?]$\^'_\
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MX?\ _A>7W_RFH_X2/XX?]$\^'_\ X7E]_P#*:O5J* /*?^$C^.'_ $3SX?\
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M'_\ X7E]_P#*:O5J* /*?^$C^.'_ $3SX?\ _A>7W_RFH_X2/XX?]$\^'_\
MX7E]_P#*:O5J* /*?^$C^-__ $3SX?\ _A>7W_RFH_X2/XW_ /1//A__ .%Y
M??\ RFKU:B@#RG_A(OC?_P!$\^'_ /X7E]_\IJ/^$C^.'_1//A__ .%Y??\
MRFKU:B@#RG_A(_C?_P!$\^'_ /X7E]_\IJ/^$C^-_P#T3SX?_P#A>7W_ ,IJ
M]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH
M \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH
M \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\
M1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A
M_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^
M%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??
M_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C
M_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_
MCA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T
M3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?
M_P#A>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A
M>7W_ ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_
M ,IJ]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ
M]6HH \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH
M \I_X2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_
MX2/XX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/X
MX?\ 1//A_P#^%Y??_*:C_A(_CA_T3SX?_P#A>7W_ ,IJ]6HH \I_X2/XX?\
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M/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\
MX?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?
M!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H
M5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!
M_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""
MZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^
M3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^
M'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P
M0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%
M;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?
M^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ
M_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#D
MR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#]
M **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_
M/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\
MX?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?
M!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H
M5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!
M_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""
MZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^
M3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^
M'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P
M0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%
M;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?
M^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ
M_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#D
MR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#]
M **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_
M/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\
MX?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?
M!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H
M5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!
M_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""
MZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^
M3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^
M'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P
M0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%
M;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?
M^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ
M_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#D
MR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#]
M **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_
M/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\
MX?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?
M!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H
M5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!
M_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""
MZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^
M3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^
M'U7P0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P
M0_Z%;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%
M;X@?^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?
M^"ZQ_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ
M_P#DR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#D
MR@#] **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#]
M **_/_\ X?5?!#_H5OB!_P""ZQ_^3*/^'U7P0_Z%;X@?^"ZQ_P#DR@#] *\I
M_:Q_Y-9^,G_8F:S_ .D,U?*O_#ZKX(?]"M\0/_!=8_\ R97%_&C_ (*W?!_X
MG?!WQWX.TKPYXWM]4\0Z#?Z1:S7EC9K"DT]O)$C2%;MB%#."2%)QG /2@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>lgnd-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgnd="http://www.ligand.com/20201231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgnd-20201231.xsd" xlink:type="simple"/>
    <context id="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5ad18ea90a54b5b8bba0e1555ad9875_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idd5c9735b7574d1eb48ed78ec5db3eb5_I20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7153cd81712409ba213861c38901324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98d16dd704b74221b973893e02cd3023_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec0387ebb91c44aaa14fe5f411316aab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0863c3664c064309a61c97efd34cc22b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74270c6229d54e75bedc1e83d6c7f2d7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i824ae14f7d55450f96a50e45e1e00275_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fe8f99853d84177abbd1d204189cdc9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i076d26d185984399b35b035b9c392324_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icd387f8ff7744137980599559a1c5f77_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i346897ea83804fdd8c657865b763ef87_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib59bfab0480542cda230d78e7ef5e82e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i911fa320b1ef4643bd62d2f1d873e78c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id001411ddc1a48f3be1dce3344a83372_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7054e445350945b5a3ac6b9a4827ce2a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie14c67e9b9e04b7093d188b4497bf574_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i63ee9751e8804e03bbd45e0f38940a0c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie3a7c5c2af724c429803e6c84d4842b6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib37bbc9e048046e88b85c63fa39515f5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id67458ea516e439bbc83b615b79b3518_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf82073fee7b42059c5ceb699522c8e2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iea39822ada3c494db6a1bf3fd99d48b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i111967c6372740459aedf8ec7bb0ce69_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6f450afb88d04c82a9ea8a0fe0f120af_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5d4b2e9889a945be999a04e9bcc088b7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i651d151d6b5945ae854d15dfa48f1c67_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59f3bec8971d4633aec80a74abc60a98_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41f9c1547a2345d6875efa9ab06fc528_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74ce61c0bc144472b7631a9d4df3f9f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5781b4d9f661461796c8363bed666193_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f4968cadd8f471d9ce10c3dac04adeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic556fe238be54d7ea1cbe97cfc3b66cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3886328178847949eca5c819b9d1a5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9438636ad1d45ac9d842c540b69c517_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f2a6466d039469193ef347cfe3c1115_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb83d5853ca34bfe8b02f1ad840f88e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d45dbab0ab74a33aec9e7b5fc42b546_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c73811c3a6b413583f19b4f18914422_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ec746f5f2a1420e8b4a73e3b14f2911_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54f2cab9b1344c4ca4467e441c736d9d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i05df3adf0d3445b08cd69ac5d9c78c78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f7c735f7f3a43aab5151e4131cffac0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie64ebeef7e4d4fce822fce49568cde02_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2dd5f6f2356147aaa9c76736d1bbfb27_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i002a7e38519e40f2946a2312278fcbbf_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="ia66f417c4e0546919bf13f281a215faa_I20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-06</instant>
        </period>
    </context>
    <context id="i5e2203c889594b6d90a943e1d333ba3a_I20100131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="i66b0dfc7fe6b439496e5480f51985a93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefcf79e0add14931bd42a44ad86cb894_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecf467e784d54b05975c3202c53c6bd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11a9f3d7057749e18b761924cf8ff3cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b989251dff94234ab86b62cbfd1d634_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f0edea451a947568476fa7759c97496_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="id68885846d2347bdbc1bf3e58a6664b7_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="id45ea6b88b7b4ce99056d77dfb9e072a_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="iba869b10f43242e5b6c4fdd407e85a06_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i39c93e649e774e64b8ccfd071af32e96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bfcf4342f7f486e81aa9acfe6e847f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cdf88f6a2da48ab9f7072c95808b688_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b43e6ec0024459cad6c7d3d2e8f6e3d_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8918e216e1f459c9ab0ac50491f1cf4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf035009648e4002a74fb15717a19c83_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i3bc3b17ca38f450f93f33b56115ecdac_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="iefbf54fee39c450eaef1dc95742c7f6a_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="id0f6f413f8494ec9b556f99a873dab70_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="idd2353e9253d4a1aa25a32912238e563_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i2d7158892fbf44ed81d8c9568292e404_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i569ef336eca149ea8ce1ab7ef2a48105_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib905672f26f34c6ca6ac51ce2c25db59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9eb8f7f86660458caf621f649275af47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida12bcf9ff53440e84c2633931d5fcca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i17a6bd9499ad4be8b30f8a074e5a4747_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib762c00218db440eabd64c06b5cbeb17_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05b26e3a5c35487591dbea42ea400987_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i12906a0a0841439f945d94aff020ae08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8e03c8cbe544fe2b60dd5184c74c3fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d572ef2b8494f9fa8c4e977a195c4f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifea7a020b78c4b429f74dae393a5908a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74da4f182fe445218f31adabb243815c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7cb20656a8d498d86e9974aeb28d3ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31dbb0c91f244d82be41bfabf480335e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i237f75928ac747deb799e5591927eeb2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic58de6fecf534ed0a1da850b2cff8a8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44536cfe5ccd4fd58d70bd6fa6a9bbe7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66c1d00145a84fc9849e6e8261b1e931_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i38a84b0ab35142d58562b6af8b4ed5a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9a2317a4d4b4c3e918e6cc04ab22e08_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic073f00141a744d8b9364ba86efafc46_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5e4954555f1f4c42a396f5d8999d8fa5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12c2c62904f340b6aa85bf2c884b4476_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b8da33f34df41008bfe20ee259d58b6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if7f17131fa164971b710daf95103fef2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd93f549e0fa415b9e51a92f0daf7bb7_D20070101-20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia580ec3f4bff42659168b12a15f67809_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4bc8d4c0ee94b9dba90c475ab5a47fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4236aad26ee440e0b4e5773018b84e4d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="ib0b6ced4e4e74197bd6f08f6e744dd49_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="ifea99838f3eb4029ace6787bc75b67d4_I20201201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="i55f09740f6734811b4be02fd7bc044ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01ab621af16c4274a42e8324d4de973e_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="id0bbacdd5fd54f5989b4a62974637a61_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="ie261b70fecc64fc3acc322f37f4fbb70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i389fb553398f4fb5809d534052c56744_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3839777e750f48b3970c5b559eed73b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3736760d3c7340649ea390cca0ce15fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic665f012e5c54711abae64ce09f53a48_D20180101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0213fb27da746f78658b704b667e575_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="id7ccafcd4382434aab44acf88304dbff_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i937655058f00466eb023f3a052a305a9_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3722684bf7fe44dd891c916f6dafc459_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="idc0825ac3f9e433dbbbf222c70233130_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsAlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i2bc05913ba57443492a26d3b59204160_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i90111327cda4413486d72b7e169d1885_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i203357e791ee4e05a98b8573e4a989e4_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i22ae29ffee0842cc89e6ee8c5f22ccd8_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsJazzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i4b0bc7404b304067a3243b8534e113e2_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="ica518070bfb04532a62ae6496bac0810_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsSIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i2e6809a505f14eb48603ff22d2339675_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="id0e4a9163e7b41fe9f7db2ee091c394e_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">lgnd:ContractualRelationshipsArcellxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ie1c5bd0218924d9ba52a0cf66da8376b_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i3e224ad1e1fc4df0a08700f496a00009_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i058f44a298dc4b5cba311ad359517ca8_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i386227a58a154f12b0c88d447866796f_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i9d3e28c670344068a7dccc625bd2d1a3_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="ib636b729155f4a749fd149d8b766cfd7_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightForInternalResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="ia074696e58a149c1995c46517312190b_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="ief985e0d5a6e476ca3e8f1deefd76040_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:ContingentValueRightOnProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="i8dc30f6eb26f47a0a96ce21282bdd8d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-09</instant>
        </period>
    </context>
    <context id="i1be13e965a8f4da5b69ebbcc4a009825_D20200909-20200909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:TaurusBiosciencesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-09</endDate>
        </period>
    </context>
    <context id="i68f1407f97f14a568173adad6da04c53_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="i145875c08ac643eb987fa42283dc0c10_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:EarnoutRightsForPartnerResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i7e76f65e64ab4ec5a35fb2b202c36fda_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i7e1fdefc6b2b422989b6e605a3d10f27_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">lgnd:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="ib48f53a633bb468199177a6ba86fca12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie15ddfad84344f9092e1706ff640ffc9_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="if7ed9c03cb994049a1d3a5de61dbd7e8_D20200908-20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:XCellaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="ie7604f5c2dda42bcadd9b8697034b298_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie23c947370d64bf7b1e94889103679fd_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="ieeed7ae64c0d4c0a83986dde7c9fa1d7_I20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="ic6329bfacc0e46999912decad0f41945_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i96dc5cd222804e959a28968aa702662d_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i91f10778634c436b8efd5b90ec1f5c3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff99e585e3164b03a575580fc0b45900_I20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="i3c19ea46b38444f6b60a4af0f07a64a5_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="iba9013bb387c441fb61e592bae9e466f_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i09c35816fc7c45c68db42cb9ad26c032_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b31bfa216b54d2e87051f21519216ee_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ida6c60fab2814867a46699ae1d38afb9_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i8c70e7e03138499ea135008f92ae636a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7b304285ad04468834c9942bcb940c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71e787593a0f4a95ae7e6faf6902fb14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c0b482524274e4f862807e22f04339d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5b897c6c62a4eb0b9c455c2a5e3c9c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2d7240c3b2641f7b93fefce9ba43997_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60c05d3e8a024a8480cfb6b10bc43054_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i066e6e259ad14a0083f5921dcfe54962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0128c7696ac747c0b7cb29daf26b7d23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib655d0debbde4feb93a3f225e8d31237_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8884ec54ac6436b9f6405038ca8d51e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i985674008c3e482dae7633f65d66191f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44c24d33a6514e0e90a361e94093f011_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i325849b89a604daf9659e7cd5fca620c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c8dc920224d41959a40fbf2fb518de0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63c7cd32e8b844f784308ca4fe584644_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i137c86d7cd6446daa9d2bb7abb2b4ec3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib66b0db35db44f8c8369e77da14013ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9b6c6ceb9d7450496a7b9d016f7dbbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1c8f26d622543f39f164698f8b83b7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81ab0ec6924f4304a39b0bf8f5001c7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a70d84e512248ac9fba2353f9f99a60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d1c28bffdd04f8392e2e09f40101997_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia485d5109cc4438e997246e17ebfc4ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8606ca98858540a5963136c5f3cd6569_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib98368e7d660497ca20cee33026379c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2fc9d0e319d49ed89ca0eebf9f35bff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5029c0e076064d15bcaaa31e3d8187fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87f8caf1622a41fa91f4942f87f67bde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ac63a2559a74326abe6d930f6accfb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b487fdb37824d4f9ef1a0400ee9dccf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d1dd4fca49c48fb9be8bec85e267e45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i033d9d285210428ca8efab5d8a1ee24d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i539792c492b3485dbdd59cf131d570cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5abb3f5f216147b0bc15b06e777edd38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id09c77184f6647d4bfadfba8681652ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyPfenexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d368fdfb8cc44779ec8d9c4b178bb55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic74f3ffda69b453e9607122edad77fdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i100d3ad1f1d043d7ba7a409ef38f47a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic92c7c3420a147f186540d32f570459b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bed8cb3b0ed4b978d1785374324f715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0af1caad2ec4bb3b5063b4f40c26520_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3faaf97bade2466badfff2a3a6a9a037_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9480b683b415427882bd5e8708c90123_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i044b313dd18245adafea8294b91bf524_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97080b1df6004dca997119afd07fb422_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbf5ad2f46ec4ee98ca750ce92cee1c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iceb7ec904b154a24ac4500272466e24c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b3b19e4b35e406ebcd52022bb02eda0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idce9786861db4e7cab91a951db9a86ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia21553bca1b1431b87f6ef73264c6a08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6055eb2a56ee4de58267511ac1b63e34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d83a1f143a24e3f875bf1146a570289_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i078cb5087cab4be7ba5189ff529510ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4a273d6b52d4ba48768b5519b0c3665_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b3bca9d1ae7450e90354484c1d5f005_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia57d66428a1f493aa864bbf8e827485c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c5cf083ca134bf79668ec12b74a240c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecfb0ea4403e4557afd920f82e95aaab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5202115d56d44835a5e19d2567442658_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13aae0d9ac5c46eda486f9147f718cc7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib35aa47334744f07856c9d53b543fcc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77b8c8ad9a5c4b95bcdd1ef1f93fd6cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i945a71f3ec5741968deafb92ba14c4d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic218f09432544a61968a84902b4b6b12_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ebb572aba124b47ac39a33fd2538183_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb5a9499dd5044ea8aea5a77be53c4ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifeb7330e33f14407916171e7e0d390c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i020a06568fff458680224e0c17f7e1e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5bd39e73b51b426faf5d3000ec040cab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd5f225519564e599eb1b5523a3a9fd0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42909e8f9c30495abe5bb1c928de6828_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i546f06ef7f934d938a78d35cc7bd6f13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee3c61a29b7d488e9481564d3568bfc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c7e8aa3d64f4299bb8749e88d06bc86_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyIcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib37b745566de4dda9b10c642d417c89d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9cc73ea0d9c420c800a11a503944b1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fb52bcb659e47438837272f49d907bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39e9c330c7d843a6b978f225237f75fe_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="idf639990efe546a2ae48d957d3513d96_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i034232aba8564ecda5fc7d8eb72396d9_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i28107efd47144a3abd7964318b557020_D20181231-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i2f492ad4dfa64cb6b2319778404cfec8_D20181001-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i62894ef4375a4892a57a4a49a14e7ac1_D20190815-20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-15</startDate>
            <endDate>2019-08-15</endDate>
        </period>
    </context>
    <context id="if187349176e84ceda4964da4edd883be_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="i5eec6b1c21f0498da88860217bd3e1b7_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i220b0c6c496e42fc8ea7dccfde48d81d_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="ie35fa90cf89940babbfb526c040370f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id18f5551b94641ff880e77978a598895_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a15352b902e4da3bb0205dc843b9a3f_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i661dd10b9d474519ba9a2208b86c8de9_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ifc84240a812d4182830716e5492a75f0_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="ief51a740808646c0be978c4781f49b06_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i323e527963b14f6ab5f0f11b66cf75a8_D20180522-20180619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-06-19</endDate>
        </period>
    </context>
    <context id="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65069fa42dbc40d2941743d3f4afb5f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i352234f55c94428c9659aebe6d102ea0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6c815b5da3a452d8a7e3e5be67a017e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib69a1d348c964f9585625ef80a9b7fa8_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i50cd7daf68e54877a8d9e082be5523ad_I20210128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="i350edb2222fc4ac0a3c6507827c9b80d_D20210128-20210128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-28</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="iff2786e1861d4292b0275af1d7b92525_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf28578e57ba441195176b5789f4dde3_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i32a4018efce8403baff24ddd52876e90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i114a6a856e5944a982c509306ce6ccda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3644aaff90b0425b94d88bd354d543ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide70d0b7f442498693f401787562d65e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i882b43ad553b45d298444f65918a460d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3b17149c809471b94d0d5841711e32b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee918a3da8aa4671b06dc59a2cafc994_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63fcda9c6a804dc59452ea6868c24acd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1eea505c815c4979a95d55f6145b57ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d6097c094df4052a9ce95b736093c1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9459b2ffac154d2e998968c36fce5d3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71a8ac2029b245f392545bc4eda8d56e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d69bc05694444f0adbc0858ee3a6715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id417fab3cf0d4c5e917425392e1fd9cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14454ce086d24095ba714d9760e0fb96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7514fb8f24a742d49edc89c4cb021e3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8f4b58b88f645d89c208af91b28f2cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44a1b1bd10fa49dead7f5c9e02e131de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bc43418c7cf4e05b0c7f76c2cc94620_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i646d4825dcfe46109944de937f3380eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88bf4f32a33946e492417f9d2dc73c52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i453759ea8cff4f2ab3008749a56e3265_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e3ae4a6112a4341988947a8a9dd966c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9dc7611933a43fe92197068c75cff82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d307d89e01d4dc1a92c17f8c98db873_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idcc4e97847f9451da65751e2c293f78c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e81490ee5e44b6f8903898601190850_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14712e5300454f86a3bed5deb1f6d271_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4833f2fd94e489fb8b7467d472e39b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8faf4085074f419d9384b54bc96efbf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1128ec95e7954d9c91d5362eeae281d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6602a2330fa646ef83a50932115be131_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91c6ced26abf49119a93a11e832e5a52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2153eb1062134c4caa172f7dd8ec0db3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5666f75fbad04ecc8c0e8a27df194c97_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie6283a65f02747708d90a686259eb715_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i13b7e192f2c8428f85754de4b57ade3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i380589f68b0345c98cb55270231bdd72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3791d21ca45848d09706bba5675782e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0f29ffa2d604282aa3977c1329d5123_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6420ef91bf1d4a1bba260796e56a4947_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5fa7210a5ce4cf1a32446731c009ebf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i264ffb3aecca43f8bd0831902d08bf27_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24cc2ace08aa413b9bb245ce5edda280_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a4db53852ed4656a0f1f7d4738cf64b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:IcagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8b713c7049f465f8770df03d4238b33_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie528dc87bee94f8caf3f8a1e273dd57e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia82f7ae16d724ecc956f678166ebf230_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:PfenexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff2792a74cce448d9d3e648d7b956be5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42695687f81e405c9d3cdbe7d31e2a8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8a106a25b78411482849d23ad9a09e8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifc06096f96b64e82ac914c97075da05d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd0e4043c1aa44d99e0496901785ab2b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7c0367d73764a1aa9aef7ba6ff77792_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i953919e814ac433bba490fdfd486bf52_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic40ca45f254145e681e785bbb6305a78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d99a0a13be944d08abee4b0e2287edd_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62ccd602f6fa46788dc3ed55853a87b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbaf2eb117fe4ea38353a1add365f4de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2feaed30df5b4d19a7bfe180fab28929_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifea3774c1e854faabbb9b9bd56df18b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i821fcc2beda34395937a25762f2616bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66de6c8533c64de1b961a16a8db0723a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffa8849f70694c158893145638a42fb0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic614e71f57294a5ba7f5c4c3d606053f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7268d74272cc4722ab1c1b9e43253848_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibaefa4ff41be4dc6899f87dced50851d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if79e2805487e43c19b53a5d41d9eda6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e0842e1697e470bbb3fd3777f23811c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28daf0e5db1049f18fd204ea459bc201_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff77d9443603499199481d702061cfc3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i69928414acf4456c871c5c27e2b76219_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if56ecb42bfb845cdbf6b43bfa81634cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacd51de929754bda9511cd8c27350601_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1115896595ee46f58722433b8bebfcc6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3b624942505415386809d9280250f36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2c71624a82f425e97a2dd558100c435_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26da0a13ba874bfeb0373d75e17b5d4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0398cc7bf5994c79a7c821c2a8c34c80_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i304f82f2dad244e382a657b3d676fb43_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i931b931a1abf45438f4f158f651d36c0_I20190123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-01-23</instant>
        </period>
    </context>
    <context id="i0e34e1285b384e0d8ee4bc840f707708_I20190911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-09-11</instant>
        </period>
    </context>
    <context id="i6ab16e1f7dff4858bc4003f7815ab55f_D20190911-20190911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-09-11</startDate>
            <endDate>2019-09-11</endDate>
        </period>
    </context>
    <context id="i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:LupinPatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i338fe8a7f9a14546aadd061a86a8794a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9dac967dc794fbabfc9e438958fbe78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e7f6ee2f38047f4bf987be2ec85087b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20cb5a20013b480c8b516e20e1aace66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6df4a7ca341f4c80b8357649cb1d8155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c7d29ba6dd34ca2ac02b4e24d20ead9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0176de2e50c3447c864e3818f9715431_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i00351799e1f0421bb7f825c963509503_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic55d7c252e32432b8ac5deb25dbbe252_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lgnd:right</measure>
    </unit>
    <unit id="acquisition">
        <measure>lgnd:acquisition</measure>
    </unit>
    <unit id="pure">
        <measure>lgnd:pure</measure>
    </unit>
    <unit id="trading_day">
        <measure>lgnd:trading_day</measure>
    </unit>
    <unit id="day">
        <measure>lgnd:day</measure>
    </unit>
    <unit id="position">
        <measure>lgnd:position</measure>
    </unit>
    <unit id="patent">
        <measure>lgnd:patent</measure>
    </unit>
    <unit id="civil_complaint">
        <measure>lgnd:civil_complaint</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8xLTEtMS0xLTA_0df145ea-10e6-467e-99ff-4606e685d86d">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8yLTEtMS0xLTA_22e670b3-ef9b-4cd3-a4ef-29cbbc5fc3b0">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGFibGU6ZmVlZTY3ZDZjZWFhNGQ2NTljNzhmY2VkZmUyN2ZlZTQvdGFibGVyYW5nZTpmZWVlNjdkNmNlYWE0ZDY1OWM3OGZjZWRmZTI3ZmVlNF8zLTEtMS0xLTA_92dd95dc-7604-43cb-84ff-e7bbdc6e0e7e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGV4dHJlZ2lvbjo1Y2ZmMWZhZWNlNTI0NGZjYjhkNDY0NTFjYTMxMmE1MV82Mg_ebc10c45-c38d-43d2-84c0-b65b4e3db6ca">0000886163</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF80L2ZyYWc6NWNmZjFmYWVjZTUyNDRmY2I4ZDQ2NDUxY2EzMTJhNTEvdGV4dHJlZ2lvbjo1Y2ZmMWZhZWNlNTI0NGZjYjhkNDY0NTFjYTMxMmE1MV82Mw_226deebc-ab67-415a-a5c0-9e1d85f50832">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMC0xLTEtNDk2Ng_219e2ce5-02b5-469b-a2fa-1b0d64350836">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124">P42M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie9077f805ad04ec8a9844f76534e6b52_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84NS9mcmFnOmVkNDExMTM1MWM1ODQ0ZjFhODg4ZWQxYzFhNWQ3YjBjL3RhYmxlOjIwMDczN2FjMGUxNjQ1YzFhZmM2MjAyOGRmMDJmYTdiL3RhYmxlcmFuZ2U6MjAwNzM3YWMwZTE2NDVjMWFmYzYyMDI4ZGYwMmZhN2JfMS0xLTEtMS0w_ba2dc4e9-e2d3-4273-acee-b9eff8c4f3a4"
      unitRef="number">0.1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1585086dfa31461d9798a9c8657e480b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84NS9mcmFnOmVkNDExMTM1MWM1ODQ0ZjFhODg4ZWQxYzFhNWQ3YjBjL3RhYmxlOjIwMDczN2FjMGUxNjQ1YzFhZmM2MjAyOGRmMDJmYTdiL3RhYmxlcmFuZ2U6MjAwNzM3YWMwZTE2NDVjMWFmYzYyMDI4ZGYwMmZhN2JfMi0xLTEtMS0w_85f0dfd9-4ebb-4163-b113-e3fff61160cf"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDYvZnJhZzo0Y2JjOWNkMjFhOTU0MzI0YmVjZDI0YTM0NTJlNzZiNS90YWJsZTo5YTQzYjIwZTM2ZTE0YTM3YmQzNDAzZWY2Zjc3NDIwOC90YWJsZXJhbmdlOjlhNDNiMjBlMzZlMTRhMzdiZDM0MDNlZjZmNzc0MjA4XzItMS0xLTEtMA_f0b1bc8a-dc2c-4d0f-b3d8-dcbe48217245"
      unitRef="number">0.0133251</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ibf28578e57ba441195176b5789f4dde3_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDYvZnJhZzo0Y2JjOWNkMjFhOTU0MzI0YmVjZDI0YTM0NTJlNzZiNS90YWJsZTo5YTQzYjIwZTM2ZTE0YTM3YmQzNDAzZWY2Zjc3NDIwOC90YWJsZXJhbmdlOjlhNDNiMjBlMzZlMTRhMzdiZDM0MDNlZjZmNzc0MjA4XzItMi0xLTEtMA_1a5134d8-ca4d-414c-ac20-639b93627181"
      unitRef="number">0.0040244</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4MQ_17ee1139-a959-4580-b6e3-e99ff17f0d7f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzE2_5a5bbb9e-bff3-4770-9414-585cc268bb0e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6ZmUxMjRhYWU2NDNiNDMyMmEzMDA3YWY5ZTJmMWQ0YjUvdGFibGVyYW5nZTpmZTEyNGFhZTY0M2I0MzIyYTMwMDdhZjllMmYxZDRiNV8wLTAtMS0xLTA_ec834805-a5aa-407b-aa2e-0068e4eee58c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yMTk5MDIzMjU5Mjky_99427b2b-5b61-467f-9de6-8cd2da7e17de">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6NTUyNTg1NGVhNTFjNDIxMzhlYjczMWUzNzAzMDczYWQvdGFibGVyYW5nZTo1NTI1ODU0ZWE1MWM0MjEzOGViNzMxZTM3MDMwNzNhZF8wLTAtMS0xLTA_18a554a6-f859-4801-ae19-eee306885d71">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEw_b36f2c84-2cd3-475d-b227-720efc5645d7">001-33093</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEx_aa6986c9-38a0-4a21-873b-60ddad41aa5a">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8wLTAtMS0xLTA_f6d0281d-0d31-4ff2-9038-a1469b1e1d4a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8wLTItMS0xLTA_5916388d-4bec-4ea9-98ec-976591d8d202">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl8zLTAtMS0xLTA_8f1f08f0-c811-42d5-9c3c-bfac7587273f">3911 Sorrento Valley Boulevard, Suite 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl80LTAtMS0xLTA_83f7a559-6bb0-4ee5-bbbd-2b9c7b88d639">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl81LTAtMS0xLTA_61fef456-386a-4c91-be92-cb60bf987e5f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MzI4MWI0YWFlZmY5NDk0NDk3YWM4ZDY4MDk5MGRkOGYvdGFibGVyYW5nZTozMjgxYjRhYWVmZjk0OTQ0OTdhYzhkNjgwOTkwZGQ4Zl81LTItMS0xLTA_f324b9af-053d-4d2d-bfb4-208953247104">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEy_26f5bfd4-eda1-4b80-9e0d-94c081b55386">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzEz_da08a50d-7b91-409d-9167-9f3ff17eac38">550-7500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTAtMS0xLTA_a1ff2250-054d-4751-8700-021e7a19b2c8">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTEtMS0xLTA_4b8678c3-3e35-4510-acd3-0cdd51c2e76e">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6Y2E0NzgwNDBkMzM0NDkwZDlkYjRlNzBkMDJlOTc2MTYvdGFibGVyYW5nZTpjYTQ3ODA0MGQzMzQ0OTBkOWRiNGU3MGQwMmU5NzYxNl8xLTItMS0xLTA_d9046087-418b-4370-b8c5-aa0e4e41156d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA5_5befc269-3a1a-4815-94cc-c8bc777a5cd0">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA1_95593080-d159-432c-b0bf-db5ff1d4973b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzE0_531345ea-7c2d-4827-addd-f7510f793ac9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA2_18481c53-628f-4348-9be9-c342940c8a44">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTAtMS0xLTA_3e6110d0-1003-46f0-b02b-7a7482062423">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTgtMS0xLTA_c646c22b-40a1-4629-aede-5b48218ff9a1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGFibGU6MDRmNmQ5ODc1ZTNlNDYyMzkwZmNhZGExMDQ4NjMyMjEvdGFibGVyYW5nZTowNGY2ZDk4NzVlM2U0NjIzOTBmY2FkYTEwNDg2MzIyMV8wLTEwLTEtMS0w_c6407533-0de7-48e0-9a18-f8f0cef6b3ad">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yMTk5MDIzMjU5NjY0_fc9745ee-2bfd-43ae-a647-d6b232a935ce">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zNzA3_b7a17849-2cbd-47a8-aeb7-a34166f35a11">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="id5ad18ea90a54b5b8bba0e1555ad9875_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8yNTY2_59f549c6-f46c-4a9f-bf2b-28cd50565ff6"
      unitRef="usd">1200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="idd5c9735b7574d1eb48ed78ec5db3eb5_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xL2ZyYWc6NTE1MGExODgxYmNlNDc0Y2FjZjIyMGI5ZDk5NDJhYjQvdGV4dHJlZ2lvbjo1MTUwYTE4ODFiY2U0NzRjYWNmMjIwYjlkOTk0MmFiNF8zMTc5_f100cf77-6284-4fd7-ab30-9a9605e5e2c3"
      unitRef="shares">16612422</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNC0xLTEtMS0w_a5b7900b-879c-4c5a-9242-a9e6109a5b5e"
      unitRef="usd">47619000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNC0zLTEtMS0w_323e7169-7b65-4ccd-bf1d-eaaf63bead7b"
      unitRef="usd">71543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNS0xLTEtMS0w_54f39b84-38fa-4360-a885-8b91d6f20350"
      unitRef="usd">363567000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNS0zLTEtMS0w_52c3a7c9-19e5-4494-b3f6-284f9157e0e9"
      unitRef="usd">998324000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNy0xLTEtMS0w_253a5a2b-834c-4f69-b35d-b9919f57787a"
      unitRef="usd">56847000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNy0zLTEtMS0w_0b7da190-8ac0-4e42-bc7d-672089d94f6e"
      unitRef="usd">30387000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfOC0xLTEtMS0w_9cc0d9e5-e416-4c9f-a400-ac4875698a33"
      unitRef="usd">26487000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfOC0zLTEtMS0w_bc3125bd-d3f5-4dc7-b833-5ffe3eb73d86"
      unitRef="usd">7296000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTAtMS0xLTEtMA_8678e118-a389-4ae4-b8d1-459a94249713"
      unitRef="usd">2217000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTAtMy0xLTEtMA_71f5db6a-9b4f-49a3-89a6-b60002e89e9f"
      unitRef="usd">11361000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTEtMS0xLTEtMA_f1a1acde-3ac2-44fc-92b0-6ddafae120ef"
      unitRef="usd">3822000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTEtMy0xLTEtMA_8e3103c7-7a74-4c61-9810-5d2d4285838b"
      unitRef="usd">4734000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTItMS0xLTEtMA_c7d75c41-3dae-4ee2-937e-6f4f7c531668"
      unitRef="usd">500559000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTItMy0xLTEtMA_8785fe35-c1cf-4241-a5db-b27be64bc89f"
      unitRef="usd">1123645000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTMtMS0xLTEtMA_2b48eca7-946c-4c96-b86d-c9b069c12fb4"
      unitRef="usd">24320000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTMtMy0xLTEtMA_49f2a677-96cb-4d0b-80c1-e24be855bf0b"
      unitRef="usd">25608000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTQtMS0xLTEtMA_77945f5d-10b3-4fa8-a9f6-ef8caf8e2ef6"
      unitRef="usd">595330000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTQtMy0xLTEtMA_3fd9402c-1d59-463a-81fd-68972b5b19b1"
      unitRef="usd">210448000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTUtMS0xLTEtMA_30577564-7a4a-46c3-b137-a764e3b77cf4"
      unitRef="usd">189662000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTUtMy0xLTEtMA_66ce6909-ce48-45c2-a69c-2fa783412d10"
      unitRef="usd">95229000</us-gaap:Goodwill>
    <lgnd:CommercialLicenseRights
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTYtMS0xLTEtMA_67ad3a26-db1a-498c-b11d-076e45d6d15f"
      unitRef="usd">10979000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRights
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTYtMy0xLTEtMA_2477d86a-7c9e-4db1-abd4-c45602f315f6"
      unitRef="usd">20090000</lgnd:CommercialLicenseRights>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMS0xLTEtMA_e73a0bb2-a93a-4111-9cba-3f52cbf9fead"
      unitRef="usd">14434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMy0xLTEtMA_959f3eeb-5473-4d4f-8e4c-4e1784f71f44"
      unitRef="usd">7185000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTgtMS0xLTEtMA_f65c1c06-fefa-4168-bfa0-0a1c9e010c3f"
      unitRef="usd">6892000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTgtMy0xLTEtMA_0f763f7e-2751-47d8-93fe-d68d137cd838"
      unitRef="usd">10353000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMS0xLTEtMTIzNA_876a3328-339b-41c9-a8ca-96e2332e3ffd"
      unitRef="usd">15842000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTctMy0xLTEtMTIzMA_e5e1c71b-dcfc-4265-9377-201c68e7bb54"
      unitRef="usd">84000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTktMS0xLTEtMA_7140f24f-3683-4e44-96f1-9e9a45405d7e"
      unitRef="usd">4267000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMTktMy0xLTEtMA_7f08c311-b339-4d31-a855-94bba4133aa2"
      unitRef="usd">2273000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjAtMS0xLTEtMA_4454680a-04e8-432d-8783-0f3e79ff0260"
      unitRef="usd">1362285000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjAtMy0xLTEtMA_210ba5b5-fe24-48f8-bcf6-d27bb22676c5"
      unitRef="usd">1494915000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjMtMS0xLTEtMA_2ed6f30d-decc-431f-994c-95989ed98ef5"
      unitRef="usd">3784000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjMtMy0xLTEtMA_8a048e3b-0778-4ae7-8f30-f4f5a9d9084b"
      unitRef="usd">2420000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjQtMS0xLTEtMA_ffaf20dc-a708-4ee8-ab76-673543476126"
      unitRef="usd">18530000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjQtMy0xLTEtMA_d75f1565-b371-4cce-bea6-86a3d29b39de"
      unitRef="usd">8581000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjUtMS0xLTEtMA_8f162e00-7a77-478d-b610-94196b6891bb"
      unitRef="usd">39884000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjUtMy0xLTEtMA_ada6e43c-637e-4d17-b80b-bc7d461741b3"
      unitRef="usd">2607000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtMA_de0a41d0-7c75-4d6a-9d65-6c7e77f38852"
      unitRef="usd">29435000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMy0xLTEtMA_03f0cec8-882b-4ef0-82a1-14657e422678"
      unitRef="usd">2139000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtNDM1NQ_3a17e475-b5bf-45de-8aeb-7268df1d06f7"
      unitRef="usd">1885000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMy0xLTEtNDM0OQ_0e24c62b-5563-4d3d-af5e-6e6bdc06870c"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjYtMS0xLTEtMzI5NA_edec4244-a7de-4570-a682-743a2396f1c3"
      unitRef="usd">6593000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjctMy0xLTEtNDg5Ng_4fb683ad-25c9-47f8-b86e-13daad49d24c"
      unitRef="usd">13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjktMS0xLTEtMA_e62099a2-d43d-42e1-a2ed-1cfe9294a449"
      unitRef="usd">100111000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMjktMy0xLTEtMA_69010c11-da35-4e31-b142-4c14c4cdd1bd"
      unitRef="usd">17002000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzAtMS0xLTEtMA_fc3d8708-836f-4ca3-9736-bc28c45452e7"
      unitRef="usd">442293000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzAtMy0xLTEtMA_06c9d8fa-d884-4c79-ba7d-261bf2a5ef3e"
      unitRef="usd">638959000</us-gaap:ConvertibleDebtNoncurrent>
    <lgnd:LiabilityForContingentValueRights
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzEtMS0xLTEtMA_77fd1a78-05a9-4f5d-bc24-eb7299803a4d"
      unitRef="usd">9249000</lgnd:LiabilityForContingentValueRights>
    <lgnd:LiabilityForContingentValueRights
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzEtMy0xLTEtMA_75c783a8-0e9d-42b1-9c30-185dcb213417"
      unitRef="usd">6335000</lgnd:LiabilityForContingentValueRights>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzItMS0xLTEtMA_6116e46e-5a0e-44c8-9ba3-f91bc384b834"
      unitRef="usd">64598000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzItMy0xLTEtMA_c946db09-0fc8-414e-a1af-dcb462ead16a"
      unitRef="usd">32937000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzMtMS0xLTEtMA_87c28f49-8b8d-460d-a078-9d280dbcbc7c"
      unitRef="usd">5643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzMtMy0xLTEtMA_e69094e5-9694-4fa1-9ff2-a8b316ef5fa2"
      unitRef="usd">9970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzQtMS0xLTEtMA_d8ee7b35-aaf4-4a48-bcb8-fd068426abef"
      unitRef="usd">30866000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzQtMy0xLTEtMA_ce56956f-e06d-4f35-9db8-606e3dee9a65"
      unitRef="usd">22480000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzUtMS0xLTEtMA_b6b89fdf-26ff-46fd-86e7-60e4e593492f"
      unitRef="usd">652760000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzUtMy0xLTEtMA_764adb3f-fe6e-4f1f-b3a0-d3694200a132"
      unitRef="usd">727683000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzYtMS0xLTEtMA_ba13fd88-22f8-44df-bbf9-631d971f8b0c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzYtMy0xLTEtMA_b903fc98-bfe1-4fce-a57e-f214fbd2b502"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzI3_45e05943-d2b8-41c7-99b7-c95bdadbaaf0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzI3_af68105d-2a97-4cda-84ec-c37a332dcb1f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzQx_52a1c28c-01c1-4579-8548-06dab034d55d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzQx_78745170-d7f3-41af-8f35-99b676800e58"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_0bc1edee-73ad-4011-a057-6184a85db955"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_50baeb07-085a-467a-99a9-fcc8a77bb237"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_7e780e74-5388-4416-bb72-3900bd0e320e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjEzN2VjMDdjMTEwMDQxYzdiMGZhMDExMTVkN2FjY2Y1XzYz_cf7f6708-817d-4d57-abde-21a5678793b2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMS0xLTEtMA_693586b0-0866-45a0-9287-6fea696c4da5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzgtMy0xLTEtMA_9702a264-39c1-4970-968a-30f5493c6327"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzE5_a3541e4a-a4f9-4ed8-bb41-de22cffb81db"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzE5_ad5e6bf0-d945-47a1-9188-21dbe31c3279"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzMz_b38fbe69-5fc8-4d7c-9387-f760bd9d5a83"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzMz_d96c1535-ef78-4cbe-8246-85f5567ed8d8"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzU1_29695590-96e8-4eb4-9589-554b0d788612"
      unitRef="shares">16080000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzU1_47b86367-62f3-4a1b-a605-0e3d939260f3"
      unitRef="shares">16080000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzYy_303f6f63-2334-4dbd-b832-9f330f368858"
      unitRef="shares">16823000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjgyMzJhYWJmNDk3YTQ5NjBhNzc2ZjdhZDAyNzQ2YWRiXzYy_eec3b3aa-a97f-4ed6-aa2c-09e0bf6b5097"
      unitRef="shares">16823000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMS0xLTEtMA_60b80b9e-cf57-46e8-a8e8-f1740a0b7513"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfMzktMy0xLTEtMA_b379640a-6b60-4880-871d-712ff48c23ed"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDAtMS0xLTEtMA_58c9d275-9645-43c7-97d1-136746fac533"
      unitRef="usd">318358000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDAtMy0xLTEtMA_35b2e42c-2f41-48e0-b416-04c954545fd2"
      unitRef="usd">367326000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDEtMS0xLTEtMA_0d6fd849-e917-4b29-bd47-66938fd0f503"
      unitRef="usd">-801000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDEtMy0xLTEtMA_04ee680a-90e5-456f-9c44-35c12404689c"
      unitRef="usd">-216000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDItMS0xLTEtMA_1f7467eb-b408-4dc9-8743-43af0688f6ec"
      unitRef="usd">391952000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDItMy0xLTEtMA_6556d959-355f-46cc-97d4-cb424d3a5734"
      unitRef="usd">400105000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDMtMS0xLTEtMA_e56fe4ef-8839-4bfa-ab90-4ccbd065f8ce"
      unitRef="usd">709525000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDMtMy0xLTEtMA_6bd943bc-2ed0-4e7a-9f37-e9165590dc6a"
      unitRef="usd">767232000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDQtMS0xLTEtMA_2ac79a54-304b-4190-ad29-c4fff5e60731"
      unitRef="usd">1362285000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82NC9mcmFnOmU4MmU3NTU1OTIzMTQ2ODViNGNmNGQ5OTU3YTc0ZWZjL3RhYmxlOjViMmYyOTc5ODg1MjQzYTVhYzhmZTRjOWI2YjE1M2RiL3RhYmxlcmFuZ2U6NWIyZjI5Nzk4ODUyNDNhNWFjOGZlNGM5YjZiMTUzZGJfNDQtMy0xLTEtMA_6abde775-a94d-4c90-9db1-90a7b941f88a"
      unitRef="usd">1494915000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy0xLTEtMS0w_acd3d0ca-a082-4031-82d6-f22da3c1bf84"
      unitRef="usd">33796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy0zLTEtMS0w_28aa5e55-c543-454c-b7ac-9309c49d5a4e"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98d16dd704b74221b973893e02cd3023_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMy01LTEtMS0w_20bb3c1c-57d4-4c0d-88ff-cbd01ffc64d0"
      unitRef="usd">128556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC0xLTEtMS0w_191a0c76-db11-4604-8fb4-67b4d733fdf4"
      unitRef="usd">109959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC0zLTEtMS0w_442c0143-b95b-4caa-804c-5dfdfbc9b19e"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNC01LTEtMS0w_62836712-213e-44b0-a580-582b9e2b48bf"
      unitRef="usd">29123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS0xLTEtMS0w_eb3a823f-a2ab-4f4d-8774-3816543258db"
      unitRef="usd">42664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS0zLTEtMS0w_46142b8c-d6cb-465c-87cb-ff6a8c7297eb"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNS01LTEtMS0w_732d4f60-8ed3-4c49-91dc-e63ecd66908f"
      unitRef="usd">93774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi0xLTEtMS0w_a12b7f97-b860-4b8d-9056-eb00963698dc"
      unitRef="usd">186419000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi0zLTEtMS0w_d378bbc2-a5b5-431a-a6ba-cc60531f75cb"
      unitRef="usd">120282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfNi01LTEtMS0w_6cccb8d4-7e21-4f5e-bcf7-0d84d47ae176"
      unitRef="usd">251453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostDirectMaterial
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC0xLTEtMS0w_1cce1fc7-cff8-486b-b977-6bbd14e9fe5b"
      unitRef="usd">30419000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC0zLTEtMS0w_cc2610c0-569a-4bcd-9cdf-fc8e4e801c1f"
      unitRef="usd">11347000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOC01LTEtMS0w_3e14a252-7a6f-45ac-abb1-85678fcbe7c7"
      unitRef="usd">6337000</us-gaap:CostDirectMaterial>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS0xLTEtMS0w_8653a583-b7e9-412e-a115-f49cb100cc2c"
      unitRef="usd">23442000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS0zLTEtMS0w_07c27447-6a1b-4b3f-87b1-1cc50a834da3"
      unitRef="usd">16864000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfOS01LTEtMS0w_1bf8532b-32be-40ff-b6b9-6d15ff122abe"
      unitRef="usd">15792000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtMS0xLTEtMA_ef617d9a-a3f9-419d-93fb-958f0f55a51c"
      unitRef="usd">59392000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtMy0xLTEtMA_e7203b91-7238-4333-8152-6fc7b0e6379a"
      unitRef="usd">55908000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTAtNS0xLTEtMA_3e10086a-3b82-43a9-8a3f-0aa237e666c2"
      unitRef="usd">27863000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtMS0xLTEtMA_bdd1df6b-f021-44bf-85f3-89d465f9ff58"
      unitRef="usd">64435000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtMy0xLTEtMA_d80809ae-5747-4caf-b5e9-3caa1ae4fb71"
      unitRef="usd">41884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTEtNS0xLTEtMA_4fc2677b-a405-41bf-8683-edd7a563c10f"
      unitRef="usd">37734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItMS0xLTEtMA_68eb4c52-3988-4b01-83a4-1581439f66b4"
      unitRef="usd">177688000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItMy0xLTEtMA_c3cd7152-f655-41d4-9e27-be56ba3683dd"
      unitRef="usd">126003000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTItNS0xLTEtMA_263db1dd-fc29-44bb-bb2d-8d8163792eb1"
      unitRef="usd">87726000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="iec0387ebb91c44aaa14fe5f411316aab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMS0xLTEtNDUzMg_6368b139-71d5-4282-87e7-12cec84dbb20"
      unitRef="usd">17114000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i0863c3664c064309a61c97efd34cc22b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMy0xLTEtNDkzMQ_8bd357d1-aa75-4ad2-ab68-8d88c7d5d544"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i74270c6229d54e75bedc1e83d6c7f2d7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtNS0xLTEtNDkzMQ_89a4dc3e-a317-439f-b93e-8d9d102877eb"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i824ae14f7d55450f96a50e45e1e00275_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMS0xLTEtMA_5e4eee4f-60cb-4fe1-bd64-13995c94dfed"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i3fe8f99853d84177abbd1d204189cdc9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtMy0xLTEtMA_7161b66e-be90-423e-af57-f529a8e80a23"
      unitRef="usd">812797000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i076d26d185984399b35b035b9c392324_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTMtNS0xLTEtMA_6c9bfc90-96d5-4e2b-b748-4d8d7e6ebb6c"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtMS0xLTEtMA_da823f0d-0c69-42db-ac9f-4b26be9efece"
      unitRef="usd">25845000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtMy0xLTEtMA_5e970d4b-94a4-43d2-b3ad-cf9103535a4c"
      unitRef="usd">807076000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTQtNS0xLTEtMA_9f07dff7-13be-42d1-b9ea-71798e7d6e2d"
      unitRef="usd">163727000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtMS0xLTEtMA_81a79d5c-65d9-4b68-a9fd-cfb12550a58f"
      unitRef="usd">-16933000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtMy0xLTEtMA_bc10c456-1c35-44aa-9ab6-0173b9a21a0e"
      unitRef="usd">1049000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTYtNS0xLTEtMA_93f35829-26e5-4491-9bc4-28e222fd8be8"
      unitRef="usd">50377000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctMS0xLTEtMA_624ab436-83c4-4f3e-b4a7-9ec530cc5269"
      unitRef="usd">8078000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctMy0xLTEtMA_51e52824-aac4-4a1d-a4ef-d4de074ebc22"
      unitRef="usd">28430000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTctNS0xLTEtMA_4b580584-d4d2-4667-899e-65aca9ac70e8"
      unitRef="usd">13999000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtMS0xLTEtMA_9df12dcb-08b0-494a-b5f5-4a50da180658"
      unitRef="usd">27420000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtMy0xLTEtMA_d2dc4d23-59ce-4b81-8895-d0a58af85f12"
      unitRef="usd">35745000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTgtNS0xLTEtMA_88684f4b-5bdb-47e1-8788-fbddafd16645"
      unitRef="usd">48276000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktMS0xLTEtMA_92516fcc-6915-43fe-a32b-e10d20a177f4"
      unitRef="usd">-108000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktMy0xLTEtMA_f92b23d1-fceb-4fb2-af40-65cea331dd74"
      unitRef="usd">-4171000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMTktNS0xLTEtMA_bc9d10d3-1d87-43b5-b5d2-3c43da1626d3"
      unitRef="usd">-6497000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtMS0xLTEtMA_f9222e1e-e4d8-4908-8914-daa8bbaf82b5"
      unitRef="usd">-36383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtMy0xLTEtMA_0e31bc69-0dca-48a9-aaff-c618d282c01e"
      unitRef="usd">-10437000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjAtNS0xLTEtMA_3256209f-d6ca-4067-a2d3-5afdf3cc89a0"
      unitRef="usd">9603000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtMS0xLTEtMA_22ee5d60-1170-4888-a565-55ff8e4fb12b"
      unitRef="usd">-10538000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtMy0xLTEtMA_28765865-d706-428a-ac99-e99a3a8d478d"
      unitRef="usd">796639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjEtNS0xLTEtMA_c764bbcc-467b-4a44-b0dc-943972dad1c6"
      unitRef="usd">173330000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItMS0xLTEtMA_482ae3b8-42fb-4bbb-96fa-4c6abc65cf2f"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItMy0xLTEtMA_eddc59dd-2fe0-4388-a157-c6812dc357a0"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjItNS0xLTEtMA_023bca65-9607-4558-8646-59b6fc9f7447"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtMS0xLTEtMA_1708385d-2b4a-4d43-939f-499e3984c21a"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtMy0xLTEtMA_4db02522-c416-4996-b05b-3c99820fb80f"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjMtNS0xLTEtMA_98c6cac4-8887-48e5-abde-5c2f2be6f562"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtMS0xLTEtMA_cdd08476-14ea-4be3-bcc2-76b8f552c622"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtMy0xLTEtMA_f5cfbe4c-eed9-4d63-be5c-2e5be6c343c6"
      unitRef="usdPerShare">33.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjUtNS0xLTEtMA_fbb83081-d250-4885-8aed-4e766b353205"
      unitRef="usdPerShare">6.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtMS0xLTEtMA_89820d2b-1012-4df9-a58e-9ec15451ff6b"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtMy0xLTEtMA_46f82a12-1b2c-49dc-8a5c-ef236a6dfb26"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjYtNS0xLTEtMA_b6e23b0c-c33d-4fae-ae8d-d77a1a1a63aa"
      unitRef="shares">21160000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtMS0xLTEtMA_329e916a-c67f-4385-b2b7-ae60815a9309"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtMy0xLTEtMA_48f2faa0-6d85-42e3-853c-867f4b5ec8da"
      unitRef="usdPerShare">31.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjgtNS0xLTEtMA_13c37400-6635-4a54-ab3b-f4cef95194bd"
      unitRef="usdPerShare">5.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktMS0xLTEtMA_b89fb953-3309-4ae9-9169-d119ff1315d4"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktMy0xLTEtMA_9b3f8e16-7b6d-47f0-aabd-21d7ba9fa381"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF82Ny9mcmFnOmE3Yzc3N2U0MGVhYzQ1Mzg5OTdmYmViYjViYWE4OWJkL3RhYmxlOjIzNmJlMDEzODc3NTQ1NDE4ZTJhZmViOGRlMjgwN2U5L3RhYmxlcmFuZ2U6MjM2YmUwMTM4Nzc1NDU0MThlMmFmZWI4ZGUyODA3ZTlfMjktNS0xLTEtMA_1ab4a104-59ba-4fd6-8b81-01b4be1f2424"
      unitRef="shares">24067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi0xLTEtMS0w_26c2e6a0-384e-4917-b6e8-4496da8988a4"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi0zLTEtMS0w_3202b1f0-dfc7-40f8-8b4f-1d87e8870d24"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMi01LTEtMS0w_94483b0f-21f8-4509-8bd8-c17b1664cf26"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy0xLTEtMS0w_f0599c63-4647-4b84-b6c1-fe4e2499fd02"
      unitRef="usd">-162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy0zLTEtMS0w_cb567001-e55a-410c-905b-bfffebc3cdcc"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfMy01LTEtMS0w_0fdde55b-d06d-437c-954f-53d91c4e2f46"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC0xLTEtMS0w_f91f56ce-9f4c-47f7-b307-c782abc14a51"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC0zLTEtMS0w_f1b82f29-3de5-4972-b785-43900e753f11"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNC01LTEtMS0w_4db53640-f1e1-4490-a857-97d3a24d6600"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi0xLTEtMS0w_b144fe3c-7848-46ec-94e9-191ed6e4b7a9"
      unitRef="usd">-3570000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi0zLTEtMS0w_71696353-a4a7-4107-aa8f-40802639d2f9"
      unitRef="usd">630110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83MC9mcmFnOjllMGUxNmI3MjczMTRlNzVhNjkyZGMxMmRkMjMzMjEyL3RhYmxlOjgwNjU3OTY4OTdiNDQ4YjliOTQwOTliMTRmM2E2MzZlL3RhYmxlcmFuZ2U6ODA2NTc5Njg5N2I0NDhiOWI5NDA5OWIxNGYzYTYzNmVfNi01LTEtMS0w_bc95c8aa-0a72-41d0-aea6-1470889dd465"
      unitRef="usd">142473000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="icd387f8ff7744137980599559a1c5f77_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMS0xLTEtMA_6223f524-42b8-4508-bef8-d15a17b8dff3"
      unitRef="shares">21148665</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd387f8ff7744137980599559a1c5f77_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMy0xLTEtMA_606d8e52-7d9e-4348-87af-e3cba3f05f10"
      unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i346897ea83804fdd8c657865b763ef87_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtNS0xLTEtMA_c0576344-6742-4c09-8ed2-69b98e8ec768"
      unitRef="usd">798205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib59bfab0480542cda230d78e7ef5e82e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtNy0xLTEtMA_3318f02a-e44c-42df-9c8a-8107dbc91eeb"
      unitRef="usd">2486000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i911fa320b1ef4643bd62d2f1d873e78c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtOS0xLTEtMA_f96adb9c-f200-415b-bc1b-720fdf2b2479"
      unitRef="usd">-400924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTAtMTItMS0xLTA_1339a01c-e725-41c7-a92b-91a62ef82cfe"
      unitRef="usd">399788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtMS0xLTEtMA_9a4cab1a-fe9d-4fe6-b26f-de982b0c932d"
      unitRef="shares">399116</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtNS0xLTEtMA_d5688300-aa86-435c-b0e3-6d749b66b9b4"
      unitRef="usd">16417000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTEtMTItMS0xLTA_c31d1aba-0899-4181-a69a-62ee7d63034c"
      unitRef="usd">16417000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt
      contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTItNS0xLTEtMA_2d8bb92e-2d52-46b7-8073-684f5564cb58"
      unitRef="usd">18859000</lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTItMTItMS0xLTA_6309f941-beeb-44fd-b365-2404b1f917d8"
      unitRef="usd">18859000</lgnd:AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTMtNS0xLTEtMA_71437800-f55c-41f1-a9a1-d867683eae8a"
      unitRef="usd">20846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTMtMTItMS0xLTA_dd78ccd6-c28a-4755-9ee4-80e7001cd3bf"
      unitRef="usd">20846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8ebffee3304349549a88e0cbf7ed8b32_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtMS0xLTEtMA_12828d8c-0431-4675-a10a-67308f50302c"
      unitRef="shares">782248</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtNS0xLTEtMA_6adc63bf-94de-4647-884b-fdd2b86957fb"
      unitRef="usd">127481000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTQtMTItMS0xLTA_a45294d4-070c-45e9-b234-9c9cd6039ec5"
      unitRef="usd">127481000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTUtNy0xLTEtMA_b2debb6e-b06b-4b03-86e8-484eb118456b"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTUtMTItMS0xLTA_66595342-3fea-42aa-8a55-7eca57724038"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7054e445350945b5a3ac6b9a4827ce2a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtNy0xLTEtMA_0514e11f-8339-482d-8bc7-a26c700e2240"
      unitRef="usd">-2662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie14c67e9b9e04b7093d188b4497bf574_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtOS0xLTEtMA_f04e2b9f-1350-4f71-9a54-b630d2089458"
      unitRef="usd">2662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63ee9751e8804e03bbd45e0f38940a0c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTYtMTItMS0xLTA_afb142e5-a42d-4834-aded-1958166a5da0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3a7c5c2af724c429803e6c84d4842b6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTctOS0xLTEtMA_5f506a38-fb6a-48d1-b08f-35f9aba566cd"
      unitRef="usd">25581000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib37bbc9e048046e88b85c63fa39515f5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTctMTItMS0xLTA_e8e06eaf-65e6-43ce-a733-cde46b821203"
      unitRef="usd">25581000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTgtNS0xLTEtMA_3df77f91-02c8-4839-82e0-712b09b9ac9f"
      unitRef="usd">-1559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTgtMTItMS0xLTA_ade79b0f-5079-4c51-a7c3-d6ba0126224b"
      unitRef="usd">-1559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes
      contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTktNS0xLTEtMA_1290c20b-471d-4336-9617-f2970cfb38a4"
      unitRef="usd">3187000</lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes
      contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMTktMTItMS0xLTA_63d98d4d-9598-4943-acf7-f7cd6b037e4f"
      unitRef="usd">3187000</lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased
      contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjAtNS0xLTEtMA_1bd36fd8-78f5-4fa4-b55e-684449ecc155"
      unitRef="usd">30472000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased
      contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjAtMTItMS0xLTA_d6640a08-04f6-4258-8326-72cab7c3d632"
      unitRef="usd">30472000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants
      contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjEtNS0xLTEtMA_b6fdd6ca-99b5-474b-9c77-7cf0ab9b08de"
      unitRef="usd">1792000</lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants
      contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjEtMTItMS0xLTA_92ac6282-b24a-497d-8e04-64b99257b830"
      unitRef="usd">1792000</lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="iace215d6d6e3468da9f73d0ed51475fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjItNS0xLTEtMA_ff272bdc-4af1-463a-a942-2208e258bcce"
      unitRef="usd">1680000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="ic255172c121b4d9f8d8f800d4e7d5166_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjItMTItMS0xLTA_b65f9c5d-0a9f-46a1-a7d6-2ccd1b4c080b"
      unitRef="usd">1680000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjMtNS0xLTEtMA_12283259-75de-493d-8170-2c53a5318c35"
      unitRef="usd">-1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjMtMTItMS0xLTA_ad774514-10cf-400a-902f-0f3efe32e88a"
      unitRef="usd">-1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjQtNS0xLTEtMA_0ef35b4d-1678-4f04-93a5-b406a5e941e6"
      unitRef="usd">97805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjQtMTItMS0xLTA_423a343b-5ee9-4b71-a68a-a35cd7969232"
      unitRef="usd">97805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="if3cc698769354243bb1a10e1da1a6986_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjUtNS0xLTEtMA_c7da4880-5480-42c5-80c9-784e81467a66"
      unitRef="usd">3181000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="ib749282e285a45b58a4a7264be5d37a8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjUtMTItMS0xLTA_ead2955b-5493-4ffd-8c0e-035ec0c568e8"
      unitRef="usd">3181000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib8eae5c4905b48a5a846277f611293d6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjYtNy0xLTEtMA_081d10ac-195c-477b-9ecd-319d7bd08fd4"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjYtMTItMS0xLTA_5de819dc-cc33-4921-a982-3e471cab7c51"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i78392aeb8d0d4d69b7d12c4780e86396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctNS0xLTEtMA_79badb6d-de68-4ba5-8246-299fc4a462c2"
      unitRef="usd">183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="id67458ea516e439bbc83b615b79b3518_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctOS0xLTEtMA_74e8608b-fc3d-4358-854f-8418e18c8155"
      unitRef="usd">163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjctMTItMS0xLTA_67fc0bf7-5221-48bc-bbea-30bda184a9db"
      unitRef="usd">346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="id67458ea516e439bbc83b615b79b3518_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjgtOS0xLTEtMA_005fb4b4-e981-471f-aa73-c3bfb81229ab"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjgtMTItMS0xLTA_dcf28036-f449-41f6-8afe-0ed9366e2241"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="idf82073fee7b42059c5ceb699522c8e2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMS0xLTEtMA_f826254b-0c31-4d92-abef-5ecbac3dff5e"
      unitRef="shares">20765533</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf82073fee7b42059c5ceb699522c8e2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMy0xLTEtMA_a70f36fc-b26e-44f0-96c7-d61658175288"
      unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea39822ada3c494db6a1bf3fd99d48b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktNS0xLTEtMA_042c29d8-b315-4b95-b098-18cdf40056a5"
      unitRef="usd">791114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i111967c6372740459aedf8ec7bb0ce69_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktNy0xLTEtMA_bb0fccbb-2f41-4dda-ac99-8838e8a42070"
      unitRef="usd">-1024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f450afb88d04c82a9ea8a0fe0f120af_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktOS0xLTEtMA_dfe19006-5328-4b12-9f5f-c61a4fda90da"
      unitRef="usd">-229197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMjktMTItMS0xLTA_3b8af01a-080f-4b7e-b8a1-2a940bfd2be5"
      unitRef="usd">560914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMS0xLTEtMA_76aca2a8-4d72-4607-bea5-43b9acda1684"
      unitRef="shares">179838</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtNS0xLTEtMA_b8f9366f-46a4-45a4-b7d9-6a988706a691"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMTItMS0xLTA_ddfb3e10-7fcd-4bd3-bc9b-5667fa795105"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtNS0xLTEtMA_bb04e3d7-649e-4ab2-9340-548c39fb89aa"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtMTItMS0xLTA_f51359b3-8406-48a4-af0c-f74fd47b8556"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMS0xLTEtMA_a2158653-a872-4490-932f-634acd5c1452"
      unitRef="shares">4122133</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7eb3a73906044047a7b3c77a45602a20_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMy0xLTEtMA_ad280bf6-8643-4b29-942d-ab6740533a43"
      unitRef="usd">4000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItNS0xLTEtMA_f8f2cc53-548e-49ab-82b3-36d444273253"
      unitRef="usd">448429000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMTItMS0xLTA_8fcf2454-1383-44ee-8bb5-9fadb6ed5151"
      unitRef="usd">448433000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtNy0xLTEtMA_6997efd3-a547-40aa-a8d5-b2e42b7ed6a8"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtMTItMS0xLTA_dc7772a3-d059-42d5-9891-dedc4b72ff77"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id22c855935de4edc89ac6e244c7d543b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtNy0xLTEtMA_aa8d42de-eb19-472f-9e9e-6b5b5cb16dda"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtMTItMS0xLTA_99c6ced1-f027-4c84-a600-8f76cdc5d4a1"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i6c8e64aeed5147ac8e35ce60509bec40_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtNS0xLTEtMA_c1d1ae53-90d3-4bce-8f7f-fa66a528171d"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtMTItMS0xLTA_b38bbfc7-a27b-40ba-a07f-fd5b33d77572"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="i651d151d6b5945ae854d15dfa48f1c67_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtMA_9e159baa-9101-4845-b6c5-a4b22dd390cf"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMTItMS0xLTA_339c1058-fd54-4156-b3f8-83c074d0e026"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i59f3bec8971d4633aec80a74abc60a98_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMS0xLTEtMA_d3386b6b-ea78-45ba-a705-60e90a66647a"
      unitRef="shares">16823238</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59f3bec8971d4633aec80a74abc60a98_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMy0xLTEtMA_2e51b44c-e887-480d-bccb-1c7f1d3549cd"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41f9c1547a2345d6875efa9ab06fc528_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNS0xLTEtMA_f6ead11e-5858-4fb3-bc04-37fb3618a1c7"
      unitRef="usd">367326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74ce61c0bc144472b7631a9d4df3f9f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNy0xLTEtMA_bb2ae411-412a-4a52-8c9d-8b50bc7c621b"
      unitRef="usd">-216000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5781b4d9f661461796c8363bed666193_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctOS0xLTEtMA_aaf5d604-362f-47a9-aed4-d3548610123b"
      unitRef="usd">400105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMTItMS0xLTA_ce662199-412d-4ff2-888d-4e5ee3cfb6dd"
      unitRef="usd">767232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMS0xLTEtMTU4NQ_a7c96509-e8e8-4c0a-a20c-a321100beb7d"
      unitRef="shares">190672</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtNS0xLTEtMTU5OA_163589b4-d70f-4d7c-bbcf-2088f2eb3773"
      unitRef="usd">1535000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzAtMTItMS0xLTQ5NDY_16351ffb-a0a7-4e04-afc7-07f1fd42356d"
      unitRef="usd">1535000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtNS0xLTEtMTU5OA_57ec9d7b-a133-458b-a3ce-bbfbc43bf85e"
      unitRef="usd">30727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzEtMTItMS0xLTQ5NDg_1c5fca43-ff2f-4c68-b641-11f06ac66ddf"
      unitRef="usd">30727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMS0xLTEtMTU4OQ_0d6015f8-3583-47a4-9db0-9c81a81c395c"
      unitRef="shares">934079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8c59a4f6a2a246c4b4d0d368916cf834_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMy0xLTEtMTY3MA_49db4d0c-d0c1-4a11-821a-43fb03d9e5d7"
      unitRef="usd">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItNS0xLTEtMTU5OA_526de405-e486-4e9f-a8c5-92da9d68187e"
      unitRef="usd">77997000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzItMTItMS0xLTQ5NTA_4ab8f732-fcc9-44d8-bb6d-cbab4ec0b414"
      unitRef="usd">77998000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtNy0xLTEtMTYwOA_56c6dfed-0667-4f14-b75a-355e8e80f058"
      unitRef="usd">-162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzMtMTItMS0xLTQ5NTI_a473b3f4-0eb4-4767-819c-1baed5259371"
      unitRef="usd">-162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib60fc6f02211430788ebc4e167ca11f9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtNy0xLTEtMTYwOA_c80a7d3d-240a-4dff-95e3-f666907eea32"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzQtMTItMS0xLTQ5NTI_d1a368bb-61e9-4b71-9d8f-55d2ddca04e4"
      unitRef="usd">-423000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtNS0xLTEtMTYwMw_97ccb69d-f9b9-4f3d-945e-0bb17cfc649e"
      unitRef="usd">-3236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzUtMTItMS0xLTQ5NjM_16487eb4-7b51-454f-823c-f3b21fb7c53e"
      unitRef="usd">-3236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f4968cadd8f471d9ce10c3dac04adeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtMTY2MA_cce559de-0a79-48bc-bebb-c16298fa5085"
      unitRef="usd">-5168000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic556fe238be54d7ea1cbe97cfc3b66cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtMTItMS0xLTQ5NTU_8a6bc129-2a02-4aac-a1e5-9787c66b2278"
      unitRef="usd">-5168000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i3a634a0effe34cc5a1cb74fc7382f8dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctNS0xLTEtMTYxNA_621f28ea-1dc3-4aa3-a463-a1552cf669cf"
      unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzctMTItMS0xLTQ5NjE_f7d5fa44-49c5-459f-a015-05d6851ab218"
      unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="ib3886328178847949eca5c819b9d1a5f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzYtOS0xLTEtNDc4_c56f54a2-d8f4-401c-bce2-fe03910d776a"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzgtMTItMS0xLTQ5NTc_9fbf8c41-f1b5-42b0-8bd3-3a2552af2c4d"
      unitRef="usd">-2985000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id9438636ad1d45ac9d842c540b69c517_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMS0xLTEtNDk1OQ_ad21e7ff-91c7-4931-ba74-f11d0ac5d2b5"
      unitRef="shares">16079831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9438636ad1d45ac9d842c540b69c517_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMy0xLTEtNDk1OQ_60087417-408e-4344-813b-37d5596a4fd3"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f2a6466d039469193ef347cfe3c1115_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktNS0xLTEtNDk1OQ_6ba4f808-b774-4d9a-a7d7-ce0517ec7c49"
      unitRef="usd">318358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb83d5853ca34bfe8b02f1ad840f88e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktNy0xLTEtNDk1OQ_16a601bb-3314-4ee8-b545-70039d715585"
      unitRef="usd">-801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d45dbab0ab74a33aec9e7b5fc42b546_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktOS0xLTEtNDk1OQ_d00d9ff6-a8ea-4f4a-a97a-02ff65318be8"
      unitRef="usd">391952000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83My9mcmFnOjU5NGJlZmM3YmQ3YTRlZTA5YmUwOWI0MjM5Y2E5NGU4L3RhYmxlOjhhNzAyOGEyNTMxNDRhNjg4NTc1ZmMyNDc5NTkxZDk2L3RhYmxlcmFuZ2U6OGE3MDI4YTI1MzE0NGE2ODg1NzVmYzI0Nzk1OTFkOTZfMzktMTItMS0xLTQ5NTk_b79276a4-de65-492b-bcca-31c7021f9eaa"
      unitRef="usd">709525000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy0xLTEtMS0w_909245d2-a065-46a6-b8eb-4870b0a3bb6e"
      unitRef="usd">-2985000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy0zLTEtMS0w_545cf2c5-9951-4f16-85ad-52044325af74"
      unitRef="usd">629302000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMy01LTEtMS0w_9e45b040-1732-4db6-b35e-af9e376ae8c7"
      unitRef="usd">143321000</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS0xLTEtMS0w_f172651e-23c1-450e-923a-7683c60f6304"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS0zLTEtMS0w_47ac9ee7-5177-4d2b-922d-1b662c1fbb04"
      unitRef="usd">812797000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNS01LTEtMS0w_984b24a6-8841-4b85-b909-b973c7079c09"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNy0xLTEtMS02ODk1_d4c930da-84a6-4204-a61a-74e2606c23d4"
      unitRef="usd">17114000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0zLTEtMS02OTM5_4f181f8d-f2f9-450f-bdb3-3d8235c7dd9a"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi01LTEtMS02OTM5_82576ef8-1e04-478f-b9ca-4ed226d7b268"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0xLTEtMS0w_fe7cd832-cdea-4b2f-837a-c60bd1137cbd"
      unitRef="usd">-963000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi0zLTEtMS0w_84e65b07-be87-45fc-931d-5d1f8756d189"
      unitRef="usd">30000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNi01LTEtMS0w_4d18e708-1ed2-4301-8021-7eba3d1d55c6"
      unitRef="usd">-3448000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC0xLTEtMS0w_9837d8ac-4d12-43b5-b571-6ef53b0ab019"
      unitRef="usd">25691000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC0zLTEtMS0w_19c500d6-1de1-4a3f-8523-aa15b8918194"
      unitRef="usd">18361000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOC01LTEtMS0w_3a0c1d9a-c99c-4a7d-94bf-1a2daf877f45"
      unitRef="usd">12784000</us-gaap:DepreciationDepletionAndAmortization>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS0xLTEtMS0w_af0fbb02-f5e6-4463-97eb-9da81aa85e71"
      unitRef="usd">-16933000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS0zLTEtMS0w_bde0ec40-7bc6-49be-9289-e4dc2f981079"
      unitRef="usd">1049000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfOS01LTEtMS0w_b4f80856-0b03-44e7-9208-4bde38038189"
      unitRef="usd">50377000</lgnd:GainLossOnShortTermInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtMS0xLTEtMA_eb38e01d-e574-4066-a929-42c8492320b3"
      unitRef="usd">-1479000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtMy0xLTEtMA_7f92b88a-537d-491d-a58c-c1a033247fc5"
      unitRef="usd">10274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTAtNS0xLTEtMA_6b85fb56-0acb-4acb-9084-a8e7f6b73abe"
      unitRef="usd">5452000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtMS0xLTEtMA_9ad594d8-6dcd-493a-b58a-162f2cc54653"
      unitRef="usd">23077000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtMy0xLTEtMA_bcf8a3af-1d9e-4188-989f-dc75d38662fc"
      unitRef="usd">29988000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTEtNS0xLTEtMA_3f67fd62-6cb3-4912-ba89-9221f56192ab"
      unitRef="usd">43954000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItMS0xLTEtMA_d07465b4-5534-4652-b470-a9c7fc73bfcf"
      unitRef="usd">2275000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItMy0xLTEtMA_c7b98f9a-ee5a-44b8-bd1d-5d85097c8853"
      unitRef="usd">25370000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTItNS0xLTEtMA_caf33d48-3123-48bf-9094-c95fee76bf14"
      unitRef="usd">1934000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <us-gaap:ShareBasedCompensation
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtMS0xLTEtMA_aa5fa713-afb5-4b54-ab48-ec72491c208e"
      unitRef="usd">30727000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtMy0xLTEtMA_d06eaaea-93b0-4091-b3e8-991bcc884de0"
      unitRef="usd">24515000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTMtNS0xLTEtMA_d22be599-ca17-4e62-af9e-05317e63b1c9"
      unitRef="usd">20846000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtMS0xLTEtMA_4984e573-d9ef-4e35-af57-6486d85ef032"
      unitRef="usd">19053000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtMy0xLTEtMA_6a2603dc-beaa-4d9c-9e32-9485bcd23fd6"
      unitRef="usd">-74829000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTQtNS0xLTEtMA_bc6478d9-d537-4d2e-ac7e-a6e6fbb6471d"
      unitRef="usd">-29739000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtMS0xLTEtMA_79d002b8-e579-40fe-b52c-b3e97ee35ae5"
      unitRef="usd">0</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtMy0xLTEtMA_9bacd2be-2dbb-440d-979b-60894b9b4bf0"
      unitRef="usd">0</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTUtNS0xLTEtMA_47437a2d-9dd1-4edb-aade-2fe6e4b7ef8c"
      unitRef="usd">32707000</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtMS0xLTEtMA_4249b97f-6955-4f40-83af-047023d371f1"
      unitRef="usd">2657000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtMy0xLTEtMA_3631559e-3ff0-4d37-95f0-1a3ef6dc89ce"
      unitRef="usd">-3498000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTYtNS0xLTEtMA_9f843340-32a5-4b20-a070-2cc552a031ff"
      unitRef="usd">2931000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtMS0xLTEtMA_1975277c-12d6-404f-8c23-80a69373e08e"
      unitRef="usd">26061000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtMy0xLTEtMA_0b3adf6b-89d2-4437-aa5e-c032bbf37a87"
      unitRef="usd">-25463000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTgtNS0xLTEtMA_2aa76fbf-3a2d-4127-853b-c65f865bfc00"
      unitRef="usd">29544000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktMS0xLTEtMA_3017090a-68b5-4ca2-a824-01a243b73c41"
      unitRef="usd">17799000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktMy0xLTEtMA_16eeea86-0bbd-4943-9a11-0175698ceb48"
      unitRef="usd">2061000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMTktNS0xLTEtMA_a2558859-2dcb-4b0e-8fd9-c4a58f62c43b"
      unitRef="usd">2559000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtMS0xLTEtMA_90f0746d-8595-4f14-be32-8d7e54b46260"
      unitRef="usd">-1245000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtMy0xLTEtMA_abfe2b41-76f0-47a3-8950-44fb7fadbb8b"
      unitRef="usd">-6664000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjAtNS0xLTEtMA_30b9c8f6-7112-48ab-8f6a-4fb8c6d86bc2"
      unitRef="usd">-4533000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtMS0xLTEtMA_7c96b014-2e32-4fec-b92c-8c3d3ae1877b"
      unitRef="usd">-9144000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtMy0xLTEtMA_aaab17d8-e80b-494a-abe9-538a6a038e6b"
      unitRef="usd">11219000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjEtNS0xLTEtMA_73783323-9170-43c3-9225-40bb5c922e28"
      unitRef="usd">-318000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItMS0xLTEtMA_d550a5f9-1fe2-4ac9-ae49-c71bbb20dc30"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItMy0xLTEtMA_a54c6c98-04dc-46de-8a8d-0780b2218679"
      unitRef="usd">-12000000</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjItNS0xLTEtMA_200bfdec-437f-4b54-935e-397fd7ca1c80"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMS0xLTEtMTIxNTg_691f46d6-49fb-4c97-9941-d5e0fde7669d"
      unitRef="usd">29236000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMy0xLTEtMTIxNjc_6933426f-5cc3-4a69-b9b0-96c625a49ec2"
      unitRef="usd">-1147000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtNS0xLTEtMTIxNjI_fe2b55a8-25fc-4855-a010-7f6b53e3eac6"
      unitRef="usd">-1158000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMS0xLTEtMA_e887e9de-41b6-474a-90c3-dd44741a3eac"
      unitRef="usd">-3339000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtMy0xLTEtMA_97eefbae-86ea-4868-8b0d-c0f9f2931029"
      unitRef="usd">3575000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjMtNS0xLTEtMA_77d0e158-c5f2-4a92-b86d-2b0e8922eb08"
      unitRef="usd">-4300000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtMS0xLTEtMA_f6f86d4a-ed57-44dc-a93d-82fc62452078"
      unitRef="usd">54586000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtMy0xLTEtMA_ff52b97f-6509-466a-907b-05b3c562ce02"
      unitRef="usd">-29336000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjQtNS0xLTEtMA_cde81a83-18d9-47ed-8cc2-a7320d3ce4c5"
      unitRef="usd">194059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtMS0xLTEtMA_07be16e9-a7d4-46b1-bf75-580a1ba940e1"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtMy0xLTEtMA_fe4363f3-b1ad-4a8f-b179-ee5ac4ff613e"
      unitRef="usd">812797000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjYtNS0xLTEtMA_13794dd2-4243-44c7-b80f-d438bd6ca302"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctMS0xLTEtMA_de638754-7366-4915-a03a-df15b9a04d58"
      unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctMy0xLTEtMA_003dbe07-26e5-47b9-b501-80dceafd75e3"
      unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjctNS0xLTEtMA_37f7aed7-bd4a-49a3-bd1c-f3dc15202fa1"
      unitRef="usd">10000000</lgnd:PurchaseforCommercialLicenseRights>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtMS0xLTEtMA_b55c1f8e-bba3-4f4b-9768-17e655727407"
      unitRef="usd">404884000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtMy0xLTEtMA_21c4dcc0-5bda-4ffe-87f1-d3215d4ac6da"
      unitRef="usd">11840000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjgtNS0xLTEtMA_46d4d3a4-9259-458f-a79c-3b40a746e6ef"
      unitRef="usd">5856000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktMS0xLTEtMA_c9284dde-245c-40cf-a463-4c644d6cb6f2"
      unitRef="usd">4458000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktMy0xLTEtMA_d1eb2ee1-4dd9-4d18-910c-dc07946db60d"
      unitRef="usd">2553000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMjktNS0xLTEtMA_cc0a7246-605e-4b11-b6b7-9f80516c1788"
      unitRef="usd">887000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtMS0xLTEtMA_c1763e2d-37bd-4c86-be4f-654b33e16c3f"
      unitRef="usd">422523000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtMy0xLTEtMA_a975da25-8340-4798-8871-cdb76ff92959"
      unitRef="usd">2356545000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzAtNS0xLTEtMA_b09944f5-ab37-439d-96d3-6974f60c156b"
      unitRef="usd">1434255000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzMtMS0xLTEtNjkxMQ_d702742f-538a-4d8c-b497-66e12a2d96f8"
      unitRef="usd">1358000</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMy0xLTEtNjk0NQ_ab2e754f-c97c-4319-bce8-1206aa81537d"
      unitRef="usd">0</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItNS0xLTEtNjk0Nw_80b85cf6-6333-4835-ae64-2114c922b8d7"
      unitRef="usd">0</lgnd:ProceedsFromCommercialLicenseRights>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtMS0xLTEtMA_de624c25-f415-4886-861f-bd40f3af6e1f"
      unitRef="usd">394539000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtMy0xLTEtMA_bc39b759-f0f9-4774-a493-f1e42f35a750"
      unitRef="usd">535877000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzEtNS0xLTEtMA_25973ca6-c875-45b9-aed4-128fc5340cc7"
      unitRef="usd">131942000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMS0xLTEtMA_86c0f0f9-fb04-4a8f-85ec-bae7c888807d"
      unitRef="usd">644155000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItMy0xLTEtMA_8d91432c-f989-4cf1-8969-61c44bc36013"
      unitRef="usd">1494851000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzItNS0xLTEtMA_3d009157-9274-4d6b-8dac-828bb3308749"
      unitRef="usd">892873000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtMS0xLTEtMA_d10dee03-4949-4e20-aae5-b988a132762b"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtMy0xLTEtMA_ac27ad25-5090-4fa2-966b-2bde7b722e92"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzQtNS0xLTEtMA_dc78fe26-9e46-4e6b-ab7f-cd36481fb8e9"
      unitRef="usd">3914000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtMS0xLTEtMA_6203f7d2-23eb-4ea4-9f76-b2a27106eb25"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtMy0xLTEtMA_3bd26bef-f6d4-4802-81d7-fe7ff14b12b7"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzUtNS0xLTEtMA_bf1ab145-acd4-4cb5-a109-e5f102142667"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMS0xLTEtNjkyMQ_9ec27d89-3413-466f-8250-f463605cef29"
      unitRef="usd">22061000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMy0xLTEtNjk0MQ_83762e07-efa6-45dd-9015-09a47099a6e0"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctNS0xLTEtNjk0MQ_c5c7a5c2-5a7b-4846-9c84-956497fcb46d"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtMS0xLTEtMA_fde80fff-083b-438d-ba33-1aed3d19f653"
      unitRef="usd">-1900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtMy0xLTEtMA_8d246d0f-078a-42f2-8cfe-da890d273f02"
      unitRef="usd">4669000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzYtNS0xLTEtMA_2879dd50-458e-4c61-a0c7-40f787db206d"
      unitRef="usd">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMS0xLTEtMA_1ebfb988-785c-4d07-9141-ed5c8753aa74"
      unitRef="usd">231648000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctMy0xLTEtMA_7701c1f2-0e35-40fe-9d7c-b2f99d63f62d"
      unitRef="usd">466918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzctNS0xLTEtMA_11952258-782d-46f3-b954-141b46fe4241"
      unitRef="usd">-423269000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktMS0xLTEtMA_6ba7db55-9d96-4fb2-adc8-b2538e9bf79a"
      unitRef="usd">222209000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktMy0xLTEtMA_d8881729-ad99-4711-8f9a-890bc4476bb7"
      unitRef="usd">27323000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfMzktNS0xLTEtMA_f7e42eb0-e63a-4f4a-ac7e-b2103ea950f1"
      unitRef="usd">217674000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMS0xLTEtNjkzMQ_2b78340d-4ed5-42d3-9de4-7c215278cdde"
      unitRef="usd">9549000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMy0xLTEtNjk1Mw_aca7664b-d4b1-4bad-ba4d-9b218b59d2ed"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItNS0xLTEtNjk1Mw_40410e0a-af6d-45fe-b854-9c77496e52dd"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtMS0xLTEtMA_43de4e37-364a-4412-bd97-5dea35d1a9f6"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtMy0xLTEtMA_65de2593-2ef2-4d89-ad47-72e2270880ee"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDAtNS0xLTEtMA_f30b4054-5778-4e19-be67-2ab2dd5739f0"
      unitRef="usd">750000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtMS0xLTEtMA_69de22a8-d984-4484-87d7-439b6dfa8f05"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtMy0xLTEtMA_f42e1cce-ba3a-4bfe-8429-64ec9ab6b078"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDEtNS0xLTEtMA_0a1b0ba1-b731-43b5-99a4-ee1c507b1764"
      unitRef="usd">16900000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMS0xLTEtMA_183443f1-39f1-4eab-9639-c42929451cdc"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItMy0xLTEtMA_4241e480-fde0-4e84-ab62-5b487253098f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDItNS0xLTEtMA_cefe6558-d51c-490a-a8fa-b0764c7ed331"
      unitRef="usd">90000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtMS0xLTEtMA_4b38601c-8a50-4136-a30c-1a912e54bd3e"
      unitRef="usd">0</lgnd:PurchaseOfConvertibleBondHedge>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtMy0xLTEtMA_cf6f0638-69be-4bd8-950b-1edda54fbc68"
      unitRef="usd">0</lgnd:PurchaseOfConvertibleBondHedge>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDMtNS0xLTEtMA_cc56e9b7-fe52-42fb-9774-5bce0193c037"
      unitRef="usd">140250000</lgnd:PurchaseOfConvertibleBondHedge>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtMS0xLTEtMA_116b14a0-24cc-44d2-862a-1e2d0b0cbef5"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtMy0xLTEtMA_1441911f-8ab5-4520-89ed-8940b88ecd3b"
      unitRef="usd">12401000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDQtNS0xLTEtMA_bd14e999-3cf0-43d9-af5b-da400f384052"
      unitRef="usd">439559000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtMS0xLTEtMA_9b57973c-0346-41b9-809b-d742aa6f2899"
      unitRef="usd">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtMy0xLTEtMA_d5f47d7a-eaf6-473b-8637-b9b30836f891"
      unitRef="usd">12401000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDUtNS0xLTEtMA_37533ca6-4c50-42b4-953c-10edf1500ab5"
      unitRef="usd">439581000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtMS0xLTEtMA_5f75f783-a68d-478d-bfa8-1fb15b71196f"
      unitRef="usd">3017000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtMy0xLTEtMA_d8045596-3f06-4bd5-b94d-63eaaa785bbf"
      unitRef="usd">2997000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDYtNS0xLTEtMA_0777cf79-d863-48fc-a754-4446234a66c2"
      unitRef="usd">20183000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctMS0xLTEtMA_42227736-1aec-4cf9-9ee8-a30a3de1e114"
      unitRef="usd">1481000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctMy0xLTEtMA_2ac55862-a86c-42f6-846c-bddb7230e1c8"
      unitRef="usd">4418000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDctNS0xLTEtMA_6fc54f9e-1855-4df4-aad2-c1140a3f258a"
      unitRef="usd">3765000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtMS0xLTEtMA_6fd2267e-84ce-4429-9859-e382003ee44d"
      unitRef="usd">77998000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtMy0xLTEtMA_85db8291-4822-4063-8ed2-69d0179bc18f"
      unitRef="usd">453048000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDgtNS0xLTEtMA_cddcc1bb-3152-41de-a9e7-49b7171ce818"
      unitRef="usd">122868000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktMS0xLTEtMA_f632509a-f464-4f75-a80b-9ae9bc1c7ef1"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktMy0xLTEtMA_8edf8864-1310-49a3-be73-c10a249924d7"
      unitRef="usd">380000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNDktNS0xLTEtMA_27f233dd-ac6c-420a-bca8-587a4f8c2b9d"
      unitRef="usd">30094000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtMS0xLTEtMA_7ea5e163-a39c-40b7-9556-8cafda8f7ba4"
      unitRef="usd">2325000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtMy0xLTEtMA_1013797b-015b-497a-8991-5cc98f92eee9"
      unitRef="usd">3000000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTAtNS0xLTEtMA_57b85d9d-f0db-4788-b4a9-ba413d6c4992"
      unitRef="usd">25000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtMS0xLTEtMA_78a945a7-aac2-46db-947a-376155a15415"
      unitRef="usd">-310545000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtMy0xLTEtMA_83e60163-97d3-41ba-a102-52a19526de07"
      unitRef="usd">-485172000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTEtNS0xLTEtMA_6a62b3b2-7e5a-4da1-a2c3-f7ceb59049c2"
      unitRef="usd">328585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItMS0xLTEtMA_e6cba2b7-c042-42a3-b25b-f00afe78e93f"
      unitRef="usd">-24311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItMy0xLTEtMA_ddb0ecbe-26d6-47b0-98ca-d4aa2f043836"
      unitRef="usd">-47590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTItNS0xLTEtMA_1ea1cdb8-a9d2-4a7d-a642-7e565511ea0d"
      unitRef="usd">99375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtMS0xLTEtMA_5ed5cedd-c708-4b0a-b07d-6ba03a7e3b68"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtMy0xLTEtMA_64f7e6c7-ab26-45ea-9f83-0c073d7778af"
      unitRef="usd">83000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTMtNS0xLTEtMA_615b57b0-bc96-4bd1-b37b-24c7e3f9f2b9"
      unitRef="usd">-215000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtMS0xLTEtMA_28fbc02e-909b-42d8-9b4e-0c5cd6c11b24"
      unitRef="usd">72273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtMy0xLTEtMA_06084afa-c034-4350-adb0-9bfea34e0a3a"
      unitRef="usd">119780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTQtNS0xLTEtMA_2a7e4af9-0998-4823-be50-9d2aa2f51db5"
      unitRef="usd">20620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtMS0xLTEtMA_b4d9fad8-7d4c-444b-8a07-8552ae895137"
      unitRef="usd">47962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtMy0xLTEtMA_9121c0c3-6527-4137-b8a6-11410d49e7fa"
      unitRef="usd">72273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTUtNS0xLTEtMA_4d275164-05d5-4541-8470-e24213a68387"
      unitRef="usd">119780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtMS0xLTEtMA_237e27b4-c3f7-46ff-8ccd-5fe2b88a425d"
      unitRef="usd">4463000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtMy0xLTEtMA_55882d65-788b-4ec2-8496-4e917cd3af3d"
      unitRef="usd">5827000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTgtNS0xLTEtMA_c85a144f-652e-43d7-9cb9-e030b63da4b7"
      unitRef="usd">1513000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktMS0xLTEtMA_648545ba-16b3-47cc-8a2d-4670da5632d9"
      unitRef="usd">2130000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktMy0xLTEtMA_a2a9bd39-ba4a-4cd3-b343-449b0a705904"
      unitRef="usd">103817000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNTktNS0xLTEtMA_eab6661d-3219-4819-a55f-db093f280759"
      unitRef="usd">341000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RestrictedCashCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtMS0xLTEtMA_043b7dc4-57e6-4fc1-a56d-6f15c481a642"
      unitRef="usd">343000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtMy0xLTEtMA_76d2c531-b674-4d9a-89e0-aeedb17cbe7c"
      unitRef="usd">730000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjAtNS0xLTEtMA_5e1f1728-2543-4fbb-aaea-b4f73016be67"
      unitRef="usd">2616000</us-gaap:RestrictedCashCurrent>
    <lgnd:AccruedInventoryPurchases
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItMS0xLTEtMA_d81b6c00-25eb-40a3-8e4e-1c7d3cf7e798"
      unitRef="usd">1562000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItMy0xLTEtMA_617363f1-8d05-4ef4-922a-04579c91ab32"
      unitRef="usd">170000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjItNS0xLTEtMA_891eb4dd-5421-44f5-bc09-b991bdf613fd"
      unitRef="usd">2059000</lgnd:AccruedInventoryPurchases>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtMS0xLTEtMA_ffbb6184-acf9-4cf3-aed1-5ce69fa8ff97"
      unitRef="usd">-212000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtMy0xLTEtMA_52080f73-6f89-455e-a690-f1c8c0495e04"
      unitRef="usd">256000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjMtNS0xLTEtMA_2fe77905-4629-4d9d-903f-72948c16cdad"
      unitRef="usd">48000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtMS0xLTEtMA_52a2088c-ff34-46ac-ac06-5dc1b1883f77"
      unitRef="usd">249000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtMy0xLTEtMA_bcd3d947-de3d-40f3-9ef0-3d393c06f20c"
      unitRef="usd">495000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF83Ni9mcmFnOjlhM2FlNTNkZTE3OTRmMTNhYmRkNWMwNjY1YWZmMzgxL3RhYmxlOjUyMmY2ZWYyMDdmMTQ0MTFiNTJiYWE0NTMzMTY5MTQ5L3RhYmxlcmFuZ2U6NTIyZjZlZjIwN2YxNDQxMWI1MmJhYTQ1MzMxNjkxNDlfNjQtNS0xLTEtMA_26aadedc-5aa5-4a69-bc63-1e0d90dfdb6b"
      unitRef="usd">15000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTc_f23885d2-5cfa-49ef-91c3-ccbce0ed71d4">Basis of Presentation and Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking common stock and warrants was reclassified from &#x201c;investment in Viking&#x201d; to &#x201c;short-term investments&#x201d; in the audited consolidated balance sheet as of December 31, 2019. Additionally, &#x201c;gain (loss) from&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;short-term investments&#x201d; in the consolidated statements of operations include both the gain (loss) from investment in Viking and other short-term investments, which was previously included in &#x201c;other income, net&#x201d; for both the twelve months ended December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year-ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &amp;amp; Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  We periodically review available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To date, we have not identified any other than temporary declines in fair value of its short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2020, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $0.3&#160;million of allowance for credit losses as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2020, 2019 and 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1"&gt;ten&lt;/span&gt; years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;amp;D is capitalized and assessed for impairment annually. IPR&amp;amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Pfenex in October 2020, we will pay $2.00 per share or $77.8&#160;million as a CVR in the event a predefined regulatory milestone is achieved by December 31, 2021. The CVR Agreement provides that the required milestone will be achieved upon the receipt of a notice from the FDA that the teriparatide injection is therapeutically equivalent to FORTEO&#xae; (teriparatide injection).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $10.5 million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d;   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2020, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights as of December&#160;31, 2020 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and reduce our asset as the funds are expended by Novan. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2020 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2020 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of adopting ASU 2016-13, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic and recorded an additional $0.5 million reserve for credit losses in other expense, net, in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard. See additional information in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsection below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we own. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted for in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when control of Captisol material is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. We have elected to recognize the cost of freight and shipping when or after control over Captisol material has transferred to the customer as an expense in cost of Captisol. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract revenue includes service revenue, license fees and future contingent milestone based payments. We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment.  These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December 31, 2018 was $3.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical Study and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2"&gt;six&lt;/span&gt; month anniversary of the date of grant, and 1/48 each month thereafter for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124"&gt;forty-two&lt;/span&gt; months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the twelve months ended December&#160;31, 2020, all of the 0.6 million weighted average shares of outstanding equity awards as of December&#160;31, 2020 were anti-dilutive due to the net loss for the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Warrants associated with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2019 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees and partners, patients, communities and business operations, as well as the U.S. and global economy and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#x201c;stay-at-home&#x201d; orders, and restricting business functions outside of one&#x2019;s home. In response, we have restricted in-person access to our executive offices, our administrative employees are mostly working remotely, and we have limited the number of staff in our research and development laboratories and other facilities. The continued spread of the COVID-19 pandemic and the measures taken by the governments of countries have&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;affected, and could continue to affect, our business and the business of our partners, including future disruptions to our supply chain and the manufacture or shipment of drug substance and finished drug product for Captisol, delays by us or our partners in the initiation or enrollment of patients in clinical trials, discontinuations by patients enrolled in clinical trials, difficulties launching or commercializing products and other related activities, which could delay ongoing clinical trials, increase development costs, reduce royalty revenues and have a material adverse effect on our business, financial condition and results of operations. Several of our partners have reported that their operations have been impacted including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who have contracted the virus or to&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prevent the spread of the virus. This may lead to clinical trial protocol deviations or to discontinuation of treatment for patients who are currently enrolled in the clinical trials being conducted by us or our partners. In addition, certain of our partners have reported negative impacts on product sales which will impact our royalty revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and Vernalis partners have initiated antibody discovery programs for the potential treatment of COVID-19.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We adopted ASU 2016-13 on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance sheet of retained earnings to be recognized on the date of adoption with prior periods not restated. The cumulative-effect adjustment, net of tax, recorded on January 1, 2020, is approximately $5.2 million. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under previously applicable accounting standards. See additional disclosure on credit losses under  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Accounts Receivable and Allowance for Credit Losses&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Commercial License and Other Economic Rights&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; discussed above and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Short-term Investments&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (8), Balance Sheet Accent Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Test for Goodwill Impairment, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement: Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the disclosure requirements on fair value measurements. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We adopted this standard on a prospective basis on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures. We intent to adopt this standard on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTM_5c0c64a4-d703-492e-8453-a4de71521470">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTg_abfe0ee3-7210-4fad-98a9-9d1cd08c2c3c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjE_30e7eedd-5c7e-411b-9ea1-3f853e2c36d0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking common stock and warrants was reclassified from &#x201c;investment in Viking&#x201d; to &#x201c;short-term investments&#x201d; in the audited consolidated balance sheet as of December 31, 2019. Additionally, &#x201c;gain (loss) from&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;short-term investments&#x201d; in the consolidated statements of operations include both the gain (loss) from investment in Viking and other short-term investments, which was previously included in &#x201c;other income, net&#x201d; for both the twelve months ended December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDA_e8fb0bff-5d21-410c-9e40-861977b99c2e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTQ_8491760d-888a-40e9-b328-078344174e6c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDk_6854d0bf-1d80-4dbc-ac86-2f3cd6f749bc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year-ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c73811c3a6b413583f19b4f18914422_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi0xLTEtMS0w_2d9bd376-3e52-4b46-840e-666b26de52c8"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8ec746f5f2a1420e8b4a73e3b14f2911_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi0zLTEtMS0w_7ed9e830-19f9-42b2-ae3e-ac8ce070b009"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54f2cab9b1344c4ca4467e441c736d9d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMi01LTEtMS0w_78750b7b-de34-42b4-bbb2-eee637597326"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05df3adf0d3445b08cd69ac5d9c78c78_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy0xLTEtMS0w_9d21f6e9-fcb3-4af2-82c0-d2425f448871"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8f7c735f7f3a43aab5151e4131cffac0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy0zLTEtMS0w_2e2e6b62-3647-433a-98fd-e51b962b8f2c"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie64ebeef7e4d4fce822fce49568cde02_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfMy01LTEtMS0w_db4e66bf-8f08-4167-b8f1-daae37f51947"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2dd5f6f2356147aaa9c76736d1bbfb27_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmEwZjIxYjlhOGUwMzRmM2I4NmUwMWVkNmMyNTMwNjYxL3RhYmxlcmFuZ2U6YTBmMjFiOWE4ZTAzNGYzYjg2ZTAxZWQ2YzI1MzA2NjFfNC01LTEtMS0w_5b2009db-143f-446b-9704-e033cda0f6fc"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDE_a93c0c7c-2164-4a89-9e82-060bcef3bab3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &amp;amp; Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  We periodically review available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To date, we have not identified any other than temporary declines in fair value of its short-term investments.&lt;/span&gt;&lt;/div&gt;</lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock>
    <lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjkxNQ_dd224f85-8b4b-43c4-ad17-2580774d96bb">P3M</lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDc_cedd8f07-c92f-42b6-8f50-b32df211cac1">&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2020, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $0.3&#160;million of allowance for credit losses as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <lgnd:AccountsReceivableCreditLossExpenseReversalCOVID
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDk5NzUwNQ_7f744440-752c-4052-af02-52aad931e9bc"
      unitRef="usd">300000</lgnd:AccountsReceivableCreditLossExpenseReversalCOVID>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0Mjk_6b0fa08a-8acc-412c-9b49-0ea35953ba9c">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_61c7065f-488f-4b65-829c-1c6d3751acd3"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_66d1155d-9a19-439a-a450-281a13eefac2"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYxNg_9a4141d1-c1d6-4a0b-acc9-815b435d153b"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTk_857710d2-2ab5-448d-a596-0baa49f83213">&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1"&gt;ten&lt;/span&gt; years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTA_ed4bbb13-9c93-44d8-b6e9-8b0bf30f27f1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;amp;D is capitalized and assessed for impairment annually. IPR&amp;amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</us-gaap:BusinessCombinationsPolicy>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfOTM0NTg0ODk0NTE5NA_8235ceb4-297a-4963-91e2-48aeb2a161f1"
      unitRef="usdPerShare">2.00</lgnd:BusinessCombinationContingentConsiderationLiabilityAmountPerShare>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfOTM0NTg0ODk0NTE3OA_ebf19fc5-d07e-4016-8c57-5066977dc841"
      unitRef="usd">77800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzM4ODc2NA_02e7ab58-a7df-4ff2-bddb-a09b3785afc9"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="ia66f417c4e0546919bf13f281a215faa_I20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfODM1NQ_c50c769a-15f2-40dd-8f16-202f8b4c5623"
      unitRef="usd">10500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <lgnd:NumberOfContingentValueRightsIssued
      contextRef="i5e2203c889594b6d90a943e1d333ba3a_I20100131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfODg4MQ_8c7de68f-6a9c-45ed-a95a-8f5cae01c0e4"
      unitRef="right">4</lgnd:NumberOfContingentValueRightsIssued>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDg_8aa8059e-6a1a-4095-a948-b8430b99fc7f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2020, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <lgnd:CommercialLicenseRightsPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MzA_263700e3-26f2-4120-b0e1-33ec959ad9aa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights as of December&#160;31, 2020 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and reduce our asset as the funds are expended by Novan. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2020 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2020 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of adopting ASU 2016-13, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic and recorded an additional $0.5 million reserve for credit losses in other expense, net, in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</lgnd:CommercialLicenseRightsPolicyTextBlock>
    <lgnd:ScheduleofCommercialLicenseRightsTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTc_f5d0c5d1-e92a-4e7c-bff1-e52767c8a183">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aziyo and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</lgnd:ScheduleofCommercialLicenseRightsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0yLTEtMS0yMzY5_79b13149-a5a6-4316-9a79-49c76a248f14"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi00LTEtMS0yMzk4_795dc368-eb25-4dd5-baea-81b408a1e42a"
      unitRef="usd">9588000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i66b0dfc7fe6b439496e5480f51985a93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi02LTEtMS01MDY5_5caa54c1-db65-403e-997e-ee51c99e4a23"
      unitRef="usd">8108000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi04LTEtMS0yMzQ1_fb2fafb0-e20b-4238-9411-b1a5459bbcf0"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0xMC0xLTEtMjM3OQ_c4730d42-39c2-40e5-bc4c-b23e9b81ae6f"
      unitRef="usd">5500000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6e7c0ddcfa15425d90a326d8a5cc4267_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMi0xMi0xLTEtNTA3NQ_b54bb5e0-59f6-4f00-85f8-e03947525e57"
      unitRef="usd">12196000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0yLTEtMS0yMzY5_55ec5f9a-42f4-4ba9-9c3b-1020428dea6b"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy00LTEtMS0yMzk4_a67f4bac-acc0-4f79-b138-99c9a199e560"
      unitRef="usd">10000000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy02LTEtMS01MDY5_a4e67314-d298-44d9-b346-47348c4faab6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy04LTEtMS0yMzQ4_4e35e545-afa2-4324-a65b-e1a25d5ec702"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0xMC0xLTEtMjM3OQ_74489b6b-2a28-4e50-9c8d-32e04fbf5938"
      unitRef="usd">7492000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iefcf79e0add14931bd42a44ad86cb894_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfMy0xMi0xLTEtNTA3NQ_8854a8e1-3e9e-491c-85dd-b0fd2d27f4a7"
      unitRef="usd">2508000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0yLTEtMS0yMzY5_2cf27f00-914e-4682-956a-a7ae076ea52d"
      unitRef="usd">10602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC00LTEtMS0yMzk4_469b1987-adf8-447c-841b-8e5fa1ec6aac"
      unitRef="usd">7731000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iecf467e784d54b05975c3202c53c6bd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC02LTEtMS01MDY5_63c3bdeb-b936-489f-90e6-ef36875910a3"
      unitRef="usd">2871000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC04LTEtMS0yMzU1_da5aeff4-bed4-41cb-b6e1-864159d8d07c"
      unitRef="usd">10602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0xMC0xLTEtMjM3OQ_a4da72d0-f4b3-409b-a118-8fd96652efa9"
      unitRef="usd">5216000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i11a9f3d7057749e18b761924cf8ff3cc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNC0xMi0xLTEtNTA3NQ_70793569-be52-4fe4-a89a-7964ba13efed"
      unitRef="usd">5386000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0yLTEtMS01MDY1_20fc6f7c-d6f7-49de-a38f-a75a1c809647"
      unitRef="usd">38298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS00LTEtMS01MDY3_f3e099dd-5ca3-40e9-a5f5-63af28fb66ad"
      unitRef="usd">27319000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS02LTEtMS01MDY5_1a409439-9cde-4d3c-a480-ef219b15c85e"
      unitRef="usd">10979000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6f0edea451a947568476fa7759c97496_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS04LTEtMS01MDcx_125bff8d-1999-47e8-8570-66d35435a525"
      unitRef="usd">38298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments
      contextRef="i6f0edea451a947568476fa7759c97496_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0xMC0xLTEtNTA3Mg_bf250273-c070-4e04-bed7-d6615a663997"
      unitRef="usd">18208000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6f0edea451a947568476fa7759c97496_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOmUyMmMwMTkxYjUwOTQ0ZTBiNmI1OTYzMTYzNGJjNDZkL3RhYmxlcmFuZ2U6ZTIyYzAxOTFiNTA5NDRlMGI2YjU5NjMxNjM0YmM0NmRfNS0xMi0xLTEtNTA3NQ_b8b434ec-8f47-41b1-bfa2-2a08dd809abf"
      unitRef="usd">20090000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDkzMTUyNQ_f015141e-be51-457d-87aa-87e4be3124ca"
      unitRef="usd">21300000</lgnd:FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5ODUzNDkzMTUxNg_63b0aa50-66b7-452c-91b9-41f178fa15c3"
      unitRef="usd">6000000.0</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i1b989251dff94234ab86b62cbfd1d634_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NzI3OA_63b0aa50-66b7-452c-91b9-41f178fa15c3"
      unitRef="usd">6000000.0</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NzYyMw_0c4c5617-38b7-4f55-adcd-5b6d415ac747"
      unitRef="usd">5500000</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:LicenseUpfrontPayment
      contextRef="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTMyNTY_474b559b-548c-413d-a3db-f176eb0cf1e3"
      unitRef="usd">12000000.0</lgnd:LicenseUpfrontPayment>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="id68885846d2347bdbc1bf3e58a6664b7_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM0ODY_e6b3f538-77b3-4da9-9c73-a0ed2abe5136"
      unitRef="usd">20000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="id45ea6b88b7b4ce99056d77dfb9e072a_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM3Mjc_f8082a25-abd3-487c-bdb7-e5041b6c2c04"
      unitRef="number">0.070</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="iba869b10f43242e5b6c4fdd407e85a06_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTM3MzM_1c889ba1-7cad-45b8-89a2-ad8f2625c2b2"
      unitRef="number">0.100</lgnd:ProductRoyaltyPercentage>
    <lgnd:LicenseUpfrontPayment
      contextRef="i7850eda3aef046fe8d05c384e5743737_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQxNDI_474b559b-548c-413d-a3db-f176eb0cf1e3"
      unitRef="usd">12000000.0</lgnd:LicenseUpfrontPayment>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="i39c93e649e774e64b8ccfd071af32e96_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ0MDk_9b5472b2-c2aa-45ad-94f6-24fafd87352a"
      unitRef="usd">8000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i6bfcf4342f7f486e81aa9acfe6e847f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ2ODk_babdc1f3-5e4b-48da-99ee-48da2e86f585"
      unitRef="number">0.050</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i8cdf88f6a2da48ab9f7072c95808b688_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ2OTU_a01e4de5-4027-4e6c-b15f-9e0b87d97a1d"
      unitRef="number">0.098</lgnd:ProductRoyaltyPercentage>
    <lgnd:LicenseUpfrontPayment
      contextRef="i5b43e6ec0024459cad6c7d3d2e8f6e3d_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTQ5MTM_9d278c0f-3100-41ec-a309-8f73bb472d99"
      unitRef="usd">10000000.0</lgnd:LicenseUpfrontPayment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica3f7617c6b3480b8d0cd8fbc188aaec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1ODE2NQ_57b6721d-e0e6-4dbe-9a42-b204a43a8388"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8918e216e1f459c9ab0ac50491f1cf4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1ODE3NA_21abb091-f987-476b-8d66-e1301bffd0bb"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="idf035009648e4002a74fb15717a19c83_D20170531-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTU4NDI_b98867a5-6d63-417d-bba2-a445d19dde6b"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i3bc3b17ca38f450f93f33b56115ecdac_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTYxMTI_32390fc9-1507-4a30-ba31-5444f552d73e"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="iefbf54fee39c450eaef1dc95742c7f6a_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTYyMDk_98f19dae-3686-4ecb-8f4d-9ec3d484c148"
      unitRef="number">0.20</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="id0f6f413f8494ec9b556f99a873dab70_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0MzY_52d5c7c1-213d-4b94-a459-64c00cb637e8"
      unitRef="usd">10000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="idd2353e9253d4a1aa25a32912238e563_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTcxMzQ_c5c35940-1675-42fd-b701-3afb7b5459ee"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:RoyaltyAgreementExpirationPeriod
      contextRef="i2d7158892fbf44ed81d8c9568292e404_D20170531-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTcyMTk_7733a7b9-32c1-4f79-bd5f-4ea826cb26b2">P10Y</lgnd:RoyaltyAgreementExpirationPeriod>
    <lgnd:ForecastedCashFlowsEffectiveInterestRatePercent
      contextRef="i569ef336eca149ea8ce1ab7ef2a48105_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTc3MTc_d27e9de0-58e3-4b93-967e-14b071d8f968"
      unitRef="number">0.23</lgnd:ForecastedCashFlowsEffectiveInterestRatePercent>
    <lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments
      contextRef="i2906b1a9f5ad4d9ab4203a37c1693478_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU2MTExNA_0c4c5617-38b7-4f55-adcd-5b6d415ac747"
      unitRef="usd">5500000</lgnd:FiniteLivedIntangibleAssetsCreditLossAdjustments>
    <lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU2MTE3Ng_5d017edd-82bd-44b9-a5e9-47708b5e3fba"
      unitRef="usd">500000</lgnd:AccountsReceivableCreditLossExpenseReversalCOVID19>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTg_ac869dc9-c171-462d-9267-b85b7bc4e128">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard. See additional information in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsection below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we own. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted for in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when control of Captisol material is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. We have elected to recognize the cost of freight and shipping when or after control over Captisol material has transferred to the customer as an expense in cost of Captisol. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract revenue includes service revenue, license fees and future contingent milestone based payments. We recognize service revenue for contracted R&amp;amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment.  These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December 31, 2018 was $3.3 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjY3MTE_90376dd2-cae3-4f99-b380-7888f07b8d85"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjY4MTc_d42cc94a-22e8-43be-9203-13ce905eccc0"
      unitRef="usd">3300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjQ_6e43c2a5-36e8-4a1c-9cfa-d39dce5bb321">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib905672f26f34c6ca6ac51ce2c25db59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC0yLTEtMS0w_1181baab-994f-4ce7-ab52-006804085805"
      unitRef="usd">25164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eb8f7f86660458caf621f649275af47_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC00LTEtMS0w_db1e72c3-afec-477d-bff7-717f99519ec6"
      unitRef="usd">25046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida12bcf9ff53440e84c2633931d5fcca_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNC02LTEtMS0w_8d781570-6bd4-4513-9bc2-e1c5c8544062"
      unitRef="usd">21686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17a6bd9499ad4be8b30f8a074e5a4747_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS0yLTEtMS0w_0e7b81eb-d03c-4a42-9423-22207350df9f"
      unitRef="usd">6377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib762c00218db440eabd64c06b5cbeb17_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS00LTEtMS0w_efdeb716-f4b1-4b8d-984d-bc151a381d77"
      unitRef="usd">5171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05b26e3a5c35487591dbea42ea400987_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNS02LTEtMS0w_d4b0610b-afec-4b07-ad5a-37eb146b7384"
      unitRef="usd">5658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12906a0a0841439f945d94aff020ae08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi0yLTEtMS0w_eeba7220-3223-469f-a944-8e98b916be67"
      unitRef="usd">2255000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8e03c8cbe544fe2b60dd5184c74c3fa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi00LTEtMS0w_6d469aba-b124-4729-b62e-46a77771a290"
      unitRef="usd">2566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d572ef2b8494f9fa8c4e977a195c4f2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNi02LTEtMS0w_2ee4b1ef-7a48-4402-a514-d1821a241ef7"
      unitRef="usd">1952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifea7a020b78c4b429f74dae393a5908a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy00LTEtMS02MTY1_b53cc64b-c3b8-46a0-b8e5-55ad67ced83f"
      unitRef="usd">14193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74da4f182fe445218f31adabb243815c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy02LTEtMS02MTY1_28fff164-6c07-42d7-94a1-0c21120bd8f8"
      unitRef="usd">99260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74c45035bd3b4f46b89626825e45bdb6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy0yLTEtMS0w_7037656e-7942-43b3-862e-2e8afd6abf71"
      unitRef="usd">33796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1931a0405a6f4d2c98e929009ba37485_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy00LTEtMS0w_bbbbf573-e31f-4a9c-ac42-b03fed319328"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98d16dd704b74221b973893e02cd3023_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFmOWIxMzVlMzNiZDRkZmE4M2I4NDMxOGM0MGU0MjNiL3RhYmxlcmFuZ2U6MWY5YjEzNWUzM2JkNGRmYTgzYjg0MzE4YzQwZTQyM2JfNy02LTEtMS0w_9b2c4715-5529-40a6-9d9c-25c8fd9f677a"
      unitRef="usd">128556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56ad38ab46864660b4be2d09833f45d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy0yLTEtMS0w_191a0c76-db11-4604-8fb4-67b4d733fdf4"
      unitRef="usd">109959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9c7cc1c38504d7cb13a14abd2035cd9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy00LTEtMS0w_5fd40edb-3761-4a52-8d8c-48d49dca4237"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie469a52b0af940f797077e66a1fcb7f5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfMy02LTEtMS0w_f6e6ef90-d6b9-45e4-8745-40a095d92fa4"
      unitRef="usd">29123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7cb20656a8d498d86e9974aeb28d3ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS0yLTEtMS0w_e46e4d6f-03ac-441f-afe9-49811cee2614"
      unitRef="usd">21803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31dbb0c91f244d82be41bfabf480335e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS00LTEtMS0w_39d5b461-4666-4252-9145-0d8af77c4959"
      unitRef="usd">16776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i237f75928ac747deb799e5591927eeb2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNS02LTEtMS0w_66c60cdb-13ec-4bd3-8f58-efe9d6485b75"
      unitRef="usd">4749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic58de6fecf534ed0a1da850b2cff8a8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi0yLTEtMS0w_2b0901dd-489f-4642-8fdc-df3f569b217f"
      unitRef="usd">4378000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44536cfe5ccd4fd58d70bd6fa6a9bbe7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi00LTEtMS0w_b4c957ce-1a79-416f-baa4-1ccf547b6a91"
      unitRef="usd">6199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66c1d00145a84fc9849e6e8261b1e931_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNi02LTEtMS0w_771bb476-a3a5-416d-a7fd-b1e9257a97c5"
      unitRef="usd">78195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38a84b0ab35142d58562b6af8b4ed5a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy0yLTEtMS00OTQy_6a71f701-91df-478d-b8fc-92848921b4db"
      unitRef="usd">11516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9a2317a4d4b4c3e918e6cc04ab22e08_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy00LTEtMS00OTQy_7c6ef5b7-70c8-4b23-b830-45d964b51c17"
      unitRef="usd">17173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic073f00141a744d8b9364ba86efafc46_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy02LTEtMS00OTQy_0eb6ad7c-8587-4412-b55a-be2e471f7f5a"
      unitRef="usd">6577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e4954555f1f4c42a396f5d8999d8fa5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy0yLTEtMS0w_c9196b55-92ff-4a7a-96e6-3354b5a093cc"
      unitRef="usd">4967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12c2c62904f340b6aa85bf2c884b4476_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy00LTEtMS0w_cc6be7b9-2016-44d3-adaa-846a8548bf5d"
      unitRef="usd">1669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b8da33f34df41008bfe20ee259d58b6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfNy02LTEtMS0w_2b5c4c43-6316-44b9-801a-2aa3cb5475f1"
      unitRef="usd">4253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24599ea15eca4ad2bf3ba9d6702cbc8e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC0yLTEtMS0w_5d0073d0-707b-4a5a-9d9c-2a629e530f2c"
      unitRef="usd">42664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i036bc3fdcbfb4f32ba89dfa108d13010_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC00LTEtMS0w_387bad31-9116-4652-ba8d-29b385d0cab2"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ffd5c18396c45338058792c85126ba6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjFiNjdjM2NjZTQ2ODRhMDI4ZjMwZTI4YzgxODJhYTc5L3RhYmxlcmFuZ2U6MWI2N2MzY2NlNDY4NGEwMjhmMzBlMjhjODE4MmFhNzlfOC02LTEtMS0w_fac591fd-a8c3-4194-b663-33bcfbcc0a41"
      unitRef="usd">93774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTI_e8aa3e11-4fd5-432a-a287-d078d997a596">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical Study and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.&lt;/span&gt;&lt;/div&gt;</lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjY_5c134508-ae80-44c6-8359-051bb5aeb5f1">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjM_2928ca79-fb71-4b39-8401-c90aabe543c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2"&gt;six&lt;/span&gt; month anniversary of the date of grant, and 1/48 each month thereafter for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124"&gt;forty-two&lt;/span&gt; months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="if7f17131fa164971b710daf95103fef2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzE3MjQ_7b3f1412-4098-40e1-8bd6-527ccdd53805"
      unitRef="number">0</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ibd93f549e0fa415b9e51a92f0daf7bb7_D20070101-20071231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzE4MTk_c2c9e48e-528d-4b62-842b-81037baf96f7"
      unitRef="usdPerShare">2.50</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia580ec3f4bff42659168b12a15f67809_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzM5NjA4Mg_24d30d6f-cf99-489e-937c-85360071485b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia4bc8d4c0ee94b9dba90c475ab5a47fd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI2MjY_7b893787-3157-4a61-81cd-31a035b59697">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMjE5OTAyMzMxNDc1OQ_c7a63a8c-4aa9-4839-a9bd-44d0df7e1af8">Derivatives&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4236aad26ee440e0b4e5773018b84e4d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI4Njk_ab26f839-b0a4-450b-9c7a-0cbbea9b9489"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4236aad26ee440e0b4e5773018b84e4d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI5NDk_021138e9-ae87-4b42-b712-aa63f5a07f95"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzQyMTY_60703790-a792-4c4a-8595-62f5c0679b87"
      unitRef="usd">245000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzUwMjg_f82365ba-ccfd-4ebd-86d0-f1408ec5b764"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8250ef38f1ce4aa3ab43885f74dec95c_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzUwMjg_fa5e3fb4-dd74-43e1-b314-ff99e72dfd27"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MjA_21b2ba95-9a8f-435d-b4c4-135e7132b385">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDYzOTY_0f59f494-d890-4c71-832f-88ce6b7be3c7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the twelve months ended December&#160;31, 2020, all of the 0.6 million weighted average shares of outstanding equity awards as of December&#160;31, 2020 were anti-dilutive due to the net loss for the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and &lt;/span&gt;&lt;/div&gt;delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib0b6ced4e4e74197bd6f08f6e744dd49_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMTY0OTI2NzU1NTYyMQ_27877f7b-fbf3-4aff-b0c0-18dd997bebcc"
      unitRef="shares">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0Mjc_1f267137-e0a1-4058-b66f-6bbf3dcb6379">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Warrants associated with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2019 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi0xLTEtMS0w_89820d2b-1012-4df9-a58e-9ec15451ff6b"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi0zLTEtMS0w_46f82a12-1b2c-49dc-8a5c-ef236a6dfb26"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfMi01LTEtMS0w_aa63a3f9-e8de-4621-9f49-42f13e0b4002"
      unitRef="shares">21160000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC0xLTEtMS0w_dff33504-1638-4a61-9887-3d1cecf2f98c"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC0zLTEtMS0w_1e126742-c394-46c0-aa2a-eff6b90e47df"
      unitRef="shares">43000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC01LTEtMS0w_20ba26b2-ed98-417b-8185-ad3003354aa0"
      unitRef="shares">72000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNC01LTEtMS0w_7a71e8ef-2214-4a85-9ff4-10ca2d6ef491"
      unitRef="shares">72000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS0xLTEtMS0w_6d16df9d-c8f3-4790-bbae-d4a96f50b1fc"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS0zLTEtMS0w_2ee7db49-257c-4001-b4c4-cecba2e7aa15"
      unitRef="shares">719000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS01LTEtMS0w_84f283f9-93c9-4d46-b6fd-119cb91a70f2"
      unitRef="shares">1125000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNS01LTEtMS0w_885f68d6-91cc-4319-96f9-af15e3dd1ed2"
      unitRef="shares">1125000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi0xLTEtMS0w_655a7b22-5e20-4a3f-846b-bea193e81616"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi0zLTEtMS0w_72c77f8a-2728-46d7-89b1-e8ecddeaeb47"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNi01LTEtMS0w_9d119449-865b-417f-9ec4-054d1eee1388"
      unitRef="shares">1017000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy0xLTEtMS0w_1f7315df-ff59-41bd-9b43-8996a0b9fe17"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy0zLTEtMS0w_7823ef0e-b250-4b1b-b16f-2a2f7e921fc3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy01LTEtMS0w_9ac807a8-eb67-4c68-998d-42e37b16adc2"
      unitRef="shares">693000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfNy01LTEtMS0w_a6b07d5f-bdb1-4a15-a4dc-f297fa614c45"
      unitRef="shares">693000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC0xLTEtMS0w_5820134b-0214-40af-b2ff-4eadd1fbb09c"
      unitRef="shares">16185000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC0zLTEtMS0w_7925833a-d28f-417d-83ff-568a0cb33ccb"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOC01LTEtMS0w_a9b22807-198a-4332-bef8-6cf500ccd4e6"
      unitRef="shares">24067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS0xLTEtMS0w_33bb10ea-3d5d-4753-900a-63f4648595ab"
      unitRef="shares">8458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS0zLTEtMS0w_2f07f30d-f8cf-41c7-a213-6122c9d79ce2"
      unitRef="shares">8926000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS01LTEtMS0w_3fbf5c3c-026a-4ce5-97a9-e000a4a6391c"
      unitRef="shares">2845000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RhYmxlOjIzYjY1MTA5OGQxYzRkMTQ5M2MxNzdiMzU3OWY3MjFhL3RhYmxlcmFuZ2U6MjNiNjUxMDk4ZDFjNGQxNDkzYzE3N2IzNTc5ZjcyMWFfOS01LTEtMS0w_d87946fa-fa03-4108-93fe-510f1d3d5aa7"
      unitRef="shares">2845000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDQ_cfbc4141-ceee-4427-b9c4-fcd6f06befc5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MTY_e2ab9503-c2b6-4d33-96f8-9e8f55af8d68">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDY0MDU_0838ff63-a172-4aa5-9d60-aa41e46b025b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We adopted ASU 2016-13 on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance sheet of retained earnings to be recognized on the date of adoption with prior periods not restated. The cumulative-effect adjustment, net of tax, recorded on January 1, 2020, is approximately $5.2 million. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under previously applicable accounting standards. See additional disclosure on credit losses under  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Accounts Receivable and Allowance for Credit Losses&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Commercial License and Other Economic Rights&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; discussed above and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Short-term Investments&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (8), Balance Sheet Accent Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Test for Goodwill Impairment, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement: Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the disclosure requirements on fair value measurements. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We adopted this standard on a prospective basis on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures. We intent to adopt this standard on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTQ0OQ_3a26745b-4486-4597-b985-6ffa7ee1e57a">Sale of Vernalis R&amp;amp;D and Promacta License&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Vernalis R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;amp;D) Limited (the &#x201c;Purchase and Sale Agreement&#x201d;) with HitGen UK Ltd (&#x201c;Buyer&#x201d;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships.  On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $26.7&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;amp;D has the input, process and output elements defined in ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $6.1&#160;million, goodwill allocated to the selling business that was written off was $3.5&#160;million, resulting in a $17.1 million gain from sale of Vernalis R&amp;amp;D recorded to income from operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Promacta License&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 5, 2019, we entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with RPI Finance Trust (&#x201c;RPI&#x201d;), doing business as &#x201c;Royalty Pharma&#x201d;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#x201c;Purchased Assets&#x201d;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg0Nw_cb21b75a-25b5-4124-a0c2-cc8253eeda26"
      unitRef="usd">26700000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifea99838f3eb4029ace6787bc75b67d4_I20201201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg2Mg_54f6d31c-21d7-4cbb-9ece-e0fa45e68e3a"
      unitRef="usd">6100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i83a3e814db004c61ba61a5d521fde419_D20201202-20201202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMjE5OTAyMzI2MDg4Nw_3b79df0f-4b8b-4ffe-ab16-070026823319"
      unitRef="usd">3500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i55f09740f6734811b4be02fd7bc044ad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTA5OTUxMTYzMzIzOA_e2fca502-ef97-4791-a996-d26c828c12b4"
      unitRef="usd">17100000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i01ab621af16c4274a42e8324d4de973e_D20190306-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfOTQy_4e7039b1-2b69-44c9-baea-7eecf4241984"
      unitRef="usd">827000000.0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id0bbacdd5fd54f5989b4a62974637a61_I20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTExNg_3511eb43-395a-493d-badb-0592d36446b4"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTE2Mg_173018ea-0959-4e02-a304-3bda1d1cc1ae"
      unitRef="usd">14200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i54d4ccaa6dc543ce8de7360d00b9285b_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84OC9mcmFnOjdhZDNiMDdhNjRjZDRiNDdiMzE4NjJmNWMyMTFlZDVjL3RleHRyZWdpb246N2FkM2IwN2E2NGNkNGI0N2IzMTg2MmY1YzIxMWVkNWNfMTI5Nw_888d6d2e-124f-452a-a0ca-3876b3837d36"
      unitRef="usd">812800000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTY4OQ_4cd63f8b-31be-4eb8-be50-0e4a7d5e3fe8">Short-term Investments: Investment in VikingOur ownership in Viking was approximately 9.8% as of December&#160;31, 2020, and we account for it as an investment in available-for-sale securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and December&#160;31, 2019, we recorded our common stock in Viking in "short-term investments" at fair value of $32.8 million and $48.4 million, respectively. We also have outstanding warrants to purchase 1.5 million shares of Viking's common stock at an exercise price of $1.50 per share. We recorded the warrants in Viking in "short-term investments" in our consolidated balance sheets at fair value of $6.3 million and $9.9 million at December&#160;31, 2020 and 2019, respectively. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Fair Value Measurement.&lt;/span&gt;&#x201d;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="ie261b70fecc64fc3acc322f37f4fbb70_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfNzM_ac610598-fca6-485c-a5f8-24435d295499"
      unitRef="number">0.098</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTA1MQ_8442220d-0923-4f28-b5ed-b609bf8ea202"
      unitRef="usd">32800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTA1OA_b01f847e-271b-466b-8371-6e024877870c"
      unitRef="usd">48400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTEyMg_764c170a-af85-42b7-a825-e2fa302a8fde"
      unitRef="usd">1500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i389fb553398f4fb5809d534052c56744_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTE4MQ_c5426890-0df2-44f3-8210-db9977987de4"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i3839777e750f48b3970c5b559eed73b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTI5OA_b6a7bbed-c7d6-4662-bec9-c6d6e998d018"
      unitRef="usd">6300000</lgnd:InvestmentInVikingCurrent>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i3736760d3c7340649ea390cca0ce15fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85MS9mcmFnOjY2ZTdhMWQ4Y2UxMTRiNWZhZTNhNTc4ZjRjZmVhOTE4L3RleHRyZWdpb246NjZlN2ExZDhjZTExNGI1ZmFlM2E1NzhmNGNmZWE5MThfMTMwNQ_2f5e8485-423e-4f12-8e9e-db7add3e3822"
      unitRef="usd">9900000</lgnd:InvestmentInVikingCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcxMw_56edba36-0122-42c0-b4a8-dfd4ef8842d4">Acquisitions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As set forth below, we completed six acquisitions from January 1, 2018 through December 31, 2020, of which four (Pfenex, Icagen, Ab Initio and Vernalis) were accounted for as business combinations and two (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfenex Acquisition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preliminary purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a contingent CVR payment of up to $77.8 million in cash based on a certain specified milestone with an estimated initial fair value of $37.0 million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $1.5&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was 7.1%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $17.3 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $429.6 million. In addition, the fair value of equity compensation attributable to the post-combination service period was $8.7 million.These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded $20.7 million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts and unbilled receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is expected to be deductible for tax purposes. The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Approximate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jazz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arcellx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from 12% to 15%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Approximately $2.0 million of revenue and $19.3 million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December&#160;31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December&#160;31, 2020 and December&#160;31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $7.1 million in 2020 and $4.8&#160;million in 2019. The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taurus Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price of  $5.1 million included $4.6 million in cash, and a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $4.5 million tied to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;partnered and internal research and development and for up to $25.0 million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. We account for the CVRs in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the contingency is resolved and the liability becomes payable. None of the CVRs are recognized as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;xCella Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#x2019;s antibody discovery throughput and efficiency. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We paid $7.1 million in cash (including a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $5.0 million tied to our use of the xCella technology for partnered research and development and for up to $25.75 million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. We account for the earnout rights in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the contingency is resolved and the liability becomes payable. None of the earnout rights are recognized as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Icagen Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of $19.9&#160;million included $15.1 million cash consideration paid upon acquisition, and a CVR of up to $25.0 million of cash payments based on certain revenue milestones with an estimated fair value of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was 5.5%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1 million of customer relationships and $1.7 million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6 years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of 9.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ab Initio Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of $12.0 million included $11.9 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vernalis Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we acquired Vernalis, a biotechnology company for $43.0 million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and product reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 34.0%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately nine years. We retained the core technology after the sale of Vernalis R&amp;amp;D in December 2020. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (2), Sale of Vernalis R&amp;amp;D and Promacta License.&lt;/span&gt;&#x201d;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <lgnd:NumberOfAcquisitions
      contextRef="ic665f012e5c54711abae64ce09f53a48_D20180101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjU_2e18ba92-ae1c-46fb-be04-ffd3da8c5d20"
      unitRef="acquisition">6</lgnd:NumberOfAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzM3Nw_6c11a62e-18b5-4d10-af4f-a90d3f7f3154"
      unitRef="usd">465100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzM5MA_1c9f55d8-93b4-4888-a316-a82bd6cb2367"
      unitRef="usd">429600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzQxMQ_ebf19fc5-d07e-4016-8c57-5066977dc841"
      unitRef="usd">77800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA1MzQwMQ_5f78a8bc-d53c-485e-9f60-5fcdef3b0913"
      unitRef="usd">37000000.0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA3NDAyOA_25411368-0801-4483-8e51-06f483611d4f"
      unitRef="usd">1500000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id7ccafcd4382434aab44acf88304dbff_I20201001"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzMyMjQwMQ_1ca39e35-9612-4ae6-9467-6ee47e35d06d"
      unitRef="pure">0.071</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions
      contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2NTE2Ng_35c0d188-8807-44f7-9b74-a4d76ea93f40"
      unitRef="usd">17300000</lgnd:PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfOTM0NTg0ODkwMjk1OA_1c9f55d8-93b4-4888-a316-a82bd6cb2367"
      unitRef="usd">429600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i937655058f00466eb023f3a052a305a9_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2NTMxNA_738acab9-84f2-4125-a4f3-55dd5a230e74"
      unitRef="usd">8700000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ib0213fb27da746f78658b704b667e575_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2MzMyMQ_853daaa4-9fb0-4a40-9151-d2d4b3d313f4"
      unitRef="usd">20700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5MQ_d51ab565-c06b-4000-9113-2551fc318a48">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts and unbilled receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMS0xLTEtMS0zMzAy_047c588f-eb8c-4cd4-a255-2e124ef2d9ed"
      unitRef="usd">51407000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMi0xLTEtMS0zMzAy_2175e933-7a6f-4556-886b-221d182c6c60"
      unitRef="usd">200000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMy0xLTEtMS0zMzAy_da713b0a-c180-4f88-b7db-f8dce20ab0f7"
      unitRef="usd">1359000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNC0xLTEtMS0zMzAy_6fa1516c-8b8a-45eb-b599-485264a762e5"
      unitRef="usd">7823000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNS0xLTEtMS0zMzAy_20bd78e0-3258-46d1-826d-a37e67e74840"
      unitRef="usd">3070000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNi0xLTEtMS0zMzAy_ece548ec-e53a-43ce-9bc1-70a7d956d17a"
      unitRef="usd">1338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfNy0xLTEtMS0zMzAy_093476e8-ffff-424f-932c-63c49a569073"
      unitRef="usd">385000000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfOC0xLTEtMS05MjA4_cca0e2d6-a28c-4ade-bdf1-66c3c20f49ba"
      unitRef="usd">90750000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTEtMS0xLTEtMzMwNg_3b23f132-606f-4404-8e86-9348a8700d01"
      unitRef="usd">6814000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTItMS0xLTEtMzMwNg_90a82ac8-5835-4de1-9619-b665684ab223"
      unitRef="usd">7379000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTMtMS0xLTEtMzMwNg_92479b2c-98c3-4043-aa3a-52952513c2a5"
      unitRef="usd">3908000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTQtMS0xLTEtMzMwNg_df3d13eb-a461-4f8d-a610-3e497b0cc582"
      unitRef="usd">3070000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTUtMS0xLTEtMzMwNg_68de82e4-b7cd-48d7-a794-1e3851843aff"
      unitRef="usd">1382000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTYtMS0xLTEtMzMwNg_d51d7d46-b115-4c9c-9641-ec3a1483aeed"
      unitRef="usd">53296000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjk2MjU2MDc4ODZlYTQyY2E5NzEzYmZmY2RlODU2NTJiL3RhYmxlcmFuZ2U6OTYyNTYwNzg4NmVhNDJjYTk3MTNiZmZjZGU4NTY1MmJfMTktMS0xLTEtMzMxNw_b7cddcbe-dc95-48ed-b0ac-96bee8c44c84"
      unitRef="usd">465098000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjQxNQ_a61f57d4-c517-449c-b383-e551aed2eddb"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5Mg_984516cc-7431-4af1-bfd5-7e9dddd86bce">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Approximate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual Relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jazz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arcellx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired Technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3722684bf7fe44dd891c916f6dafc459_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMi0xLTEtMS0zODI0_5e3022ee-004f-4c17-a979-c08110aa6dd5"
      unitRef="usd">114000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idc0825ac3f9e433dbbbf222c70233130_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMi0yLTEtMS0zODI0_efeff7e6-4a5d-4efa-9309-e1c7b21117bf">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i2bc05913ba57443492a26d3b59204160_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMy0xLTEtMS0zODI0_ad2ca0cb-4eb8-41d7-a118-27f0b9ac93c4"
      unitRef="usd">117000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i90111327cda4413486d72b7e169d1885_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfMy0yLTEtMS0zODI0_3c222c48-8b36-4395-a868-67f05f080bba">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i203357e791ee4e05a98b8573e4a989e4_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNC0xLTEtMS0zODI0_35f77eaf-7131-4e8c-9df4-50bff48c16ae"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i22ae29ffee0842cc89e6ee8c5f22ccd8_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNC0yLTEtMS0zODI0_8357f99d-db33-4aa0-a95b-e4d1111269f3">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4b0bc7404b304067a3243b8534e113e2_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNS0xLTEtMS0zODI0_75ee2bd6-56ce-4694-a7f9-e198c14c4b12"
      unitRef="usd">49000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ica518070bfb04532a62ae6496bac0810_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNS0yLTEtMS0zODI0_59085cde-92af-4c00-98f4-7ed20bcef806">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i2e6809a505f14eb48603ff22d2339675_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNi0xLTEtMS0zODI0_f327aa54-c18f-414d-96ee-2559183b4a9b"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id0e4a9163e7b41fe9f7db2ee091c394e_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNi0yLTEtMS0zODI0_402774eb-397c-4678-b662-70c9ca49dc0f">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie1c5bd0218924d9ba52a0cf66da8376b_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0xLTEtMS0zODI0_6c5a2f40-f47b-4691-9ac9-e1adf0a37c1c"
      unitRef="usd">23000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3e224ad1e1fc4df0a08700f496a00009_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0yLTEtMS0zODI0L3RleHRyZWdpb246N2IxNDEzNzgzZDBkNDNmODg3NGNmOTAxMzI5ZDM0YzFfMzI5ODUzNDg4MzM1Mg_cee49c3d-cc13-47ff-bb2f-741d858e7c06">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i058f44a298dc4b5cba311ad359517ca8_D20201001-20201001"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfNy0yLTEtMS0zODI0L3RleHRyZWdpb246N2IxNDEzNzgzZDBkNDNmODg3NGNmOTAxMzI5ZDM0YzFfMzI5ODUzNDg4MzM1OA_94417da1-aa8f-44c5-920e-8325967c9f31">P19Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i002a7e38519e40f2946a2312278fcbbf_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjA2Y2MwZjY2NzY3YzRlYjY5ZmE5MjU1ZWUwNTRmZGU3L3RhYmxlcmFuZ2U6MDZjYzBmNjY3NjdjNGViNjlmYTkyNTVlZTA1NGZkZTdfOC0xLTEtMS01NDgz_b642d91d-5c4e-4a17-98c9-03876eae1f5d"
      unitRef="usd">385000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="i386227a58a154f12b0c88d447866796f_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTY0OTI2NzQ5OTUyNQ_d198b1d6-b0fe-43de-a9ba-d3ec9425f9fd"
      unitRef="number">0.12</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="i9d3e28c670344068a7dccc625bd2d1a3_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTY0OTI2NzQ5OTUyOA_83dd7607-3bf9-4725-a78d-922883d3b3e9"
      unitRef="number">0.15</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA5OTUxMTY2MTMwMQ_50ed7da6-0c9e-44f0-b277-e43aacf0e684"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA2ODMwMQ_1810f148-6b4c-4679-9d72-477b041487ca"
      unitRef="usd">-19300000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA4OTAxMg_b313ea66-6e3d-4352-88d6-4513cda3ba76"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfODc5NjA5MzA4OTAzMg_3eb3d8f9-d842-4c82-87e1-e18b09421bd2"
      unitRef="usd">4800000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjE5NQ_63c4097e-1597-44fe-bb8e-70aac1cc33d1">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMi0xLTEtMS0zODQw_1c2eadb8-6b4f-46f1-a0bd-53d20e98022b"
      unitRef="usd">189203000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMi0zLTEtMS0zODUx_05d9154a-0e80-4e3d-a147-05a6c55c3238"
      unitRef="usd">170608000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMy0xLTEtMS0zODQw_2b1165f0-eed0-45bb-bd7f-d7a9753aa19c"
      unitRef="usd">-60059000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfMy0zLTEtMS0zODUx_22fc13b1-7a2e-4001-8d3a-5677e6195ead"
      unitRef="usd">594941000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNS0xLTEtMS0zODQw_a7a346b9-e237-4c0f-aacc-bbb66257b532"
      unitRef="usdPerShare">-3.71</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNS0zLTEtMS0zODUx_a77746b9-44fc-4645-a0a8-a5622e242253"
      unitRef="usdPerShare">31.32</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNi0xLTEtMS0zODQw_35e3ffd7-7745-4654-9695-22d729a07d75"
      unitRef="usdPerShare">-3.71</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjExMWJhMWVhOWYyZjRlNTZiNjhmZjQ1M2Q4OWUxMzA4L3RhYmxlcmFuZ2U6MTExYmExZWE5ZjJmNGU1NmI2OGZmNDUzZDg5ZTEzMDhfNi0zLTEtMS0zODUx_12d50937-4246-4dd2-98ce-b09c4a8e7725"
      unitRef="usdPerShare">30.11</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc1NA_d03520b3-cb55-4603-8fa7-fb78b9f7aab6"
      unitRef="usd">5100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc3MA_d7399796-bb85-4d66-beb6-c3a668449fb5"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:BusinessCombinationConsiderationTransferredHoldback
      contextRef="ie22f318552984cf9b687e5a5e2e4f8fc_D20200909-20200909"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc4Mg_6bd847d5-a35d-407d-9c58-4bc344813185"
      unitRef="usd">500000</lgnd:BusinessCombinationConsiderationTransferredHoldback>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib636b729155f4a749fd149d8b766cfd7_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5Njc5Ng_6be5b29d-d3d9-45d2-b1fb-15437bb3cce7"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia074696e58a149c1995c46517312190b_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NjgwOA_efa4cd0b-32ee-4e45-b48e-586a4ef628b5"
      unitRef="usd">25000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues
      contextRef="ief985e0d5a6e476ca3e8f1deefd76040_D20200909-20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NjgyMQ_ce586a06-f63f-48d4-8b94-4e626c290f1c"
      unitRef="number">0.25</lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i8dc30f6eb26f47a0a96ce21282bdd8d4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjI0MQ_58efb2a9-886d-419e-9790-ee800e9fcfe6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMC0xLTEtMS0xODA4_32eb6652-b960-4a9d-89b7-3110e673e681"
      unitRef="usd">47000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMS0xLTEtMS0xODE3_07019eba-dd21-44db-9fba-922c5af67e5f"
      unitRef="usd">5005000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjBhY2E2M2ExYTk5ZjQ4NGNhODkzNTA4NGU5MTM5NDJlL3RhYmxlcmFuZ2U6MGFjYTYzYTFhOTlmNDg0Y2E4OTM1MDg0ZTkxMzk0MmVfMi0xLTEtMS01NDIz_3281264a-fb87-412a-b689-73830f8e3fc9"
      unitRef="usd">5052000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1be13e965a8f4da5b69ebbcc4a009825_D20200909-20200909"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDg5NzE2Ng_abab2d80-f757-4043-b187-e3f36cab4b55">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icd00c2f9ab0540a7b3763c32cb278c0b_I20200909"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjM4OA_03a43baa-0b59-4fcb-bbf4-9d246d7b8c3b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i68f1407f97f14a568173adad6da04c53_D20200908-20200908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzg5Ng_9ac4f3d5-3c81-4a70-b52f-80bfa43da87b"
      unitRef="usd">7100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <lgnd:BusinessCombinationConsiderationTransferredHoldback
      contextRef="i68f1407f97f14a568173adad6da04c53_D20200908-20200908"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkwNw_0b54090a-deb0-4ed0-bda6-9b5cb002eb0f"
      unitRef="usd">500000</lgnd:BusinessCombinationConsiderationTransferredHoldback>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i145875c08ac643eb987fa42283dc0c10_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkxOA_6c3b839a-7d1b-4eb1-ab7f-ea38c8d459be"
      unitRef="usd">5000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7e76f65e64ab4ec5a35fb2b202c36fda_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzkyNQ_0730e2ca-b1fe-4833-8169-93d9bb3a497a"
      unitRef="usd">25750000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues
      contextRef="i7e1fdefc6b2b422989b6e605a3d10f27_D20200908-20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwMzk0Mw_56331d18-d4ce-4d06-8462-c0fcd046adab"
      unitRef="number">0.25</lgnd:BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ib48f53a633bb468199177a6ba86fca12_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjI4NQ_a2c2049a-3f0f-44d1-9f39-22c2fec7da1e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMC0xLTEtMS0xOTMw_3b84d61d-d661-4c1e-87ca-74bde365b456"
      unitRef="usd">240000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMS0xLTEtMS0xOTMw_57b8400f-d488-4634-bffc-280be2b50494"
      unitRef="usd">142000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMi0xLTEtMS0xOTMw_fd0dfa61-1b1d-4ab5-8318-9076071e4584"
      unitRef="usd">820000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfMy0xLTEtMS0xOTMw_cf957e94-eba1-4859-878c-63f53dc5db7a"
      unitRef="usd">7798000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmNiMjJiMGE5M2Y1ZDQyY2Q5OTlmYjQ4NWIxMjk5NTY0L3RhYmxlcmFuZ2U6Y2IyMmIwYTkzZjVkNDJjZDk5OWZiNDg1YjEyOTk1NjRfNC0xLTEtMS01NDQ1_f02ab253-d384-48b6-b52d-ad0d4e34c1cd"
      unitRef="usd">7076000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if7ed9c03cb994049a1d3a5de61dbd7e8_D20200908-20200908"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNDQ4OA_648de516-0863-40b8-a0a2-7a87589ee287">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie15ddfad84344f9092e1706ff640ffc9_I20200908"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjQwMw_afeb7072-a9cf-415b-b174-3118d5592777"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjM4OA_1aa37c3a-17b6-49a0-8ac5-9cce8df20311"
      unitRef="usd">19900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjM5NQ_28e81043-efd3-4aa1-baae-9ea42755b87b"
      unitRef="usd">15100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjQxNQ_1b2722e9-f5c0-45aa-84a3-8a7b0f72894a"
      unitRef="usd">25000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwNjQyNw_7f4e0cc8-02cb-49c9-8b4e-ff2ff3eedd29"
      unitRef="usd">4800000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie7604f5c2dda42bcadd9b8697034b298_I20200401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzMyMjQwNw_2060495b-2ad8-4345-879b-fbfef7019e29"
      unitRef="pure">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjE5OTAyMzI5MjMyOQ_273420c3-6376-4882-b801-c98b459585d6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMC0xLTEtMS0yMDU2_dc5351cf-ff5e-49e6-90bf-cc0cb867875e"
      unitRef="usd">1173000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMS0xLTEtMS0yMDU2_f9865833-b36c-4b4e-933a-d29b48a1fdc1"
      unitRef="usd">588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMi0xLTEtMS0yMDU2_8328726a-b9f4-4f4f-bd85-b5a6862933b1"
      unitRef="usd">812000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfMy0xLTEtMS0yMDU2_aeb4ffcb-31ff-46ae-861b-c3108f1a673b"
      unitRef="usd">3685000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNC0xLTEtMS0yMTM2_263b586e-8ef7-4c4a-8758-6d2738b6eb5c"
      unitRef="usd">861000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNC0xLTEtMS0yMDU2_5a66a2c3-03c4-493f-96b2-c138958c824e"
      unitRef="usd">12800000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNi0xLTEtMS0yMDU2_8551450b-4085-42a3-b1c8-c192b6624f43"
      unitRef="usd">9015000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i48711ba1f7cf4e298a5da4dd91a5397a_I20200401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOjc3ZjM5NmQyNDk2MDRhNTI5Mzk3YzcyNDk4ZDRhZTNmL3RhYmxlcmFuZ2U6NzdmMzk2ZDI0OTYwNGE1MjkzOTdjNzI0OThkNGFlM2ZfNy0xLTEtMS01NDQ4_3dfcd9ac-64d6-4e43-9c3c-c1e7cfa4744b"
      unitRef="usd">19940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie23c947370d64bf7b1e94889103679fd_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODc4OA_825c97b3-d315-4a34-b268-6a3d74376b3a"
      unitRef="usd">11100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ieeed7ae64c0d4c0a83986dde7c9fa1d7_I20200401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgwMQ_29f882a7-8ea4-4da5-8f30-997fabcb5efd"
      unitRef="usd">1700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgxMQ_73aa8205-837c-4764-8662-38435bde0943"
      unitRef="number">0.17</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgxNw_a7a87373-ee7e-4a70-a20c-e1871fe1fa49">P9Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate
      contextRef="ic6329bfacc0e46999912decad0f41945_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgyNg_73aa8205-837c-4764-8662-38435bde0943"
      unitRef="number">0.17</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i96dc5cd222804e959a28968aa702662d_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgzNw_d2fd7f3b-dcb0-494e-a543-b575b79978be">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ibcf24952d727469c8fdcdffc60598210_D20200401-20200401"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzI5ODUzNDkwODgzMg_cd49380b-dfb2-4f6d-b255-9c55ebf32ee0">P9Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTA4NA_a969273d-b763-4fbc-b51e-93e0646087ef"
      unitRef="usd">12000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTEwNA_a0fa25d1-290b-40dc-ae27-c919d4919da7"
      unitRef="usd">11900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims
      contextRef="i6c52d5a5a60b4f70b754206a03ada852_D20190723-20190723"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTE4Mw_4aa9b8ce-7601-4bdc-903c-4a865017df36"
      unitRef="usd">150000</lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i91f10778634c436b8efd5b90ec1f5c3e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcwNw_42bfdd1a-cbbd-4108-a801-d212e22a8860">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMC0xLTEtMS0w_8ea9f65a-ca19-4fb6-a237-199dc93a0d93"
      unitRef="usd">28000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMS0xLTEtMS0w_1d01b18d-0de8-4a9d-b90b-f41551af8f9b"
      unitRef="usd">83000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMi0xLTEtMS0w_99597c43-555b-4c50-b7eb-6098b4944dd4"
      unitRef="usd">146000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfMy0xLTEtMS0w_5416c6bc-572e-4180-b6b2-459a3d0a94cc"
      unitRef="usd">7400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfNC0xLTEtMS0w_cd021f42-c4df-46c2-9e98-541118c31c3a"
      unitRef="usd">4812000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmI0NzQ3MTM1YjUyZjQ0OWE5MTE4MzI0YWQyY2MyY2Q0L3RhYmxlcmFuZ2U6YjQ3NDcxMzViNTJmNDQ5YTkxMTgzMjRhZDJjYzJjZDRfNS0xLTEtMS0w_d75fa383-c85e-4d60-a4fc-2c5c9f3b30c5"
      unitRef="usd">12011000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="iff99e585e3164b03a575580fc0b45900_I20190723"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMTkxMg_35b5938e-9b4f-4282-9240-80ce86a073ca"
      unitRef="number">0.120</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3c19ea46b38444f6b60a4af0f07a64a5_D20190723-20190723"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjA2NQ_df00e907-6cd4-402a-9523-b45b5f6c8fcf">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iba9013bb387c441fb61e592bae9e466f_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMjU4MQ_bdc89b5e-4c90-48d1-a47b-ff6971d1948c"
      unitRef="usd">43000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i09c35816fc7c45c68db42cb9ad26c032_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfNjcwOA_38ef745f-b71e-4d59-a43e-0fb75efbcf48">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and product reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles assets with finite-life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMC0xLTEtMS0w_a44a386d-682f-4b29-8b8a-4d31dbc42643"
      unitRef="usd">34286000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMS0xLTEtMS0w_d5b2b5c8-4db7-4948-8f09-55bd0e86d903"
      unitRef="usd">2836000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMi0xLTEtMS0w_16cb9bc7-e70f-44eb-aca6-6c887f30e8db"
      unitRef="usd">6383000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfMy0xLTEtMS0w_6142c8bf-9a2a-4793-938b-f2c514e1bf3c"
      unitRef="usd">3479000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:RestructuringReserve
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNC0xLTEtMS0w_a1be74fd-4b42-4e6d-9da0-d19d027dd1dd"
      unitRef="usd">9241000</us-gaap:RestructuringReserve>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNS0xLTEtMS0w_399c43c3-8aa8-4643-bd1c-9ea6882b37f5"
      unitRef="usd">746000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNi0xLTEtMS0w_cd168e71-c3f4-4626-b4f7-c5742f02e807"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfNy0xLTEtMS0w_a53265b2-9c60-4603-920a-2818fc8ba48f"
      unitRef="usd">5939000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RhYmxlOmMyMjBmYTBlOTc2NDQ2YWY5Njk2ZWE4N2Y4NDcyYzc4L3RhYmxlcmFuZ2U6YzIyMGZhMGU5NzY0NDZhZjk2OTZlYTg3Zjg0NzJjNzhfOC0xLTEtMS0w_2f1f6836-3be7-4f7b-ac9a-21e1023b1e15"
      unitRef="usd">42978000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="i0b31bfa216b54d2e87051f21519216ee_I20181031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzMwOQ_534decf0-df0b-4bcf-be46-64e892f084ed"
      unitRef="number">0.340</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ida6c60fab2814867a46699ae1d38afb9_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85NC9mcmFnOmQxN2I5NGRjOWEzYTQ4NGVhY2VlMWI3YThhNTU4ZDRhL3RleHRyZWdpb246ZDE3Yjk0ZGM5YTNhNDg0ZWFjZWUxYjdhOGE1NThkNGFfMzQ2MA_2dfacaa4-adbd-4a2e-8f06-241a42a258db">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM3Nw_7187c5d3-f45e-4dc8-b48a-2ad61f8ea5b8">Fair Value Measurement&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs such as quoted prices in active markets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Pfenex &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;gain (loss) from short-term investments&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (3), Short-term Investments: Investment in Viking.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the third quarter of 2020, we paid a $0.5 million contingent liability based on revenue milestones to Icagen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6) The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities due to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Measured on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than a reduction in goodwill resulting from the sale of Vernalis R&amp;amp;D disclosed in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (2),Sale of Vernalis R&amp;amp;D and Promacta License&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;, there were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for additional information related to the fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM4MA_b8393e04-0f66-4dc6-8634-1419630e5a14">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Icagen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Pfenex &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;gain (loss) from short-term investments&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (3), Short-term Investments: Investment in Viking.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the third quarter of 2020, we paid a $0.5 million contingent liability based on revenue milestones to Icagen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6) The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8c70e7e03138499ea135008f92ae636a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC0xLTEtMS0w_cd1eb3da-9baa-4deb-b264-12c7e9e9fc13"
      unitRef="usd">324478000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7b304285ad04468834c9942bcb940c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC0zLTEtMS0w_839e062d-0944-4ed9-b85f-ec76a3d2388c"
      unitRef="usd">3438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71e787593a0f4a95ae7e6faf6902fb14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC01LTEtMS0w_5a5c8906-e8f0-40fa-8867-84e9f6ce32ee"
      unitRef="usd">320647000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c0b482524274e4f862807e22f04339d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNC03LTEtMS0w_f034107c-b5da-451e-9749-a2a129e1ee7a"
      unitRef="usd">393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5b897c6c62a4eb0b9c455c2a5e3c9c0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS0xLTEtMS0w_47d98db6-f2ef-49ec-856a-34603ad2d3db"
      unitRef="usd">32763000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia2d7240c3b2641f7b93fefce9ba43997_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS0zLTEtMS0w_db0c08e9-7ffa-4140-af46-4db0bb3a0302"
      unitRef="usd">32763000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i60c05d3e8a024a8480cfb6b10bc43054_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS01LTEtMS0w_7e411454-d49d-4457-a2a7-2ea821b7cdd4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i066e6e259ad14a0083f5921dcfe54962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNS03LTEtMS0w_e148163d-0f71-4c10-9b3b-ff27aa1904fc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0128c7696ac747c0b7cb29daf26b7d23_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi0xLTEtMS0w_dd8019d1-3418-4b48-aef9-dc98b4d9a533"
      unitRef="usd">6326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib655d0debbde4feb93a3f225e8d31237_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi0zLTEtMS0w_d16bcd7b-03ea-4748-8be1-f8c2aa7444b4"
      unitRef="usd">6326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8884ec54ac6436b9f6405038ca8d51e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi01LTEtMS0w_adfc97dd-0ed7-48b5-a0e7-fe6930684d5c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i985674008c3e482dae7633f65d66191f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNi03LTEtMS0w_f2de785f-d16a-4980-a0ef-6ac19284b302"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i44c24d33a6514e0e90a361e94093f011_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy0xLTEtMS0w_d16b12e6-00b6-41c7-9fd5-be28ee704444"
      unitRef="usd">363567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i325849b89a604daf9659e7cd5fca620c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy0zLTEtMS0w_78aca9b3-d679-4dbd-b3e0-80adaec6cb07"
      unitRef="usd">42527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c8dc920224d41959a40fbf2fb518de0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy01LTEtMS0w_f7e84e69-17ae-4bfd-bd06-1c3920d166cd"
      unitRef="usd">320647000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63c7cd32e8b844f784308ca4fe584644_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfNy03LTEtMS0w_525ba619-cf72-4d20-bcff-3bae133a9bf5"
      unitRef="usd">393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i137c86d7cd6446daa9d2bb7abb2b4ec3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS0xLTEtMS0w_87d91351-a610-4b2e-bbc5-ea008030054b"
      unitRef="usd">800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib66b0db35db44f8c8369e77da14013ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS0zLTEtMS0w_30e31563-52bb-4473-8505-4f8fe914d07d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if9b6c6ceb9d7450496a7b9d016f7dbbb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS01LTEtMS0w_9879ddf0-21f8-41a2-99a3-64cd10a1ac52"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic1c8f26d622543f39f164698f8b83b7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfOS03LTEtMS0w_c04529ab-3580-4f1e-baec-54892dd93841"
      unitRef="usd">800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81ab0ec6924f4304a39b0bf8f5001c7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtMS0xLTEtMA_e89448b4-2e9a-4149-a1d3-891905644ce0"
      unitRef="usd">508000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4a70d84e512248ac9fba2353f9f99a60_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtMy0xLTEtMA_1415e90b-a4b0-477f-a7b7-8f4d83c05ae6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6d1c28bffdd04f8392e2e09f40101997_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtNS0xLTEtMA_7c44bff9-4d35-4e15-97be-7b44ee127609"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia485d5109cc4438e997246e17ebfc4ca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTAtNy0xLTEtMA_95b9db5d-76f6-4c44-aee6-d6cbee103bbd"
      unitRef="usd">508000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8606ca98858540a5963136c5f3cd6569_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtMS0xLTEtMA_cd5484d1-818d-4517-adcc-f8698a9d0010"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib98368e7d660497ca20cee33026379c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtMy0xLTEtMA_f6ea6c42-fd3b-42e1-96ae-1147405e757b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie2fc9d0e319d49ed89ca0eebf9f35bff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtNS0xLTEtMA_404e0c49-3e73-4b3b-9a09-f543fddd722d"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5029c0e076064d15bcaaa31e3d8187fa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTEtNy0xLTEtMA_7d7eb2a2-5b64-480d-815b-42cb8ae47b34"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i87f8caf1622a41fa91f4942f87f67bde_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMS0xLTEtODE1Mw_0812e350-4f10-4994-88ea-fd8fd4f42bf2"
      unitRef="usd">6404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9ac63a2559a74326abe6d930f6accfb4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMy0xLTEtNzYxNQ_81b6f724-8eb7-41cb-a3d4-d1185319bab4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4b487fdb37824d4f9ef1a0400ee9dccf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNS0xLTEtNzYxOQ_0d1511c0-8317-462a-9389-3f15222643ad"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7d1dd4fca49c48fb9be8bec85e267e45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNy0xLTEtNzYwOA_cef98b10-859e-4253-8f01-3c7f7a3704bf"
      unitRef="usd">6404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i033d9d285210428ca8efab5d8a1ee24d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMS0xLTEtODE1Mw_b98e7f28-8cc7-4f67-bd20-d206dc92ceac"
      unitRef="usd">37600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i539792c492b3485dbdd59cf131d570cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMy0xLTEtNzYxNQ_f72e965e-6a62-417a-a0d5-2822ee8d38f8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5abb3f5f216147b0bc15b06e777edd38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNS0xLTEtNzYxOQ_08246943-4b3f-4977-b10e-070bed45baa7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id09c77184f6647d4bfadfba8681652ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNy0xLTEtNzYwOA_1b741af5-bbbb-4a64-adb6-1ec0d8dc0743"
      unitRef="usd">37600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0d368fdfb8cc44779ec8d9c4b178bb55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMS0xLTEtMA_d310ee0c-b30d-4c37-affd-42aa26aad342"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic74f3ffda69b453e9607122edad77fdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItMy0xLTEtMA_15224261-ecf3-4f44-8317-be01c90f3259"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i100d3ad1f1d043d7ba7a409ef38f47a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNS0xLTEtMA_f2f23985-46f9-4766-9827-144d01412f0e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic92c7c3420a147f186540d32f570459b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTItNy0xLTEtMA_821b594a-668a-45f1-ba01-874c04003c8e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i44c24d33a6514e0e90a361e94093f011_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMS0xLTEtMA_7c2add0b-9fe0-4e57-bd3b-dc06e9b57aec"
      unitRef="usd">49193000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i325849b89a604daf9659e7cd5fca620c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtMy0xLTEtMA_a74ebc2b-dc85-4f81-9d4b-150af7d05c5b"
      unitRef="usd">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1c8dc920224d41959a40fbf2fb518de0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNS0xLTEtMA_5b051b35-217b-4de4-86a5-9e5ab4ce7f48"
      unitRef="usd">3821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i63c7cd32e8b844f784308ca4fe584644_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjg2M2ZhMmU2MzAzYzQxYjI5NDE0MTY4NTc4ZDYxM2ZmL3RhYmxlcmFuZ2U6ODYzZmEyZTYzMDNjNDFiMjk0MTQxNjg1NzhkNjEzZmZfMTMtNy0xLTEtMA_9d0296ad-bcac-47dd-abaf-1d0726b5b71b"
      unitRef="usd">45312000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7bed8cb3b0ed4b978d1785374324f715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC0xLTEtMS0w_0109b73a-c068-44ff-9bab-264ab272a782"
      unitRef="usd">939989000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id0af1caad2ec4bb3b5063b4f40c26520_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC0zLTEtMS0w_780bbbce-351b-4352-af4a-eb8c042a1b54"
      unitRef="usd">3073000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3faaf97bade2466badfff2a3a6a9a037_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC01LTEtMS0w_42ca127d-094a-45a9-950a-d2c13797908e"
      unitRef="usd">936791000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9480b683b415427882bd5e8708c90123_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNC03LTEtMS0w_f52f096e-9f01-438d-9742-1105c4a95915"
      unitRef="usd">125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i044b313dd18245adafea8294b91bf524_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS0xLTEtMS0w_e968fb66-0c12-414a-8e2a-f06c16a663a5"
      unitRef="usd">48425000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i97080b1df6004dca997119afd07fb422_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS0zLTEtMS0w_2e6b0764-4b96-4de3-8bc3-130011dadb4e"
      unitRef="usd">48425000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idbf5ad2f46ec4ee98ca750ce92cee1c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS01LTEtMS0w_ac19774b-aefe-421d-aaad-a52fe22127ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iceb7ec904b154a24ac4500272466e24c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNS03LTEtMS0w_e99c6a7b-f979-4946-b635-dc03deeae2c7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b3b19e4b35e406ebcd52022bb02eda0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi0xLTEtMS0w_be209d99-6da3-4fc2-a4f5-03d174865dea"
      unitRef="usd">9910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idce9786861db4e7cab91a951db9a86ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi0zLTEtMS0w_617d8277-786c-4439-84a9-0614a7b54cbd"
      unitRef="usd">9910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia21553bca1b1431b87f6ef73264c6a08_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi01LTEtMS0w_4da81fb5-9086-472b-9953-2a12c4c5e530"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6055eb2a56ee4de58267511ac1b63e34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNi03LTEtMS0w_a4609a2c-cf0b-4788-a804-48e47c5411ab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d83a1f143a24e3f875bf1146a570289_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy0xLTEtMS0w_760d2ecc-6890-4e67-84c7-b7e477c91109"
      unitRef="usd">998324000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i078cb5087cab4be7ba5189ff529510ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy0zLTEtMS0w_d0b1230b-8544-41dc-a808-df711a585abc"
      unitRef="usd">61408000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4a273d6b52d4ba48768b5519b0c3665_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy01LTEtMS0w_8fe2c85b-a638-4963-bac9-d756016c2593"
      unitRef="usd">936791000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b3bca9d1ae7450e90354484c1d5f005_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfNy03LTEtMS0w_b175cb4f-67a7-42ea-a987-31573854b540"
      unitRef="usd">125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia57d66428a1f493aa864bbf8e827485c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS0xLTEtMS0w_bd792633-ba92-4c2e-8351-48c0f92cf1d2"
      unitRef="usd">2659000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8c5cf083ca134bf79668ec12b74a240c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS0zLTEtMS0w_0ef7e34c-1bc1-46e7-8a1b-f96e38dfd2c7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iecfb0ea4403e4557afd920f82e95aaab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS01LTEtMS0w_5eb33027-2bbb-4e95-aaeb-9c786673caed"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5202115d56d44835a5e19d2567442658_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfOS03LTEtMS0w_c18d5d67-bdb7-49a9-b246-c9b71045a2b5"
      unitRef="usd">2659000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i13aae0d9ac5c46eda486f9147f718cc7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtMS0xLTEtMA_7439e471-6f7d-4b23-bfe8-f518fe1b6b95"
      unitRef="usd">348000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib35aa47334744f07856c9d53b543fcc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtMy0xLTEtMA_dcd19468-1cf4-4698-b26d-03de2d2dfd1c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i77b8c8ad9a5c4b95bcdd1ef1f93fd6cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtNS0xLTEtMA_56b144c1-4669-4423-8dd5-03b4782abdc2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i945a71f3ec5741968deafb92ba14c4d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTAtNy0xLTEtMA_7fdea6a8-0e5f-49d3-82b8-fde2d92b6813"
      unitRef="usd">348000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic218f09432544a61968a84902b4b6b12_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtMS0xLTEtMA_61a69bce-9672-4caa-8589-533548b93d82"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5ebb572aba124b47ac39a33fd2538183_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtMy0xLTEtMA_062798ca-0f42-42e1-9d3d-2d41f0d05184"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifb5a9499dd5044ea8aea5a77be53c4ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtNS0xLTEtMA_90a874c8-ab84-40fb-863c-30f287a0d702"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifeb7330e33f14407916171e7e0d390c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTEtNy0xLTEtMA_4473e3f6-9d49-4ff9-8f55-a6dcea6ad496"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i020a06568fff458680224e0c17f7e1e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItMS0xLTEtMA_cea43929-d653-4b0e-9321-2b4191a664ba"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5bd39e73b51b426faf5d3000ec040cab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItMy0xLTEtMA_f5338997-d1ee-4e82-ad93-bf896d4325a1"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icd5f225519564e599eb1b5523a3a9fd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItNS0xLTEtMA_051d09d6-c8eb-4546-95c8-a3bf413ece64"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i42909e8f9c30495abe5bb1c928de6828_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTItNy0xLTEtMA_b72c0a33-0b91-4f16-a1ad-474501cf8c9e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3d83a1f143a24e3f875bf1146a570289_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtMS0xLTEtMA_2a50e5d2-b41d-4796-ad7c-63d5fb214df8"
      unitRef="usd">9017000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i078cb5087cab4be7ba5189ff529510ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtMy0xLTEtMA_a63e60e2-4190-4848-adfb-7b27491efe15"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib4a273d6b52d4ba48768b5519b0c3665_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtNS0xLTEtMA_6c2a743a-a631-4a37-9b0b-0711d170241d"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2b3bca9d1ae7450e90354484c1d5f005_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOjhkMjBmMTRkOTI5MjQ1NTU4OWE5MzEzZjEzM2ZiNmU5L3RhYmxlcmFuZ2U6OGQyMGYxNGQ5MjkyNDU1NTg5YTkzMTNmMTMzZmI2ZTlfMTMtNy0xLTEtMA_bcb7f76d-202f-4e2f-92ca-d00c8bd90b9c"
      unitRef="usd">3007000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfMTA5OTUxMTYzODIzMg_1256a06d-90e9-42c1-8cb9-88f59257f59a"
      unitRef="usd">1800000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="i546f06ef7f934d938a78d35cc7bd6f13_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNDM1Mw_6a4d48ac-57ce-4a14-a853-7f713936a71f"
      unitRef="usd">375000000.0</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="iee3c61a29b7d488e9481564d3568bfc8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNDQ2OA_679bc18c-9b4f-4092-8c8b-f4a158aa1080"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i5c7e8aa3d64f4299bb8749e88d06bc86_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfMzI5ODUzNDg5MDQwOA_c62a2778-7347-43c2-8359-35a5b626b547"
      unitRef="usd">500000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNjM3Ng_c73ba17d-a063-4484-9e12-c263350268ae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities due to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib37b745566de4dda9b10c642d417c89d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMS0xLTEtMS0w_be4dc37e-b13e-493e-9765-cb462a782f64"
      unitRef="usd">3007000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMi0xLTEtMS0w_20c65b84-024f-44e3-b815-5aef4e91f86d"
      unitRef="usd">2325000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i43eed80ef8db460ea73c2b5f60ba3736_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfMy0xLTEtMS0w_feea78d8-0f58-4144-8a93-4f328f5e10a8"
      unitRef="usd">-2830000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfNC0xLTEtMS03NjY4_7e9d731e-4fac-4497-a541-fa21948630a7"
      unitRef="usd">41800000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia9cc73ea0d9c420c800a11a503944b1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RhYmxlOmJjZGFkOWJhYTJlNTQzMmNhNGZmYTRkOWRiYWE0YzAwL3RhYmxlcmFuZ2U6YmNkYWQ5YmFhMmU1NDMyY2E0ZmZhNGQ5ZGJhYTRjMDBfNC0xLTEtMS0w_f31b0740-4cdf-4afc-b44d-1aed7bf7f12b"
      unitRef="usd">45312000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF85Ny9mcmFnOmM0ZGM1YTI1MWMwYzRmYWU5NjJlNTJkMzMzYTZjYjcwL3RleHRyZWdpb246YzRkYzVhMjUxYzBjNGZhZTk2MmU1MmQzMzNhNmNiNzBfNTgzNw_4ceea7f7-f97f-46c7-bda8-88940c8b4182"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTI_a83eb8e8-dfd9-4947-8a19-e9826389c154">LeasesWe lease certain office facilities and equipment primarily under various operating leases and one finance lease. Our operating leases have remaining contractual terms up to three years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial in prior years.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered into an agreement with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol. The agreement is considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. We allocated consideration in the agreement between lease and non-lease components using relative standalone prices. As of December 31, 2020, we have paid consideration of $35.3&#160;million and have total future commitments of approximately $24.1&#160;million through 2021. In October 2020, we determined the lease had commenced and recognized a right of use asset of $16.1&#160;million. We allocated $25.8&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and have a remaining lease liability of $6.6&#160;million as of December 31, 2020. The right of use asset is to be amortized straight-line over the remaining 8 year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4 million for the twelve months ended December&#160;31, 2020. Operating lease expense was $2.1 million (net of sublease income of $0.3 million) and $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of finance lease liabilities was $9.7&#160;million for the twelve months ended December&#160;31, 2020. Finance lease expense, which was recorded in cost of Captisol, was $0.2 million for the twelve months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTI_fb1617fa-bcf3-46ac-8355-e41474cc8b6b">LeasesWe lease certain office facilities and equipment primarily under various operating leases and one finance lease. Our operating leases have remaining contractual terms up to three years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial in prior years.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered into an agreement with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol. The agreement is considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. We allocated consideration in the agreement between lease and non-lease components using relative standalone prices. As of December 31, 2020, we have paid consideration of $35.3&#160;million and have total future commitments of approximately $24.1&#160;million through 2021. In October 2020, we determined the lease had commenced and recognized a right of use asset of $16.1&#160;million. We allocated $25.8&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and have a remaining lease liability of $6.6&#160;million as of December 31, 2020. The right of use asset is to be amortized straight-line over the remaining 8 year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4 million for the twelve months ended December&#160;31, 2020. Operating lease expense was $2.1 million (net of sublease income of $0.3 million) and $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of finance lease liabilities was $9.7&#160;million for the twelve months ended December&#160;31, 2020. Finance lease expense, which was recorded in cost of Captisol, was $0.2 million for the twelve months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i7fb52bcb659e47438837272f49d907bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzE1OA_5565397c-0fb0-4c9c-a17c-014ab57a1bcf">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7fb52bcb659e47438837272f49d907bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIyOQ_14ef5596-33b3-449d-8d96-b708695a475c">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <lgnd:PurchaseCommitmentConsiderationPaidToDate
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjY5OTI_6756af34-7826-494b-8866-e60919057ac5"
      unitRef="usd">35300000</lgnd:PurchaseCommitmentConsiderationPaidToDate>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMDc_e22766a5-b472-4795-b850-b34a54c10cce"
      unitRef="usd">24100000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i39e9c330c7d843a6b978f225237f75fe_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMjI_c0b9db46-b746-4b7c-8376-fd5e3597395f"
      unitRef="usd">16100000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwMzc_0027be0e-6f74-4885-9079-1531d8a57099"
      unitRef="usd">25800000</lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzIxOTkwMjMyNjcwNTI_e8dfd88a-f5c9-4c7d-b65c-a3e3eb7beba1"
      unitRef="usd">6600000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzg3OTYwOTMwMzA0NTA_2124ef56-fed2-4392-8881-ddec6dd5ca99">P8Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <lgnd:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTM_882d8b90-56ff-4801-87d5-79267ab2d444">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzEtMS0xLTEtMA_f65c1c06-fefa-4168-bfa0-0a1c9e010c3f"
      unitRef="usd">6892000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzItMy0xLTEtNDMyNg_0f763f7e-2751-47d8-93fe-d68d137cd838"
      unitRef="usd">10353000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMS0xLTEtNDM0Mg_8a572a1b-e736-44db-b664-9006e365b5c9"
      unitRef="usd">15842000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMy0xLTEtNDMzOQ_3028c0b8-fc0c-4aeb-90de-330f1892f303"
      unitRef="usd">84000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMS0xLTEtNTIzOA_507c399c-7f3d-443c-9e7f-722f644f251c"
      unitRef="usd">22734000</lgnd:LeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMy0xLTEtNTIzOA_63cfd995-fc38-455c-80d2-354bffd3a98b"
      unitRef="usd">10437000</lgnd:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzMtMS0xLTEtMA_3a17e475-b5bf-45de-8aeb-7268df1d06f7"
      unitRef="usd">1885000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzYtMy0xLTEtNDQyMA_0e24c62b-5563-4d3d-af5e-6e6bdc06870c"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzctMS0xLTEtNDQxNw_edec4244-a7de-4570-a682-743a2396f1c3"
      unitRef="usd">6593000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzctMy0xLTEtNDQyMA_4fb683ad-25c9-47f8-b86e-13daad49d24c"
      unitRef="usd">13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMS0xLTEtNTI0NQ_d339ca53-762a-40fe-954a-b50cfdd8a945"
      unitRef="usd">8478000</lgnd:LeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMy0xLTEtNTI0NQ_27aaec7c-64cf-4d93-bbff-714115c18df3"
      unitRef="usd">1255000</lgnd:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzQtMS0xLTEtMA_87c28f49-8b8d-460d-a078-9d280dbcbc7c"
      unitRef="usd">5643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzktMy0xLTEtNDQzOA_e69094e5-9694-4fa1-9ff2-a8b316ef5fa2"
      unitRef="usd">9970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTEtMS0xLTU1MTY_09eef19b-1732-49d2-92e1-b4cf346b8970"
      unitRef="usd">112000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTMtMS0xLTU1MjU_52ba791f-6de0-488a-a9fe-afaf380d210f"
      unitRef="usd">71000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <lgnd:LeaseLiability
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzUtMS0xLTEtMA_f839b2ed-e4a0-418e-9a97-4b3032a7245a"
      unitRef="usd">14233000</lgnd:LeaseLiability>
    <lgnd:LeaseLiability
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTplMWY2M2U5MmViMWU0ZjA0YTMwZGM0MTYwYzhjZjBiMi90YWJsZXJhbmdlOmUxZjYzZTkyZWIxZTRmMDRhMzBkYzQxNjBjOGNmMGIyXzExLTMtMS0xLTUyNDg_87d90a9a-7a40-4e43-93b2-4175d6f01863"
      unitRef="usd">11296000</lgnd:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTQ_60cead37-8c90-4fd2-bf14-ca3d5470af83">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3NTQ_b5881a71-4514-4501-b9e4-51a882dda66b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzEtMi0xLTEtMA_c0e034d3-e06e-47ea-815f-b4c4f1622439"
      unitRef="usd">2259000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzEtNC0xLTEtNDc1MA_bf838af8-d482-4525-af04-690fb67383fc"
      unitRef="usd">6649000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzItMi0xLTEtMA_9858fd8a-2eef-4da8-be4a-82dd3f282b05"
      unitRef="usd">2129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzItNC0xLTEtNDc1MA_04798266-b29a-4d9f-bc78-ae722a448996"
      unitRef="usd">56000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzMtMi0xLTEtMA_9aa73a86-ad7e-4acc-8474-43afc5a8983d"
      unitRef="usd">1766000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzMtNC0xLTEtNDc1MA_a7fafd27-8c57-4089-8092-7631be2d49ed"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzQtMi0xLTEtMA_349769f9-f58f-4d24-bcfe-83d68c056ce5"
      unitRef="usd">1013000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzQtNC0xLTEtNDc1MA_4afffcef-3ef8-4af4-ac54-5cbeb199c786"
      unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzUtMi0xLTEtMA_2f473148-27bc-495b-a1b7-a91cd5e4d9f8"
      unitRef="usd">792000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzUtNC0xLTEtNDc1MA_539f8530-8a8e-4ee0-bf84-8a4a3181a438"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzYtMi0xLTEtMA_4e30dbe6-b4b9-4fce-9e20-c6274db525c8"
      unitRef="usd">700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzYtNC0xLTEtNDc1MA_7490469e-edc8-4714-a4dc-3391781ec7e2"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzctMi0xLTEtMA_350f04fc-6f24-4c1b-b988-a6a106aef6b7"
      unitRef="usd">8659000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzctNC0xLTEtNTIzMg_1bacc059-2f9c-49a2-abec-9ee80d29cd1a"
      unitRef="usd">6758000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzgtMi0xLTEtMA_feed1b18-c5e1-4b78-beab-18643e2dcded"
      unitRef="usd">1131000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzgtNC0xLTEtNDc1NQ_d8f2b2b1-9273-4a14-a9a5-9a17f51bd46e"
      unitRef="usd">53000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzktMi0xLTEtMA_30ef6675-01e3-4f58-a0fa-1d53bdcbd622"
      unitRef="usd">7528000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90YWJsZTo3ODUxNGZkMTYwYzc0NmY4OWNhYTA3MWFjNTQ0NzY3Mi90YWJsZXJhbmdlOjc4NTE0ZmQxNjBjNzQ2Zjg5Y2FhMDcxYWM1NDQ3NjcyXzktNC0xLTEtNTIzMg_e2eb251b-c5bb-4800-9053-866914a45a43"
      unitRef="usd">6705000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI1MDY_e3ebe87e-4355-453d-bfc1-78c05e01c388">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI1NTU_37a6dab2-a8b0-42a1-b3a3-79e3fd14938e"
      unitRef="number">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI2NDQ_490609b8-805d-4449-97ad-d31ab0c0dde1"
      unitRef="usd">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI2OTA_002c4a42-d194-49df-87a6-124acf777830"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzI3MjA_1d7c1775-b518-405d-b60c-97a162a86c06"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseExpense
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzEwOTk1MTE2MzkzNTU_776330e4-b06e-4686-932d-ca8e43d1ba48"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzEwOTk1MTE2MzkzODk_16f366f9-5310-47ac-9618-5f45096071c0"
      unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNjM_0e3a5e31-42de-4620-b256-630c986103e5">P7Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNjg_d43cdbb3-f837-4290-ba1e-b80402649d02"
      unitRef="number">0.035</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzg3OTYwOTMwMjkzMDE_705f3291-6c64-4111-ba72-c502562fb1c9"
      unitRef="usd">9700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDAvZnJhZzoxMDRjODNmNzYyMWQ0Y2NlODY5YzdiY2QwM2JkMDNjMi90ZXh0cmVnaW9uOjEwNGM4M2Y3NjIxZDRjY2U4NjljN2JjZDAzYmQwM2MyXzMyOTg1MzQ4OTAxNzQ_95b89e56-3951-4a98-862d-62b8b026dad6"
      unitRef="usd">200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE2MjM1_57d0d2d4-8f2e-40c8-8f6c-40cf6e4ed2f3">Convertible Senior Notes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2019&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;                                                                                                                               &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $340.0 million and marked it to market as of December 31, 2018 to $22.6 million with the resulting $119.4 million increase, net of $471.2 million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $11.6 million for these warrants and recorded this amount to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of 525,000 warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#x2019; equity to a derivative liability on the modification dates, resulting in a $28.3 million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $30.1 million and recorded a $1.8 million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December&#160;31, 2020, there are no warrants outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $144.0 million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $13.5 million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December&#160;31, 2020, the &#x201c;if-converted value&#x201d; did not exceed the principal amount of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $3.2 million was recorded as interest expense for the twelve months ended December&#160;31, 2019. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $2.5 million reflected in other income (expense), net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2020; (2) a $35.0 million reduction in debt discount, and (3) a $3.2 million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. After the repurchases, approximately $495.3 million in principal amount of the 2023 Notes remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $19.2 million and $7.5 million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, in connection with the repurchases of $234.4&#160;million in principal of the 2023 Notes for $203.8&#160;million in cash, including accrued interest of $0.6&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp;amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 28, 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp;amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwMQ_60703790-a792-4c4a-8595-62f5c0679b87"
      unitRef="usd">245000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE3NQ_592b402f-de77-4e17-9e2d-7af2a29966ea"
      unitRef="usd">239300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI2NQ_a559ea28-8377-4758-9cc2-41a10a5e6430"
      unitRef="number">0.0583</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzUxOA_205f01cf-1571-480e-9b94-cc2488c1955f"
      unitRef="usdPerShare">75.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e26d5b33c154962a5f1ac3b37751fc1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU5MA_60d18702-39f3-4473-9cbb-4d6ee9e57bc8"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk0MA_ebfc14bc-d1e9-4c5f-bf76-c9d6082384d7"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk5Ng_25fed931-a90b-4775-a800-38378c61ec11"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="idf639990efe546a2ae48d957d3513d96_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzExOTE_d9f715f6-3c8a-4427-8042-3a29ec455c61"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNTY_56ab5464-b0ad-411e-a9ca-bc515c93bae2"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzMDU_3bc67613-0180-4885-887f-5086fea3fcb1"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i9d4fc65d24bb438588787a9b62857c2f_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0MTg_dbeda4c3-a704-40bd-b1fa-cd85de65a597"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i034232aba8564ecda5fc7d8eb72396d9_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIxMzA_08720770-e902-419f-85ec-3c8ae59f714b"
      unitRef="usd">341600000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i28107efd47144a3abd7964318b557020_D20181231-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIyNjA_171f8f90-0aaa-46ff-8418-67869f4aec56"
      unitRef="usd">23400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal
      contextRef="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIyODI_04504865-278b-4d1e-8d27-033e48505474"
      unitRef="usd">118700000</lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI2Mjk_05612114-012a-46c8-9fe8-01607ea78ecf"
      unitRef="usd">21800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="iafb6ca320ac144959c637e03c42f632e_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI4OTU_661adae6-f39d-47ae-b9d2-0a88cf080763"
      unitRef="usd">31600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzI5OTg_cae367f9-a78d-4a62-9ce6-6037aa263cde"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ief2a8b10da13496f8244a648b1950f2d_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzMxMTY_cb87298c-c822-4495-9ced-9912614e1029"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i2f492ad4dfa64cb6b2319778404cfec8_D20181001-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzMyMDc_a95c4b10-4554-46ca-b46c-51d779a72b85"
      unitRef="usd">439600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzM1MjE_e75a6ce9-bc3a-40a1-95e2-692d2bb18a43"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQwMDc_17bedda3-4bbd-4a12-94a6-f06d6d7036e1"
      unitRef="usd">1000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQxNzI_e3811ac0-47ae-4a17-801b-73325624e292"
      unitRef="usd">1000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i18324d0fbd504a279f554c22c0b383a6_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQyNzU_61e4f3fc-1467-49d1-9fb7-fa1d7204803d"
      unitRef="usd">500000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i62894ef4375a4892a57a4a49a14e7ac1_D20190815-20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQzNzY_15c072ec-3509-465c-a309-8485fb682102"
      unitRef="usd">26300000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="if187349176e84ceda4964da4edd883be_I20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQ0MDA_4d8a304a-cf83-46b9-96fb-3ad1173a17f9"
      unitRef="usd">11900000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzQ1NDQ_4ef766be-5d34-4adc-ae70-3e4366428b23"
      unitRef="usd">-11000000.0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU1MzE_aa34711d-610a-46b2-9599-c51a0e2fd313"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgnd:ExercisePriceofConvertibleBondHedge
      contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzU4MDc_1b03cf72-5667-488a-a741-c4676124756d"
      unitRef="usdPerShare">75.05</lgnd:ExercisePriceofConvertibleBondHedge>
    <lgnd:PaymentsforConvertibleBondHedges
      contextRef="i78b5cac108114c5da7c3e97cec70c249_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzY2MTc_1433d5ce-75f6-4865-8473-8493d8a4caba"
      unitRef="usd">48100000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i220b0c6c496e42fc8ea7dccfde48d81d_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyMTE_41d8c6f7-afac-4631-9474-a051b089b5a5"
      unitRef="usd">340000000.0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie35fa90cf89940babbfb526c040370f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyNjU_288d1132-a24f-4803-959d-7bda680f5b38"
      unitRef="usd">22600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i04a74fe39f6b45e394e08d00eafd8e23_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzcyODc_dda93f18-b768-4195-8269-2df59e19bedc"
      unitRef="usd">119400000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities
      contextRef="ia4c7b689f26942249a7d719514cbc8b2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzczMDc_16a763b2-e70f-49d0-b172-df79d10410b7"
      unitRef="usd">471200000</us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id18f5551b94641ff880e77978a598895_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc1MzQ_fb6f7dc3-1849-4ef2-8818-fde54632aa03"
      unitRef="usd">-10200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc3ODI_54a4f0f7-2619-4d6d-8ec8-e8e9ae489f08"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5eec6b1c21f0498da88860217bd3e1b7_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzc4MzQ_acfe6762-97a5-4c08-b6ba-490471fa4644"
      unitRef="usdPerShare">125.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i5a15352b902e4da3bb0205dc843b9a3f_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzgxOTU_d994a092-3188-4cbd-9261-0bad12a00a07"
      unitRef="usd">11600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgnd:WarrantsSettled
      contextRef="i661dd10b9d474519ba9a2208b86c8de9_D20181101-20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzg4MzU_c1379454-8b7c-4603-bdad-f5e03a6bf788"
      unitRef="shares">525000</lgnd:WarrantsSettled>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkwNTM_ce96b995-4002-4c74-a6f0-f9d18410cf68"
      unitRef="usd">28300000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkxNjU_0cb76e94-bdc3-460e-accc-3b720ed63ca0"
      unitRef="usd">30100000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzkxODM_cbb9987c-c3f6-460f-a1d4-17e38dccd2bd"
      unitRef="usd">-1800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzIxOTkwMjMyNzk1MjY_d0cf7f96-0b40-471b-a806-be84d08a2a58"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk1NjY_06e54966-0f1d-40ae-8e87-927662d06592"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk2NDY_02273d25-6380-42c0-9b3e-ba42e7066fe5"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzk4MDk_74694f1e-1ea6-47e8-9975-261d6410516d"
      unitRef="usd">733100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwMTMw_c9c8570a-27c6-4f96-9131-8e32170fc949"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNDYy_f2fc933b-89db-4db0-894e-5b7643d14340"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNTE4_66775c8f-89f2-4b5b-be7d-1aa8640ddbb2"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i31d1c5191a9046a181fd2b919d8d7e85_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNzEz_f695ba15-dd1b-4f2b-9e6b-d35ffc70514c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwNzc3_6ee7e7d0-57a6-4d6e-a670-0d23ed2a2774"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwODI2_03e61605-2d49-43cf-9d8c-7f7125f7574b"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i04d560ca08f74bbd965c56f0937ab8ca_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTM5_11032bef-8e3c-467f-81f1-ec3a35283d31"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzExNzU0_c808867c-edf7-4280-8add-7875ade322fb"
      unitRef="usd">144000000.0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i323e527963b14f6ab5f0f11b66cf75a8_D20180522-20180619"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyMTc5_bdd284ea-fdf0-4f43-b4ad-e3d60fd731bb"
      unitRef="usd">13500000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNTc2_7a395a67-e772-4af3-acc5-4a52a082d557"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyNzQ5_afbfd354-5ec0-423e-96e0-2a5f20a4853b"
      unitRef="usd">16900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEyOTIw_c749916a-1ba7-4a02-a7a6-27806111ad4b"
      unitRef="usd">3200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzMDQ0_5202db03-b660-43ff-a26d-14d667b45128"
      unitRef="usd">13700000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i65069fa42dbc40d2941743d3f4afb5f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0MjY_e46996dd-e66f-4d53-88dd-c4b3476664c2"
      unitRef="usd">254700000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0NDc_1c740020-383e-4008-a26f-407e8b5be05d"
      unitRef="usd">222800000</us-gaap:RepaymentsOfSeniorDebt>
    <lgnd:DebtInstrumentAccruedInterestRepurchasedAmount
      contextRef="i65069fa42dbc40d2941743d3f4afb5f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0Njg_b3dcbd0e-09bd-4530-b1e0-099313320342"
      unitRef="usd">600000</lgnd:DebtInstrumentAccruedInterestRepurchasedAmount>
    <us-gaap:GainLossOnRepurchaseOfDebtInstrument
      contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc0ODc_d2b4ffc7-82ce-4393-9390-b016a6fd6955"
      unitRef="usd">-2500000</us-gaap:GainLossOnRepurchaseOfDebtInstrument>
    <lgnd:IncreaseDecreaseInDebtDiscount
      contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc1MDY_b41296ad-3f80-45bf-8bde-21540a54a7a7"
      unitRef="usd">-35000000.0</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ic42973c95f2d4925a1bb724b9a95b79a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NDc1MjY_381d01f3-c8f8-4131-85ff-449b2224be03"
      unitRef="usd">-3200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3NjU_8af11274-c95b-4e02-992a-1419558704a6"
      unitRef="usd">495300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzNTk3_4296bb73-e50f-4272-8243-1fa0ddebc77e"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzODcx_ed6b70a7-6752-4032-8d7b-a67fe5a01209"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lgnd:PaymentsforConvertibleBondHedges
      contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEzOTU0_8f119635-21b3-462b-bccf-7d870b6b835e"
      unitRef="usd">140300000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0ODM5_735b48de-a612-4812-af81-1a48234eb889"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifc84240a812d4182830716e5492a75f0_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0ODkx_6f9d271b-a0df-4202-bf3d-75e0878e34a3"
      unitRef="usdPerShare">315.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ief51a740808646c0be978c4781f49b06_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE0OTQ5_9fb68440-1520-42ff-836a-80b93a53e338"
      unitRef="usd">90000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE1ODk1_70f51cc0-4e1d-47c2-ba01-d690506cd3bd"
      unitRef="usd">19200000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i65112402885d4f22a4c73817d2d6a7c3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE1OTAy_fb14aabc-9cd4-4a70-badc-9e91273b5414"
      unitRef="usd">7500000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if6c815b5da3a452d8a7e3e5be67a017e_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE2Njg_db4f3d42-6d66-41d1-a18c-66ea87a30dc5"
      unitRef="usd">234400000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ib69a1d348c964f9585625ef80a9b7fa8_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MDE_57e014c8-bdbd-4758-b58f-d1262215635b"
      unitRef="usd">203800000</us-gaap:RepaymentsOfSeniorDebt>
    <lgnd:DebtInstrumentAccruedInterestRepurchasedAmount
      contextRef="if6c815b5da3a452d8a7e3e5be67a017e_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MjA_bbac8de1-1813-4085-a934-a8b767993e82"
      unitRef="usd">600000</lgnd:DebtInstrumentAccruedInterestRepurchasedAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i50cd7daf68e54877a8d9e082be5523ad_I20210128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3Mjc_c90e46a6-a1b5-4f5c-8090-7874ff71ad31"
      unitRef="usd">20300000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i350edb2222fc4ac0a3c6507827c9b80d_D20210128-20210128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3MzQ_7947d6b4-5873-45de-9dd7-fdfaedb96a91"
      unitRef="usd">19100000</us-gaap:RepaymentsOfSeniorDebt>
    <lgnd:DebtInstrumentAccruedInterestRepurchasedAmount
      contextRef="i50cd7daf68e54877a8d9e082be5523ad_I20210128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzEwOTk1MTE2NTE3NDE_81468538-d775-45c5-9d60-d5b424e32b41"
      unitRef="usd">100000</lgnd:DebtInstrumentAccruedInterestRepurchasedAmount>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90ZXh0cmVnaW9uOjgyNjc3YWNkNTdkZDRhODNiYmYzMjY1NmEyNDgxMzAzXzE2MjM4_3f145ba8-afdd-4a67-9862-d56338abc650">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzUtMS0xLTEtMA_9739ef14-145a-498a-bdea-4b1ea91bb373"
      unitRef="usd">495280000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzUtMy0xLTEtMA_f9768cb0-6ec6-4716-a62f-54d5c2f7dbdc"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzYtMS0xLTEtMA_187fdefa-d8c4-4cd4-8aa2-10f6efd0b6d7"
      unitRef="usd">52987000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzYtMy0xLTEtMA_cd897c4c-4fbf-4001-8db0-a92dcf4007ac"
      unitRef="usd">111041000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzctMS0xLTEtMA_a0d19246-6650-4de0-b437-2b57c7a0858b"
      unitRef="usd">442293000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzctMy0xLTEtMA_fba76649-4e8a-4e76-a853-67441322c804"
      unitRef="usd">638959000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzgtMS0xLTEtMA_7738e849-c9d2-4e30-a669-ca97ffadc8c4"
      unitRef="usd">48397000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzgtMy0xLTEtMA_752f815f-c082-4ccf-8032-bdc1216b0e5a"
      unitRef="usd">101422000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i352234f55c94428c9659aebe6d102ea0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzktMS0xLTEtMA_884a6042-5269-49aa-b93e-981075e43d2a"
      unitRef="usd">466053000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="iff2786e1861d4292b0275af1d7b92525_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDMvZnJhZzo4MjY3N2FjZDU3ZGQ0YTgzYmJmMzI2NTZhMjQ4MTMwMy90YWJsZTo0OGYzOTE2OTkxMDg0OGQzYmRmYjg0NjU5YTBhZmRkYi90YWJsZXJhbmdlOjQ4ZjM5MTY5OTEwODQ4ZDNiZGZiODQ2NTlhMGFmZGRiXzktMy0xLTEtMA_4309b38e-0258-421c-987f-8ed8e9256918"
      unitRef="usd">647280000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODM_1c40a2e7-d4b9-442e-9659-27bbae3578b1">Balance Sheet Account DetailsShort-term Investments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual Fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of  December&#160;31, 2020 and December&#160;31, 2019, we recorded shares of Viking common stock we own at fair value of $32.8 million and $48.4 million, respectively, in &#x201c;Short-term investments&#x201d; in our consolidated balance sheets. We also own warrants to purchase up to 1.5 million shares of Viking's common stock at an exercise price of  $1.50 per share. We recorded the warrants in &#x201c;Short-term investments&#x201d; in our consolidated balance sheet at fair value of $6.3 million and $9.9 million at December&#160;31, 2020 and December&#160;31, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 14 positions which were in an unrealized loss position as of December&#160;31, 2020. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4MQ_17ee1139-a959-4580-b6e3-e99ff17f0d7f"&gt;three&lt;/span&gt; to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $1.8 million, $1.5 million, and $0.9 million was recognized for the twelve months ended December&#160;31, 2020, 2019, and 2018, respectively, and was included in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $23.4 million, $16.9 million, and $15.8 million was recognized for the years ended December&#160;31, 2020 and 2019, and 2018, respectively. Estimated amortization expense for the years ending December&#160;31, 2021 through 2025 is $47.1 million per year. For each of the years ended December&#160;31, 2020, 2019, and 2018, there was no material impairment of intangible assets with finite lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For CVRs associated with the Pfenex and Icagen acquisitions, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (4), Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes rollfoward of contingent liabilities as of December 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additional Contingent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Icagen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pfenex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,542&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1NzY_92936957-174f-47f1-9243-62731672439e">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Treasury bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual Fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32a4018efce8403baff24ddd52876e90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMS0xLTEtODE1Nw_629185b3-d2b4-47d0-bb43-27f8ef4b726e"
      unitRef="usd">151512000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32a4018efce8403baff24ddd52876e90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMy0xLTEtODE1Nw_c97528cc-051c-4427-95ed-b1bc5e0f76ef"
      unitRef="usd">386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32a4018efce8403baff24ddd52876e90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNS0xLTEtODE1Nw_94d136f0-bc86-48af-9a7a-e6e26fd71fa6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32a4018efce8403baff24ddd52876e90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNy0xLTEtODE1Nw_93693e97-baa4-46cc-9bbf-b823098f5d5c"
      unitRef="usd">151898000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMS0xLTEtMA_fd4d7a54-517a-406b-aabb-be2f0adc46b4"
      unitRef="usd">84120000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtMy0xLTEtMA_777a2b99-b996-47da-a1c8-88024d351a77"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNS0xLTEtMA_273ce77f-5f31-4a04-b74a-c41ed30ceddd"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i114a6a856e5944a982c509306ce6ccda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzMtNy0xLTEtMA_5a339a6b-002a-44c2-b4de-94dc4ea57537"
      unitRef="usd">84154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMS0xLTEtODE1OQ_edd1eb49-0205-4b36-a6d5-7990872647b1"
      unitRef="usd">45459000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMy0xLTEtODE1OQ_06a86758-cd87-40a4-b868-5a5513d9d3b6"
      unitRef="usd">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNS0xLTEtODE1OQ_79139193-9a49-42f4-9557-2994de0fab53"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3644aaff90b0425b94d88bd354d543ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNy0xLTEtODE1OQ_891a9107-259f-4fa9-9fce-29599d4cfa0f"
      unitRef="usd">45485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide70d0b7f442498693f401787562d65e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtMS0xLTEtMA_d725d49a-1fba-4327-9a24-f9df840e3cb6"
      unitRef="usd">30512000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide70d0b7f442498693f401787562d65e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtMy0xLTEtMA_12cd4c88-d687-4182-92e3-03f5bc7a750d"
      unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide70d0b7f442498693f401787562d65e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtNS0xLTEtMA_c81de1e2-740c-46cc-b95b-d206a9c72f47"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide70d0b7f442498693f401787562d65e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzQtNy0xLTEtMA_80a7462b-069c-44b2-832c-c9455094d0de"
      unitRef="usd">30610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i882b43ad553b45d298444f65918a460d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMS0xLTEtODE2MQ_402b9c40-dbbd-4281-a3a7-d9663bc8e881"
      unitRef="usd">4499000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i882b43ad553b45d298444f65918a460d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMy0xLTEtODE2MQ_cec84587-b66e-4cc5-af91-7b204f2b1bf1"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i882b43ad553b45d298444f65918a460d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNS0xLTEtODE2MQ_51b11386-3ff4-4812-be88-c8210f844a1d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i882b43ad553b45d298444f65918a460d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNy0xLTEtODE2MQ_40e53807-e08b-40b5-81d8-fc23ebc1d6fe"
      unitRef="usd">4501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3b17149c809471b94d0d5841711e32b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMS0xLTEtMA_bef1eef3-4599-405e-a289-ff784bfce4b9"
      unitRef="usd">4466000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3b17149c809471b94d0d5841711e32b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtMy0xLTEtMA_9d741ead-4715-4457-94bc-cb1ab7661039"
      unitRef="usd">360000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3b17149c809471b94d0d5841711e32b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNS0xLTEtMA_72e93d38-a3e4-403e-ac5b-80791ab3b062"
      unitRef="usd">1388000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3b17149c809471b94d0d5841711e32b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzUtNy0xLTEtMA_4f2c89f9-3727-44ce-84e0-4df5df5a2c8e"
      unitRef="usd">3438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMS0xLTEtODE2Mw_bc4dc319-52e6-471b-a25b-79cff2203484"
      unitRef="usd">3999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMy0xLTEtODE2Mw_2b3f1b04-6064-4b84-9949-f8b6c7e1db41"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNS0xLTEtODE2Mw_cb8daa5e-d87b-480a-8c52-3cce7d47f3b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i294d18f49eff4ac9b26c05f39f1dfb8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNy0xLTEtODE2Mw_f678dd4d-d4b3-4be5-866d-7bce89103f78"
      unitRef="usd">3999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMS0xLTEtMA_97f0423d-eb34-44c9-aa6b-395048731697"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctMy0xLTEtMA_5d54f4a7-670a-4e50-af30-4976a626f9a0"
      unitRef="usd">393000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNS0xLTEtMA_6cca6809-b457-4342-b43d-33d80497ba15"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee918a3da8aa4671b06dc59a2cafc994_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzctNy0xLTEtMA_b358de91-2c54-4f22-8cf0-404278785379"
      unitRef="usd">393000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMS0xLTEtMA_ccbb077f-b0dd-45e5-ac1f-8da9522c2cb9"
      unitRef="usd">324567000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktMy0xLTEtMA_4531ac0a-58ac-42ae-81f8-586c543d8173"
      unitRef="usd">1302000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNS0xLTEtMA_dbfbc3d8-9c8d-459f-bbd0-bdc0de671785"
      unitRef="usd">1391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63fcda9c6a804dc59452ea6868c24acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzktNy0xLTEtMA_d69d3ec4-4977-4fc7-bdfc-37e1e84a3dd7"
      unitRef="usd">324478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTEtMS0xLTA_4ead8c61-77fb-4bdb-b26f-a784582f9bb6"
      unitRef="usd">411690000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTMtMS0xLTA_66121bed-114b-4204-89d4-f38e7dbad5e6"
      unitRef="usd">188000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTUtMS0xLTA_d63c7a6f-982d-4191-bf2f-e46818a9962d"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1eea505c815c4979a95d55f6145b57ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEyLTctMS0xLTA_f44ead00-49aa-4cc5-a0ca-b54d4958e63a"
      unitRef="usd">411875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTEtMS0xLTA_497c6664-a204-421f-a1ad-3e7611be0200"
      unitRef="usd">63818000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTMtMS0xLTA_b37958cf-02e2-450e-8b1c-d916fb7a894f"
      unitRef="usd">161000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTUtMS0xLTA_09321964-7ba5-461e-b322-935982021fee"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d6097c094df4052a9ce95b736093c1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzEzLTctMS0xLTA_43485ba9-f4cd-4f85-be3d-fd5021c23731"
      unitRef="usd">63979000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTEtMS0xLTA_8aeba9f5-8864-4dee-aaf4-25e028543204"
      unitRef="usd">4506000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTMtMS0xLTA_26839c4f-5b68-4f9e-b1f0-07c66e8f8553"
      unitRef="usd">416000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTUtMS0xLTA_adb3e69c-ee2d-4d7d-a898-fc19f8fedcd0"
      unitRef="usd">1850000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9ba365afb5a4ea59597c6bdc13dd28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE0LTctMS0xLTA_fd2e4c99-5080-4b44-aaa1-0fb465e73c32"
      unitRef="usd">3072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTEtMS0xLTA_2545362a-6d42-4b26-85c1-31fdbb22b51b"
      unitRef="usd">210525000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTMtMS0xLTA_7f14e32b-88e6-450a-9afc-693b2936e10d"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTUtMS0xLTA_607dff35-695d-4ff7-b3ef-78f51ac8377d"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9459b2ffac154d2e998968c36fce5d3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE1LTctMS0xLTA_e586d28b-40e3-4936-8a23-b063d2c5f645"
      unitRef="usd">210552000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTEtMS0xLTA_eae87bcd-8de0-4b5c-924c-1bc4bcfa7e75"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTMtMS0xLTA_c5bd3015-f83a-4f4d-a04e-dd9e52631276"
      unitRef="usd">125000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTUtMS0xLTA_d7a50d24-735b-4e17-94a2-b522d8ebfcba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71a8ac2029b245f392545bc4eda8d56e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE2LTctMS0xLTA_017be535-3c29-4f3f-b66e-5a4b8716a148"
      unitRef="usd">125000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTEtMS0xLTA_183ddb34-7021-472f-8271-f539676b5fd1"
      unitRef="usd">250636000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTMtMS0xLTA_a8f1d61e-a6f8-4ba6-a605-8514f0464db8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTUtMS0xLTA_421cbb42-d258-47a9-946f-cbcde1ec8c5c"
      unitRef="usd">249000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ef909d1974d4b4193bb6274b4fa1f71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE3LTctMS0xLTA_3b2bb577-11f4-433e-bd5f-161cfc01c981"
      unitRef="usd">250387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTEtMS0xLTA_f82ec215-fafa-4ce5-9116-a63ae478b97b"
      unitRef="usd">941175000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTMtMS0xLTA_1f936087-1d5c-49a9-bd25-a164ac112051"
      unitRef="usd">933000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTUtMS0xLTA_83fa4914-2f1c-4296-900e-e4ed9f63f0c4"
      unitRef="usd">2118000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d69bc05694444f0adbc0858ee3a6715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4MzMxYmVlN2NmNDM0NDJmOTIyZmM1ZDRkNDhmMzM1Ni90YWJsZXJhbmdlOjgzMzFiZWU3Y2Y0MzQ0MmY5MjJmYzVkNGQ0OGYzMzU2XzE4LTctMS0xLTA_36d58f0c-62bc-41bd-a339-1283fa26221b"
      unitRef="usd">939990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODEw_8442220d-0923-4f28-b5ed-b609bf8ea202"
      unitRef="usd">32800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODI0_b01f847e-271b-466b-8371-6e024877870c"
      unitRef="usd">48400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODQ2_764c170a-af85-42b7-a825-e2fa302a8fde"
      unitRef="usd">1500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODY4_ca1cbbed-f1df-4b81-b66b-121f2193bdea"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i3839777e750f48b3970c5b559eed73b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODgy_b6a7bbed-c7d6-4662-bec9-c6d6e998d018"
      unitRef="usd">6300000</lgnd:InvestmentInVikingCurrent>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i3736760d3c7340649ea390cca0ce15fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEyNjQ0MzgzNzI2ODky_2f5e8485-423e-4f12-8e9e-db7add3e3822"
      unitRef="usd">9900000</lgnd:InvestmentInVikingCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzIxOTkwMjMyNjg5OTA_28de4c27-0199-4253-8227-6cf795043c30">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzItMS0xLTEtOTM4OA_ab600148-cc33-448d-8ce0-26371879bec8"
      unitRef="usd">141732000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzItMy0xLTEtOTM5Mg_e96a4c5f-10fe-4196-a64d-d16c56c8ddfe"
      unitRef="usd">141793000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzMtMS0xLTEtOTM4OA_b3cc0f16-d782-4035-919c-baba6b6413cf"
      unitRef="usd">26856000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzMtMy0xLTEtOTM5Mg_70bd0549-7ae2-45cb-b062-c11c5259f443"
      unitRef="usd">26956000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzQtMS0xLTEtOTM4OA_be622a58-88a7-4d71-aa20-1cf6d8990b81"
      unitRef="usd">0</lgnd:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive>
    <lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzQtMy0xLTEtOTM5Mg_7b09c8fa-6f2c-4bc5-be0e-b33e71d7cc2e"
      unitRef="usd">0</lgnd:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzUtMS0xLTEtOTcxNA_671110f3-e5ae-4ae5-870e-ade6c9240181"
      unitRef="usd">168588000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTpkZmQxNDlkZmI1NDc0NGNjYTA5Mzc3ZWYzN2RiNzNhOC90YWJsZXJhbmdlOmRmZDE0OWRmYjU0NzQ0Y2NhMDkzNzdlZjM3ZGI3M2E4XzUtMy0xLTEtOTcxNg_93dd0c90-1fb0-4ad9-ba90-4408f69d3531"
      unitRef="usd">168749000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzIxOTkwMjMyNjg5ODk_8ecc4a24-16b6-4950-9f92-7df910ec992f">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMS0xLTEtOTQwNg_852be713-da9f-4aa9-b5cc-16c58e8d051b"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMy0xLTEtOTQwMg_6c70969b-e1b6-40b6-adc4-43ddbed9edf4"
      unitRef="usd">14013000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtNS0xLTEtOTcyOA_6b7afc57-0bbc-4cc7-934e-9362a7c78018"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtNy0xLTEtOTcyOA_48109385-235a-4b23-a37b-c8bb7a98a22c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtOS0xLTEtOTcyOA_e472c66c-e24b-431e-b7c1-b73e322cb49a"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id417fab3cf0d4c5e917425392e1fd9cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzMtMTEtMS0xLTk3Mjg_8bab0536-7c13-484d-862a-51235b1f5faa"
      unitRef="usd">14013000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMS0xLTEtOTQwNg_5fa3771a-cd79-4dbe-865a-ddd151d58f2a"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMy0xLTEtOTQwMg_6f0e8b40-7465-4b27-bdb2-0cc4b7f8777c"
      unitRef="usd">4526000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtNS0xLTEtOTcyOA_78f5f6f3-9f56-4a71-aedf-cf4fbc29a690"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtNy0xLTEtOTcyOA_565977b4-839e-42ef-92d4-b54da41c4c84"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtOS0xLTEtOTcyOA_742aecd7-25ba-4c2c-b028-afc8d4893f67"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i14454ce086d24095ba714d9760e0fb96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzQtMTEtMS0xLTk3Mjg_b2f17a22-7c87-4bbb-94c4-7521605c2f88"
      unitRef="usd">4526000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMS0xLTEtOTQwNg_12f2fac8-5019-43af-9a69-5461ff4212d4"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMy0xLTEtOTQwMg_b2c43263-9465-43c3-977d-fdc3e9f00d22"
      unitRef="usd">7693000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtNS0xLTEtOTcyOA_815fdac0-c956-4089-91b9-5be11e3b2fba"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtNy0xLTEtOTcyOA_81a95169-ca27-446b-be36-b2118d0cb917"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtOS0xLTEtOTcyOA_a1046d27-5386-4e39-ae15-699122eb9d85"
      unitRef="usd">1000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia87eae20e42b42d88806d1cb1ba3b88f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzUtMTEtMS0xLTk3Mjg_b062c989-9f94-4c32-b611-7f9b7b658950"
      unitRef="usd">7693000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMS0xLTEtOTcyOA_52e963e7-a089-4bdd-95dc-649ba76a3716"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMy0xLTEtOTcyOA_bd3e7c2f-5f20-40d7-a4b2-7cae5f8a7b94"
      unitRef="usd">26232000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtNS0xLTEtOTcyOA_146a0e36-7f1e-43d1-9319-51455bb87b80"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtNy0xLTEtOTcyOA_ae497fab-5f22-49d2-babe-f2da33dc0b71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtOS0xLTEtOTcyOA_9c859720-6cc7-4f17-9945-a5fcab611cf9"
      unitRef="usd">3000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzYtMTEtMS0xLTk3Mjg_51595ed0-5d7b-48f2-bc83-875a616e719a"
      unitRef="usd">26232000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMS0xLTEtOTQzNg_9ca897ef-6a57-4b7c-9344-c1d6425b94fb"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMy0xLTEtOTQxMA_1ca83e43-5120-44a1-a7e5-825170f3c1bc"
      unitRef="usd">58584000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktNS0xLTEtOTcyOA_bfd264ff-4d4c-4cb5-987a-ca8d9460a93e"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktNy0xLTEtOTcyOA_a0a8ab41-b79a-40a4-839b-0ba3b75b8d68"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktOS0xLTEtOTcyOA_28b2ab59-9184-487b-91c1-2757dea42c30"
      unitRef="usd">3000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7514fb8f24a742d49edc89c4cb021e3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzktMTEtMS0xLTk3Mjg_10a48005-a0e7-4430-8371-51cef749c008"
      unitRef="usd">58584000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTEtMS0xLTk0MzY_9ac8618b-373a-43f7-8764-420706a37cc1"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTMtMS0xLTk0MTA_a2f48fec-afd3-4d15-af4c-987ca7738762"
      unitRef="usd">79362000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTUtMS0xLTk3Mjg_9ba5ab8e-d8fa-400d-8e8e-1b009de8620b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTctMS0xLTk3Mjg_01bdfba5-403a-443d-9736-c8d9af10fb79"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTktMS0xLTk3Mjg_6c883876-5c10-48e3-945f-e87a714458ab"
      unitRef="usd">16000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id8f4b58b88f645d89c208af91b28f2cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzEwLTExLTEtMS05NzI4_c40d4cd0-878d-419d-8d82-eeb79ed86319"
      unitRef="usd">79362000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTEtMS0xLTk3Mjg_cee3d1f8-90f4-486f-85f6-e131cd788a2b"
      unitRef="usd">19000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTMtMS0xLTk3Mjg_b240320e-654c-46c1-ac75-f0853a671d05"
      unitRef="usd">137946000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTUtMS0xLTk3Mjg_2b17b7b0-3781-4ef8-9f47-8cdd9ab3c43f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTctMS0xLTk3Mjg_aa325aba-90f7-4040-b584-c954df851ddb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTktMS0xLTk3Mjg_08fea67e-f98a-4114-80e0-fabcb36f7407"
      unitRef="usd">19000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo0MmE1ZDViZTYxMGQ0MmIwYjg4NjBhYWM0YTZlODQwMy90YWJsZXJhbmdlOjQyYTVkNWJlNjEwZDQyYjBiODg2MGFhYzRhNmU4NDAzXzExLTExLTEtMS05NzI4_4ef303f9-6460-4bb0-9769-96a516590cef"
      unitRef="usd">137946000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzMyOTg1MzQ4OTY3NjE_8564d478-5128-44d5-8dc8-3669f89c8754"
      unitRef="position">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODU_f1fc3298-1bc0-4980-92e4-b54283355093">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44a1b1bd10fa49dead7f5c9e02e131de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzItMS0xLTEtMA_62b63f0b-3b9d-44c8-ba0d-802e42cb4ebb"
      unitRef="usd">14666000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7bc43418c7cf4e05b0c7f76c2cc94620_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzItMy0xLTEtMA_1a9cc125-8f76-4904-be0c-d406f17d8ad2"
      unitRef="usd">6307000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i646d4825dcfe46109944de937f3380eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzMtMS0xLTEtMA_d2c401f4-3a6d-4ca8-877e-2023d2623c45"
      unitRef="usd">3519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88bf4f32a33946e492417f9d2dc73c52_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzMtMy0xLTEtMA_26291e0a-9b3a-4db5-b62d-50d076a16036"
      unitRef="usd">2729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i453759ea8cff4f2ab3008749a56e3265_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzQtMS0xLTEtMA_0d448f96-a4b1-4b4f-869d-2deaaa88650b"
      unitRef="usd">1056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1e3ae4a6112a4341988947a8a9dd966c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzQtMy0xLTEtMA_797c5631-d946-4dea-97a5-fdd8ba6aab1d"
      unitRef="usd">999000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzUtMS0xLTEtMA_d61b1a98-6c72-4cdf-ac34-529554b6fbec"
      unitRef="usd">19241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzUtMy0xLTEtMA_072af97d-ba18-4d84-8a4a-77234c1fa6a5"
      unitRef="usd">10035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzYtMS0xLTEtMA_61ad4df2-bf9e-498a-85b8-9795d8e76baa"
      unitRef="usd">4807000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzYtMy0xLTEtMA_03251ea3-3010-4744-abe8-b61af945bbf9"
      unitRef="usd">2850000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzctMS0xLTEtMA_0e37de04-7d8c-4994-b52d-4f7ba3bd18fd"
      unitRef="usd">14434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3YjQ5NjNjMDAzMzA0ZDEyYWEwZjA5YjY2YThmYzRhYi90YWJsZXJhbmdlOjdiNDk2M2MwMDMzMDRkMTJhYTBmMDliNjZhOGZjNGFiXzctMy0xLTEtMA_ed9b5cc5-a07b-4737-af81-d2399c9dfd31"
      unitRef="usd">7185000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4Nw_baf87db8-0366-4ed4-a97e-c5ab1f111c2b">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU3NQ_5aded146-ea82-41ec-a6cd-77d78e80057a"
      unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU3OQ_5af10020-3365-42c9-8c3e-93915532bac8"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzU4Nw_efb2e2c6-2036-43c7-80fe-c974bf52a2c8"
      unitRef="usd">900000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1Nzc_3c6984ff-c964-497d-8abc-84438577e37d">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzMtMS0xLTEtMA_3828f1ff-598b-4138-a6b7-23c2a85e1706"
      unitRef="usd">189662000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzMtMy0xLTEtMA_22deb345-b375-4062-b2f0-278a2482d0b9"
      unitRef="usd">95229000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib9dc7611933a43fe92197068c75cff82_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzUtMS0xLTEtMA_9479fae1-805a-4fb1-919b-ca3cbc5b70b7"
      unitRef="usd">277740000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2d307d89e01d4dc1a92c17f8c98db873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzUtMy0xLTEtMA_09671e3e-660e-4353-92d3-808b39462206"
      unitRef="usd">242813000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib9dc7611933a43fe92197068c75cff82_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzYtMS0xLTEtMA_54539e33-17f5-4e90-b3d5-a43d297131b1"
      unitRef="usd">63600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2d307d89e01d4dc1a92c17f8c98db873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzYtMy0xLTEtMA_a8d6fe63-c111-4919-a6fc-9e81cdb1ca6d"
      unitRef="usd">50203000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idcc4e97847f9451da65751e2c293f78c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzctMS0xLTEtMA_8232f11f-343b-447d-a807-7db5a0aafa95"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0e81490ee5e44b6f8903898601190850_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzctMy0xLTEtMA_a79dcfd6-d5ab-4684-a571-62a729abf772"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idcc4e97847f9451da65751e2c293f78c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzgtMS0xLTEtMA_3b7a6c5b-d63e-4cb6-a168-14cca1dfef44"
      unitRef="usd">1312000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e81490ee5e44b6f8903898601190850_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzgtMy0xLTEtMA_a1f01cb5-b8c6-4aa6-8ad1-4acf80295064"
      unitRef="usd">1180000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i14712e5300454f86a3bed5deb1f6d271_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzktMS0xLTEtMA_e20d5c89-e84f-4d3c-a50d-4f3acd998fed"
      unitRef="usd">40700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if4833f2fd94e489fb8b7467d472e39b6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzktMy0xLTEtMA_e3975623-be89-4e05-8ed7-728330eebe14"
      unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i14712e5300454f86a3bed5deb1f6d271_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEwLTEtMS0xLTA_5b9bb4e8-bc66-42a3-9fc7-3af5e2c874a1"
      unitRef="usd">15597000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if4833f2fd94e489fb8b7467d472e39b6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEwLTMtMS0xLTA_5990764a-ebe7-4abf-873d-a8a7f069ba30"
      unitRef="usd">13224000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8faf4085074f419d9384b54bc96efbf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTEtMS0xLTI3MDM_39489c8f-324f-4f4f-b48a-f2cac528d866"
      unitRef="usd">362000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8faf4085074f419d9384b54bc96efbf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEyLTEtMS0xLTI3MTY_e4eba5e8-1bd1-4e6b-b0f2-baaee9506510"
      unitRef="usd">7243000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1128ec95e7954d9c91d5362eeae281d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzEyLTMtMS0xLTI3NDQ_2809d71d-f059-476f-8d80-3daa40597396"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTEtMS0xLTA_536c6dd9-9609-4a90-9423-1127b1a35a01"
      unitRef="usd">784992000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo3MjhiZDIwYjY2NDE0MTgyODMwMTgyN2JjZDcwYTdkZS90YWJsZXJhbmdlOjcyOGJkMjBiNjY0MTQxODI4MzAxODI3YmNkNzBhN2RlXzExLTMtMS0xLTA_cb1e5c2c-745f-4985-a023-90103a5ed463"
      unitRef="usd">305677000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExMTA_a2adf9ee-7333-4e8c-b6b8-d8dd9d65ea1b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExMzg_7dde701b-e181-40a7-9531-542c067b493c"
      unitRef="usd">23400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExNDI_ef2cc15d-bfe3-4ca0-972a-811cc5d92db2"
      unitRef="usd">16900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzExNTA_abf9c560-550c-418f-97f1-faea08a1e903"
      unitRef="usd">15800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_032cac24-afb8-4f99-b218-c5402abf596a"
      unitRef="usd">47100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_3250cfb7-acb5-42e1-9004-23d2cc76f61b"
      unitRef="usd">47100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_bb437583-d0cf-44aa-8dcf-622878ef8108"
      unitRef="usd">47100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzMDc_e219b290-c7a8-4564-aad3-80dfcc4e762d"
      unitRef="usd">47100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_29ab127f-09d4-43fa-a479-ec95e21d7c66"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_859ef221-6930-4913-a727-943fcab247a7"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzEzNzQ_9bdf792a-b77a-4c04-bfe7-9e572d66f95d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1Nzk_7bef97b8-a617-499c-a24f-a04c75fc4844">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzItMS0xLTEtMA_915c286f-11bf-4fa8-bbd4-35a8b587ce4b"
      unitRef="usd">8810000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzItMy0xLTEtMA_8a676342-ef00-42d8-bd1b-ea931a625149"
      unitRef="usd">1986000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzMtMS0xLTEtMA_350a0d4b-e2f4-48bd-9036-2f222c7a1471"
      unitRef="usd">977000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzMtMy0xLTEtMA_093efc37-e1a7-41a3-aa94-c3d460f16b97"
      unitRef="usd">1135000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzQtMS0xLTEtMA_3a0b6448-b194-40d8-83a8-aadf48a8080b"
      unitRef="usd">421000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzQtMy0xLTEtMA_4b4f8767-5bc6-4e78-8658-3ab3c1c09ed8"
      unitRef="usd">381000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzUtMS0xLTEtMA_1bee57a0-a353-4012-90e0-d423cbe649b5"
      unitRef="usd">693000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzUtMy0xLTEtMA_e2e863d4-653c-483e-9c5e-1f722bbf778d"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <lgnd:AccruedSalesReturns
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMS0xLTEtMA_a3cb73bd-15de-49df-81ae-0dd05a00dbe9"
      unitRef="usd">687000</lgnd:AccruedSalesReturns>
    <lgnd:AccruedSalesReturns
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMy0xLTEtMA_7d53ceee-0a41-4f21-a149-65e5a57f8a13"
      unitRef="usd">3027000</lgnd:AccruedSalesReturns>
    <lgnd:AccruedAssetAcquisitionsCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEwLTEtMS0xLTc3OTA_31bba73a-8993-42f5-ba94-e1dc04726521"
      unitRef="usd">1500000</lgnd:AccruedAssetAcquisitionsCurrent>
    <lgnd:AccruedAssetAcquisitionsCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzgtMy0xLTEtNzgzMA_75d0f7ef-769e-44a7-994b-c07b81436e0c"
      unitRef="usd">0</lgnd:AccruedAssetAcquisitionsCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTEtMS0xLTc3OTQ_28eeb1a9-f594-405b-90e9-767aac0bf529"
      unitRef="usd">733000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzktMy0xLTEtNzgzNA_5def315d-528a-4c80-9110-717d78a44ca9"
      unitRef="usd">0</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTEtMS0xLTc3OTk_1a922803-a307-4630-a993-1c1fa6482483"
      unitRef="usd">604000</lgnd:AccruedSupplierExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEwLTMtMS0xLTc4Mzg_5ea0ac77-5e26-4c33-8a0c-bb5f6b03a9c0"
      unitRef="usd">0</lgnd:AccruedSupplierExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTEtMS0xLTA_a04e28ab-4a06-4a90-b7b1-35d8b499cebc"
      unitRef="usd">4105000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzExLTMtMS0xLTA_05db3f7d-9772-4797-81ea-7f1adfeb80fc"
      unitRef="usd">2052000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTEtMS0xLTA_3b8bc6c9-8f59-47a7-b7e0-7cde894d16d8"
      unitRef="usd">18530000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo4YWNhOWY3OWQzNWY0MzcwYmI1NjBiM2JiZTRiY2Q3Yy90YWJsZXJhbmdlOjhhY2E5Zjc5ZDM1ZjQzNzBiYjU2MGIzYmJlNGJjZDdjXzEyLTMtMS0xLTA_41cbfa0a-e2ed-472b-b24f-c3f84a1f0784"
      unitRef="usd">8581000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:ScheduleofContingentLiabilitiesTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzI1ODA_de5f3e4f-1b0c-4fa4-88aa-d215fb144540">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes rollfoward of contingent liabilities as of December 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additional Contingent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Icagen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pfenex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,542&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofContingentLiabilitiesTableTextBlock>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i6602a2330fa646ef83a50932115be131_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMS0xLTEtMA_be7614fd-41af-4b82-bff2-ccbb8fef7885"
      unitRef="usd">514000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMi0xLTEtMA_d2de9b1c-9f8f-4749-a0a5-0547f7e33b0a"
      unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMy0xLTEtMA_c6650b22-55e2-48e4-abf7-5e4d6ec53c71"
      unitRef="usd">-116000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="id39ae5cdafcb4b8282956cea4407a9b7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNi0xLTEtNTI3NQ_6f181470-7554-4474-a1f4-8bf7b3f33d33"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i91c6ced26abf49119a93a11e832e5a52_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNi0xLTEtMA_5fa7e205-0c7c-457c-96b0-e046f4381702"
      unitRef="usd">348000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOC0xLTEtNjk4Mg_adafe6ec-f37c-40bd-95c9-c488da605717"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtNy0xLTEtMA_6f11eda8-96a4-4dfa-bdd2-5142b1ccd22e"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOC0xLTEtMA_eeac6c1f-0b8b-4968-a598-578c2189b057"
      unitRef="usd">160000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ib1bf6c2a19b34ddc94acc475e4d028e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtOS0xLTEtMA_bad9dd06-20f5-450f-b433-1fd9a77e3144"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i2153eb1062134c4caa172f7dd8ec0db3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzEtMTAtMS0xLTA_25ccc6d7-9bdb-4b81-951c-89f2a72a1deb"
      unitRef="usd">508000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i5666f75fbad04ecc8c0e8a27df194c97_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMS0xLTEtMA_e49ec457-230d-4147-9bb5-8e1f00070cee"
      unitRef="usd">5551000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMi0xLTEtMA_4a59c0c3-f134-4b9f-89a3-11afe90e0b1e"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMy0xLTEtMA_63fd7296-6f2a-4f63-b7d5-9ad82a0f161b"
      unitRef="usd">904000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ie6283a65f02747708d90a686259eb715_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNi0xLTEtNTI3NQ_100ba27e-2d7b-4dad-880d-8081bfba4864"
      unitRef="usd">520000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i13b7e192f2c8428f85754de4b57ade3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNi0xLTEtMA_c8c15b75-2473-4f53-8fc9-51b2cd4638e8"
      unitRef="usd">5935000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOC0xLTEtNjk4Mg_06722bdc-fc62-4e62-bf02-32e46077f099"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItNy0xLTEtMA_05eb38b1-8902-4880-93be-e8f8d5c1f0a0"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOC0xLTEtMA_40d1f7c1-98fe-4214-b116-e65c3de93c30"
      unitRef="usd">-1867000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i380589f68b0345c98cb55270231bdd72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItOS0xLTEtMA_acdf30dd-1e61-4536-8f43-bc8d18e9abba"
      unitRef="usd">247000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i3791d21ca45848d09706bba5675782e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzItMTAtMS0xLTA_0377c3d3-0031-4cca-bdc1-27868fc352d6"
      unitRef="usd">3821000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="if0f29ffa2d604282aa3977c1329d5123_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMS0xLTEtMA_464eab02-6c37-4514-91b2-f121e5d78794"
      unitRef="usd">6477000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMi0xLTEtMA_bf3ff765-2902-4319-88e5-07541e6b6fe1"
      unitRef="usd">3000000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMy0xLTEtMA_7b016b0d-69c2-4c62-9516-048c7fa54926"
      unitRef="usd">-818000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ice6a1c72bad44729809591e52fa7d95f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNi0xLTEtNTI3NQ_f24c5615-263c-4a8b-be0a-25125b8f763d"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i6420ef91bf1d4a1bba260796e56a4947_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNi0xLTEtMA_84936405-08fc-4797-943d-fa70befbbc57"
      unitRef="usd">2659000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOC0xLTEtNjk4Mg_e5c29d0b-0181-4243-b500-3722cc53a4b4"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtNy0xLTEtMA_8f694e23-1705-45a8-af0b-90bf1bc0ca23"
      unitRef="usd">1800000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOC0xLTEtMA_08415f07-9de4-45b0-ac0e-ce9634a45e14"
      unitRef="usd">-59000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ifb61372d96e44913b0ef0e6887e20930_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtOS0xLTEtMA_07de6480-6fc2-47f5-ba98-18e1ad96443e"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="if5fa7210a5ce4cf1a32446731c009ebf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzMtMTAtMS0xLTA_89a71d4c-6c56-4d7e-b250-0190142f6118"
      unitRef="usd">800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i264ffb3aecca43f8bd0831902d08bf27_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMS0xLTEtNjk3OQ_dd3d4ee4-93a3-4da7-8b00-7818ccbc0978"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMi0xLTEtNjk3OQ_79e42828-4468-441b-a01e-447926b62dfc"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMy0xLTEtNjk3OQ_66885bf9-59da-4a45-b867-be90fbd0aff7"
      unitRef="usd">0</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ie9d2d6bdc52343baaf889ec4fb8ccc81_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtNjk3OQ_f7c2e700-44fc-4b50-b612-394d70235976"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i24cc2ace08aa413b9bb245ce5edda280_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNy0xLTEtNjk3OQ_4e1ce5f5-7eba-425e-9177-05e916517270"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOC0xLTEtNjk4Mg_dc8ee912-b14a-4944-bd17-7762d5774fd9"
      unitRef="usd">4800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOS0xLTEtNjk3OQ_914a8d5d-5444-4c3e-9746-577efe6e25f5"
      unitRef="usd">525000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTAtMS0xLTY5Nzk_b2c09296-8301-491a-bed2-e924a548cb05"
      unitRef="usd">2129000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i7c8259c465284426a74ca47ef2e9fcf5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTEtMS0xLTY5Nzk_d7366115-efb9-4782-a4b9-343abe45bdcf"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i0a4db53852ed4656a0f1f7d4738cf64b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTItMS0xLTY5Nzk_2233e163-3a5a-4cf2-9f86-a785373c28d0"
      unitRef="usd">6404000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ia8b713c7049f465f8770df03d4238b33_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMS0xLTEtNjk3OQ_b5d67f82-c7ec-4ee9-afb2-71c6c11fb4c8"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMi0xLTEtNjk3OQ_df83fd94-0498-4c8a-94ee-8c70b090505b"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMy0xLTEtNjk3OQ_5b9da0ae-a70c-4c35-ba08-6554186035a7"
      unitRef="usd">0</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ie6d240f7bf5f410c9019df22b4d23f38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtNi0xLTEtNjk3OQ_e401b850-e45e-4516-a36e-6a8776ad602b"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ie528dc87bee94f8caf3f8a1e273dd57e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtNy0xLTEtNjk3OQ_a51640cc-1d16-4ecf-84dc-76fbb9d79a80"
      unitRef="usd">0</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtOC0xLTEtNjk4Mg_b82d5bda-c9e2-4278-ae47-a4fd19e18b05"
      unitRef="usd">37000000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtOS0xLTEtNjk3OQ_f9dd4f54-5b17-4c76-8174-277cd02c60d9"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTAtMS0xLTY5Nzk_178d2c6a-88a9-4519-8724-1a6b53b30965"
      unitRef="usd">600000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTEtMS0xLTY5Nzk_d077d4ca-5df4-4818-a53d-03493e095985"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ia82f7ae16d724ecc956f678166ebf230_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzUtMTItMS0xLTY5Nzk_877dd740-7f04-4786-bffd-fc2c523a450b"
      unitRef="usd">37600000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMS0xLTEtMA_331c95bc-1256-437d-bb49-ab3c441b901a"
      unitRef="usd">12542000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMi0xLTEtMA_076b40cd-f4ec-4b05-a547-80096309a0d2"
      unitRef="usd">3050000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMy0xLTEtMA_5cf061a1-4f38-4944-bf38-53c237fd5256"
      unitRef="usd">-30000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtNTI3NQ_958176f7-9d1d-4aaa-b31f-a18d8d359968"
      unitRef="usd">520000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNi0xLTEtMA_aa7a5650-da42-403e-9f9e-4a7576eaa320"
      unitRef="usd">8942000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzYtOC0xLTEtNjk4Mg_86258e98-8bb9-4ba6-9a03-091804060193"
      unitRef="usd">41800000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtNy0xLTEtMA_5643398c-3e7c-4159-adbb-51145025812d"
      unitRef="usd">2325000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOC0xLTEtMA_af74ed73-227a-43bb-af51-5d7f5f56dee7"
      unitRef="usd">963000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtOS0xLTEtMA_8ecb859e-9e01-4eec-9c24-279f83eda27d"
      unitRef="usd">247000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90YWJsZTo1YWFlMjI4M2M1MWE0ODA4OGZlN2Y3MjZmZjQyNGQ3My90YWJsZXJhbmdlOjVhYWUyMjgzYzUxYTQ4MDg4ZmU3ZjcyNmZmNDI0ZDczXzQtMTAtMS0xLTA_6e7d6ab7-9f55-400c-845f-abad9a049971"
      unitRef="usd">49133000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTQ_6004a8fa-9fd7-4f71-96fe-81c92616149c">Stockholders&#x2019; Equity&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-cash share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 1.1 million shares. As of December&#160;31, 2020, there were 1.1 million shares available for future option grants or direct issuance under the Amended 2002 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160; thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all stock options granted during 2020, 2019 and 2018 was $41.39, $48.65 and $58.85 per share, respectively. The total intrinsic value of all options exercised during 2020, 2019 and 2018 was approximately $11.9 million, $10.4 million and $51.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from options exercised, net of fees paid, in 2020, 2019 and 2018 was $2.5 million, $2.6 million and $19.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.05-$14.47&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.92-$56.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$63.58-$74.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82.90-$95.35&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$97.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.02-$113.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.97-$195.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7%-3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%-49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33%-36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 5.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 to 5.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $37.2 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, unrecognized compensation cost related to non-vested stock awards amounted to $10.6&#160;million. That cost is expected to be recognized over a weighted average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, 52,808 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 6,455, 4,745 and 3,386 shares issued under the ESPP in 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased 260,000 shares of our common stock at a cost of $191.14 per share. In September 2018, the board of directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years (the &#x201c;Repurchase Program&#x201d;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $350.0 million of our outstanding common stock under the Repurchase Program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading &lt;/span&gt;&lt;/div&gt;plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2020.During the twelve months ended December&#160;31, 2020, 2019 and 2018, we repurchased 934,079 shares for $78.0 million, 4,122,133 shares for $448.4 million, and 782,248 shares for $127.5 million, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTU_7f70360b-4d7f-45ec-b572-ca2625d2f0b9">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-cash share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iff2792a74cce448d9d3e648d7b956be5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtMS0xLTEtMA_2567f037-d919-4be1-b38a-a8859d17852e"
      unitRef="usd">13497000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i42695687f81e405c9d3cdbe7d31e2a8a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtMy0xLTEtMA_8d7a270e-ebcc-4350-bfd7-9c8ff4ac50d5"
      unitRef="usd">9641000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic8a106a25b78411482849d23ad9a09e8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzMtNS0xLTEtMA_3e9b0b8f-8ba5-40fe-9bc4-41a5423fd974"
      unitRef="usd">8352000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ifc06096f96b64e82ac914c97075da05d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtMS0xLTEtMA_94eae887-6818-4261-9c8c-91f56f335ec4"
      unitRef="usd">17230000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="idd0e4043c1aa44d99e0496901785ab2b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtMy0xLTEtMA_b29a8b22-364f-4c2b-8ac5-f18fed037808"
      unitRef="usd">14874000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ia7c0367d73764a1aa9aef7ba6ff77792_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzQtNS0xLTEtMA_3e89bd99-a735-4263-b751-dcdb894872be"
      unitRef="usd">12494000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtMS0xLTEtMA_542ed660-f81b-4f44-885b-cf6d9df76660"
      unitRef="usd">30727000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtMy0xLTEtMA_f7283bad-0354-4d3d-9291-2be45563c805"
      unitRef="usd">24515000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NjY5ZWE3YTRlMmM0MzIxODlhMjk1ZTJmNDAzODVlOS90YWJsZXJhbmdlOjU2NjllYTdhNGUyYzQzMjE4OWEyOTVlMmY0MDM4NWU5XzUtNS0xLTEtMA_518229fe-423c-43a3-a712-fd11efebd475"
      unitRef="usd">20846000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i953919e814ac433bba490fdfd486bf52_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMyOTg1MzQ4ODc1NTM_3bcd0b01-e794-4467-bed3-28a6a4ae0259"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic40ca45f254145e681e785bbb6305a78_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMwOA_c52db972-b955-47b0-9b1d-f132da5643b3"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTY_33a22767-5b0f-49dc-8649-93e0f25cb770">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160; thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMS0xLTEtMTIzOTM_43123c02-3143-484d-bb6e-dfcd8316a104"
      unitRef="shares">1876332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtMy0xLTEtMTI2MjI_16a504ca-9e4a-4b7a-be3a-faa095c8d0c0"
      unitRef="usdPerShare">53.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9d99a0a13be944d08abee4b0e2287edd_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtNS0xLTEtMTI2MjI_53d8f60b-e7f2-4c51-b3e5-e4c3e7fcb68b">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEtNy0xLTEtMTI2MjI_0bf717bd-e34a-4eb2-a1b3-5c4a0d0de09d"
      unitRef="usd">157340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMS0xLTEtMTIzOTM_90da0ff7-166c-4962-a40b-478c7b8bf8d1"
      unitRef="shares">228362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMy0xLTEtMTI2MjI_c8509cf9-bf5d-4d95-b7b2-c3160a9277e2"
      unitRef="usdPerShare">162.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMS0xLTEtMTIzOTM_fd0390b1-0f19-4b6c-ab4c-77d4c95d421c"
      unitRef="shares">358162</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMy0xLTEtMTI2MjI_b30a410e-5360-44af-afae-eb01aeeee9ca"
      unitRef="usdPerShare">55.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMS0xLTEtMTIzOTM_014ad7be-e57b-4c61-bfb2-37d3ff341faa"
      unitRef="shares">10228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMy0xLTEtMTI2MjI_f8820e21-6ad1-4cbc-904f-27d2cf63be25"
      unitRef="usdPerShare">114.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMy0xLTEtMTI2MjI_07a827e1-80b6-48b1-a875-2b945ef9c3f0"
      unitRef="usdPerShare">66.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNS0xLTEtMTI2MjI_0d3f73fb-2cc4-45e4-a71b-f2b76d344533">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNy0xLTEtMTI2MjI_ce09dc83-6487-478b-8576-16756ee84966"
      unitRef="usd">125858000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzktMS0xLTEtMTIzOTM_4100c24a-da47-43ca-abca-7bd3b2c6dec8"
      unitRef="shares">1313374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMy0xLTEtMTI2MjI_080df20d-211f-4cf6-b49a-eedccfdc40a9"
      unitRef="usdPerShare">47.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNS0xLTEtMTI2MjI_b0ed6fff-c735-4ba6-8bb5-8d542b877b7d">P4Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNy0xLTEtMTI2MjI_4741db96-1eb7-4cb0-a5cc-d21bfb3ee46c"
      unitRef="usd">117314000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEwLTEtMS0xLTEyMzkz_1287ed8b-e57a-4d75-a80d-439d2c1dfdb1"
      unitRef="shares">1736304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMy0xLTEtMTI2MjI_a25e134a-23ca-4ca0-a653-9b160f36a6b5"
      unitRef="usdPerShare">66.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNS0xLTEtMTI2MjI_db55aa04-f7c7-4c0c-a80f-a55eca0734fd">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNy0xLTEtMTI2MjI_29a236b5-f01c-4caa-987c-da97948bcf73"
      unitRef="usd">125858000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTEtMS0xLTEyNDAz_c6065688-6f42-46af-8647-ed00d7b3c2f9"
      unitRef="shares">338617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEwLTMtMS0xLTEyNjI3_72a9f16d-561b-4a10-ae7b-09b151d7a46d"
      unitRef="usdPerShare">116.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTEtMS0xLTEyNDAz_fa80d4d5-3ea7-4ff7-825e-ab1a0a6f88b4"
      unitRef="shares">112011</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzExLTMtMS0xLTEyNjI3_d0c5aa9f-c0dc-4f8a-bfd0-986a65151867"
      unitRef="usdPerShare">23.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTEtMS0xLTEyNDAz_cb08b64b-2860-459c-9644-f6e59d428eff"
      unitRef="shares">6531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEyLTMtMS0xLTEyNjI3_4b9a9cb1-4a42-4f9f-ad23-6d4285c44a3e"
      unitRef="usdPerShare">139.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE2LTEtMS0xLTEyNDAz_c5b165d0-22b6-470d-a27d-56c05dc48bc0"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTMtMS0xLTEyNjI3_db34e470-f7e2-41a6-9e3f-6892e057f753"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTUtMS0xLTEyNjI3_3a8a8858-b77e-41e2-8028-9213e5e31615">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzEzLTctMS0xLTEyNjI3_9d07ded3-5579-4d78-a1cb-a513809fdcc4"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE3LTEtMS0xLTEyNDAz_41b36487-66a1-45fd-b58d-4466ccf67926"
      unitRef="shares">1454726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTMtMS0xLTEyNjI3_48b433d7-2d85-4913-b58e-3e62cafe1de2"
      unitRef="usdPerShare">61.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTUtMS0xLTEyNjI3_77a46015-1f87-4590-b55b-259df8244a74">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE0LTctMS0xLTEyNjI3_99360e8d-c8fd-4a64-a772-88c8061f1b76"
      unitRef="usd">70345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE4LTEtMS0xLTEyNDAz_e23f4048-219e-4dfe-8f55-5305197e9de1"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTMtMS0xLTEyNjI3_eeb7d645-5ac3-45f2-b571-2a0db5b46b4b"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTUtMS0xLTEyNjI3_398b1733-0d72-45b9-9eed-b5e4e4195256">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzE1LTctMS0xLTEyNjI3_3842e43f-fb9b-4f18-9d44-39688958bd09"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMS0xLTEtMA_6e5c78d8-8af7-48da-9b1b-33fd3ef52659"
      unitRef="shares">806300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzItMy0xLTEtMA_29a11b3d-0e60-4e6a-bafa-1cbe0f31fd40"
      unitRef="usdPerShare">92.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMS0xLTEtMA_9c542a4a-8df1-4205-947a-5d9837b2019d"
      unitRef="shares">156845</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzMtMy0xLTEtMA_5efa489f-db95-475f-80fc-2bd0e0e3a3d5"
      unitRef="usdPerShare">21.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMS0xLTEtMA_1b36be94-41d4-4b28-97bd-c191c57aa78d"
      unitRef="shares">44012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzQtMy0xLTEtMA_089c353a-5852-404c-98e1-2af4d41377cb"
      unitRef="usdPerShare">91.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMS0xLTEtMA_75837816-ac88-43a5-a5c2-9ad3a958aaf6"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtMy0xLTEtMA_fd947631-ffec-4d43-bf08-682b4444142c"
      unitRef="usdPerShare">85.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNS0xLTEtMA_785626af-9108-46dc-99a5-c93f5df1614c">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzUtNy0xLTEtMA_b369c25f-f80f-47ec-bb96-de0245fc7b74"
      unitRef="usd">59033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMS0xLTEtMA_57d88e08-ba67-460c-b981-3f84d70c6076"
      unitRef="shares">1611830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtMy0xLTEtMA_b85908b8-a21e-4fe0-986b-ec5c77176ed7"
      unitRef="usdPerShare">76.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNS0xLTEtMA_cdb14d04-a66d-41ae-9799-26395f9b8a9b">P4Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzYtNy0xLTEtMA_48b7e9f3-ac64-4e74-85af-985328cf1cc0"
      unitRef="usd">53286000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMS0xLTEtMA_5bb4a45d-5fca-4999-b747-2bd44b3db83d"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctMy0xLTEtMA_ba93a733-7aff-4287-acc3-8638fcb88c48"
      unitRef="usdPerShare">85.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNS0xLTEtMA_ba71b22d-50c3-4c53-81c1-9dd7620d0ac5">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTphMTkwZjU0YjE2OTY0MjBhODZkOWRmMjgwNjI2ZjMwNC90YWJsZXJhbmdlOmExOTBmNTRiMTY5NjQyMGE4NmQ5ZGYyODA2MjZmMzA0XzctNy0xLTEtMA_99ab1cd6-021f-4c65-97ba-ac4eebe4cabc"
      unitRef="usd">59033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU4NQ_60ca8f2a-dbc2-48d0-9d6f-d6417ac1e522"
      unitRef="usdPerShare">41.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU4OQ_ede0d3c2-d3ae-4202-9a88-f5349b03cbf4"
      unitRef="usdPerShare">48.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzU5Ng_35ca9a8c-082e-40e2-82ea-46bd232912d2"
      unitRef="usdPerShare">58.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcxNA_4480ea2e-1c15-48e0-a621-b56dd6ebaf52"
      unitRef="usd">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcxOA_e5868368-e4e6-4ab1-87d7-0d2cdc56bb70"
      unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzcyNQ_6c0d38a4-b347-41ac-ad94-31c77e99ad85"
      unitRef="usd">51900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgyMQ_e7671868-4c15-4087-be2c-b37ca1d9cad1"
      unitRef="usd">2500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9095817cd9684faeb5137cb9e4930f23_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgyNQ_0fd4bd90-a43d-4822-b6a7-b5e6770d8472"
      unitRef="usd">2600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3ad2c6ec307e4f9aba409d901f84821a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzgzMg_67f46715-3122-4f72-804c-79dbaf77a26c"
      unitRef="usd">19800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTE_b2b64d7d-ea69-42e0-930f-80e4977132c3">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.05-$14.47&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.92-$56.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$63.58-$74.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$82.90-$95.35&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$95.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$97.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.02-$113.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$117.97-$195.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMC0xLTEtNTM2My90ZXh0cmVnaW9uOjM0NWFlYTFkMjc5YzRmMThiM2QyMmYwNDUwM2I1YjkzXzMyOTg1MzQ4ODMzNTM_f6432b27-4def-4a04-9f9d-f8e59093492e"
      unitRef="usdPerShare">10.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMC0xLTEtNTM2My90ZXh0cmVnaW9uOjM0NWFlYTFkMjc5YzRmMThiM2QyMmYwNDUwM2I1YjkzXzMyOTg1MzQ4ODMzOTA_42857bff-0d07-422f-a8f2-db12af70224a"
      unitRef="usdPerShare">14.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMS0xLTEtMA_ffb6d144-e9c3-4012-9021-4d927d6d6eee"
      unitRef="shares">284184</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2cbebff3158947598e721bfe0ecbab9c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtMy0xLTEtMA_7f79b69d-2c20-41f1-9f16-d34371463416">P0Y10M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtNS0xLTEtMA_68ac55cc-3906-40f0-8a3c-8feb1c43d03c"
      unitRef="usdPerShare">13.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtNy0xLTEtMA_d7f30b06-9d74-4f96-b308-887273301933"
      unitRef="shares">270184</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i62ccd602f6fa46788dc3ed55853a87b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEtOS0xLTEtMA_93ac24fa-fd4a-406e-a9a7-2d3901861c48"
      unitRef="usdPerShare">13.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMC0xLTEtNTM2NC90ZXh0cmVnaW9uOjU2ZDU1YjA1OTc3NzRjODQ4ZTM0OTUzMWQ4MmZkZTQxXzMyOTg1MzQ4ODMzNjI_9100f8f7-6884-499b-80bf-0706016b2294"
      unitRef="usdPerShare">21.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMC0xLTEtNTM2NC90ZXh0cmVnaW9uOjU2ZDU1YjA1OTc3NzRjODQ4ZTM0OTUzMWQ4MmZkZTQxXzMyOTg1MzQ4ODMzNjY_b2489d09-3b73-4455-ab0e-2e9985de31ff"
      unitRef="usdPerShare">56.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMS0xLTEtMA_704fcd87-574e-4b47-8f95-33ddd7d742e2"
      unitRef="shares">344629</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1737fb93e7b84d80b1120a37ee8541b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItMy0xLTEtMA_38c452a5-5aec-442d-8c91-1522dd179932">P2Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItNS0xLTEtMA_e22757a1-127d-49a9-a049-f7689776d801"
      unitRef="usdPerShare">35.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItNy0xLTEtMA_994ea3ba-3719-49ab-9db9-28d066bcb3ae"
      unitRef="shares">344629</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="idbaf2eb117fe4ea38353a1add365f4de_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzItOS0xLTEtMA_4b454454-3bb3-4450-aa5c-7c3510e0f0e1"
      unitRef="usdPerShare">35.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMC0xLTEtNTM2Ni90ZXh0cmVnaW9uOjU2YzBkZWVmNjRhZjQwNzRiZTEzNGNkNDAyYTk5NjcxXzMyOTg1MzQ4ODMzNjI_9cf8db9d-9dea-4415-916e-d3930c30eb96"
      unitRef="usdPerShare">63.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMC0xLTEtNTM2Ni90ZXh0cmVnaW9uOjU2YzBkZWVmNjRhZjQwNzRiZTEzNGNkNDAyYTk5NjcxXzMyOTg1MzQ4ODMzNjY_b6173550-e57b-4e53-a024-fb33cff0ce05"
      unitRef="usdPerShare">74.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMS0xLTEtMA_c2bdd742-a80a-40f5-9c9b-38b7d568cb21"
      unitRef="shares">307356</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic9d7f9ee43684fdb977516728a51e561_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtMy0xLTEtMA_cf3f5587-49c0-43df-9fd9-51793d4693b5">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtNS0xLTEtMA_6c57af73-4be0-44ce-9816-39fefdd913bb"
      unitRef="usdPerShare">71.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtNy0xLTEtMA_c96423d6-b957-4013-8c73-5f7cc370e7d5"
      unitRef="shares">220650</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i2feaed30df5b4d19a7bfe180fab28929_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzMtOS0xLTEtMA_539dc999-ea5a-461c-8ef1-005624abe651"
      unitRef="usdPerShare">73.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMC0xLTEtNTM2OC90ZXh0cmVnaW9uOmQ4NTFiN2UwYzUzMzRhOThiNmVlNjU4YjQ1YzZhMjI3XzMyOTg1MzQ4ODMzNjI_ad557723-1a08-45f5-96e5-c56e5e5dce6a"
      unitRef="usdPerShare">82.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMC0xLTEtNTM2OC90ZXh0cmVnaW9uOmQ4NTFiN2UwYzUzMzRhOThiNmVlNjU4YjQ1YzZhMjI3XzMyOTg1MzQ4ODMzNjY_552174e9-4308-4304-88d1-7b1db57cb9bf"
      unitRef="usdPerShare">95.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMS0xLTEtMA_e655b6e6-35aa-4dc6-97a0-4499bb96ce23"
      unitRef="shares">185033</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i731d0810373e42cc9a2d54bfe7173c73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtMy0xLTEtMA_2eda93f5-b238-4471-9913-b3c20213282b">P6Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtNS0xLTEtMA_a4113210-92df-41a7-89c9-d8aeb968fb17"
      unitRef="usdPerShare">86.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtNy0xLTEtMA_8913f69c-3811-44d1-9cb5-8dc3e6752cc2"
      unitRef="shares">140400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ifea3774c1e854faabbb9b9bd56df18b8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzQtOS0xLTEtMA_87f52432-3049-42e2-9b4e-dee361e57943"
      unitRef="usdPerShare">86.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMC0xLTEtNTM3MQ_b037a16d-df82-406b-8dc5-c173a79cb2ac"
      unitRef="usdPerShare">95.68</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMC0xLTEtNTM3MQ_fc9f6546-c355-470d-9aaa-014154ea9b06"
      unitRef="usdPerShare">95.68</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMS0xLTEtMA_b93a4b65-82a8-4307-a21c-4e93863f9b90"
      unitRef="shares">305106</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i821fcc2beda34395937a25762f2616bb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtMy0xLTEtMA_23afb9bd-0dd6-469f-ba94-b2719670335f">P9Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtNS0xLTEtMA_a62451a9-7b5a-48ca-93fa-58b1ff5db47e"
      unitRef="usdPerShare">95.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtNy0xLTEtMA_dfc0bd19-3d04-4d0d-afaa-451cb0379330"
      unitRef="shares">63059</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i66de6c8533c64de1b961a16a8db0723a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzUtOS0xLTEtMA_f5e67613-336c-4010-996e-25fcd34bb70b"
      unitRef="usdPerShare">95.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMC0xLTEtNTM3Mg_189cfd14-e7ef-4c1c-ad19-436792bbfff7"
      unitRef="usdPerShare">97.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMC0xLTEtNTM3Mg_4bc3ceec-588b-48d5-b2a9-458853cb5502"
      unitRef="usdPerShare">97.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMS0xLTEtMA_f9d9ad48-6a9e-4928-80a9-2d2acfabab7e"
      unitRef="shares">4976</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iffa8849f70694c158893145638a42fb0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtMy0xLTEtMA_a3c8c054-4d65-4b5e-a1c9-6ddc2725cae1">P5Y7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtNS0xLTEtMA_7be5a151-151a-4f38-b814-8a61e89d59c3"
      unitRef="usdPerShare">97.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtNy0xLTEtMA_1af252a5-9b6c-4c37-b4ad-a5f3beed40ff"
      unitRef="shares">4976</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic614e71f57294a5ba7f5c4c3d606053f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzYtOS0xLTEtMA_90af2ead-24d9-47ae-84d2-ba9285487268"
      unitRef="usdPerShare">97.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMC0xLTEtNTM3NQ_24bdf3b3-b807-4308-bece-152c183a1e72"
      unitRef="usdPerShare">98.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMC0xLTEtNTM3NQ_f7213bc2-1548-458b-ae24-68a7a0feb83c"
      unitRef="usdPerShare">98.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMS0xLTEtMA_38fbaebb-4691-4e77-9a32-6c066e534bab"
      unitRef="shares">270850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iffa4fe2dc558455980677b0000e0370c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctMy0xLTEtMA_3f529275-f85c-4008-841e-fb498469dd3c">P9Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctNS0xLTEtMA_5f764228-9d79-4137-8c9a-3401215abbde"
      unitRef="usdPerShare">98.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctNy0xLTEtMA_9c5c661c-e3d1-419f-a754-cb8b1135d514"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7268d74272cc4722ab1c1b9e43253848_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzctOS0xLTEtMA_f3c450fa-c0d8-479f-b54c-6fca78135237"
      unitRef="usdPerShare">98.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMC0xLTEtNTM3Ny90ZXh0cmVnaW9uOjc5NDk2YTBhMmM5ZjQzN2I4ZTAwYjAxZTA1NjMxNzdlXzMyOTg1MzQ4ODMzNjY_8fdb1dd6-bccc-4a7c-bd4c-c7ebeb5f54dc"
      unitRef="usdPerShare">100.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMC0xLTEtNTM3Ny90ZXh0cmVnaW9uOjc5NDk2YTBhMmM5ZjQzN2I4ZTAwYjAxZTA1NjMxNzdlXzMyOTg1MzQ4ODMzNzA_ceb8061e-f07c-497a-9b6b-4574ebc5f508"
      unitRef="usdPerShare">113.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMS0xLTEtMA_5e38dd5c-fea0-427b-8dca-eb8f6ed34c53"
      unitRef="shares">257914</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i536e2b1e6a0c43db9211a002b3bf07f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtMy0xLTEtMA_2b60e2cc-4155-44d9-ab2a-428655372355">P6Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtNS0xLTEtMA_58b81800-4618-4ebb-84eb-0c41785a0a70"
      unitRef="usdPerShare">104.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtNy0xLTEtMA_9947195f-0e08-4ea6-89df-570a2019cb6c"
      unitRef="shares">220092</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ibaefa4ff41be4dc6899f87dced50851d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzgtOS0xLTEtMA_6b6cbd93-a049-4289-927b-6ee193027f98"
      unitRef="usdPerShare">103.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMC0xLTEtNTM3OA_521d85f7-b18b-4461-baa3-4c0598ba4e52"
      unitRef="usdPerShare">117.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMC0xLTEtNTM3OA_7904fc5d-1c49-4f87-b823-60ebf93c0d31"
      unitRef="usdPerShare">117.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMS0xLTEtMA_f17c9848-b0e0-4f44-9d3e-0e72123295e8"
      unitRef="shares">19744</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibc7df2a400044bf9859896d3c9c98ef8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktMy0xLTEtMA_8469c985-3ac7-4f56-ad5f-83521fabce60">P9Y5M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktNS0xLTEtMA_60721167-7b18-4e8f-ad12-14b1fc43e035"
      unitRef="usdPerShare">117.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktNy0xLTEtMA_292fe8b1-4736-4642-ba70-bcf18e261ac0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="if79e2805487e43c19b53a5d41d9eda6c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzktOS0xLTEtMA_cddc6ef8-8956-465f-a654-9c8de3f7f7b8"
      unitRef="usdPerShare">117.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTAtMS0xLTUzODAvdGV4dHJlZ2lvbjowNTgyMDIzZDk5YTU0MGI3OTAzYzY4ZmU5OThlZDYyZV8zMjk4NTM0ODgzMzY2_262283a5-072e-49c2-b208-5869a691ec4c"
      unitRef="usdPerShare">117.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTAtMS0xLTUzODAvdGV4dHJlZ2lvbjowNTgyMDIzZDk5YTU0MGI3OTAzYzY4ZmU5OThlZDYyZV8zMjk4NTM0ODgzMzcw_9b6d739e-77d0-4ff9-83ef-dd620520bfdf"
      unitRef="usdPerShare">195.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTEtMS0xLTA_673a9646-0f6c-4c1c-bfa7-7804660d06f1"
      unitRef="shares">582030</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i49933f5bd05442a89d6b4bc299861236_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTMtMS0xLTA_787373db-bdd9-4977-9738-623edd23062f">P7Y6M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTUtMS0xLTA_844b49a2-803a-43e2-8dcc-390368ab1a1d"
      unitRef="usdPerShare">137.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTctMS0xLTA_5c16b4b1-3dfc-4c6e-bb36-2834955671c2"
      unitRef="shares">347840</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i981bfa9fd1e34a3e9b1f8cbe866b210d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzEwLTktMS0xLTA_474fd656-99b3-43c4-8a7c-879377d021c2"
      unitRef="usdPerShare">141.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTEtMS0xLTA_aee02545-599f-4e7e-9545-1365afcaed1c"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i28daf0e5db1049f18fd204ea459bc201_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTMtMS0xLTA_342c55bc-c340-4ec0-85fe-83ce6c7e11c5">P6Y1M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTUtMS0xLTA_ca3fffb9-81ce-4d0f-b5e5-699b1119539f"
      unitRef="usdPerShare">85.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTctMS0xLTA_121ac835-f76b-4fa2-bf22-7875b712c67f"
      unitRef="shares">1611830</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i5e0842e1697e470bbb3fd3777f23811c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZToyOTk1MmQwMjcxYWQ0YTAyOTMzY2Y2ZGE1Y2RmZWVjNi90YWJsZXJhbmdlOjI5OTUyZDAyNzFhZDRhMDI5MzNjZjZkYTVjZGZlZWM2XzExLTktMS0xLTA_c3ff9b36-dd51-47ea-8eab-ff3b1a028a3c"
      unitRef="usdPerShare">76.05</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTk_655437dd-2586-48c3-a597-80803d9f12ab">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7%-3.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%-49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33%-36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 to 5.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1 to 5.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMS0xLTEtMTE3NjYvdGV4dHJlZ2lvbjo4ZjhmZDkxNTllZjI0YzZhOWMyMTM4NzQwYTk2NmQzZV8zMjk4NTM0ODgzMzQ1_fff5db73-5664-4b3e-ac47-88f514e61f39"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMS0xLTEtMTE3NjYvdGV4dHJlZ2lvbjo4ZjhmZDkxNTllZjI0YzZhOWMyMTM4NzQwYTk2NmQzZV8zMjk4NTM0ODgzMzUy_eb77f249-f6b8-4e52-911f-db42afb55b9e"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMy0xLTEtMTE3NzIvdGV4dHJlZ2lvbjo2Nzg4ZTZlM2EyZDM0YWEyYmQ3MWYwODBhMmM0NzUyZF8zMjk4NTM0ODgzMzQ1_c5fb90d0-6565-4982-8f46-046135883421"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItMy0xLTEtMTE3NzIvdGV4dHJlZ2lvbjo2Nzg4ZTZlM2EyZDM0YWEyYmQ3MWYwODBhMmM0NzUyZF8zMjk4NTM0ODgzMzUy_10244775-05a8-42a8-8fa3-cc115b11a757"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItNS0xLTEtMTE3NzgvdGV4dHJlZ2lvbjo2ZGMzY2VjYTAyNWM0ZWRjYTQzMmIyNGYyMjhlNDhiOF8zMjk4NTM0ODgzMzQ1_ffe5797a-752f-4c73-b8c1-9375d755d3a5"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzItNS0xLTEtMTE3NzgvdGV4dHJlZ2lvbjo2ZGMzY2VjYTAyNWM0ZWRjYTQzMmIyNGYyMjhlNDhiOF8zMjk4NTM0ODgzMzUy_50da8c0b-0742-4896-a5d5-facbd826b9b4"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMS0xLTEtMTE3ODQvdGV4dHJlZ2lvbjo5YjhlMjk2NTIxMzE0YTQ5YTY4YzFjMDJhYjA1M2M0ZV8zMjk4NTM0ODgzMzQy_5d1ede26-77c5-4f56-8142-298e2cb1423f"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMS0xLTEtMTE3ODQvdGV4dHJlZ2lvbjo5YjhlMjk2NTIxMzE0YTQ5YTY4YzFjMDJhYjA1M2M0ZV8zMjk4NTM0ODgzMzQ4_d8adeb77-8087-451a-85c0-44aa8fcd1ae0"
      unitRef="number">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMy0xLTEtMTE3OTAvdGV4dHJlZ2lvbjo3NDAxMDE0MDFkYTU0MmFhYjYyYTc5MjNmZjQzNzg5N18zMjk4NTM0ODgzMzQy_3783dba2-08de-415b-92bd-690b323e55ef"
      unitRef="number">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtMy0xLTEtMTE3OTAvdGV4dHJlZ2lvbjo3NDAxMDE0MDFkYTU0MmFhYjYyYTc5MjNmZjQzNzg5N18zMjk4NTM0ODgzMzQ4_0d3a57e3-5f63-4715-aa41-cb134e741a41"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtNS0xLTEtMTE3OTYvdGV4dHJlZ2lvbjphYTAxYTg5MTEyZmE0MDdmOTI3NDI3ODc0NDcwYThmZl8zMjk4NTM0ODgzMzQy_3dd5cf3e-f29c-429c-adb6-c8ae7aa6763d"
      unitRef="number">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzMtNS0xLTEtMTE3OTYvdGV4dHJlZ2lvbjphYTAxYTg5MTEyZmE0MDdmOTI3NDI3ODc0NDcwYThmZl8zMjk4NTM0ODgzMzQ4_7656511b-8719-4bf7-ab26-85c1a48a217b"
      unitRef="number">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMS0xLTEtMTE4MDIvdGV4dHJlZ2lvbjpmOGRlZWVkZDRlNDc0ZWRjOWVmYmNiZTU1MmFhY2I4NV8zMjk4NTM0ODgzMzUx_e52b88ec-0a79-40c2-99f4-80b4c7394985">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i42121d23f781449cbd98a3c26b241ecb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMS0xLTEtMTE4MDIvdGV4dHJlZ2lvbjpmOGRlZWVkZDRlNDc0ZWRjOWVmYmNiZTU1MmFhY2I4NV8zMjk4NTM0ODgzMzY0_8574aaad-aa45-469c-a458-7ac0f99e0cb6">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0cc27fa8da7543e4b8e6c958e7ee6a85_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMy0xLTEtMTE4MTAvdGV4dHJlZ2lvbjplOThhYzE1ZGRmNjQ0NzQ3YmI4Y2E5ZDQzOWZiY2Y4NV8zMjk4NTM0ODgzMzUx_9c300ba7-2247-4521-b776-bbf2cb27cb84">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i523f745af8bf4f52a1d1bda7e345e397_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtMy0xLTEtMTE4MTAvdGV4dHJlZ2lvbjplOThhYzE1ZGRmNjQ0NzQ3YmI4Y2E5ZDQzOWZiY2Y4NV8zMjk4NTM0ODgzMzYz_8bc2bee9-341a-4258-bc04-b6094d4ab2b8">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iff77d9443603499199481d702061cfc3_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtNS0xLTEtMTE4MTcvdGV4dHJlZ2lvbjo0MWIyZjk0OTExOTA0ZGUyYmZhMjkxZGRhMjkyOTcyZF8zMjk4NTM0ODgzMzUx_4014b605-98a8-470b-9fee-c0fcb12f37e7">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69928414acf4456c871c5c27e2b76219_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo4YTM1ZTE4YzFkNTg0NGJmOTYwYmRkOGZkY2MxYmIyNS90YWJsZXJhbmdlOjhhMzVlMThjMWQ1ODQ0YmY5NjBiZGQ4ZmRjYzFiYjI1XzQtNS0xLTEtMTE4MTcvdGV4dHJlZ2lvbjo0MWIyZjk0OTExOTA0ZGUyYmZhMjkxZGRhMjkyOTcyZF8zMjk4NTM0ODgzMzYz_732a27ff-3737-4278-a2da-a30130f3c7bb">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if56ecb42bfb845cdbf6b43bfa81634cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzExMDc_58726873-ca1f-4d62-87bc-4fa39dd50d96"
      unitRef="usd">37200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia8fb8fbdb1874a699813bbd496df4580_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzEyNjE_338f5bf2-70c4-4e23-bdba-3df6da129df3">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM2MTc_385b257e-8e93-4a69-aed5-13d609c0e7e1">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iacd51de929754bda9511cd8c27350601_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMS0xLTEtMTI2NTY_16344d7c-f738-4a08-a3ee-fde54cea5aed"
      unitRef="shares">133294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iacd51de929754bda9511cd8c27350601_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMy0xLTEtMTI2NTY_7de9a49b-53b4-442e-acbd-78771dca2ccc"
      unitRef="usdPerShare">91.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMS0xLTEtMTI2NTY_4610a3c2-a551-4bc3-a68c-8bd1db6ea445"
      unitRef="shares">62133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMy0xLTEtMTI2NTY_1051f5e3-f4d7-48ac-8abe-c18fb4fa695f"
      unitRef="usdPerShare">169.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMS0xLTEtMTI2NTY_c9758824-0bd6-4cf5-b1e5-bef647e10ae8"
      unitRef="shares">61989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMy0xLTEtMTI2NTY_17b9980e-cc40-44d7-8a1d-55a1e896dbe7"
      unitRef="usdPerShare">86.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMS0xLTEtMTI2NTY_f7f6b88b-90a4-458a-b346-abb98b9c0467"
      unitRef="shares">1165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i00840e840fa4418d837ced3aa23dca7c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMy0xLTEtMTI2NTY_8634b96a-e139-4b7d-bfbd-a168c669e44a"
      unitRef="usdPerShare">125.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1115896595ee46f58722433b8bebfcc6_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzUtMy0xLTEtMTI2NTY_75eb1e0d-8b52-4df9-9172-a19fbf2ee333"
      unitRef="usdPerShare">130.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzYtMS0xLTEtMTI2NTY_ca957a71-c6d1-43e3-bc89-c9f75b9d2707"
      unitRef="shares">118498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzYtMy0xLTEtMTI2NTY_40768add-4a6b-42b7-a520-b9f7c1caa3e8"
      unitRef="usdPerShare">115.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzctMS0xLTEtMTI2NTY_90a08dcd-5061-4b09-8904-2c4e81f27848"
      unitRef="shares">102846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzctMy0xLTEtMTI2NTY_dd87cd66-013f-40f5-b5f6-ca46b337e00a"
      unitRef="usdPerShare">121.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzgtMS0xLTEtMTI2NTY_418355ff-c89f-48ea-a93e-225d26f7a76a"
      unitRef="shares">666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iba90a971a8804ee7a85db7cd2ddc5648_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzgtMy0xLTEtMTI2NTY_d1f3571d-ac6a-4be5-9872-a195c12f78a3"
      unitRef="usdPerShare">134.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if3b624942505415386809d9280250f36_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzEtMy0xLTEtMA_9c3d2326-9ffa-4c81-baeb-2c9b10437a85"
      unitRef="usdPerShare">125.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMS0xLTEtMA_1692baab-7d24-40ad-816d-9055ceac3362"
      unitRef="shares">111306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzItMy0xLTEtMA_35d410aa-9949-4397-9c8b-6af9342bcd45"
      unitRef="usdPerShare">89.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMS0xLTEtMA_6b0a3547-5e38-4a19-a333-ba7f26a6768d"
      unitRef="shares">52363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzMtMy0xLTEtMA_6db531b7-0b04-45fb-b6e5-d72104315dcc"
      unitRef="usdPerShare">121.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMS0xLTEtMA_d952f3c8-b119-4aac-b35d-590a85b7c80f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzQtMy0xLTEtMA_ef88213d-a2c4-46dd-9db2-6fef45c51771"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90YWJsZTo1NWQ1OTYzNWVjODg0ZWExOWY5NGMzNTgxMTBjOGVkYi90YWJsZXJhbmdlOjU1ZDU5NjM1ZWM4ODRlYTE5Zjk0YzM1ODExMGM4ZWRiXzUtMy0xLTEtMA_5d579b56-28b3-456c-9f24-8017688a791a"
      unitRef="usdPerShare">106.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i414a50a3d90c4d9998a79fdaf7f66e3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE0Njg_c070337b-281b-4497-9be5-e9b041da5f97"
      unitRef="usd">10600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic8346581bd0640acbf52a891e2b7a460_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE1NDU_31a0a98a-bae0-46d8-839c-c082d7717c30">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia2c71624a82f425e97a2dd558100c435_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE1OTA_3b118ca1-c5d4-4aab-a83b-7ce57ab437d0"
      unitRef="shares">52808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE3NjU_4dfe7cc7-3e13-4f4b-b865-6b11050bd14c"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzE5MjM_fa17ca29-30ae-4f65-ad3e-85c6f3d8d1f2"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i2b94334c6535433280ae213de2fd38d9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNjQ_49910b67-d5e4-4899-9bde-b8c97faed3e3"
      unitRef="shares">6455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i26da0a13ba874bfeb0373d75e17b5d4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNjg_99214687-ca08-4065-a940-63912f84a011"
      unitRef="shares">4745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i0398cc7bf5994c79a7c821c2a8c34c80_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIwNzU_0817efc9-a63f-40f1-8deb-7c32725d93b4"
      unitRef="shares">3386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIyMzk_52357342-db21-45cc-97ef-58cb1e622d65"
      unitRef="shares">260000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIyODI_fe6f8516-8ef0-4e26-894c-0614924d22ad"
      unitRef="usdPerShare">191.14</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i304f82f2dad244e382a657b3d676fb43_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIzNzI_40bae01d-1af7-424f-8326-3521c3fdf519"
      unitRef="usd">200000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i931b931a1abf45438f4f158f651d36c0_I20190123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzI2MTI_3da8be5a-5621-40a1-88a3-657c280610f6"
      unitRef="usd">350000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0e34e1285b384e0d8ee4bc840f707708_I20190911"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzI3OTY_5abd90a1-4075-44f7-9920-8f85c898b064"
      unitRef="usd">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i6ab16e1f7dff4858bc4003f7815ab55f_D20190911-20190911"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzIxOTkwMjMyNTk5Mzc_7dbc95d2-98c7-476a-a45e-445f68f4ad3b">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i931b931a1abf45438f4f158f651d36c0_I20190123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzMyODQ_3da8be5a-5621-40a1-88a3-657c280610f6"
      unitRef="usd">350000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM0NDA_4f6f5e5a-0c32-471f-b424-16ba98a85afe"
      unitRef="usd">248800000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Mzc_bf0aabb4-4216-4c29-9bf4-9329775beed8"
      unitRef="shares">934079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1NTE_f2731d1c-d4dd-4086-87a2-0bddb9ffe139"
      unitRef="usd">78000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1NTU_ffa0f9ea-a003-4a70-9293-b7a60c109e1b"
      unitRef="shares">4122133</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Njk_6fff24af-d7c9-4145-bdc4-4803ef6346df"
      unitRef="usd">448400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1Nzc_14463fbd-1530-4c72-a01a-85fb6b1a6cae"
      unitRef="shares">782248</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMTUvZnJhZzpjMDI2ODk3MGJjMWY0NTgxYjkyOTQ3Mzc5YzViOTNiYS90ZXh0cmVnaW9uOmMwMjY4OTcwYmMxZjQ1ODFiOTI5NDczNzljNWI5M2JhXzM1OTE_037cec8d-f554-4859-b4ba-f727c92c63c8"
      unitRef="usd">127500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzU2MDY_a6c33e28-8871-45fb-86fe-764f44e6f491">Commitment and Contingencies: Legal Proceedings&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 450, Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#x201c;Alembic&#x201d;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#xae; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or U.S. Patent No. 10,040,872 (&#x201c;the &#x2019;872 patent&#x201d;), and alleging that these patents, each of which relates to Captisol&#xae;, are invalid, unenforceable, and/or would not be infringed by Alembic&#x2019;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#x2019;s ANDA constitutes infringement of each of the &#x2019;088 patent and the &#x2019;582 patent. On July 29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#x2019;s counterclaims. On April 7, 2020, the Court ordered that the Scheduling Order be amended such that, inter alia, the fact discovery cut off occurred on November 2, 2020, the close of expert discovery was set for March 22, 2021, and that May 17, 2021 would remain the first day of a five-to-six-day bench trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#xae; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or the &#x2019;872 patent, and alleging that these patents, each of which relates to Captisol&#xae;, are invalid, unenforceable, and/or would not be infringed by Lupin&#x2019;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin&#x2019;s counterclaims on January 2, 2020. Fact discovery is ongoing. The Court&#x2019;s scheduling order sets close of discovery on May 7, 2021 and a five day bench trial starting on December 13, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2019, we received three civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#x201c;JPML&#x201d;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#x201c;MDL&#x201d;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May and August of 2019, Pfenex Inc., which was acquired by us in October 2020, filed three petitions (IPR2019- 01027, IPR2019-01028 and IPR2019-01478) for inter partes review of U.S. Patent No. 9,422,345 (&#x201c;the &#x2018;345 patent&#x201d;; entitled &#x201c;Expression System&#x201d;), which is owned by GlaxoSmithKline Biologicals S.A., with the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) of the U.S. Patent and Trademark Office. In November 2019 and February 2020, the Board instituted trial on the invalidity grounds in IPR2019-01028, but exercised its discretion not to institute trial on IPR2019-01027 or IPR2019-01478. In May 2020, GlaxoSmithKline Biologicals S.A. (&#x201c;GSK&#x201d;) filed two petitions (IPR2020-00890 and IPR2020-00962) for inter partes review of U.S. Pat. No. 8,530,171 (&#x201c;the &#x2018;171 patent,&#x201d; entitled &#x201c;High Level Expression of Recombinant Toxin Proteins&#x201d;), which is owned by Pfenex, with the PTAB of the U.S. Patent and Trademark Office. On June 29, 2020, GSK filed a motion to withdraw IPR2020-00890, which was granted on August 28, 2020. In October 2020, Pfenex and GSK executed a confidential settlement agreement agreeing to terminate the proceedings before the PTAB resolving these issues. Pfenex and GSK filed a joint motion to terminate IPR2019-01028 and IPR2020-00962 on October 30, 2020, and an amended joint motion to terminate on November 4, 2020. A decision granting the parties&#x2019; joint motion to terminate in IPR2019-01028 was issued on November 12, 2020. The PTAB subsequently granted the parties&#x2019; joint motion to terminate in IPR2020-00962 on December 30, 2020.&lt;/span&gt;&lt;/div&gt;On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claims that the Company is in violation of the assignment provision of that certain Commercial Platform License and Services Agreement, dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We allege that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#x2019;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims are deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it seeks to dismiss its claim without prejudice. The arbitration will be conducted by a three arbitrator panel, who have not yet been appointed. The parties must each appoint one arbitrator by February 26, 2021, and the two arbitrators will then appoint a third arbitrator. We intend to vigorously defend ourselves against this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNTI_9064e0e7-ea6f-4d52-ae3d-7a6c19ec96d7"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNjE_432e1e50-31e8-4e4e-b6b3-ccda0649e5b2"
      unitRef="civil_complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i14cf21cf99e14fa19c7f2cce9bdac27f_D20191031-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjEvZnJhZzozNjU5ZmQzZmMyODI0YmY5OWU2YmExNzA3ZTk0N2Y3Yy90ZXh0cmVnaW9uOjM2NTlmZDNmYzI4MjRiZjk5ZTZiYTE3MDdlOTQ3ZjdjXzIxOTkwMjMyNzkxNzI_f8cdcb7f-94c3-4139-a617-a0894dc35add"
      unitRef="civil_complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTc_01ee6f1e-107d-4c66-9105-2f09fac3cae7">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Vernalis R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2020, 2019 and 2018. The valuation allowance decreased $116.5 million in 2020, increased $136.9 million in 2019 and decreased $2.5 million in 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we had federal net operating loss carryforwards set to expire through 2037 of $162.4 million and $129.3 million of state net operating loss carryforwards that begin to expire in 2031. We also have $9.2 million of federal research and development credit carryforwards, which expire through 2040. We have $23.1 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $110.1 million of non-U.S. net operating loss carryovers and approximately $17.6 million of non-U.S. capital loss carryovers that have no expiration date.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2019 we had approximately $713.8&#160;million of non-U.S. net operating loss carryovers and approximately $14.6&#160;million of non-U.S. capital loss carryovers. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020 were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (2), Sale of Vernalis R&amp;amp;D and Promacta License."&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &#160;&#160; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2020 are net of any previous limitations due to Section 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2020 is $30.2 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2020 and December&#160;31, 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2017 tax year to the present.&#160;The state income tax returns generally remain open for the 2016 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2020, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2016 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTM_0489c6df-d5a2-48a8-a222-ace8457e201c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtMS0xLTEtMA_fc617999-1ed8-4155-b2c1-bb4d5bceffae"
      unitRef="usd">10889000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtMy0xLTEtMA_7e58e716-165c-47c0-81cf-48a44cef2a69"
      unitRef="usd">89471000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzMtNS0xLTEtMA_615165d2-e944-41fa-8510-0e4e3511c276"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtMS0xLTEtMA_d187d0a1-3bb0-487a-ac9a-4a9fd94155c8"
      unitRef="usd">589000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtMy0xLTEtMA_c2477fdf-6d70-478d-bbc5-34cf4269cb6e"
      unitRef="usd">3103000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzQtNS0xLTEtMA_80af975b-cd17-496e-a9a8-902fbb0bbc55"
      unitRef="usd">424000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtMS0xLTEtMA_e4adf8a2-fe2b-44fa-964d-129085c7aab7"
      unitRef="usd">23000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtMy0xLTEtMA_9cfa0ada-21e1-402e-bc6b-429a3d621784"
      unitRef="usd">-66000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzUtNS0xLTEtMA_4bbb3750-d0c4-4e89-a8f3-7580825b3cd7"
      unitRef="usd">-158000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtMS0xLTEtMA_241a96ff-16c1-46bb-b5d9-0c66c335416f"
      unitRef="usd">11501000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtMy0xLTEtMA_6a1d67ce-8c67-485e-a144-c89dfb0ac3fe"
      unitRef="usd">92508000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzYtNS0xLTEtMA_b5c35ade-d336-41f6-829e-247b4f1e88bd"
      unitRef="usd">266000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtMS0xLTEtMA_7be9e7dc-393e-4a6f-91e5-dd9c9a1f6f74"
      unitRef="usd">-15672000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtMy0xLTEtMA_5915e411-e5e6-4f56-915c-3c989178ac0b"
      unitRef="usd">74627000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzgtNS0xLTEtMA_6c580ca0-2f3b-4e53-9211-fd1c3c9cf785"
      unitRef="usd">29928000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktMS0xLTEtMA_bee2db2b-5469-45e4-9299-7c8793aa1db4"
      unitRef="usd">-3382000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktMy0xLTEtMA_42e97419-4fa1-438f-9232-11bd375e728a"
      unitRef="usd">202000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzktNS0xLTEtMA_20715175-eff9-4ca2-89a0-57d9927ef4bb"
      unitRef="usd">-185000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTEtMS0xLTA_92235b64-590c-4145-a463-d8eefc234593"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTMtMS0xLTA_38f2a6f3-2241-4c70-8587-e1ca45d95f09"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo0ODhhMjBmODY2YjE0YTBlODFjNzdjYTE1NGY2NGQwMy90YWJsZXJhbmdlOjQ4OGEyMGY4NjZiMTRhMGU4MWM3N2NhMTU0ZjY0ZDAzXzEwLTUtMS0xLTA_74cf0014-f6da-4ed2-9fb0-742b633f565c"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNjI_9e7513d9-1c73-4ebb-aaa9-9b1f34c1d32c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of Vernalis R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItMS0xLTEtMA_fd62cdfd-dbca-43d7-b568-5101c616c680"
      unitRef="usd">-2213000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItMy0xLTEtMA_413f2d7a-7f8a-47ec-aa2a-904006d92ea4"
      unitRef="usd">167294000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzItNS0xLTEtMA_f7cf42ba-e5c4-4710-99e6-44eaae4ab872"
      unitRef="usd">36400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtMS0xLTEtMA_8debbde2-56c7-4628-b89c-e8b8c1807e94"
      unitRef="usd">-1456000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtMy0xLTEtMA_219fdb91-72dc-4fd1-92bf-c06c96ceeb1b"
      unitRef="usd">2466000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzMtNS0xLTEtMA_2856c82e-ca5a-42c1-8621-c433754d0fd8"
      unitRef="usd">1635000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtMS0xLTEtMA_c492dcfa-9440-4d1f-a4ee-e58f8dce5e0e"
      unitRef="usd">-278000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtMy0xLTEtMA_5141ccb9-716c-4c14-82e5-33e712de1354"
      unitRef="usd">18000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzQtNS0xLTEtMA_e6a74e86-bed4-45a9-a69c-dcb990dcb95b"
      unitRef="usd">948000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtMS0xLTEtMA_2549c0ad-f7f6-406f-b916-fd0dafbd32e3"
      unitRef="usd">-362000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtMy0xLTEtMA_daa0614d-4c87-4c53-a6df-bfd749bf05f2"
      unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzUtNS0xLTEtMA_48c86cb7-2852-4eed-b4cd-4a93444fac03"
      unitRef="usd">-8131000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtMS0xLTEtMA_7cf84da1-c5c4-49c1-b17b-c397d88edf6a"
      unitRef="usd">1652000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtMy0xLTEtMA_19c944a4-e6e9-4151-9717-2cf3a735719a"
      unitRef="usd">402000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzYtNS0xLTEtMA_286777f7-a304-498b-91c6-e6fd8ee55a1b"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctMS0xLTEtMA_2a4da8bf-a527-4094-a673-b28b56641b1a"
      unitRef="usd">-699000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctMy0xLTEtMA_e1da89d6-005d-443e-b07f-a8c9b0ad7efe"
      unitRef="usd">-879000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzctNS0xLTEtMA_79c4d6de-7fbe-4eb8-8387-58ea462bb39e"
      unitRef="usd">-2758000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtMS0xLTEtMA_aaf84a23-5bc4-495c-bb6f-f1ac09dd33bc"
      unitRef="usd">650000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtMy0xLTEtMA_5717a24e-37a9-4018-b10c-86dfd0b62d5a"
      unitRef="usd">-441000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzgtNS0xLTEtMA_2743b473-acf9-4463-afc1-a9f8b8b768e0"
      unitRef="usd">-858000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktMS0xLTEtMA_85ea9879-0a48-401f-9df2-4ccfbbd0cf1f"
      unitRef="usd">-173000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktMy0xLTEtMA_78b4262e-2f5e-4be6-b296-34be0fa40f41"
      unitRef="usd">-210000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzktNS0xLTEtMA_172c33e5-c901-4367-84f9-d3fc5b760cc8"
      unitRef="usd">178000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTEtMS0xLTk1ODY_32fbc2b5-fa7d-4ac9-9f06-a29069a392d2"
      unitRef="usd">4803000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTMtMS0xLTk2MDU_fb1a6db8-5900-4de5-a121-b7817fcbbf41"
      unitRef="usd">184000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTUtMS0xLTk2MTE_8052db8b-c3b1-4c60-905f-99c32bbba7bc"
      unitRef="usd">150000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTk2MTg_9ad73547-42c6-4f17-9142-4bf7f4d3683c"
      unitRef="usd">-3839000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTk2MTQ_4d24123a-e6e0-45d6-8a3a-3aaf5bfbb73e"
      unitRef="usd">57000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTk2MjM_5ccd19e1-3b09-423d-92c2-7908d34bd223"
      unitRef="usd">-14000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTEtMS0xLTA_64116801-0660-4a15-be2e-4d66a69a3bcf"
      unitRef="usd">-121876000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTMtMS0xLTA_e2521004-6fda-49ef-853d-8ae74b531e92"
      unitRef="usd">-1193000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEwLTUtMS0xLTA_ebcc0938-e3e4-4fa4-9fe1-e3e8a9a2a207"
      unitRef="usd">-4225000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTg5ODU_4ac9ab06-175a-4c33-bfd9-9ef4fb7d92b0"
      unitRef="usd">127372000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTkwODQ_42ca5001-06b2-471b-bcd4-3c487a78763b"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTkwODQ_550cb15c-fabd-4de9-92fe-67c066337cd8"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTEtMS0xLTA_5e3ccd08-ee57-46a7-995e-1be3f2d22f76"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTMtMS0xLTA_f0e2be30-23d4-4c08-8682-a61af20b9058"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzExLTUtMS0xLTA_ab99bb5b-ad20-473f-873f-1a354e96a1c0"
      unitRef="usd">3054000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTEtMS0xLTA_85e59159-906e-4e42-b42c-3fdd134e5ac5"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTMtMS0xLTA_60e49dc8-2815-4918-8c8c-40bc266bc71f"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEyLTUtMS0xLTA_77ac3b6c-5d32-486c-95c0-657bb5cce774"
      unitRef="usd">615000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTEtMS0xLTA_42748256-b489-4421-a81f-27eb4208865f"
      unitRef="usd">3076000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTMtMS0xLTA_32375db7-5631-4c37-a9f6-d0845567f8cf"
      unitRef="usd">748000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzEzLTUtMS0xLTA_cfbf6dde-62dd-49f9-abd3-c26bef0f2e28"
      unitRef="usd">1599000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTEtMS0xLTA_5841c629-058c-4f8a-b772-152756ccafe7"
      unitRef="usd">-7553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTMtMS0xLTA_614c6f84-8ead-4429-86ff-3b670f59ef34"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo3MjA1OWJlMzQ4MGY0MTQ4ODQyMWY3N2ZjMjI2YzZmMC90YWJsZXJhbmdlOjcyMDU5YmUzNDgwZjQxNDg4NDIxZjc3ZmMyMjZjNmYwXzE0LTUtMS0xLTA_ad7b9e6b-ff51-4066-918b-ba2f32a2be38"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE1NjM_aff4b494-21d0-44b4-95e1-db6eda152f33"
      unitRef="usd">-116500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE1ODU_05ee012a-e5e4-4c06-b867-60bca66a79a7"
      unitRef="usd">136900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2MTA_2cae04a8-bb5d-4eb2-bf7e-c55e92bcdf32"
      unitRef="usd">-2500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTU_6b81c1e1-9191-4971-94b6-cbf093c69b98">Deferred tax assets (liabilities) are comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzQtMS0xLTEtMA_3a77938d-5048-410d-8b3b-5f9a646e5db9"
      unitRef="usd">64147000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzQtMy0xLTEtMA_67b22dda-d548-4135-9fb8-17bcea75bef5"
      unitRef="usd">150727000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzUtMS0xLTEtMA_47a98a53-be1a-4441-ac50-b28318f6c7fc"
      unitRef="usd">19623000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzUtMy0xLTEtMA_dcff8cd3-2566-41f8-b11b-fd141b81f6a4"
      unitRef="usd">14843000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzYtMS0xLTEtOTY0Mw_6142489d-b007-4135-91ea-523414889cb6"
      unitRef="usd">11994000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzYtMy0xLTEtOTY0Nw_9a9b62c4-da7f-4834-8459-344f51d3ec94"
      unitRef="usd">9544000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzktMS0xLTEtMA_2052798e-eb70-405e-896e-2be944493a03"
      unitRef="usd">13120000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzktMy0xLTEtMA_d9845875-8673-4bce-8aa8-a399fba0178b"
      unitRef="usd">10602000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEwLTEtMS0xLTA_7c550865-c68f-439d-9f5b-35c1e6f8573d"
      unitRef="usd">108884000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEwLTMtMS0xLTA_75ee4258-2a2b-494f-a8b4-c76adb5cc7fb"
      unitRef="usd">185716000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzExLTEtMS0xLTA_53d4bc63-78ae-445e-b562-0f89b248d9fd"
      unitRef="usd">24858000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzExLTMtMS0xLTA_70c7a353-c3b6-4070-976c-ea388a5337a2"
      unitRef="usd">141338000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEyLTEtMS0xLTA_33aae867-1d9b-4005-ad57-210e0fcb48e7"
      unitRef="usd">84026000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzEyLTMtMS0xLTA_761aebf8-ec60-4722-a0dd-cf1403cecb79"
      unitRef="usd">44378000</us-gaap:DeferredTaxAssetsNet>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzE3LTEtMS0xLTA_7b039c40-670a-4460-a924-52e2e659c204"
      unitRef="usd">119381000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzE3LTMtMS0xLTA_bb7fb947-3faa-4898-8085-9fd75110fc87"
      unitRef="usd">40768000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIxLTEtMS0xLTA_51543795-99b1-480f-8a8c-2f5281c322ef"
      unitRef="usd">4923000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIxLTMtMS0xLTA_c812d3ad-a394-4759-a5d0-0262fcd657a9"
      unitRef="usd">10939000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIyLTEtMS0xLTA_2cbd7904-be13-45e2-9c89-9220062ee196"
      unitRef="usd">124304000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzIyLTMtMS0xLTA_4d9b8f17-aa96-4b7c-8835-93de446629d1"
      unitRef="usd">51707000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzI0LTEtMS0xLTA_53744c2b-336d-45ab-8502-b0f0f12e1868"
      unitRef="usd">40278000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTpmZDlhY2UxMTU2MGU0ZjFhOTU5Zjg4ZTllMDJkYTQwNC90YWJsZXJhbmdlOmZkOWFjZTExNTYwZTRmMWE5NTlmODhlOWUwMmRhNDA0XzI0LTMtMS0xLTA_634b4503-e83b-4ada-bbcf-8d222d526718"
      unitRef="usd">7329000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i338fe8a7f9a14546aadd061a86a8794a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIwMTU_30e05718-d543-4546-a50c-c11d932fb4d9"
      unitRef="usd">162400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if9dac967dc794fbabfc9e438958fbe78_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIwMjI_9da76dce-0d03-4e80-8d74-154ad60e1498"
      unitRef="usd">129300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8e7f6ee2f38047f4bf987be2ec85087b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIxMDg_3e740191-a89c-468d-a78d-72e57fbb367f"
      unitRef="usd">9200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i20cb5a20013b480c8b516e20e1aace66_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIyMDI_beac6dfb-73c1-4099-a434-9b000db6e03b"
      unitRef="usd">23100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6df4a7ca341f4c80b8357649cb1d8155_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIzMzA_57a6c011-1ff0-48f0-be3e-b4ed52b63fda"
      unitRef="usd">110100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i3c7d29ba6dd34ca2ac02b4e24d20ead9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzIzOTM_ade50f64-314e-4781-9b96-183e8f7fa498"
      unitRef="usd">17600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0176de2e50c3447c864e3818f9715431_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2NDkyNjc0NDk4NTA_537bc941-ad07-4520-95da-85ffb6db61bb"
      unitRef="usd">713800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i00351799e1f0421bb7f825c963509503_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzE2NDkyNjc0NDk4NzA_fbcf0c03-1841-41a2-b16b-f7a0447aaf21"
      unitRef="usd">14600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzUyNTY_baf278cb-4e1d-4a20-a9e6-75b2a0f38b62">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItMS0xLTEtMA_8f2d0796-eeb0-4ec3-8b96-62b4eedbdf9b"
      unitRef="usd">28736000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItMy0xLTEtMA_9a735ec6-1499-4fde-82a6-95f62684862c"
      unitRef="usd">30289000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id001411ddc1a48f3be1dce3344a83372_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzItNS0xLTEtMA_6f5a6e14-beab-4220-b0e1-30fe39da5efb"
      unitRef="usd">29363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtMS0xLTEtMA_89c196ed-f42d-4f8d-9565-198b8b61b8a0"
      unitRef="usd">3911000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtMy0xLTEtMA_dc222be6-12fe-4286-8355-6f482668f688"
      unitRef="usd">543000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzMtNS0xLTEtMA_df955716-3603-4622-8896-a57a7ea0a55b"
      unitRef="usd">1247000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtMS0xLTEtMA_7334d3ec-ea05-4d9e-bae8-a36ea2724e1c"
      unitRef="usd">179000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtMy0xLTEtMA_fa09b8ba-79e2-4c92-9206-1bca0f096a43"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzQtNS0xLTEtMA_06547469-2d28-4fc6-b2ef-266447056511"
      unitRef="usd">336000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtMS0xLTEtMA_dc572bc9-dbc0-4faf-b45b-51792ace9d20"
      unitRef="usd">955000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id1bf528fdaef4bfe89b242130bd9a454_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtMy0xLTEtMA_49afb90e-fe69-4a15-8446-87e433a176c4"
      unitRef="usd">2096000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i88b95a28d2054712baf9c5184035a19e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzUtNS0xLTEtMA_c6deed97-91b6-4761-b777-6da2e21a9978"
      unitRef="usd">657000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtMS0xLTEtMA_68270f3e-1638-4d16-8e53-0a42c518522a"
      unitRef="usd">31871000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib7153cd81712409ba213861c38901324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtMy0xLTEtMA_76e3dc5a-c096-42c0-ae4d-31d6a421fae5"
      unitRef="usd">28736000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5d4b2e9889a945be999a04e9bcc088b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90YWJsZTo2ZTQyNzRiY2MxNGI0YzdkODJlYWI0M2VjMGMwN2JmYy90YWJsZXJhbmdlOjZlNDI3NGJjYzE0YjRjN2Q4MmVhYjQzZWMwYzA3YmZjXzYtNS0xLTEtMA_e1a49a54-29a7-4e65-81dc-f2bcdeaeceec"
      unitRef="usd">30289000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjQvZnJhZzowMzQ4OTAxODIwZjk0ZGU4ODhmY2NlMjE0MzNlYTQ0MS90ZXh0cmVnaW9uOjAzNDg5MDE4MjBmOTRkZTg4OGZjY2UyMTQzM2VhNDQxXzM3Mjc_e2edb0a3-c2e4-4b75-b5cb-f84d8aaef7b7"
      unitRef="usd">30200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90ZXh0cmVnaW9uOjA0MTlmNDNjZmNmNTQ5YTU5ZWZlNjE0MDkyMTAwNTAwXzM2Ng_e94fcdab-30f5-415e-aa2d-f638e5dc2ff8">Summary of Unaudited Quarterly Financial InformationThe following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,077&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,694&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,684&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes pre-tax gain from sale of Promacta license of $812,797.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90ZXh0cmVnaW9uOjA0MTlmNDNjZmNmNTQ5YTU5ZWZlNjE0MDkyMTAwNTAwXzM2NA_f963d125-3e90-4048-bdde-7fedaefe3996">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,077&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,694&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,684&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Includes pre-tax gain from sale of Promacta license of $812,797.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItMS0xLTEtMA_90e43bf0-2640-4f57-8144-de8cd6641097"
      unitRef="usd">33161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItMy0xLTEtMA_371db142-373a-487b-bddc-50a9cf984665"
      unitRef="usd">41420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItNS0xLTEtMA_ed6fb089-8dd6-4dba-bdef-40f06f4c7c80"
      unitRef="usd">41848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzItNy0xLTEtMA_8a042e1a-2792-44df-a496-f7c8f5eb6e01"
      unitRef="usd">69990000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtMS0xLTEtMA_36524197-b45f-4a02-a850-f67f3362f208"
      unitRef="usd">29373000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtMy0xLTEtMA_e9292aa5-052f-4743-a572-b87db7814180"
      unitRef="usd">34320000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtNS0xLTEtMA_fc1fdc28-32e9-4bf9-8370-78bf7cc04674"
      unitRef="usd">38101000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzMtNy0xLTEtMA_7ddaa3ad-f659-42bc-ac46-2f3756b5d7ba"
      unitRef="usd">75894000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtMS0xLTEtMA_7b9638dc-72eb-42ad-9fc9-fac5f59b7a73"
      unitRef="usd">-6284000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtMy0xLTEtMA_f4df870e-46ee-488c-8f3d-35c9f23d5fe2"
      unitRef="usd">6033000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtNS0xLTEtMA_1835339b-138e-4048-92e3-087a263199dc"
      unitRef="usd">-4911000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzQtNy0xLTEtMA_aedfe795-f75a-454a-8413-d275bf448498"
      unitRef="usd">-2391000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtMS0xLTEtMA_9858aac2-8dd6-4d6a-a9d8-922b1593d265"
      unitRef="usd">-24131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtMy0xLTEtMA_25d04a03-3e90-48a5-a9ac-2ef9f5cf5c48"
      unitRef="usd">22086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtNS0xLTEtMA_55e39db7-a94a-4cf6-bb20-87f8568dba08"
      unitRef="usd">-6701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzUtNy0xLTEtMA_97aca354-ce08-4bf7-9920-97c0b122c5da"
      unitRef="usd">5761000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctMS0xLTEtMA_df076092-5cbd-4f95-9622-eb4fb7f9e169"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctMy0xLTEtMA_1ab85048-580d-40a9-901d-7a530fbcba21"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctNS0xLTEtMA_48115b26-bae1-4e3d-89f9-e2c25e415897"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzctNy0xLTEtMA_aa62a8ae-7a08-4087-bbe6-1c8f14b7159f"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktMS0xLTEtMA_01023afe-4e84-4eaf-8f33-888721abf59a"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktMy0xLTEtMA_e69120d4-5db8-41ed-b564-ec4d977ce31b"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktNS0xLTEtMA_5d9d4b7f-9e5e-4db1-a413-e7f73f22a593"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzktNy0xLTEtMA_f82a7f8c-4b55-44f5-8a99-642ea0c50d3f"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTEtMS0xLTA_c3d5e758-0f33-4c63-88d4-99e065f9b100"
      unitRef="shares">16529000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTMtMS0xLTA_ad5237fb-3d75-46dc-9122-e1c7b841958a"
      unitRef="shares">16055000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTUtMS0xLTA_3da7496d-f420-4441-b31b-6ebb12ee5e98"
      unitRef="shares">16082000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzExLTctMS0xLTA_3ec3dcca-41c2-4127-bd21-7154a6bed6ef"
      unitRef="shares">16077000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d94fe2891fc4588b552294a140c6046_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTEtMS0xLTA_6b0eaf0a-7477-4c97-a668-f1bc32568322"
      unitRef="shares">16529000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6f494eb5830f4c7694023c454d94ac1f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTMtMS0xLTA_aa4aa99c-845f-4a4c-97d9-37b5915447e9"
      unitRef="shares">16694000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id9f22d5c4645498d8d2397c41e41b1d3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTUtMS0xLTA_a4afeb02-5b00-4b80-8971-3e32bd609ffa"
      unitRef="shares">16082000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzEyLTctMS0xLTA_460d6da4-951e-4176-950b-d893c557d5f2"
      unitRef="shares">16684000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTEtMS0xLTA_0fdbe555-10c6-4180-aa74-071a542fd4c1"
      unitRef="usd">43484000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTMtMS0xLTA_2842b913-7c99-420e-ad05-4230b3fbffa6"
      unitRef="usd">24987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTUtMS0xLTA_3e5d1269-71e2-4cab-a8fe-b9e923960d12"
      unitRef="usd">24808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE4LTctMS0xLTA_6d3071f0-8fdb-496e-98c5-f0fe5f05d488"
      unitRef="usd">27003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTEtMS0xLTA_f4b748a8-5c13-4b5d-af1f-73ff8ef15faf"
      unitRef="usd">29738000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTMtMS0xLTA_94d41dd4-8013-49e6-ae92-3070bdef8a80"
      unitRef="usd">29117000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTUtMS0xLTA_786e3412-65ee-4236-a353-692b138b12ee"
      unitRef="usd">29966000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzE5LTctMS0xLTA_684c824b-51ac-4e98-9da7-1b308a146f67"
      unitRef="usd">37182000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTEtMS0xLTA_e7c81b1b-06e5-43b5-8da4-02b4a920c3b5"
      unitRef="usd">176376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTMtMS0xLTA_c96c7353-e984-4c9b-a414-ccf3c37eb52a"
      unitRef="usd">-3609000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTUtMS0xLTA_386dbadc-31dc-4438-9aa3-1a48af25def8"
      unitRef="usd">-4620000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIwLTctMS0xLTA_eea32adc-6cdb-4ad7-b5e5-5d61465159c5"
      unitRef="usd">-810000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTEtMS0xLTA_a93c9057-8c9a-4820-ad12-b460eb9a75e8"
      unitRef="usd">666337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTMtMS0xLTA_7df25211-da1c-4c62-8462-2efac77ae8f9"
      unitRef="usd">-14419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTUtMS0xLTA_f196cbcc-08ff-427f-8d5a-3dd6c7175a43"
      unitRef="usd">-15251000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIxLTctMS0xLTA_3172a00c-9211-433a-bd68-d4158ef0aee4"
      unitRef="usd">-7365000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTEtMS0xLTA_e15d0454-6bea-45d5-a5d8-d423698097db"
      unitRef="usdPerShare">32.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTMtMS0xLTA_12b8747c-1117-4e4c-8e1e-7a128309806f"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTUtMS0xLTA_895804f2-f559-4434-911d-76f81f8392f0"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzIzLTctMS0xLTA_b66c28fa-cc55-469d-8fe2-8438e7fe6c34"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTEtMS0xLTA_dc264408-2f08-4fe3-9552-e50a6392eead"
      unitRef="usdPerShare">31.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTMtMS0xLTA_66f0e53a-6c4d-45c1-9e47-40f16654c6b9"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTUtMS0xLTA_3ae22609-1a01-450a-9f19-63a31c508081"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI1LTctMS0xLTA_1305ba65-b98e-4505-99c9-a01a14b2bb68"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTEtMS0xLTA_d305ceaf-61b5-460a-b509-893f3abbbd24"
      unitRef="shares">20447000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTMtMS0xLTA_16ab3b8b-24dc-4d23-a9a5-c1524f0d7c90"
      unitRef="shares">19558000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTUtMS0xLTA_ce5f12aa-5d69-4db9-a2ac-3da796cf80bc"
      unitRef="shares">18770000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI3LTctMS0xLTA_729297c4-4440-4caf-a575-686a6a1fae03"
      unitRef="shares">17243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5b6674de4b3942f5ad6b45811738a2fa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTEtMS0xLTA_d8472c5a-3b66-4d08-8fb0-8fbe675e992f"
      unitRef="shares">21277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i66400e0efbe84e9abba1d66a09e2f16f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTMtMS0xLTA_da7ae80a-735f-410a-a38b-fec7c2194b9c"
      unitRef="shares">19558000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c2913dfa687463db4f19db551a8484b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTUtMS0xLTA_0942fa34-3fb8-4144-b904-d3f32c59fb89"
      unitRef="shares">18770000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9af257610594c53b35f9c8ffb13bdc8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTctMS0xLTA_1bafc6d2-fca8-448d-b56d-7aa8bbd4ea23"
      unitRef="shares">17243000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ic55d7c252e32432b8ac5deb25dbbe252_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMjcvZnJhZzowNDE5ZjQzY2ZjZjU0OWE1OWVmZTYxNDA5MjEwMDUwMC90YWJsZTowZDNiMjU1YjllZWI0YjVlODljODllY2I2ZDM3NzhlOS90YWJsZXJhbmdlOjBkM2IyNTViOWVlYjRiNWU4OWM4OWVjYjZkMzc3OGU5XzI4LTAtMS0xLTUyOTkvdGV4dHJlZ2lvbjoyMTQ5NWQ3OGE1ZWQ0ODEzYWVjOGE2OTIwOGU2M2U5MV8xMDk5NTExNjI3ODUx_1f6ea604-ffa3-428c-b1ec-fb844de8a9fe"
      unitRef="usd">812797000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567914040120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3911 Sorrento Valley Boulevard, Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,612,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567987418440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,619<span></span>
</td>
<td class="nump">$ 71,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">363,567<span></span>
</td>
<td class="nump">998,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">56,847<span></span>
</td>
<td class="nump">30,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">26,487<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">500,559<span></span>
</td>
<td class="nump">1,123,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">24,320<span></span>
</td>
<td class="nump">25,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">595,330<span></span>
</td>
<td class="nump">210,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">189,662<span></span>
</td>
<td class="nump">95,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Commercial license and other economic rights</a></td>
<td class="nump">10,979<span></span>
</td>
<td class="nump">20,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,434<span></span>
</td>
<td class="nump">7,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">6,892<span></span>
</td>
<td class="nump">10,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">15,842<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,362,285<span></span>
</td>
<td class="nump">1,494,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,784<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">18,530<span></span>
</td>
<td class="nump">8,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights', window );">Current contingent liabilities</a></td>
<td class="nump">39,884<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">29,435<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">100,111<span></span>
</td>
<td class="nump">17,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">2023 convertible senior notes, net</a></td>
<td class="nump">442,293<span></span>
</td>
<td class="nump">638,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LiabilityForContingentValueRights', window );">Long-term contingent liabilities</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="nump">6,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">64,598<span></span>
</td>
<td class="nump">32,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">9,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,866<span></span>
</td>
<td class="nump">22,480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">652,760<span></span>
</td>
<td class="nump">727,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 60,000 shares authorized; 16,080 and 16,823 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">318,358<span></span>
</td>
<td class="nump">367,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(801)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">391,952<span></span>
</td>
<td class="nump">400,105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">709,525<span></span>
</td>
<td class="nump">767,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,362,285<span></span>
</td>
<td class="nump">$ 1,494,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentPortionOfLiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908532696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">16,080,000<span></span>
</td>
<td class="nump">16,823,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">16,080,000<span></span>
</td>
<td class="nump">16,823,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906361288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost of Captisol</a></td>
<td class="nump">30,419<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">23,442<span></span>
</td>
<td class="nump">16,864<span></span>
</td>
<td class="nump">15,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,392<span></span>
</td>
<td class="nump">55,908<span></span>
</td>
<td class="nump">27,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">64,435<span></span>
</td>
<td class="nump">41,884<span></span>
</td>
<td class="nump">37,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">177,688<span></span>
</td>
<td class="nump">126,003<span></span>
</td>
<td class="nump">87,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">25,845<span></span>
</td>
<td class="nump">807,076<span></span>
</td>
<td class="nump">163,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from short-term investments</a></td>
<td class="num">(16,933)<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">50,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">28,430<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(27,420)<span></span>
</td>
<td class="num">(35,745)<span></span>
</td>
<td class="num">(48,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(4,171)<span></span>
</td>
<td class="num">(6,497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(36,383)<span></span>
</td>
<td class="num">(10,437)<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income tax</a></td>
<td class="num">(10,538)<span></span>
</td>
<td class="nump">796,639<span></span>
</td>
<td class="nump">173,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">7,553<span></span>
</td>
<td class="num">(167,337)<span></span>
</td>
<td class="num">(30,009)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 33.13<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic per share calculation (shares)</a></td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share (USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 31.85<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted per share calculation (shares)</a></td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 33,796<span></span>
</td>
<td class="nump">$ 46,976<span></span>
</td>
<td class="nump">$ 128,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">109,959<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
<td class="nump">29,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">42,664<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
<td class="nump">93,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="nump">17,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_PromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 812,797<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907811544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(162)<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(423)<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (3,570)<span></span>
</td>
<td class="nump">$ 630,110<span></span>
</td>
<td class="nump">$ 142,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567987272584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>2019 Convertible Senior Notes</div></th>
<th class="th"><div>2023 Convertible Senior Notes</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>2019 Convertible Senior Notes</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>2023 Convertible Senior Notes</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th">
<div>Accumulated other comprehensive income (loss) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,148,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 399,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 798,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period (Accounting Standards Update 2016-01) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,662<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period (Accounting Standards Update 2014-09) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="nump">16,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt', window );">Reclassification of equity component of currently redeemable convertible notes</a></td>
<td class="nump">18,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 20,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(782,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (127,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Convertible bond hedge and warrant transactions, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,559)<span></span>
</td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,559)<span></span>
</td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes', window );">Loss on settlement of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased', window );">Warrant repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants', window );">Loss on repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions', window );">Tax effect for Notes transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,680)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,680)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">143,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,765,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2018</a></td>
<td class="nump">$ 560,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">791,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="num">$ (1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(4,122,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,122,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (448,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(448,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized net gain on available-for-sale securities, net of deferred tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">629,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,823,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">767,232<span></span>
</td>
<td class="num">$ (5,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">367,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,105<span></span>
</td>
<td class="num">$ (5,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 30,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(934,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(934,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (77,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(77,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized net gain on available-for-sale securities, net of deferred tax</a></td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reacquisition of equity due to 2023 debt extinguishment, net of tax</a></td>
<td class="num">(3,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(2,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,079,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 709,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 318,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification of Equity Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906632648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain from sale of Promacta license</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(812,797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain from sale of Vernalis R&amp;D</a></td>
<td class="num">(17,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="nump">963<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">25,691<span></span>
</td>
<td class="nump">18,361<span></span>
</td>
<td class="nump">12,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_GainLossOnShortTermInvestments', window );">Loss (gain) short-term investments</a></td>
<td class="nump">16,933<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="num">(50,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of premium (discount) on investments, net</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="num">(10,274)<span></span>
</td>
<td class="num">(5,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance fees</a></td>
<td class="nump">23,077<span></span>
</td>
<td class="nump">29,988<span></span>
</td>
<td class="nump">43,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights', window );">Amortization of commercial license and other economic rights</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">30,727<span></span>
</td>
<td class="nump">24,515<span></span>
</td>
<td class="nump">20,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes, net</a></td>
<td class="num">(19,053)<span></span>
</td>
<td class="nump">74,829<span></span>
</td>
<td class="nump">29,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement', window );">Royalties recorded in retained earnings upon adoption of ASC 606</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="num">(3,498)<span></span>
</td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(26,061)<span></span>
</td>
<td class="nump">25,463<span></span>
</td>
<td class="num">(29,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(17,799)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(2,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,245)<span></span>
</td>
<td class="num">(6,664)<span></span>
</td>
<td class="num">(4,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">9,144<span></span>
</td>
<td class="num">(11,219)<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInOtherEconomicRights', window );">Other economic rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">29,236<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other</a></td>
<td class="num">(3,339)<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
<td class="num">(4,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">54,586<span></span>
</td>
<td class="num">(29,336)<span></span>
</td>
<td class="nump">194,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of Promacta license</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">812,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseforCommercialLicenseRights', window );">Purchase of commercial license rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition, net of cash and restricted cash acquired</a></td>
<td class="num">(404,884)<span></span>
</td>
<td class="num">(11,840)<span></span>
</td>
<td class="num">(5,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,458)<span></span>
</td>
<td class="num">(2,553)<span></span>
</td>
<td class="num">(887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(422,523)<span></span>
</td>
<td class="num">(2,356,545)<span></span>
</td>
<td class="num">(1,434,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProceedsFromCommercialLicenseRights', window );">Proceeds from commercial license rights</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">394,539<span></span>
</td>
<td class="nump">535,877<span></span>
</td>
<td class="nump">131,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">644,155<span></span>
</td>
<td class="nump">1,494,851<span></span>
</td>
<td class="nump">892,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds received from repayment of Viking note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="nump">22,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="num">(4,669)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">231,648<span></span>
</td>
<td class="nump">466,918<span></span>
</td>
<td class="num">(423,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(222,209)<span></span>
</td>
<td class="num">(27,323)<span></span>
</td>
<td class="num">(217,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance lease obligations</a></td>
<td class="num">(9,549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds from issuance of 2023 Convertible Senior Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseOfConvertibleBondHedge', window );">Purchase of convertible bond hedge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Proceeds from bond hedge settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,401<span></span>
</td>
<td class="nump">439,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Payments to convert holders for bond conversion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,401)<span></span>
</td>
<td class="num">(439,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock option exercises and ESPP</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">20,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,481)<span></span>
</td>
<td class="num">(4,418)<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchases</a></td>
<td class="num">(77,998)<span></span>
</td>
<td class="num">(453,048)<span></span>
</td>
<td class="num">(122,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="num">(30,094)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(310,545)<span></span>
</td>
<td class="num">(485,172)<span></span>
</td>
<td class="nump">328,585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(24,311)<span></span>
</td>
<td class="num">(47,590)<span></span>
</td>
<td class="nump">99,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">72,273<span></span>
</td>
<td class="nump">119,780<span></span>
</td>
<td class="nump">20,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">47,962<span></span>
</td>
<td class="nump">72,273<span></span>
</td>
<td class="nump">119,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">5,827<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="nump">2,130<span></span>
</td>
<td class="nump">103,817<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash in other current assets</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) gain on AFS investments</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of fixed assets recorded in accounts payable</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Commercial License and Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During the Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_GainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_GainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash change in estimated fair value of contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseOfConvertibleBondHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Convertible Bond Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseOfConvertibleBondHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseforCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase for Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseforCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Recorded upon Adoption of New Accounting Pronouncement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902775256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking common stock and warrants was reclassified from &#8220;investment in Viking&#8221; to &#8220;short-term investments&#8221; in the audited consolidated balance sheet as of December 31, 2019. Additionally, &#8220;gain (loss) from</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">short-term investments&#8221; in the consolidated statements of operations include both the gain (loss) from investment in Viking and other short-term investments, which was previously included in &#8220;other income, net&#8221; for both the twelve months ended December&#160;31, 2019 and 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents &amp; Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  We periodically review available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To date, we have not identified any other than temporary declines in fair value of its short-term investments.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2020, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $0.3&#160;million of allowance for credit losses as of December&#160;31, 2020.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2020, 2019 and 2018.  </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2">three</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1">ten</span> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Pfenex in October 2020, we will pay $2.00 per share or $77.8&#160;million as a CVR in the event a predefined regulatory milestone is achieved by December 31, 2021. The CVR Agreement provides that the required milestone will be achieved upon the receipt of a notice from the FDA that the teriparatide injection is therapeutically equivalent to FORTEO&#174; (teriparatide injection).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Icagen in April 2020, Icagen selling shareholders will be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $10.5 million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2020, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,208)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2020 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and reduce our asset as the funds are expended by Novan. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2020 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2020 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic and recorded an additional $0.5 million reserve for credit losses in other expense, net, in our consolidated statement of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard. See additional information in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsection below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we own. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Captisol Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when control of Captisol material is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. We have elected to recognize the cost of freight and shipping when or after control over Captisol material has transferred to the customer as an expense in cost of Captisol. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract revenue includes service revenue, license fees and future contingent milestone based payments. We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment.  These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December 31, 2018 was $3.3 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2">six</span> month anniversary of the date of grant, and 1/48 each month thereafter for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124">forty-two</span> months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2020, all of the 0.6 million weighted average shares of outstanding equity awards as of December&#160;31, 2020 were anti-dilutive due to the net loss for the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,845&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees and partners, patients, communities and business operations, as well as the U.S. and global economy and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have restricted in-person access to our executive offices, our administrative employees are mostly working remotely, and we have limited the number of staff in our research and development laboratories and other facilities. The continued spread of the COVID-19 pandemic and the measures taken by the governments of countries have</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected, and could continue to affect, our business and the business of our partners, including future disruptions to our supply chain and the manufacture or shipment of drug substance and finished drug product for Captisol, delays by us or our partners in the initiation or enrollment of patients in clinical trials, discontinuations by patients enrolled in clinical trials, difficulties launching or commercializing products and other related activities, which could delay ongoing clinical trials, increase development costs, reduce royalty revenues and have a material adverse effect on our business, financial condition and results of operations. Several of our partners have reported that their operations have been impacted including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who have contracted the virus or to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevent the spread of the virus. This may lead to clinical trial protocol deviations or to discontinuation of treatment for patients who are currently enrolled in the clinical trials being conducted by us or our partners. In addition, certain of our partners have reported negative impacts on product sales which will impact our royalty revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partners are working to develop drugs to treat COVID-19. For example, we are supplying Captisol to partners, including Gilead for Veklury (remdesivir), the first FDA-approved treatment for COVID-19 for the treatment of patients with COVID-19 requiring hospitalization and, as a result, we have extended our Captisol supply agreement with Gilead until September 2030 and worked to increase our manufacturing of Captisol to meet this increased demand. In addition, certain of our OmniAb and Vernalis partners have initiated antibody discovery programs for the potential treatment of COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, the businesses of our partners, our results of operations and our financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the timing and extent of governments reopening or further restricting activities, and the economic impact on local, regional, national and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We adopted ASU 2016-13 on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance sheet of retained earnings to be recognized on the date of adoption with prior periods not restated. The cumulative-effect adjustment, net of tax, recorded on January 1, 2020, is approximately $5.2 million. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under previously applicable accounting standards. See additional disclosure on credit losses under  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Accounts Receivable and Allowance for Credit Losses&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Commercial License and Other Economic Rights&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discussed above and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Short-term Investments&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (8), Balance Sheet Accent Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Test for Goodwill Impairment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the disclosure requirements on fair value measurements. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We adopted this standard on a prospective basis on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures. We intent to adopt this standard on January 1, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901618344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Vernalis R&amp;D and Promacta License<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Vernalis R&amp;D and Promacta License</a></td>
<td class="text">Sale of Vernalis R&amp;D and Promacta License<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vernalis R&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 11, 2020, we entered into an Agreement for the Sale and Purchase of the Entire Issued Share Capital of Vernalis (R&amp;D) Limited (the &#8220;Purchase and Sale Agreement&#8221;) with HitGen UK Ltd (&#8220;Buyer&#8221;). Under the terms of the Purchase and Sale Agreement, we transferred certain intellectual property on completed collaboration licenses to Ligand UK Limited, which is a subsidiary of the Company, which we retain rights and interest to and are entitled to receive future milestones and royalties. Under the Purchase and Sale Agreement, we are also entitled to a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships.  On December 2, 2020, we completed the sale. Pursuant to the terms of the Purchase and Sale Agreement, at the closing of the transaction, Buyer paid $26.7&#160;million in cash, following adjustment for debt, cash and net working capital. As Vernalis R&amp;D has the input, process and output elements defined in ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we concluded the sale qualifies as a sale of business. Net assets sold, net of working capital adjustment, was $6.1&#160;million, goodwill allocated to the selling business that was written off was $3.5&#160;million, resulting in a $17.1 million gain from sale of Vernalis R&amp;D recorded to income from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Promacta License</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903387960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments: Investment in Viking<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Short-term Investments: Investment in Viking</a></td>
<td class="text">Short-term Investments: Investment in VikingOur ownership in Viking was approximately 9.8% as of December&#160;31, 2020, and we account for it as an investment in available-for-sale securities, which is measured at fair value, with changes in fair value recognized in net income. Viking is considered a related party as we maintain a seat on Viking's board of directors and we do not exert significant influence over Viking.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and December&#160;31, 2019, we recorded our common stock in Viking in "short-term investments" at fair value of $32.8 million and $48.4 million, respectively. We also have outstanding warrants to purchase 1.5 million shares of Viking's common stock at an exercise price of $1.50 per share. We recorded the warrants in Viking in "short-term investments" in our consolidated balance sheets at fair value of $6.3 million and $9.9 million at December&#160;31, 2020 and 2019, respectively. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Fair Value Measurement.</span>&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902934312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth below, we completed six acquisitions from January 1, 2018 through December 31, 2020, of which four (Pfenex, Icagen, Ab Initio and Vernalis) were accounted for as business combinations and two (Taurus and xCella) were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Except for the Pfenex acquisition, for all other acquisitions, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfenex Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, we acquired Pfenex, which develops next-generation and novel protein therapeutics to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases using a protein expression technology platform.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preliminary purchase price of $465.1 million included $429.6 million cash consideration paid upon acquisition, and a contingent CVR payment of up to $77.8 million in cash based on a certain specified milestone with an estimated initial fair value of $37.0 million. The CVR will only be paid in full if the milestone is achieved by December 31, 2021. The amount of the CVR included in purchase price was reduced by $1.5&#160;million which was determined to be post-combination expense. The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on market participants' cost of debt reflective of the Company, which was 7.1%. The liability is periodically assessed based on events and circumstances related to the underlying milestone, and any change in fair value is recorded in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition, a portion of Pfenex's equity awards that were outstanding and unvested prior to the acquisition became fully vested per the terms of the merger agreement. The acceleration of vesting required us to allocate the fair value of the equity attributable to pre-combination service to the purchase price and the remaining amount was considered our post-combination expense. We paid $17.3 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid of $429.6 million. In addition, the fair value of equity compensation attributable to the post-combination service period was $8.7 million.These amounts were associated with the accelerated vesting of stock options previously granted to Pfenex employees and were fully paid in cash, which was recognized as general and administrative expenses during the fourth quarter of 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $20.7 million of acquisition-related costs for legal, severance and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for 2020. The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is expected to be deductible for tax purposes. The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-19</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contractual relationships were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones and collaboration revenue streams derived from the licensing of the related technologies over the estimated contractual relationship period. The fair values of the acquired technologies were based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, collaboration and product revenue streams derived from the licensing of the related technologies over the estimated useful lives. These projected cash flows were discounted to present value using discount rate, which varies from 12% to 15%. The intangible assets acquired are being amortized on a straight-line basis over the estimated useful life. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately $2.0 million of revenue and $19.3 million of loss before income taxes of Pfenex were included in the consolidated statement of operations for the year ended December&#160;31, 2020. The following summary presents our unaudited pro forma consolidated results of operations for the years ended December&#160;31, 2020 and December&#160;31, 2019 as if the Pfenex acquisition had occurred on January 1, 2019, which gives effect to certain transaction accounting adjustments, including amortization of acquired intangibles and stock based compensation expense for retained Pfenex employees. The transaction accounting adjustments do not include non-recurring adjustments related to Pfenex's executive salary, board of director compensation, and salary of Pfenex employees involved in the reduction of force as part of the acquisition, estimated to be $7.1 million in 2020 and $4.8&#160;million in 2019. The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taurus Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2020, we acquired Taurus, which discovers and develops novel antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price of  $5.1 million included $4.6 million in cash, and a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021. We also issued nontransferable CVRs for up to $4.5 million tied to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partnered and internal research and development and for up to $25.0 million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:78.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. We account for the CVRs in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. None of the CVRs are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">xCella Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2020, we acquired xCella, an antibody discovery company. xCella's xPloration platform is a proprietary microcapillary platform that can screen single B cells for specificity and bioactivity and will increase Ligand&#8217;s antibody discovery throughput and efficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid $7.1 million in cash (including a $0.5 million holdback to satisfy indemnification obligations which will be settled by September 2021), and issued earnout rights for up to $5.0 million tied to our use of the xCella technology for partnered research and development and for up to $25.75 million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:78.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. We account for the earnout rights in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the contingency is resolved and the liability becomes payable. None of the earnout rights are recognized as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Icagen Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we acquired the core assets, including its partnered programs and ion channel technology from Icagen and certain of its affiliates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $19.9&#160;million included $15.1 million cash consideration paid upon acquisition, and a CVR of up to $25.0 million of cash payments based on certain revenue milestones with an estimated fair value of $4.8 million. The fair value of the earn-out liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company, which was 5.5%. The liability is periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amount paid may be materially different than the carrying amount of the liability. As the acquisition is not considered significant, pro forma information has not been provided. The results of Icagen have been included in our results of operations since the date of acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1 million of customer relationships and $1.7 million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6 years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10 years. The total acquired intangibles are being amortized on a straight-line basis over the estimated useful life of 9.7 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ab Initio Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of $12.0 million included $11.9 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vernalis Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we acquired Vernalis, a biotechnology company for $43.0 million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and product reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 34.0%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately nine years. We retained the core technology after the sale of Vernalis R&amp;D in December 2020. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License.</span>&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901357912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the third quarter of 2020, we paid a $0.5 million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2020 is as follows (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities due to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than a reduction in goodwill resulting from the sale of Vernalis R&amp;D disclosed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2),Sale of Vernalis R&amp;D and Promacta License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, there were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information related to the fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902727240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesWe lease certain office facilities and equipment primarily under various operating leases and one finance lease. Our operating leases have remaining contractual terms up to three years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial in prior years.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an agreement with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol. The agreement is considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. We allocated consideration in the agreement between lease and non-lease components using relative standalone prices. As of December 31, 2020, we have paid consideration of $35.3&#160;million and have total future commitments of approximately $24.1&#160;million through 2021. In October 2020, we determined the lease had commenced and recognized a right of use asset of $16.1&#160;million. We allocated $25.8&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and have a remaining lease liability of $6.6&#160;million as of December 31, 2020. The right of use asset is to be amortized straight-line over the remaining 8 year lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:53.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4 million for the twelve months ended December&#160;31, 2020. Operating lease expense was $2.1 million (net of sublease income of $0.3 million) and $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of finance lease liabilities was $9.7&#160;million for the twelve months ended December&#160;31, 2020. Finance lease expense, which was recorded in cost of Captisol, was $0.2 million for the twelve months ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesWe lease certain office facilities and equipment primarily under various operating leases and one finance lease. Our operating leases have remaining contractual terms up to three years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial in prior years.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered into an agreement with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol. The agreement is considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. We allocated consideration in the agreement between lease and non-lease components using relative standalone prices. As of December 31, 2020, we have paid consideration of $35.3&#160;million and have total future commitments of approximately $24.1&#160;million through 2021. In October 2020, we determined the lease had commenced and recognized a right of use asset of $16.1&#160;million. We allocated $25.8&#160;million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and have a remaining lease liability of $6.6&#160;million as of December 31, 2020. The right of use asset is to be amortized straight-line over the remaining 8 year lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:53.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.4 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4 million for the twelve months ended December&#160;31, 2020. Operating lease expense was $2.1 million (net of sublease income of $0.3 million) and $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our finance leases have a weighted-average remaining lease term of 7.9 years and a weighted-average discount rate of 3.5%. Cash paid for amounts included in the measurement of finance lease liabilities was $9.7&#160;million for the twelve months ended December&#160;31, 2020. Finance lease expense, which was recorded in cost of Captisol, was $0.2 million for the twelve months ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901700888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $340.0 million and marked it to market as of December 31, 2018 to $22.6 million with the resulting $119.4 million increase, net of $471.2 million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants had expired between November 13, 2019 and April 22, 2020. The warrants have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $11.6 million for these warrants and recorded this amount to additional paid-in capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of 525,000 warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#8217; equity to a derivative liability on the modification dates, resulting in a $28.3 million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $30.1 million and recorded a $1.8 million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December&#160;31, 2020, there are no warrants outstanding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $144.0 million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $13.5 million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December&#160;31, 2020, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $3.2 million was recorded as interest expense for the twelve months ended December&#160;31, 2019. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we repurchased $254.7 million in principal of the 2023 Notes for $222.8 million in cash, including accrued interest of $0.6 million. We accounted for the repurchase as a debt extinguishment, which resulted (1) a loss of $2.5 million reflected in other income (expense), net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2020; (2) a $35.0 million reduction in debt discount, and (3) a $3.2 million reduction to additional paid-in-capital, net of tax, related to the reacquisition of the equity component in our condensed consolidated balance sheet as of December&#160;31, 2020. After the repurchases, approximately $495.3 million in principal amount of the 2023 Notes remain outstanding. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $19.2 million and $7.5 million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, in connection with the repurchases of $234.4&#160;million in principal of the 2023 Notes for $203.8&#160;million in cash, including accrued interest of $0.6&#160;million, during the quarter ended March 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 28, 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,987)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,397&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,422&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were no events of default or violation of any covenants under our financing obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901702728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account DetailsShort-term Investments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual Fund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of  December&#160;31, 2020 and December&#160;31, 2019, we recorded shares of Viking common stock we own at fair value of $32.8 million and $48.4 million, respectively, in &#8220;Short-term investments&#8221; in our consolidated balance sheets. We also own warrants to purchase up to 1.5 million shares of Viking's common stock at an exercise price of  $1.50 per share. We recorded the warrants in &#8220;Short-term investments&#8221; in our consolidated balance sheet at fair value of $6.3 million and $9.9 million at December&#160;31, 2020 and December&#160;31, 2019, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,749&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 14 positions which were in an unrealized loss position as of December&#160;31, 2020. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,241&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,434&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,185&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF8xMDkvZnJhZzpkOWU1ODc4OTNlZGI0OWZiOTFmNTJlYjgxNWM5NWNiZi90ZXh0cmVnaW9uOmQ5ZTU4Nzg5M2VkYjQ5ZmI5MWY1MmViODE1Yzk1Y2JmXzM4MQ_17ee1139-a959-4580-b6e3-e99ff17f0d7f">three</span> to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $1.8 million, $1.5 million, and $0.9 million was recognized for the twelve months ended December&#160;31, 2020, 2019, and 2018, respectively, and was included in operating expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $23.4 million, $16.9 million, and $15.8 million was recognized for the years ended December&#160;31, 2020 and 2019, and 2018, respectively. Estimated amortization expense for the years ending December&#160;31, 2021 through 2025 is $47.1 million per year. For each of the years ended December&#160;31, 2020, 2019, and 2018, there was no material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,530&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,581&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CVRs associated with the Pfenex and Icagen acquisitions, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes rollfoward of contingent liabilities as of December 2020 and 2019 (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(520)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(247)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901642008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 1.1 million shares. As of December&#160;31, 2020, there were 1.1 million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358,162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313,374&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,617&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454,726&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,300&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2020, 2019 and 2018 was $41.39, $48.65 and $58.85 per share, respectively. The total intrinsic value of all options exercised during 2020, 2019 and 2018 was approximately $11.9 million, $10.4 million and $51.9 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2020, 2019 and 2018 was $2.5 million, $2.6 million and $19.8 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.05-$14.47</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.92-$56.26</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.88</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$63.58-$74.42</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82.90-$95.35</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.68</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$97.92</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.20</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.02-$113.76</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.58</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.97-$195.91</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%-3.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-71%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%-49%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%-36%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 5.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 to 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 to 5.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $37.2 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.9 years.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,498&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, unrecognized compensation cost related to non-vested stock awards amounted to $10.6&#160;million. That cost is expected to be recognized over a weighted average period of 1.5 years.</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, 52,808 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 6,455, 4,745 and 3,386 shares issued under the ESPP in 2020, 2019 and 2018, respectively. </span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased 260,000 shares of our common stock at a cost of $191.14 per share. In September 2018, the board of directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years (the &#8220;Repurchase Program&#8221;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $350.0 million of our outstanding common stock under the Repurchase Program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading </span></div>plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $248.8 million of our common stock remained available as of December&#160;31, 2020.During the twelve months ended December&#160;31, 2020, 2019 and 2018, we repurchased 934,079 shares for $78.0 million, 4,122,133 shares for $448.4 million, and 782,248 shares for $127.5 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902977160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies: Legal Proceedings</a></td>
<td class="text">Commitment and Contingencies: Legal Proceedings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 450, Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. On July 29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#8217;s counterclaims. On April 7, 2020, the Court ordered that the Scheduling Order be amended such that, inter alia, the fact discovery cut off occurred on November 2, 2020, the close of expert discovery was set for March 22, 2021, and that May 17, 2021 would remain the first day of a five-to-six-day bench trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin&#8217;s counterclaims on January 2, 2020. Fact discovery is ongoing. The Court&#8217;s scheduling order sets close of discovery on May 7, 2021 and a five day bench trial starting on December 13, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received three civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and August of 2019, Pfenex Inc., which was acquired by us in October 2020, filed three petitions (IPR2019- 01027, IPR2019-01028 and IPR2019-01478) for inter partes review of U.S. Patent No. 9,422,345 (&#8220;the &#8216;345 patent&#8221;; entitled &#8220;Expression System&#8221;), which is owned by GlaxoSmithKline Biologicals S.A., with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) of the U.S. Patent and Trademark Office. In November 2019 and February 2020, the Board instituted trial on the invalidity grounds in IPR2019-01028, but exercised its discretion not to institute trial on IPR2019-01027 or IPR2019-01478. In May 2020, GlaxoSmithKline Biologicals S.A. (&#8220;GSK&#8221;) filed two petitions (IPR2020-00890 and IPR2020-00962) for inter partes review of U.S. Pat. No. 8,530,171 (&#8220;the &#8216;171 patent,&#8221; entitled &#8220;High Level Expression of Recombinant Toxin Proteins&#8221;), which is owned by Pfenex, with the PTAB of the U.S. Patent and Trademark Office. On June 29, 2020, GSK filed a motion to withdraw IPR2020-00890, which was granted on August 28, 2020. In October 2020, Pfenex and GSK executed a confidential settlement agreement agreeing to terminate the proceedings before the PTAB resolving these issues. Pfenex and GSK filed a joint motion to terminate IPR2019-01028 and IPR2020-00962 on October 30, 2020, and an amended joint motion to terminate on November 4, 2020. A decision granting the parties&#8217; joint motion to terminate in IPR2019-01028 was issued on November 12, 2020. The PTAB subsequently granted the parties&#8217; joint motion to terminate in IPR2020-00962 on December 30, 2020.</span></div>On January 12, 2021, Abvivo submitted a JAMS arbitration demand naming the Company as respondent. Abvivo claims that the Company is in violation of the assignment provision of that certain Commercial Platform License and Services Agreement, dated October 9, 2019, by and among OMT and Crystal, on the one hand, and Abvivo, on the other hand because the Company allegedly withheld its consent to a proposed assignment required for Abvivo to negotiate a discovery and development alliance with certain third parties. On January 26, 2021, we submitted a response to the demand, denying all claims and alleging counterclaims against Abvivo and Brian Lundstrom, a Company employee and the sole owner of Abvivo. We allege that Mr. Lundstrom breached his fiduciary duty of loyalty to the Company and that Abvivo and Mr. Lundstrom fraudulently induced the Company, OMT and Crystal into certain business transactions and contracts. Abvivo and Mr. Lundstrom&#8217;s response to these counterclaims was due on February 9, 2021, but they did not submit a response. Under JAMS rules, the counterclaims are deemed denied. On February 22, 2021, Abvivo submitted documents to JAMS which indicated that it seeks to dismiss its claim without prejudice. The arbitration will be conducted by a three arbitrator panel, who have not yet been appointed. The parties must each appoint one arbitrator by February 26, 2021, and the two arbitrators will then appoint a third arbitrator. We intend to vigorously defend ourselves against this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903389080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:66.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2020, 2019 and 2018. The valuation allowance decreased $116.5 million in 2020, increased $136.9 million in 2019 and decreased $2.5 million in 2018.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,716&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,026&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,329)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had federal net operating loss carryforwards set to expire through 2037 of $162.4 million and $129.3 million of state net operating loss carryforwards that begin to expire in 2031. We also have $9.2 million of federal research and development credit carryforwards, which expire through 2040. We have $23.1 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $110.1 million of non-U.S. net operating loss carryovers and approximately $17.6 million of non-U.S. capital loss carryovers that have no expiration date.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019 we had approximately $713.8&#160;million of non-U.S. net operating loss carryovers and approximately $14.6&#160;million of non-U.S. capital loss carryovers. The year over year decrease in non-U.S. deferred tax assets was attributable to the sale of Vernalis in December 2020. The remaining non-U.S. deferred tax assets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the portion of the Vernalis business that we did not sell. We have a full valuation allowance against these non-U.S. tax attributes. See detail in &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (2), Sale of Vernalis R&amp;D and Promacta License."</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2020 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:66.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,911&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,096)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2020 is $30.2 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2020 and December&#160;31, 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2017 tax year to the present.&#160;The state income tax returns generally remain open for the 2016 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2020, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2016 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901392056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Summary of Unaudited Quarterly Financial Information</a></td>
<td class="text">Summary of Unaudited Quarterly Financial InformationThe following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.46)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.46)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,529</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,055</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,077</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,529</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,694</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,684</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,447</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,243</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,277</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,770</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,243</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Includes pre-tax gain from sale of Promacta license of $812,797.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907532728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking common stock and warrants was reclassified from &#8220;investment in Viking&#8221; to &#8220;short-term investments&#8221; in the audited consolidated balance sheet as of December 31, 2019. Additionally, &#8220;gain (loss) from</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">short-term investments&#8221; in the consolidated statements of operations include both the gain (loss) from investment in Viking and other short-term investments, which was previously included in &#8220;other income, net&#8221; for both the twelve months ended December&#160;31, 2019 and 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="text-indent:24pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock', window );">Cash Equivalents &amp; Short Term Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents &amp; Short-term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.  We periodically review available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To date, we have not identified any other than temporary declines in fair value of its short-term investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2020, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $0.3&#160;million of allowance for credit losses as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDg5OA_9d81d3db-816d-4474-8356-957524b81ba2">three</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfNDkwNA_3231c314-77f5-4043-99bb-ce2ee9b0d8a1">ten</span> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div>Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2020, noting no impairment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsPolicyTextBlock', window );">Commercial license rights</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,208)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights as of December&#160;31, 2020 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and reduce our asset as the funds are expended by Novan. As of December 31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan had been fully amortized as of December 31, 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congenita. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2020, the fund has been fully expended by Palvella and our cost basis for the asset has been reduced to zero, and therefore we will recognize milestones and royalties as revenue when earned. During 2020, we recorded a $3.0 million milestone from Palvella under contract revenue, which has been included in our consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2020 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we accounted for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. During 2020, given the expected cash flow from the Selexis program, we started to account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2020 is 21%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2020 were accordingly allocated between revenue and the amortization of the commercial license rights. We still accounted for commercial license rights related to Dianomi on a non-accrual basis as of December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of adopting ASU 2016-13, we now recognize an allowance for current expected credit losses on the commercial license rights subject to credit risk. We recorded a $5.5 million pre-tax reserve for credit losses upon adoption of the standard on January 1, 2020. We estimated the credit losses at the individual asset level by considering the performance against the programs, the company operating performance and the macroeconomic forecast. In addition, we have judgmentally applied credit loss risk factors to the future expected payments with consideration given to the timing of the payment. Given the higher inherent credit risk associated with longer term receivables, we applied a lower risk factor to the earlier years and progressively higher risk factors to the later years. During the twelve months ended December&#160;31, 2020, we further considered the current and expected future economic and market conditions surrounding novel coronavirus (COVID-19) pandemic and recorded an additional $0.5 million reserve for credit losses in other expense, net, in our consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard. See additional information in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsection below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we own. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Captisol Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when control of Captisol material is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. We have elected to recognize the cost of freight and shipping when or after control over Captisol material has transferred to the customer as an expense in cost of Captisol. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract revenue includes service revenue, license fees and future contingent milestone based payments. We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment.  These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December 31, 2019 was $0.9 million. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December 31, 2018 was $3.3 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock', window );">Preclinical Study and Clinical Trial Accruals</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI0NDQ_66537b75-9710-4b54-9022-3191c5e4adf2">six</span> month anniversary of the date of grant, and 1/48 each month thereafter for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI2OWExYzI1YTE1MTQ4ZjliOTVhZDZlMzM5MmRlNjA4L3NlYzpiNjlhMWMyNWExNTE0OGY5Yjk1YWQ2ZTMzOTJkZTYwOF84Mi9mcmFnOmY5Y2YzOWE0YTAzMjQxMDRiMTk4Y2FjNzRkMmMyMTBiL3RleHRyZWdpb246ZjljZjM5YTRhMDMyNDEwNGIxOThjYWM3NGQyYzIxMGJfMzI1MjI_311507f4-9e02-4033-abcd-0d529201e124">forty-two</span> months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div>Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">Derivatives<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (loss) Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2020, all of the 0.6 million weighted average shares of outstanding equity awards as of December&#160;31, 2020 were anti-dilutive due to the net loss for the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and </span></div>delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We adopted ASU 2016-13 on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance sheet of retained earnings to be recognized on the date of adoption with prior periods not restated. The cumulative-effect adjustment, net of tax, recorded on January 1, 2020, is approximately $5.2 million. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under previously applicable accounting standards. See additional disclosure on credit losses under  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Accounts Receivable and Allowance for Credit Losses&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Commercial License and Other Economic Rights&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discussed above and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Short-term Investments&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (8), Balance Sheet Accent Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Test for Goodwill Impairment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the disclosure requirements on fair value measurements. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. We adopted this standard on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard is expected to reduce cost and complexity related to accounting for income taxes. The new guidance eliminates certain exceptions and clarifies and amends existing guidance to promote consistent application among reporting entities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We adopted this standard on a prospective basis on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This standard removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures. We intent to adopt this standard on January 1, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical Study and Clinical Trial Accruals [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908251928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenue from Significant Partners</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year-ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock', window );">Schedule of Commercial License Rights</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights consist of the following (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aziyo and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,319)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,298&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,208)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,090&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">1) Amounts represent accumulated amortization to principal or research and development expenses of  $21.3 million and credit loss adjustments of $6.0 million as of December&#160;31, 2020 . Of the $6.0 million credit loss adjustments as of December&#160;31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal or research and development expenses as of December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,845&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Commercial License Rights [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofCommercialLicenseRightsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907986456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and unbilled receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Pfenex and expected synergies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Finite-Lived Intangibles Acquired</a></td>
<td class="text">The intangibles acquired and their weighted average useful life are as follows (in thousands, except useful lives):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated useful life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Relationships:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SII</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired Technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-19</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Information</a></td>
<td class="text">The pro forma financial information is not necessarily indicative of the operating results that would have occurred had the acquisition been consummated as if the date indicated, nor is it necessarily indicative of future operating results (in thousands, except per share amounts):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:78.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:78.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and product reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles assets with finite-life - core technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902731032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Icagen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Pfenex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Crystal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Cydex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black Scholes value estimated by management on the last day of the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;gain (loss) from short-term investments&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note (3), Short-term Investments: Investment in Viking.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2020, we paid $1.8 million contingent liability on development milestones to former Crystal shareholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the third quarter of 2020, we paid a $0.5 million contingent liability based on revenue milestones to Icagen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) The fair value of the CVR liability was determined using a probability adjusted income approach. These cash flows were then discounted to present value using a discount rate based on the market participants' cost of debt reflective of the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2020 is as follows (in thousands):</span></div><div style="text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities due to acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567998302056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating and Finance Lease Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:53.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902719208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Equity and Liability Components of the Convertible Senior Notes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the equity and liability components of the 2023 Notes (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,987)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of equity component of 2023 Notes</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,397&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,422&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903532040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investment Categories</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Treasury bill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual Fund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,749&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</a></td>
<td class="text">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,241&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,434&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,185&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,992&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,530&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,581&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock', window );">Schedule of Contingent Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes rollfoward of contingent liabilities as of December 2020 and 2019 (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Contingent Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Icagen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(520)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(247)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Contingent Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofContingentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906996664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-cash share-based compensation expense (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358,162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313,374&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,617&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454,726&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,300&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Option Plan Activity by Exercise Price Range</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.05-$14.47</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.92-$56.26</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.88</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$63.58-$74.42</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82.90-$95.35</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$95.68</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$97.92</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.20</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.02-$113.76</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.58</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117.97-$195.91</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,030&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%-1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-2.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%-3.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%-71%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%-49%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%-36%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 to 5.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 to 5.9 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 to 5.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.578%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:12pt"><td colspan="12" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,498&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,306&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907587000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:66.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,758)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate change for changes in federal or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of Vernalis R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Deferred tax assets (liabilities) are comprised of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,716&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,026&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,329)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:66.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,911&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,096)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903022312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.46)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.46)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,529</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,055</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,077</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,529</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,694</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,684</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First Quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic per share amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted per share amounts:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,447</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,243</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,277</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,770</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,243</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Includes pre-tax gain from sale of Promacta license of $812,797.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567891770952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>right</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum', window );">Maturity period of cash and cash equivalents, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID', window );">Adjustment to allowance for credit losses related to COVID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs related to obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,990,000<span></span>
</td>
<td class="nump">$ 41,848,000<span></span>
</td>
<td class="nump">$ 41,420,000<span></span>
</td>
<td class="nump">$ 33,161,000<span></span>
</td>
<td class="nump">$ 27,003,000<span></span>
</td>
<td class="nump">$ 24,808,000<span></span>
</td>
<td class="nump">$ 24,987,000<span></span>
</td>
<td class="nump">$ 43,484,000<span></span>
</td>
<td class="nump">186,419,000<span></span>
</td>
<td class="nump">120,282,000<span></span>
</td>
<td class="nump">$ 251,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19', window );">Additional reserve for credit losses due to COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
<td class="nump">2,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,892,000<span></span>
</td>
<td class="nump">$ 10,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,664,000<span></span>
</td>
<td class="nump">41,817,000<span></span>
</td>
<td class="nump">$ 93,774,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare', window );">Contingent consideration liability per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsIssued', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,979,000<span></span>
</td>
<td class="nump">20,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent', window );">Effective interest rate of forecasted cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember', window );">CorMatrix | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RoyaltyAgreementExpirationPeriod', window );">Expiration period of royalty agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member', window );">2023 Convertible Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member', window );">2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Loss Expense (Reversal), COVID</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableCreditLossExpenseReversalCOVID</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Loss Expense (Reversal), COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Amount per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forecasted Cash Flows, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ForecastedCashFlowsEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of highly liquid securities maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProductRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProductRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltyAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltyAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_CorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140568026646472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 69,990<span></span>
</td>
<td class="nump">$ 41,848<span></span>
</td>
<td class="nump">$ 41,420<span></span>
</td>
<td class="nump">$ 33,161<span></span>
</td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Partner A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Partner B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Partner C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567904510632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details) - Licensing Agreements - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 38,298,000<span></span>
</td>
<td class="nump">$ 38,298,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(27,319,000)<span></span>
</td>
<td class="num">(18,208,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">10,979,000<span></span>
</td>
<td class="nump">20,090,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments', window );">Accumulated amortization and credit loss adjustments on finite-lived intangible assets</a></td>
<td class="num">(21,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments', window );">Credit loss adjustments on finite-lived intangible assets</a></td>
<td class="num">(6,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments', window );">Credit loss adjustments on finite-lived intangible assets</a></td>
<td class="num">(5,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Aziyo and CorMatrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">17,696,000<span></span>
</td>
<td class="nump">17,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(9,588,000)<span></span>
</td>
<td class="num">(5,500,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">8,108,000<span></span>
</td>
<td class="nump">12,196,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="num">(7,492,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Selexis and Dianomi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">10,602,000<span></span>
</td>
<td class="nump">10,602,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments', window );">Adjustments</a></td>
<td class="num">(7,731,000)<span></span>
</td>
<td class="num">(5,216,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,871,000<span></span>
</td>
<td class="nump">$ 5,386,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Amortization &amp; Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible Assets, Credit Loss Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567914091000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 69,990<span></span>
</td>
<td class="nump">$ 41,848<span></span>
</td>
<td class="nump">$ 41,420<span></span>
</td>
<td class="nump">$ 33,161<span></span>
</td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,796<span></span>
</td>
<td class="nump">46,976<span></span>
</td>
<td class="nump">128,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember', window );">Royalty, Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,164<span></span>
</td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">21,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember', window );">Royalty, Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">5,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember', window );">Royalty, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember', window );">Royalty, Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,193<span></span>
</td>
<td class="nump">$ 99,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567891712168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 69,990<span></span>
</td>
<td class="nump">$ 41,848<span></span>
</td>
<td class="nump">$ 41,420<span></span>
</td>
<td class="nump">$ 33,161<span></span>
</td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,959<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
<td class="nump">29,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,664<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
<td class="nump">93,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,803<span></span>
</td>
<td class="nump">16,776<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember', window );">License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
<td class="nump">78,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,516<span></span>
</td>
<td class="nump">17,173<span></span>
</td>
<td class="nump">6,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,967<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 4,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906559928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (shares)</a></td>
<td class="nump">16,077<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">16,055<span></span>
</td>
<td class="nump">16,529<span></span>
</td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">20,447<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Dilutive potential common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Restricted stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">2019 Convertible Senior Notes (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted income per share (shares)</a></td>
<td class="nump">16,684<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">16,694<span></span>
</td>
<td class="nump">16,529<span></span>
</td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">21,277<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
<td class="nump">2,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567904299640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Vernalis R&amp;D and Promacta License - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,330<span></span>
</td>
<td class="nump">$ 210,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember', window );">Vernalis | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill written off</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember', window );">Vernalis | In Process Research and Development | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember', window );">Promacta | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds on sale of Vernalis R&amp;D, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember', window );">Promacta | In Process Research and Development | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907820984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments: Investment in Viking - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Warrants investments in Viking</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member', window );">Viking Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership interest (as a percent)</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InvestmentInVikingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Viking, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InvestmentInVikingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567909602632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>acquisition</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfAcquisitions', window );">Number of acquisitions | acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 465,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="nump">429,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Fair value of contingent earn-out payment</a></td>
<td class="nump">37,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Post-combination expense</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions', window );">Gross payments to acquire business attributable to vested portion of stock options</a></td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash to settle unvested stock options recognized as share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill acquired that is expected to be deductible for tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree since acquisition date included in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input (as a percent)</a></td>
<td class="nump">0.071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Customer Relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Customer Relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Core Technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex | Core Technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationConsiderationTransferredHoldback', window );">Holdback from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Contingent Value Right for Internal Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Contingent Value Right on Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues', window );">Proportion of milestone payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationConsiderationTransferredHoldback', window );">Holdback from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Earnout Rights for Partner Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues', window );">Proportion of milestone payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Fair value of contingent earn-out payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average useful lives of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims', window );">Cash holdback for potential indemnification claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Cash Holdback for Potential Indemnification Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationConsiderationTransferredHoldback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Holdback</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationConsiderationTransferredHoldback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightOnProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_ContingentValueRightOnProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=lgnd_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=lgnd_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567904499784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 189,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts and unbilled receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets', window );">Intangibles acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908401592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details) - Pfenex<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 385,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Alvogen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 114,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Merck</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Jazz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - SII</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Contractual Relationships - Arcellx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Approximate Fair Value</a></td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Minimum | Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Maximum | Acquired Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">19 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsAlvogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsAlvogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsJazzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsJazzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsSIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsSIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsArcellxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_ContractualRelationshipsArcellxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908633000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Financial Information (Details) - Pfenex - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 189,203<span></span>
</td>
<td class="nump">$ 170,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">$ (60,059)<span></span>
</td>
<td class="nump">$ 594,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareProFormaAbstract', window );"><strong>Net income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="num">$ (3.71)<span></span>
</td>
<td class="nump">$ 31.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="num">$ (3.71)<span></span>
</td>
<td class="nump">$ 30.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareProFormaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareProFormaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907889720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Allocation of Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 09, 2020</div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 23, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 189,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember', window );">Taurus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember', window );">xCella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther', window );">Cash and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring and product reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,978<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_TaurusBiosciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567909031128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember', window );">Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember', window );">Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for contingent consideration liabilities</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">363,567<span></span>
</td>
<td class="nump">998,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">49,193<span></span>
</td>
<td class="nump">9,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">6,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">37,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">324,478<span></span>
</td>
<td class="nump">939,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">32,763<span></span>
</td>
<td class="nump">48,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">9,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">42,527<span></span>
</td>
<td class="nump">61,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">32,763<span></span>
</td>
<td class="nump">48,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">9,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">320,647<span></span>
</td>
<td class="nump">936,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">320,647<span></span>
</td>
<td class="nump">936,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">45,312<span></span>
</td>
<td class="nump">3,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">6,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">37,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time | Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transferred over Time | Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyIcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyPfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyPfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567987319672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">$ (2,325)<span></span>
</td>
<td class="num">$ (3,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="nump">963<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities', window );">Contingent liabilities due to acquisitions</a></td>
<td class="nump">41,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at beginning of period</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="num">(2,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at end of period</a></td>
<td class="nump">$ 45,312<span></span>
</td>
<td class="nump">$ 3,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Acquisition, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902958600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567904501064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidToDate', window );">Consideration paid to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Total future commitments through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use asset recognized</a></td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory', window );">Portion of consideration allocated to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Remaining finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,593<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of finance leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for amounts included in finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid, Allocated to Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567913269032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 6,892<span></span>
</td>
<td class="nump">$ 10,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">15,842<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">22,734<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">8,478<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">9,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 14,233<span></span>
</td>
<td class="nump">$ 11,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906975256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating and Finance Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">8,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">7,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">6,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 6,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567890262216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 19, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>trading_day</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($) </div>
<div>day </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ExercisePriceofConvertibleBondHedge', window );">Exercise price of convertible bond hedge (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_WarrantsSettled', window );">Warrants settled (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled', window );">Deduction to additional paid-in-capital for warrants settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="nump">30,094,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,236,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member', window );">2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,805,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,280,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term portion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,293,000<span></span>
</td>
<td class="nump">638,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0133251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">If-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="nump">$ 341,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal', window );">Increase (decrease) in if-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notices for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,900,000<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion value over the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
<td class="num">(119,400,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000,000.0)<span></span>
</td>
<td class="nump">$ 119,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities', window );">Proceeds from derivative instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0040244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of the conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) in derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200,000)<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount', window );">Accrued interest on repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnRepurchaseOfDebtInstrument', window );">Loss on repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInDebtDiscount', window );">Reduction in debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Increase (decrease) in derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount of debt instrument</a></td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="nump">19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount', window );">Accrued interest on repurchased debt</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense | Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Settled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentAccruedInterestRepurchasedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest, Repurchased Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentAccruedInterestRepurchasedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ExercisePriceofConvertibleBondHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Convertible Bond Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ExercisePriceofConvertibleBondHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsforConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsforConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_WarrantsSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Settled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_WarrantsSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnRepurchaseOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnRepurchaseOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567901493512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details) - Convertible Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="nump">$ 495,280<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount (including unamortized debt issuance cost)</a></td>
<td class="num">(52,987)<span></span>
</td>
<td class="num">(111,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term portion of notes payable</a></td>
<td class="nump">442,293<span></span>
</td>
<td class="nump">638,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of equity component of 2023 Notes</a></td>
<td class="nump">48,397<span></span>
</td>
<td class="nump">101,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible senior notes outstanding (Level 2)</a></td>
<td class="nump">$ 466,053<span></span>
</td>
<td class="nump">$ 647,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567905209720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Investment Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 324,567<span></span>
</td>
<td class="nump">$ 941,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="num">(2,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">324,478<span></span>
</td>
<td class="nump">939,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember', window );">Mutual fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">151,512<span></span>
</td>
<td class="nump">250,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">151,898<span></span>
</td>
<td class="nump">250,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">84,120<span></span>
</td>
<td class="nump">411,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">84,154<span></span>
</td>
<td class="nump">411,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">45,459<span></span>
</td>
<td class="nump">210,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">45,485<span></span>
</td>
<td class="nump">210,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">30,512<span></span>
</td>
<td class="nump">63,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">30,610<span></span>
</td>
<td class="nump">63,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">4,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">4,466<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1,388)<span></span>
</td>
<td class="num">(1,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">Treasury bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">3,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907479592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>position </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in an unrealized loss position | position</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Warrants investments in Viking</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InvestmentInVikingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Viking, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InvestmentInVikingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567902707240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 141,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">26,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive', window );">After five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">168,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">141,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">26,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive', window );">After five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 168,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140568014042632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">26,232<span></span>
</td>
<td class="nump">137,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">26,232<span></span>
</td>
<td class="nump">137,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">14,013<span></span>
</td>
<td class="nump">58,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">14,013<span></span>
</td>
<td class="nump">58,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">7,693<span></span>
</td>
<td class="nump">79,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 7,693<span></span>
</td>
<td class="nump">$ 79,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140568023322136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 19,241<span></span>
</td>
<td class="nump">$ 10,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(4,807)<span></span>
</td>
<td class="num">(2,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,434<span></span>
</td>
<td class="nump">7,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">14,666<span></span>
</td>
<td class="nump">6,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">3,519<span></span>
</td>
<td class="nump">2,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567913108200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 189,662,000<span></span>
</td>
<td class="nump">$ 95,229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total goodwill and other identifiable intangible assets, net</a></td>
<td class="nump">$ 784,992,000<span></span>
</td>
<td class="nump">305,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated amortization expense for 2021</a></td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated amortization expense for 2022</a></td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated amortization expense for 2023</a></td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated amortization expense for 2024</a></td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets with finite lives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Complete technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">277,740,000<span></span>
</td>
<td class="nump">242,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(63,600,000)<span></span>
</td>
<td class="num">(50,203,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">2,642,000<span></span>
</td>
<td class="nump">2,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(1,312,000)<span></span>
</td>
<td class="num">(1,180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">40,700,000<span></span>
</td>
<td class="nump">29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(15,597,000)<span></span>
</td>
<td class="num">(13,224,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contractual relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">362,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (7,243,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906692472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 8,810<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent', window );">Amounts owed to former licensees</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSalesReturns', window );">Return reserve</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedAssetAcquisitionsCurrent', window );">Acquisition related liabilities</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSubcontractorExpensesCurrent', window );">Subcontractor</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSupplierExpensesCurrent', window );">Supplier</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,105<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 18,530<span></span>
</td>
<td class="nump">$ 8,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedAssetAcquisitionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Asset Acquisitions, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedAssetAcquisitionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSubcontractorExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontractor Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSubcontractorExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSupplierExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Supplier Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSupplierExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567905540232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">$ 8,942<span></span>
</td>
<td class="nump">$ 12,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">41,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(3,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">963<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">49,133<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember', window );">Cydex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">160<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(1,867)<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember', window );">Icagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">6,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare', window );">Contingent consideration liability per share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions', window );">Additional Contingent Liabilities</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">$ 37,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Amount per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567997206696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 30,727<span></span>
</td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="nump">$ 20,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">13,497<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 17,230<span></span>
</td>
<td class="nump">$ 14,874<span></span>
</td>
<td class="nump">$ 12,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906472584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased in period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,079<span></span>
</td>
<td class="nump">4,122,133<span></span>
</td>
<td class="nump">782,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Price per share of shares repurchased (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,800,000<span></span>
</td>
<td class="nump">$ 248,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,998,000<span></span>
</td>
<td class="nump">$ 448,433,000<span></span>
</td>
<td class="nump">$ 127,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember', window );">Pfenex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash to settle unvested stock options recognized as share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.39<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
<td class="nump">$ 58.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="nump">$ 51,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,200,000<span></span>
</td>
<td class="nump">$ 37,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember', window );">Amended ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,808<span></span>
</td>
<td class="nump">52,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EmployeeStockPurchasePlanAbstract', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Shares allowed to purchase in employee stock purchase plan per employee (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued under amended ESSP (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CorporateShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CorporateShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EmployeeStockPurchasePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EmployeeStockPurchasePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_PfenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_AmendedESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906427320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period (shares)</a></td>
<td class="nump">1,956,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">806,300<span></span>
</td>
<td class="nump">338,617<span></span>
</td>
<td class="nump">228,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(156,845)<span></span>
</td>
<td class="num">(112,011)<span></span>
</td>
<td class="num">(358,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(44,012)<span></span>
</td>
<td class="num">(6,531)<span></span>
</td>
<td class="num">(10,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period (shares)</a></td>
<td class="nump">2,561,822<span></span>
</td>
<td class="nump">1,956,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (shares)</a></td>
<td class="nump">1,611,830<span></span>
</td>
<td class="nump">1,454,726<span></span>
</td>
<td class="nump">1,313,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (shares)</a></td>
<td class="nump">2,561,822<span></span>
</td>
<td class="nump">1,956,379<span></span>
</td>
<td class="nump">1,736,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (USD per share)</a></td>
<td class="nump">$ 77.54<span></span>
</td>
<td class="nump">$ 66.71<span></span>
</td>
<td class="nump">$ 53.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">92.93<span></span>
</td>
<td class="nump">116.69<span></span>
</td>
<td class="nump">162.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">21.26<span></span>
</td>
<td class="nump">23.65<span></span>
</td>
<td class="nump">55.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (USD per share)</a></td>
<td class="nump">91.30<span></span>
</td>
<td class="nump">139.37<span></span>
</td>
<td class="nump">114.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (USD per share)</a></td>
<td class="nump">85.59<span></span>
</td>
<td class="nump">77.54<span></span>
</td>
<td class="nump">66.71<span></span>
</td>
<td class="nump">$ 53.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">76.05<span></span>
</td>
<td class="nump">61.82<span></span>
</td>
<td class="nump">47.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (USD per share)</a></td>
<td class="nump">$ 85.59<span></span>
</td>
<td class="nump">$ 77.54<span></span>
</td>
<td class="nump">$ 66.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">4 years 6 months 14 days<span></span>
</td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">4 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 59,033<span></span>
</td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="nump">$ 125,858<span></span>
</td>
<td class="nump">$ 157,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">53,286<span></span>
</td>
<td class="nump">70,345<span></span>
</td>
<td class="nump">117,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 59,033<span></span>
</td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="nump">$ 125,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567907637064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Breakdown of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember', window );">$10.05 &#8211; $195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">2,561,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 85.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">1,611,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 76.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember', window );">$10.05-$14.47</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">10.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 14.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">284,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 13.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">270,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember', window );">$21.92-$56.26</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">21.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 56.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">344,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">2 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 35.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">344,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 35.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember', window );">$63.58-$74.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">63.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 74.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">307,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 71.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">220,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 73.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember', window );">$82.90-$95.35</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">82.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 95.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">185,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 86.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">140,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 86.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember', window );">95.68</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">95.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">305,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">9 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">63,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 95.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember', window );">97.92</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">97.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 97.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">4,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 97.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">4,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 97.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember', window );">98.2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">98.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 98.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">270,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">9 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 98.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 98.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember', window );">$100.02-$113.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">100.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 113.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">257,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 104.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">220,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 103.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember', window );">117.58</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">117.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 117.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">19,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">9 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember', window );">$117.97-$195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">117.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">582,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 137.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">347,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 141.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140568008079576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908546760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">111,306<span></span>
</td>
<td class="nump">118,498<span></span>
</td>
<td class="nump">62,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(52,363)<span></span>
</td>
<td class="num">(102,846)<span></span>
</td>
<td class="num">(61,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (USD per share)</a></td>
<td class="nump">$ 125.11<span></span>
</td>
<td class="nump">$ 130.63<span></span>
</td>
<td class="nump">$ 91.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (USD per share)</a></td>
<td class="nump">89.73<span></span>
</td>
<td class="nump">115.90<span></span>
</td>
<td class="nump">169.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (USD per share)</a></td>
<td class="nump">121.69<span></span>
</td>
<td class="nump">121.55<span></span>
</td>
<td class="nump">86.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134.36<span></span>
</td>
<td class="nump">125.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (USD per share)</a></td>
<td class="nump">$ 106.88<span></span>
</td>
<td class="nump">$ 125.11<span></span>
</td>
<td class="nump">$ 130.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567908254936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>civil_complaint</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember', window );">Lupin Patent Infringement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember', window );">US District Court for the Northern District of Ohio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of civil complaints filed against entity | civil_complaint</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_LupinPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567906421016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, change in amount</a></td>
<td class="num">$ (116.5)<span></span>
</td>
<td class="nump">$ 136.9<span></span>
</td>
<td class="num">$ (2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">162.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">129.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California and New Jersey Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">713.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US | Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567987227800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,889<span></span>
</td>
<td class="nump">$ 89,471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Income Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,501<span></span>
</td>
<td class="nump">92,508<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,672)<span></span>
</td>
<td class="nump">74,627<span></span>
</td>
<td class="nump">29,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,382)<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense from continuing operations</a></td>
<td class="num">$ (2,391)<span></span>
</td>
<td class="num">$ (4,911)<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
<td class="num">$ (6,284)<span></span>
</td>
<td class="num">$ (810)<span></span>
</td>
<td class="num">$ (4,620)<span></span>
</td>
<td class="num">$ (3,609)<span></span>
</td>
<td class="nump">$ 176,376<span></span>
</td>
<td class="num">$ (7,553)<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
<td class="nump">$ 30,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903789304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,213)<span></span>
</td>
<td class="nump">$ 167,294<span></span>
</td>
<td class="nump">$ 36,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,456)<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationContingentValueRights', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
<td class="num">(8,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount', window );">FDII</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,652)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
<td class="num">(2,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change for changes in federal or state law</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount', window );">Provision to return adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,803)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax differential on income/loss of foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,839)<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,876)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(4,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Sale of Vernalis R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount', window );">Expired NOLs and credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives', window );">Change in derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense from continuing operations</a></td>
<td class="num">$ (2,391)<span></span>
</td>
<td class="num">$ (4,911)<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
<td class="num">$ (6,284)<span></span>
</td>
<td class="num">$ (810)<span></span>
</td>
<td class="num">$ (4,620)<span></span>
</td>
<td class="num">$ (3,609)<span></span>
</td>
<td class="nump">$ 176,376<span></span>
</td>
<td class="num">$ (7,553)<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
<td class="nump">$ 30,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Net Operating Losses and Credits, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567997690392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,147<span></span>
</td>
<td class="nump">$ 150,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">19,623<span></span>
</td>
<td class="nump">14,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">11,994<span></span>
</td>
<td class="nump">9,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13,120<span></span>
</td>
<td class="nump">10,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">185,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(24,858)<span></span>
</td>
<td class="num">(141,338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">84,026<span></span>
</td>
<td class="nump">44,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(119,381)<span></span>
</td>
<td class="num">(40,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(4,923)<span></span>
</td>
<td class="num">(10,939)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(124,304)<span></span>
</td>
<td class="num">(51,707)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="num">$ (40,278)<span></span>
</td>
<td class="num">$ (7,329)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567903480712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 28,736<span></span>
</td>
<td class="nump">$ 30,289<span></span>
</td>
<td class="nump">$ 29,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">3,911<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(955)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 28,736<span></span>
</td>
<td class="nump">$ 30,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140567891755800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information - Summary (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 69,990<span></span>
</td>
<td class="nump">$ 41,848<span></span>
</td>
<td class="nump">$ 41,420<span></span>
</td>
<td class="nump">$ 33,161<span></span>
</td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 186,419<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">75,894<span></span>
</td>
<td class="nump">38,101<span></span>
</td>
<td class="nump">34,320<span></span>
</td>
<td class="nump">29,373<span></span>
</td>
<td class="nump">37,182<span></span>
</td>
<td class="nump">29,966<span></span>
</td>
<td class="nump">29,117<span></span>
</td>
<td class="nump">29,738<span></span>
</td>
<td class="nump">177,688<span></span>
</td>
<td class="nump">126,003<span></span>
</td>
<td class="nump">87,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">2,391<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
<td class="num">(6,033)<span></span>
</td>
<td class="nump">6,284<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="num">(176,376)<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
<td class="num">(167,337)<span></span>
</td>
<td class="num">(30,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,761<span></span>
</td>
<td class="num">$ (6,701)<span></span>
</td>
<td class="nump">$ 22,086<span></span>
</td>
<td class="num">$ (24,131)<span></span>
</td>
<td class="num">$ (7,365)<span></span>
</td>
<td class="num">$ (15,251)<span></span>
</td>
<td class="num">$ (14,419)<span></span>
</td>
<td class="nump">$ 666,337<span></span>
</td>
<td class="num">$ (2,985)<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic per share amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) - Basic (USD per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 32.59<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 33.13<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted per share amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) - Diluted (USD per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 31.32<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 31.85<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares&#8212;basic (shares)</a></td>
<td class="nump">16,077<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">16,055<span></span>
</td>
<td class="nump">16,529<span></span>
</td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">20,447<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares&#8212;diluted (shares)</a></td>
<td class="nump">16,684<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">16,694<span></span>
</td>
<td class="nump">16,529<span></span>
</td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">21,277<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_PromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted per share amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,797<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 812,797<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterimPeriodCostsNotAllocableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterimPeriodCostsNotAllocableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@OM"I0W@^Z64YG"3ON#X3X/A?U!+ P04    " !IB%A2<!*9!A4'   ['@
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*V9V6[;.!2&7X5PBV(&2&)N
MVK(!:=)."W2:H$EGKAF9B85*HDO13M.GGR-YD2TN3H"Y263[)_5S.]\A>?JD
M](]F*J5!OZJR;LY&4V-FQ^-QDT]E)9HC-9,U_/*@="4,?-2/XV:FI9ATA:IR
M3#&.QY4HZM'Y:??=C3X_57-3%K6\T:B95Y70S^]EJ9[.1F2T_N);\3@U[1?C
M\].9>)2WTGR?W6CX--[4,BDJ63>%JI&6#V>C"W)\R;L"G>*?0CXU6\^H;<J]
M4C_:#Y\G9R/<.I*ES$U;A8!_"WDIR[*M"7S\7%4ZVKRS+;C]O*[]8]=X:,R]
M:.2E*O\M)F9Z-DI':"(?Q+PTW]33)[EJ4-36EZNRZ?ZBIY46CU ^;XRJ5H7!
M0574R__BUZHCM@H0[BE 5P7H2PNP50'6-73IK&O6E3#B_%2K)Z1;-=36/G1]
MTY6&UA1U.XRW1L.O!90SYY?77V^OOWR^NKC[<(7>7WRY^'KY =U^^O#A[A8=
MHN^W5^B/MW^BMZBHT=U4S1M13YK3L8$WM^7'^>HM[Y=OH9ZW7,G\"#%R@"BF
MV%'\\L7%2;9;? SMW32:;AI-N_J8K]%SK65MD&@::9KC0(UL4R/K:N2^&D4S
M1= W*&\?Y,]YL1 EO,+95\NJDJZJ=IDMSGD2MPU;;'>)K4I(Q-E&M>.3;WSR
MH,_;J=+FT$A=P8@N9&,JG\EE/?'6ZUG,HC@9N+1E698RRMTVHXW-*&CS(L_5
M'(Q!H,@E=.5]*0]0+8W+:&0YB.*4#WW:*H99FKAMQAN;<=#F9^C"VBC][/(5
M6V^D,4^'OFQ50K/8;2O9V$KVV,I5)9$1O^1V#[I,)K9)2H8>;1$A+"9ND^G&
M9!HT>6VF4D.$VUZ)+H>I/7 II0.'MH@GS#,'LXW!+&CP3AE1OL!@9L\_C*-H
MN)QM&2&4Q3QRNR2X#^ XZ/-*/DCP.($%W0^[=[6L*ML9<<[:H+SCUB6+8IQZ
MS&[1ANR9FD;4CP7,QE6/^HT2NU^SB#'+J:VC!'/NL]HS@M"@U;^4FCP59>DT
M1^W13+,X'LY+ARZ+*,T\WGK:D#VX454E=5[ !"V+')(JV<%'=6M*YJI650$5
MM2F,F];,]H^S9#AG'3)(#S/LL=]#B(0I=*,A#=7FN3/=PG+68L@_%6S($,ZW
MUO?*K2U+2.I;7SV*2)A%UV!5F*)^1*44C0Q$ F)#)DXS:T[8*H)9Y $[Z5E$
MPC#Z6-2BSN5^ES9R2)1RRZ8M2ST1E?1@(F$R+8-^P)N-&DZMG,.AHC3Q=6 /
M)!(FTC+@!\S9E $,4KHUQ5;^'$*>\8SXYF*/))*]*'$M"W%?E(4I9#![I3U$
M:!@BFX1K)IY]N0*UF<"2=+@*'2K*J2=DT!X<- P.,*CG +FMECL]VC2 $&!!
MPR%+H]23T="M;448&>OA@0#<!HS!2#G]VH!@66IWJBVC,?9DK[3'" UC9),Z
M: F)[-P]Z@X&9)P-Y[Q+1I@'=+0G!0V38MVC:A"$]W6K@QBIM4Y=*KH5"'<]
M]\"@86"L/3_L!.1]CAWLB#(V=.Q@AR?NT1X<- R.W41WGT\'/3 FA R=.G0)
MQK[.[0E"PP2AF+)V?2T@?^C2R$;6A=*H5B:0]5('5SCD85;_VKJ8I5GDF\<]
M6VB8+5]4_;C<=K\B-M@8R2@?YF@.5<R8AS2T)PT-[WY>MZN@]NX&=C99.O1J
MRQ@,@B>.L9Y>+$ROOG=?&2>8#:LHYL-9X5!E6>)!&NN1QL)(6R9#Y<;[/J\V
MLQA.XWAHUK$?HCSUN>W9QL)L6T:)?1YM3L413>(A?QVZ!&2I)Y:QK6.X_1NC
M8GFHM3R.6Z^VW.<X6%][B'[<S$0NST8S+1NI%W)TCEPGF/]#1;MM[AG)># I
MO#4J_S%5Y43JYMV;E)+DI-M4F>?@R6;/,Q;FV8U>QX*F?=,!>HN/(.1#JJC1
M0I1S>8*B XPQ:J8"FH;$W$R5+G[+R0GZ+;5"1=.TJ5NW0YV;QL!#NT*%05<R
ME]4]K(+UV7 GLD]Y5V-ET\^:6"');OM[/K(P']LYI6I_XV/L:SV)#W"Z;!,\
MID"NE6A_C[Q[0V)\8G7+ :1JS4QV=Q^E\]B1.<!KQ0@7G#W=U).9A<E\,9D4
M[<T,1(F9*":'18UR,2L@:CAMVJ1E)&71$!DN79PPZCDB93V169C(L*&85_-2
M&+D^-P'.P=*<ME=4"R"':MP!P^;M88J'Z8]+18G/=$]E%J;R-VD$?#5!4N@:
M9HS;H8.R&<FBX0[?H>,PM;$G=^ ]CGD8QTM4--ZPY+QNL!F;8/ \S-E=NCBA
MS)-8\I[&/$QCBV_=FGME(XAU9^,^(7 )G2<$XZV;O?9:]6^A'XNZ@>SF 4KB
MHP3BG5[>5"X_&#7K+OONE3&JZAZG4H#]5@"_/RA(E%<?VOO#S7WQ^7]02P,$
M%     @ :8A84M2EW"O0 @  :0D  !@   !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6R=EEUOVC 4AO^*%>VBE3KB)'R$"I H4'52UZ*FW2ZF79AP(%:3.+,=
MZ/;K9SMI!FV =%R [9SW/<]Q3G &6\:?100@T4L2IV)H15)FE[8MP@@2(EHL
M@U1=63&>$*FF?&V+C -9&E$2VR[&73LA-+5& [,VYZ,!RV5,4YAS)/(D(?SW
M%<1L.[0<ZW7A@:XCJ1?LT2 C:PA /F5SKF9VY;*D":2"LA1Q6 VML7,Y<; 6
MF(AO%+9B9XQT*0O&GO7DRW)H84T$,8126Q#ULX$)Q+%V4AR_2E.KRJF%N^-7
M]VM3O"IF001,6/R=+F4TM'P++6%%\E@^L.T-E 5UM%_(8F&^T;:([?0L%.9"
MLJ04*X*$IL4O>2DW8D?@M \(W%+@-A5XI< SA19DIJPID60TX&R+N(Y6;GI@
M]L:H534TU;<QD%Q=I4HG1Y/[N^#^]LMT_#B;HJOQ[?AN,D/!S6SV&*"S.>&0
MR@@D#4E\CCZC3\A&(E*K8F!+E5U[V&&9Z:K(Y![(-(6PA3SG KG8Q37R26.Y
MT]^7VZKFJG"W*MPU?MX!OT 2":H?)6(K=$U3DH:4Q&C.!#7]]6.\$)*K+OMY
M))E7)?-,LO:!9'/5F\ Y+)&ZH>'S!<H(1QL2YX#.GH(IRH 7^WI>MZ^%MV^\
M]6.Y&>$6QL[ WNQNWZFH/?!V!=[^"#@BN8P8IW_4PEG1"+7$A6EWAZ6#S><-
M\^FX/>I.1=WY$#45(C]!W'E'\I;U6,0>9;>B['Z(4OW)"DG2)4W71U&[)U&/
M1>RA]BK4WE'4"4L2]4S\3_/V&C7OJ:@]:K^B]AM3-^U<_]W6=7%MZS8(W(/N
M5]#]YM -&K?_CL/I8K\&N"[0=[V#P [^=X3@YLA-N[CT; !>&UE+;N^<@_HE
MY"OA:YH*%,-*27&KIYYA7ISKQ42RS!R-"R;506N&D7H7 JX#U/458_)UHD_;
MZNUJ]!=02P,$%     @ :8A84EW6 URX!@  ,QT  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RU6=MNVS@0_17"V(<4:&SQ(E$JD@")G>X&V#9!G'8?
M%OO V'0L5!:](IVD^_5+72+:),4&#?H26\J9,<_,< XO)T^B^B;7G"OPO"E*
M>3I:*[7],)G(Q9IOF!R++2_U?U:BVC"E'ZN'B=Q6G"T;HTTQ05&43#8L+T=G
M)\V[F^KL1.Q4D9?\I@)RM]FPZOL%+\33Z0B.7E[<Y@]K5;^8G)ULV0.?<_5E
M>U/IITGO99EO>"ES48**KTY'Y_##C$2U08/XFO,GN?<=U%3NA?A6/UPM3T=1
M/2)>\(6J73#]\<BGO"AJ3WH<_W9.1_UOUH;[WU^\?VS(:S+W3/*I*/[*EVI]
M.DI'8,E7;%>H6_'T!^\(Q;6_A2AD\Q<\==AH!!8[J<2F,]8CV.1E^\F>NT#L
M&<!DP !U!L@V( ,&N#/ KS4@G0%I(M-2:>(P8XJ=G53B"50U6GNKOS3!;*PU
M_;RL\SY7E?YOKNW4V?3Z\_SZSZO9^=WE#,SO],>GR\]W<W#]$5S?7-Z>WUUI
M #@&7^8S</3;.R#7K.(2Y"6X6XN=9.52O@>_'3R?3)0>6.U^LN@&<=$. @T,
M B+P291J+<%EN>3+0P<3S:BGA5YH7:"@QQE?C &&[P&*4.09T/35YC#SF,]>
M;YX&V. ^2;CQAP?\W?)'7NZX_!#P17I?I/%%!GS="<4*/6-;C[Y<M?:TL:_;
MQN,93!-2Q^%Q/X(>F YVB@YA,Q>&8DABW,,.6,0]BS@8D>LMKYC*RP>P$%))
MH.L.\&?=#&4X2DGO/PE&::J] K$"4[95N12%+TZMAV2/&8[<,+DH"#&A5I1<
M5((Q]<>(]AQHD,/Y1E0J_X\U_55SR4O%RH?\OO"GG3I#0)@0*YU3%P4371T6
M'0\JIAGR\TE[/FF0SRV7G%6+=9/LI2[@0FRU BD?F=090)SAS";C0<59E%ID
M7!2B:3)0P%E/)@N2^9V7NH*+A@M;ZL:>2U57]"/WT<G<\B $QQ8=%T5@FMJY
M<5&84DS\=&!D="1Z15\1@7GIU87(K11*D]3*P=2'0TD488N<!Y=2BI(!=GLJ
M"8/LKLJ%V'"PJL3FA:,H_8R@6RYQ2NQ<>6!I1".:V(1<'$PP10.] 2+#"(4[
MJ%KS2O>$AM=1EZ-WH=X)C5Q!'"YNO=X$1X60\ET;,KG6K>A8\6JC?_&12U7/
M6W_XL,/W&"89QG;\7!R,2&9'ST7%D2[W@> 9#85A$;TJ-1=-HXN?EPCQ)=BI
M:Q>%4H(CFX<+@SC+L@$>1D5A_#H>7?Z]1&(W(X@2%-E4/#@<4[OR9SX<21$=
MFJ-&LF%8L]N*[IB\!R7W*@-TI?88VCU_ZD,12*'-Q0-+2#947T:Y85BZNV;J
MG:+#S%S5/<8)3IVIX\'IN8/M-8D'ER71@.Y!H^(P+.-=*^W:PSW7>U?^0E*Q
M9R\S5X+UB&/L9,W%T2Q)L-,67!RD&.]-NT-N1M1A6-6O>AJ:6,E7N3)Y\Q)S
MQ9C&L9,P%Z5[(L5NQCQ '$710)] 1MQ16-P_<]7789,W'YG.!SUH%%EJ*Y\'
MEJ ,1_;&P8.#!&,$!\@8+4<PJ'R7K"KU"D6"&SV[YO5^%OQ]?E\OOQ;JG]#>
MTV@K0L%P73"9+^II>A@TH!<.[08:'-7[Z?[1'\[V-[+]<$9C:->\!X;Q&-H+
M(P\L&0\)(3)*C\)*/V^/ W:2+^LS@/N&N*&Y8,5B5[0[D*/VZ,#/U:/F"71+
MQP-+L\Q6& \,09@,S&YD5!^%57^6%SNEB;XUL>1UB75A&([MF,P\L'B<#8@I
M,BL#%%X96(E==M1_(K6NW'M3ZX%E-+8[G >&2)0,U;%9.Z#PVN%6?&>%RNU-
MRJ$W(]^(OOF\!AG!1&'!_/&)3>> 'O0 FB5VC%T823)GR^&!093&\5!-&75$
M877T'Z8<GH@92<+1FV.,C2;@\/[NQS'&GHU8I'N/?=[CP6%(4GL)XH&A#**!
MU14VTH/#TC,592-D+UQ"T=D[?GS[^2,V;12_]002N]L=@A+[E&GJ@\$4VCW#
M \OT'G#@Q .;%HG#+?(KKTI6Y*&6@4T#PLDO.=#$IBGA\)ZBV92WNW%6\,,#
M0<"DY/X-.?:<Y5$(G5RX,'L3&X0<DC*]$8=[XXWFHZN=A2)D^A/.?DD.B&E:
M)+R._LD<$'<I;.^^/9 4(IK9DR'HJF4UV;M-VO#JH;F5DSHFNU*U-S#]V_[F
M[[RY[[+>7\ /L_;^SKAIKQ,_L>HA+R4H^$J[C,94S[2JO:%K'Y38-G=6]T(I
ML6F^KCE;\JH&Z/^OA% O#_4/]/>D9_\#4$L#!!0    ( &F(6%*A^9H;(P,
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M?<:?3EU'&-2(?R7\OMQXC80KUWG^4[PYBG>V',&(IWQ:B2$B^'?']WB:BI&
MQU_-H%OK.87AYNNGT0]KY\&9ZZCD>WGZ>Q)7LYVM8 O%_"9:IM5Y?O^5-PZY
M8KQIGI;U7W3?8)TM-%V653YOC('!/,E6_Z.')A ;!LSK,""- 5$,W*X9:&-
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MOW>FQC_2IM& ^\W29$NUT*6NX3Q476W3HMTFP$.%!JXJ-8ZJVJ6NU1J&@&@
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MAL0M\(9"8[: G7;K=6%TG:B_5:!X2K"/;Y!3X)CM5VH#L*#05$#Y1.'TS9;
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M9>LU[4J#T38T8P]7R"4.5:&@V*6#$(4<7_@R *'OVA!.]I\5:D<Z;!"]@O#
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M9/0SQ5L5Z=P\@%D\)_$?<03;FL+*'5"\ C.CK6H*H=$#"!J(5UP]S7_KR*[
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M2(EIY1B)FW<@J\#&=&S&N8PDRL>0]8#ZVYK<:*"WN@0]Z QN2A81I04D"88
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M0"C9"_Z EB[,W#HHP8;<'C&:X39"^=L%P4)Q/@I9XG&5!O-/H=+9+SU1*E
M@KEMQJ%>7;+<W.5X8M0YG$H31BEV58,(6AP]*-H-V^M#F3SGHMPS\\,5QS[Q
MR?H/#QY880/P<!$=T8V-&*<S-*3GY)F0AQ9%,P@5^I/AD/A^'L;G$C2!/Y9@
M;282XB;"XL2G>%[A5NU< _N1A=+6Z_*-E;6BR[VS0];%/D1;"I:C1>E"8IR
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M0 H;>'UM.8/=) 3HOSL6_P!02P,$%     @ :8A84C:PW 80%   WD8  !D
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M=MD*XB?Q;80F3VBV& SJ5YCV)M$P=;5)BLI\S0Y-*\CDO"+&Q-3G;K<HA!&
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M<5?F=SO#U)856559*I88+B@=\)\HC#!,JDXGK;KGSD).1^W2).VS+Z5ZDUR
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M,9-?W["!79-J"O&4#0)47@BJ=%A<<6>AJ7*5Q[DJ^4Z0_VZK1P6=.0-.?P#
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MG/8+P=$!UCLF[M$EW2[4N,I5<"\F$"@*"E]AN0N.SKVX),6%\4RZHZ*@2NO
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MS@ 9+AAAL;Y)#*3&50,VP6('<COIT;I69Y3W$0M*DN191NW.=DB+7:*/-:E
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M:#\ AX",7,%/? T?6>I(62(=SLHF1PF&:)B4=A#OW<IS.SEP[LZY>(LM GL
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MEWD>]KL9=)@)7\7C)SYP>F>JX_?MH=,+3JV_LA7"Y1+S3D9#O*_"OKN'5<Z
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MB4C46M9I]0]S]ZVRYUD@O=BD)?TK[GAM='4BXKJL3&8?!@XRG?/_\H.5@_?
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MW-Z:F.#'!6U HU15!6_AMO"P+CKP WPBNDW$34DR(1;N3)TF8BM1@Y3"V!'
M%GD":HE*03DL)G:I>]<.TD>- J/)=)V19V4X=]=!.TKK%YMKMQME%M7W[/4
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MMNU6A$Z(67]@*G0BUQO143^:HMX*J[+&%#4I'SOB6 2Q"YI.D"2@ZX1!(KY
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M >;G&J'=O= !P_]-O/P?4$L#!!0    ( &F(6%(-VWQ8  L  +,;   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U9:7/;NA7]*QA7;I,9"B:XTUEF
MG.TUG:;Q.*]YT^GT RQ!$ALN"DA:=G]]S[U<1-F6,WWI%XDD@(MSMW,OR)>[
MRGZK-\8TXK;(R_K5R:9IMN=G9_5B8PI=RVIK2HRL*EOH!K=V?59OK=%+7E3D
M9Y[K1F>%SLJ3UR_YV:5]_;)JFSPKS:45=5L4VMZ],7FU>W6B3H8'5]EZT]"#
ML]<OMWIMOICF[]M+B[NS4<HR*TQ99U4IK%F].KE0YV\"FL\3OF9F5T^N!6ER
M757?Z.;C\M6)2X!,;A8-2=#XNS%O39Z3(,#XWLL\&;>DA=/K0?H'UAVZ7.O:
MO*WRW[)ELWEUDIR(I5GI-F^NJMV?3:]/2/(655[SK]AU<SWLN&CKIBKZQ;@O
MLK+[U[>]'28+$O?( J]?X#'N;B-&^4XW^O5+6^V$I=F01A>L*J\&N*PDIWQI
M+$8SK&M>?VFJQ;=-E2^-K?\DWG]OL^;NY5D#R31^MNBEO.FD>$>D*$]\JLIF
M4XOWY=(L#P6< =*(RQMPO?&>E/C.+*3PE2,\UW.?D.>/>OHLSS\BK]-,_//B
MNFXL0N%?3\@,1ID!RPQ^TG9/2J&L.Z^W>F%>G2"M:F-OS,F!Z#_^(?%4_*+?
M0'S9:&OF%(E+\;8JD)VUY@!_?TO71ORZ,6)5Y4BWK%R+1E_GIL^Y[#^F%F55
MSA>ZWHAZ(F@Q%61Z0<^R4C2;JJUUN:R?GPOXQ!37QHY^P8]*Z2<Y0/6H,%T+
MS2-5:<I&5*MS<05MM5UL!.0CDV[ $-N"!OLUM9@)Y3M!&N,B=:) X3]Q_- 3
MOYC26)WS2KU$7F3D5DKP_6(5.Y[O"A4X21P(Y4%0  &^Z\0>2?0")U0A7;A.
M$D2";2XN<UW6XF.YUY8T=435TI7K]=,^E@L@I?UH@=B1>L".X!=-);)R 8:$
MU@U\4;8LIEIU%L?$&YWE[!:0JLCJNM60)J[OA)(*29[G9+ANLA07-2U]8'N'
M9%LC=O3S<-V]359MTV)>M66?K*TN&XBU8IE9T.,>0PL-+*.^Z+5AG4E'*3Z,
M0961,WL>)W1DG)KMTN^P):,PXU+(DI>LR74#>5G951+,.N^BIA:_,7=B\.(&
M7ET;A+*QBPSVN[094#T8OS)4;PC)6] .Y7.+8/C5V +RQ3\05;6X6*^M66-/
M^*JQ&<K(0GS5>8NX_CB-:_%&YZR[;L1?=-F22FQC1+5"Z$2.[WN(DM"7*A:A
MC"EV5!@[?N"*7\B29"4/<1G1-!5YTG5'#9;BF1\F#IX^)QFA] +8T:Y,1LN>
M*=?!4AI2*I"A/P5SS^4,)_8!QZ4PCB(9*\ )8H1VZ"1A,NS)3C^RWD<^^3&M
M#V+I^@)[1M@:RJA ?&;?U>+&U 2.O$;)M&BZH*;'E,8/H_$XM-D(;K"4[R=.
MI'A$13)*IY922%)7*3*'Y\LHG%HJ<D*?1Y2?2C]^RE IT*0AT,0IYL>Q# -"
M$XH8XA'-/[ 3+0_" "P1D3)*)A[L%'@B=N'S\"?,=!38;( V6"EQR9@N\9XG
M4__ 2!"0!"$;24E@G!@I"& _CK1427#?<2,1>3MAA #W*&J34(:IB*2;BC!U
M7-__@9&P7,&-6.X3R!@K0PHFZ.,[7A+]?B,=!S8;H%&!V_64,-<])3"GS9>4
M[RN=67'#J0[Y.L\/N*GNI@+'LK5$(1V;LGL()H<S\?DL@ U3!_\)Q2*-S<)$
M)J'8 BW3K -:JTDK%(+\3C*RIFK 1=G(.0= !@AF].</0.CMUE:W&0@3&XB9
M4C(=F![(E"N#D?@[@ <3#M&]I:H/OC>X7XJ5K8J'>!Q1&JK.8F5 S%N=X0DH
M]:B-/!E.\'@R.H2C4ID<@W.OG*Q:2Q5-7*-R?EM6NY)04"4:,.)(43>02BN.
MA YZ"EVNV=J#1F)+):0> W(J9:PK0Q#9L:[DV<J0XG=<2QY,/)0^"C>3I/G1
M&G*>&\YGX'T0I9<$CDH"X<HD8I*3;B(\, X][.Z1:$CXU)O/PHCRWD>V1Q[Z
M+YDDU->$T@_&A\/]+/)EF,QG,3.8[X+IP?@H0YRV$!>A=KE.%/*]+ZG'2D Y
M[GR60D H5!)RTF%+G_(1_QYZ*M<)F)YP3]41<Z,$XD-'N9%(I:+<[1Y&ON.&
MZ7@[2V/H( (GC0F'RQ,GCX:[69H02#)! G"I9#;N'G)'[+T8[V%*V!*&4; 3
M9'BHSBD*&M<7&,\-"!#IZ:9<HUV?%,=T4#!J5^K$08 M C9U]W"_1_^ 9Z<Q
M-H$B*>I; LH&^\540LE#L412^$$,=B;+***/9$)F/8EUC/:0/8D[-/JPHH^E
MEMB!>C?* <J;;)49ZJ.VE6TH1,%"6;6L.=%H#K(+1U$: ;DR8W"2/,Z4XCY3
MCIS&_=PA4YYS2]6=[9X\!5QE];?YRAI*G0:-*4C>TCZN]$[G2@:G@G[FH(E3
MA&U\.D=8G_+!A0O#384>,<NI90PP&*M3$;BG\R ]1=N R=%D;D/-7B!CJB8A
MVM\N40,0$#](^P<TQ ^2_L&/VFDB-;C2&WF,6(@IO2W!G=6ZQ"GJWAEG49&B
M?8.+W>B(U1>^@\I#!0*UE*=G]4%!O";_C=(KN J4N+M/(9W+"9(W:"CI&(5:
MPX*ZL\G%T'<?G@0?:]KM?FV']'_NV>=#3\ZMBWA'[OY 8=7UVI^GI/U(@^VC
M7>!C&1J6:-]/1YZ#(6ZG4V*#KYTUGR&5TB1]WA$/HF[:2J/)YJX(':=4T?V=
M'VE9?<_Q8M[$=V7DCYLKE>"LF'#J(Y+<<7?E>G12[#91,CQL4*-NP ^D_\/=
M00 @"H]YD?&JR>YHTUVBE"25@#=L'GHX8?C#WM%4]SU7#5=/;\\Y&SF>VY%A
M1 7D:%[\1-CKG;9$4$75EOT<JGICC_!_S =X8\B']\4VK^[ 0?V!OK6+#9W%
M^:!^5$V8-T')[4_/?7I W8*.U)TVH(='3]5/G)Z?PN+0 ?S]E\O+KF^D*U*H
MR' T-WFVSF@;TPNHR2C;87F[I5N% '(GB/^:K2EK#T 3K2]T#C0@<#(0A8/&
MN;]>D%, UE;M>H-.[\Z"*01 MXN1K(9>!6MVFVRQZ87"5P.4Y41IUH#\^)U.
MXP"8A*=#$\>5!LSS#=WEV!'3P ':JNPF9[;F)A1\E=V*@EXMXG9E[+[ND?%&
M>U Q<SJ(AD(%($!ZQK(.PTN2"*>ZT$&;$0==-X^C,)JMWG[DQ$>T>;3UO=_)
M,B6"AP<\_/[HD[[K)V>4*N6_V[)[$;W+2!M^G826ZF\5U>FEN6Y&#:$)1?_>
MQ%Z$SL5UGPS.AE^O=69#BZ(D^I^QIDL"],5LF^&-%L$B):\K9"@MZ5X$52B0
MNFTVE>6T:SGJ]DCZN)MYU&Y-"^0#.'RX0!-"QZ'NOT_A?<9VLA!_R(ZN-#\C
M1,1@GOMB;TQQ:2OT(04/J!?/I?A<CG7$\SO7'-6&7_\_\E+NH7QGU)R"[(CJ
MFMZ]9T5;L)G]\!$[3 \8!S;9A];#S5FIO8.4&M0BB6\&M=[MG43'0CK%Z5[X
M!.FV$WF@3M<?CE-&\\_"W^M*?K-I;INI!R6Z@I[%V5B+[RT0#V$+*J%WT#C&
M#J1#GY;F/2DT*'^U[JB'$VVCZ64NMY'4@;#QKUI0HG*OP[FB!6SC+5,IK2B0
M<;R@G[Y<9B0.7/38NL<^ )Q-/J04QJ[Y<U$MF"J[;RKCT_&+U$7W(68_O?N<
M]4G;=095<K/"4E?&X8FPW2>B[J:IMOQ9YKIJFJK@RXW1"!&:@/%5!6;H;VB#
M\3O=Z_\"4$L#!!0    ( &F(6%)"T?$<[0D  $ :   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;.59:V_;.!;]*T0&&,P CE])FK1)"SA)'VF3QJ@S
M[8?%?J EVN)4$E62LI/]]7ON)27+>4TQV 46V"^)19'W>>ZYE_;)VMCO+E/*
MB]LB+]WKG<S[ZM5@X)),%=+U3:5*O%D86TB/1[L<N,HJF?*A(A^,A\,7@T+J
M<N?-":]-[9L34_M<EVIJA:N+0MJ[4Y6;]>N=T4ZS\$4O,T\+@S<GE5RJF?)_
M5%.+IT$K)=6%*ITVI;!J\7IG,GIUND_[><-7K=:N\UF0)W-COM/#1?IZ9T@&
MJ5PEGB1(_%NI,Y7G) AF_(@R=UJ5=+#[N9'^CGV'+W/IU)G)O^G49Z]WCG9$
MJA:RSOT7L_Z@HC\')"\QN>._8AWV'HQW1%([;XIX&!84N@S_Y6V,0^? T?")
M ^-X8,QV!T5LY;GT\LV)-6MA:3>DT0=VE4_#.%U24F;>XJW&.?_FS!2%]HBR
M%[),Q9DIO2Z7JDRT<J_$I5K*7$RM291*L>Y.!AY*Z>@@B0I.@X+Q$PI&8W$%
MH9D3;\M4I=L"!K"V-7G<F'PZ?E;BN4KZ8F_4$^/A>/B,O+TV!'LL;^\O0^ >
MQD"<:Y?DQM56B7],YLY;X.B?SVC=;[7NL];]_U[@_Z,*Q#>%(DN,3;%=*.<U
M(*^$60@IX+\3ZTR5PF<J/&DG$H/23)55J:BLF<MYKEA3.(NGOOB6X34)T'*N
M<^WOZ-S69L\[L"J%E3"/%#;*TZ"*MI5&R,+4\$4'(\)FG"L,SN?ZN\KO\ *F
MR_).&!(KRKJ8XU_W1$^L6S=I$16EB[KHJFQ-M2KG%6]X:Y)+79 PF=!Q628*
MM>HS,9F=B?V#8>\></IB MO35!/[(-:Z#!1*7#2'!07VR)74.<6"[9+.*?A+
MRBKCD3B-8X_:8VHK0,N4.&SP>AG$4J2L6FF(X2V-5ZXOOM R]CCR8.L=1?PQ
M=8FI\U30%HL7B*XN*F"?#UOEP'I\%.W!LG8HN2[%I+(Z%R^I.$?X>W9WKFY[
M?&:=&4C9->L2/KAZ#NQHM($>I4.!F8$[,956+JVL,G'Q523*>KW02?#ML_$:
M$;]4'@:)A36%F.2JF.M$O,\!J%Q\,'E \FPB?OOUEZ/Q>'@<M_#3Z/AWX;RD
M%!%2?'L^DVP0JH7""PA-/I]/FK2_.Y_TA%/J.QV3%<"[@BZ\+&19+Q 0, ,<
M7"Q@%5;1;_(>)X(^P27  0%,Q$I9;F0(V=NOUU=O+R>__C(ZW#]&.6AC&VWJ
MMM(AG%QY!.4%OR /1H?'P\-#44E*UO'6\M%17.YUEP^.QNTR=/S1G_418GI&
M./MB-.P-]X>]H\-Q&Z_.85H.AYOH!;^ !;5L8X@#3L5]KB>43#(R>9UI? B(
M=>3<F:R\=B8/3D,257V)4.JT)^I247$D*I0"M Q@[IH!6!J/<J'JL51;J9C?
MB4Y68:@+^4)FTCKQC,(K>2?&>UL@% N=,\90>15*F6AQB7^NQ4&O!<0TDZC4
M1-6 G,SAUJ5/^\'[)[=<E.A*D6HXT&@<'HGWH(7:>K&@).-=NXPHG2,^:TGX
MH=*WOAM5LI>>L>U1=XE]O?8UQ;<)#I,]$6C,PJ,(:6CW(4@X=!]KE/JX+>#&
MWQ@]XABW!M1)2$*$K"P3HVMK)%58B)1 1I2FW-TRD([&U!//2,9'U^00#&HK
M 59T @!&7=9+3$1B]/+1S+:V0=S]D&V9VB&JPS!%A*H)B0*W<T]K$S'#()S6
MG(QK>D=PE/ D91Z#V;2S!Y>(F."5#-*(&T2*Z<&@]$&G-:4&?)DDM27YS&DK
MQ2UJW#6#QHW0!V_!K5T9:TEA#EBZDA:JQ^'DJ!>S"I,)^Z/@URC6D%4TGD=4
M640PE7>ALR] O+O>[#I]NTN+<S0O.$2,SU&:J<H'$T<OMH/^MUG[LJY@"U54
MRSJ\]#A'A]W_+PS]*/W^S]!NFZ9'2/<ICD68KA-O&.1MV;:^1$;:IH?(RJRM
M'P%PO\0A%M> B,Q1D/N DW""*J4A)(,*^K-.EV'21[2Z),0SYGVBXA#"6(BA
M@6O#1EON:EYKF&<[2-L4":L_ I.8>IJ*[XMWVS2A:=?2P(:^N&DXJ17G-E3$
M-$5LX#:$L1%C0@]L:( !Q,4N[E4Y55MH/%LAW0L'F0.:_.V-FOR%&3J4O\^L
M F?I%=BT3;MK0A/[X>RI;OC96!K5RZVV>)UI(WA*SF2^H!6GX!6,O<#("Q!@
MYYR&VIMG)6C78?66S3_6J4[(\:DL5<Z!PBBK=]OCEYMYNN&GC].KRY:>,L "
M'4HO:8[EVP=?.TQ)'TSM&(4A')(&\5"3F43LYPI7J%3169[D2=)/J+\ZWVAG
MZ534AM1?E!CL7XG/,MXQIAC,$ZOYM;BN--W@-@)#P+CX8GL.^0%XNIDS2<U0
MY59,7YI 0+@FI&J!MB>Y?/B&Q9YSS\)YXL)X5]/(TTJG-<KK7U2%1,(PKZMZ
M$Q"9KN@RE;:57[-A'6J-&&MM[(?+ZI\*\:+RC.5E)6X^+>@Z+H6) ]7+EZ>5
M7AJ+1&'."0[%&."J@U*%\(M0/#SNA8D#=@3D3[$?A4_#7B]FEIJR3'[4V@:6
M#-:WI,=M/51#<*-27H<0_'8Q_4)B=\5P-!RC5IMG>CQB_9N5_<.CW[ELPIQ1
MH6J1%+KMJ379=W^X?]G;QW"PMW_P<+9_<4S+6[/]L:#[GR<KX^ZWMQ7 Q UQ
M=N<P!&QN <%O8BJ^R\'G][F\-3.TY^P3?0TA3K7)S9(G8S'K3RA6=%,F"Z*)
M-TP^'.*J4OAX:B3NY(VMTYO):8OYB(*NAW3PQLH4@XW]+JX7&#@4)VXS4C4=
MX9V:VT"Y[805=.EF@$XC%4;,=]K"$C@I4T[H5FYZ8HYQ3MV"V0/D #(B7ZNX
M\JAY>K-1L)'?E7)('7\KP2WT@JE_%=4V6N]GG]I@1:BMS0.@C8>[P^'1R^$&
M6+SR\L7XIX#59U@=]0[VAKW1X>@Q6-%RG%FB/0]@]4$O,XR#*U!O!V%0\X6^
M$IGK4A(XS"TB/K7&*\3P.>"%>NS""\#Y><#P?0>1#:,)QWSVJ9UB"L/91"9)
M?&KE6FP%LLL F']+'Z;ZR!F$DM#B+^[30601LHGT 4<)PY &IW*AT_A=#)H[
M0A>'(E#'YA//@9A'E2TTM9+PG5'GR[RY6H3.%"."0)M\%<9'XCKM7$T=])XE
MC>=_&IK=-OYO%#U!40V2NO,><!+]Y?&C;"]-3TOOWHGVF_!-:(+C+Z]"E*,7
MC%0TIC@</2/U?O5RPC@"V[>P43N4W31QH^^IU(\:@<_OVAS_+>7="+5S5A.B
M_F-?* \ZW^H7RB[YMXLX4H8O^-O5]N>12?A58+,]_+:"RR+F;2=RM<#18?_P
M8$?8\'M%>/"FXM\(YL9[4_#'3*%:+&W ^X5!+<8'4M#^:/3FWU!+ P04
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M3@PA:MBRQ8P%%TD0MCY:;.T!SP#SB#@KV@*0T23!,+D;,R!%E;>]<\=8%02
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M.-2P5V"]NZSFG>+9U"MXV@'3:&^27Z;7T^3[BXLK/G4!1"LPI%.$Z2N8$8>
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MA\?SSQL8JX8SJO."5,YEUMPD".[;K/ P,!0W37YS\G?B/BUQK?3*CK496A#
M]Y>2>!,I8DVRJ6Y=71)MK]RB31H'+!@8D ,"-G2_J9&_@VP%/('WAL]N.X+Y
MNBM7O+ E" V6%*Q%K0#%FKRE1:)I1!*E 9+G1=(K_0UZ^4E(OX[./&\[B],U
M;EVW#=,A;G[G5L#E"F 3-'7RKFRZFGCPI6P$:3#WWZ)HEF,DP0:;SQ9%#@Q[
ME6RZ?.402Y!8B@SM)@3I"OZM@T2D;0!6R['PVL)NL[5K6;4H<M@F@'L_19X
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MD4Z YY1MX%Y;![)Y;,3>62&5^*.B 0'BA#\#/+!'B!)T\X %6%NMH3,Y#"O
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M$4N-5@BHT&H@(H;5'6VPWM!JMK@\ 0]#<H6:>D,N[%OGS6PFB;UX9$G=9 5
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MQRSTAE7"O"3M!NTOK[^OX7!J)\ZI(6]&PQ*).O;_>6=V8)M3/RFR!!_7ZC-
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M=P[[W%BT(_'YK%[>2&@K.+7$MTD$\71^:H++)K!/+,^Z(/#AE]-9>'8\TIR
M7L(($SU]:-0#HZ3)TQ?3%_YMJ71@/S3Y?,2W QM$<=.PBY 8SZK:*8^XN/X%
ML>_EY/0L-3G.[TR.\R2YY)7]0/'S%+6)_\Q =0,.JS1/"/F7 N)@^<2C"/80
M1,R2$[1X@)+SBJ+M+%?AE$$^HAU- K#:9P5P[EVV9Q^!#*[Z(H58E#* $US
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MKS?&MTCW75+K&3:3Z(--\!$A'2+VE;_]RF?@BJE$6!_N#TU^JH)GJM<#^.%
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M# \^)&HMO(>+7>@2#/3$&]+H99NC8#17H/X3C-YFE8L$#A4VH.8UCE.YM28
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M-_FN!AT0JX?D$GH-V8M0,$^^#\C-7/3 &D7//)_/@IXI,HRIQ/"RVHZ)WNV
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M9<5B8>1B*)5]I=F') ?9<J-Z9E>BE!<C;P]S+T>7G_2CJ-WCMMYXF.R\Z3&
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M%Z(!LY*MI@U]>0UTUEC/4/7G?6R)1CNH-[;*,?#._ XROQ@Q&J/0C].XS^/
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M0Q*-F.J>P;L/(U?VZ7DF#>JK'2X%"K:B#5B?2VFV'\2@_V?$Y;\!4$L#!!0
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M4(D >'5MS]A)/<U#.F[L- ^=/D D)*(A 04 +:=?WP4HRT[C:U^$!;A[]G8
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MN19\4?P;>8BU>8A5/<3N-:(H\UB\D"7/XRR2CPM9\50%P>H%_ZN,5RR!YT,
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M=V]R:W-H965T<R]S:&5E=#,Q+GAM;*V8;6_:.A3'OXH5[4JMM#5Q$B"I *E
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MY0O;/N*L0RVM%[%8F+]@F]DZ%H@V0K(D@U4$":'I+_J9#<0!H'3* 3<#W&/
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M<4?PFO (H+YO&).7EZB#[%9I^#]02P,$%     @ :8A84CB]^99X!   ^A,
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M;13R;=LY1GTUH-S ;OCU9$*%@7^,FAB\=]S /49-VR@88#<KJD/8LP&F*S=
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M&W;=4/Q4W3EW7.D;;/5XU%\E(,P _7[/N7IIF&ML^YVS_@=02P,$%     @
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MFRRKKP750(NE.Z$_"&W.^^YR 70*TCY@[L^$T$\#>^AOOMF,_P=02P,$%
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MCQ!V1VB)\.F41%B@^Z3)*]CD%;P.F<NIX,O"<.;AY@BAB\!$F_2BMP;F+%*
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M=,+&,"JN9S$"NXH);8"5G]=DUH\; 4A]QZMNC9Z$AMZD.1? 7<^3FB.&SL6
M[E>'-U5J+F%(AG+"G.QK$,F!3ICY'N+O55G7W8/9JF3:H*3-4@^=6H8B&/?N
MG"2/.1DPF5\E/]-\D0LP^D"Z:+]HY6/[]?H@5NE^D25-6;U\0'])\L>_BIUP
M+G9%4X$;NDHS\3TL"[Y<Z9N4MW-]+5^23'VXW$[&DA(P-TM3DEF=,/-=A3VN
MZL/U6.BKP$ZDAXV*U;[OGL':'F%1-,OGCFX^W3SH]7/W=-,)A"^?$GN55/=I
M4:.,WXFA^%/[.[]J^=S5Y9NF?.P>77I;-DV9=R_G/)GQJ@T0?[\KRV;]ICW
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MS\*\QU!: [.^%D(_#VP _\);_ 902P,$%     @ :8A84B7BDA(4 @  4P0
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MQ=U<+QJN%Z_D6G,TH$KKT#WF7<5O[L>=D"=@2GN2+PK;<AUZL7ZX1@;9&7O
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MCP;V<JU/;T28 #V_Y%SM!^9\4)T'Q_\!4$L#!!0    ( &F(6%)7_%H,)0,
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M%:3SA5 ,I^O"T3:MR;P=TDFQ&H59[58LUZ7=.N'1-?6IALE,B,BH(C(*$\^
M>F?=<MF]Y#FK%M]L)3B0XHKG*,QS^W< 9[1=/F#M*;W1C#R6&V#0#A0O4I@7
M-ZIZ?3=.RW^5V(WC9&-()46!%&:ILU62Y.YM--S<-!4ZWTXK41LM ;9=%50&
M;P\E!#S5B@TIS(;[=@IGM%W4''=%09L*>X* *2ID,!7.MG+:6GTPU9XQ3>EC
M80B4F&([]L[UC/S\5OABL2PJMYG<0^RCZT@ Z0Y3%,4.4N<PQ0NLYRIAM;B7
MI"=AH[K%0K[[FN^IYZ*,::J=+MLW+A%ZRIQ:&0D(J?!612SLJ)CF"J%+,<43
M#.:)NRSV?E:I>Y8$CX]YGA C+Y3X$#R\MMA X@;R*C3I3YY[%L=4%B,&E#XS
MQ1ML>'VT?W3__AQ#VB@.8-9!HELA.H,1O3.ZNX*G#=4=A153&,U@C'Z7H&[#
M->X(:J[ E\/@>^6^!(O50F8YLNZ;QZ%?-SK6RFT&?'\@]RSHV#UQS!5*\WU0
M>K\V,%=HS ^"QERA,7_GKM.4MW&XISO)%1SS]^XZ37D[5[<HA=(SWKC#A7%P
MG][.925SN[=C,(,PUJ&10E,.H^D[]W:FU7+-W@YA]IC9'8HJH.5PLOVFYLZT
M1WA?<X<KN.8P7!^T')MRS<TNA5HD7&$\'WBW^[;''Z:\C?/4P#8E5L<3!0KL
MS9Y,>[]R:UJ)W3 :,Z#JVU0@;L(@_CZ/%4RK59JGAF(^IAVGQE1P;\+]H1TN
MY:9FNW7C@#!L*E(P^TBA6=WGAZ !.7&9F&DJ/UTB,37;=($9 _54=&'"=-'1
MUQQ<E%Z8;?+ 5-=3FYGM)-_BT"84R9@[=X2T=M2T=DRHM6,V'OX90"J'N8,W
M-0V=[5Y>9>#V2+#I9RHJ,F&VN*T?X/#1PZ[ISA>SW?TAE.E:^-?5T(T*E3,(
M[TU%5"9,5)N=R[3,,SNL_L74]'\,:FMUUK6*"-3M-A5'F3!'??*\I.0FE0LD
M#6=TJM_N_^B:U]=FF[N@)I>EJ,N"J>M[G%^ 1%N/_@RXY+<TSR1!*&$IYK)@
MYKJMGYX*JH3*#U*OXZ;@VM(\9@1>#%N*HBR8HOHQM^A@:GN 5OL!(NQ A]Q2
ME&7!E+5S>28_OUO=IQ+8<CB;/K4\NJF(XB2+':)BLQ1?6#!?O G./EMM&B%@
M<F4I&K%@&MD%HCY;FCL!!ZK:K,:CHS#>[PD[GZTVTH,**>RV>KK\>\3FK@U>
M2Z&RY1PB0&V%GC:,GGLV>"]M#7AVV-Y6N&GW7"6_O1=V:>L>QNQ03.&H#>/H
M01N\ESV+]S=X;86\]OLC[ZX-7EO!KWT0^+45_-HP_.X=W7QHH]=6B&OWW,F^
M1W!K@+@KN!4$VS $OWNC][)GP=Y&K]UX<!]&ZVM9[R1H^K(4TJ32?N_YN*&M
M4-H^"$H["J6='I3>_S[?T3SZ8T!IG*/@VH'A>N_K9:>=\1YW*#5I?.LT_\+Z
ME9L\RJ0)A>)!SLU[BR.4E-\!+]]D\;+X(NI]G&7QHG@Y%Z[4+1\@/W^(I=NK
M-_EW6^MOXI_^'U!+ P04    " !IB%A26_-33A8#  #R!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,"YX;6R-55MOVC 4_BM6M(=6:IM[ A,@;735)G43
M6MOMV80#6'/LU':@W:_?L9-F*:2H/!!?SN7[ON-C3_92_=%; $.>2B[TU-L:
M4WWT?5ULH:3Z2E8@<&<M54D-3M7&UY4"NG).)?>C(,C\DC+AS29N;:%F$UD;
MS@0L%-%U65+U_!FXW$^]T'M9^,DV6V,7_-FDHANX _-0+13._"[*BI4@-)."
M*%A/O4_AQWEN[9W!+P9[W1L3RV0IY1\[^;::>H$%!!P*8R-0_.Q@#IS;0 CC
ML8WI=2FM8W_\$OW&<4<N2ZIA+OEOMC+;J3?RR K6M.;FI]Q_A99/:N,5DFOW
M3_:M;>"1HM9&EJTS(BB9:+[TJ=6AYQ F;SA$K4/T7H>X=8@=T0:9HW5-#9U-
ME-P39:TQFATX;9PWLF'"5O'.*-QEZ&=F<REVH Q;<B!W()A4Y(<TH,DE^?)8
M,_-,J%B16T:7C-O97):5%"",)G)-;IB@HF!B0SXI1<4&2K=S=@V&,J[/,4H_
MP4ODA[MK<O;AG'P@3)#[K:PU)M$3WR A"\LO6O"?&_#1&^"OH;@B<7A!HB *
M!MSG[W8/QZ_=?92QTS+JM(Q<O/B-> V]!7VF2/:"S&NE4 XGX \IBF9Z(D_<
MY8E=GN2-/ O%4/2*<D)+66,&K 0J$+?Z8J]J@TFQ+$.2-K%S%]OV^&Z6C--H
MA/KM^M(=F^5I@+_.[!7TI(.>G(3^(! RGH:_L"(KI@L'_PSI\-KB)75_'Y:&
M,*UK/&) "JG-^1"?)F'6 WJ91N-1?L!GP"P,PR )APFE':'T)*%[:; .7(K-
MI0%5DLJBQ^L)2R)<-:KF. PA3X\@)4D4C>,#Y,=F63P:I^-AX%D'/#L)?$Z5
M>K:2[RBOP>*%IM^+EPY_?:R&"&3'!$;Q^%#Y8ZLP")'H,/Z\PY^?Q']#F?J/
MO>C=,KJYQL1A,Y"S6]@!)]'@,<J/VR++@O2P&,=F69+WNZ<AX_=N9/L:?J=J
MPX0F'-;H&%SE6%35O##-Q,C*7=)+:?#*=\,M/LJ@K 'NKR72:2?VWN^>^=D_
M4$L#!!0    ( &F(6%(_0&%IP04   H@   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;+V9VV[;.!"&7X4P>M$"32V>9*EP#.2PAP);H&C:[<5B+QB;
MCH5*HDM12;M/OY2LB+9X2!P(1H'&LH?#7T/.IQEJ_B#D]VK#N0(_B[RLSB<;
MI;;OI]-JN>$%J]Z)+2_U+VLA"Z;TI;R;5EO)V:H=5.13%$7QM&!9.5G,V^\^
MR<5<U"K/2OY)@JHN"B9_7?)</)Q/X.3QB\_9W48U7TP7\RV[XS=<?=U^DOIJ
MVGM9904OJTR40/+U^>0"OK^BM!G06OR=\8=J[S-H;N56B._-Q8?5^21J%/&<
M+U7C@ND_]_R*YWGC2>OXT3F=]',V _<_/WK_O;UY?3.WK.)7(O^6K=3F?)),
MP(JO69VKS^+A3][=4"MP*?*J_1\\=+;1!"SK2HFB&ZP5%%FY^\M^=H'8&P")
M9P#J!J#G#L#= -S>Z$Y9>UO73+'%7(H'(!MK[:WYT,:F':WO)BN;9;Q14O^:
MZ7%J<<ER5BXYN&GWS,5R*>I2@6NN6)97X Q\*.]YI?2Z*7#%%+\3,N,5>-T9
MO-$67V^NP>M7;\ KD)7@RT;4%2M7U7RJM+IFCNFR4W*Y4X(\2J[Y\AW \"U
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MTL00C(S5^A,'P^(AP1Q&Q%>U$,,O,EKS3QR=/<3)L+-VFB74DS?$@)&,<P)
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M,YI(78*H?R>ZHEFF*RD=_]1%@^:<.O%Z^ZWZYZIYU<R&"+IBV=_I5AX6P30
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MH%XLL(L%9Q:SJT"]R@5:"2X[BUO&&]IX1FWN9WA, CQQ[]N,=UAYGC^HK?;
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MW3#_&#(U!%P;/)J]F#KA<[45JD0(L Q_;&-1C3/P[9,J Q\E3X4+/5CC$A_
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MI]7EFC.%PM) /5_EN7R^*2MHO@M9_ =02P,$%     @ :8A84GC6KBS^ @
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MLEOMTOT<3KK.VTGN?+B7)67]4W)#SW?VS&P*"SIAL&=G4Y@7=(,]0^U:N\J
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M/[Z2?4:ZI++C%F"V!W6Z*=GKQU<[PN?@SU^E2' O:)+]95.IUOA JW5CDJV
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MXW)/9WF01OMB'^5]E*;1MGB[-L'*Q/D)V?</490>#W(%IYVUM_\'4$L#!!0
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M_G)_],C]>.O3]VWWH[ %RX#"G#&#@PG?AFU;61N0J4,W6!GBWA*F)7=_M/X
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MH?I<\.K06-U(MBL']U<FU4&@O-RJ@S;A!4 ]7S,FCS?%!LW1??(?4$L#!!0
M   ( &F(6%(2==TQQP4  &D7   9    >&PO=V]R:W-H965T<R]S:&5E=#8X
M+GAM;*5876_;-A3]*X0Q#"V05J*^U3D&FCAIG;IKD+3=P[ 'VJ9MKI+HD;2=
M_ON1DBP[U)5BH"^)))]S=8]XO\CAGHL?<DVI0D]Y5LC+P5JIS3O'D?,US8E\
MRS>TT+\LN<B)TK=BY<B-H&11DO+,\5PW<G+"BL%H6#Z[%Z,AWZJ,%?1>(+G-
M<R)^7M&,[R\'>'!X\,!6:V4>.*/AAJSH(U7?-O="WSF-E07+:2$9+Y"@R\O!
M>_QNBE-#*!'?&=W+DVMDI,PX_V%N)HO+@6L\HAF=*V."Z'\[>DVSS%C2?OQ7
M&QTT[S3$T^N#]=M2O!8S(Y)>\^POME#KRT$R0 NZ)-M,/?#]1UH+"HV].<]D
M^1?M:ZP[0/.M5#ROR=J#G!75?_)4?X@3@K8#$[R:X-F$H(/@UP3_7$)0$X)S
M"6%-",\E1#4A.I<0UX3X7$)2$Y)S"6E-2&U"U+5P[F'EW'/?@9O%;JUV)^6P
MW+A<;Z<*K#(JQT21T5#P/1(&K^V9BS*T2[X.1E:8+'Q40O_*-$^-)L6<YQ1]
M)4]4HC?H@<YY,6<9(V6.\"4Z M#-D\Y]2=&K*UK0)5.OT:LQ581E\K6F?GL<
MHU>_O4:_(5:@KVN^E:18R*&CM)?F7<Z\]NBJ\LCK\,A'GWFAUA+=% NZ /AW
M_7SL]1AP].=IOI%W^$977J_%,9V_13Z^0)[KN8!#U_WT1[K1=+>3/NZGWVV+
M7OI-/_TS$;W.WYZM':< _</9VD'ZQ[.U@_3)V=I!^MVOK?NG7_MTT_/I24\4
M^TVF^Z4]_\5,;R?R!;K6*<.*+2M6Z,N&BC+]Y<5I]ENEX>_W,ZF$;J+_]/@6
M-+X%I6]!AV_&/E%H21?ZU1F2BJBMXN(GTHY0:.$J<W%IS@P:N]$;S\/^T-F=
MKD\;A:/82X/GL&D;YD>!ZS:H9Y+"1E+8*^E1:Z 7J-"#E*ZB!V6SZH-#DBIS
MT:DD'(21):F-\H+( DW;(!SY(:PG:O1$O7JJ %G10B$= C,=!XI1J+S?16TA
M7IQ8.MH@;$&F;4@:)+"(N!$1]R_*F@CZQDQM"Z0#VV1!&<V0C+@MPX\\2P8
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MJ.GU&Y]7P\2W\Q" A;$M&C"%@P[-QP$"]T\0QRS<D6Q;C2@DR_B>Z*0$%06
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M&:^:RYV9@$%: _-\(X1^7=@9JY^I%_\#4$L#!!0    ( &F(6%+F?Q G0@,
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M"X#^?2F$VCX4#IK7?5?_ E!+ P04    " !IB%A2,DU'.FH"   H#@  #0
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MR++,\TO?-E4WFB^V"\"WB]>__ -02P,$%     @ :8A84K % +TV @  '"H
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X
M[HND%6?4DTRC;  YY8=B&T312K+[MIR!?5 />A)Q1JA 7'XQ^(2 QY=\:,=]
M=RJ[?5\6G\?#J:RJW3CVO^JZK'?YV):[KL^G\Y%--QS;\;P<MG7?KM_;;:YE
MN8QZN)U1/3W>SER\?O7Y?R9VF\U^G7]WZS_'?!K_,;C^Z(;WLLMYK!:O[;#-
MXZJJ/P_7W:6^;-+=>7*U>'Y;5</S6ZKJN8,$@F3^((4@G3_((,CF#W((\OF#
M H)B_J &@IKY@^XAZ'[^H <(>I@_*"U1QB5!T@1K JT3<IT(O$X(=B(0.R'9
MB<#LA&@G K43LIT(W$X(=R*0.R'=B<#NA'@G KT%]18"O07U%@*]9?*P3:"W
MH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>BWDJ@MZ+>2J"W
MHMY*H+=.7I80Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H
M;:BW$>AMJ+<1Z&VHMQ'H;9.7W01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$
M>COJ[01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'K[Y&,E@=Z.>CN!WHYZ.X'>CGH[
M@=Z.>CN!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81 [T"]
M@T#O0+V#0.] O8- [P;U;@CT;E#OYB?U+N/7(9=KS_<:K_^35(_G<_/U\I?E
M]\[)3;C@7-]6E*>_4$L#!!0    ( &F(6%+ART;(_0$  #TI   3    6T-O
M;G1E;G1?5'EP97-=+GAM;,W:34[#,! %X*M4V:+&]6\!43; %EAP 9-,VZA)
M;-D&RNUQ4D "004J$F_3J+4];^*1OE7/[IX]Q<FV:_NX*-8I^5/&8K6FSL;2
M>>KSRM*%SJ;\-:R8M]7&KHB)V<RPRO6)^C1-0XWB_.R2EO:A39.K;?XY-JY?
M%(':6$PN=AN'K$5AO6^;RJ:\SA[[^E/*]#6AS"?'/7'=^'B4-Q3LRX1AY?N
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M4$L! A0#%     @ :8A84M2EW"O0 @  :0D  !@              ("!;A4
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &F(6%)=U@-<
MN 8  #,=   8              " @708  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !IB%A2H?F:&R,#  !H"   &
M@(%B'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :8A8
M4KF']E%$"0  *R\  !@              ("!NR(  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( &F(6%(:+&713@P  *\Y   8
M      " @34L  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !IB%A2/QJ?_T\H  !UA0  &               @(&Y.   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :8A84G)W5('&!@  +Q   !@
M             ("!/F$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( &F(6%*DVLE#NP,  (,(   9              " @3IH  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :8A84C:PW 80%
MWD8  !D              ("!+&P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !IB%A2'J+2QK4-   1*   &0              @(%S
M@   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &F(6%++
M^SG9ZP@  $PJ   9              " @5^.  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ :8A84O6J$WP@$P  ^4D  !D
M     ("!@9<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F(6%*8W@UG;00  +<*   9              "
M@:;9  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :8A8
M4D,=SR#V-@  ^<(  !D              ("!2MX  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !IB%A2?\>38AH'   I$0  &0
M        @(%W%0$ >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( &F(6%+@'"DT@0<  'L<   9              " @<@< 0!X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ :8A84L[:NUH3"P  "B
M !D              ("!@"0! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !IB%A27P$O:WT#  "5"@  &0              @('*+P$
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &F(6%*O:FVK
M' ,  )P&   9              " @7XS 0!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ :8A84J79:&BQ"   F!@  !D
M ("!T38! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !I
MB%A2DZUBW*H'  "C$P  &0              @(&Y/P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &F(6%+JLNM*F@8  "L0   9
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M970S,BYX;6Q02P$"% ,4    " !IB%A2LH[^I3<$  !A$@  &0
M    @(&Q9P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M &F(6%(XO?F6> 0  /H3   9              " @1]L 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ :8A84G(+PA>Y!   %Q(  !D
M             ("!SG ! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !IB%A2=AJ&418$  !F$@  &0              @(&^=0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &F(6%(0)+(A4@,
M /,*   9              " @0MZ 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ :8A84BSCDZ7A"0  9SP  !D              ("!
ME'T! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !IB%A2
M.Z^(W,(#  #S#   &0              @(&LAP$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &F(6%+BK0'4J@,  +\1   9
M      " @:6+ 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ :8A84O@4R?G9 @  CP<  !D              ("!AH\! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !IB%A2)VPN)(@%   3&@
M&0              @(&6D@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( &F(6%+9MTU+, H   I7   9              " @568 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ :8A84CF?E0,N
M P  [0D  !D              ("!O*(! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !IB%A2)>*2$A0"  !3!   &0
M@($AI@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &F(
M6%+-"?EA8 0  ((0   9              " @6RH 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ :8A84EK GHWP @  &PH  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( &F(6%)I;;[O]P(  '((   9
M  " @27( 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M:8A84G9P8**B @  J@<  !D              ("!4\L! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !IB%A2]*V.4T4$  !#%0  &0
M            @($LS@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( &F(6%)1WU?WRP,   X/   9              " @:C2 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :8A84@,/#M.9!
MV!,  !D              ("!JM8! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " !IB%A2PTFL?3$#   ?"@  &0              @(%Z
MVP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &F(6%*Y
M-9GO)@8  ",B   9              " @>+> 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ :8A84GC6KBS^ @  E D  !D
M     ("!/^4! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M" !IB%A2$$Z/F9T&  #E'0  &0              @(%TZ $ >&PO=V]R:W-H
M965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( &F(6%)HLR6]I 4  +\9   9
M              " @4CO 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L!
M A0#%     @ :8A84AD0;IED"   93L  !D              ("!(_4! 'AL
M+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !IB%A2OKK$;40#
M  #"#   &0              @(&^_0$ >&PO=V]R:W-H965T<R]S:&5E=#8S
M+GAM;%!+ 0(4 Q0    ( &F(6%*PUCX HP,  *T,   9              "
M@3D! @!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ :8A8
M4G!H*!:, @  6P8  !D              ("!$P4" 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " !IB%A28YN#(?,#  #I#@  &0
M        @('6!P( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( &F(6%+XD-T4_ ,  ,8/   9              " @0 , @!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ :8A84A)UW3''!0  :1<
M !D              ("!,Q " 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " !IB%A25*<.L6<#  !?"P  &0              @($Q%@(
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &F(6%+F?Q G
M0@,  )0)   9              " @<\9 @!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ :8A84BQ$WP9-!@  ^AL  !D
M ("!2!T" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !I
MB%A2,DU'.FH"   H#@  #0              @ ',(P( >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( &F(6%*7BKL<P    !,"   +              "  6$F
M @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &F(6%(/5V=3?04  $ O   /
M          "  4HG @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !IB%A2
ML 4 O38"   <*@  &@              @ 'T+ ( >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !IB%A2X<M&R/T!   ]*0  $P
M        @ %B+P( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5
(  "0,0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>440</ContextCount>
  <ElementCount>613</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>136</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Sale of Vernalis R&amp;D and Promacta License</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense</Role>
      <ShortName>Sale of Vernalis R&amp;D and Promacta License</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Short-term Investments: Investment in Viking</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking</Role>
      <ShortName>Short-term Investments: Investment in Viking</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2145109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2153110 - Disclosure - Commitment and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2155111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2162112 - Disclosure - Summary of Unaudited Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332305 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2346307 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2356308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2363309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails</Role>
      <ShortName>Sale of Vernalis R&amp;D and Promacta License - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails</Role>
      <ShortName>Short-term Investments: Investment in Viking - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails</Role>
      <ShortName>Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Acquisitions - Allocation of Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails</Role>
      <ShortName>Acquisitions - Allocation of Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Operating and Finance Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430419 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Convertible Senior Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails</Role>
      <ShortName>Convertible Senior Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails</Role>
      <ShortName>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Investment Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2441426 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2443428 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2444429 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2449432 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2450433 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Breakdown of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451434 - Disclosure - Stockholders' Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452435 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454436 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2457437 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458438 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2459439 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460440 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461441 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="lgnd-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2464442 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lgnd-20201231.htm">lgnd-20201231.htm</File>
    <File>exhibit101_ligand-2002stoc.htm</File>
    <File>exhibit1067_bondhedgexbarc.htm</File>
    <File>exhibit1068.htm</File>
    <File>exhibit43_ligand-descripti.htm</File>
    <File>lgnd-20201231.xsd</File>
    <File>lgnd-20201231_cal.xml</File>
    <File>lgnd-20201231_def.xml</File>
    <File>lgnd-20201231_lab.xml</File>
    <File>lgnd-20201231_pre.xml</File>
    <File>lgnd_123120xexhibit211.htm</File>
    <File>lgnd_123120xexhibit231.htm</File>
    <File>lgnd_123120xexhibit311.htm</File>
    <File>lgnd_123120xexhibit312.htm</File>
    <File>lgnd_123120xexhibit321.htm</File>
    <File>ligand-ex1069xbondhedgeame.htm</File>
    <File>ligandcydexex1072_gileadsu.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lgnd-20201231_g1.jpg</File>
    <File>lgnd-20201231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lgnd-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 38,
   "contextCount": 440,
   "dts": {
    "calculationLink": {
     "local": [
      "lgnd-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lgnd-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 854,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 15
   },
   "keyCustom": 86,
   "keyStandard": 527,
   "memberCustom": 68,
   "memberStandard": 58,
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.ligand.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Short-term Investments: Investment in Viking",
     "role": "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking",
     "shortName": "Short-term Investments: Investment in Viking",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Acquisitions",
     "role": "http://www.ligand.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Fair Value Measurement",
     "role": "http://www.ligand.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Leases",
     "role": "http://www.ligand.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Convertible Senior Notes",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Balance Sheet Account Details",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145109 - Disclosure - Stockholders' Equity",
     "role": "http://www.ligand.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153110 - Disclosure - Commitment and Contingencies: Legal Proceedings",
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings",
     "shortName": "Commitment and Contingencies: Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155111 - Disclosure - Income Taxes",
     "role": "http://www.ligand.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162112 - Disclosure - Summary of Unaudited Quarterly Financial Information",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation",
     "shortName": "Summary of Unaudited Quarterly Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.ligand.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.ligand.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Leases (Tables)",
     "role": "http://www.ligand.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332305 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Balance Sheet Account Details (Tables)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346307 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.ligand.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.ligand.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables",
     "shortName": "Summary of Unaudited Quarterly Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i3c73811c3a6b413583f19b4f18914422_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "lgnd:CommercialLicenseRightsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i1b989251dff94234ab86b62cbfd1d634_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "lgnd:CommercialLicenseRightsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i1b989251dff94234ab86b62cbfd1d634_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ib905672f26f34c6ca6ac51ce2c25db59_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "id7cb20656a8d498d86e9974aeb28d3ba_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Sale of Vernalis R&D and Promacta License - Narrative (Details)",
     "role": "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails",
     "shortName": "Sale of Vernalis R&D and Promacta License - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i83a3e814db004c61ba61a5d521fde419_D20201202-20201202",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Short-term Investments: Investment in Viking - Narrative (Details)",
     "role": "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails",
     "shortName": "Short-term Investments: Investment in Viking - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i389fb553398f4fb5809d534052c56744_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ic665f012e5c54711abae64ce09f53a48_D20180101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ic665f012e5c54711abae64ce09f53a48_D20180101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i002a7e38519e40f2946a2312278fcbbf_I20201001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostDirectMaterial",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i002a7e38519e40f2946a2312278fcbbf_I20201001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
     "shortName": "Acquisitions - Intangibles Acquired and Weighted Average Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i002a7e38519e40f2946a2312278fcbbf_I20201001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Acquisitions - Pro Forma Financial Information (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
     "shortName": "Acquisitions - Pro Forma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if3e368fbc8e24a1d98a6992d87fcf1b1_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Acquisitions - Allocation of Consideration (Details)",
     "role": "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
     "shortName": "Acquisitions - Allocation of Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "icd00c2f9ab0540a7b3763c32cb278c0b_I20200909",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i31e71b0d7d0746ed9890d7a526a3c3cd_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:PaymentsToContingentValueRightHolders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:PurchaseCommitmentConsiderationPaidToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ligand.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:PurchaseCommitmentConsiderationPaidToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:LeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430419 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i88b95a28d2054712baf9c5184035a19e_D20180101-20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Convertible Senior Notes - Narrative (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
     "shortName": "Convertible Senior Notes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i5eec6b1c21f0498da88860217bd3e1b7_I20140831",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i352234f55c94428c9659aebe6d102ea0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
     "shortName": "Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i352234f55c94428c9659aebe6d102ea0_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i63fcda9c6a804dc59452ea6868c24acd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
     "shortName": "Balance Sheet Account Details - Investment Categories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i63fcda9c6a804dc59452ea6868c24acd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441426 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
     "shortName": "Balance Sheet Account Details - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
     "shortName": "Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443428 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ib7153cd81712409ba213861c38901324_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444429 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Contingent Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i5d4b2e9889a945be999a04e9bcc088b7_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails",
     "shortName": "Stockholders' Equity - Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "icd387f8ff7744137980599559a1c5f77_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "icd387f8ff7744137980599559a1c5f77_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "id0b5dcd23b3d48ffb882929caa82534f_D20180501-20180531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ib7153cd81712409ba213861c38901324_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449432 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i5e0842e1697e470bbb3fd3777f23811c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450433 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i5e0842e1697e470bbb3fd3777f23811c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451434 - Disclosure - Stockholders' Equity - Assumptions (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
     "shortName": "Stockholders' Equity - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "if82097139d0d45c1a4aba40e3d9c9170_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "iacd51de929754bda9511cd8c27350601_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452435 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "iacd51de929754bda9511cd8c27350601_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454436 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails",
     "shortName": "Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i51bd95c1392b41fdb593a68493ca3cd2_D20191029-20191029",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457437 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458438 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459439 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460440 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ibaa72e20a0654ebdbcd5c3c853a2ef70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ib7153cd81712409ba213861c38901324_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461441 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "id001411ddc1a48f3be1dce3344a83372_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464442 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails",
     "shortName": "Summary of Unaudited Quarterly Financial Information - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "i0af99172e2234d32af27be433d5ae8ac_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Sale of Vernalis R&D and Promacta License",
     "role": "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense",
     "shortName": "Sale of Vernalis R&D and Promacta License",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20201231.htm",
      "contextRef": "ifac5ec6238044f5bae7ee1395e1b5368_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 136,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lgnd_AbInitioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ab Initio",
        "label": "Ab Initio [Member]",
        "terseLabel": "Ab Initio"
       }
      }
     },
     "localname": "AbInitioMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AccountsReceivableCreditLossExpenseReversalCOVID": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Loss Expense (Reversal), COVID",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal), COVID",
        "terseLabel": "Adjustment to allowance for credit losses related to COVID"
       }
      }
     },
     "localname": "AccountsReceivableCreditLossExpenseReversalCOVID",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccountsReceivableCreditLossExpenseReversalCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Loss Expense (Reversal), COVID-19",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal), COVID-19",
        "negatedTerseLabel": "Additional reserve for credit losses due to COVID-19"
       }
      }
     },
     "localname": "AccountsReceivableCreditLossExpenseReversalCOVID19",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedAssetAcquisitionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Asset Acquisitions, Current",
        "label": "Accrued Asset Acquisitions, Current",
        "terseLabel": "Acquisition related liabilities"
       }
      }
     },
     "localname": "AccruedAssetAcquisitionsCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedInventoryPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Inventory Purchases",
        "label": "Accrued Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedInventoryPurchases",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSalesReturns": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Returns",
        "label": "Accrued Sales Returns",
        "terseLabel": "Return reserve"
       }
      }
     },
     "localname": "AccruedSalesReturns",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSubcontractorExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Subcontractor Expenses, Current",
        "label": "Accrued Subcontractor Expenses, Current",
        "terseLabel": "Subcontractor"
       }
      }
     },
     "localname": "AccruedSubcontractorExpensesCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSupplierExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Supplier Expenses, Current",
        "label": "Accrued Supplier Expenses, Current",
        "terseLabel": "Supplier"
       }
      }
     },
     "localname": "AccruedSupplierExpensesCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Royalties Receivable Under Sales-based Milestones",
        "label": "Additional Royalties Receivable Under Sales-based Milestones",
        "terseLabel": "Additional royalties receivable under sales-based milestones"
       }
      }
     },
     "localname": "AdditionalRoyaltiesReceivableUnderSalesbasedMilestones",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants",
        "label": "Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants",
        "terseLabel": "Loss on repurchase of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes",
        "label": "Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes",
        "terseLabel": "Loss on settlement of Notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Reclassification of Equity Component of Convertible Debt",
        "label": "Adjustments to Additional Paid in Capital, Reclassification of Equity Component of Convertible Debt",
        "terseLabel": "Reclassification of equity component of currently redeemable convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfEquityComponentOfConvertibleDebt",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions",
        "label": "Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions",
        "negatedLabel": "Tax effect for Notes transactions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Repurchased",
        "label": "Adjustments to Additional Paid in Capital, Warrants Repurchased",
        "negatedLabel": "Warrant repurchase"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Settled",
        "label": "Adjustments to Additional Paid in Capital, Warrants Settled",
        "terseLabel": "Deduction to additional paid-in-capital for warrants settled"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsSettled",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AmendedESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended ESPP [Member]",
        "label": "Amended ESPP [Member]",
        "terseLabel": "Amended ESPP"
       }
      }
     },
     "localname": "AmendedESPPMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Commercial License and Other Economic Rights",
        "label": "Amortization of Commercial License and Other Economic Rights",
        "terseLabel": "Amortization of commercial license and other economic rights"
       }
      }
     },
     "localname": "AmortizationOfCommercialLicenseAndOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Operating and Finance Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_AziyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aziyo [Member]",
        "label": "Aziyo [Member]",
        "terseLabel": "Aziyo"
       }
      }
     },
     "localname": "AziyoMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AziyoandCorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aziyo and CorMatrix [Member]",
        "label": "Aziyo and CorMatrix [Member]",
        "terseLabel": "Aziyo and CorMatrix"
       }
      }
     },
     "localname": "AziyoandCorMatrixMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation.",
        "label": "Basis of Presentation [Line Items]",
        "terseLabel": "Basis of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of Presentation.",
        "label": "Basis of Presentation [Table]",
        "terseLabel": "Basis of Presentation [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationTable",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment Additions",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment Additions",
        "terseLabel": "Additional Contingent Liabilities"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAdditions",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "periodEndLabel": "Commercial rights at end of period",
        "periodStartLabel": "Commercial rights at beginning of period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "label": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "terseLabel": "Projected cash flow discount rate (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "label": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "terseLabel": "Cash holdback for potential indemnification claims"
       }
      }
     },
     "localname": "BusinessCombinationCashHoldbackForPotentialIndemnificationClaims",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationConsiderationTransferredHoldback": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Holdback",
        "label": "Business Combination, Consideration Transferred, Holdback",
        "terseLabel": "Holdback from acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredHoldback",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityAmountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Amount per Share",
        "label": "Business Combination, Contingent Consideration, Liability, Amount per Share",
        "terseLabel": "Contingent consideration liability per share (USD per share)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityAmountPerShare",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "label": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "terseLabel": "Fair value of contingent earn-out payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues",
        "label": "Business Combination, Contingent Consideration, Liability, Percentage of Acquiree Revenues",
        "terseLabel": "Proportion of milestone payments (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityPercentageOfAcquireeRevenues",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities, Current",
        "negatedLabel": "Accrued liabilities",
        "negatedTerseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilitiesCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Current Assets, Other",
        "terseLabel": "Cash and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndCurrentAssetsOther",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets",
        "terseLabel": "Intangibles acquired",
        "verboseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "terseLabel": "Discount rate used to value intangible assets acquired (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities",
        "negatedTerseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "label": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "terseLabel": "California and New Jersey Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "verboseLabel": "Cash Equivalents &amp; Short Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During the Year",
        "label": "Cash Paid During the Year [Abstract]",
        "terseLabel": "Cash paid during the year:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Rights",
        "label": "Commercial License Rights",
        "terseLabel": "Commercial license and other economic rights"
       }
      }
     },
     "localname": "CommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CommercialLicenseRightsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Rights [Policy Text Block]",
        "label": "Commercial License Rights [Policy Text Block]",
        "terseLabel": "Commercial license rights"
       }
      }
     },
     "localname": "CommercialLicenseRightsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "verboseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContingentLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Liability [Roll Forward]",
        "label": "Contingent Liability [Roll Forward]",
        "terseLabel": "Contingent Liability [Roll Forward]"
       }
      }
     },
     "localname": "ContingentLiabilityRollForward",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ContingentValueRightForInternalResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Right for Internal Research and Development",
        "label": "Contingent Value Right for Internal Research and Development [Member]",
        "terseLabel": "Contingent Value Right for Internal Research and Development"
       }
      }
     },
     "localname": "ContingentValueRightForInternalResearchAndDevelopmentMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContingentValueRightOnProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Right on Product Revenues",
        "label": "Contingent Value Right on Product Revenues [Member]",
        "terseLabel": "Contingent Value Right on Product Revenues"
       }
      }
     },
     "localname": "ContingentValueRightOnProductRevenuesMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Revenue",
        "label": "Contract Revenue [Member]",
        "terseLabel": "Contract revenue"
       }
      }
     },
     "localname": "ContractRevenueMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsAlvogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Alvogen",
        "label": "Contractual Relationships - Alvogen [Member]",
        "terseLabel": "Contractual Relationships - Alvogen"
       }
      }
     },
     "localname": "ContractualRelationshipsAlvogenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsArcellxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Arcellx",
        "label": "Contractual Relationships - Arcellx [Member]",
        "terseLabel": "Contractual Relationships - Arcellx"
       }
      }
     },
     "localname": "ContractualRelationshipsArcellxMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsJazzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Jazz",
        "label": "Contractual Relationships - Jazz [Member]",
        "terseLabel": "Contractual Relationships - Jazz"
       }
      }
     },
     "localname": "ContractualRelationshipsJazzMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsMerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - Merck",
        "label": "Contractual Relationships - Merck [Member]",
        "terseLabel": "Contractual Relationships - Merck"
       }
      }
     },
     "localname": "ContractualRelationshipsMerckMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContractualRelationshipsSIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Relationships - SII",
        "label": "Contractual Relationships - SII [Member]",
        "terseLabel": "Contractual Relationships - SII"
       }
      }
     },
     "localname": "ContractualRelationshipsSIIMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ConvertibleSeniorNotes2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes, 2019 [Member]",
        "label": "Convertible Senior Notes, 2019 [Member]",
        "terseLabel": "2019 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2019Member",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ConvertibleSeniorNotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes, 2023",
        "label": "Convertible Senior Notes, 2023 [Member]",
        "terseLabel": "2023 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2023Member",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CorMatrix [Member]",
        "label": "CorMatrix [Member]",
        "terseLabel": "CorMatrix"
       }
      }
     },
     "localname": "CorMatrixMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorporateShareRepurchaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Share Repurchase [Abstract]",
        "label": "Corporate Share Repurchase [Abstract]",
        "terseLabel": "Corporate Share Repurchase"
       }
      }
     },
     "localname": "CorporateShareRepurchaseAbstract",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crystal [Member]",
        "label": "Crystal [Member]",
        "terseLabel": "Crystal"
       }
      }
     },
     "localname": "CrystalMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CurrentPortionOfLiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of liability for contingent value rights.",
        "label": "Current Portion of Liability for Contingent Value Rights",
        "terseLabel": "Current contingent liabilities"
       }
      }
     },
     "localname": "CurrentPortionOfLiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CydexPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cydex Pharmaceuticals, Inc.",
        "label": "Cydex Pharmaceuticals, Inc [Member]",
        "verboseLabel": "Cydex"
       }
      }
     },
     "localname": "CydexPharmaceuticalsIncMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_DebtInstrumentAccruedInterestRepurchasedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest, Repurchased Amount",
        "label": "Debt Instrument, Accrued Interest, Repurchased Amount",
        "terseLabel": "Accrued interest on repurchased debt"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterestRepurchasedAmount",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "label": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "terseLabel": "Increase (decrease) in if-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "label": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "terseLabel": "Maximum threshold of debt trading price trigger (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year Five",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearFive",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year Five",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFive",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "label": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "negatedTerseLabel": "Identified intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFiniteLivedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties",
        "label": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]",
        "terseLabel": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties"
       }
      }
     },
     "localname": "DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout Rights for Partner Research and Development",
        "label": "Earnout Rights for Partner Research and Development [Member]",
        "terseLabel": "Earnout Rights for Partner Research and Development"
       }
      }
     },
     "localname": "EarnoutRightsForPartnerResearchAndDevelopmentMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Derivatives",
        "label": "Effective Income Tax Rate Reconciliation, Change in Derivatives",
        "terseLabel": "Change in derivatives"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDerivatives",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "label": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Net Operating Losses and Credits, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expired Net Operating Losses and Credits, Amount",
        "terseLabel": "Expired NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossesAndCreditsAmount",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "label": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "negatedLabel": "FDII"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "negatedTerseLabel": "Provision to return adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EmployeeStockPurchasePlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Abstract]",
        "label": "Employee Stock Purchase Plan [Abstract]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanAbstract",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ExercisePriceRangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Eight [Member]",
        "label": "Exercise Price Range Eight [Member]",
        "terseLabel": "$100.02-$113.76"
       }
      }
     },
     "localname": "ExercisePriceRangeEightMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Eleven [Member]",
        "label": "Exercise Price Range Eleven [Member]",
        "terseLabel": "$10.05 \u2013 $195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeElevenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "95.68"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$82.90-$95.35"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Nine [Member]",
        "label": "Exercise Price Range Nine [Member]",
        "terseLabel": "117.58"
       }
      }
     },
     "localname": "ExercisePriceRangeNineMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$10.05-$14.47"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Seven [Member]",
        "label": "Exercise Price Range Seven [Member]",
        "terseLabel": "98.2"
       }
      }
     },
     "localname": "ExercisePriceRangeSevenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Six [Member]",
        "label": "Exercise Price Range Six [Member]",
        "terseLabel": "97.92"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Ten [Member]",
        "label": "Exercise Price Range Ten [Member]",
        "terseLabel": "$117.97-$195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeTenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$63.58-$74.42"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$21.92-$56.26"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceofConvertibleBondHedge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price of Convertible Bond Hedge",
        "label": "Exercise Price of Convertible Bond Hedge",
        "terseLabel": "Exercise price of convertible bond hedge (USD per share)"
       }
      }
     },
     "localname": "ExercisePriceofConvertibleBondHedge",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Acquisition, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Acquisition, Contingent Liabilities",
        "terseLabel": "Contingent liabilities due to acquisitions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAcquisitionContingentLiabilities",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "negatedLabel": "Repurchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "terseLabel": "Fair value adjustments to contingent liabilities",
        "verboseLabel": "Fair Value Adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Amortization &amp; Credit Loss Adjustments",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization &amp; Credit Loss Adjustments",
        "negatedTerseLabel": "Accumulated amortization and credit loss adjustments on finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationCreditLossAdjustments",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization, Research &amp; Development Expense, and Credit Loss Adjustments",
        "negatedLabel": "Adjustments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationResearchDevelopmentExpenseAndCreditLossAdjustments",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FiniteLivedIntangibleAssetsCreditLossAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Intangible Assets, Credit Loss Adjustments",
        "label": "Finite-lived Intangible Assets, Credit Loss Adjustments",
        "negatedTerseLabel": "Credit loss adjustments on finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsCreditLossAdjustments",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ForecastedCashFlowsEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "label": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "terseLabel": "Effective interest rate of forecasted cash flows (as a percent)"
       }
      }
     },
     "localname": "ForecastedCashFlowsEffectiveInterestRatePercent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_GainLossOnShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Short-Term Investments",
        "label": "Gain (Loss) on Short-Term Investments",
        "negatedTerseLabel": "Loss (gain) short-term investments"
       }
      }
     },
     "localname": "GainLossOnShortTermInvestments",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Icagen",
        "label": "Icagen [Member]",
        "terseLabel": "Icagen"
       }
      }
     },
     "localname": "IcagenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_IncomeTaxReconciliationContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Contingent Value Rights",
        "label": "Income Tax Reconciliation, Contingent Value Rights",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "IncomeTaxReconciliationContingentValueRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Debt Discount",
        "label": "Increase (Decrease) in Debt Discount",
        "negatedTerseLabel": "Reduction in debt discount"
       }
      }
     },
     "localname": "IncreaseDecreaseInDebtDiscount",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Other Economic Rights",
        "label": "Increase (Decrease) in Other Economic Rights",
        "terseLabel": "Other economic rights"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_InvestmentInVikingCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in Viking, Current",
        "label": "Investment in Viking, Current",
        "verboseLabel": "Warrants investments in Viking"
       }
      }
     },
     "localname": "InvestmentInVikingCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Current",
        "label": "Lease, Liability, Current",
        "totalLabel": "Current lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-of-Use Asset",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for contingent value rights.",
        "label": "Liability for Contingent Value Rights",
        "verboseLabel": "Long-term contingent liabilities"
       }
      }
     },
     "localname": "LiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "label": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "terseLabel": "Contingent liabilities - Crystal"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCrystalMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCydexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Cydex",
        "label": "Liability For Contingent Value Rights Company, Cydex [Member]",
        "verboseLabel": "Contingent liabilities - CyDex"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCydexMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyIcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Icagen",
        "label": "Liability For Contingent Value Rights Company, Icagen [Member]",
        "terseLabel": "Contingent liabilities - Icagen"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyIcagenMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Metabasis",
        "label": "Liability For Contingent Value Rights Company, Metabasis [Member]",
        "terseLabel": "Contingent liabilities - Metabasis"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyMetabasisMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyPfenexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Pfenex",
        "label": "Liability For Contingent Value Rights Company, Pfenex [Member]",
        "terseLabel": "Contingent liabilities - Pfenex"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyPfenexMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "label": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "terseLabel": "Liability for restricted investments owed to former licensees"
       }
      }
     },
     "localname": "LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees",
        "label": "License Fees [Member]",
        "terseLabel": "License Fees"
       }
      }
     },
     "localname": "LicenseFeesMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMilestonesAndOtherProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees, Milestones, and Other Product, Other",
        "label": "License Fees, Milestones, and Other Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LicenseFeesMilestonesAndOtherProductOtherMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Upfront Payment",
        "label": "License Upfront Payment",
        "terseLabel": "Upfront payment for license"
       }
      }
     },
     "localname": "LicenseUpfrontPayment",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LupinPatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lupin Patent Infringement",
        "label": "Lupin Patent Infringement [Member]",
        "terseLabel": "Lupin Patent Infringement"
       }
      }
     },
     "localname": "LupinPatentInfringementMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MaterialSalesCaptisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material Sales, Captisol [Member]",
        "label": "Material Sales, Captisol [Member]",
        "terseLabel": "Captisol"
       }
      }
     },
     "localname": "MaterialSalesCaptisolMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of highly liquid securities maximum.",
        "label": "Maturity Period Of Highly Liquid Securities Maximum",
        "terseLabel": "Maturity period of cash and cash equivalents, maximum"
       }
      }
     },
     "localname": "MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_MetabasisTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Metabasis Therapeutics [Member]",
        "label": "Metabasis Therapeutics [Member]",
        "terseLabel": "Metabasis Therapeutics",
        "verboseLabel": "Metabasis"
       }
      }
     },
     "localname": "MetabasisTherapeuticsMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Member]",
        "terseLabel": "Milestones"
       }
      }
     },
     "localname": "MilestoneMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash change in estimated fair value of contingent value rights.",
        "label": "Non-cash change in estimated fair value of contingent value rights",
        "negatedLabel": "Change in estimated fair value of contingent liabilities"
       }
      }
     },
     "localname": "NonCashChangeInEstimatedFairValueOfContingentValueRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_NovanMolluscumProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novan Molluscum Products",
        "label": "Novan Molluscum Products [Member]",
        "terseLabel": "Novan"
       }
      }
     },
     "localname": "NovanMolluscumProductsMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NumberOfAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Acquisitions",
        "label": "Number of Acquisitions",
        "terseLabel": "Number of acquisitions"
       }
      }
     },
     "localname": "NumberOfAcquisitions",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfContingentValueRightsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Contingent Value Rights Issued",
        "label": "Number of Contingent Value Rights Issued",
        "terseLabel": "Number of contingent value rights"
       }
      }
     },
     "localname": "NumberOfContingentValueRightsIssued",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_OtherBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Balance Sheet Details [Abstract]",
        "label": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "localname": "OtherBalanceSheetDetailsAbstract",
     "nsuri": "http://www.ligand.com/20201231",
     "xbrltype": "stringItemType"
    },
    "lgnd_PalvellaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palvella Therapeutics, Inc.",
        "label": "Palvella Therapeutics, Inc. [Member]",
        "terseLabel": "Palvella"
       }
      }
     },
     "localname": "PalvellaTherapeuticsIncMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner A [Member]",
        "label": "Partner A [Member]",
        "terseLabel": "Partner A"
       }
      }
     },
     "localname": "PartnerAMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner B [Member]",
        "label": "Partner B [Member]",
        "terseLabel": "Partner B"
       }
      }
     },
     "localname": "PartnerBMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partner C [Member]",
        "label": "Partner C [Member]",
        "terseLabel": "Partner C"
       }
      }
     },
     "localname": "PartnerCMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options",
        "label": "Payments to Acquire Businesses, Gross, Attributable to Vested Portion of Stock Options",
        "terseLabel": "Gross payments to acquire business attributable to vested portion of stock options"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGrossAttributableToVestedPortionOfStockOptions",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToContingentValueRightHolders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to contingent value right holders",
        "label": "Payments to Contingent Value Right Holders",
        "negatedLabel": "Payments to CVR holders and other contingency payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHolders",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToContingentValueRightHoldersFinancingActivity": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Contingent Value Right Holders, Financing Activity",
        "label": "Payments to Contingent Value Right Holders, Financing Activity",
        "negatedLabel": "Payments to CVR Holders"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHoldersFinancingActivity",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsforConvertibleBondHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Convertible Bond Hedges",
        "label": "Payments for Convertible Bond Hedges",
        "terseLabel": "Payments for convertible bond hedges"
       }
      }
     },
     "localname": "PaymentsforConvertibleBondHedges",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PfenexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfenex",
        "label": "Pfenex [Member]",
        "terseLabel": "Pfenex"
       }
      }
     },
     "localname": "PfenexMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_Phase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 Clinical Trial",
        "label": "Phase 3 Clinical Trial [Member]",
        "terseLabel": "Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "Phase3ClinicalTrialMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical Study and Clinical Trial Accruals [Policy Text Block]",
        "label": "Preclinical Study and Clinical Trial Accruals [Policy Text Block]",
        "terseLabel": "Preclinical Study and Clinical Trial Accruals"
       }
      }
     },
     "localname": "PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ProceedsFromCommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Commercial License Rights",
        "label": "Proceeds from Commercial License Rights",
        "terseLabel": "Proceeds from commercial license rights"
       }
      }
     },
     "localname": "ProceedsFromCommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ProductRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Royalty Percentage",
        "label": "Product Royalty Percentage",
        "terseLabel": "Product royalty (as a percent)"
       }
      }
     },
     "localname": "ProductRoyaltyPercentage",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_PromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promacta",
        "label": "Promacta [Member]",
        "terseLabel": "Promacta"
       }
      }
     },
     "localname": "PromactaMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "label": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "terseLabel": "Portion of consideration allocated to inventory"
       }
      }
     },
     "localname": "PurchaseCommitmentConsiderationPaidAllocatedToInventory",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PurchaseCommitmentConsiderationPaidToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Consideration Paid to Date",
        "label": "Purchase Commitment, Consideration Paid to Date",
        "terseLabel": "Consideration paid to date"
       }
      }
     },
     "localname": "PurchaseCommitmentConsiderationPaidToDate",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PurchaseOfConvertibleBondHedge": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of Convertible Bond Hedge",
        "label": "Purchase of Convertible Bond Hedge",
        "negatedLabel": "Purchase of convertible bond hedge"
       }
      }
     },
     "localname": "PurchaseOfConvertibleBondHedge",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PurchaseforCommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase for Commercial License Rights",
        "label": "Purchase for Commercial License Rights",
        "negatedLabel": "Purchase of commercial license rights"
       }
      }
     },
     "localname": "PurchaseforCommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RestrictedStockUnitsAndPerformanceShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units and Performance Share Units",
        "label": "Restricted Stock Units and Performance Share Units [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceShareUnitsMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Recorded upon Adoption of New Accounting Pronouncement",
        "label": "Royalties Recorded upon Adoption of New Accounting Pronouncement",
        "terseLabel": "Royalties recorded in retained earnings upon adoption of ASC 606"
       }
      }
     },
     "localname": "RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RoyaltyAgreementExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Expiration Period",
        "label": "Royalty Agreement, Expiration Period",
        "terseLabel": "Expiration period of royalty agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementExpirationPeriod",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_RoyaltyEvomelaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Evomela",
        "label": "Royalty, Evomela [Member]",
        "terseLabel": "Royalty, Evomela"
       }
      }
     },
     "localname": "RoyaltyEvomelaMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyKyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Kyprolis",
        "label": "Royalty, Kyprolis [Member]",
        "terseLabel": "Royalty, Kyprolis"
       }
      }
     },
     "localname": "RoyaltyKyprolisMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Other",
        "label": "Royalty, Other [Member]",
        "terseLabel": "Royalty, Other"
       }
      }
     },
     "localname": "RoyaltyOtherMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyPromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Promacta",
        "label": "Royalty, Promacta [Member]",
        "terseLabel": "Royalty, Promacta"
       }
      }
     },
     "localname": "RoyaltyPromactaMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ScheduleofCommercialLicenseRightsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Commercial License Rights [Table Text Block]",
        "label": "Schedule of Commercial License Rights [Table Text Block]",
        "terseLabel": "Schedule of Commercial License Rights"
       }
      }
     },
     "localname": "ScheduleofCommercialLicenseRightsTableTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ScheduleofContingentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Contingent Liabilities [Table Text Block]",
        "label": "Schedule of Contingent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Contingent Liabilities"
       }
      }
     },
     "localname": "ScheduleofContingentLiabilitiesTableTextBlock",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_SelexisAndDianomiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selexis and Dianomi",
        "label": "Selexis and Dianomi [Member]",
        "terseLabel": "Selexis and Dianomi"
       }
      }
     },
     "localname": "SelexisAndDianomiMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_TaurusBiosciencesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taurus Biosciences, LLC",
        "label": "Taurus Biosciences, LLC [Member]",
        "terseLabel": "Taurus"
       }
      }
     },
     "localname": "TaurusBiosciencesLLCMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_TwoThousandTwoStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand two Stock Incentive Plan.",
        "label": "Two thousand Two Stock Incentive Plan [Member]",
        "terseLabel": "2002 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwoStockIncentivePlanMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US District Court for the Northern District of Ohio",
        "label": "US District Court for the Northern District of Ohio [Member]",
        "terseLabel": "US District Court for the Northern District of Ohio"
       }
      }
     },
     "localname": "USDistrictCourtForTheNorthernDistrictOfOhioMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VernalisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vernalis",
        "label": "Vernalis [Member]",
        "terseLabel": "Vernalis"
       }
      }
     },
     "localname": "VernalisMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period One [Member]",
        "label": "Vesting Period One [Member]",
        "terseLabel": "Vest 1/8 on the six month anniversary of the date of grant"
       }
      }
     },
     "localname": "VestingPeriodOneMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period Two [Member]",
        "label": "Vesting Period Two [Member]",
        "terseLabel": "Vest 1/48 each month for forty-two months"
       }
      }
     },
     "localname": "VestingPeriodTwoMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VikingTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viking Therapeutics, Inc. [Member]",
        "label": "Viking Therapeutics, Inc. [Member]",
        "terseLabel": "Viking Therapeutics, Inc."
       }
      }
     },
     "localname": "VikingTherapeuticsInc.Member",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_WarrantsSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Settled",
        "label": "Warrants Settled",
        "terseLabel": "Warrants settled (shares)"
       }
      }
     },
     "localname": "WarrantsSettled",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lgnd_XCellaBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xCella Biosciences, Inc.",
        "label": "xCella Biosciences, Inc. [Member]",
        "terseLabel": "xCella"
       }
      }
     },
     "localname": "XCellaBiosciencesIncMember",
     "nsuri": "http://www.ligand.com/20201231",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r145",
      "r152",
      "r245",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r145",
      "r152",
      "r245",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r145",
      "r152",
      "r245",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r215",
      "r334",
      "r339",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r357",
      "r359",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r593",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r357",
      "r359",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r593",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r215",
      "r334",
      "r339",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r213",
      "r334",
      "r337",
      "r594",
      "r659",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r213",
      "r334",
      "r337",
      "r594",
      "r659",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r346",
      "r357",
      "r359",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r593",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r346",
      "r357",
      "r359",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r593",
      "r660",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "terseLabel": "Price per share of shares repurchased (USD per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r441",
      "r442",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r17",
      "r38",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization/accretion of premium (discount) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r53"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r624",
      "r652"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties owed to third parties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": {
     "auth_ref": [
      "r30",
      "r32",
      "r616",
      "r645"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.",
        "label": "Accrued Sales Commission",
        "terseLabel": "Amounts owed to former licensees"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r287"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r74",
      "r75",
      "r76",
      "r647",
      "r671",
      "r675"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r142",
      "r143",
      "r144",
      "r486",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average useful lives of acquired finite-lived intangible assets",
        "verboseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r39",
      "r403"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r439",
      "r440",
      "r441",
      "r442",
      "r596",
      "r597",
      "r598",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r313",
      "r319",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Convertible bond hedge and warrant transactions, net of tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Reacquisition of equity due to 2023 debt extinguishment, net of tax",
        "verboseLabel": "Debt issuance costs related to the equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Other tax adjustments"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r360",
      "r362",
      "r405",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r304",
      "r313",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant derivative",
        "verboseLabel": "Value of warrants issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r122",
      "r538"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r122",
      "r271",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r122",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r202",
      "r205",
      "r211",
      "r240",
      "r481",
      "r488",
      "r523",
      "r613",
      "r644"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r65",
      "r133",
      "r240",
      "r481",
      "r488",
      "r523"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r222",
      "r253"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r226",
      "r228",
      "r635"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r226",
      "r229",
      "r636"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r226",
      "r227",
      "r634"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r220",
      "r223",
      "r253",
      "r622"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r364",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r356",
      "r358",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Post-combination expense"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "verboseLabel": "Value of share consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic (USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted (USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill acquired that is expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net Income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r469",
      "r470",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r468",
      "r471",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Integration related costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Income (loss) before income taxes of acquiree since acquisition date included in comprehensive income"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree since acquisition date included in comprehensive income"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts and unbilled receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable and accrued liabilities",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedLabel": "Deferred revenue",
        "negatedTerseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liabilities, net",
        "negatedTerseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Approximate Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible asset with finite life - core technology",
        "verboseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r130",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of fixed assets recorded in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r15",
      "r46",
      "r124"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r115",
      "r124",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r115",
      "r525"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (USD per share)",
        "verboseLabel": "Warrant exercise price (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued in public offering (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r59",
      "r298",
      "r625",
      "r651"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies: Legal Proceedings"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend declared (USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r37",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; 16,080 and 16,823 shares issued and outstanding at December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r80",
      "r82",
      "r83",
      "r89",
      "r628",
      "r656"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r215",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r215",
      "r520",
      "r521",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r215",
      "r520",
      "r521",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r184",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Business Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r189",
      "r190",
      "r215",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Total revenues (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r215",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "terseLabel": "Gross contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r322",
      "r323",
      "r335"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Contractual relationships"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "verboseLabel": "Fair value of convertible senior notes outstanding (Level 2)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "verboseLabel": "2023 convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r28",
      "r614",
      "r641",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r347",
      "r355",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Cost of Captisol"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r435",
      "r445"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r138",
      "r435"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r435",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total Current Income Tax Benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r435",
      "r445"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r188",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notices for conversion"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r28",
      "r30",
      "r31",
      "r614",
      "r617",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Conversion value over the principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "netLabel": "Carrying value of equity component of 2023 Notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt conversion price per share (USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r56",
      "r314",
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible debt conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "If-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger to classify convertible debt as current (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount of 2023 Notes outstanding",
        "verboseLabel": "Face amount of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r55",
      "r309",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest on debt instrument (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased face amount of debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r57",
      "r136",
      "r314",
      "r316",
      "r317",
      "r318",
      "r536",
      "r537",
      "r539",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r536",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discount (including unamortized debt issuance cost)"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r536",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt issuance costs related to the liability component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r237",
      "r258",
      "r261"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r237",
      "r258",
      "r261"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r237",
      "r258"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r234",
      "r255",
      "r261"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r254",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r233",
      "r257",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r236",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of positions in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r436",
      "r445"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r34",
      "r35",
      "r425",
      "r615",
      "r640"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r436",
      "r445"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r431",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r413",
      "r428"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Bank deposits"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r122",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r122",
      "r200"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r66",
      "r67",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative asset"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Net change in fair value of derivatives",
        "terseLabel": "Gain (loss) on derivative liabilities"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r66",
      "r67",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r139",
      "r499",
      "r500",
      "r501",
      "r502",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r364",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r282",
      "r284",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Vernalis R&amp;D and Promacta License"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r90",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r158",
      "r161",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r629",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) - Basic (USD per share)",
        "verboseLabel": "Basic net income (loss) per share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic per share amounts:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Dilutive potential common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r90",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r161",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r629",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted net income (loss) per share (USD per share)",
        "terseLabel": "Net income (loss) - Diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted per share amounts:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareProFormaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Pro Forma [Abstract]",
        "terseLabel": "Net income (loss) per common share:"
       }
      }
     },
     "localname": "EarningsPerShareProFormaAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of the conversion option derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Cash to settle unvested stock options recognized as share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average period in which cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost, restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147",
      "r155",
      "r157",
      "r180",
      "r245",
      "r313",
      "r319",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r239",
      "r601",
      "r603",
      "r605",
      "r607",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Measurement input (as a percent)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r25",
      "r29",
      "r238",
      "r642",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities",
        "verboseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r507",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r508",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r507",
      "r508",
      "r511",
      "r512",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r353",
      "r355",
      "r508",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r353",
      "r355",
      "r508",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r508",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of level 3 financial instruments at end of period",
        "periodStartLabel": "Fair value of level 3 financial instruments at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r514",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r542",
      "r550",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r545",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Cash paid for amounts included in finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r541",
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current finance lease liabilities",
        "verboseLabel": "Remaining finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r544",
      "r552"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments under finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate of finance leases (as a percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r554",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r257",
      "r259",
      "r260",
      "r261",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "Estimated amortization expense for 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r272",
      "r274",
      "r277",
      "r280",
      "r595",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r277",
      "r599"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      },
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Definite-lived intangible assets",
        "verboseLabel": "Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r272",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r277",
      "r595"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets, net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain from sale of intangible assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r95",
      "r122",
      "r221"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) from short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnRepurchaseOfDebtInstrument": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase.",
        "label": "Gain (Loss) on Repurchase of Debt Instrument",
        "negatedTerseLabel": "Loss on repurchase of debt instrument"
       }
      }
     },
     "localname": "GainLossOnRepurchaseOfDebtInstrument",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r122",
      "r487"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Gain from sale of Vernalis R&amp;D"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Gain from sale of Promacta license"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r122",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r266",
      "r267",
      "r612"
     ],
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r130",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "terseLabel": "Goodwill written off"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r235",
      "r237"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for 12 months or longer.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 months or greater"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.",
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r230",
      "r633"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r122",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets with finite lives"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r137",
      "r202",
      "r204",
      "r207",
      "r210",
      "r212"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Condensed Statement of Operations:"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r11",
      "r12",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r416",
      "r423",
      "r430",
      "r443",
      "r447",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r156",
      "r157",
      "r201",
      "r414",
      "r444",
      "r448",
      "r658"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "negatedTerseLabel": "Income tax (expense) benefit",
        "totalLabel": "Income tax expense from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r130",
      "r410",
      "r411",
      "r423",
      "r424",
      "r429",
      "r437",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r409",
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Rate change for changes in federal or state law"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "terseLabel": "Sale of Vernalis R&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax differential on income/loss of foreign subsidiaries"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r118",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r61",
      "r623",
      "r653"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssets": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Assets",
        "terseLabel": "Increase (decrease) in derivative assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Increase (decrease) in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisition:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r171"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Warrants (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r166",
      "r167",
      "r171"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "2019 Convertible Senior Notes (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r171"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r270",
      "r275"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net (excluding goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total goodwill and other identifiable intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r86",
      "r199",
      "r535",
      "r538",
      "r630"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r112",
      "r117",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Interim Period, Costs Not Allocable [Line Items]",
        "terseLabel": "Interim Period, Costs Not Allocable [Line Items]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableTable": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Table]",
        "terseLabel": "Interim Period, Costs Not Allocable [Table]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r16",
      "r62"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r63",
      "r130",
      "r176",
      "r262",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-downs related to obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r94",
      "r198"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term of finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52",
      "r133",
      "r206",
      "r240",
      "r482",
      "r488",
      "r489",
      "r523"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r44",
      "r133",
      "r240",
      "r523",
      "r619",
      "r649"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r133",
      "r240",
      "r482",
      "r488",
      "r489",
      "r523"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "verboseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Total long-term portion of notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r57",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current and Noncurrent [Abstract]",
        "terseLabel": "Notes Payable, Current and Noncurrent"
       }
      }
     },
     "localname": "LongtermNotesPayableCurrentAndNoncurrentTotalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of civil complaints filed against entity"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Investment Categories"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual fund"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r115",
      "r119",
      "r123"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r78",
      "r81",
      "r87",
      "r123",
      "r133",
      "r146",
      "r150",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r168",
      "r202",
      "r204",
      "r207",
      "r210",
      "r212",
      "r240",
      "r523",
      "r626",
      "r654"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "verboseLabel": "Lab and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "terseLabel": "Total operating costs and expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "verboseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r202",
      "r204",
      "r207",
      "r210",
      "r212"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate of operating leases (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r554",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r14",
      "r141",
      "r195",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r53"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r71",
      "r72",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized net gain on available-for-sale securities, net of deferred tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r79",
      "r82",
      "r85",
      "r88",
      "r313",
      "r526",
      "r531",
      "r532",
      "r627",
      "r655"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentedTechnologyMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.",
        "label": "Patented Technology [Member]",
        "verboseLabel": "Complete technology"
       }
      }
     },
     "localname": "PatentedTechnologyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Payment for contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForHedgeFinancingActivities": {
     "auth_ref": [
      "r111",
      "r120"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for Hedge, Financing Activities",
        "negatedLabel": "Payments to convert holders for bond conversion"
       }
      }
     },
     "localname": "PaymentsForHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r101",
      "r104",
      "r140"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Share repurchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedLabel": "Repurchase of warrants",
        "terseLabel": "Payments for repurchase of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r102",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Gross payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Cash paid for acquisition, net of cash and restricted cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Cash paid for equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r364",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds received from repayment of Viking note receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from debt issuance"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Investing Activities",
        "terseLabel": "Proceeds from derivative instrument"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds on sale of Vernalis R&amp;D, net"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "auth_ref": [
      "r107",
      "r120"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Proceeds from Hedge, Financing Activities",
        "terseLabel": "Proceeds from bond hedge settlement"
       }
      }
     },
     "localname": "ProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r105",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Cash received from options exercised"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Proceeds from maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Gross proceeds from issuance of 2023 Convertible Senior Notes"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of Promacta license"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r105",
      "r395"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Net proceeds from stock option exercises and ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r78",
      "r81",
      "r114",
      "r133",
      "r146",
      "r156",
      "r157",
      "r202",
      "r204",
      "r207",
      "r210",
      "r212",
      "r240",
      "r480",
      "r484",
      "r485",
      "r496",
      "r497",
      "r523",
      "r631"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r286"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property and equipment , gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r26",
      "r27",
      "r288",
      "r650"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r130",
      "r288",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r26",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r26",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r33",
      "r618",
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Total future commitments through 2021"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Summary of Unaudited Quarterly Financial Information"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r45",
      "r130",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r354",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r354",
      "r559",
      "r561",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of notes"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r407",
      "r698"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r130",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r15",
      "r24",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash in other current assets"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedLabel": "Restructuring and product reserves"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r40",
      "r319",
      "r403",
      "r648",
      "r670",
      "r675"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147",
      "r155",
      "r157",
      "r245",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442",
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r196",
      "r197",
      "r203",
      "r208",
      "r209",
      "r213",
      "r214",
      "r215",
      "r333",
      "r334",
      "r594"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r196",
      "r197",
      "r203",
      "r208",
      "r209",
      "r213",
      "r214",
      "r215",
      "r333",
      "r334",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofVernalisRDandPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r553",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use asset recognized"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "terseLabel": "Royalty Agreements"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r189",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAllocationofConsiderationDetails",
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AcquisitionsProFormaFinancialInformationDetails",
      "http://www.ligand.com/role/AcquisitionsTables",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Equity and Liability Components of the Convertible Senior Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangibles Acquired"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r272",
      "r276",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r49",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r364",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Plan Activity by Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r369",
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Weighted-Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Significant Partners"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service Revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (shares)",
        "periodStartLabel": "Outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Shares [Rollforward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "periodStartLabel": "Outstanding at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "verboseLabel": "Shares allowed to purchase in employee stock purchase plan per employee (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase the number of shares under the 2002 Stock Incentive Plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for future option grants (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value per share of stock options (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r371",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares [Rollforward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end of period (USD per share)",
        "periodStartLabel": "Balance at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Options vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Options vested and expected to vest at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Common stock issued under amended ESSP (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r361",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r130",
      "r364",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting right (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r388",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining life in years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r29",
      "r620",
      "r621",
      "r643"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r60",
      "r142",
      "r143",
      "r144",
      "r147",
      "r155",
      "r157",
      "r180",
      "r245",
      "r313",
      "r319",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Condensed Balance Sheet:"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r180",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Equity Awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r36",
      "r37",
      "r313",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r37",
      "r313",
      "r319",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r36",
      "r37",
      "r319",
      "r363",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r36",
      "r37",
      "r313",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (shares)",
        "terseLabel": "Shares repurchased in period (shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r36",
      "r37",
      "r313",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Shares repurchased in period"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r37",
      "r42",
      "r43",
      "r133",
      "r219",
      "r240",
      "r523"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r133",
      "r142",
      "r143",
      "r144",
      "r147",
      "r155",
      "r240",
      "r245",
      "r319",
      "r400",
      "r401",
      "r402",
      "r441",
      "r442",
      "r478",
      "r479",
      "r495",
      "r523",
      "r526",
      "r527",
      "r532",
      "r667",
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r551",
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r533",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r533",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r533",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Core Technology",
        "verboseLabel": "Acquired Technologies"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsIntangiblesAcquiredandWeightedAverageUsefulLifeDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r334",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r334",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r439",
      "r440",
      "r441",
      "r442",
      "r596",
      "r597",
      "r598",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r347",
      "r355",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Treasury bill"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized (loss) gain on AFS investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r408",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r182",
      "r183",
      "r185",
      "r186",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, change in amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Short-term Investments: Investment in Viking"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinViking"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Investment in warrants",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/ShorttermInvestmentsInvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r160",
      "r171"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "netLabel": "Shares used in diluted per share calculation (shares)",
        "totalLabel": "Shares used to compute diluted income per share (shares)",
        "verboseLabel": "Weighted average shares\u2014diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r158",
      "r171"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "netLabel": "Shares used in basic per share calculation (shares)",
        "terseLabel": "Weighted-average common shares outstanding - basic (shares)",
        "verboseLabel": "Weighted average shares\u2014basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.",
        "label": "Weighted Average Number of Shares, Restricted Stock",
        "verboseLabel": "Restricted stock (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3581-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e34017-109320"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r699": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r701": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r702": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r703": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r704": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r705": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r706": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0000886163-21-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-21-000050-xbrl.zip
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M7 R&9Q>U(;>]SM<9]. @4/\Y?Z?DU85:G%?!^(WG('_-L3]K''L@_C.^CO.
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M5I2[FN00Q1Y]RR]\&Y-4P1>'J0.A>.?9)4J8J>?"*_ O842W*?S?0IVG $(
M1T]^ 9T?3V$1,O4::8:YT:/#7]9Z5_F6VR6#/+&U]VTIM_[IX/7@Y>!T,/YM
MJ][EX_.K*X)L:P62VM)-W6K* \27-Q*?HTP(00//Y^GM#N?NZ#][<<>_EUBQ
MY+N9!-,OV/*&*]6G-I NZ8^9%3$Z/'.N]D."%I$!9]SM2O:J9<Y:)@VLXW*N
M;!M6]130!2,6< MHKH(GE6;DN7"\6!NJQG21\)$]ULM-D]G9N9"E;^):0IGW
M$S=P'#U_Z,#),QA[IHNRH,ETIVPY90REU;XZA=_UI2Q!B"(T:!+!P-% H/N3
M*8HV)IP]7*-;,#/(W^=!\/5L1] U2:E]'<XITP\FD&&C^*QUT:Y(\N.$%F%1
MFE/O(@1 T$<Q[F^U-!8RQN^*F80S)4,NX!YJO?0L>%\"1\#WCGF$RL@Q]C1X
M6G0Q9#'0=@),$-BU>S$*G XF&I6KR+I.+!"]-EV^"#_$BW*!P65TW6@AQ*_I
M\0S.DE$33$[")'$F"4%*\"&8ZK&)3=-/S#1YHB1F>['BM"&D+HGFZH:CO'/,
MREANMV9DPD9;S-RV99=%XN$;;#/M/:2TQN?:!-';;)/U=* 1'/O2,!4U>1,U
M$KJXJ]<%DW\D2TTV@X>WR7*ZF(R/6U6X-2F0ZM+2 &K.?\W6RC]J;>E27M@[
MDI'XV7VNM0BPVH?>\PYXS+F8(H+'G,NWG'.!0R-/M4?.L<S81,[I2SY"P.U"
MB  C!"VH7*C*N7CW\A_]XW$P'NXJ^N8C @875GR'TW^7>8'1=:5;00FPO:OL
M(AT@>N_1 A6P(FLIQ@.P&@!5 T6(LR@#ZU,^HS'\#?;8#]UGAT^[/SQ_9E0_
MW9D'8"+RZH;E)')0!F#>@OV>)HQDQ?-!!B_^*3178YH,$$,%#"))U5V#5^ H
MO _G9:25*.OU3G!X\%Q/Q,<^HWY_M6.K47-U"_!ZKBB$(Y?E0"TQFTKJ<*MI
M!I=[K97" :R]4-;@IZN'RY9,'LP;Q*IA791%?'65(>("AE!?UWS#C;A=4N>3
M4#MG*6Y2,N5$J,ZL-,\JX:_(P)/@*(C[(KKML*O>!_[K6VQ=6&&6 K+5$P"K
M3L,LN(O"K)H=2>I;T&:=JUM.CK8;D"^I/"Z."TW"')-Q)O!N*VTJ'V.2'.Q#
M/ U[(L$0NFYI,.6 )B44T0M"&_M5G*@_XG >]-0W98)S>0$O@=-&D:S&KX[3
MJ<T[CM-E/ E^./S1Y$F4LH0$.07!E*N?=HQ5G1M7&?9P4R+*#:2I=Y&O3>I;
MAX0PN[KR%M,RTXOBK**-X-N($NP><2+_X_ESW"I=4^&$X_Z/'^ECO92UV\(A
M5 .E )?:).'<S0BO&O-!@.BO!@L#!HBX",IOZ7($//;S>*&,.)@A  3<Q-,R
MG*].]<%+*-,N"S'9#!MT$F>3<@&[&5U>O[GC@MLX1RC3@P;TB0+4DWET1T-G
MUZ1_]"$+Y^X^T O5$+.?,@H#=QCJ#YWAMI?C')ECI?;C K9 $J5E9;]-#:0C
M3F[2.0YL=?;TH[!QBS"[4GX#.U[HZZ#-'6-T%!V)S^X?-(OH8_-"7_[IORQA
M"R17^_-H5OQ\]/S@IR.8AS$)534_&#D&@#!$U:"$D9.IL%MQ]6/4 +,HQB++
MZ,,R1JDOW0#X2U^*(@L"I<IMCPI$7,"10L&\IS;-[34D;FD#P>[K<#RP69DT
M>_[UQW5US+9P7DQ['OP"91;Q&YAMC..B@8(QH([K%43F .9[$\9S@\&8E7"U
M#H1:<5PU)Q,T0Q8@\Z$*%>(P*<,1:&1H15(H,+%O#@$;1,4*]*B&>%3UCC#(
M@O RO8G:K+BJ]H1_A*CF8.)BCIE26@VEAF<=C+&%<'5.A+<LG !)P_21)J7)
M<L:OM##FIO6MUYETS/ZAW>VS-R$CPM%GM1QD0!+\ 6;I.IH;X+#47K@C[Q:\
M<6@;,=X"XW]\+"CZJ@;QTR]DFJ\Q"HRXB6&(,-6J4<'65__* 7  ;D?X@7Z>
MS@FU=CF/KRS&P 6NZ$@QG%9/99%Y#_^+2+/9>Q_24;"582G9RE<SJC9<P@MN
M:J7I'O;4Z>GVWCM-[%+PB:=QDWMTXQVZ#N!.-2XM5;I)G:SL]ZBPXT$AH)0M
M&"TYPV[DZJN[<NTBHDG66NTOL\(UCTX4E>R _#H@ 49KJ:V=;G"M"S9@3]7]
M@PJP2V,R;V GU2/&#7,$ YY&\]BDJ,+5R[58XMJX2_6K6*9Q^ %L:G#CJRN8
ML7D%1F=N;!TP!2%9E)LT5O4:=%EM3L%L,3E ,2*XJ6=$'SV"BN3_F#UER^Y
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MH[O4\"*T"DM1S[$E&\BWZEL^/)_9T&JB"ERKW1I2IYL8T$:& HK[1$/<*D%
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MFXXR,?^:R&X & :''<N2H9.IQ1<B?BIGAF]*35+Z23^NN?EA6!U5S]1V4J@
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M9,41ETD=3B5KIX1D<B@8I5RGPI''#& ]/-(Q-*K^E!$%(S[,'5"VF"W5-DX
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MD;JY!C:2(T6?G!Q!]:-E+>+M:A;CP8M?*S7$."6!(*$RFSMM6_$=L.(60CW
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M8@6O$:1Z3D;^+DRE;X[&WL39</RF/V) .]7;KH7BY02DK8U=">6%CHM2?N[
M;*ZS,=^U4%SU1M!?M;(M)XY"\\:I2<M#WZ3++/T=.B-=AYAUD3=03EMB^#[J
MM5K&'01B8.?!K&LK-V\=3GH+.M1I.<H]G".A[G0)M@A+-P:C.2.W7E :.:/G
M .1'&<>EWPGE]A@3BR-WIL:0C,"[[<+A76>[O6_=;N/!\>"\5]]S+ HUGIPI
M0)/F9G!-J(/[8G[>,@KB7[UB\5Q$?XZ5T0*F=LWCUY]; E%&$@&H I#;X'1
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MMWC]%N[.41_@=GUHNA[T7[V";L[O6XC:S,KIO =&=0G:!#(1E:1.B4Q2"",
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M$:#E /LCN3YQ#4LBC4CU7H'G@YE$RI)E<-K*VB.Z*&-I)3"&5,VU>8S+!,E
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M\A2*7RD9<A0SK"SNS+-.<#DZ-K9L8,O\XAM6AZ6'8*6G5=+ML>4K^,,C[HX
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MT;L[[WWOV@:H;(#*,Q&'&Z"R8<T-4"DC9[YHH/)"'8P4'9CQQ^.U3:M?Y[G
M75Z*,WC3[P P[[TS1X>R?< (VRZL:LA'6ARY/X[Q"'G()T<RHC6BAXZGF\.@
M#MU(ZO/0!G9(PICB?-25FAEY L-- M>S+:Y0434)YLL.]BK-^O+B6J6^M&QE
MLY7ZP>.WNG=0V3MH?E6SJ\H:E7JSL=:355I>L\2PBWK$H]^V]K9FQ,Q1C1D)
MX]K+JKZ9J]H8?6$S84$,\<WM>3S:6D%TC=J:?LZEC_UHR^%<]C$,>S7@8!7X
M8/W@9,G<R;))UIP$D/[J]VX\QL;-5WWHQCTI(%JP(L79O?[:V9DM> )=>O#+
M-)SZR!,P.<?LW[$245>H?C;C[[/[:U2U4A\( ./^:+O+@+E5^>Y4]$AZ&B%?
MCK66K_(C!PH?-+X"INK\[Y7'VJ>7]]#[ S=I:K.)EJJDJN\53?6O$\LKQ=D&
M%3X(%5:[<3"!7X-D&/[^_U!+ P04    " !IB%A2176%>*T5  !0<   '@
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MDS+ 6.(,D$Q8Q[UOV0$^O8/CO#Z2A6]PS(D.HC%;WX#9NDG'<$/3W.0JE@R
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MYCUN[\C@B*EQ8V=\(C<38UJ]5ADUJ5-&1J7;XG7PW[X((OJ87S6Z(,"Q.CR
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MX<^CP1NYK4\/7?@MG$^F7VG._O3[]N$#'D]&@_%EI[WJH+YPBA\NWOV7QGZ
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M:,I@6G@X[,VLCVHJ6(#CD$%73C50-B*#DBXV 6^L3U_ILGH+Q+JX3*US6S)
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M=WMOZ/+7E2Y:DFC3E=EXT#7D9"O7PBDCV)3"ABZ=H,M&:E["7:^*<F0YHC*
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MC<'EJC5X=$&9F'I%V6\$,Q5BR4[%)N,@<\CH=$RU.B.*3F&_PM6-M+I] F5
M$RSY[ Q!1HC!Q^R<3ED5ZWV_,F$V0N?V"61R$^:)-'+KPL!)60<0H6AR5:EO
MA$";6:NO#^Y<JVX()F*K(&01HX><:^1H D37+Q>VZ2ZP:CK%XDI5T1;4%G(-
MR?O(19L<VG2^VM"I'W3:B+5+N,VE9L4(H"R#<P$K):-J-)P<(N9><;M38NW;
M'6A=X79;J=+:D?,D\M$Z=*P3F=8W'(QW_9KC[92.W'![U=S6HFI944+1)N"9
M),SV-;7-54''4OJ5>[WI,;#B&1NQC0C!6A#+6%6(SI=$SN;6**Z<EH3?D*GC
M9-K(VTN8'4*.):+823&3.;E<B#1779.MY$^K9&V8O5D-[I_-3N PZ&JYN  Z
M^4B,-2>344,!ZE=FUIJ)VWXZD*XPNQ@=JTI@C0- W[B-$9(R&;+/NE_[%#9]
M!59/*,<YNV#D,6H#&0(6F]"* ##.1AW[M<_O6R;41N)>PNZ:'29(B<@I ,:(
MC"(-0F9G"_1L!K?3[-[(W!6PFW.P5K&8:PV@0M)>!\V!%=FD2K\RR-9+YO;8
MD72%W<HH5-[Y6&L%%WU4Q@"KHD,-K+E?[.Y^7:QOA%4NBVWD8+/3&8RO6!U9
M09^+ E7641&L,ZLVHO>R.0)RU9B65.H\L$N)L\[.&8L64^W9[%?W*;Y1OK=/
M<3!))8XU%:L@.91X+F==DHG$/II^92^L,<4W>;I?OSU( CF=%052H24QI)CD
M#3KCT19;Z(\'[7)**[VU;ER_?G+,5X H9YW.'^"<3V&4QZH^P/CQNP\/F#X>
M>@'Q\V^^1IJ"KZIMM*W) B4;,42RKI20R5=MNUL(>#:=__AD.J'C,M^;/N/I
M&[%%GV#[H)F"R5$[V5-^>3S$^61Z(GB*U2H#P7(P%(,V&?/L[ICVY0:8GDY.
M<+C,4AG[@Y$P:J_N3W$\JSS=JS]/)O39S7XX^.P@N9&]-SR5W_)U[Z,]H:<H
MG#Z]4GN[@^\&H^/139JC9?:.9UN\1I-R((B1$T0M\E+XZ6.NI<-]A[Y SB>'
M.&-[?S@8#PH.]Z>#Y67>W3#IND(-5P)'1$L>J@BSE',,(.HLDO*Y1-\\E5!#
M+3Q5-SER$Y[J2OTIK^FH&HKJ:H[J<\"OX:BR#3F <]X3 Q&FK%7Q8 AT*#%1
MK]3WC6G;K@A)L,P4%==(&;QB#+:8[*I7&6VP9\/S3$CV9GAV";;/1N15I>,2
M1R0F48F64;6F4D:5J!1JC4[9!)!UO]JG=@G:FVF'4+,SN63O$D, &Z,-)I@*
MB9(2L=]=M'HO8VWB5*Q5)5 $B[XUHVB3I<:&&ESES[6*NGD,;M;EJ^48F!"S
M*UBTBEI#<82A6$ZA< FJ&$B+V0A0\70V0EYTC[OGEN/Q9/QRSM/1 \[S_9.C
MSV2X*#I1W_-!'O+N9,ZS)WB"\GI9(4&[Z+;0=WK<[OH35?G)=9_Q>#"9+J[>
MA, -3W7 EHI7G.I8'/JU=#H>#TZY-)\BB6;^@_#D T5&IQ-UIX_BDP/.SW7^
M_?G[=K)+>4K5VY22J!UVX-$@0Z3D@L2IVE+R&YY^#4^?,O'H:"Y'/%E@?/%6
M_O[8O?%F\"QO\/SEH/F:P9((:O&.#.0L*L3%&&*0:,Z;Z$(Q=3-8;GNP[+^=
M; ;+=0?+Q2PB"\:V].;8%L,+H:M-^W$.QB9/I\(E*F?,UOF+#<=[02?ADMLR
MYBIT^NS0:]#)1*T"5X*@ =!BII \6-V*> 41W*=T:J';UOF+#9UZ0J<+,>;?
MTVE9\S8*,$!EFZK/X.1?8!5)*<8J-LK8,^MTMLB[H5.?Z'3E%>3ET0EK]@6M
M41*I R27BK>!E2U@)"XR?$8G>T8G!59MZ-07.MDKTTG!EE5+H!-7@S%K1:VV
M5_(UFK;G$.2CY%0U=$:G<$ZG37S0(SJ%J]-I25*\37 ;)* J)"K99_%F*80(
M"DKE$L^TDSIW=GICG7I#IZM.2;=#]7*L$T()V<=4C4]@#"0,%,0R:>%6B=GT
M*$%N0Z?59]_I: V0JKEM%4434G4.BC%%91LM^C,Z^3,Z*;^Q3OVAD[\RG>30
MI5@G;Z($<Q5L< A1_)X+""A&2@,'D>=G=(K:;9V_V-"I+W02)^:N2*=/#[T&
MG:J.032X#IXCE%;2+GF0_S)1C#:?=9':L*C+++J0W76!&->JW\'%9UV,K@I2
M)(P"G3(Z9+*L\VFMPUM9NOEG3^"S&?[K5,0W*JOBBXP(!E-+9!&"I51J2[_Q
M-/=I,['?FZ'QV5S]=5+6K:N85*DQ)5 9<VYY5[YM]+5!U1[TA-H0XV9:,NHH
MXM[IG,"#KC5&Q2&D$-&E&)/;1(Y7N_CVN$Q&_&PNFJ;=]N-)P;:4??$>]N:'
M/'WX[JAM3EPK:JX^9'6HG74F)V58Q*!MC6>5HQ+!YH1V%?D;O<@)\%X3:943
M08#6>PD3BHJ(.?H2B<]R K2^Q8G(KYAQ^P?+2TN:<1-M!0841MVV>D03K0K:
MLVO3NL%5M5%:R[5:YF:WF"Q1:56G,31+$SV(P,JMY7&!$%N+H:S\)LFF1PQ9
M?9*-U:2+V&4MZAT\B@6N)%Y.)XH4.+IS.IVO.[J-/EOC)-[;X?B5%T/=LC)_
MR'E54,4:(&=*WA7GJTHV8(X%-QS_EG)OUY/CUEAV)B1OLX;J,8M&K%IG[TL-
M#N/GLL#KM.%X?^AT95G@MW1:1MCFM);PP\3H"*HQ+0' 1AW(D&_[T3;3-GVE
MTTIF3[Q3/E4$0[F (I- ![!D*V 52Q6ZNPMWPZ(_1[-+W"-<P*1@2W+5$"3C
M4.<<#.2$R>60L$<%$S8,67UM!BOZQD)UKB0 $XLH_82<V9-6AE%]FW:F*X.]
M^A*URX[0(CA#$0.+:A5X BH=^!2=3:9\E\?X!6)<2'Z_3M\_GU"3A39@H287
MG3>.:U28<JBGP4LCQID7V#"DRPSYW O E;W LO92.%4H$%8?V4$, 2,E5M%D
M7E1F/JWY(I+"Q V+;H5%5[[TL^,\6Y29G3]\(__Y\Y_^V0$W:M^:?-DR<0GV
MS3K%E(W\KQ; HM 6B8A"-*&D'-5B<\\I(;<VS-PP\PIV]3-N_IU=_>S0ZZQ)
M5Q.B9RVD(HG;3%8F.*R:0I;0S;AO,\GK>@O#2VR>7%LI$7%Y(2. ;KMS@L_R
M2:I Q':SRM%3$;6J!044O1VY%HZ@;$89_<(C<B8&SZD'H?3'XOU_YM#.\?P8
MAX^.Q]23V%EK0-\*J[!+ )BB*4XEJWQA7PIAO^%XP",4JO+19#:8?ZD0>5<@
ML5Z D&&15%9@7$Y ,6:R#LB!Y=)O2#[6C'^"\E!Z@@EQ4*1RJ  &4O3)5K%B
M(0;G#7G'?<=D>C29BD%O/NI9:[(QN$+A_JY@$R4"!PF_G;,9')D4 :!ZEW1$
M\*K#I5BO@LW=EZTY2N] J3;KH"&5J!*$EJ9/BEP$^5"S-;G?H#S\WV.YU=Z!
M8@0%'2LDKA6PI-QVTKAJD\1:-<>>._O?GNU/%V43^P<,<S-6EC"BF*S6,\A3
M<0E-P5I2@GX#\QRG4[SA2;7E8>%M%=V;BJAB!0T%<(;11Q^+D4'3<W?R[' R
MG>]+#/Q)"[*> *.9T2G7UOH*I-"6\L7G5Z_!91<8NS]-U(U099D-SLBK%(JX
M>!(][(P,&VX)%E8^MD5SOR%9@2Q>9@O1E-%ZUQ*A$&3D)"=(^4Q%6R(3>]#A
MI2L*;(F@B#,1U54K%BWAO.&48A+'8GTM[,B6?H-RB[']$C$)6F17$5<ER$!3
MP\:)1RG (L?(^9X;L5L07TO$PG!-*I%. 0@RZ&1S]B;(RXJZ!MUO+&YG=GB)
M<&CR*4N(Z!.T.16%).^BB\P6)4SIP<I<E[3P,LL?@ X5LRU5$10GX6, X\1T
ML:Z4^A"D/!J,<=Q<Q>=K8KV>N]< #@JKZ,F $BF,00.EX!6KFI-? USZ/5F,
M42)%-HK!9# 48U2>=,E:Q'*.L:X%0'U<80E.0\VQFE9.O27M,Y68"I2LC.8^
M*.,.6;1E>II8(;O8QH8'1P*)41%KTMD(6*4'8627!LSU@/G00FC!(/DC+^\C
M=/[M^5FNW$P( +580M*J(B1BI%!=2:Q$5EA-/5CE?#*=R".<GSP9RE.].Z8V
M3;!H6G[OY,_Z;Z_60>$/A_3%4$IH:D''$DH%5BZK$FKPQ922P!O5_0'959"6
M:#4]>()H')7*X+5*$D 1)QNJM5%Q#Y8__Q%(C\7"\.%D2-NCH^GD#?=I62'&
M7*%:@];*^&%(IL56B0R58(LS:S:>;AVJ9;;!=C:XQ!A+%<B,Q+_R. ,D=)ZM
M\6Y-1M595NCHZ'C.TP]'R-'/)G7^%J=]V9<GLAT9T&MML+FL5I@1 D9,1,G[
M'DCZ[L.US$3O)!9/P$K6"ER5D]$I*"]"P\EXBZ;[HTN4_F#.CP=OF+;'\AA>
MMISJN[,9SV?W3G;PU61Z?XBSV46#^ 3G<A6F?2Z'X\EP\O*D)\/+D%5! C)6
MFH"*QF2*>*Y84J0<@^W^\.H!7LN,I$N!5E0/1%V TX3>!:?9%)-L#;$'>;U?
MA=?^%(EW<=2;*4+%44-2S(X!LJ\Q*1M3]$JWZORN!P%6AW%:YN(4!&W8B08$
M!S5ZM)G)$6==/9G3M<(U'$_WCV?SR8BG3WFX*-4\.QP<]65H58C65E,I 4-,
M-<<<P >"8-BF[-=T:-TZ9$L<9;%BA6;V E21\)1LA.P@E^2YYMJ/%:VO@$R>
MP11+6Z]_.GAYV)O9#(FU(I?D."0'E$K2Y*PWW!:]HJ9U=5ZW"M<RYPF],FBL
M5:V?H@RH:+%MOS-:N]SFW$_+<7<9KGO'L\&8!8\BD>_INL.G8?$)\;LGAS@=
M8>'C^:#@<+8]+C>*3ER>8K<)V17"6C+D:*))SA=& !5:"9D>52OL"$RK+QF8
M=!$(R7C,%9)(>DP6M>9H14MB'Z9[.P+ES<Q!:9$4Q:!.V0)128 2-0>)Q$B)
M8X,>U>WK"$RK+YYGM+,2E"EOM(4"!5$'4P.1"!5%V79?078$RAL1C,Y[7X.K
M&4D!EQ*+XH@F4-4)2@I]5R [/,>,L\%L_Y"G>+0 Z&;5X?+T!WO3VM:ZJDR
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MP'X)ASU-90>KRSW7U-W M4W+\]T K%(#3!,;MM/T5L .>7$YGLSS+<WGCNZ
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MU>P%E'#3<[G./=M2X4_/_X3@;+93[H?Y-DO3:9"DZ'!=WI]D1<Y$5SW78NC
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M-JO''8=G;='Z#T.8C)*S])S+9)C$;Y<"(+8!9N]R[Z(MHD N5^G_/FP;;P]
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M),;AVS"E_944&H.$1Z7R-55E<:<E#8/TS^@,BKP QH(% OW7FR_$.&FD<&S
M8R1-Q+,E:Z"$$ UW<2QB^.IZ*#74325-IF VE%6"8-JPGTD,?R7E0HFD4Y*5
M3DE@VVTVR4-0;"NF5#(6(3_+-E%PEU5%(P63EU_ ?2;*3@$7AT"KY^*MHJL4
M@13PK[@O<*9ROU*>!.33O (S%_\KMWA."*/X@5M. 0$.XZ-]MJ4T[F.@<W:%
MS]##^ 9L+H]RSR-:QQ0Z^ ]^ 9/'46MA(G8"O_)PY2!#)0V<@F!3]H04+6G
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M'V[O'NTH@_W7,VO97+S=QU.0Z2..R-'SE%T"=[R"7SV=6OJS(()G*37U+<O
M37B/'>>+M''PLRJ>Y$O,4:[445;+R'>5[!.<C ("GX]Y 60"ES30D'!\>_ K
M+,>-&'N@6JK=N07V3P6AUGL20KTXI=JE4<)E\67DD-B5(':L")0RNH#?H?5;
MEMTYDQX(@:AE)8QE?MX+"@B"P>?H<K"/<A66TQRK+)U<5@1;4F)(0KQG=ZL&
MG,NQ*]QQB??U[^XX<^Z-"7@.<#"!W2PK7#1@4M_#@3W;F@8(VJD65.6](EJQ
MS%_TZ4)"M YBQK#,1Z9@>9H*U"6Q-GCKR[(_<-6#"5]6=1)7!/JWQ_@H$G'Y
M1I&]EU8I&JCR)DI6EQ& >UG"TYCP.LS!YMF$4:;'[*"K=PS[(84 " +UC3?J
MG>%V@(K@TN<REY;N.E@^ZB;(N92N\;0]I$AJ_T0%_Z<"KM'FOP*C$ 7E99B^
MWFSX#B@WIJRG2.HM/$&Z6"E^R:^,S,"K\A!"H:6X.((M0/,&28E8C"(?)2D5
MS6F6:6QD]<3%&)2V(JN#H\ :F*I'4Z+8SY8B"67.U5&7L,"\&(]JN.<A7%_P
M=RI' _KN;?6F:JXB"UEN1JWQUH5UY#3* HE862P*N;^)N$E6@NV$:RAJ(D!Q
MS:*P)OUDNJ@.BM)XU;0VJR*:H(-/F.QC,>;2G5@Q2,RY+S*@HN:B9N5$8TV-
MJ!V.(WY>!2A%C+H:O(Q7K6"=IT_8<< O4W&\,)/J!! 'E2QC%>"G=FZ4Z^[P
MF%%)R(-DQ*]A'RHP; F$!Q*-1&L#7NZD2Q5BR&U791BBC51%;,H8H*R95I7<
MVE*V=SOEFT(J*1>""0 +$JGU(D$$^)&=ESP'I#+!^UH^ 6K*N2@SFP!+ !%G
M@@ME)ABAVW%$EB\,1_T3&O=5:2XB?UZ7]='T1D!QX54("R/4:6D"8JX?EF.3
M?A;A(Z]PQ3[&EF="RW2EB@DG[M>R#8S8K,;.S#FC2AT,ZV U<&%LSF(F.)F'
MMJW'11%;L7JD4,IM$_XK60X5S/)"UG3#*?^W"&6B)"Z;*_^%&QAO6V(SR9'[
MNU7H#;T0$_;?XLG: _WL+?24E] #B)B53;"H4N)VR%RITRM>?=PY>;VZRG4S
M$7 N$Q OFP?,!%RL?O(#28#/*06PD:E2II16B03-<JA &)6[<Z9"N"]N?+';
ME+M<YH*@G-U2CB2N'09HFK]WP+:O/=\_[?F>SR&:P1;6L+&%#")Q*1]Q.-N<
M7\SD_8@+4#0CF$=-P2EKEFUWNYN5UQI(+MJL"T J <L1) \WI *; .\>3?TT
MB1BIY*/01425U'Y8W0)A)B?\)NFU54^X<IB6,Y7SDNH27,= _P7J\!Y5Q,FR
MRO'4@$YN'PU+#VUV9P8G:)3?!,65NQMP7NG8R^!4E-WTFVXN1U,)"36/=T-F
MCWGI)D"D07A-;(R$40+H&QLS(O <B =1-Z&A<_VF]V:+X8"M'^8R!S24YA>J
M[?N[ V4_2ESXZG.(%8:P,L]P>WCSA=H:&(ZYPC"<9JN<KP4HS\%T+5V_$U=<
M"#J!:$IB)D'@#:<!UMT/.#H98CX;I6,4'LX*X:D8<Q+6'<H) 7D(7)TJKR:#
MG8/7!.QI5*LO\3VBY1U:F?@W@C$%\%)1OEEB?ZK8>T_QL7U?:8G.F3B+X9;$
M%W6JT2LFW"[>"%8(4C-Q1<UR%%R3(L)F+&G5WD%YM7U\LO.Z- K/XS"'FYZP
M[F/RPY3 H]GIEIB1#@EB67.#TA:I^!BF.8ILN:;'$H/J$V F(;<OI8C6],X(
M=1@9HR#%[K+TPJ1EZ%[&IH3K0Q9MAVOC"@1VQV<A>DVJ&,?,$5Z&<&YP*LLC
M!+CXK9(6$#M;5].)N5N(2LXSXY5UV\-+"BF6=7QVC][WC\ DU6B"\^<EC']\
MF<AQYZ*B0365)7[9I\F@_$'K1-81_)'T[X>>NGZW[-_&/ZMG+,WEJ)=-*IJ@
M]+H[1Q551J8248A;2TS.U(PDT^F,_*95<+II"20>V2M57OC:)'C<2VO *$ K
M*@1P:?*5#6FDLDKR\33QT-$X5<1 :'C235,2ALA@21MV0PU2#&>*\FBV#) V
M4O?1 BQ+;V225BK?U@VE2&4BB4B+%8@J$3RFQ-B9'U%#(\Q_Y01?@*E2Y-GG
M9;WXRP;^0JR4'+A,E)2<3VF1D(E+L%D:#@1L32.C:(T"J51O>7:KYG$5XN$;
M$BN^GYG2, O*+(R>6>GO. <J1E?N-,6:R6:8UED9V8B<RDP$3]S9?),2ZH.]
M[2KV;O@0JH/Z?H7"-=,^!-,NJ7 EZH"Q.>?.G!&_'['K9 @6W.BO$K(ED%?!
MM-G$H;:^A1E9LA0RB]2ZL(B?+*@_3L">)U2P8+-LD<^HTQR+OF= 8_RAGO!R
M [J95=:;R2D389$E;#/3GN6N+*1953W8N@00 ?K*-]QN?I<,%<LV7"(E8)YS
M%CEMS3J/ZP);IN;(GD!U$9DRO6^Q96#9Y$S9GA*@>"]TJ9&?LH?!8HD;JMKG
MQ8AQQ!L4[8FR9F'#>5ME="\ZFT6MQ"J:%TUE]Z>R%FS5XJC1 BJ\K3#40@1B
MB9%_WXHA-X[T]("A8SK;JO3_RH8SCIO^A4WI8FB4^-G$E@!HE6\N) 3!$]0U
M))Y%%0%!=J1HYS+<$8Z5O>'^4+01HQ!RH^:G++]98*&$*I'HU=[)Z>[KTF;=
M^7!RN/L?"?LCAY:"8'G.+[(97/"6,JPGU8B@X@5VLW%?@89A/OC:F5!H YTC
MT:6;2IBZ/(.EP$M>3?Y/W5)5QYP#_<]F;(UXM0\,N'&:47SZ_!S!5_-[B=Y3
M I?4/?Z0K3MU1@!Y+)@ 5I,3E::[+#4 [^%JKEO*N[*J/>$'ZJJ^2Z97'3M]
M$_NBDJ=HJU27;)7M23V/5W,KRU;0_5XM"A\C"I '*O76$8L":26(^K$E&+,L
M_UIB*AM#':<3;!)'Z,N=!A)RJ9?DX+P/=^=DE"83EH^FP@F3-$B^K%Y;KW<6
MA5.5]=U&#[6@V5>[VZ^I/' YNT1,:0[C.;?\[\T-;!>)=*8ZL<R;SAU1"1^?
M=^"<G!Z?[6Z?*4/B#FQ/M&S1.(+1[2#/5(>]E/-J"J!VU!4 L$;#C\+41]A
M*@O'TNG]XDCWK\CI7"[XSQH-PE9/W/>I$Y), UW:UH3DD< *51WCZC9Y58M
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M?/I:1MQ+.B>YVJ@[\PJ1RK+235F_4.2I9LB750W$&61#]7O4X!)?MO)T.5!
M694[5@@>KO[1I_]J?Y2DA NDKI%"0]_$-A+"C44HPJH;!0W3,(^4W<9+ZTJ/
MV>NRUBE5E"P-#>Q/5UM&F\K>\>G9[K$LA?9J^8:^%BU89]J3BD0!%C>[F?S6
MZVW9S=1Y417@/.7G^+MR-^%0F4SS:9 %P<H_GE8.2WY)XJJL%XDT4E)#W5<%
MCQ %VK0"]WXO?G&Y&)O0K%I7$TC1LAKRLHHA9?4%?'7-'DE3)]2M^6#"NB+
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M,%@;=9*$M].)J7!);L)/$<5L\;5 =$F'N7%"89*,$&@U&\U=QY=W55H4I>R
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ME,ZGI*3*8W/Y1+FVU7#_^*J!>:=^58P8IOGH8R:P@M,OGG^/U\+H\I><]:O
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MKL0%4,\='J=T#X,%:L&!.\E !D1$ONB#ZM!\WU$?5+M9>"\-7C$3C*23Q+!
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MC&$%$2!]T8%E1@H+G3XBM#*?D.-BKCXK>!C5_O5?C9WZQ],.C7#*:(CF19#
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M_PJY*T//N>5\H)IT46<OU.S41 F<-4,Q6LDI,5=<,K5_AFQHDA'/;]+8BIH
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M/JCD@OY:[I8T#@3&5R0\:F):&!V%9?-]FCIC _Y#QY# @QCI%H<A\T"H<+
M8V L['E7[<F[BC'P2#>EL3*7^D8&(&:R0:NP+RG@M#$C!=5RS4'SYKF<$<LI
M85@JY1$DDRA*L+T:4(2V1\R13=9[ZY9/A)7P9X<&1W%LU/Z1*P?*THE' ]6%
M=B)ZI1Q/U3B,SG_T+6J:2(T>6>%T@^H&R$0_M;B,2:*9H.:HF:@3*PRX#I$)
MX%%T_B)/9"T<E;FE6N5F[78[2KCE[)FLS]L@]VKF_0,.*M%WI7"!CI4B)=QI
MYNH(RB=-@4-/E8>:K5ZX\34<*1V9X^WWJ&_RG$@=*$/EOC/5]E&=A:'G&(,I
M@3T]I]B E#] )]]1/-4F2'?Q\3&DL=S\QX\3D#_@]!;6'%[VA2%E9V*J<'E>
MIGF)!MMS*,;IO6R^C@;8G&ZV$GE]]J9Q&O8V? =D;8:N*9WKMKGR3K-:J]_E
M@;;-"Q<2S=Q%7T>S +Q0-Y)$RCE7W:</I+PM-%A,OYUV&,6C5:#&W FT1TDQ
M$9YU:V==43K=@J?',1B!X'?__^R]:W/;UKDP^E<PV;MM,@/1O(BZV#V9<9QD
MU[M-XS=VFG,^G0&)11$Q"+"X2&%__?O<U@T$*<J2;%' GMW6(HF%M9[UW*^7
MFN09A3WL-'O^1W+%,TOM'BIG=C1Q\3P306-VA\A]R^LGDX% "ITJ*#0QGIQ@
M7"["F!W(HVLR@&B<M!Z7:<)] 6J%N)6DV)*RJ^BC,H^A0JH']^K]#<!&\A8O
M69/%*<2IUCMY<YRMLN#,#9UH, C^EM_@"B"]*]K_3,%O.7Q(.0LH!&F:KM@H
M-$XUC>H,&!?=#\5M-*OY#@RLCRHKDACN_)UO:$HFCCF/YC24*C%3S(5C#M3#
M@@#\I4K1>^/OFUTMYQ3 RN'"BH;5/ <SCB3SG,V?.4JBGS,+1X8\,-<WR3J-
M "]6B,0O^*]?W[\.P7Z8#\!N0)3'NX>+8'C*"&4:E6JBH@3=4/-.G'G+6$+#
M4YE,OJ<4,SCJ&U 7*E!5Z& LNM(DE@B<D(_(-AF"6R@3HG9U/-XL.?'6P&;A
MJN]H+: S<%8DNUC*^""6,GCLH,_>M]/,YYTZQ==/QGRBS:K!U9>$U2!D_B:!
M1H 86+HT [D 9JZ^X6P81_7:S<2UJZ;!I\N[+('Y>UKGTZ.9_9FN@Z!AQ0M5
MZPP<30SR-#K/52&SXJT5X6D7>&I62^@,HHF@TF23V79LYJZRO2W$=;L)T(@"
M/L8<T\O3P<7%Y%/FF(ZF@_'D$2:.3@?3T]U?WV/9L\OI$2W[:$ X;.YJ:^'-
MZ*(YDK*UJF!_C<TM90?.U]LS+6\I2V!*>2J#+2G*O64,[ 3NY0'39X\%.+<F
M&Q!L/&-A9PW-'>%RS#AU&-C>Y 4FWN6LX/Z8%_#EW:9%'4:[=P;5YZL*.@Q0
M'T07?&>4P,,']CY[X)#9)GZQ?^:#'C(^9'ZPRNSW!TX$[ AX_M=1H7NPV')0
M(25R&O=PL969/B%1?'#Z:EM<[:S/[$[NY?AH<B][\_1H[,AG;9XV>(2$@1H,
MM\AO^-_G!S?3>" K897$<:J^E)7PTSXIU$V@G(? $\*+T=YN<=T$S>F+T>F+
M\7 \O4\_FV>CM/S:0^&K;T?A^>DT')Z=]L#811]WD4,[(?64NM0]*GT<WT&!
M!"Y&X=G%I[47/;[S7KRX>"0D?TI-WCZ'$#BB@X[#\=E9>'EYV9'S/AZ2'Q_!
M=X:3 Y*?#\/A^*PCY^TY>0<Y^20<#4>?C.3'=]Z>DSMQ&4Q?Z@AS.P7+=!*>
MCX<=.6_/S!\"SX_OK--P<GD:GHX?9"S4$9SW_DX6X[P]ZY+S]E!G?Z> <AZ>
MCL[#X>FX!\T6:(#(D,[N90P]%\_N_4S@YP*%!_%T/A=@]/I6!XWGW@W:7>.Y
M=X,^T_/VG+R#G+QW@W:7D_=NT.=[WIZ9]V[0+ISW =V@G<IA_;7<6ZC53:"<
MAZ>7H_!\N#>+LYN@N5_.\S/S>?5NT/OG/#\S8#QBSO/Q">7.6,_WBP0<WWE[
MZ[F;?M![./N/[[R]Z=Q!3GX_9__QG;?GY!WDY/=S]A_?>7M.WDTGZ/V<_<=W
MWIZ9=S.H=3]G__&=]P&=_=,N.6\/S7GN%%#.P_/)>3@:'9;SW"G0C,8O,.UY
M?-YWL^@;G&A/Y\7H,IQ,[Q57?C; $/KH%:XN6<_H!QV&%Y-[A4"/Z+R/B.7'
M9V)UR1%Z-@K'DZXX0GM>WE'C^32\O!R&HVG/SCO(SKOD#9V&H^%%.!UVI5AK
M^N+R@9Q$CVC2/#VC_]",T$X!Y2(<C<'L/=VK#743-'U&:)\1VF>$]AFAO;[5
ME^#T[9Z[:$%/P[/163@]ZTIB:!]^[L//#VA9C(?G8%WL59^["9I^OD8??GZ,
M0IOG HP^W:^#T><'L:V/Z+R]^=R;SYTX;V\^]^9S)\[;<_2.<O2^'.=+!*"/
MR^9_D_\4O @^1PSZN."BW42/'X ^+K@\;O3YF+C-(X6>CPD$CQMW/B9(]#I6
M1W6LWFKNK>9.6)&]U=Q;$T\BE_6X(*+MB+TEO1V$2Q]K[F/-#VI-/#-@]'I6
M9_6LOK=,;SEWP)*\GT%Q?.?M#8H^//' 9L7XLC<K^N*XOCBN+X[KM:U>V^KC
M%+W]W-O/?9S"0?3/YCY[>IK@+<5OW0'$97AZ.0FG%WO[K7Y&\^"+-EE[,<9>
M3).^F^9#J#_/!1 @+D;GX7D?B]I-(I_DICH]&&I\X"9K>28^B4.]5SVX1%Y-
M1Z-PM+]M6@^TAI-C^&(\0C7P7FKOLTC%[/-ROQV'YY=GX6C2Y^7NH(O>X?7L
M'4#3\.P<_O.)#/'XSON8F'Y\7I$N>;S.PN'%*+SL3(>"S\#3]ZJ,1P2JAS+Q
MCQX09^'YZ#0\>Y#<PJ,'QCX">E%%LU3!_\;)];=_A?_2>]LR?V3OW_YU5KSX
MUBS4?&P5%5=)9F#&U/B@9YX.QHU3GS=//1[^Z=4Z+Y,JR;.7A4JC*KE6KU"S
M/1D/+M;;EQ.5"A?XZML__]?%>#Q]I8_WH!N_N.VRQF3._+%.B@AW'L11!<OF
MB^"'NLC7"K8297% -*Y*%:SAZZPJ@ZA0 9QE7L,Y51Q$93 >!AL5%66P*/)5
M4"U5 '^EB2JK(,NS=9%?)R6\($J#10([N*(W!54>W"R3^3)8%TE>)-4F2,I@
MGD9PN#BD5\<Y/%\%5?11!4D&OX_F<Z";*@!<41DN6<+;HHJVE!?!*MH$,Q5$
MUU&2(IK!0[@;V/OO=9&4<3+'<Y:#+XA-HZ&^%5KQ95(!2LQO1:^OOGT3K:L$
M^,'.O1,!)5D,=_1R?/Z8.]^+3^\TEL#]K56&/$LP)XC6:S@KX1I<= Y$@5_J
M@]$3*U4M\YB0<!5]]+_&.[[) .-FFZ N!\&'I<5)LQHBGWD$,"^NYU48) O
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M.?NTE/4.0>HA#9T'!-138U,/904]8Q#=3Z9U!DR?)O#BI%RGT>9EEF?(*/:
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MJ98$7%!<5B7>$_Y1J'(-OP5D#Z*K0JD5WE$8Y'41%+ADB:L4:J[P%T6^B5(
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M"CR[J]1JG>8;!:^$F\P7"S(2T(Y';0F4F"OZ)6IJ@+SD8EA'FU"O*L81"B3
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M&/*:7YD75T;V\FUF.44M@Z6*TFJ)%)4N\*VR(M +$8+9D5SPRSNP4(F8GF
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MJ8VM9<JEU.*+7\8X-DCHP@496\.;D:2]6Z],* FS=DLEF9/7^4>,3",@==)
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M(9IX/=8I9R0R'5'DS]Y<($'@?&+0?%6Z $-B@6/X4 ? #JUV_@!1!O;10ZT
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M)M('!LVEAO:/3UCL-R.LS(PO'0<JV;=/Z*+'%9FY*Y[?$.,22<9&EK= Q/$
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ML:A.IR<QFO\.7-NXH;MY5X@V6*^Y)P#PGCXB3U;]>R\%*A8$)E5UOD21*GA
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M*&!'_Q"@U=H;/F_63927;N#VM.;$F)V-G9MI$L9Y>F"RR[%J-:_U].45=[]
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M%RM5-$*-C&L\E<BW?,-V5:6!8K;7[!Y#6<-;TT:;M^Y&*C*\!DDK%(6VL .
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MC5,\/> !EG;.<M-=)M*11I9$.B;)',YM6F?F=Y@M;$_.T][2MM=X70<P44F
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M]*<PP[=^>.\_I*]^*"UD%D27"X1;7/-ZXB^Q8.8G-S"@)&B/-A4QNB UV=U
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M['5"HV/O#<):GHLQ-AD+'UP8/A0I4 "+Q.Z#5,!")K G898-9TN57SFYD@*
M_(F3&S^"]R>.GSI3.'B =V_7KDLJK$O43F_;O85E77J#%UL7ZJ563YLB1YH"
MC?@6,02#\:.3>E>BEM=I=)$Z*S=EX\CSWD@ZV!&9'X28I%#H&-SQI #N1)0+
MVAWB^UQ$J4 Q2?;960WGRAGKC5M\886*V>D3WE!]8@ **')& EX'K2 U TE&
MLU*2P8:"TV\<1\6_I# 1M;UWJ.Z1NU=1E,.DOPK,(7=@TC_%R<SQFI?_Q2R&
M4V *JX9''H2?+##94?S%$P?E\S[(;NF=ZX_O:3 Q2G(_>7!:?9:UQHXV_WIU
M;37=DS7=S\&_\@!D]8$D];W$7@6)!<$8BY?6>255]TW ).G43Y5>*MDCAA6"
MK="UE>,ZXUL_NH%Y27DO#!?5?I0-H_+OL)=ZP)T;EB76"N4QA?+S='I9;F1S
ME23(0N:&\Y)"^8=P;GTX\:(8I&QZ.9+33&F:OCE-*S3/*C1PYF:)/\[P*/M<
MH$.\K ;[S1_E(9R9:+2%<9HG@C19%-]'J+STA$TX"Y_TU\+YNNK8M/)T5'E*
M HKK.%?@ >=1AC[K%SALQH%@-_=CF@4SGUS=EY2Q\B&9!C=1,(5Y1YD^]NX%
MF-MA %X"*"CPC6=HY^$#X'P;L03R]M,TG\VE',+/_LPG-WRDTH,A10&63MY5
MD8#UXFIE\P#^*;;@*TEF$D?P]_$"\5]$Z8'[X( 8S=#H!Y%,>+)^,=EY:;*.
M/Y\#*2C8#A*YE72Y3BI$A;W&0</P!J_+X;'K'-9+_T8"88L^BM>VWOU*A;Y
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M63!N.#IW@?=E$"E*$*H++"SAORG"%*M/Q#1$L"T8E]174FQM/2A.*^=5XSR
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MV1=>WQT.6J>IEG=)IWF"(%>0J6[?ZU2'I]7(P#GM7O6?T/\!XUH&(L^K[_#
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MS0%YT]6\ >:T&X.E+<(G>9$L*U)+_X/1OVD@#EP,&FV3^K+F$0NJI>C3D9_
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MYR<Q2@A$E[8$XI)=S9,@E*!K,+LT![V:\4XH<-T40AL!)$<3A4-)7VHXCS:
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M!3CR.;*?^^]29ZS$R2_$::[%*:4Y@!6GB((Z,@9C)9@A2?PH4_#I^,_$?T
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MF]=,&[U05KLI2XY\H#XKG]NK=!D&<#+_&_QV'OICF*+I%!8^U"S'2R3!W:^
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M'V5GC?9=_.:BRX-+1EU.^QJ5$^XH:FW'/JGL[5?TQHN5R2SGC1N#YXXBY-R
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M+]+NVU-A?Z]I]VU%YK(#XWJ;#UQ,J/D)$VKL/CT5=MM]6IFY[,"XX:N_;Y^
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MN*A;E0;$M8$2643;+UXG56O$E3?HPUSWIB3S#O76;1%[=N7V?63BRLC6C>*
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MAP7,G)!!6QT0LQ)IZG'RS1C3TD8N69D!L*PXGQS&@E@@5D? B=>!18E!&\[
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M6V3%@U [<;#=$X5L[C(D& 5FB0;-B =CA62(4VH83:@M:%U1M#YE#+  >=%
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MR&"$2XK]<=7K6M?M_77J[G/W::PS,W'*4+W/_?!R?]#?!=::BNMM__5<6&]
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M.,<!&64<DE@;[HP#8>,"\,T'^(/E0!64/Q3*&Y8)5YPI2P';(9 \D\\A:P.
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MB8+J^T!U<]2\,(IY*Y'7"LYJX0R8%8$C KSM!>/8>S K"",=PVF+4/V\PA*
MELFP.SY?LVGQ'-P?CV5:[$U%UHVC=\-X.@NM[O3#KNWU1C,>&Q<>NYO'<\EC
M6GI<*R;)83[M(*E![BC+VVOX'\[>3LEYAUP362W>SDV!^V/9' 7N#Q?@R' /
MAG!&/4I&@S'B$T':2(,D\9R#I2(Q874JA>$=+4@!_,8"_K',D0+XAPN!Y!91
M 6-#A$*&*CC?@W1(!^N1IMHYQK!6W&QM:T,[6EW-;][X\,?B2Q^K5]3"7AE&
M'[M?8Y@:+@MH9,OE7]TO><A*?S".LY=9UXO/L454>_K.7D=MNX->+]8+.TC[
M(*S1^X6P"H6M1&$7QD@&@D.,F"%02D!GB10C:Z- SFAM":-*4M?&OMC%@=IJ
M$Z4@^H$1W:C1\%390 42V&#$DZ7(2-!,J M1.45I-*WL=%\0O1DV2('U^F#=
ML#6"5SI%*I&)7,)!#8BV3B7D Y-<D^1T!%N#=0RYVKZQ1$0>IAMM;@4U/J].
MXOAX$!J!D.<5!WG@<N_OU(N]KF6R5XNDN#U^E(H^-FT&23%+*E!$671 1;E-
M75(2.6JI(EA&1\76MFA+6^SBW-RDDNZ"YS7A>6DQ,!>H=#&A)//H2HTITB0H
ME*)*B7 'NF-.MVA/H_N"Z%:;"C<:_P7+]X/E9CEW(M81+I#U&<O>P6\$&Q1%
M(I@23J4L%1F/&8H ),[K,?X5AWU8UJAZ_]_VY/3G5],)%J4>HV5)4Z^ZF9FZ
MX\DP'J1EO^O"4BNQE&_6=9_O_79DHJ<J:(,8)PQQ*1/25&"4N&02"Q\3S;UD
M: ?+.Z=*%#=E:U']"(&' N@U ;I1VPV UDQ)F@?@Q60EXB($!'(3"(,<%3;&
MRHA+X&'S$?T(\[(+HM>#Z&9Y-R#:"Z^L\!0)JQSBFDMDO.;(",F-2MYQN;YN
M#27J<&LP'HR/X["V%IY79.%AC8417"[\]@/.RC>#89.=:G%-_1NPWSNP]J]U
MCF:AIY7HZ5,S!I%"U!CX F'-@)J8#LA9QA"Q,;! 3)*BSK4VU_@L2YYUJU'>
M]E!$0?<]H;M924%!M<" ;I5[OM%$D?8IHF"UP8$JEG ]7D;*JZT:2D1B$X#]
M&#UF"[#O!]C-RFZM3 @"YY%V,4^+(LABKQ#'26D5',79HFA1J'%-<8GZNYEJ
ML4VQ'\?3*=FGP\'7;HBA<N?53Y-1S(E,?YLE,^5*";L PETB%6XP#'&(X')?
MYNT9#7K=4,TO\NE16TO#&"#4G*'V;B;27\X_@CS?]@NIK2^: :1&HDNY7@(I
MG8?A!:R0(9R@&$1N8,&L57QK&^38D?S./6I7Q<\3\HH^7TYX2#.F<,*]!T2
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MX2&-@ZE_(?Z:Q?-NV.W[[JGMS658J&D%:MI_];99:/3GWF]'U*D\KCH@'H-
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M9^&&B3^?=</X>*Z0-MXX_9*7>/D6ZT:#WF1\\UL:Z_9PC\;A[:&[,^S:W@V
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MJ%P$+66^A+EXZB(1>-^RP=9H7K&72:D7+ZPG=Y;)7S#;L!B6WUJ_"81G>_!
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M:/R9O^._'G""J;A@@;[L3T["8#Q[_H(!>O4\G+9ZRF.D7T^5JMPQ8@A\4F_
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ME!.ATUR7IJA8+K4I_LJ;47<'^K4'6IH\9\RD G8[I860*?!1EA*>R[RP%G0
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M*8>,!:^^QZX^(>6J;7@TWI*G7<]QS7ZNP_J#]<V;89H^=;=QOZYN(,K03LU
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MA_#/T:__>G_T\M\?FM_ NQ;_)G^4_SXY6+[[O/_I^.27^NADGQV]?#,\_/6
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M?KQU/AS%1->8 -JE\O0SX**BL-*6H]':0UZ4/YF^MC=K2WEQUWUDO^F/%B0
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M5IB\TJ5U3%5IE6F>4D4*8/(B2_&6BY(JENL<NRA7@[S:A5?_QDRNLZIP:,*
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M"\HRGDK+LY127::\8"+-6*X4DU9A0')-6\VRRA:DU*XL,UHQ(G)&2"D4S:4
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MC.;#91,F"A#E?=ERN4IXWE'N/1WXGF#EFQH53;6(P#?:^C:W0%0-$'B%5.A
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MT:U?OT"*4DI#2FLIS6"#J&555<"(BE-+#;IT<YZQ+2ZY6]<[O;1J?C "B;1
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MMDU*5V7D2SQ@-.5+2]#MM'5B(3?PNNDH.[*NGL>2!Z]Y-6HY?CT<SV)Q!>P
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M31S#)JNT<$1Q0 :9*YU9P[FUR-14;A3RKD+9:V3XU9!A!1A9ULAP-\C0\H(
MWAEXR8262A/!.2/&!T5R&V266>N$SY\\8V(CRW\:9/A5*K&6-BJH2"EK*OK$
MY=_F_:Z:[<SRV"<V_/4!V?UZ/G?;\&J-;3? MG8-%^?&T,QKPIUT1!22DS++
M-,EY$+E0$K096#UJ0TBU#L2OWDZ]3T]DO5,?8*>VZKM"5@2>.1*41?_$%D3#
M2I.<,F9+5Y36,]RI)5ML9;?>J0^^4^_3,UCOU ?8J5-_@0< 9<LMR5@._H+U
MDI2%+HD'>=1"Y[RD=BT^:_&Y1'R<*DJ1!PVHE7$ ^DR1D@=/),T"=6"G:5V
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MF9G 21L/8+0XD]UJ(>(+SN^+9J;B7./^G)DN!/_*X ! :&^;Z";-3;_Q<5%
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MV&0GH6V-IBBZ4M5!PI6C[*=!C/791GSBT*7G+<P7GI$A!IU%N0!Y_R^YR3H
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MV?CQ*>:&5?LS4U%:TV]YEC<;-U,/NG&GL<=FI]GX4FD3@\IM@LFM*JGF[?"
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MFV-0SBVT@Y^>C*8:I<6=^F16VG 8MW$[C-8%\RS362Y!$3IC'79D5Y)KY@/
MX*OO/DA+I2'3_NA_?MWMKHIK\0 6R!;=>7.@A&",90[<7,:)" PL$.D=,7E6
MF@#^+QYQ/^/+/(OFI S%ZE9+75#)K5.T '\&'J,9Y2JGEBMP*SD3*2BV7NJ[
M7.J]K0.3T:!$X0DKJ"$BSPT!UY&2W&=,J*)016:?/!-J4URZU/',_*0^*TGU
M))@J&<.TV&$/JSF2480L'*E6J&$S6RTT^% -<:OO$M_FWG3\CUA47ISO'!X4
MN;"TR#3104DBF"F(5DP2SX+F&=,J. Q^+4FQ:$ AYLM&9=28 #,J)1;)1*5O
MNPW3W74ZX[4?QISK.6D!X A&2O"N%1K-4F6EDUQDDEF9%T(LEY97NW_.R\1S
M['^^%RK1V!M&P7A1C?$U#K'Y<%1].J*-L&2/3U@$J! K!<L!NDGF B-"!$X4
MHQEQIBR+HE2%\R(*R^(1T+3@+V+)-#)UY*<0<C/CH[ND^&F&"GOT??8)5QS>
MIO"%S()0!G[)K 2A*[UW!3?J.Q"I=]AW3Z?N^*M^>MW4.GQE4K\>0+Q>251;
MN2Z, 9/$%BY'M<6(\;8D-G>Y+TOE,JHPF9#?G8'""YX7>>:X+0!%<E%ZS<O,
M6IU93V5PWV&@K-?ZDK7>.=U]<\""]$I$E<,]6*.4$>5+#U!2:.>XYXHQ=+++
M*]9Z?)7WDWR=62,&J=KK)DL5WW5U(+W"O,WR]XU+^!FG$>P%/WEUPG/7>\\-
M=??\6ZQ.LOZ5!!7?>3P@'OYX0/SXXX$ZC:95Z+!Z9P.[]:'?\9NS7?9*[KY\
M^QF>=_$1GK/[\I^CC^R?WLZ'5_SC_A%@XGOQ:?OMT4)GK^T7'.Z??7J)W;T
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M[^O@T-\Z5/L(0JZ_9NB4%XSE2IA0!"\$F/<EM27-0^YTL$*6*Q8ZG7?M8I+
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M3B0HZJMWR^:HH,$K4V]Z.0;19@9!>,8[ M=>'%Q].#WX!![,R9^=%GP?G@/
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ML8F)Z<257?*,LG;@7S31(!<RT429T0)QF9D8E)3(:*H0X3Q@P@E-.-9)!F]
M@/.)B?)@3V%+N$I$2\%!I&D2"G-A:MK62@GP5/F"8#IAN$52:HNX2 0YBPG2
MBON<Z,6\KJ0 UZV_R];?,QD'=?_OYWK_5X/2+]#_NX;J9\E:* BO*&Q*[)!)
M$2,>1<Y88 X%CV4T3B@;_<8V-YMD?=JNU<TC:ZBK6A?P&L]>((,#\,PJ'IVG
M&<!TT;>$(!.X0T1@FU3 P@NWBKA/C64UEJTWEKU M^\:YIXEQP5@3C@LB&,"
M4:(<XB%RI*45R$1A'?=1):Y7RQ)2(UV-=%5Z\1=I^5TCW??- <HTKP%3(VU
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ME]'S&(WV5@GL8^Z&$8E?,@9Z&XE3+;@K$MQIR,%Z8I3B#MF8<F<H$I"U%GZ
M7Q I)52E5'.GOP')]=&I".XX=^"C6\JMYP)CJG+X,%+N:\FMA.2R&8/9>&F5
M0\DH@[CA$CG)1";S82%&&ZFO9->#-Y-8<Z,+?V'[?9MKN=8OP>8'6K>>O^_8
MQ3%'3.2.B<BQC,X'D4DWG,.9+[H^ JX,DK9G0@\N4FR",4@&F^FC/466)X$
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M:#G'+'(AE$W!4)PTC498:UV-1M5!HVG86T3'&*8*4><<XK!6R-KHD/%*2ZE
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M$1K.+CE\-<0L7S 7(%&#_)P1_)5B,D9!>$2)91.<RVB5[S8 2VQ&D+;R;F[
MV+M'\88]ULXRX+,&+_9OGB>*?SZR\.\?0!0&/Y:"<;/@%]\F/^<+"V$$\<O*
MO]B*@R'\9SS!L^(),@:@UX=Q]!L!;,)SF!B8QNG#GZ4P>K+ABAO^U!Z"H>&7
MV(*MO!]^8#]NSB+Y=$\.?KIQ@VX][SO<.>+QHC360<#9C\7VG-F0L%O&K2C\
MS47T%_8&(;$@&#TWUCSE0XLM#5(*4GP&GUI_O-5H]@83D9^Y_P35,RA/P#9D
M.>V=E;NX#X)R=-ZQPU[_<JH/!HUB-*D8RECWQ_X1;&X+:K24@$+7CMYJ:_&%
M00('Y^XDEM)<Z$RX:4KPAQ+12]DM1+[=/3L?%KHQ/V>A&+^T]EM@ 0%$E+^7
M;UA:-G-&\V@5.-U2N>3_.A_ 13L,C\>^Y<R%(S< 3R^Q#H3^?'C[)3/&OH?9
MB/WE7>2=/F#U+3O,++7#-%Z8I9F?Q_WQ$,Y 92('5L\79!.,\"?;N;"7@XU_
MS;T([#>T,'&+[WR[B)4_%]:D='\]CH2G2)+!DEMEG5#>60G.G97*F[1QRW5$
MY=-XG\"#=SP&:40^DQ=2&[@;%>E9"#"6$^RI/5U8V5D.1P[.U#Z9Z.2Q_9)5
MT9'MA['I!'\M1+L;YH0;I!=$N0VR.58O'KS'K+%FY#7W>X?K;A39K<;NU#X;
M7L1.UJ+P2L<PE&Y6A+N@_T]=[)<.,R.;H,@I+HS),PO.[?]Y2-H$B8HX'%3
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MZ5N8N)()IE, XV0*YTKKYVOQB]2AN4?WOL;%MVIXV_'G)<Z61S[E^9 O<RT
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MP!T&*6[[BW:14;*E=0^M+(%%(=;%\V^YIE>@^G 8<+*D52;>W0C^O>WU+K,
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M99M4\DW)YP0GHU:MF7%.D+%3"%=/068K*I$S6TZ&GD%HV"EH H=%:7CSS %
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MQ951=]?XA6\V3O,L5%D1KQIG2IZ$8K?;_*LIJM S%?0%G3-PUME>#[XZE(U
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M-GQR1/B=];$DY'C-1HSL@T+BXD9+4,A$0N8NBTA'K9"A2DH: #@S'X<2BSJ
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M- F8)(:\3GG=1I[,%0G\,FX<>&,<'#-V0\+LAM5A W:[X2Z.<_M]<WKQ'T!
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M8A2$XY1'1ATGV4NZ06H6>$E35'6UH_1B'*52(/9!Z7HM/Q4762^BEY1IS,&
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MZ'NN,QNK:$O([9*"$>NQ14);CSBU$6F2-/PJP<^#*(HH5O0]XU5Q)=Q:D6I
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M%$JAQS+Z:1,:[NL<1E2;G9%*@VJST[79ZYV6:NZRU9%XQPSNM :(<>"(UEQ
M8!DWVR+H0I>ID#-FLPOOI!?UHI:[KD9$ZSGJIY)X?%DN<)&4V_SAC?GL$U64
M/C^K&"D:71^9)?R]FYJBTL.X-C)9]P):Q;*)L&SG1I8$<Q%BYL1GFTHFLB-&
M>H.N@Y71)*UP'2RMPK*YX^BPJCLOAJ4_/Q>IEOY:EC["6@27+#E!!"TB[AJ
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MI^.3_F$IO$W]?U)UY9]K*^]^.8PWG(+AP"^,?OT+P<>-IL(.-V<M?"1,QD3
MQDP,<XG0&*ETE$:?+&[;YLFJ2M5AGV'#?+[8?K79:=GL]9:O(\Y62FBD#AB!
MS!EQ#"PR@"2=U-DX5M30EBF?):M=()]]+?S?26?0:<RJ/\PZ&2WDJ#[[\V4X
MCN))4Z4W,A?UI/!1V#+:3"^(K>VU7<&\=UHX8JQ%7YYG27PY+DPL!@J:*\E+
M0[UE.6DWF^K-S\E>/N[-5[-[QBU]\_S+>=G69:19ITRTLJEH=6AB+7@2J/:&
M@5")ANK)/ZN=_77BBS&5,>WUJR/_(H[\Z)!?:+I41'G<1O[MYD9>NHVDY)FS
M),OF.%[Z$I2WB##:N4"+T )Z]UI,&)2OWOU<6>NS,X)JPU.SX:\W6,'FVJZ,
M*8LB,"JY*<(;AA++&"6:Z:B- PC.SF'#H/EB!4='W4YZ""%8<"29ZKX_'-0*
M%T_:\L]N;OE?=W&WY]Q009R@FH 2E+CBQ;/ LE-@.!BQM*KH;2WJZKDO_CY=
M;6XZ\;++HI8 10!>)D==T)K(Q!7NT4(0XV@@WLNL/!7.!EH]]V>ULZVB'%D]
M]E?4'&AFX+9:6<68I[KR:[N.0D+V[PG@_ U;R'GM&1$R&E^TSY(/2ZNPS.B$
MY3O5D9\K(W[^$KQJQ%,VXNL>9E1&+[*.Q&K-"6BKB6')$9V9BSEY0W/I$K-,
MY9.[0+Z\&W^?$LCW>JC1[[516S!%D.F-P^*@V?-3D@IDTX\RK.T*;WQ0P1*3
MFQ;F3B,;293H$).Q$)DJ!4/,+$LQJ0#2U,SD94(4%>4JRKT^9ZLH-SV4NZ9K
MP(+/CCJ2>(J(<MP37P2F@\@&',M4&R@J;W+BPLA7![F'-6M]G9ZL$\IH_X+O
MP.$HBO$C"9BW%;)GL,'LQF%!BL,TA)!&VK[I^SJ26]K+K5_Z9X/C(HU_V-H*
MQSV?^J53BEYNG:96(_TZ[$;;:U#G]DBTO!O@._!:+NQUTC_I4EP_X )QG6'1
MBNN'O:8'BR^=:]-@4)J[I,%Q#W]ON0%^5;=;_GO]F7_2X4EJ?>FY[DJKM4"#
M?;:>OI6A_MT=GKC^61EJU@QU9S H:NVN5;Z_U.KBF__^<]",&B)VKW0H0-N)
M5V-T]W2LM#ZEUH$[:_F$HXC?W1^6_!ZXKW@S:-G'0S6O(W=6)FK0.CFZ?^H"
M/F:Q\>8F^NG+2=<=]_"F1R:OJ29.%\\UV'/]M-?K(K@,;_RF"$GKXJ7;/17F
M=C[;"4'.#3J#L3FEM\TG]T[Z94I;[DL_I>'@-Y>]OL;H^*VTMLNXEB6 ;^T<
M(WR7[[\<W6*/;K!W/8]H/;E,./ZC>U;^A?.)]S+H?&L=]$JGLO*WHWX/'?>(
MO_?+\@BIZ37MSUHG%PNA:2F-.WJK=SEKI3L /J@[/+OL&G!]O[%_\@4YQ3^I
MVSMJU@Y>_TO?'0PG_^J"8ZNK-(_LY Y^\?4Z&EL29;,8KN\3-VSI,=*#X&*:
M@*]HB5-YU!M.Q[LF3QX?Z**%P 61&OG@Q89(KS_B/.Y])\?W?^26#O;#^>!:
M:3ARSQJT#UJ"QHZ-RLC/O?ZUZ_ E$=]/[BMQ&>_PG>N>NK/!TK]O-F[H')*Q
M@1M_YON-\ %V.C9A0S:(KG?F@G.3E("8C>5)1^]SEDI:UC1G>C7[+KW$A@ [
M&/1"IZFPN++R/W(Z1#PKJW@CX/@>CMK]8!DQ.K7*81N_YF OS5;N?JK-WG%J
M_0O^9[DUFC[]S/?XW3MJAHG]U/2!/>@A['0.AWX'WM@D&\'S=,-ISJXO6^'T
M\C79J]UPKKOA;*VO[<8DLTCHG3!?NA!G!\08YTCD3&;/ "30%^V&\]U%MWVC
MN<U%@YJ3@P/7QXL,6GU\*?=.73\V;.=N7NL:#G;9?^-F-^0?]LMY4"^H6\UT
M;K==>*;V.@CZ*W0(_)/VUU$K0JJI=ZPQ*XP]K&'-1+V 5JR:?G>=B>[UCEC?
MY50AG*5'O7.".U56SLE</=<*D'Q^1N"Y9NMA5WWD0=QDJ;>SUTWF"N&'/6.9
M>4!/GKEZP#\N7,1%>ZY?7:??^MMU3U)K+>Z?#([+4S[@(9^,O_,^<'^FHY-^
MV'.#[Q22S^FCC1NS7;0'7+L.X8U$IO_S &F .7W@BEYS_)!O!VG&6OG-=4+T
MPSHV_G(6T[=%;4;WL"%8O/9,#WON";(3E*+<<2%H*0U2*1OA)+6"HU/B$Q.L
MR4XP/RCH^OGBU' DIGF]^?U2>AKCJ#81Q3]ZQ^6TQ'5_<8.]BZUC[?C]8=S*
M?^"C]N*B9"S@-7_MMO<WH,W;K/T)OVM]#;9^^]S=Y/@4^Y\//N]_.-O\[8-H
MW\I8^'MOY]/'L_;^E_.=\X_?=O"YVNM?X//!1_%Y/YQM'GP^V%S?H)_7P_E_
MS]^/*KGYI!6#'$M[ATS &TY\SIR$X+W)*6MCY-*J9!,6?KUJ4[H*6&\!L/XU
M 6)%85V2(;H<?%GCAENI0G( 5#OK=3E-8/;B-.%[(O,-=%W2U^W>-6(UK._/
M<GO_W_ TMX+2I*#4N0*ER&.RG@5BLT%0TF")HTX2*D%GG83PU"$HW<X3_9\*
M1Z]MEA6.7@2.!OB\^-L-7"KN9X-#[>0&)_TF.:,<?W\\[/DB,ES.CS8.CTZ.
M!W\FO)_0Z78:@H7_.NGW<9A_+AD@EW&'LZO+7?NR=YZE5J2;%.FN13F#4I)Z
MSHF4B1,P"8CSN90$0U0I2!%*9SO&;K?)G$FH>\:3L0J?"PV?+XN>/Y0^N M*
M/ST>2D=B9A5"IP&AFQ=D<7-[0VQ^V%69&0::$BTE$$#&2!S+0 QBJ1=9B"C$
MM.6.*G6LV/?BV&=90*B+7"%+ ,N8=58XQI(1O*AX\Q\U2:NAMQD!+N1^,CN=
M.$6W-NA 0.(/JSPEB8+*( S3E"^M"C 5L"I@S=1S3U+)R'Q6@3MFO8 8@P47
M NCBWU".[LZ=>;P3DK4GXMG%Z7LE89-BV=8O%R1L_RNTO^PZ9.0)G5:21<$S
M6KJTRV!) &.B4U1JIBL)JYA6,>T!F%;/&)Z%?5U'WM!E9"DZ@YS+H<L8LR,^
M1DXD ^Y9")'S5-&JHE5%JWK&,(=(=\G-2J_/Y((*+!/JC2=@E2%.6D.D-H$S
M8STRLZ55Q+.*<A7E9NJY9XR3U4.!&<>\D;0V%VV,5.%D9TE TDP\"$%8CM9I
MG00#J.RNXM[<XQYG4B3/J.),0(#@'-,\ZQA-"C1Z\:#F"O5 X!630;;7KM3#
MN PAJ*B)]=&79%Q&K&2!&)NYT[BYQ>1+WMO<G A,7#*1F__-4\G$E7+.HV3D
M[WC>UU:@GCI$2:54UC+CGDPAA6 "3<9Q'3.S$*R^OUS@87U=*WJ]%GIMC%82
M)+ I@-2$"UK*":# F)?$))9Q*6J*F(/@M2SEI-*'#T2))R>MO75#38H;X93,
ME&O0FIIHJ5-&<6E3422=1F)5C6L_BQE>9Q6 DS;0($A&0H@<PF:D#PX]'^9R
MLC11SZ87UZZ&.*N&6$.V\V?$(X=3(D?-K2(*B3^!K 3Q.DIB733<T<P40T?
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M&.FS)=)&1TI(C7BC-/')THSTRN4\O09=55FL0D:-W\T-5&S>9 )9!YXT\G"
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M8@4T>70-P"!J=0Z'6UE!D.<FK ]#BC$/YX=2#L\GW,"5?8QP ]B5X9-,75[
MZH?)"TRJA?"XJ]:;?:6;Y0 OHC)Q^ZUS4<4^9,P/J-&>S@!\-_0Z'?HUS='Y
MU/PCQ7L!=D;N<PV'%-G@K-_F^V^I'SIWR&S-V'W^@?QS[":K953+>,;;_#,=
MN,XA+HU9O]$B05N" R>N.^NWNIWZ!TC99_TV=Y+K#RK8?->(OWSIIR_H@LWZ
M7&Z@<70.!YTPZS?::.C/^DW^:^-PZ-^.R!;>82@O5-6'WNXK'8+_[+I-&-4=
MMWYWAR>N?S8<EB:F/R9"-6%)P,.:O<][L<"=YQF14@:,Q1B8 Y.%3RR&) 2
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M"F&6U=-[']24HCEAAV\BI>B)X%>%-^<']T[_L]V^QKW]#;&KN;.9J4BD8IZ
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M#\J#K]DQ-5Y356 7% _&DV:L\4P+06A$+Q&DM\2F5 ZM$B1@5G*I7BYIILK
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M4O<.G"2*"9!(42B'>!0,C%O*47*,^92PCUBLK"F^RF^&-V<_[;;TQB=-T<;
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M(27E?WD!Y-NT1]+&B*G@ @EC4FY[$I')?Q(FA4W>QD#R,>ZFD*2IZ0,/<K\
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MG!M7]/W6>52O'PT+]M\)6W,RW@^Y6G*-L!NYNG+V L[[F"LOY2VNK#N @]X
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M."<<LK#IB"N6D,X_B&6"1R,M\3CG4P-!S!'G+WT<9)*U%7)3&9MYY:V= 5E
M,V42N!UO6D&GAZ'3Q;1!HD44A@B##):Y+C>GR''J$4LA$,:C@'V?1T]*<9,N
MJ4%2&/PI&'QB>D@<N0E>(ZJ)0-P0,#V\]HACYZF4SJM<D*XP^-(S^,N?02^L
M_!2L/+$DE+*>.>F1"(PBKN$W(SQ&4B@P,$#Y5XJOK$ER,Y6J1#R>C0-W!D>Q
M5\(;<YP\5>W05/F+@D$/PZ#+:7N!4\4U%1*L!)TK<%."K"8)417!;L!:2Y$J
M;\8MQS>*'W-IV/JECH@7WIV9=R>F *-,B> 4$I+E@C5,Y<+Y$@6LN1!2)9T/
M7P%_%\Y=7LY]B0A$8>KG9NJ)4>"32S*$B"0- >S[9)!U@2$P[EU,.-%(<\G;
MIKBE+^[BAA>N\_>/[G/=7H@]5 _B'8-1A^Z9:\?&B#>'%X =\2[/J=]MM\+X
MRQ\BPFTFR:L"PG\]U-9[P@6:;ZA<G!/J[[^=QDX__AP[,;5*#/:!((FOI%UI
M3F ?#<(BNSZ3ML@I11$15 GIO4U1@>;3%.()^G(\'2N]LN^T@&H!U7FT' N4
MOCB43L63"/<R:8YTM+EI.X"JEBDAYJ3"29B8& =]4ZHF8T]56*P@:D'4@JAS
M9=$71)T14:<2!(-R)DJ'4A($<2PE,D0[Y"Q-C-J<. P6/,--C&<VX><&4"L'
MP+\&%EX*_X;6U[71U+;/3H!E?/UW)O16IZ[(L?9ON&PTM2&S<+JJ!##4Z(S=
MNUYL5Y'FG\Y;87 T8J:I&X=SQI-;K(/IG0WNOF5J9CX"X_7NCPGKO99MWX$$
MYD= 0/- #!]O;KU*4S^/>J,AG-K#B%POVB_()ACA.]L^MQ?]E7]=F<A)JX.N
M+=SU.=<S6_NWZ\&MM[SXNY=<V[ :"KA/VE'/E/.6QV!TT"+90(U*B=-H:S2#
M>V)8SQ#$"$O,@2X8$^;18Z, V[105$D6;1+3XWQ!5*XVX^_8Z,63:/MG^9#;
ML+DO8&E=1*:J/&ZK,C+5V;=VR[I6&X@,!N!L'R[(/9".X!EV !_90>/\J.6/
M\D<7#=N+C0B@FCN!U8V2@'_Z58)JOB6=#>"=S>$=K7[C$)"W9]OMBP8E_[W:
M:/P)Y-E*P&^= 2SHR6FWDUVKN=)']ZQWKR':ZNJ-Z..)B[T:6!AI-K)KH[HX
MZ^/5./M'W?-.P\5V]WRU 6N2']CO5^.LN>IKK&[HQ,.*&1OQ:RO$CH]Y8B$"
M?0(EPM12HW^68,PM&.IPAGF &12&%=L;YZUV&]XTG.YP;<Y@7?++XK?6_\_>
MNS>WC2/KPU^%E3WO5O(K02% D 22K50YM]G,QG8F=B:;^2<%DJ#-1!*UI!3;
M\^G?!DB*U,V6;-F6*)S:\5%T 7'KY^EN-+IS%;6^:'A=ZQC&+>N4C#"V23<R
MF8][JC&87=@4(#S*$:TV8M@;*VR#YF%YU#/ZXD>:):.KZV:RZB3(7P]V4P3+
M\>_T0BT@+)AJ(AGHC2(698A4 TKC&!J:;*@!O%ZX8GFSMS#_"3PC+Q\[&64^
MAAU2_0)F=%Q5H;YVA3OE\A;KS+K6*0Q^47=!,X 'JMW\?P_H2G-OXTJ;3^8T
MF^^I"E&:N>?@[:@:\]=_S^VP_^= ?.7CXQ\'2A5Q#]^^HX<_7O>/3S]#^V?T
M^+>_?GPC7ZZ@SW\?DC_/C][^<0DJ"3[Z<?A= "0'E%-$<&2#<1=0I%8(18$G
M(X%=4$A49EGL=>=CC"S VYY&_4&YH4"$;[%3[NH@<,T&N9\-HE+FV*Z4()P"
M25?JBVP>"ICG(\\&=O<\X7/APP9QO.Z\JCJ]04JLN1V:W-7D,6ARSYN%'()A
M0T(A;2H8"@(W0E0&! 6Q+U'HNI*3((S O'GRBMR()8J-K&E-\UHU]#'5PY+)
M@2Y74PNOK!_C+,FC1 ^\HRCZ0L*/A?KNE:7-&6AB 1%W=&-#4&64,@"J2E^I
METI% 5'1!IO^92!ZFK;S<ZGZ!<U:,-,H'&<J'7O=R5+?FO352K-)3Z^LI^J'
MPV$/]$M0SIYUK7]-&6L;X/II63L)SV4T[LGC>"Y#X\$@^EC/X*GJSRD\^G4O
M#7_NG:!]N3HZ_?+="Q@.,? T!SY$E/OPB@8>"H/8YD[H\8"S63.+2R^RF6!>
MY#G4]APNHC"0PL9A+$@4@5DF ;Z&ROS-QO+)J[<+=O/3QE9^IG5-97G =E:F
M3ES8+:G:K\I;,&_?S\CLQ$H5V1D8JJ6A[FD'ZD++\L8AO/J7=C#4IK]V:@ :
M],0PER^J%R^C)!_VQ-6+9*!E6O]H081Q:2QSO\ML7]G+90!#V7QI2G>U*3WC
MB2D^\[TN]=G2C^TN7OK9=<WRKN>16[5Z_6= K??05X:=E5J](41DS0#Q^W'F
MLI5\N8M]=),Q\57&5#B>'F=4_L)1S9F14P/<F]5KG :MX3/=[J55K+RI 2^-
MQ)QKIP3\^:;:-+&8[Z>8\!:*R5/MFTW'T$24/UMG77?_VM,"=?#%*I!QZ\#M
MQVQC0\DPBB-Y9YN7]4@9?E4R&$N72PU%EEW%:78ALF@N0<:=K]3N?DA".X,*
M B%\(HDM;,^E,HB",')#)V2N(XB,??O[ASM?UYNS[*>R$+UI;KN6Q!<,^W^]
M[9V#%7]Y>/J%'/[VQ?[KQ_OSX],O[E\_SNA?I[W>X=O??\)O+HYFXPOZ?_T\
M_OK^QU^GJH_?+OXZ_=P__/K./3KM]>&9O>.O7RY@7.=';P_L__[]1QE;\&YT
M>/#=$;[/'18AUZ8,46Q'B 5.@-R8"X]ZTHT"_N251SN8MK 0I &HM@*4CUTG
MC!CV,:$V#P3!#O-PZ#!N8X=0!5!W#!\U '6/ '4U 2C/#XARUZ'(U0#EN(C'
M 4/8#T(I?#>0*N@#NW;')]N$4!O2\7= *_PL<RFR\+S,YGR]2FBN6CZF#@4O
MBM2-!IYN#T]?FOH3]05GPG50(+% E%*,1.C:*"#,P2SV0C\. 9YXQR/SEX?,
MQ>GV2/,C*!Q&FC<CS;6R$85QS,+(0<3U/% V8H8"C ,41YCB@.'8$^KZ"NTP
MNDW2O#\>J)-1&OZTWJ1]=;] '_::I*Q;IF!4[Y5W0)IK=3"(RBLA^<FYR.1K
M%=K5_,*;-&_+;9&'PJ]O$VWD^/2;?7BAKN 1RGB$ MOV2X,)2X%<XE!,&>-A
MX*DHS0[G=TXIO7T>'2/^CZR1&/%_:/&_JL7_Z.([%SSP2$A1)/P84>90Q*C+
MD:."[7#DR)"#"L,[+MTFZ=\?;XG)"+EU2HM>$H,[:^'.SZ83A-@N\3F32 :^
MC:CM2L2X)Q$))*>4<D?8ZF*(T\$J<FAKS";C!&F!RF&$]U;"V_!Y<- /F.\B
MYOD.HD$(PBL$0\+A/ Z$C7T6@/#:'<^^<YGK+?)YW,5P6!JDUG;Y?@1R_BU+
M6U,2]Z'D^]U%,[V9'[JNS3P7A1X#B\#A$>*Q&R#'#;'T8N;Z3J0$G'48VY1-
ML)J$[)"O8&]%_A$HW8C\[42^3L/ENU)2XC*D$L0@RFF,! LH"GU/1*H8A!\K
M3F=NQ\=WSL3^("+?^I#I/Q<D4P 16G1/=,^\!^OD9'T,#67^YK?!KO6P:[H(
MMA.!$>(YR&="(DI=B0+7(\B.=:X'%O$8U!5".\R=3T6_>CI6XT?89C%^!*W#
MB/$&Q+BA@MBA+QS70:HH%:*V;R/N>R&2PF$J8,KQ!5&A%+CC.%LBQZVO:GNT
M.'/4QC2]E<RAW0^9W\,LHH^A5\%N-0B\'@)/%>]U'"&D2K^$(PY&H&V[2$2N
MCPBVI1V' 64JK3VC'9O<NPVX99X?@W &X;9 Y30(=QN$:^B8'A8RB!F2H6<C
MZA."A!W!9HXQM9U0AH'/G[RBM./X=ZY:]E (5RJA,YF,54S+D^VY\KXM;;1>
M8Y]*I-#(IW6[; JKGH<\9AO[$PGV(9*#41(G.KW>2 S.DJ GC7/W48P07;6\
MP<^-'(+O$^B1_)C\DM&'R3(5_&W(>SWR=J:.I0/;X2&UD>?;ZN8<,+C@A"(7
MEEAZ+@^)K>[:8-YQ&-X.!Y%Q].Z0H]>(] .)=*V/!X$?!YSZR(D%B#3C##&;
MJ0O[D>]B;,<A\T$?MSN^9UR^#R.,A96S[._M@]%W]PK-EF@<"YP"#80R4:WK
M8]&'Z6-D[%+'YP ^/," 17:,F& A(JI\ ! ,@04$+.KP!??RUR[JN46N32.]
MC^32,])[9^FM-8F081(Y(E)1Z!11W^5(N)&-;.*1.(P\UQ=<!Z5S9[Z4Q*.(
M;^L#U.8.CQONJ'55MSM$T^[PX<IZ@V\1#C^<%C6I0-E 8P/$ZP'QU"$R"8/(
MYS95^8T<1%U)$ \91YP0V_:(E)BK; *$=AQ[_O+ VC;==MP;N,%_8]#-H-NC
M:)D&W3:";K6:22,>L!C[2 CN(1KX(6),)4QQ(DFIYQ$>X2>O7-SQ[?G<DEL&
M;ALY.-Z%$\(M.F7<7FW][7SE+IEW5.W06^[:Q=6@#=?=>6I:Q(2/Y2TU'+@>
M!]K3]VU\2D,2(,?Q(M#P18"8:Q,4V+$=8R(Q\Y@^M"$+@JANRX%W$IG=4/\-
M8!K W![3P0#F'0&S-AH\AP;4M1TDF1,@*B*!@B",$8L((9%+/!\#8/H=A]S%
M-;T%>*F5Y.>ZWN4K/9)FD<U76UUK]^#:6O87TCH7D15+F#S14TKQM66-+%7P
M=I1:\G*89*!*G\-"G9U#6XZOGK).:6K'8;%DPH^YP-2EGH!ELCTLF">8SZE8
MHB*M4[5\A3(4^U=R^L,%(,1WQY:V"]*I:DDH9R;UD'#M$(481]PA<4 C=:KD
MD>Z\*W-2=%K555YGR6,>B9![?A3" L>!".*02PH0[[(XD#XS2WYO2_[CPW>8
M?-^+0HGL"!";2F8#3OL481> V[,EIIPI_S7OSH<!3)8<A#P?B9&\&2E&YV)D
M!?),U?Z; (8N4^[@KO556K"X*8#/+[E>17OIQYZ4)%9%L_V8!C%G?B")!./*
MAE<;V$,+D\GO?:GZ#Y>';\^^.]*G2A%#@O$048]%2/CP!ZQ=UX^#P/'\^,DK
MWIW/C];<0A7=9%6]%(4DD?PE>^FPKZJM+ZJ? F1UGL!WY[B'VGH_K;V5B!T&
MKE %UIV ,CMD@8L],-HE%B*4GF>VTGUMI:O#MQ^^!U*$7A0'R'="C$#IYTA0
MAR(>@$(4!9ZTG>#)*^)TYT.>FWOI#>AK,+&#1*RWG0J TIMF4.)3D70F GCK
M6A^ WD!O5.^46A)\40R'67H)"SV2O:NU]AH,E H_% [%,0V9'3#']3W*PP"#
MT>.ZAOKN::O]??CWP7?7%UYH8XQP'-N(,O@32$>B@$JP4@+/B2.A NSM&_8:
MO(^^=$^Z2]DO!2LBU]OO]EO%"?V(@ 7L19%#0T%$:!/H**$10).(N(&E>]LK
MQZ>'WT4D73OV*'(PE8CZ# ,B<0]AYD@6^[$HU"2_.W]3?.%6"<4P&0'7S6Z2
MZ^''JJS'ILFX]&#GP6S)T<20M H;$O/*A+S]AK<QZ*6@P8']X5#JA\RCTF&8
MQ=Q7D:MXB>_'8.,=]_L[<O3VY]71C]"&_T^/"@=X$')5N"M2!3-<8B/N1@(Q
M-XX##S@9!T#)/G:ZRRX1/S18VK;C8I]SB6.;$JRN73#B@I'IN#9W;6<#>\>
MY0J;!T@V#L+8#L&TQ QV$,6"H ![ 8I]88-8"Q$3K-(<+0#.Y7MG"7IVK=-S
M:5V!MF>I?Q>O8/TR*7)M94X:6)#DQ[H0L.U&HRP)QMJEIPS4$;27PUJJI_\I
MLP%HE;EJ:()WBG2+QV:R+Y*!VLO7/D5HQ]LB''\HN%[L] / SN16TLO"11FF
MV:C<%>J?D[4)QCDTD)=$"B04)1$LR,C*9:]7&X3"BL>]GO5K04Y)<0;+F(]4
ML[FLUU(O8=D1"3OM1$+;<B22GMH/__P'(Z1.EO#0\Z<?]4*)1!*N,*-'Z4A:
M3\FSCG4RN[<__U/TAR_?:OS]E,'#PY&P/B:A*E73??+XSFOLJAUA->]H68_?
M*SVKG\99/A8#[0D_D05'.8SHJ7284VW5#\!3:K*MSV"*#L;2>I-&>@TP9UY'
MX0/PS""24<<:CY)>\K>H-GHZSA:PIBS(LC!F<ZLOKJP 0&L<_( ^J+Z(P6"L
ML#+IPP91;6D$4UU1'1BIEL7@RLJ3LT$2)Z$:03P>C3-IA>=B<";UUU73Z<4
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MI?<5Z(F >P4[B$L]T/'H/,U@D!TU';VQ.NE3FS'MC:OMI_9!)GLP#JUH2M
M+9@]=?Q[5K0.<Q5*M2L[5J *<5EIL8U',CP?J#-!F)Y,RT5<4E(QJ*YU#():
MJP.-:R!Z@<; ,ID:TM14Y'J3#I6S:J#Z5&[7T<+M#AWJ*;+*JSZI#="'O7>E
M'@BJL#[HU&,KOVGEY["66[Z32PW_:*PF-IPY)1*A*T./* <_C=U 2%]*['!7
MXL!U//;]K9)T&]L8U8Z0:97])#R7T;@GC^,O@WJS@B)?%5U[=UGNE4*/SS\5
MZP1OG*;O]+[37_\L ?H&^>>TUWM?Z/VG:O.=0E]?]]+PY]YI_5^NCDZ_?0]
ME?=9&" J<82H("I?A?20[P9$V+'# H\4=EH"M!<=*"O+#@%=B,?C*%"'O8PY
MGN=387LV#6PFP8"28$L-81&!<>235P<:90"$0*B:^I_0"Z;^-6XLK1:8$J&4
M;K_TO%M[+!3:PPNF84J)JE()<^NI9B]@"_@\?_:BLE+*33ISGC\?!-"0L7*O
M4]+U79"'2O)?:!A*?LF7%TDT.J\RLS5^6 8WV/5/1*"Q;/E/&H$,H0*4;'61
M/L@ XI<(,E])CKD[,RN-O^>3 .RA.),H -OL)Q(Q]/"%Z%V(J_S)\VE@ E2:
MF;C9,2\/KRC^SJQ)(9T.=F(GX(+*V*8RM+DO"&.N3WS/D2)VGRR"QW(A/(V0
M"YN]<4._^E=AQTR65@>HP'+TQ#"7+ZH7+Z,D'_;$U8MDH.=7_VA!]'0Y&=SO
M,MM7\U'&;)?-EU/5U5,U$U)3?.9Y70\[2S^VNWCI9]<UR[NV1V_5ZO6?N=3?
M\[XZGKM2JS=$\-]X<P"[<]]=$')9@,O#!!BR&?#QEP3VUZ[HJ6"RNTY((R)V
MU:BR[9XIQ7VKI,F[<;3[-&68FRE;=\K8.G*X^U>+7I<F5Q7II*U 4$V5.WIC
M5^+V*R#>)%K>:-#[$ONW)5'O*;3WQ]71WY^3;^3P\NBW#_:WOZ.?QV]_[WW[
M^L$&L_7'X6^'%T?D]_ZWJYFH]Q]_]8[>?G".?OO]Q[>_W]G??GS^<43^H(?]
M/\^__?CC[[^^'EY\^_O ^=;_Z\=___[0+/'+8A+9/O>0E($-)G#H(*8"!#P5
MI2&C((JYBEMB'=^Y<S+Y=65C-^X#&8S;'XQS(QH0R1GC@E,WD)QS 68X#\+0
M9BSP-<8Q@W';@'%U)60N?$<Y81&FG",:1Q(Q(CS$W=@C'J/,(^&35X[=(6S^
M9H_!.(-Q>X5QD6UCBG$4A5A0%CN!Q%$H'8=2P1S')QKC?(-Q6X!Q1[4>Y\6N
M\"16^9Q$@"@A-@ILB9%CQ]+AD7"EJ@Q+>,?QYB_$;"G&K>CYVIW* -<G[3TH
M(_3SQKGMU$EK=>Y;QA*%XRQ39]F+[/,%V4)W,"GH.K?Q;G/.NEGX^C H(O;R
MSSI\!.;Z?9;VWQ2K] EF(%7?_E0MIT&[M=#N<,IJY2'FGHQ03$D$&AV+0)GS
M7(0Y"Y@*[&7"!HVNP_'\%8AKP>[^5+,U\OJV6U(C'*A4S7$DI+KP*'7U7X(=
M.XBXH"Y5DHIY*:F+'49&'+=!'&L#*PH)(8$$ XO$$I0/YB'FN"[R8LJ(Y['8
M8^S)*Y>NJ7D88;QW860LX*X@+"*V2T&I#T3,0Q<S:CNNP%QJ8625,-Z+9\/(
MZ?W*:<-(B&+NNC[VD..I2_,>(8@QKI(E^,*7PA:N"T8"[A ZGQ7QWB5U?PJ$
MK6H&J*C+:0L@C<OP8J7S[UM)L8>U!NZ 79_4$AGDNB-R_=%4^'W'H9$C59EY
MVT4TXA+!HC(D'$\*XA,J<:CNL6[*?[M%+EHCU1NT')K*RM\R2R.1GQM9WP99
MKZV)6-@<K'B!?"X)HB$GB!,;C(L@%'9L<T]01Y$H(YB\-/+>7GG?@'%B)/O1
M);MA?ZC\P3[U."(188C&H8<"(F-$/(]2WW8]%^,GKYR-19J80XBUK8_/,AJ'
M&S,_=A"?ULGS^E!FQEMI .J^ .I+T\R(0M<G0<A1%(0V )2(44#= *FL'$2$
MD@,5J7M"[LH)8(T/\_[%<,-VP6V<F$9"[U5":^. <A$'W)8HEJ!'4(%=Q"CU
M$/,E=1R!?2^D3UZ1#I@)1D:W2$8?2I<W@GB?@MC0Y4,ODC+B/N(X\!#U/8P"
MW_>1%PDB"1:<^^S)*\]=O;[2%ATB;*_VWKBD(P?1':_G+,X^;U^7@'Z_XCXW
M,4';C>';50;(!(9N J>_-4T:CQ'?CAV)L.<P1",,NI)T'60+2A0!NX2()Z\<
MW&'^FK%2#R \NQ$=;V#4P*BY)]E&&*WM3M^33A2Z H6VJBA*0AL)22/DX,@#
M),6QD.[]W),T,&I@U,"HN8JYNS#:\!I(+"@7+D6$"Q]1Z;F(X2A$,0%K0@H)
M^_V>KF(^(HRN6F]M*@E:,HCD8/2"T$E:PZTJQ/9!YZ?4=8CU9:0J7^/M4MFI
MW'7K)$J_I2FZ3J+T)<)_>BY&7]-Q+_K0'T(_W\6Q2KSZ2Q5O_RQ&<H]SJ!\Z
MAS_"[Y+(*+"%@T(BJ:J\[J+ #0,4,QHQ(6!Q E\)^ TUE::VC<JVVK&2N)&J
MU;I0:V E>A&*++W52EB9KCEQ>BY5]M=,5Z2HC[#5H791>:G*_BKR= "B>:6^
ME"<Z&ZO*[JK:G$YY6N6,O8!N-M,.PT^3,H)$I6*=)&Z_2$;GZJ<7L@>]ZL/^
M/<^W/)/I5UG/,0QJ!%.8CW2&R:$<B)[.!=NXA;@L):Q*O#Q)YZOR)^LTW-9U
MQ1OU0Q9]A+FN6-18>IB6I*^J*ZB$CXT4FHO[JY.GQTE/-KN4%:E0*_#Z D@#
M#9^H],!YQ_HE,IUFN:@-]V.<)7F4%$$1G>J[_P%2B-)^1S_LC1B(2.@%5S_6
MV6S5CU7*==6S1K[F(L=P53*L_-+T=\H<O+E*,STHHC#@)^K2M>Z[K@Y0I9,O
M\NYVBPE3+1=]7C#4,]B]\,C>5=G\7.M>H_6R&MG\(X[FJU^H"9C4JEI8FPJF
M,U=?GV3&+G+4ZR 2+:&Z>)[NCRZN5V=*3F+=_,4Y?%2DTY;1O AM%SWJ5.]?
M"^AII#.'R2W'5.XYE9U?#6YJMQ73J1)7 [Y,;SW8R&I_Q=!!>1G*8;D?IQ.(
M6U/%4$OTZZ6#,_BHT1G]K Y\H-)!PYI4#VS,O4["K3,WETFIJSS0U2[)JPS;
M>N_H9;KFB7JXU;8OMR<T-A1760IP6N!$X^'+GN1WK:-T:F.K1Y97H6%S@_X'
M#Y[)MJV29L\,!9K9@JVLL"F0O40"0:0Z^S;L-WA=Y-M>JD:I;/-:A3Q3][_5
M9TF>CU7&>_@PDO\;*PS0: 0-#JM\^C#-NF.ZLS-2M#@!L-9@ H\+'!)78!=3
M%G-UCAMYTG$XB:1GL^^8^$^N)S1,'X#1YM+X:4;#I&O=<W[N/\8B ^;I7;VO
M$LU_&!1J)DSD]F37#B?ZX-';=^Y?8*=](W_]^.O'%QN>BX^__MF'[UX>O3UP
M02>\.'S[Y>+PS9P^:!^>]OI';X]^_-4_ZA^=_N%^4T6YOX(]J/3(MS]!)SRX
M.(+_0!\D1V??):=Q&(E Y:%P$<6N1$*0",6>PZ0;A22.V6QR;6XSZ8@X<%72
M$>%[PHM\J2Z8NK"D4>3,)M<^&8,VD%TI&/PR$.-(\_-D4:S)JEB-9;D^'?;6
M<<HDS?Q\YN:;9VMZ=D4L06I%A)T8UD9PP4/L4>+BR/<BXD</F,[^>L'9KMST
MCR ]!]]C[CD1)BYR)+<1M2E#011)Y .1@BDE'<Z]V?7%L!=4V3-"F*11* 0-
MI7 $MR6 =F#C6>G1ZJC.&:]XK:Z5D=1+ 2P2]X!%<LTA _6VJG:K2%=7K8A^
MC/.1*JLQJ6H+3-BI%)UTF Q*JPY$0)SI AP=:R!5E0HEMXKLA!6+)+/J AUE
M@ORB$DM)>2(']4<GMZ^T_:0/BKZ*ZE&5C30,:+;\WT3X(S$2^@$3&Z/(F:^8
M>DFN_$ZI7JF6K?Q<?[6HJ[ HB_Z\-V>)?;<_6?2]K<JB?YML^*MAY/SO;I2]
M>\JBS[O$X[?)HD^]KDW8QK.]8]QU5TSWOF9J>L<SG=VMSO)-9OU_U-.]V;SA
MUUVO62'9^DYE0W^?9/FH4JK7&-P*^>)W:AY.5!F?R$S$J\KCF&1F-D \TG$V
M.E\X$9M%MH<(/+Z?JAO-P]0UEO\N!2?V_)&MCX4_34?:$-7U2.>NH][Y[OSN
MQPVU,_+'C\ HDX1Q'(?492QP74(X%9C:H6=3;\8'93MW" $JB]WJC&30!]4[
M=0KS9IS#5,FLKKRH"F[F.E)@B\*#;N>T*L.#+OYZ>Y0<_OB"O_WH]?[Z^L'^
M]N//WO';W@_XK_>-?"!_O3UTCOX^[QV?S(8'O?YY2#Y<'9W^F< S>M]^?$Z.
MOGZAQU\/X;\_?WS[\=?/P[]#Y_BW+^Y,-0JPE*D3Q#8B'E7W;UT?,4PIBB0+
M(\^CV.8J>L#I8&]3P>H[%"=I$&N;QK8&8GDQY50&+G/LF(:^QZE-', N"D@F
M0AR7B$4KQ/(<VR#6-B-6'1?N^#@*,"7(\1V!*/,#Y:(/D6L+'L:<4<]SG[RB
MN$.5^FP0RR#63B!6Q&-"(C>D'J 49Q&+B,/]D&))<8 CIT0LOT(L;A!KJQ&K
M&8(=>7%@,XY8%'F(1H$ Q)(QHG9L>XJ>0F9KQ&*4&<0RB+4CB&6+F'.LHL*)
M2A5*5%7W0.4$B5PAF0@+Q()F-U  PB#6 R!6K6,Q85,BL4#$YP11&L5(4.ZA
M&* J=F7@276TZO$.Y]ND8^V>Y_<Z-UL=*AFF>1F1449VMS03W):ZI(ZKA7BC
MUN%@$+TK5\% S%H0,U50QO%<0C'W5;HW4(6$39!@KHUBSX\=QR,QL5E1/LLW
M12RV3?H>TKUBI&]CTE<3O.2$$R%<9+L$I,^GCBI)05# _"CP&:98F20.[3CK
M.E&,]+7*56"D;U/2UW (Q "144@8<HCDB 8Q1\SQ;>2S #3L$-07GX+TL0ZH
M+T;ZMDSZ'M+L-=*W,>EK)):)(B$<H:[$N"!]) B1 "Q%)'9\UPO<R _$DU>^
MVV&<[FQ1INTU;C_4-V6?EN;LL^JFG:FO=(_VKKI #Z_6@)]BJ4[%90D[94H&
M SYK@<]T6:6 >PZ+0@0$HJI& PSQ..1(7?.*71[XPG>>O/(ZA*V)/;MP%-!R
M<5XG._-#6M!&C#<DQHV*232*F6]+1#T)?Q@+$8N="#EN",89J(* U4J, 8=7
MSL9L)/C1)?AAC7!#R(\ER0U;'#/'=1P>(.PP6=SXY40ZR&:^()Z#.8_")Z_H
M^H7-C3CODCAOP*HWXOQHXEP3LY!1+'WNHMAW!0)H%HA1[*"(^&X04\H JU6U
M$H=ODSBWY>!:9?@I4PT]5?E]YE2==G@+UU'T'\5PAW4HL.4C+(*!D[7@9*H\
M&6<N$R(D5>B>)Y#@D5(12(!=[D1$!1L3VL'./)Z8ZD=[<4!MA.U.PE9S-W$C
MFPK;*9/O,.&"L(D0$1GSV WA?U1Q-^G8;,V,[T;B'J FX&,8Q$;V[B)[#3/8
M=:7#H\ 'B0.5F8:QAX* V(CY,7,]%@5"A6-Y'7_!B;3AN5TV6XVL/8RLU3S'
M?1$*QZ4HE#93X1\^XAQD#=#2#C AH1N))Z_<CK_NE5MS_KR"=+T6>1+.IYI[
ML4JJC5O[UTP;V]-&6YPMUY>5O]$5LTZ6DQ;<S6I)O9YK-?)/,CM1F+99%Q1I
M*.;3&L$[D0U@WO+JN1I:)YJ!;32#%32#L.ENBF+;]VQ.D!L&$:(Q=Q'W"$$R
MH''@QUQBCS]YA;MT]5+;CU2R[*;;H 9U=@EU;@$Z=_3 $8,U]X(UM16"1<!<
M==SM,ANPQA8<<1M'R!<N+%D0JC*9"FN<=>^D&\ Q@/,8:LX='9!&S;E?Z&DX
M&RG#V V(AP(A,:+2B1#C,4>2A,2%U7*92CIF=^E\R3*CYAC4V28UYXX.6*/F
MW _6- *"A$<$$Q+T&N5LM9F/@D!Z"(<LQE25!N>QPIJUBT@_2 W3-CMBWR:J
MI$:T85?LIA(%WZM?TG3R\3IIW+]&0]E9#66KW;\EH!MM92UMY6?3 0RK0!P1
M2S"*&(4_(E;WBAS$&/,)%D'L<F$<P 9W=L RNF\'L$&;6Z)-(PN0QU7)2HK<
M* #;",L(!:Y'D0QAD7P_E X.M MXW@]C7,"/+9)MAYRM=@$;\+D=^#0C3B,>
MT<"/$9>N5%F1,1+JII;T8]^!910N=XP3V.#.#J@Z]^T$-FAS2[1I)&Q@1/@Q
M"Q$%\Q>I2MJ("<Z11XD4=NC:D5.X@=TM4W5*=U7UO&JK.AII=L+A9CJY5YUL
MBW_UJ_Z'C"P!71)GLCBCR/_Y#T8P>1FH<[F[U9S=(>HKAOZ(*;BKQ3@HUN)H
MW ]D=AQK=LR/QZ-\) 9JGJ>/2\W=E%5X\EW!D5HS/_@>@M(B?9<A6_D=:>@I
MYV-$$>?2]MR8![!5GKS"7L<E?(XJ'ZP@[:[+SD/>3S:R<[^R<SB1'1&YQ/'C
M #F1#TJF%X6(8Q6^C4,_8!1SEPDM.[8[KV8:V5E1=AXR_;61G?N5G2\3V7$B
MX5/N12BFQ 8#C6(4.#A G@P"3*1TI4K<HV2'S3N$C.RL*#L/>5_8R,[]RDY8
MRXX$K2T,!:(X)/"'^"B("$8^=JGP AEY,BYDQ_>OEYW6!YU=;]5%A:-M$U>!
M6P@>6V#PE9[0.0PQ\+$>?%PU33XOL*6(;8%\ZOM@\G$?"<]C*,9!Z!#78PXA
M=S'Y'N2*=POE;0N,1"-O&Y.WAIDHJ!"<AX@5I<\HF(F K<CQ Y<#95-?<BUO
MWH("%$;>VFQ8&GG;F+S5IB6(6RP#FR WL,&T#)B-&/<Q<J1#@LBS>1R+NYB6
M1MYVUA@U\K8Q>:O-4>K9D1<)BKB+)9BCO@>O[ !%C#NAZ_J1&Q?ZI+>@R,DB
M<W2=P^];^'G,5V]S@'LW1]JU84U1\JMJHO&34 )V9)M&-C8#;/Y"8'N?9/G(
M^F,L,NA"M44WV@^W2U;HR<MAFB=*3EYDLB=&R2_Y4AW-(])5XYB=3Y%+U<"3
M5T]Q'3('D_L CM)BL1Z&G%9;PA,)Y!/-KN$>3L3I>9*9>0"93L?9Z'SA1+3(
M#;IX[*!-<7/+UG321('=8-&<IB/1LS+Y2P[&,E\A[^IN!W&W)$Y[QM!T \_S
M:21IX'!*8E=$7D!=AK'O,$%BH0Q-S,N#"WAQEX.+S\56>9^E_3?0!]6[K\GH
M_,TXAZF2V;O+L#=64WR0YQ+^%YV*2V-LKF=LTN;AA1U'@71=%V$[])"J6X^$
M\"FR?2Q<6.R(AOC)*^ITZ+H5-1_MPHB!D^V&$\^#)J0MXT R*KD( H$CSQ,V
MER3&7ES"":W@Y"[G,@9.'@).ZK,9PB@).':0'W)5'-R62$2V"Z\<.W#B((Z%
MIPO^<#8?2F'@Q,#)+6HXA 0V7 0;B_G4<Z* QIA'@>MBP8"T@A)._ I.[G+L
M9.#D(>"D$=4HW0@3CR,?2X)H* (D6"Q1P"4G#O=L^%3#";/73+-JX,3 R4(X
M 84D)J[O8=OE-'2=P'%C'K(X#K 31"$KX*0\58,7=SE5,W#R$'!2GZQYD0-V
M36PC!E8/HMR3B+/01;$=2S>VW8@R52'-[]CV?-UQ4SIF,\Z@="@S,8(.PR#S
M46Z)063)HH#OG(-H,@U[7V#Y(7TPQ]4*O5$+=#"(ROK*IFK5FN#C-CTM,0U\
MR@1#;@CV$0W<"(D8Q\AWXIC)&+NQB %\>,=?.V6\*96^0Y+\D.X/(\F;D^3:
MR<%I1'$44<1L)<E<>DB /8) N;"#2,8@Y+:69$!G(\GME>2']#P82=Z<)-?^
M!9]YTJ&8(,^54CDI09(=UT$>)V#N,7US4DLR]];-;VXD>8<D^2&-?B/)FY/D
MAFG/:,@(#1" ;XA KV*(1\)'.'!L)C#U8L]_\LKQ.WA!D/KC27);XCR*RL;6
M2%Q:3TMC_ID5R(&,D]$*1OT.HLLZM=T?TG@O5N)47):P\KI8! ,N:X'+AXNF
MZ2[]D.$ !\CVI(NH$[B(J0!]FP14<&*'\,Z35]CW.HZ_>F;QAS^":(?D/:RM
M/<EH:R3PP26P-KE#[H6^TLR!V*FZ8QVH;+<4A6'LA(XO Y<(H/>.9\]?L=ZR
M<\"]$\(-F,E&"!]/"!NG\<R+ A&%R,'PAU('=&PA'(0%9<I^4JZO)Z]HQR.V
M$<(M$\(-6+A+<KL;2=N4I-76K)3"(4K2O% =5(O(1X$+JJ<;>6#*NMCE(2B<
M##^"G+7^E/K&TE_&;?88=BTL2X$T'V%-#+BL!RY3*6H%=T)NNSYB(1>(,F(C
M$6&" NK9,N#"=R70N.>!->N8\ZM=$]]U_%*/8AX;0;Z;(-=&L1^!2D<P1I'
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MU3%5<P4*Y3^O;(OF7( "))*>UN652J9Z!<L7BR2#EYF,>R#O>B9&,&-Y<9(
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MK% 4L^7U,#^5"VY]5"N^N'883*%%ZFK/1;&P2E$Z'L*?PW20ACVM\YS*\'P
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M93-'W,DL&6.!8U/>HP&+CJX??08NN".@9I1*A@K$*E@I6&6$E3&!56&G@9;
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MN9RO8 -WIS('LN3A9>2YFD?LW2^TYV1ICP>#C(M0V8"5JY*\H>EKOA+BE''
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MM'P;H(=0OWXHA;YM\M[ .,W>F[5T^**^SJ_G8Q+T4YA<G%89L9@DJ<( $Y2
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M;.IR=(8'\@DNV]JAI%#&*"E*02R!)2-T#%TVM!KMR1]MP[0_40XTSI'694)
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ME\!7=7_NN>L_,2SPS__T_P%02P,$%     @ :8A84OHXLK4^K0  %(8' !4
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M*8@+QA:7$A/%T\A<T21='5CR7OIH FILT]>HQ6A.3W<?E.\&R7A[#^I6!$U
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MXG/H8XL%HN&83L>6>"S$KUG&#C^\7POM>@1S"X MC97[ #[04>MC48FM5/5
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M D;P6K LE'I&"9KY$B*-- FMO4PNI5W8N_'TIT[>_J+J^B;A M#9]#..EX<
M&D)VW-56IJH6-N0L1@',E.RD,)#4:E+QW<Q=>_93YVU?,75])V\!A_:%<_+V
MEWHDM+(!;6$B&<FTSIEY9QQS)7"E9>9"ZUV(N_GXI\[= <+:>%?NL<2HY^Y>
M_/9A=#E.#Q:D7H_B,71>NU,R*V'JP&.PJ++QSFM!!I;*Y#,G T9&98SKHM7:
M*I[&<>H45/1:)N9"KE8B[2V0I6?66XXR<%<D_%'BU!9+ J>!!:F [.0B610B
MT#+"(ZW9TL!J^8X_X]3[:5(7<>I=V#IVG%KH KQXS>JI)NT@1K%@:N(N1H=9
M&UHZFIQX/(DX]2&*TIG4'VV<FBLL0<?()+C:#L63\5%(6&BT=,:(G*S90G5.
M*TZ]$[/WQ:EWD?#Q@I1;@/JCQ:EW(FJ[:.4>4CZ:"A 0@9R\1JEKB8[$Z]W!
M5,B5R5+HF(S6G15*?N1QZNZ9WT6X70?!?H$ICOLPF!7R?P$74_(1!M\O=+I4
ML&@6:Y1 ^U!8!%&8XTH&8Y+R:._SS.Y[R6.)2._$P:B! +L.3F]HZQZTU3$#
MBQ%FT8A$PS1DY 0THL9;35!;4;KV\4^>S,.%UJ*KR7QPWY,4O4VH'/D2IC "
M)IC/BC-OI"P I3C=I-O-#13'([HK6E:K"^TMTZX7X$7EW9\1EV<BVENC2E*U
M3%)-0XV&!24SX\"SL48+]-LMN[<>_61IZT!279] _-*G]7XZ&BZ'Y4 G<@02
M*R9%IFNNDQ<E,<Z#M06]SFZ[2Z$K#W[:G!TBI:Y/'Z[KSQ)6W3QFIR-+4^_:
M20DBJ*Q,8DF1>:>5(T,O%<D C:/=)4@PVU7,W?'%3YOQEE)^[ <:+V"0:FU,
M^C>C\@K&0_IL<H'C#Y]A_%#'&UMA>MCJ^#M+;?7HPPB>@K<^2M0V)"A2)9Z%
MT2'I0X\^=I7?+KI6?891^2>.AS#H3]Z_I ^7QWV+:;2/MFSQU(/YWA7Y"F-9
M6-#2")KR6=-$IX4&,4?GI2@*T/=V&T.W,G\+X]HL[\LA,W:/MQR!D[M'ML)1
M!!Y<L-&"J^U_C"=OEEN%46=CN-J&HUOO.\P1>CVDL>('FL"S./=S&, PX8?/
MB%/:8)[E/!,9#%[V)S5,?DG3_?DW^N9B-('!W\>CRXM:C&!^6E-_9U0G^B7F
M,YK.LPE^K71I5,:E)&H]$TN&2I'(O/:%25 JFR PQB9NUA''>*A?2F0GFK63
M>C+VDDB>3/M3PG-6GE].Z!WU.*PGP4(.23!I:TTP3P(ESXI&'4J*.CJ99)-C
MRRVP'?^8\K'J[ZISW#6Q#4XXUU2V_WX0^_?1*/_>'PQZ9#X*;<G%R+[F.QF4
MS-<+I :"T%S%Y$N3E-MMP/VI?9NTKW-J&X3DECA^&_>GM&F>E?(>9S7Q/X[J
MKG@U4WXE5GM<@N"U'4<R]2:+<,A .<V,DJ%8+0SMJBWT<">4?RKD)H5L1W:#
M.CA_)\G7^OIGP[FD^O,3Z]5)U3,U$!,T,.ZS)K=;&^8QBMEM"S1&<8]-[)LM
M\?VIC1NUL0'!#0KFW),U]5U4U[.F4K;%U=B/+D(P'8UDD'U@T2AG1.U.VJ:2
M[QY8_]3//=/E#B:^00.0]J*=9PKQP#4*GI@//E6;V;(8:_!;>"5B$-;F1O;H
M4<9WK"2^IS(3'J-:/71JX?%D,Z]/JWE0*2A&[FR]+9$,B]HB2PJC4RDAQ"8U
M&8XSO(=*AWR4BGWTR;>S@C7P0W<"?+W^]A:P6U8NW!/WPQ0W?(RJ=#OU_&AZ
M\(C4V&8AE"%?&[-&IJ5-9#<J74O"Q:(*&F];71!Z/.I[3_G%$];>7>CO.FUK
M>>RUR&+@/)E4+V/2_F3(@_&>AE]K5WH- C@@INW*2-]\[H-<I6K/Q:@;079>
M$O[F55MT*EH?.4-#>+0&9$$&RQ0/020EC%QM]KBI!OP#7T@^.J<'"/*XW<EN
M==0*W%M="U 8&B#3P2F"&C7C00CM46B3FS@,3Z#5XE.P^EM1W2!0OVO/KFW@
M_MFGL17_!S;/VX>\1]"GT4MI:"H:9B0*II61+$*MNUQ0RR1+BFUJES\*7>NP
M3^,Q56T7SAJHV.OA+'MD,GF/$Z0G?ZZ-0O +#D87===86 09A<_!2@;)SKJ/
M9!84;4-).@U2VN!MHTCX%N@>?__&G3B^%1CKFJ V!0RNS(;9Z&?YN3,6ZH0"
M, ZB<0Q4K1HG%/D+-&::52:7@EBP34?L>W#]:9IM-LVZI+3!>?4=\!:3;AN
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M#CQ#6ZO:""@2FT3']T)[6LK4GK"NJ]I<F:JO%Z;JB\OQF+[M*>XT#5:Q>EK
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MJ=YHG"<]T(("6CE61.!%2$U>[3:59[>B[\:;C[>M'B3[41>"Z]"9F@&!K]>
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MF"A<U:%9GL40',.LLB';.<K2)2)RIOVY=[$$=I=OCWT-5KNK=H%QIOVYM]+
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M[+BO+N:?4<LW:CW'J,[^&R"JHC3MNKYD,MATR<RGF)DRY-IH$R"%U-<QMP[
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M9#C.UQY/TB'($)E$062$@LRGD)C1X*,4GKM#C%9=!^T\[<"]E=!\(MDJPF5
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MG ))&I03]23B@20G7&5OF5=HZKS3P#R/B64% B !:FQR;]H3_I_</C0)&F0
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MS_&^<NW1$+T!L0A5=8&QQ4UO=S4?8TC@'AI8U>$>XFNHS6*CT*$$QFT--_H
MQ$AC6 9 0=M9\J'+!>AI:''#G67_2MQ&:CTK[W>2U.75Y;)+B0=>$&N\A$XA
MG= SD#FQR'-P=#RI&+M4O792W[TG'\YHVTOVXSX$UV/<:0X$_KX#Q$605EE)
MQH32]5P0#- "XQRXS]X'V\D"[Z;!NT]^AAK<67"'C,O\\N-F.*@LP(6FE6$"
MQ;2L0\B=5JR@45HX$H$\;(CY%MM9VDNM='/(P$T%N+AF[ *Q94Y=!XS'297K
M7;]=^;.G<@ZY#=V!&CU/SHC">)QG_ .YJKDVV2^.;)V:J9";M,8X&G^>R%T[
M!?ILHY,&M'E?RC#A#;#E*"%A:]L[P;RVII:&..8#'='S(0T"<\K0)#]M+9H3
M"@ONJK=QWT)O< /Z#F&*7\<7^>WEM\GX.]X=4J5DC6O).K=%DI$,N?951*0S
M.$AG@^(A-K%?'L%T?JSH2P$][A+SF0NOQY??KF8XN5EOS9P:E]E?,%D:\C$J
MF8$#66:N#C'C!+0.I=6^& #!I0LKE]X;1E@\_:SST7L+X1XW)>P?XW'^:WA!
M/\[O9U]Q\G8T(V]O2%;\J^D49],FZ6%=']HP56RG=:\.A\O*:XF1\P(ZE@@N
M>1XRHDXBIX2/I(UU??S>I67#&;X;?L>\^H#;&Q&K%.<1"^U36&-J]#+$8C*S
M"K*SG+PWWR0/H0NX?0_(I9@'4@KG$X$(Z#)YI#XR$$FS(JV;3UNV;:RC)8##
M;X&]ZW[U[-M)M@V,H$<6>IVFEI6V(%"Q$)2ES1@-\])&)C@/2KE /V]B"3T%
M[ PYT:LN&KA.C^"[DW-V-[=L #QKJY)C*@LR$URL$T)\825C32$3"64X,'LV
M0'U9?.I#7PUB@ZLP_\#9VU&ZN*H3$V]V3!=#R#G-"^3)**SC$[P@C)!<B#*C
M<;))5E<7<&?(HMYUTB"S:[,0[F2?A0Q%2TT8774I+7<LBCKF(+@21#'D;C:9
M=]H%W!GRIG>=-,@1N[OWU:E6]^4P\.!5"0X9:EV8QAI_*([0@0!>K!+<-F',
MX[#.D"L]ZN$A2TQ+N^<.\-_^_H:C*?Y!?N[GO_#B.RZZLWEB,=EFL7:;-43T
MPAEPH9@0P67019K2Q'O:#_89LNR >GS(0GM8%OY?A,GGO\8#'24$79,- OD-
M.J?"8HJ>T28K0D$)&@Y\Z#V"]L5S;A>M/:2:.P+5B#LXX!(U2$D.:32BOB&2
M><B2&71:^&"#SNY$R%;Q_J3;3II[2#A_>,*]&5]-2%(62C&1.56MQRJDH*IQ
M$)10J7!3TJ&#KX_ _4FW7?3VD&UA[RC#Y3<83NK=TT-;\WI%%W5% VF\"-I9
M5HPE#T6C91&@,&Z<TE L'?Y-LD<ZXCM#/K70S)I Z-Y1\]M<OD=$<IW-YU26
MUGO' @$F<<3:$H5.=ENRE9C11=7$ .L.\5#U1<W9TT@KQZXQZB"_7W[\#O\Y
MGKR^@.ETGL1%KT1VM<NM"X8\9O"15FHL"UD(864,C7IH;X'Q^'FX_;*D^]&X
ME[8.>Z]S"_0/N%SF?G2!VS([=TN\1VMJV4;_W7G6F_).@',)I>*H/"OH/--I
MWEU1!A:YP&"D*@Z;M*L\":X]W9'R)*FVC<Y:)(C#C$Y=S)\Q?1V-+\9??BSR
MRVS*5AN4+&L3R-FUP+R!P&0 $3$ZX=M<(&X"=%*&_/Z:7,T)[T,-#3)?/D\@
M8UWC,N74Z:QU*IKE4M,.K2"G0B7#%*^5<I(G57@+6JP".6\Z["7V%CTCKZ:S
M\25./N+%/%8Q_3K\MH2&668?K&?"6\NT!,[ $%)CN,DB^F#:3-E[!--YDZ,O
M931(3;DSF_[C\,O7FT1UR5&0<ZI8ME:PVA^# 3>:E:)#)#>AN-@D!KD!SYGS
MHP<E;$P_.4C&.'TWN<+\;@AQ>#%OG=LD1WSS8QIFA7=<VTH>>%1<6B5E\@YT
M4"6:P+4LIL2<HA:/M0_MM,I^]'8]S.7+O!M.6]4]^J2&VNN^PM5$?@ZHG';*
M1Z/K-:7#I)QR7EAO4<,C"GSTF?OMU[]<38<C)*\G_=?5<+J4TR+**&2)BJQ,
M9J"66-=V&$% 9D;Y+$V6CL<F0=G'0.U5LK3\X-?CRS@<S<_.6]G25],A[71P
M_;QK0?]X=5D5\0$GG[["! ?1E.2REDQ!$C7'QK.(DE;@$^CBBG]0 ;FAHFEO
M*(<_PGKCRKU*I\/JI(&'M,,"!A9"EN2^,<0BR9K7[GI:D)1"N) X9-/$M]X!
MZQGP[%":ZK_"<G7?__%Q?''Q9CSY"R9Y('2T21K/T$4R$;WV-=/*,@A@,.@8
MR>;O6%WYV'/.@ !]2[-'Q^G>'GAGP1N(^6%<PT1#N'@-TZ\?X,>\-'3VVRB_
M+[0?#L=Y@ $5K\,&; HDGPB.$?3(BI/.D;UHA<Y;G5 ]@#H<A7K7]+JCZM!J
MZGM?V7,=.5]/#!T4'H30!ID.]#YJ\DI9!*Y8D"5Q[[+UPAR":DM /VFVLWKZ
MWM$68*:?Q[?0Y],2YP&)?Q]?T#.F TD;=^UPR[+QF6EM,XO"2'H34!DZ=$EH
MJ1.!.CWN3.C1OVA[+#6:([P9C?D[0ITU7.'^-9Q]_7,TCE.<?*]9 V]'WZYF
MTX^8QJ-$LIG3^6,=E#2A%?T"T^'T1FJW$V#S?UY-9Y?7;\%#CW@0;"2KC&@N
ML1#KN=.U$49AX&0(,FJ2;^Q$IR,MX$P(^AS4WV.5U,8U_W/W-7_$;U>3]!6F
MN#[X,U"Q>*7([ W1T=Y>:\.\S:7.$9.*E%8G).],]8; SYCBIZ+N'DN[^K=Z
M<S(" )E%[NJH=UI'4/2M]SGQ6+@$<5SG9)\LUS6@IK_\N//=(E\N.309%+/S
MZ7#:* 8))5/))Z-1Z-"ZDWXWH(?*>&T6[VFJF5/)=UVSM'D*4XC!>HV%.653
M=0$T"T8+)JTE.Y"V-S($#Q2\/XT\UA8<V!!@W$<7#9(WUL&J7TYP>=O<!6#+
M7-4G$1XG.[47?7;@R/[*. IKK(DIN&@(:*B3SVI.$@^!@4:31+;&JH-M,0=@
MRQ/YI<<ARS8ZZ/U^XD?&OS]\A<DE[9!7LV&"B^G;45IV<0_>VVC)N ZA&M?*
ML\!39EYH471-8[.EDZWWZ&-.XG9B'YV,FPBTQWO..;+?<0:Q^BR?OY)=_6T.
M;IE65&SQ''1BF=<R[%#=E&0%\]QYP2/W9,!U4O0C#SDK-?<ES-[?Y\F/Z0PN
MEB.G#7<R@&?)U_ QNFH(Z<""%\EJK'/)5+?W]^['GI4B=Q=8W_'VMPG(\UT"
MT=QJ64?*I9H[R UG0,<,@V)4-A%I<=V"0W<_]:P4M[.X^@Z5?R@XPK\70, I
M>J),+-3>/=J!9C%A8$D;H\GO\+ ZK773=<B=3STKO>TLKHWQWA[363_-QNE?
M7Z_O7VK?YMF/75(>UWS*WNF,3R%;255TUN@<0BF9[(JB(-(+DC6OP;DB4W&#
MQS'N)[.Y%[Y3LNC&SVH@OW4H5Z3HDU/2$"VC1QWHY#9%JYS)@"LQ2*762/$A
MWOUD.<^/^P6FF&L_<?)C%B.N=\['W?81#22_Q9I6%*( I)/5W\JV:H(<,YZP
M>!5D2E*'-0IY_&%[QHW7?O:KR:1.PKJ>-G+[*\O =;VVN V.:JZ+]5*R$',=
M+NT5B[;(.H0D>0!3'#:9SKL_]+U;$E[,?P?S>B@WS<EF[\MG^'N@LB43K)#3
MK<@1U]D5%G2="J8T"NE5DKQ)<[GM8![^J#XP!Q\T-&RGQ0:)OK>AY"?%-MTD
MM^L8<Q(Q(A1@IG9GT3X'1J=#8:HD&X#S7$*3BKG>5G"HJZ$C\_,X&C^5FZ6W
M(SJ&\=.,7M#Y?.OZ!\N@9HK..E26T<(X(PESYC%Z1D8W^4]&&1D:=9?>B.GX
M-TP')<F#_M/]**O!1<(&:,M"QP[@6EX]/8KN.-=.O>FR&T?V4,3!V0). P]9
ML\QYI(/?T"LBI692"XN)JZ!#$XOW""QYXKKI."391OX-R/$1IT@?^/75*/^*
MW_%B/)^-M; 3%V&A$+CQJB@F2ZY6HO1T]*O,7#0\Z.2M;]/+MP.VPQOX/6IS
MW%85#0SV?^ ()W!!"%_E2Q+U=%93PK[C?9 B18C%$LC@5)V>%AE80S))8(*V
M B$V:6C2"=TY,:9_=6S<89I&=?^ R37P7@-I#SZU0>SL<>0KX3*K3=92UWF%
M19?D(EF@7&O(1O+H+5\3+GOP^4>/D 7NZBPH9%9B'0(/CH$(D:$A_\]*EVEI
MYQDA^XUH./Z!^ DGWX>UK< Z0#4G]LW%^*_?2L$TJ]_]2;_Q>?P)9[,+G .:
M#@1W]-*%PDS&6D=4.(N.?!,C,46+RGC1Q.;J;07/,JZV#7-7=]KCZ+Y%R&U7
M.?YQ517TOBRKX>!B_GO35U>SK^/)\+\Q#[)1&*,H+'%> T-:,R_H9'-""U3D
M?:-LTBNQX9I>'-%/A1\-7)V]E[98T'<ZB&MTZ<UX\@_ZV]D@@RM.)\54!L$T
M)U&# LFLE3PA!%IHFU;;C1;TD_3'8$:#WG$[K^O]MWDR_WP1T[>CZ[*>?V(M
MA\7\ZCLY'5]P_L-?R:FY*=T:5"_42169!_)@M,R" 5K-Z#M//R/GQC=)7S[P
M.G^^'R?$HP93'?==[F]_XR0-IWBSXL_C&5R\'<TFP]%TF*[7J!062.3M&Z<M
M(W>PEF%A846H(NE85"A/*]-@B\7]?$&.S9@&,RL_3,8),4_?D/#?3J=7M;7>
M\N3[<T3/>$O_,*JQBE>C#>D''RY@-+T9XCJ/=BP$,/"A.,YU9E) '3$=:@)C
M%$PHZ970,<K4)&;8=%4O[CTX'8XT&,?9*0;PQWCT':?U=)N[^_/W^%Z,8#R=
M_3&>_5^<U3KV+Z/J&-U;I'&T.E[;[BE;VQA)9*!]JB-(E2S)>BAPM-C0OJM[
M<2_$Z7&FP8309HN\/@O)FUK\4_T],< (R@6(3(N<&*W3,Y\X9UY8)W(L 563
M&4.'7>;/5^5T6-1@U&F[C>'FDZ[_Z/WL*TX^?X71<K.@,[3H0&M&86H?=*]9
M5)R^=99S0;9E3,_L@'EBQ3_?I)/D5H_C7.>53#>KKB?CAT7WGVI-OHK3>?/^
M0<@Q8]"294 Z*^LE#,1DF$TV1L=]"/;):^9NCWHQE&L@^0:#5W<6SN_P]_#R
MZO)^F)?.D^6*!T'S(F6AS4X#9QH#,L]-8LXF(Y%<\NA.Z\KKJ14=N)U8S]3I
M*RS3J]Y;767%IQ<65Q=V(^+)L'KF]->7X]&U\'%27?.!E+(*G'8!QY'I7)NW
M^>A9,$&@!*5R:3)+O=V2SH_2Q]?\*5U67;^=-=Q4)P$M^N(I]! + D.I:QVZ
M(LL^.& "DO9HC.6RB97;ZRK.C[E'T6_?+09>CR??QA.875O6MZTF;\1$@BA&
M<V R"1*3]C5;7"D62G R:$QD&7<R-)]ZTLNR,WN5>Y/Q[/7%N<65?[VJG4FO
M&7O-X@%&[V2&P*S*D6EN!8O:2%:L=M;71N*J3:'BD] .WDBV3V6N[C7]*J*!
M!?<J);RH#5477O6=AK5OAB.XF!_3'V"8;X?R +G0B@>FLO)U0GVY#O+J1 )Q
MVFDNFR3>;HWTG(C45DTMK*C[S/\P&7^9P.5M$M[UI"<QT,$;*'6@I9BGH7ID
M9.$Y%B2WG&=NK&Z3?M -WSEQJ(5*6F2]K(5YO6>^';T9DY,@!N3T@I%%UA9J
M='9K$<GL2HZ)'%(DPU!D:.,==@!W_IS90QD-$D+68_R(571TVMX2_(YL%E0/
MTL:B"'16+A#R:)E77C&TPCF)]*R"AZ-1%\CG3Z[>%=<@!>,QN^XZ20H2@@YU
M#J\6BFEK#0->ZG2Y$+PT4OG5,0[M[>L#Y\0=U[S>7@T-,A+ZZR#A2]8NDOWF
MO:\GLR3"&R>9XM8[#.2OMVGZ_A(;R^R5@7D4C9]*8YD:I*NCSN>]"DADUIOZ
MLGE+>[0C-P0"N2%)UM8\#IP733K)W 7Q_%O';$6#U33(7=71(-"PQ+(H-^^"
MIF5SF/MPCM,-9G?U;-#S'K)MKW%R$8RA?92).AQ3EU18R%:P(&(LSAKK5)O,
MZ@-H^HF.+JT4O8U(^VXI_OFO\>>OXZLIC#)].;?$;I*J*\Q%TP='1ZDVAM-^
MY7V=\H.L9D^S EXX(2*W.G2Z@NCVO,-?1.RCDG%;>?8]*N#5Y;R+Q&^?/GQ8
MH"'[2 O-,ZTVT^&4<V)!$:M]DF XCY9.JD[:??#1SU>1^TFI18A_;DS0+\^W
MGT+V1+91$P0=B4 !6/2\=MX$Y,9&+ER3K.5[*%ZV6;:[0HZ1[K!1$+?+&.65
MEZ?+FEI:=RT6=1P;<0^N;)OW<"A%'Z.EPBYKX\B%L4C;-M8D8B]JC#$X!BE'
M%%98W::U]/,A[Q-F[XES=QO]-N#LO2RGZ\3U97,]E97.P3.,M2XD)K(7>$#&
MDW)!>TA>-+F5V(CH!--[FBM\4RW#7MIJT$CI(TYGDV&:+4KQEKWV;,20,S*I
MI6':),T@@F0BEFB2-1IXD_O1M6A^TJ<'+1UH#F3=J;//Z.KD'>)Q'90J"HM6
M L.@D3Q,YXMHDAMVL@-FC^DL]*&D!ED:3X^"Z@+PY^39W?2Y]3#1791QE,FS
M/%F(M"TR(4,=M0=D)?($C#9>HSTZD7.3[,+G-7FV+5FVT4'?8>5[<^ \&.$U
M >%>*7(9M&<!#3(#)@KPW&;>;?[HJ8_-VTKB&\?F;2.NC99HTP;+=ZSG>3U'
MF@V_TS_W.[?L\6>T&%RVQ:I66C%#T%P)L@.=3)HG'J10+B=P/@4I+:Z;7-9Y
M??OIZI<)PK_R^*_1N"S*JM]?S:8S^JOAZ$NO&NOTI 9ZVWZ%*]H+$I*+AK9;
MA:3''#F@"]F2[@S]S*_17J=G'KVY-D)2NI"#8V5MY&*C)%='(/-HP%H#TL)I
M5:V]ZZNY]GH$B[Z:-PF)\QY2*R_B3?.T>2[^QXKXW?@OG%Q_-;P<S@; @7MM
M@&57_;V4,R,_CPYP4TO8:!O@J_.T6XJUGT6=H'/?+[^[Q2*/P)"#=>7><6U_
M?OMV;VT"97!<(8,0JGDB2=Y><6:QV"Q"H WT@%U9^UG43_8?BR$'NT7:<6W+
MG@UWCO=E=YKHH'CG:JE$H5?;AGHG(B4S&@"R@:@.V7*U]_7]?"=.@#>M,@4>
MM'S8<9D/E[?2COFF#.3U>#2O%+B"B\\XN90#)[PP6I.69*J9.5:S:&OC$QDQ
M)ZUXC&U*ET]C_2_S]3J^W+?B7:MNX <3P[T_^06_#$=5)K_ 16VE*P:(R6FD
MHSE!H9-:&E-+_BQ3.DL-SF R[6RY$Q'"SQ?QN3"P1=%IBS-_\9-Z9[@\\VW)
M"52@909%FXXWD@6+R-!R1_M-Y%Z<OM.T>7TO\QTZ,=ZT*)#M<ZMXN+S'M@HQ
M .6D]:B9*/6T+CDS0'#T+2 * UQ"NV:(1UKTRWR1G@/#3KJL6'B+O,3"N#+D
M4DK.6>"BU,0F&:5*-J0VK\H++"O>B^U'T?BIE!7O<6C^\N/AVSY/H:#% H;D
M63*.Y)!39!&\8S%P2>=C2-HUJ4YNL);GGR"W%2G[LZAZ(<>I!Z(7*29=EG3X
MDIR]UG2<!+ZC\ZVE1[$'69[)>R XAQ+I[$U1N-K=S+%@4+)HM:5C6'J4[?I*
M/P?^/Y&2^!+HOPU'^DZ 7..<7.!W7%:;H"[.1U0LN3IGJ>:  I;"A ["994A
MB17Z;IH=\>AS3L6=/* >QVV4T'<1_II(Z@B7I4@I8@S%,^-,G<SH! LZ6.9]
M"9@%FNR[Y<L^\I!#]P+O41./:W@W,;9__3__-5[@2EE*XS*PVOJ.<$7.8M*&
M92%E]-8YS'%']=X\Y&S5NYL8>[Q&WX2+-+4DGO!>)R,R RDXT\XYYI,.#$7,
M1EH0M-Y=%7S[F/-5\8ZB[+LO_T-D;\97DP4PGD&KBH0C![)U9*1])5D&Y .#
M$2K2BG?4\>U3SE;%.PJRQPO 3<"&WY?40W1D>&!@T:DZG,(! <N)<96+ULYF
MY7=]BV^?<KX:WDV0/=YA;0#V:;BLL[$!72D\,NYKOV,CD=5>I0SJ5;2(CCO@
M.RKXYB%GJ]_=Q-CC)<HF7'>6FZ0A_U,4YN9YJ+$6>6=/WV+A0FC.S<Y[]*=C
M^%B'5O&.HNQQO.FF%==+O06R3/Z?KI7\(7FR$(SS#&Q13&KT26HKH^W6N^S1
MQYRMDG<59>_C-A]F10QO/+F4I*LC\.I2R=17ADS]( 4K1GKB8_&"=YRT^<A3
MSE;%.PJRQ\&9FPS]F]5&PYU*JC!9,S%U,)F%$ SC B17:'3@N[[$G\]^G]Y-
MC)L'5C4M'7XUG5Y=7N=F]%I\NN9S&Y2:/H5^I; TI>21VV2]4=IQ&W+!VGA2
M*$BN*+.FL'3-$XY>1EH4&7+.('/1DHM&;AD+UA66BB@@I-&TI)=41MH!P1L8
M3N:C"^[H\^-P^J\W$\2WHQE.<#K["#,<T!N;>2QUM).5M:>,8H%K1<9TX85^
MAK+1X*36*SN5JX=F3.]M(&43KARLJG3'!?[V]S>L?;3^8WQ!'W-!.]]\B<*G
M7%0L+)HPCQ5$YK6L=;2TO/^_O6O];2O7\=_W?Q&@]^/+ MW,]"(7W79V'GL_
M&I1$-08<N["=F>G^]4LY=F_BQ(GM<W1LIP4&Q31MCTC^*(FD^,@A..L'S)/N
ME;<?&^+$^G).@[-?8K&6*8F1U,6GF#TC21NFM?(L2AY84,: 1S#1VN&RG_M@
MZ?O< *?7CA8UI+VE#(*W,F?:L;57#M/):[K3G&.UH2(/L:00VZCY=YBYW$F7
M3X+XJ3.7%_/EZ-_Y31%L(N_<,+]J[R5!,8#(F2Q0<H@FTY;<0U?IHP_TE'ZW
MK:./5KW\K."# )]U%7R/M_PW(C;AE3W(."#W=G\]Z#^ ]7J>; <$MC'L(+Z&
M:%J1G++1,5/C9-K[PCSZS*R,V5F=.9?[]!\X#Q1W9'OV#^(A4NL9O/\F2=W>
MW6X>*YQ4*J BNZ?VZRXBLP@B,1N3=SX:Y-;T!=^CE8<S8SO)?M:'X'J,(JP(
M@;\?$"*3!N.L8L[DV@=%2N9]+1EQ@4MM;0*QSPB;_1!\N/(%(GBTX';NP:91
M_JT^Z4T:A+ZR1H/H_R%<;;T$1)2%NU2D$%P[D8(S$, +"XKG@/:9EX!75COY
MJT"*)HK,20LQ"Z:%S<QK5=L8*72U 6YH-'3[<E\%[H&]GA*P=RO#^=/R!N>_
MW\!T7:[\<3;]DV#'_.ML,GD_F]=_- H)C293F;9[K:I#7>?89G+;-'B>R?7G
MX;QBHD>Q>9'1H4/V0&_AT?9:=$Z/!_MS>]]&8X3)T.W(#5-1!Z9#" QRE$PJ
MZ4K*IA!B%[I=[CF\H)TR@*H.OZN.T+-3S$H[FM%_T">6B^OI+S@?S_*(Y!V<
MI.--9*69)D>1A>P2 ^6]XSD"A'T<K3/:3X\9_+&=3K*=.FC9*<9G'LWG_Z[P
M^,9GM"BD")(5H^KX/(_DAUM/L!15 DKAU87MIL<,_MA-)]E-';2L58_+)GP2
M"@7'#UE5/! 0-8<U*<YTBHE%$1S3!5VTOG T%[:AGO#X8T^=9$]UT[7!FE6V
ML&W)<Q4.0F%@M*@CB 2+T2MF7%(V^QB+>4L^U%E"L=6Z;F4O_01+_)8<\G '
M61ZT<,ZRR&N-'7*RG*J.(BFL#5Q'M.V::9^/'"[HI+R8(%(S/;PHIWA_<8R2
M+ &*T$SP&A@P2C%O:L]6!*M$S#4-XJWNQ0O:@.>P \YP-Q^DOA>UA1]''/80
MA''<*HPLIT(V'J<CV0>PK*"10AF?<SZO!ZZ^)?!C,Y_G9FZIR!<<6WM=$ 6%
MQ>PSRT+4H\T&$H0&)I56 NBH2^6\"MGZEL"/'7V>.[JE(E]B?.]NCMNMVY^1
M G#(*7JHF6R<Z5P[#0L0#.N01<M!)WMAV_D0]G_LY?/<R\U4^#(CBJ_+P+JL
M11# $H?$="0L8W' 7 S&"6.XA$O-;SIP$Y^R$$M9$X76EHD:>=?&:>:]E2Q;
M"%YD[AUO\X[R'19B=8KXG03Q4Q=B;;B_)Y_^\JJ@H= 9:8E<)J"^&Q4RB *=
M^72$JI!5YA;;/%,\HN+R"[0.4H197X"<(G:T4Q#_9F.::S/JCW"[Z3Z]#T_#
M3USHQM1I1BYTT)5#K;>A@+X4)<:8BI.H69#)UX'TD06%@3G'D1ME,&7_?2OO
M*_,2SEQW#\&W@<YNU:ILFC<C6E1),\V1I%0G0X!$LNX!G2,IQ48!]&>I.4-W
MN3G0L[Y1VED8T&,U&0GK=KRLLJ ?U^G-8Q+7-(UQ\0$_P^27^2PAUGFS1]61
M'?#USA5DQW*R53M&1TTI7B05-&KI"O"DM/58$KG)(OK1<3RUP>0CD'XOQW]B
MAUJ_#JL-B-G+G&YAJ%PI46F14E&Z!GQR*5)B+MHJ%-(=@.&3=;L=W?^@4^7Q
M>M_<5!VE!YDL*^0?,&VU9($N/B:="\59D;)L$IC935+7>^KQE[_^ LMZ#+^;
M3/ SYLG7ZVF9US_*?WR93=>I<$YGH0K=[5)S2<<C1A91UL%VJG"!RO+ VPMA
M'U*'O^%ZTIWM>ZHQ2@VJVS[,%HL'%'_$OZXF,+Y=O!]/ON54FLR%53(QXWP=
M=) ,B[DHQC$+;HT-KHT)O@=M;T9S^L:A@:G\A/-UDQS'K2L&F.75H]#1D$=!
MI)$G8;4H&FR;(M_GR1DJECK( 7*4C$\=\*Q='SZ0S#^OG(8K\A!6CF<2BD<H
MAO&0'-,"27F=E2Q&[<F^,*:8?7(+]^J9\73Y4X4Z^\!SUIM<>VYK\YB:ZO6M
M7;U]:.J[W=0N8H;O/=45I)UX=Y3P4.B7.F]!0VWC;GGUS17S)1->TB<CK)5F
MKXS^,T3]A5Y50X!^B&#['@OXX>[+>'IOSVZLV'I)K",QWEJ(1BB63:F4I5*'
MK$3:)RDKE8I OM]0T!>7&;;[43\PS)K(L.^9GG_\]M/X/L)V-;N;+]_/YK_?
MX,?9O&8'3#=_]*E\NAEO9AAR0)EMI!LLZMJ1+>G:D3,P([W-+A8L,>R%^,%+
M7[H6M)7U$%VSKJ?TO_@[_(U'!<D>_O/.4:^=M&R%L81&)<FZDH',JZ@"H$9M
MHDQ!"BZ2&.V@ZDBYK,R\KM)9?Z1/&3U'UW; +UJ1;3%>>- EQABDYY'DY[47
M.O'1BQ0>*:\^@J\O?:Y/&1X4/N4D0JV<"L((K7)-<34>C8]DZFLITNBE#W?S
MUS^1GP+5\UC%%NC;7\M]^N$#7S47%,%'S72IT]$@"P9!(D.A#1HA37&EA?.^
M!VU=PQ4U2^W^W6HRF?T%TT1B+3B?8R9AOULL<'EU4]^SKJ?O;F=WT^4(.(<H
M2Z9SW)8JBT#'K ],8-)6H)?2-6GH?2BAP\>\^M:D[:A'4Z@:!$UWRV.$3@2%
M63+#R7;3"HA&%3,#I55Q];;!)B_'NTEZ>^K2D_@;A$A)7:](:\?+AU2M=;;>
MI,1TG?I=IXVB(:J"KR-Q9!*1KC&]/0JP'\UX@::WIQI] ="@F.R/Z1S3[/-T
M_'^K8^V_<$KR7BY^OX'EOV9WDWQ]^P72\N=2L/9+K1;!:DY,X C$L&$Y1_(S
ME#0L*D5'G9!)JIRM=Z&%VAQ'[MO3J %@:U#GM%LJ]P%HZP6DK SSM:92QUBS
M9K1F2GD9B=!8S,!VWZ"O-Z>[H0X7_ZG?<S8\?7-4WMTM;V;S.O&Q1CG!@$\@
M)0/MD6E2:P:.;ESCK%1HN,Y\GU[H!VO2\^2<ZIVG5\!GO0N^@:GSE*IU8&P?
MNEIFG>\B[#29XWV ]ZH^=)#\D)K!M2QTF!HFHG!,2RU8"%AH$SB#I1BI2A-3
M9EB->"4=>TB%.$3@311AB?,I3'ZMTZ/O\#><_SE.>/WK;YNXMLL1A;?,5T-)
M6P7,B_H4+@5$GT4*L<D$V5?H&MZ&[0? )UK1G_1;M%5?DIG\;IH_T-^<_/-N
M/E[D<:IB7I/GHLDEYL!BJEDT/I"W)D)D0GHBC78)V";9BZ_0]4:4HT_I-S@Y
MWL_F./X\O:I^^_SK9G@,#\%"XBSF6(O]=!W_4S,ELZLO%=Q ;E(S^1PQ;T0-
M.LNY09SD^1#.ZHY$B:&@8KR(5*> 01W'IUFRJ"-F)VR!X2)H;]3;Z$?\0^G%
M@_JB?<AKZ7>\0M]IW(^>T-Q'1SI",50T_@&9-@K,*6IF)-UO.ILZBE@;AJBR
M+LX+;IID+I]$4UYQ2TZC*(<@T*;X$^F#-QN+6$NI( (#*%#'O:J:7Q]9P1"!
MQ\B=:=**^#$9PYL6O:+TM'+S6!'WG>1V!9,Q,3<= QF^'_&O?^)\@5\W!#XK
MA#75RHABI97,6ZUJ:AZR4+)AUH"R9&:)DK8.BAW);D>3\#:48D 8&IP65_!E
MO(3)MLVUT6QAC7+D3B.@)YN+(R/WFM<Q]SPY$4/P38);+U+U-M2F?P!VFJ=M
MLB1K%?UL6DL!9^7;CW_^NU;6X_I!L9^\MP,6ZC,C[EC^MG+EP 3/'3I5.T'J
M:(*R4%*A'XN$/CS*E3N.TR/Q^Q73;)K&D_$J2:DQA@<NUB>.7?C<SB(%[Z.%
M8*,*.GH/8(QP5O*@9!%1C7KA^$@\'V27U=_T@=JSG^P3F]=IWD) VT)'JO3"
M!:F+Y*"+!@ !SG'OH(P.H+ZG?;,CEZ+-OGEEL9;[YA ^MU SB-R$:#0'J9T-
M$574&1,DY"&E_-*^V9_C0_#\[>[V%N9?Z^?A+M>I0O]S!_,ESB=?WX^G0 3
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MQRJN5=,9FUA/,,9'>N_-6[F=I[P0"U9.;F(&"3!]AU@ZA]+E<"$J$:X1ZZS
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M(PEX*HI WX%T]9D<S9AVH;-[>&IRRFY2MY9'B.CO].BEQW%-W\4E &6"!3&
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M"."'\',5GFPF=U58-\V=3@L+NXS40?,B1*YFOG=^L 3&;R2>(!"$AH,UJYV
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MQIZ%=_XE,_JE_W,52OKROP!02P,$%     @ :8A84EU^&(;:Q0  OE\! !0
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M\[?F;\W?FK\U?VO^UORM^5OSM^;_+$W$U9,"F%/;<UO^DS=$R8T9G<XV*M?
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MC%R]F:-SEIM(P37_3LZ%^U(]%QQO9G*B8FEN+C6[ST/E\(E+0MR0^OM82J3
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M,$;U2ERXO"%_^:H."LED207S#,5SGF*SH6KV:'B/!)*-<+419UI8J'8R;K=
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MP'Z#/3OFV[?C\,ZY:0NK=IOWEWN+;)+T'I*EN@VQ _>T_GEB]I(X"=IS!_&
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MDY3X+"!_[DKE4U5.]V ^JX&,AU9#T'=TLW&E#+0@I\FO92U2 4N++!<2T22
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MB/9))8 F'HV7(V1JZ;F:)CVVO9QK,X*D@JIE.VA9E$54[W[-]^ CFB;;;1[
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M=W+]V+3HUENA>X+D3(%/;N\C'L:QUR<:*YB/:) ]> @H Q>#E"?4KUOX@5?
MDWL$P5=NUGM$U^V]N!/#=.C%8_8YMZG%&3B+JO[3$EO='[J,[Q.ZX0<?TJ07
MPY/+@ZF7VB*1'/@@K^]KO&(5N;-^-9^S"YZNC2J:$R\T?3:<K"O49B=R%*_:
M54N;RMVIAK9FQ.]H%KODU:NV_ST'NW]>#>):CAY&*?2G5XRI+142EQ3OBN%;
M&ZP[XI\:*1^/^-Y.8^"ON&1B*$W!02G%.N:6U9H4ZYFIG+B/A-,/"33I^4KV
MEDLGL5WKL"-S\C.Y-YX!>+NCDF,66!OQ/)AM:\B/CDK\,0I9JA2CJA=0!@G9
MSYLHVU[8U6\X.]>Y8'6Y+O7:/8=P)YB,2;A<9LU1_78 =J//QBL:*=\XZ1L_
MO+7(A??PF1>U?3SV,%7?F#((?A&X\GGD4W^3Z9,2@_:"5R^8G^'Z>KRHH)>/
M>7"9"?)"M#+K3Q_[#AG0"ZL/>DVO5.WT?O^B["E88TTPQ9K P^UQ+XF7OY[#
M/L^^ PG7-Z;Z^!C9$1^^8#$ S5_9[+-<0IZ#*N C*PA/1UH>H1*=NW@5DC)1
MQXE7KM>VJJ\:9W[)15\7H_=B/]AX6\:"UKPJR./WK"%@,2I$#-0KEPRG%9V0
M-IVN:0:QQS[N9Z29>%Q1OF7I$L&04KDJ,?W)(D9<I8AB?9O/<HR@^W[&+4O_
MI*[XP\*MZEG;Z;O5FJJ/KU0DO2^]R!_.Q.@R]9PX)', 8H=ZCI3[]>6O+US/
MWGK2:S;P?,C1^:FR9-A>A/QH(PEPT][-VC?D@<0;89$O97\NTKLMR,"'3@.A
M^J>KA\B;B]1RV<5+R2[MU*O#(L"/4&;AO\P%I##)T_GHY%B?$Q@FPHH@C/M0
MY(D4MC64M+19B_/@_V9.09GKE!?:0,?]:N"#P)/E'8HY&,H;TDR,,3PE'$S8
MT^Q:QH5BH@AQD01$]J-WCX1!I^1"I6N14)M/Y!*/;UM[_@>%:-]EANU-AJI9
MQNW!\=:YLB0@[^P?U(:B18T$#%B"?IO\?]A[[[ FMVU?.(J(@HB*%&E1 5$0
M$:5(2ZP@(D2D*2TJ(DU I-=75*0; 0&E12G2B4B5DD@'$>F$(H30.PDE!)*\
MN6&MO<]9>ZU]ON?<<[_OWG.?;_\1'IX\[QQSS#''&+_?F)ESOO\2^2^1_Q+Y
MWT$D=5LDB@GYO>T''N/4JLR_"$!1S;&_M1UG0OZ;C^<_$-FZ+1(&_\. _M(8
MLFXO\_VOZ?[OC?]-G__81O\3(EO^5T7^X[RQ;"3WG[013Z,S/P89: F'4AC$
M9="T@R-[;>.#"U*%&D/IZJXZDI415TV:;MARK%/"(TIM/;D%*M.%8BI &7./
M0IJIU]"8Y%J"31V2\^;>\<7;]4Z2MWSD]6GE3,CHM2!70\P>-<OE+QI^2D;A
M]05>37$:(^'+-GVJ*1BKU+O:GEF6EZSL#K3^,O^>%:;1_X;=RP2%>\R$[/8R
M:ROKO.W,:XEA6V!"*LJ&9ZSOM_<:!7FQ;]3R1,#.DH41X\M[O/!W2R._1-MY
M;BG4!,X=0&35'Z<?8,CT^[$1$^'! 885P,+X>&XN=5-@8V-$-,%OZ[F[.6OJ
MW3C;$ZJ104\Q&N!X6;]U.7Q<MS?>=A:*PS1/PHG25#)Y?K(S;Z@V0:3ZC'A;
MCN."W]0/EET?-VKD%I 0"UII=W_(5=W/_36_D3<T,L)_MA;AWY:\O/X=G\:$
MU(Z1[4FP7;^M1/_-O!R-"/Y5)H1?9GO]7G3;P-VOA92GLC;1Z,TCAC\=3E9X
MW<EQ >?P4QMJ*"[J^:LDHY O'6NY%DJ$"M-Z7MB"3^&&BF(U@6\22?JJ;L&$
M7/UW29U,"%=, V[M<L!18-0S&+?I8&$GD8?BO/UV8E+9H]WD/^M##U/RM;<K
M4Y8PPA^$:='/( 2 SKW;B[.!(V),R&3^WTY._*Z(U!@'R.'ERX3$%0.U$V1/
MQ@%T"/1WS?Y^%N)?$O\E\5\2__$0SY]:F"\_K]+-HN924''+!J24PM'Y(-+[
MT,?N7Q^G)UP3"+OZ;-!<+U'[0?D98>FG'^Z]X?'Z?W$!E6W:T9<B1UKZ.A:>
M'=,@=KR;+IREL5 1_\+Q4_"""<)3HVKCI*3M#_(5A3A:>JC$CO W6--XDW4,
MU$^Y"SQNZ^,1DZ7CXN"0.1<G5'R\/A6JU#6F%O)FR5B8Z^J'9SN&WNQ1QR.O
M0;S;(V'[Z\8 ?JDP-Q2O0\ >LEQ_8[)+]HS,HV5/^X*'US-T*KW'CXF^CWW^
M2KC?J>9XECU0U!Z,K@-%"SO6N<UJ38.#ES*KNDNJQ>Y$+CS]):!\C4Z=?*U_
M_OK"O,1CK@/?=AN)]]I^V*]#;*^K5B:B@X=N=G^JJHX;FS*;7]2Z]4;;W=_]
MU/#IU;.<E>_&@XR,=A@9&5U^7?K?<,WX)LH4<FD](R_?M<$4_LJ1SC S+.H^
MQH2DQ'ON/00^ON:M%09W6 X6$QV)LG=U.(^A%W4[#C0Q*$.W0.Z[W]./D=5$
MW9Z\B[A2<E+%1WPP>-823F9"MCG:2<("G!H%.(HBVK_1D%&3FP%(&G?29LJP
M3(L[8LC*G,S7>M=+KN:V^2^ 3<]RLIWQ)82'L0<?0?? PR2IX;1#3,@8]]L$
MOT/>+(N5+N^\4L9 )JZ@T* W@PFIJWYBW%"@M;"Q[,B3U?IT+^,1ETAT.*YB
M,K=ST68KI1%71OZE["7 IAZ5RS*XK0D^_*@UQU&;$=QQ59+,_$?:$>K/WLL#
M],O6(:L1NE#XQ:G/=0\<?FZ8$YYJW!P_T?ID"2UY[<;&R IVQ*F/[N3O=P2H
M.OD+-\*WLI?Q-N#48,!2]YC,G@HFI&FQQX^QVUZ)D1APP:PLWH$LN"G^ 1RL
M1F!V<'OZVB??:W_G[<&[,):VH>#_BEO2+P#'AK.5,5H9)T\GA'?B2L\(IC#N
MGM_L0KT"BH,P2S$-L =R6F '-[HA'IX,O1._(L^$6.O']6?Y+] XR.E36!:H
MOD12DLL8@_8C#S [Z+0K:+_/[=,W5P#[=]K7;*(,%[F3ST[LWU0'_;JV6D%M
M_SJP"753%T[G G=0^#6R'5A3L[@\^$J^L'CL1Q7_2MYK?^H%>A:+#@;1M#,Y
MZLQ"0'$K*#S&8.L[:++!0SOD+],-4#;H; O[[50P*!S1/: C3(5T$;ZQ-Y$)
M"?_$F@I-NJ>E&;&%4P5./HX5 0C? 5.4S<:!%5.&% <3XBR^ &^,0*]L=TRU
M!\+UZ5U^%^[EM@+UV!D70A)9APGACAS/PGH'B)T-];8J=1_'27IEK.=8 JXR
M- [A3CGZ7N#].D..B#P*U+DZW )7G"%\H=Z/:%88J(' X4*0D)B^$\&VB*H\
MDQL-YY$ 5&$E6INXW7+K@/RL'A.B"-K@BTU:R $$55?M4/5C;J'#<>MW0#..
MU=S/X$B*F)V\W*N2JWH+T9I-*\V@&UBFM1GBS?\ -XD?P_W8BDFX@'EOQ:A2
M/_IPIRZ7F>'Z':+4RCF>:>-%)L0)V*ES M^MV*\)6XOK/+AU0Q>>=QNT.O*0
MRB)CK9_\H3&SF@[3\\"0#7'BQY5(XQT12]$=!]>(D19EC"*8T(]Z#<8$VY%A
MR9@WP/(;>VRASF84?.#.\N:J7/F&]'GD&;H=([M*<HSGE5 OZF65EK?CV%YU
M=)'"V79G*=YC_E_8A0,N#C>)>&)B :*3USP8C#P(C':QK!Q>X/-NT&TX#AN,
M"21669[;_W1#R*,XYNO6^R1,M14UIF%0^>5CW:62'--9CSK4N3GK"-Z9<]ZP
MN@1JT3>D %;!J[NV%"9*RLCH7?O,<;>DY6V;3/0"0;TK.?Q9C1;YO@_>@=C>
MCS<E&Y%Z XY3"\96)K%T_B_%76+4\]<O;+&+=_2>OI*%<]_-<-,\WS)[7P*L
MMKAV)OPN/%YG,W'D J-,'?ZIZ"[5X.97,M^X:*C"LYH=5M^^B?NZ#ME/]Y6W
M+R!1:#&LPRRZUD<DV<JQS]:0TG]>)@+P?3&/O$$5&"6\ $5RDKFNEI:4L^V>
MQ?](KG85M_ZZMHO'?C&;=J0'E,#J7(87/RG7/6O(HI<)IKCH :BZ%P=%AN3Y
MBOYU?3:3K#BX8ORXSHFGV/XI,'KSTAK&JW-- UY'D1^8C5/:\D\'GG+=B5-
MIF;M+&874;:?R=0[W)N:YRV8Y"0NN&SJ""(]:KLZK]F[L$O*_J^^F$02(GOX
M]J-GG#PW,K(<^%4- ZP7)ZN3@)$4HTN;,9;:9-<QRKL18?3-CG7)BNJO,+,6
MYR0)H/Z*U:Z4)(\3572]<Z_Y][M&=V>LG[BM;V)3;),@GS 6P$MM GGE]@RV
MRSAARQ@-C0C)MT\(I&,OUMLS/+"]G9K%#@:1UQ=Z&Y-[.^9.IE;L_O_Y@2E)
M6=;(KU__L'NZ.T'_3LI1<MP+HAJ@;-IWVBV+7&=I+G%WRTD<'N2M' 9_[!QL
MNGNMN*JR;]+@>8+_UR;&^HE>\5^\=V^D'ZLL'+C"'EH/<";&IW8O:W2]3IX?
MIS$A0_"& )ER7\0NKZ.M)T<54LW*5)8G&P4XR(H<='&@.+AAO[/[7G5E:RF9
M"N+I;Z*-QW8C:7-?P1(!DI3<59]Y\7QV/]WKW99/36BQ[7F*RP*V6+X2WGG5
MDKAX_G-B2\3C'+/E$?@8KS1*+=65V#7KF&4^[WJJ!H4HD[!A; QFDDY4;5QF
M!%T;;AJL,AJ;#V]!O^=O/"T/7^^[7,^$$!3G1@09<3!A+QNKS."TGDS++W-Z
M>&%L5I,-J*:E=-Q7$FJAM? T"=YTVPBZ810_GCT^&+^8/P;G-2]!/_<[M,'K
M9AS_H^+-],>5,3;H1F<.NI\)V1Z3TYD)TO#;%^)NV0\%-$(BCN#DD1:S@Q9Q
M,8_C^HS?#'Q+.OU$\Z!6QXZPRK6T?CVDR-!:!W+P+6N^*XAI4!5+!!FFW<&$
MW']?PH4JH98U"@C$X,[)OGWXE0DI_7((P2!;%A+1 PABV2NELQTFALG 9$&F
M. *= XUA0D0QEN,E)_G2GZRE%>O=&,"J8J.SNA:*D4%A0I;A]U.'9+%H:V=K
M)YR'C&V< O3Y,^GYD\Y$:*1:INDJ-!0'K9(DM6M7)/C?'M+O&;]]K&M1RB1!
M:T%PWP+2V/E*1 J/A>K3K,U[!=Z6:P0/'YLXW##R>S*2AZ[ *'+/5V[PB1@Y
M:]+C9K:Y+UPTX:3OB<;#5_<>N0G9(P5O2)KVQ+# TLD/QN)60NW@SDPF1*2@
MXIW0VO!7YQFS3,6.+<ZPS0U0V)6X02?U 20^.'42P;.81IJZOJ&0D"1%P]BU
MS]0;^M_&K9SS3ZH46[_FA: K 77 YF8/0-J+:T11'S,AKYB0U546G(_R I%R
M.7A0:X.C*-YJ.-NA_@'C,_:(P@T]C-M+5$7?N8D G; 84)B#&,S870 G[70&
M3Z!^>YXKV@)E1S])EVG $3_#!($.>Q:F0$ZPV)A]!R,?QN?( 1YZ#E\2W;Y/
M-2<@WVP3^JLNS@)EV413<(0.\TW 27UH3MR,+1/RW9WP^Q6LK43];RS>DL:$
MG-H Z/:HW.U^SD[&6^%+44MA2JS/]I;#Y5?0-24S@!"*HX;!B9E85M<#CDQ(
MP';7I_PM,2OP<A7K_G7H:< %D'X81VX.LI1P=_H8?Q3DF]*FZ?K)1_5JA3M>
ML@JL.'61_MW%F DAIF*%@0YB)D!P! _[<N*^@U/\44.Z1,:Y,7&1"O>\J)2<
MCFP.4H-^XK<4D?*(](K]B1(V.=5)#P/,'.)9M@RCLOJ_$I#,A/B740U2&1]
M$3TB;Z/J'2O&I@?J1X0APS*3I176/C=7Z1'59+0RBZ)+U. WG"]9HX;0PWI5
ML'O]X.\]RIZO'5"E)SR6!LZFLFP0-$]:!8,U!)@0-EZZ'4#T]=-@0CZV7V-"
MOK%B4@B=V[H)9[MF6N410QNP'*< 5/<GE<B:P>MLZ.$A:>B/!]F_P#8H]QE#
M#E)R]#-7VI<9@-S'A^%I7 [>V&>D[O"1+8*^]?(ZW)C/"A20>H:;\2 M@]SW
M6$:<$Q.N@K,9133DY^@LV\31;S*BZ%(%7C *H=94,BYFC&V2$;?DFUWO$'H8
M.\IE<U)P7_8$9=Z250SLDV/YP-9>*L"$[+1AT7M%"@?]C-P.H&.12* +U3 A
M#?AVU8W%BCC<H8\HO4*! .YG[Z3>%$BA)1X];!_F>GUX?=?TKL@B$<S\.:>S
M0Q,^Y>;S\G4-M;PX"W? 5V-HU"90#BOD=Z;33RV[Q5F1D9GTT/=VVQ&"0O0^
M?B,-$7>V)/P'MKN6HN3]Z+%\H6ZCKJ7QZL\5ER3.US\5!"[S[!*[M$NHA^^&
M2*A6X:AQMG2OY&W?TJ%UJYG4L/^E[1,[];LB>KEUS+O7WFT01H8&/IVO&#.Z
MM)7PTR#":&+A&?8D!M:+5?72TFDVHV#? .QY-PE4<BU8TC0'+8XJCVGI7#MB
MXT'+5T]B95K._8#JJOTCKQNF*I_H)?00U[ Y7]2LKAW?)8EG:O@70*T6V:;!
M[^YL6\;5X7HN'NA=;7CL:8"-;C%V$WK *W[/KW<_HO6T1J_K4X7J:#<R$*/Z
M;ZO=D+Y2@\JDM%YWYQ"L4,>&?Y%9L:9E89/4NW%PYU=XAHM/V>(1XI!&JXVC
M9Q;\P0'-8+(5NBM2AN)*6DSIJRJO[!&N* KI #G/;^$=TNEJI+Z0PP,S<;:M
M75H1U\?!70/P?#GJ[7SZ9Z0O$W)T@Q U*4NN;  E'ZC#B=6%9<+UMQ%EX*ZS
M:>3#!*HF*.N5"\(53W2E.C6Z!Z/2+Z)_5L_J&SZ!'%[N0BT,QL)1IK?7.OV;
M582'4T0SP;9/4PBUN_A/Y5'8E1HQ'@:E?GHES\**XM+WL*=@_WOWS":KR@-Y
MJ\T/A_I+Q1L197QK1FSS-^Z>V:\_.4FWJ!NXN@)]R81PT;5'19_:%13D2787
MB ^=?M)ZS+$N]A[GCC=/5=>L+*O4.L,L8V>)3SIJNRENR\[GQOGX'LH>UK<(
M^H=M?O_.<RQS_[A;YA9'#O[_FW?A[?@/MDPB_[J[\K](+;5U_K"-\6TQZ\MC
M]U03((BL#Q%K!;[U*1HDPDO#TJ\%_79^#V5[OXM#/TA)D?@F DXRBF%06[,8
M1-R&Y5N7<+6GH6B/&&>Q4:'O[G9U8QYJ6?=<+J")!LZ3F2.^RQ?6T[?0/['J
MY8S/ZI[CVI9#-6(<(P.#R-:X]7C"GL-RXV^DX=2+@"TFE*"4G]="G-<".2K-
M],NZK<M/!T2:,R&F$=@]92L:R(4;;]<;#"/A)IA?J)RJ:^,H'J\;\/.F?6L,
M69<W9PH.G0MXEH2NK4IL@)8BZ]HX?.Z:CS@4G6H<$GXJ %_6+K;Z]:@<PP/6
M*G&?+"?+A2TK[GVWY+7PX.!#6F6\U'R@90F++202FX(NE^!>Y2^?L/1;O)H8
MC2@0B84^.^SZ0.J+/EUK824)WJ!B&* 3&Z":<LR3]M"KM=&$QV$4Q;:)2JY\
M;UT-%/37!M&U^2RJ1&F:=+V:GA)M=;5']""'M\4[_#F_<8'<R'MW9RF#_A57
M')Q%BT^>+:P/- IXYF(LA+I_"CCDN&4+'>QA@6+%_7&H\C*\&GW2RY?"]WP,
M64S-;/#T+/HZ?/Q._0$6@;&0^(5@K,CTJ<O1SOI=(!4TA=>]F3O/@G2S;/ER
M*7!GDRW]L$F>1]I:OE5PAFCJ$WQ;87FDE/[0E\X ?NG^V=($QXH:.T?N/*X-
MJU=GPV L#<"W+O/FP6$P6:IRC6]CX9BNZD_#^1U)ZH2-Q:>$#+?&<S'%1NUR
M=\]CTNDRT_## 4,C^[H\F]+NS DMI"VU?#:K!481J\!X; -T4&9<H#Y#9G1Y
M-^-5'^*K6VF[TOGNC2\/Y-H<OEQ0;;.\T=I^N5?%O8/&@;IO[AD&D_>2J?'%
MWR$K)3M(^\_PWY>H P<^F:UAD@0H_M1.LO@4.3@"7N2(7!XLZ=:)8''\DX50
M4,,B^!7\/H%CUA=ZMV==]*G^1M0=L\L$$E\K,+YNV?@2IAJ_AF21L++[8\!0
M>,V6Y5JGV_ 5\[?^>&O^CC+ZWB\$ZJ0+$T+J@ L%2-"Q!TC!%,<\]--91].;
M-F!":P@30A[<@M<R(1QTOM'AR#2JC5Y)+&QA:@=+NT&8V7I!TUK:T*W@&CT0
ML[;?5C:*O$$_CVF$AB*5(ZJL*3)W QAY\0B8ALL^K_ 5^_DU9+]S#<7#J2(N
M/V=.^7'0U9 6SF--^P[L?*K1'[:E0TY32%$J[?3+;;WDJ^W6L2E'1"Y8NF&.
M("VHM=?=186^6Y0JD5/D-'<<NGX^5C_I\=(E$%J]#">E!HBA-V/<D/2="%+!
M*CF=[B#]+J?7NNT4IY&DE,=/7O PHHZPQ:N I+,A2#E=8#NPW\9_<91QFI?1
M7(IJ%C%)79W5@L6B2W/I[<M2"1;M*BP^X[[-9RYO\QD_96HG"];G24/@2X8:
M2'4F8S2G7MO1['$_0(I(UY*W _@#MR_=PXHH<^O.Q&+<+?A1^FV@[BS]+(NJ
MZ V!3$C;-NAGK\YKP8K!0K--]$@=JY/3K$[N4^^S.DDN8S AVRM$.6A2"XX3
M!2>% Y.7EYF0UWB,ZW8C_P=EJ[CJ8(7*E$LL1>))N6 00,\:WIX<88H.U= 0
M1=647^MQ8D*HBSY,"*R8U:I/!E"C];OJ?!TCD)H(^^ S7*QY#EP%R(9 '=2/
MI=H'V2:08ULSDV)0(4 1:9I/7UZ&JE>F2,HM^)):TNXIA*=+/&GU/Z,UU9]#
M(#5"N7'3^-LLXM7'A'!NV)_<ZG6>!KP8Z94IO"RE[K.LX^\N1^=V)F5-,<)!
MD1:QWG #%NQXRZDP#,,V\GANR"\BYEF(D<P@+DK^8K%W012+O6_TP4FGX-1A
M**D>X,%-8PM92FJSV/+\C.K)K6%@^O[VLR/C%%'2ON\[+>??B$R[><H?\L?:
M1EYA]2HSBMQBN1:+:<FRQM[F+WH-:HJA+VBD5Z(OL H(3JH ^$+L.$OG< "4
MMU3#@(W8$Z74J-WA&<TVI,4^:]U'ULW/CVH:7Y1_OUL3TKB4!E$B5,ZJY-N-
MDP\/^>'73QDES/FY\RPTD9V)6 H)&2$>UR_OZLC=$S=BY?/NG6#+J+OB<;HI
MXP-6++)BXY6P62",WOY $N*S&5=_<BL)WV_8QS:(QIOC0MGEXCXNRI%ET*=G
MH&6/WG4)^ETA.K3N/;SXZ,O[1].,ICU:W2>JX75 B52=\R%'0_)A'[>F/-.W
MCLZHW,\#3 C*Q'^,AWT&)HUZ5)@ZNY4ZSK88EWT&%A38X V$X![*O1JD4,)U
MRKLDG;[8;9S&16,GH<_2$O<:>)5OJ8'W?9PS4.9=ZVUJ%F4TS>0L,R2+A6K(
M/KHKL'K[FB4F>AW1[[&J4^Z XZ1V.6CCEV1_:"I!*7U*[:":83PK]HM1=06/
MU[7(?'G^+JZB_?<73NQ$M"; \O6 NBRL#X>$Y0_:'O^3F#?B#(RZ_V@+OYR0
M%X^SFJ>WZYW"C<VZ%]1[0DM5RC1'+Q[C_H0DH;B0Z67UCKVIT(B'K,G&.JC<
MF[]FH3G?JJ_ZU(+GHVW!^3I L(IWK#I-AZSYWE7&+:C 6 5!W_&9D.&A]L)-
MA:_EY/<S7<;GB\Q0J6&G]OQVHU5ZQC^[>^+<R1WRBWIYPSKUJI81E9AU83-Y
M/..X-6+*(:(7J^ZEH].LT^+\"^#.DP#S [?PDC>-..'U"<ASYM'#*:':;5Z.
MTXNB+O[*41^I/MJ3<+<?D^]8CG0 ,"U01(6GG)X::2M^9X99NKV/AV:K QI-
MM2I]E++7;ML\@2BV4-08GKC>4W3!2"1:C]W5M*R^G<NV,JBOS%;4)QTQ]7GK
M90OF#&H4'DJ_=!0XX)7HJ3*$U7FQMAD62#7120=_C@A]&<0_M9B3'7X8_P!:
M<Y'%+?.M<@'.,%02>J9DOYU&%-*8D:X@K-%J9>.==6&F?D\'*!&S9;R7VC[N
MS LT<]3Y'G.*/GU.%T45X-H,6\^7^@83[51*U!#Z*6 9+?B"%1N!(NB^"@BV
M/VWNW2"A ?.]\EH YM9DS'#*7B9D#ZK!F0]H G/<^MN-'*(.--$^HZ9-BI<'
M"O9"VWI+AL+CK>+XR4'PC6[^]DG+(92/9:S+][,;4[G>.*5^7T6\P?.N@#U4
M+9U!P@#:X0W UQ-Y AA5&=HRN6^5/F!W:]/8^(VI%J/YN"'T#9]'#&Q]IKM.
M/XU^07(F3%_GH:SL81/]R[<[_[O<]N*]NX1FX*?2@177&LVMMARGZ;0YV"W?
M_YRBJ]HUH< I.U5I**]U2OEL9 ;V]HQ@KOI]&NZ(%ROW,"$\CFX#]&LY-1E:
MV7-*6[KQR=%X =?RZQ^O0>(>27T>W6T5=/LBA_:U)TS( 9B<EQDQHD]I:WUX
M'&F9'EUS/WW6TR=YJ$E0["'V6M[MZ\<MO@M=_KC#?=?S;_SSA"-5HD0"Y\R(
M./JN0(5Q:6?!VT&-XL&(P5"W,ZF#7 ^CM;$7?_J5/)8N$H%<ARQE%?C6!"AT
M!ASS\L";DQA;A-GNN$LGFB([.\.JGFJ.JC\5WVT<^<W:^MBSHV$SMO_E']UN
M0)PTX-)JOEV^TV$K-"9DT(0XDCC&E<P_7G^Z(KFZSK1E9_\O[ !?V)=)JZ.C
M+YHOC!7%7N\V22S,5U6400XT?!^LE.E?%TLNTAG*>"*VFTH<Q80*U6\A@TMB
M &#7">^C#MH?I0-CM5M37W.=;+)TP.5$I"EZ57XTS%0]-YF5X)_P>>[4>4WB
MG'1$0VIB-5 %5WVM$Y*J:1-UT"3[T3=H)%N1Y%ATH9R? Y&AYCE8TJ8Z9%>S
M6M IC\[.T\%$INPHDK0FQ[W*V]]GU'-< GJ93<10I<%=*9+S2]=9YXF?0PDJ
MF+,5C$^P(RR7RB-;)Y(02W':JD#%I\]+3,ACGB#*Z*;/Q(:YS88Q+ZINZE+;
ME7Q=9\F-9/W6PB^#$=@I7\N%3J3Z"#@T BEIC]U=Z/TZ13=G'ZO8U2N)]*1Y
M>UD XT-U@U553$BKLS1,P^O1].#'L5-RQ<XBZ+-Q/>C)330"/!R[HMNT2!8^
MEX%^;IW</[I7\4"FQN==6HH\="7EU^XWN>6(W5_O72:K#SA3.2,8TK 2G33Z
MD6Y&X#OGDY+SDJ -?B!]"@MG\8Y@ZGQ.(3^<1_VM^+%$K<I%_+Z?AT%#"AF_
M*)OKZDQ<+F1[-=8E\6V-,0XEIY/U9Q(WN1_&8H>O:_5=WUH;-?#D0?9AKUHH
M4])[^D,+L(V5GY4UGC_CH3U+X@FPRR<!E.#>>(9XX_-N%0,FA%>%%X4<_LB$
M",$^,R'3O[!$]4\'J84*("O</JY3B',G5TUH\YOX9AF:+-VL)UXHL][S6'![
MI.:24W#@JI4"A?&J)-E RH#ZK(N_3F1 G:!,Y]3?[*:4^!C0;S$A121Y2U#6
M+W5@71<?LI8+I6[V+,K^=*&U]'J+:IWXO 2>H8HUB0'A:Q?*?['9R^_4^CS<
MYL67N<"3CJ'[44LIEEI;B8:H^=Z$4D?@/IS]\B7T';S4T6G;.+[;&CQ+H0Q;
M2BQA0&>*ASM6"WP@P1 ';>+H#HPL^OU/])N]BU70L6:SNJA-N+6#F:_WFZG#
M<L&V_>@D7(!\6",)NA@T[B_38.QI*=7[J:_XZB%ORME!LZLKO,*[ZJ1/"?JG
MKW:(54L[AT*_0",46/:Q/^MUY5+B+=+< DVV?J./."2?[??*71U&[GC"T5<"
MLH,_1A0Z8-*V/L%A53('.C[8Z38-VI0FG[O_YL0M-=[5MTTB(F*]DTQ(B6JU
M,=:#-<TP GB ^ SW]43:1/H:K5O9">Z "8%=B/U TGH.NSWDURYMUH?TRS)"
MUA^ FX:#?+A%'K):LK-ES*62F#QGC])1S*?6)]I;RN/(^T-##8Z'F@[K'+YQ
M-B<,PM:QP\ -@YA;B6]28D+8QG EV?I,B'M=(\QY!/"%&9&F%\0_2:0 (72$
M=];U)E?)MSH'I(;1WG!+F3[Z>9H2G56K]960JO-_M+8G9CV:#%UG$(]"/_#-
M02./Y5M=3E(*K4,J-8XI))LXM5[;D#E@.E!CQWEEEWS=H7W2FA^-M#ZP9=R!
M]217X.7'4*$I?"33,@H^Q&U1]1IT[E.Y_JFMHVJH49E4^:==TM/Q>>][; 9?
M]Z[B0YD01X#-EMA](_P6/@/J_C&X)81A>I-%A;&Z3R)I"#\C:D@C?!=5:H&D
M\JV<?\6";ZOY<B/\H$5435]TI;&EC\#"A+_?GJ5K3T=.4C.(T-U.0BR/8\ ,
MYW?%<SZBBQ^QHG)NIM,/41?),E-D1!CNBZP$C;+HV<38>N9M0SY>@=X'UL$$
MNBFPKWES0O5I>4^"2D-H!U>5)VHQ<VNGF)!#&0Q%NE8K>Z6<%YKRBZ07@]4X
MWJZ/MX9Z7 VYQ,+E0/@/^'+8F##E+?4K67B2A'P.-CUF0CPF'4<F,)G+=TX#
M"?B.$0$J=!2Q>\%1KG;+[W;3ADV"'$Q_S5OY+)W;\YC6/7:Q(1[$:"9@LL6A
MP-],94)8Q5$C$\(JV,+]+!CQ#E);K2:5LGCP71VM:#-LODJ>QDTUT!TX49)K
MK]J3VW>!,G25<$M9>:)W+?;45D^KL%'NM16,Y/WM>FW,3XZ$_ 9R]P\B@M9F
M)!&5ZF\VNUGDB):X7D 03)O7,7_Z]M.RE*O2T"\6:[O\7SZZ^/?/#=.3.X\<
MTPD95#EH(7@_]M4EL9<F>\?DGH$0LMYXEI>![CGED;@1N:)F_U:MXA@J_D.7
MD>;3\"J+5XE:;5@)QBNZ:+:3O[A!KX(WS]5'=\>@@3MPY+D).#$>)NW%,T4"
M7N_Z+'7=>,KA\L@(\D<P69&R^Y1#P87O+7<K,>>OW=9JRB?+4$*H[HU%Q"G\
M/51>Y,,R-N<"V@/Y=>?&$@7$4,[(D4A<J+J4I[6TR/4^ PYGVL91<X!@M.X\
M>=>4$*2 Y+TR:;^E^SI;["S_RH DVVRY$"[O-II\"A/W8CI\6,R12!@L(F)"
M/.0H&Y3'K$+M=,D>L=/^9NQP\MS:,+3>QR3DP^I:OEZ[03#H<_>71.YFMN)D
MB@0C.D#8*]Q7*ZTE76_8NCO3EKRF^>L%N(DYWX>[CRK\Y9];)W:VO.B]RK7J
MX"D6RS]7SO)_VXG:'NJC\3G,)OL'B@?L\^$'6+@S&]A)V,^$3!S)QX4XQB3)
M#EKX81.=(,XU]CK 8.:8YXM'.H" %WMZDW!#5=]KD!;B#G_6</5SJ4G$&!ZS
M&3Y \815I\U:"A/A@T57\<_/I'UP,)4(7E;H%*^''ZC!D0>'>N"V[?L&HV4_
M8JLU$BX\EYOZP3-K*?GXD="+DANA<#-0\U#TZX5UH#8F@90-V+9IW7;E1Q'C
MXO0:TNU8->*S'-3T32;D9=$8(008;[\._N3(W#K7P(2DA19 %Q^K=26\K>:5
M&CR3D$).R/7.-ITE+U=\?34,KY8)@F9C#C A02[D\\B:'K\KE*O.U=#!7\!X
M863F:K8 Q1DXX9 X;.] >Q;T\NQ5ON1G1,]*L>ISUQ#X0@-D11TN48<DH%YQ
MM9(L/&YHJA6JX%7LT+Q\.I_PL\K!9O^7[/%[1\<#8]9E9HT5D8-:5TN:"S]7
M80,:=0N/T;WA&=YV5.BX>9)M$H#O@=(M?*$UF-T6,T+J;QP2V$N2U\Z!<_,'
M6B1"O&NL)29$UA>T,KSZ33=3CE>E=C^/*[,KSN\T_WDN6ZI_$B Z4FGU=-L
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MBBJ5Q*P-5Y/ZO]V B8*"MB2\5CQZB*[X\N+]84S-3=*(#QA8?K_#K&5"NE;
M*Y^%<4,FE&2S_<2M8A@!*/;L308J(;*G3,<1*/6\(=&$H[=LW"M6L^0/DT)^
ML?Z[;O&,IO%/[*-L_"WI&.F/SK?7^'W?&XAG?3=397T"RLC\/SS'^G^SG90!
M^8=I_W%9]VDV34.09;O8#7^,6,5/R*T\8Z2U_% -N:>_2%JP7] ZZZ-%#3PZ
MCE*<TA]V84T7\5K=92</F)T5\RLOID<8);4H,\JAZ.#M+LCS:J.[OG)-;.;5
MH7=J-)^L.9;N\=M_TIG0I@WOC*P4N*P"#2&@6WNH2<J8WM?E2LGW-K?T?>WR
M>8QI[V(&YQ(Y:^NO&<>]^7&;45XYP8<*WBA;/=P:20NX-8WJUN?TY.F/+O=[
MI;2V:C,<'#R8-_VT9V/V^S#WTV4E-N97@O'7'R4>.SCG  ?L;%S5M#(?H(RC
MJV>8-:48D\P.<*:5E-M8M7=XI7]*%'>I]P+TGMIIE2IYDJ:/[E<,+W $T@4B
M"2LS#U*+T[A>OX:8I1=VOBC0<].-)PY->IS:]"7<755_:<0 ^L*8A>"8U>;
M<039N_0P3A62DV^\8GD-G^#CS&\3=J!H$[QB83U^5O<QY^ES18&U,O^.)R&C
M_M64^49 *4,=H6$IA09O\3N2P$ HUEUIY7@CH0!^\96>U\(9O<5T\;;P"_\X
MLZ_V9^K:_AQP^A]9B_\-H:D3\H0\(4_($_*$/"%/R!/RA/Q_BOR+!QW[Y\\7
M$!Q>N/R-4:@>P34R?=$C"I_Z?&U;V\#X'GOH6FC0-4T[ASL.4O*K%T ,LS$@
MJEJ]?\<4:GI1"(W#."@_X@GAMMW^4((G0ZH &$;^,2CUVGR0Z98$3;P-W?O2
M=[S=568UL/::#HGPE>V'5!2X2%]O9L*KQ%>Q(R9+,C9Q4V9EE?CU0O=T;3XT
M)WI+8BXD3"4OFDOD%LB'7JD9?(;$AX/1VRC2#T4-57M'7JGL-[Q7@]*I+/EP
M]C%^W+!:B^>*&]VSQA>K/$H1GC\N4J3\#=>W+GYA1!V!+,![G/76X(-+\?7[
M#OWYBS1[1R#BHR-0="CQW1&H),'S")2UIHCQ^2LI8/X?;W\)Z!0_^V?1@QR*
M0;M_N=/O4?[G2.<7BK^RUW\\1O\4Z_QG >Q_Y?\I_FO_Y3_[XDE[#Q+_)V&=
M'8._*!>?F[I_I=JH7OZ?- 9(^5_6&G77^;/&^&<#Y626_2/-LF)>H.5 39\D
M.2P)N9D-F.L3T,'S[*4]68M9E <BM;N.HVT2)3W"UK3?Y\PC13ZG=@_0K=CJ
MC"I@XTT8\2E57Y[;3HI7$YXH+BGR?Z33\I)1HZYD$(NY.+/I^C6J0S# #"V2
M\-3'HXNM'7$#",DBW<<?V'HX*\0]'AOO,/?*MF4.7B]P2%.R\+4X$__V\]N"
M'PWYXM>^F@_]_#],3<[V>']_2JNTJK:F,J*O;U(^T2[DL[!CFJ]^0B0(1"V,
M!WVA=?Z;2L\^DX 5[F@IV75H!:^O20GIIU8&8-L$KYS1?_[F%B63.B4W"/TW
MY;A]BL:@JRNKW_,$S\>-WF)=X@FT_IQ6J4>QGEP4[M?-I7/[\L3?(ITP!AU!
MY+GCR#W1P=/%5_5&V/EVZB_IQZS5ISU.KZ2D^4CV_BTI3)])21>N.4B^3,1=
MMZB*:CFM,6.@=Z[[V:F#-ENE%TX!YC^YT7_##M(SK945+ZGN^<UUG)*6%GS4
MIDCT373K>VI+2P@()!S;</JO2_?/=]%^A\O:'3S+X'\9,M7X>H5+R/$1XM0%
MC],=J)R=+XR&_\[["Q2_-T;]FO8Y@LD7]E(X"'.[?E!)P\94=0GF,9&6PD&_
ME8>A[EF^UL1. 53G!:S@=<GR,3L?)PP7Z=X@5 1A!%R:U6$)EQ=RSX9G8WM-
M;:P[LB>-6]Q $5KF0NQCLO(QW_TDHPI]&RPQ$4 X/J@1S%&P:@^QF[DIU*)+
M=))LJ5ZNL%&.F?E8DAFH\O(])P,G?0%-C/@=$\!MQI05,)&FMS/AZMV)9%#[
MEF:]2V36L<SGAWP5<+EX>MH\XLI5%7[# ]E+M03UUK67PZ\3U=)G$S!MLF;W
MG3A?%ZPMN+SP?B$:^%1Y36UBRR1W5MSTO*G-2V4:V]$'H7GN>=K=WS([<AKG
MIN<0.>OV8X[7L;"&QNF%<#X>U7Z20L:HC8=V0$5\UDCS5T-]_=M?L92V5W*"
MOUS.X06=/6/]DZH#PWF81):%2S\GV),#"#78?3>2\&AGXMI:"4#7SCU>^^CN
MI&E"CLR9L=-OGF^EN!>%DME,UX[M3-5=[!$(@)T_5EPKBS3_?5\'>(8L4SCD
MF&(\-G]K=<@ZZ?] :($RKW</B@]Z 2YMBJ\H)JS<\1(W[%^7[6@):J"),$N4
MCU I)*XS#%V_F;_TXS]G%T[0O]?0H"#_,33 @+0*OB+Z>&AHB]_M7]OND$MJ
MH%D7")2+N-)%7'\PR'5SY61H_!=&YY49R3WU?!"%?'C\HQ)@)S44Q61+G3O%
M 7@7T'78P6QI(M&(]!_EH9$/=3S&CT !>@=WD+U>^",0F:?Y"/1[?__T?_>-
M_OSXQ1/X'QQ>8=@@(H EKUEM\186DL?/[L*LI=U$BQK&H&6F.TXB93&^]0Z_
MUTN#J"H8"[UNJ((0?USOH"DF!AZ!T@YFCD DA9 C4/LVLBG_,+5^$?/'Q1IZ
M''+3R^O4"?L/R[;A&$=V9[-#Y&#TM@KU_&4R3C.'MW:46%",@RH)A0Z2FF;$
MC4_N>H\)R[?6#%'XO".0-6Q?&@,^ F'A*!+*5.6/0V)'H'_Y;/ )^9^>- -F
M_] '!(I&CV,U4HZ,-.!9,IA$.6:92$!!3YWH>LO>GH&AW[A^:UPS??"?L0-_
M#_(Y8(\7:^/F:+7&"  K.+F@L W[;=KDTY.3;5C3$4^AQ/G)MZM-\P]_R0,4
MULHW%GS$)_\(K_R]HEY_:E72(5.,J^1+<+$G^(K4G&4/R^3<U8AE8\&%U:WV
M<RY609V-EV,N7AQ[<Z\&=.M&447MP6P0=L()%X\U-L7R\Q.TX-=V'XVP)J89
MU&'/N?E)F#VV3D"TG*$5SP<U^S*< ^T]:6990M&2;A%"6TQ/;\-)-Z8W:.$\
M#\L&K7J_;);EUWE<RV(49&M^J^,0_4/D(]59E3"MTU2I8P#%78"-P#.MVN,O
MN[A=@SH_/FX]*9@RPIA4>*G?JIJ#(_QSS[4N$%)1NQO2[OU:R:JW5@@/:V;W
MIJ_"*X>4@\^:D*!)]^(UN3D"2>*.&1_"A\U.33VL?%BC]9NR79@/2W4%+C3]
MH"X;2&KRB \C63"&?L';E\61P8%3ZNS7A#0Y8H8Y8 L:8I_O?*#G;O+KC%H5
MB7]!Q9<)Z#4;@-=:,FRA%PA>/<%CC_'>94.)'@:%A1$)#O&C;O&\5T]WOA+H
M21"OX1!XP_SLH2/F H" 7,+UO$>Q0D5(+'AD" 2:.)X8NU(]UU4W_PV693B&
MI=&T>RTI\H3S^?U4 YQ"A_+W<P^G[MF"Z3%3A*0[A UB9/QA?.J4=?T(60TQ
M5:9C)YTT[S +&_F&MNDF_3:G"B-(-Q2S #$]S2D<582%42@_/,(PJ+[?A9:Z
MR,4:ATJP+]SH^OD\M5W@V9>W[UN>898>,KXJKWZ_.2H>+*S_)8$R^GO0Y1]J
MMZA^OO_VZ Z-(9;WT46-V8=YZ5] +VCB_I<'*H6BM00>MFARCE=^WYW'R!+B
M&Y%4)&4@!#_;=#P+"M9W&,.TBL96/-#O1Q_O1_5USFUD#SI$22?P+O,+!^I\
M3/ )5[F#7C5L2=&RB9E\YCL3[?_V>](@#^]5HS ?SU=60[4<TU,-IB'@<R^M
M8]LFF8=0#S$'KE5Y$W#Y1=O$LH"2#<DV8N[# ^^[AR,:#0]SR^R_,/(2I"*M
MBKQ[ZCDP<N,CK=ZBBQY#Y6X9\/<:D6/.B]LK[8+HBL#[ZQ&GH^SA'_R1\L8_
MQL:@(0?Z<&2SQX I TEM4J*ZOU;.!M=#?P7?DIS6)%4D/"@YF++^LK-/,)\4
ME:/"Z_#R]T63>./#3\4[%@2Q($F2/LP&CVT>3;<=11\OE24*DS+?5T2:F2;=
M&\U];3B<\E4V0D1H5JI</<1:(@/3<6Y!SLF2+HRKJ69%-HG?HV[-;QSPC>M!
M=16D%/8,W:SFNM\XO@?ABT/"<TEZAYFUZM/M4/ BDMD91@]X/J@)U2*XX!K3
ML8Y.DCT)2HREXZ5&']_+A@5K/.7@<AZG3,D^D#9>>H+@ZEUSMBD/+.M;EY9%
MEP\7Q<ROMSZ7LGBOI?M1A2'ZVJ?9F_?MN(0'-S@1TL/"A &,+%X]6/8(Q "/
MV&R2E'Y$_M7W:J!@?0WG+NS_*;T2;?&16Q^$O!)><N6R]^.:*5IOOE&$%-Z9
MF[Y\8-0?95U95XVI!-T<'&SN@6Q&73?NT_A]<48-M*3"%_!O",&!N<C]IF<A
M'#-U"H^-S_XX:$:"259Y<@N!+H%)KJ46;_AN=_ U72XO#\ACH[L>^8)F+(%L
M/P7H5:NW@;D1CM6$3'^#BNR9A)E>9]KV-$%M'H>D,^V5):_GJ0W<._:^?72:
M:Y7Q-W(FLP%4!/%&$WF"U?OCG@9#F0;D4$PFD+YE@V'?]2*80#G]I]<Q=P?-
MGP6*-#Q[^O#!<]].;7N@?EHYV(61!7ZL]YLP<FA\(2K,W@Q-X*M9G+*+TV11
M%AX?:5_X@DY(;;*\FZSLQC42->8#>3+K/RD#M!R!*'>_$EZ19:KQ)!: WL7+
M85BG]&G58/:!H 9SMB7T*=U8:)KH$L69R?PJPPFDM3;CS""ZJ>Y)*P:*5PXB
M68$#G1.*UM*'MBNEP4JGF.]:J(V^<E%M6+XWU!,)I5F:O B<RD=<[EVG"BI+
M*J1<9(^5@,++@MHWHU;':X@YO Y<;0:H68XF%&!H0EV*QRZC1BJBEQ-==K!>
MJ.XMW+$>F,:&=Z"1'SC<E)P^\W\XU4D^7G8H7Y.I$$*E)>2._K(III7'F/*B
MHOC77U6DQ90F+T:KT+*J!$>K@"3,PV)1-O^6+9XFLC+I*O#,46ZX63G4L:@N
M;<G#K+]P.]F"?;F)*N:!R>BPF:3;I:NM!0HW1M]_$EZ8$,="11"T!&08^:H-
M_XU^A/D7=;MT_3U%W2"<-'U/[MBO"791K>^DF@/'A9*H=PF:JI27>)(N\$OC
MAQOW>X*S "%\/\XAWLGM2U>FW:1 /-9;P+*V\]'$[6K[PG6BH"7:=^EMS-E3
MO=1[4<S';@^5<SV35BK)%/"<D69"-HDQ!I)T1QV"D"(^==P6'RKBXD7/";G1
M'I1"\CGMVSFOAH?EL=28LI#$"+ 0<).W %2B]S59"'#5^ABDC\9OUX\,L_?[
ME(RU6PX':F=(:'^LI(3<\V )2@>T\>W>7(O5G]VX@XA#=86V,G;<K;E$1P>I
MHM\T!8\O&':$/Q(*9RIE"OY2ROL-M.>'K=B%'B_DOIX ^D%H"SI.H==V?SZ9
MO3RG!Q+OYN R%NP+B1*ZUZ]#+G:V-G2NHAVMD1XY FGW(Z0/;MGNZT9/PX G
M<1PFG('3<%$= 8;4RT;V7K<>]_XNYZ&0D.@02$ 7?WJ?=FUB@22C6MC6R*<U
MLS94\X;?WG+#I'3(WG[HQNNBC(&,@0LNX:'Y[H\5Z?AY!;X;_^+&T &:Q5B"
M ,1I%G7^.3S)M*Q?N,_YU[875UF'EH9(M'#R^YLMV-H2V4>G6U52'YYY%"=,
M,?1OV0F<@4H@+OWTEK*6-] )69<Z LWPE]5%/JSM3_^L;I]3H!)]YM>%O2B'
MT=6$4^^E5L/\"%L/JJ7]R9=LD;3VZ[72>+_FZJF@,GK.)8Q%75E)#Z)B/WD]
MF?OCYH5H48TAC8K\6HO^4G!.O76DW_YP:P^-335#$LY3F7&I'<DWE&V58_/6
MU-#VYP5A@_O1XPV33^3[?H 7:,OF-,]B4H^-BTE%P+T N--*%L8?=J,@5^BE
M3&GAKL:2V^VICL+7<A(WYTS-,^[GEZN,^%7R@AATL-XL?5 Z<O^HNC^)-D,?
M;HKU%L*'[ZP-Q689!!<$S&5VY:DZS0D\8W@\U_L+U,U^I7G-R K!B&\+J14[
MT$18A!H1+-K"2*HN,Q,T^(D)P\S"L@=]MO>B#!LR]JY(M33%NPJ7RI1>E5M*
MH0!T"I<P$%0K69X@$O\>\K#:NK?@=]^V7];HJ $79<E+T117&^'HAS4)\CA9
MFM! R?(TDARY#:C#U?,BK??JQT9-DK*\@KZ/_?:*7D]")E2N3Q$+S*U;N[,A
M(,2-5 #;B#D'&$_3.]V+X5*V_H50S[J%F^0JWQ(>[FW,4<^9=I]Z!;5LWD(Z
MQ=J7HJ3JU<5;]:9[PB&W<FW8)^6!$*KW$,F,9;N\L1'L%\GPP_%OVO.CH1T?
M/K4(-C?R,(TUUJ7=AH\7K@[\+[=\=-5#RN0)TD$NV@(N/&M\Q86O*K@#$P3;
M7.SK[NU%*XF?<>E^&O5&Y7JAQT*M5]HR60AO@LZTYIXB"1ETK67$$1,;*@YN
ME41_>'<Q\NVZ^.=WE6_/@!"E620E/!([-<K3.*K<&$YI@^9G_E8-X[7U<)BA
M([;VDKOL$-,!U;4QEA%FM67O\[HU&&3\9@Y9>K!3IS ,".O2TKM ?-&*!U]W
M*8XR^+#F2>3CFO<\23932AG^PH#&IP\ZER537:5N3DT7-T9RDP3ZR@I!\/A&
MM#<;>A(F68 0<;/W]!*Z-"4;?\W6Z>S'*;I-B(-A2L+WU&-?>R3F0/,(Y _#
MHB<ET/6 W8S7,Q<O'FQ[^IZ>8SMON$B!S,1>9PF6HN*1+N?XGJ.#Z^A8 P1+
M3 2N3M?3+U7'+,KK30H!1Z#9FX^*(3(%LF/E2>(^R^S/UYF?%19(/LPQ:_8$
MZ8[W;#D<+VMU?=#K0/]L^'"XA.!@N3)=#T/H%Q-M9A;K,>=?4MHML597[O5W
MFW:%Y:.DKGX6G,W&%S<HAYC0$-"AD$?9I%OXP-0"P)<P'__XV&!S<7*GSWF-
M?14CFL]=<%7J=%Z:[]MF]I=VL./%\!3I3@X\MD6/S$8HK ]X33*WHZ\/7IM2
M.S JT8C>$YWOUKEYIK:+X?PUX:6#RN[.P/%3_>1NC/0  HEGG.D)<0FZ=FQA
M!:W"I'Z_&L-8O>,:XRMI1K76<9= Q&>2E1J].?H@-S,,0[7%[I6];^V;<&?&
M<E.JDMA4[7[^:7_S[Y</XJ3]*^WO^<KA#ZJF#Y AIF6P]]O)5L\)LMR6L3/:
M#,M]/:H$:&9&<ZR1B>V*;%A%;#-?@OT7+L2TVM4(IY](K"R@1?8#,RGC9X&@
MX]_(H1C,*;YT! JTP<<?GH5>0,ZT$1B/0&*/CD!T_3/2^W0(E6.O/Q(')C_X
MPJB;5IM-YLIN,MWF!-X=@8+ S<JD9'62C(Y__>)5 L6Q+:T<C-Q3]+EI\'X3
M!5BBJ)$_S7%49%XDTQ%HTP6,[X*R'(&^M#4SDJZ3!8Y OY?_QT&\1(3($>A6
M9# 8</PCJ5K[P(F8)V*>B/F/(V;]N2/03_.V(]!??ET.N+L]!/%&KJ>?O*03
M,4_$/!'S1,P3,?]^8K9A3CW'!!4C]'^>?SQ83B^C2C#2K88/E1LFW[,6\.+0
MJK1NWKVF*6 J[_[I=!O/=TY>O:\__P,,=:J/<"?R@R0<^# DA>OXN6L>?^1A
MP*(VG:>8_CCYB^\AQ]L-+I?]3[=_Z'HQ2@XV9M=@8)+I8EUA,+<8> <\*KF6
MMCE%Q67<EV^^?,:+:K1*O#B GQI3'8=;:-QG:VDN,-',[!>P=(7$:!K%;ACT
M?;R.7COO'= 6O\8O[7+@#,C96]C9<YC$_1:XVB9Q15#&W*=3Y.593Q_'1;LN
M* ]Y9'3R(R[\WFP+H3UW<;C;XOGKZ+MQ]\^RO:13N>1SBLZ)I-_MYF4T=99T
M]H<>F:F8\>W5(]"%2IF]U2*Q1G!)\3L2N,AVW[^"V<YQHGY?+B6;IHOMLQ7E
M%_JHMAM[P=\Y^3/V69=G6(4_\]</?Q^\EYP2)'<$HA^<-AE5#J['\T\=@2*'
M=MI:BQE)KP!Q OOL'<-*@S;5&LUI3,BS?I?:&IT?G1E\A3^)17]4LYORJ5^\
MA]\@TWPY N$NC:*P7GRUYXL!M[M?2_ DQ;K/Q"(BNPUWOB:/Z&8HVI&G3OU!
M6N7RO=#P5'94[N?/]FG'HEOV["D@ \%$"9OZ?2T^>&13<<2D",'!#[_5Q$_;
M=^Q:VR--C&%/JS_;/,;$9^OK3]6>B>F[D6XC$J<OU+,1=?J54PKK/JH)%7@$
M.H_A7<2PXW>F(FI%\N&PNV6^#5A&?X?"8C'?B\UV![.YU>)17^(V@U<VAV-6
M4-09AZAI "8:C2S6Q-WD.'C)2=+)ADO-FO1/3JY/CVM:N9O;*(P&ZD>G1W->
MM'XPST-4N)I0;'6@ <<--V NH9K3&[VY!K>1W.@ D6$7\4:;C!'#@JL:, O-
M=2'WT'6E%Q&JYO."ZTUE_H#=@:XM1@H_W#)\?@DC4(/W#F"HS[*KJ#Y#C+3(
MO7.S;%.5'.HB]/WIS1KO'9%+@HH?A<Y6;00@2V&A$/UI+(Y/RPAUA^"/9')
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M\.I:@?YX#S1G\WG+VZ&Y],I;,-].R%H)G49]C1)GQ0?EDH58_*PV'D42'CD
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M"8[:N:,P[&5E"(PY<<9$#HIX?#?#XOYST:+GY':.E6E3KD5%5*3P8#'I$>Y
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MK)Q=Y_&7U#4*<JWP%5Q6Y#1/L.1&W[+[O/8*7YXX4Y60F-.I ?"/F@<?$_(
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MIKMK8G)VN-"W]_;7M%X+7X(Y_"R)&T<TS(0<Y$=\WBD6PN^N:K('X?NV&F2
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MQ)-0G&@LSM[+^X)=8G*G?!P&7&FO-J_TB4W0M?R=<0&6,_3BI^(/="]U=;M
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M/_LGZ5;_;EEP^0AB05#!13"72P\'<.<NOB=8=L)<I6\[5V!HYR#YFK5(6=6
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MJ)FND:+GZ<OQW@ME>2%"R6"29@%$>K>+!"2 *4I)HK2F48[;]^+MXLS1K3_
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M/7F\--Z+--_)\+WL2?W6,:^UAHNZ;,[;%M5O314H_=,LHD3RD!,=<)4093B
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M=M%UD:64IA(&<:K/_ 4(XBA(8*B+(:C53!IG]B&PDT--C2V,L*"1%FR+ZQ"
M.8VM19#+&V(#\\51L/J$K4ZCYA"A\H;>2,$H]U?.+>9DA<?)\-+I)XP72;+2
M9"=H9'='_Z($RX4)1C6)3EMEO&8Y3U$:( %Y&L<0Z=+%-*<8!C)*\B3. DFE
MB\-U:K"I<6@C*ZA,9'6YD1-\US0H<3P??1)G._?+%WH#\VD+G)&S;;%>[91;
M]%O(X1PBONLV'!UO]#(-YS0_5)7A[#V]CT@W[=)[%S(Y\80)O=N-E"8]:. :
M)19X>#[$>W2XL8_PGM/[P '>L[?T6%Q<T_<+O9W?^FXY2DF<Q0R2*&$0Y8)
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M8Y;]N;'Q"-8AZA*\KUQ^32S/40B/@^UE/2T61O$08 ],-J?QNP&UV"Z];*Z
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M_WS13VDLZ82G+!&<P8B8]D),*<@P)K"@$69Q(O(8,2</U+F1IO91[P4%E:3
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M!MRO%AKKN@T56RU%\X=2[_(=3Q8MYL'R:#$0MF,U6'_:-_*JY+T!.XG!7N2
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M),L@EISD,LE$PC*WPXF3XTSOA&(O9IU=/%^"557/C-<2>U4Z.(VQ':E=C=O
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M/@Y_.F?'ET\AN]#BI$IE%_U+*;*\:N N .?%5HI.&_69[,V"I$+&!"=0(91
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M$_NHVT1_;*%N==70%-+ZWG?T9SV/TS^TOVNTR^Q-Z?]7TSFM:&_D2JI\4U9
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MQGD#VBAWJ6TO?!1VF6O[;*3*V+D.#]2A@?<7NWR C<T$7>'7!6=,P!.;Z$S
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MWM,3+I)=U8T3+9YYY7^<134_$%]IL<TKO^<7X?PV,_#U8JJ#5SDX=/F&+LW
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MK/(^?VP+V89AE& >!)#0,( HU:LE)B&#21PD/$@"/;W8Q=/1,];<EKX6*CC
MZK9_Z*.6,49Q$L90&<L#92*%!$FB#1&6J(ACA&+EEOGOB=QITO]W]!;CT&NW
M!_-$V<B+_^E7<83X#@LZ?.Z6^H:;=$MD(??S?8_-+0/UL<%L?-M5R%I>_OGZ
MZ;5<\?L'6OQ9982$"0HSA1)(HYA"A!"#.* (\B!+HT3(+%/"22E?&'!VFKF+
M%QC 8(=W4.[-1<8ME8E''L?6*%=0Z*Y5+'GQJEHNC3FM?K%DX$C)V-XWN$3I
MX[JDRU^+]?;Q?\NE>+\NOM*E_%S4?Y'BLWK]9'[S:;VI/#K&.-WJ7S\V=NF^
MY0B),BPP##'1*DDI"IE"&40D% 'F&>6!="QCZ@?9W'17*QBH)+L!1C:HU@74
MOY-Z\D KGW&BLB=@1+RIB@QWI01[,9W+HGJ:<3N5^"+S.++N]#Z%(QARWGGW
M7+#5$[BIB[KZY?1$X5?/ PSPKM\5:['EF[HQQ].=+,P"1+_+1:84HBPB4,C4
M[%()@BQ@"H:,,Y;$819@*ZNS=Y2YJ>L&)RAJH. 5+0$U%4D,7LM.&_VT6GBS
M?9 ULDYL>6HP@CU('QPY^(Y]<#61,W@ 9VZ.W4M<]'IJS]X\G>OU$OX#7^K%
MBX>6Y:.;*E.^3NDP!?_6*W."6>T+ TDSFG(!J1),Z\240TIH"J,D#)(X,1K3
MR3W:.]K<=&.3=;0'.6COW4^PG97IC;:1M:0S8P-JOUDPX;?N6]^ $]=\LY#]
MN-Z;S4T#M]>2;3ZLRDU1K2:?](O1E*H.:<*H<?AG*<,F\@!#+%0 TY3R,$F3
MC&&KA*Q+ \U-8QB<8 ]4;XKTQ0.K@)\EUW)CZH&RL?>9P]ARWRM>H,+KUN_<
M6-/NY"Y(?+0QNW3]4/U0IX)\HS_K''2]\2O+!6,H(HHK*$*&(&)8&Q4H$Y (
M1ED8246P6FS6&[JTU0ZGAG'2#;O!QGS;F[R8#?T):(7352&<9--6'5S+T>C*
MH*''Y.S5$&] !=*G(N@CP:\:.#G2Q$J@3]IC%=![M9L"*(O-XK=\E3]L'QIO
M:A"&>B/!S!E>F$"$!8$8IRE,H@SC2":49JF-17#TY+F9  TXNT_[F*?^K_DJ
MZ4?^@!M<'GV]9Z7M^5+U/9VO5/_T_ L]?N@D'^596=KO\/P%0PHI_#0-B4MY
M5^1<?C$)LI]7;5D0%3(N8RIA*HEIR)=ED* P@!*3A% 2BXA2^V()YP>:VX?Y
M;V'PMR"!_Q:BOZ',)0._ATL+WZ8GAL;>N#<H00435#B!!CJDNWP?82YE"?P0
M-U7I@<$$.A87N,Q*?P&!GOLG+!)P68K#0@ 6UP_;HGR1CW6P:?E9?5IOY+[\
MIE 12R6#/,RTP<)-!<8P"B'F0BJ*>1@$3A5_SPTT-S6YQVE.=U<&J=LVY2RC
M=AL5'SR-K"P/*:I ^B__=XD'G[N5LV--NE^Y)/'S'<O%ZP>6JGMX7*Z?I/PJ
MBQ]:VYSNA?1I71>]$K=_T4*4WXS_H/MWTW198_I/N=F7Y-L_J;[I\^9>%M_N
MZ>KS8YU!PC&F41 S2$AF#J"C!%+)"#3]DT46Q(+AT"U@^L5D<?E:IPG'_GU5
M[ N =MNQZ1_*S0W08VWTZJ)I&-)CZ>5>&CNM^B_Q(HRLMFUZS=7R@TJ6&_#N
M)U]NA2EO4$MS PP%5:33D]QT*LK>@-L'DPSJL1#A2T^8USJ'+R;,M&447WK.
MCJHTOCB@P0D"5>6;+5U^R;_?;]J03!&3*(S,*\88AR@($<2!2J B%"DL&2-N
MQXIGQIF;2=Z!>54RT1E6[580#UR-K-^[--40QT@@ZJ?!<X3_R:&F#NSOD_=$
M/'_OY0-\F1\X_2Y7K0901+((!3"BD=F5TQAB+ EDG+"4")JRS#Y&L_ODN7WS
M-38'K]L!319^R:'"C_P1U["&N!T/WQ-[/^-0(B9R+%YX$=R\AZ=D[747'MPP
MG7_P%,X#A^#)"X89&[_2?/5Q79:?5U4HNJILF?H(=(&8C&@J.*3")"Y3RB!+
MD(14!3@6BA.ND%OSE9[1K%Z^25NE&+# 3 VH,S^4Z;+XH-4[!4MM3_;UXW:F
MVLX*N9:^:918Q=NKCU5SS_6J29?)VSI>%>8FQ,&?86+!C$_CI&^X20T4"[F?
M&RDVM[AWHWRWVN2;IP\K;1W0JFCQ6[JA35^-!<,BC#(D( ^2Q'1Q(A"S.(4L
M36*4ABP,>&9CMUP::&YF3(T5=, "@[;MI6.G/BZRVZ\[?'(V]C'L0+J<&H/:
M<'%%G]#>QT_6-M1&R&X74:OK!V98G'2[=#R/Y>NG_35M[1OC5VF\*>WI9_EA
M5??I_H<T>RLI;G]HM-_EP>GH0B(B Q%',"8\@DAP!'&8*3U%&0N0RI)4!6ZG
M"-,*,+^C@Q:> *]^__JV:M==]>FV3(][H?? SJ":[]Q.>!K0%;U[)%!6V<VG
MC@WJ\X&& G-0T)!@:K/7--R E@C0, $.8T0\YL2\R!QZ3;*95H)ILW9>9':.
MTH!>!L70H)RJ<T2YZ^V>14D:"TYABI4VGU.90IP@I0WI,!5!**-896YKVO,A
MYK?JM C_PS7\YAEW=NO -7R,K*E;:."/%IQ'?_XYN?V&USP;8^*PFM,2'H?3
MG+ENV#?\26ZJ4H[%^D<NI'C]]+O6*Q]6NX+TM\;*KCM-MF]J$F81XAF':9AE
M$#%D(F%( N-$J$0A14,LW;YR=Q#STP/['@MTA]9-)0R8"CNE,2Z](ZL5#;XI
M.]O -\;>*R.!-N)^Z;2VV$LQB@8:3J)/'34 Q:1:;#A+S_7<%4\:6F%AS?^\
M7R_U'66=A&VB%4UYF^6ZW!9RWR4F9ASS, P@$R&#2*4*$J40)%$L"4Z"A"/B
MN'6W'7M^>J\+_?\#-7C7R@NVQ%ONE<<@<^QM[@D6JY!EL,<]4M<>9[K\EFVP
M'7SB$@Z.G!R7<W!]P$"EQ>^EV)K3D=,[QPI'LS5L-.;3-Q-]W=%F.&.!B@BD
M3)EH+9% DJ94;]\2@3E-,4Y<M=G5H&:HYAJ9S,E@A;_Q*H$[?5EK>[@JONLG
MSU(C3CHA$WH$3\8'MT' K21:;QI9P#C:TQNU7M7J]:BFU;?>6#Q2Q/Z>/+SX
MSE?)MT5MJ_Z@^=(\OBFI:-(=Z-+$ZIJ3[KLF_. ]S8N_T^56/OO:$8LB%2 %
M T$CB(@*(#8E;K,X"DBHJ$BQ4PM;C]CF=J+=U=<[P:KJJ$8T4-6TV8MNS@.T
M&M]+#(S(H)79O2*0KQFWT^\O-(\C*_IG<W3S;![+JISMN2F[ 49 4$DXZ@(P
M O>^"QWY@C=Y;23/O)XJI^1[")^Q!_6R=+L2'ZKJZ_D/:8Q-#669\Z=%F% 5
MI)DVA1(90H2P@C0*)>0RQCAE,0U(ZB. H!?%# WURCQ\?71@[",(H']"KCG)
M]T;RRQK?X(\:\4BV]G#JQC\%[X<Q@Z-L*Y[LSJ/M'C6T"U@5S*65L,R_K[[1
MG^]^FG'E:[F2*M\L<! D298F,%%99&I6)D8!*JAD%@F$C3?#JENFY7ASLVL;
MG*[]J?HYM=-<'ID:64LU2$$#M:I5UX %KQJXYZ/"!G2KLB+&;\>J_B$G[EIE
M)?]QYRJ[VZXLF*UW_D?.6,<#5*MGS>C]W^'=>2N?'RV,<4+JQ-(HM9][!WZ9
M&M V7)RM!6UU\[#/X_EN9[\/JCM_;M?;\L(.:/<128EX1H(4*F;<4E%((*4\
M@P03%08)X@&W*E4W K:Y+=]7^33 'Q_SE00?],OA6MW>YW3;Z<P7FL0Y^Z3L
MYL]9[X[ M$_M[!/>I#I\!%Z?:_HQAKBN!KC>T:T?I#;&/N:4Y<L*RR)*(TYB
MG)A*X HBIF+(8L6A$%*P+"-QRH(VO_:;>T'P4V-:??.'6;;?)J@.;J+11+="
M^'(/>5B9\).$V[K]K^3O!4J&=R".5C>\CX\QJH>?'.]%:HCW27ZNDGCO/==&
MI7RHBA95B0N5PWR12D1CH4+(J,P@PI1"0A("<:)"GB4D24*W3D5GAYJ;Z=<]
MD>Q@;0ZG7+L5G6?8<DOKA;>Q][$#*;LBBN,<&^-$9QR-]D)1%^>D/A]-<?:.
M81JCRNW_M%ZMV_#>6BLU'J'=UB/(% DYIC#$ 3<[S00RPDT !*<BC5D6(^%V
MYF4W\/R.N>KJ%'D%%KR2-=Q?').0+%FWTRC^F1Q9N]04=A&##PV?#>A?1O&3
MN1'E4_%8CCRI$G)CX[E"<KS;Y^E\]=OR=KNY7Q=F=_;[2C^Q$TY6'8F]?CJN
MB5XU%%02QUD8!'JJ*(9(B !BS E,6"@ED@JEL5.C\A$PSLV .EF[?U"KQQ'F
MT]+J>ME9&EFA#ID@3T$ 7B@</TC@.I@S""+PPK-=D(&?H094LMRYUGZ3U.1J
M&"/W'_GF_O?5FI6R^&',W0^KQ^VF-)5V5USOF2O 7XSSKM!KD!8E+]O=]-,7
M^:@_L'LM7N/4^ZZ?=^!=PZ9:)LD@#H0V:BF*(%$BAB32_XS#D*A$V56O>PGX
M QQU(Z\3'<0.=2FGGO7^!6.V,SG-2K*/W;T!'>'!7UIZT!4?U/*#0P)NP(X"
M4'%PL_,[/IF_[7@PE>);)KJNR1F_-PXE4V?\_DQ4E76V[Y%;/=@7FLC>DK-3
M8YJNJNT+L7U0./>E, S;(.M-=Z%QRK>R_M\/J[>RR']0$QG:U5TTSI(P(PD,
MXE":^D"FNRA+8,20C!).L7#+7[(<=VX;V18V>"4:X+^8!"2QPS[\5-%V)NRV
MJR/P.[+AL*?V;9?:/6R_VGD@43XWFK9#3[IY=.3C^8;0]?8!F[S;?^9/ZZ8*
M/8U0&L0\@SS  42"*4AE9G)J,A:P&(G$KNGQ\P?/3>]4T!Q,VRY'%MN5@9*/
MK!$J5$,:%72E=S"Z![(PD4%LR8:;>7I"Y%[3L7O]=&;="90')M>IOP]/^?ZP
M*C=%-:-5L6)9;K[0C7RGE*S*%M_)PF3.T.]RP0+3W#DDD 69TCHG#"".<0AI
M&B0J#E5*E7-2M_7H<U-1.XB@T(#!*UH":BKY&KB.=7S=9L'.(!J-VY&58!6V
MN@=^ UKHP&"_ 7O:]_#]ID@[L^8["=H>P.1ISL[<G$ID=G_(T**OI=0WW=^N
MQ%OY0R[7CV;,YL"U62X3)E4L90##)#%U*@(,2<93R)A@'-,$!\Q)I5F,.3=%
MUD(&="7TSFX'&C2A&L[=FB^S;J?"/',YLN(ZH+&#=Y?.Y[]UG -!?JO/7AYV
MXH*TUCP<UZBUOW5@^A+GII&K\7[)O/*&F7J139^1 (4HCN((*F&ZSV$40);1
M&$J<1H0&"2/"J?]DWV!STSLM5E#LP-Z E;1LX6)%KYV>\47:V-O#EJ\O';ZH
MVIC63\OE^B^JOQ6@U@5X4TB1;ZJ$GAM_C5Y<V/*:E-,WWK19-A:2'Z7-V-PS
M3+%\E&4IY:[*[$?C?MJYT9N*%^7;K5SP!$4RS$*88,D@BH2"%"D)HYC&+.$B
MX2I9;.R386P'=E(X$V3$5%DW8%DY71\;F&[*QIIR.\4S!I$C*Z$:\DVGF'6%
M^N"T<;,&3&_/:"[\:1U7JGQJ(.NQ)]5&KHP\UTS.]U^7K?>-_JP;XE5QL N*
M"&91&$+%PQ@B&IGB4-KPR4B2TE0@0@*GVBBGAYF;R5.!&I9\]XP_6R?0M:R,
M[NWI)-S5$&] /TN#<^U.DS!&EMVSD5XDO^ZTM.<RZ\Y<[<.I_&:]^B&+36YJ
MT&FR2U,BXEM!A=8Y;^E3N>!*DBC&*:0X11!E&8)89@D4">%$$,&CQ"F\W&GT
MN2F(3UNSXS1)9)L:)! :Y37>Y$OT#_$F>R1U:F]R!_H-V($'#7KPMH_M*[W)
MEJR-YTV^!. %O<F6W/1[DVT?,M"/(_YKVZ81KF^%J&H;T*4Q<S^LWM#'7&\N
MZK498QPHR2B,,I/ZQS,%21()J-*8RT"R4*;*R:EC._+<M%F=MF9J#]"]"([N
M'6O6+7T]8W YMN-GC]GLK?:HJSV6"1IJ@'LWG9S9\NKXL1Y\6B^0*R='+B'G
M!_@PP[Y((1_J;)2JV>+;]0/-5PL:8(Z0:8D6Z]T7DC2!.-4_DECA6&"E_V@5
M4.0RZ-S4U)&1L(=]T_1>!7_4T!W3]ZRF8(@%=CVQ4QM>0SB]TN#J)VD\.^O,
MN"]H7O4ST6]57;AWF&YJ*FG6CG#^I*VT56F:$9K6%BM1_;BLXLN:2KW[-@,B
MP51P$Y-- [U=5(DVKDPM\2A%@6!!*(/826$-1C(W+=96D&TE 1WL;EIK^.38
MJ;))*!]9OYUFNY&B"@'HR@&:6N.CUAR_FE:?&G$XF$G5Y-6</=>=US]P0(3X
M79,Q\V;]\)!OFJUPF8O*M:_UMK8LS0DQKTO/F7HX*_TJ/2U,33R,N(0XU-M3
M% :Q*6X5P(1A@A.>DC"RCR8?"&)N:O1N750%,-<*\"Y^0%OP9@^6M_ =HK2'
MSE*_4IV*^Y'U:2L!V(M0.>LZ$V"DN &WW6GX,.$T. 363S =$P7ACS4M;E'[
M5_+9&^$_]-G390-<*?U!YL"USQIF[;_>EOE*EN4M_^]M7A>%O2O6>JE\H.]H
ML<I7WTN]MVAK:^1\04Q?()3$D!'"(2(AU4L4B6'*B"E%A+,D=2J]Z I@;HM2
M!0J\^OWK6Y-A $H#U#''P'D.[&SY,9D=><EIH8,.]AO3NQU4\$&+W[@K0"7!
M395:S_V9[$/9\VFI.V.8U$ ?RM!SNWSP<WSW+##.E=_HIOG)),KGJ\\K^9^2
M%KM,^H52<<@B&D A4F)*KB609IFI)4F2*&-*_\(M+/@J.'/3AC5*L%Y)\*1Q
M^FHO8#4SEJ=,D_$]A1OW?!.!KU43@8/2);5L3UV+T'A#ONHO;"EW?P9OJV0N
M(S;0XD_18<"%^6F:"E@AFDD? 1?V[%L'.#W531,+F2_>-INDRNV2UT5''O7^
M?L&#-$I(QB!- @&1C!DD21Q!GI" QI)AQC(;_=HWR-RT9HL3[(&"&JF= NTE
MM%\M^J)I;&7GSI"U?K*A8*]URE;ME)+_[?OZQ[_KVVN-H__Q7-'T/GH2]6$C
M7*L4K*X=X\"[JGU*PS!BD4P@BB35&\M4;S$QUU0B3+,0)UG,G RKRT/.3@W8
M',P.J%1K0;Z/@^Z9U9'UP*;G0^ZQJL1:C#JC ^Z^&JX.=WIJ4'38+;+IEZ0-
MXB;YPIP-M07LDY1+PI(4(H3TSH^@ %*IB-[^B01%.,IH:F69>, R/\W5Y K(
MMC\J:_JC.O82N&9^;'78)*R/KMP:PIM> R=[T[;U)(TT8"_.*.T(/- Z:E,E
M!S@OVW/)G;>++9D&//*ZPX0WZP>6K]I2DNOO*U-Y^X/0*CU7N=EMU@DME<-/
M [U=B4X]-OTWK?W%)\U?G8O;^5L=3IRH6*0L#6#$N#874Y1"DE)M+K(LY3P*
MLSB,[$I=3PO<2G],6N2ZC@(?7"=RHOEV.^Z8P1Q.?$C2D;BJ-=S(#+I"-QE\
MH!6[\OQUA .-Y#=@+_MAFSW/\>O33M<8IS(C(W^1LYQI9N/<"=!$HP\(X]IE
M7[]?%_O:QY43]$O^_7Y3+F+.@M0TX.'4=#?E.(($T<J'04*)LH#@Q*ZIF-V
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M;1!]TP]H&O(HP1,:)Q&,8JD@$DA;'/KSA9E*A"F9SPFQJL'2-\C</N4]3F"
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M?R3WM)1W^HW?I7#Q0(8R2S*(L. 0A4$ ,2$9E!)E,F-9@$-[(_CB<',SAUO
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MYF8F3SO]=N;W;"=UY/6UE1MT!+\!>]%!5_8V]:^5_B@'L"'@YJ@GD5X)*A;
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MT%,.VC,67\PL>_S,=/EBSZ ]R )[[C,CJZAH]M_H\>A+-T59DA+.H&14ZM5
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M>3-$(O3^F_M!HN%LZ('"; (*[R["M(NOIG._FF@CHM".$\HQZ)8!0ROK9"E
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M=9T]H/[8CMNY$13XR6+]VK0.?-_!8CW$9I(R3\)'-.HN65R%^%6021,C=/)
M/<\LUD]1/43>V%FK@3'T>/YJ$!TUX-+?YFHS*^G9Q>K3?-']$]+$@=1@;"3
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MHN:"N7*73J%$I =!7-*E_R[2SZ@RJ<X,[?UNB_'O^EAK&"T<>(?FY6R8'-5
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M=#$%]%90J:O+/[H$6X7^>OF;_^_YXJJ&:?GKY7LXGR^*ZC_ Z9J*35\^X[D
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M.4_O%_-\F5;O%A]P\6V6KE)W?# N6E7 9H.@0HG@(A9 9K.,Q8FH1TMO>HB
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M.E_\&1;Y+%DK7.(2=/(*5,H"O*,SPS-MM./>&]=DR$3SE76B 8Z/VG85$R-
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MT4(8W6#KKI?_!]8BONU/=<#9F=32>,WID.7$)\6TA"A8I TD./,)&?G[Q[J
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M)B%@*! 5:I4B"UHTJ53>F=+M0'E2CP)MM34J(-?YTJ5!_8&KU1E1GT54AND
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MT?\6F-I?&6-?+[S^D?'O#U_"XBL9U?EJFL+9\NTL7>[R\\Z9:!R@]Q1:.NG
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M%QUX[3F*(&4N34KTV[$TX@KQ(QC$^"@XY>/APA?4&T',EQ?D$XDNQ((!4*A
MQZZD!,C; #PDY5!KPT23T'Y0+D;<;M[I,7"PKL</KU_/%]_FB["Z2$"N-_->
M"99$5[1B 43B)%CEZLA8*<$7;X57F"B!V"JZ?NZ;MHLR7EJ=XO!*Z,%Y5C.]
M9B/_?%Z70%_8QX7-3# Z*W+P8&2.H)CA$)464(RRQGE1DFPS!_]9TD:,=H?%
MP4-;1X=32@<P>Y42GM4]S9M+CQM[Q=],9^%L'8Q\"--Z-;G^"Y,8&..2>9!9
MUGVJH5S<_ZM$ K3**B::=#'L3.F($693$+9560>8O&-E'Q;SSXOP];H>]M77
M^?ELQ2?*.QV*J8T<ZVIRAT QL*V+TPQCF6FCVE37;$??B+'>,9W@(.KI%G47
MOOWM[,V<4C ^*4($+8H GXRJ;9"1 M-D@6>?(H7./(<V>?@6Q(U3[S@6W@Y0
M3+=@^XBUOY(BBFMCNB'+C5EY86*1Q&26UA.GL4X3<!+0<&L%TG>UV7.]/\GC
M5 J.!<S!E=@?7&_%O1>UBB%A4-[6P()+4,9H"*Q.413>.Z&%=+G-A?USE(U3
M8#=N*K*[2DYEHO>=5;J7VQN'76'X]'>TV6&X U]M9G\7*:+*HD"2LD9K6D*4
ME@$7,;A0Q\VW.58&GOU]8%WV^_/5<D6Z(E/Z.#\[H^"B_G 26%+*A$P!+(48
MJI#/#IG2>Z]X=LBLY-A7X]F3['0U%7P7W U=A3^ MOMY>!Q&#A?/L1,Z(7QR
MQ8+Q)M/9D>OJVV(@,5]'*"C.F.X<\!><G&CC_H  ;6<S>V!E;W/Y=G''N@J+
M51<F<[L_[M?%?+F<Z)RB9%J#KI.1E!<*HO(2DBB1!Q&,#$W&\S?@Y41;^?LU
MFT/QTL<YLQY=OGZJO?_R<;-)X+*]+4\PD2O(3( F4=>E'_6&)B'8:'54UDIE
MV[S:[TSJB3;C-X1\6VWOCFA_@>@9?JYO'UT< R3G@M/5^>*ZDW,BM+'%QP@R
MU+XS;0+$H!GX2!:>F)'F[B3\/HZ!!W@YT1;Z?H^!0_'R(HSF?@B99)1:A]J@
M&>@DY$S5I2L&O(@F:F.<U5V:S'[I1G]-\?T:S&%8.3#=^&76A\%L#M@ZY68C
MA."$HG/6@9>Z5H(*4@EI!XH0/.;$G?"Q1X.YQ\FXB49'=U&'Z;B/].! $?S[
M19O6+-?=I'7D^:=Y_:/[+D!QJWR(%KC)'%30KCZ9(!V;40>&0J!O4_AV) ;'
M344Z,HHFB'@1MG)#!'>&,UUF8^LRL'J,E\TQ+E 8++[VT]355:K*2$@Z1PU/
M*#,GH;4I'#@ZJ^.F+1W93V.4]%"9<!P)37CP&+V*H#VG&-AFBCJU9Q"LX8P5
M'37VU9"X&W\OYIFD"<S'L<J=,'<Z#RN/CFC?9O+@;0$5YH1@SH(UFERK) '%
M8"0X[>H^,EGG#HYBE,/Q^&(>8KHPS)&P=QH1YW/"N3>S\$GY:.FL].2MHD-1
M^V 0@E$(1GE41BMOQ3@5!(.R^6(>C4["/-LA\&58Z .O"T]*2$:E,F7.H$PB
M"0GD$!$9>),]CY[;H-M-%3@BHR_F&>LDK+0E"D_#3@>*_Y%SD[0S$)@@P2!E
M C$9!X45[J- &:Q_Z3GG*;R5=6&5(V#NY;VN/1U/L.*]4P:LK3/?E*!@GSL&
M4J,+THMD.UO?MAM_XYIC1Y>F+?#P(LZMYU]CGI2745$;&0M$K<FU\-H*;!0E
MT"AU\(&\3.KR"O4PML<=\-Z161T1/?U8VSYSP)X]L:\Z3%_/9VN]GH>S3[CX
M*B;(N+%%5Q.0"*KD0*>WI#"#"1D$*SF&=F4AQ^5UW$GO0]M5QSAY$<;T^)G^
MF)#X),6(.G /25NL_;,4%*>H0$L2'0L^1]<N_3HNK^-.<^_(F%KCY$48T\XG
M^>.R\Y&58I6OJRQK#)TU>,Y2+8#F,;.Z_ZC)LH1^1##N />.3&\D5/5CD</<
M[MS9(8:18Z 8&:3AI%%K/6DT"RB*Q;I'+#K;9&E6,XY&GA_?44(UC-+[P?\P
MQ_9M4? )(T? +"^02_%U%!E"C*[N4O%)I2)#S.W>H9NP-/*0UXZ.C('4WH\)
M-+U>>?7Y\V+=!79WS:1+UC/MH7@Z*!6:#*X4#=(YA]*2)RE=WFOOS?%V!O1/
M:#HY#F@&M*_&XZ5^6F#X5Y[_-9N7^X?LH$.FMOJF)J.F=N>QS< IHY,I)4:(
MFD)S9:(#YP6"\=DJF7WBL8G;&7C@5/J"^?SL<FWI7G43G^H!-N'.("NQ ).:
MY$%6 )[1 >:D%U'(9'RCYY&A..AJK-0NZ+KG54?1:;?-%.L_75Y/LUQOYKTS
ML([D<+OLH0KHU=_3Y83X#.B3J[=C)(*<2"7!68B>B<@C16/VB$-Q#N)EY":)
M<5"Y5<1Q/(B<MI7<%\#/\WJ)->&,!?)6 E+DML[*MN U"HA&F6",<"B.6(EY
M$"\]MA(=$9_#V<L@8!G17BZV#MUCXI<S_(ZSWW'=MXNJ6!=10K)UHS12FAZP
M%.#*<YME#HG;YX+K+;[G9#$Y# ;F;132'[;>SW##AT\1HR\.M-6FSBSAX)4W
MX%SQF#GJ[,*>P+KZDC%W.@ZHQ:?1L9](^X/&I[_F&SY2%D+;6O)09.4C,HA)
M:<A<B.B,M9CCGM"X^I(QMQL>#1K[B;1#:)"6+T'.G5-)\PQ!<%:?3BRXI#P@
MCUD+$SC)9U]P7'_-F&L CP>//<7:'T#>S,\7&T98#DI6RAFR4(?R1/)_R4"@
MI"IH+F.^.^-U:WQ<?\N(FUR.!X\]A=HA.J;?+V&.:"DP0P_1RKI!TP9B)"=*
MM'-1RIHLW;[>X_I;1ERG<D1T["?4_M#QQ_3O#1_&HRV%16"NKBC2 J&N^8"0
M0I$\6F8#VQ,<5U\RXK:3XV%C/Y%V"(T;XDE"Q^!X >N]K+MW+83LZ+=8&.>*
M,;WWN?+'CGGPX$73QX;'GF+M#R"_U'JW#2>9<GJ%M64P.8J@M'403)$@%+HD
ME!'1B#T!<N-KQBD$/C) ]A5K?P!Y-[W*SE,2%J/-5324@DE-*9@7'(H6CK!?
M'&?//E,_^RWC%*L>&1Y["K4_='RZDD[4S,HD"P@Z,4%YG<%[KX'Q()A$K3S;
MUWE\VNV.=?#"S&,GM7O)M-M7JYUVLV-(4A5NP BCZYNZ "<Y@D,=C-&!\O@V
MNQP.)GWD*5H=O]PV T"WD-_SW>6W^5^XN/C5].MT-0DL,*=T@&P%R2+E#%$G
M4HJF*+-P;I@\HC$,PU2/SV3M -KRI?80M+PTR_GSV[=;LN HO*43$L(Z)PN4
MM#LG&1@L)G/OF<Q'G-HX#%,G.J:Q0\LY!"TOS7(NAIN_+S<*=#<ENY-H0W&V
M#LU2I=8W>@5>"@%:A1"R#I%^T[T1/<[?B<Y5[-">!L)0+Z9UKUMH3['<%\?6
MPQ,L=UPK15H5R8,J1D&L*: 3$7-2DL78;OO$^/R?Z##% 4US?!WLA,%_G.G>
M^B<_X>?IK,KPIT ?EY!/$)-52"%$?20B 6H-SB<#4F6A@M68=+OXLQ,AG.CL
MQ5,TX@'1V(LE#QV;W.CCO8Q-3,DI2$]B\9(<G-,"O$$$-,R2;XO,\?Z3Q,?Y
M&W<J7 _VUQF&>C&MH=S2?7$\Y9;X)$@KC$,%O-2HHN0, 8.EWP9$K@,3H=UP
MQI&8'G>$7 ]&> IH&\PR&_>.OUHNS[]>,#]HI_@#G]ND+_PY^@?J O]YNDQG
M\^7Y M^7F\C[B&=U0?'K^7*UO#?T8WG5UQN+L4HS#URB ^65@U"<@\R]RE+J
MB+I).^EA9/?391Z<$3F+ ,&Z!"HY!9Y9"^AS9CZ6Y*-IXN=?1I?Y$=';KBM]
M%PR,&!<M%ZO)=1-F#"9Y;BD[$CY2GA0DA! 9B!)*]E%GE[89;4L?>@.T]+N[
M@+WUK2^EXWLGC<\/%7\/F+DL$.;)2A,MZ%J?HYPK%!RY3 %3S-:HS)C8YJYV
M>]2,V1EX@,;NZGP/\8VL]=^GL^G7\Z^799U62.E10A2!F"\\0PP\@8G)61<U
M,K/-U+>M]'[KFT?6_#YZFP\AQ+&U'_Z^0;A(*FAK)%B=Z\.6H+S(U5HIZYE0
MQJ3 MYDJNYWV;W[S.&4 @VE_;R'V<GMR6#I=9)'D,!%L-($X#AJ\L052H;R4
M"ZUX;#<]_W_J&_>,4T8"P"E#_DV8+M9C_&[D_!^GRW^]66"=\X>$G]5'RF<F
MFMG,8J%4)9NZ=$-(TH>2P%QAA7Z&0AVQRF1 SDZ^TG$GJ YE*4UP<]K35Q\2
MR>4PS7^?G]''G$U7/]9"X2[E<K'!QJ_[6",X"LLA6Q)(]MX:-\ZVZL-Y._GR
MQV[,:0#L]'(R[3/8^2F17,SV%ZI0XIH=D&8T*"4=I2?,@Y=:!X=!1]/F K,9
M2R=?ZWBP\8R/E%-Y9/I()^QB6GE<_^Q56DV_TQ\/^N#TS'<T>7S:A:]6XX@%
M*V@<"(XU:>9UOURM,^>."TH]#+(F$QA['4<LC8Y<*0.<YU(;HQ6E_Q3,91.\
MXYDYR]KL37@9#T4'H*O=P\\N.NT@BKB@G/[R^CZ[^&(,40H\U-['XC)X-!P<
MES[+S SJ)A4JMZAX*0]".R%A/I1:.L#4_H*[9GN6:QG,N_#U<A@GQE2L0 5>
M)%>[^R(%&>C!6H9,2XTINU$RNSV8&1?A!V!KUZRLM:([ /N=J.IR%A^B09D4
M*(8DU3K8. CD$ -:2U*-.6,+M#Y(3><7<<U!,A]:8QW ;H"4,D4ZGS*38#%S
M4+RNEU&RMJ9)M#5B\J4)1O_G*6:(".'( #AER%_D"6]G9/;G:ZV\7WW!Q:<O
M8;8II'TWGWU?;VGZ.#\[>S-?U'\T\0FURIF!U?5@1&4A5#4E%1S+2CKF^[I*
MWHO-SL^&@4$\E VU1]1IO]AL+Y^+UI())ATT>3N047DZ?;V'D*, (84M*>M"
M.CY18[O@\$3M[ A /[Y-[H&YO<WQ&RZF<PHTPV+5N4G^2A^Q6KZ=?5A3/"$M
M>2O(I?(L*2C.GB+L;!,$Z2@LR3$$WVZGZQ$8/-'GU)=DD <@[H4?CQ<[0Z\D
M$PURP;V HNOZTN 0HC"4]V*1Q:/@3IZ8+=YF\$1?9U^2+1Z N-UMT5_8XFR]
M]#9W;HNDMX+3F\*1S)/JZHC:)!FH%!-$[BVH@C8:5QCJ$S/'>SR>Z ":EV21
MA^'NA1OEW5B>\GQN@R\0M.+DK^@_,3H)VB9ILHNQM'FX["M_[&^8S$LRR$,P
M=V#^^,OL9 SRSE""=8S_,WF4JUJRFXHVS"MNK8'(ZMH99!3M5]^&Y.B,9RJB
M:3?FK1\YG&@N>C*7L,TP^<]X%7E6?),DB@^%*^"L7J5I*<'I.@4(@Y$\YMIJ
M]%+M^,7?[+:SG@X]P4Y0_L?="F\A/FV9D1@AIT*9":-#P/E@H* 67&J7&Q6^
M=".!$SW+_U'NH"6H7W1(</N6\'G!%>0&L\N0.:_.U'@2G H@I)(\D'--I:]N
M[Z$E\.)OME^ -V@)ZA?^3K6YHSPG7#\OM\!"3M&%.NJ$@<IUIQ(/'+"N9S$L
MJ&1.S!GLPOZ+OU%_ 9Z@&9Q?N!O8(;TR-BON>8#$0@(52?NQV  V>FVYUDR$
M4ZVJ',8%G/(=_@MP 8V@/.C]_Z#]SR3 K]-5E07]<=V!,241SM(4E[_AYW#V
M83%/B'7R_EZ=SSM\^@ ]S_OR,E"W\_77+U_=^?[KF:97[:I))LVM$B!\J.M%
MI(+@8H+$35"E+JNS398;[D3EH6?.5E_VB>3_$_VK?TVL4UR)NGY,^0+*U<LW
M6_>]6I%<"!1VRR:SD'8C<]P;WW8HN^ME&RJOSUD0V_N/=X'.FM7T.QXP%>*
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MI(]S_8&X71_A&8+P@H-F-F82ML3,HDG(7'"N>.&=AR:UN4,0/V[6X.=Y(X;
MQG3?AS?8AV>)(HI06PT#+W7GMF;!R;J.PNGB1/*^379L".+'37J\QO>A'3:F
M<\-PRA/T2(>=C!0OZ9HH4D&P6+?:A^"T39E$BI/SY9O5!;U&\/;2X)6^_-ME
M;I7Q^[A;+&#]1\UZ <F6L/_O'04.N)[_\:Y; FFE#BPOJ_5B_Z!+\GQ]'S%
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M>@M[VWO<30RE6R2X?Y'@B1)LH?=)_F9'D,TYW9PDV2:E_2=02P,$%     @
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MRGX-*P.-VS[OMKT/86,:?ZNW?%>GN)[_F_VZ?@%[X8UI_^[VZ?\!4$L#!!0
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M?L\OQ?%1][CW&DCW/GD1OMX2U-_MC28GQGUNO^OV%#&>=EYU'Q RT'?,/=_
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M<"P)MU%<J?/L&U+%YJLO'O/#_9O>MEN/ZNWK68C=2B:Z_?7\AJVH*S:3H=3
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M,AB9Q O8IQM- =%47G<#0A-/'G#J><#Y"%-D&[N;8H#5FVB[A&"["C)D.?*
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MIH9HE9#_GBGU"83&"]60?)6"$CG:Y8RI0ZB?&1VY>!B6H\*X&,O^;)W;'#6
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MR%0$C!-.L9:TLR#]8.>DIN<B03M<*]M6I7S*@#5,22IW0))Q#&=J4&6ULIE
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M,# R<W1O8RYH=&U02P$"% ,4    " !IB%A2PQ,)\:L0   <>P  '@
M        @ &F50  97AH:6)I=#$P-C=?8F]N9&AE9&=E>&)A<F,N:'1M4$L!
M A0#%     @ :8A84N3QKW#W%0  ]YP   \              ( !C68  &5X
M:&EB:70Q,#8X+FAT;5!+ 0(4 Q0    ( &F(6%)%=85XK14  %!P   >
M          "  ;%\  !E>&AI8FET-#-?;&EG86YD+61E<V-R:7!T:2YH=&U0
M2P$"% ,4    " !IB%A2Y[,5LX[9!  Y<C@ $0              @ &:D@
M;&=N9"TR,#(P,3(S,2YH=&U02P$"% ,4    " !IB%A2_LZ]T:@:  #^+P$
M$0              @ %7; 4 ;&=N9"TR,#(P,3(S,2YX<V102P$"% ,4
M" !IB%A2>ZR/N%0X  #/9 ( %0              @ $NAP4 ;&=N9"TR,#(P
M,3(S,5]C86PN>&UL4$L! A0#%     @ :8A84OHXLK4^K0  %(8' !4
M         ( !M;\% &QG;F0M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M &F(6%(X4.6\"2T  -U3   4              "  29M!@!L9VYD+3(P,C Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( &F(6%)=?AB&VL4  +Y? 0 4
M      "  6&:!@!L9VYD+3(P,C Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( &F(
M6%)2#0:1GIT! ,M*$0 5              "  6U@!P!L9VYD+3(P,C Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " !JB%A2)^1O4B?U  #*3 L %0
M    @ $^_@@ ;&=N9"TR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ :HA8
M4MRH,L*K!   @44  !H              ( !F/,) &QG;F1?,3(S,3(P>&5X
M:&EB:70R,3$N:'1M4$L! A0#%     @ :HA84G[_0":V P  SQ(  !H
M         ( !>_@) &QG;F1?,3(S,3(P>&5X:&EB:70R,S$N:'1M4$L! A0#
M%     @ :HA84AEZ;(M9"   %CX  !H              ( !:?P) &QG;F1?
M,3(S,3(P>&5X:&EB:70S,3$N:'1M4$L! A0#%     @ :HA84O)B8!9B"
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8=&U02P4&     !, $P O!0  !W$*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
